assays_ASSI,assays_CEI,assays_ASORG,assays_BFO,assays_ASCT,assays_SI,assays_AST,assays_CURAB,assays_ASTET,assays_CONSCO,assays_Des,assays_T,assays_RELTY,assays_SASSI,assays_CHEI,assays_TISI,assays_VARI
1,,,BAO_0000019,,1,B,Autocuration,,8,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,12052,H,,CHEMBL615117,,
2,,,BAO_0000219,,1,F,Autocuration,,0,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,22226,U,,CHEMBL615118,,
3,,,BAO_0000019,,1,B,Autocuration,,0,,22226,U,,CHEMBL615119,,
4,,Bos taurus,BAO_0000249,,1,B,Autocuration,,4,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,104729,H,,CHEMBL615120,,
5,163.0,Homo sapiens,BAO_0000219,143B,1,F,Intermediate,,1,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),80001,N,,CHEMBL615121,,
6,163.0,Homo sapiens,BAO_0000219,143B,1,F,Intermediate,,1,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),80001,N,,CHEMBL615122,,
7,163.0,Mus musculus,BAO_0000219,143B,1,F,Intermediate,,1,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,80001,N,,CHEMBL615123,,
8,163.0,Homo sapiens,BAO_0000219,143B,1,F,Expert,,1,In vitro cell cytotoxicity was determined against 143B cell line,80001,N,,CHEMBL615124,,
9,163.0,Homo sapiens,BAO_0000219,143B,1,F,Intermediate,,1,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,80001,N,,CHEMBL615125,,
10,163.0,Homo sapiens,BAO_0000219,143B,1,F,Intermediate,,1,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,80001,N,,CHEMBL615126,,
11,163.0,Homo sapiens,BAO_0000219,143B,1,F,Intermediate,,1,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,80001,N,,CHEMBL615127,,
12,163.0,Homo sapiens,BAO_0000219,143B,1,F,Expert,,1,In vitro cell cytotoxicity was determined against 143B-LTK cell line,80001,N,,CHEMBL615128,,
13,,Staphylococcus aureus,BAO_0000218,,1,F,Intermediate,,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,N,,CHEMBL857900,,
14,,Staphylococcus aureus,BAO_0000218,,1,F,Intermediate,,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,N,,CHEMBL615129,,
15,,Staphylococcus aureus,BAO_0000218,,1,F,Intermediate,,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,N,,CHEMBL615130,,
16,,Staphylococcus aureus,BAO_0000218,,1,F,Intermediate,,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,N,,CHEMBL615131,,
17,,Rattus norvegicus,BAO_0000357,,1,A,Expert,,9,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,100122,D,,CHEMBL884521,,
18,,,BAO_0000357,,1,B,Autocuration,,8,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),12054,H,,CHEMBL615132,,
19,,,BAO_0000019,,1,B,Autocuration,,8,Inhibition of partially purified 15-lipoxygenase from human leukocytes,12054,H,,CHEMBL615133,,
20,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),12054,H,,CHEMBL615134,,
21,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),12054,H,,CHEMBL615135,,
22,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),12054,H,,CHEMBL615136,,
23,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,12054,H,,CHEMBL615137,,
24,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,12054,H,,CHEMBL615138,,
25,,,BAO_0000219,,1,B,Autocuration,,0,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",22226,U,,CHEMBL836324,,
26,,Oryctolagus cuniculus,BAO_0000357,,1,B,Autocuration,,8,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,12054,H,,CHEMBL615139,,
27,,Oryctolagus cuniculus,BAO_0000357,,1,B,Autocuration,,8,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),12054,H,,CHEMBL615140,,
28,,,BAO_0000219,,1,B,Autocuration,,8,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,12426,H,,CHEMBL615141,,
29,,soya bean,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,12054,H,,CHEMBL615142,,
30,,Glycine max,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against soybean 15-lipoxygenase was evaluated,12054,H,,CHEMBL615143,,
31,,Glycine max,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,12054,H,,CHEMBL615144,,
32,,Glycine max,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,12054,H,,CHEMBL872867,,
33,,Glycine max,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,12054,H,,CHEMBL615145,,
34,,Glycine max,BAO_0000357,,1,B,Autocuration,,8,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,12054,H,,CHEMBL615146,,
35,,Glycine max,BAO_0000357,,1,B,Autocuration,,8,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,12054,H,,CHEMBL615147,,
36,,Rattus norvegicus,BAO_0000019,,1,A,Autocuration,,0,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,22226,U,,CHEMBL615148,,
37,,Escherichia coli,BAO_0000019,,1,B,Autocuration,,0,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,22226,U,,CHEMBL615149,,
38,,,BAO_0000019,,1,B,Autocuration,,0,Dissociation constant with dimeric 16S rRNA RNA construct B,22226,U,,CHEMBL615150,,
39,,,BAO_0000225,,1,B,Intermediate,,3,Dissociation constant towards 16S rRNA construct A,22222,M,,CHEMBL615151,,
40,,,BAO_0000225,,1,B,Intermediate,,3,Dissociation constant towards 16S rRNA construct B,22222,M,,CHEMBL615152,,
41,,Escherichia coli,BAO_0000225,,1,B,Expert,,3,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,100263,M,,CHEMBL615153,,
42,,Escherichia coli,BAO_0000225,,1,B,Expert,,3,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,100263,M,,CHEMBL615154,,
43,,,BAO_0000019,,1,B,Autocuration,,8,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),13053,H,,CHEMBL615155,,
44,,,BAO_0000019,,1,B,Autocuration,,8,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),13053,H,,CHEMBL615156,,
45,,Homo sapiens,BAO_0000019,,1,B,Autocuration,,8,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,20001,H,,CHEMBL615157,,
46,,Homo sapiens,BAO_0000019,,1,B,Autocuration,,8,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,20001,H,,CHEMBL615158,,
47,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",12971,D,,CHEMBL615159,,
48,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",12971,D,,CHEMBL615172,,
49,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",12971,D,,CHEMBL615173,,
50,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",12971,D,,CHEMBL615174,,
51,,,BAO_0000019,,1,B,Autocuration,,8,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),13053,H,,CHEMBL884518,,
52,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),11512,H,,CHEMBL615175,,
53,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,11512,H,,CHEMBL615176,,
54,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,11512,H,,CHEMBL615177,,
55,,Rattus norvegicus,BAO_0000249,,1,B,Autocuration,,5,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,104740,D,,CHEMBL615178,,
56,506.0,Homo sapiens,BAO_0000219,1A9,1,F,Intermediate,,1,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,80002,N,,CHEMBL615179,,
57,,Rattus norvegicus,BAO_0000219,Oocytes,1,F,Autocuration,,7,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,104835,D,,CHEMBL615180,,
58,,Rattus norvegicus,BAO_0000219,Oocytes,1,F,Autocuration,,7,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,104821,D,,CHEMBL615181,,
59,,Rattus norvegicus,BAO_0000219,Oocytes,1,F,Autocuration,,7,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,104848,D,,CHEMBL615182,,
60,506.0,Homo sapiens,BAO_0000219,1A9,1,F,Expert,,1,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,80002,N,,CHEMBL615183,,
61,506.0,Homo sapiens,BAO_0000219,1A9,1,F,Intermediate,,1,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,80002,N,,CHEMBL615184,,
62,506.0,Homo sapiens,BAO_0000219,1A9,1,F,Intermediate,,1,Cytotoxic activity against human ovarian cancer (1A9) cell line,80002,N,,CHEMBL615185,,
63,506.0,Homo sapiens,BAO_0000219,1A9,1,F,Intermediate,,1,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,80002,N,,CHEMBL615186,,
64,506.0,Homo sapiens,BAO_0000219,1A9,1,F,Intermediate,,1,Effective dose of compound against replication of 1A9 cell line was evaluated,80002,N,,CHEMBL615187,,
65,506.0,Homo sapiens,BAO_0000219,1A9,1,F,Expert,,1,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,80002,N,,CHEMBL885343,,
66,506.0,Homo sapiens,BAO_0000219,1A9,1,F,Intermediate,,1,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),80002,N,,CHEMBL615188,,
67,506.0,Homo sapiens,BAO_0000219,1A9,1,F,Intermediate,,1,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,80002,N,,CHEMBL615189,,
68,506.0,Homo sapiens,BAO_0000219,1A9,1,F,Intermediate,,1,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,80002,N,,CHEMBL615190,,
69,506.0,Homo sapiens,BAO_0000219,1A9,1,F,Intermediate,,1,Inhibitory activity against Taxol resistant 1A9 cell lines,80002,N,,CHEMBL615191,,
70,506.0,Homo sapiens,BAO_0000219,1A9,1,F,Expert,,1,Cytotoxicity against human ovarian cancer (1A9) cell lines.,80002,N,,CHEMBL615192,,
71,506.0,Homo sapiens,BAO_0000219,1A9,1,F,Expert,,1,Percentage inhibition of human ovarian cancer (1A9) cell lines.,80002,N,,CHEMBL827083,,
72,506.0,Homo sapiens,BAO_0000219,1A9,1,F,Expert,,1,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,80002,N,,CHEMBL615193,,
73,506.0,Homo sapiens,BAO_0000219,1A9,1,F,Intermediate,,1,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,80002,N,,CHEMBL615194,,
74,506.0,Homo sapiens,BAO_0000219,1A9,1,F,Intermediate,,1,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,80002,N,,CHEMBL615195,,
75,506.0,Homo sapiens,BAO_0000219,1A9,1,F,Intermediate,,1,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,80002,N,,CHEMBL615196,,
76,503.0,Homo sapiens,BAO_0000219,Jurkat,1,F,Intermediate,,1,Inhibitory concentration against Jurkat cells,81072,N,,CHEMBL615197,,
77,,,BAO_0000019,,1,F,Intermediate,,0,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,22226,U,,CHEMBL615198,,
78,,Rattus norvegicus,BAO_0000357,,1,A,Expert,,9,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,100121,D,,CHEMBL615199,,
79,,,BAO_0000357,,1,B,Expert,,8,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",11231,H,,CHEMBL615200,,
80,,,BAO_0000357,,1,B,Expert,,8,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",11231,H,,CHEMBL615201,,
81,,,BAO_0000357,,1,B,Expert,,8,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",11231,H,,CHEMBL615202,,
82,,Candida albicans,BAO_0000251,,1,B,Autocuration,,8,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",11231,H,,CHEMBL615203,,
83,,Candida albicans,BAO_0000251,,1,B,Autocuration,,8,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",11231,H,,CHEMBL615204,,
84,,Saccharomyces cerevisiae,BAO_0000251,,1,B,Autocuration,,8,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",11231,H,,CHEMBL615205,,
85,,Saccharomyces cerevisiae,BAO_0000251,,1,B,Autocuration,,8,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",11231,H,,CHEMBL615206,,
86,,Sus scrofa,BAO_0000251,,1,B,Autocuration,,8,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",12083,H,,CHEMBL615207,2107.0,
87,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,8,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",11231,H,,CHEMBL827084,,
88,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,8,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",11231,H,,CHEMBL615208,,
89,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,8,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",11231,H,,CHEMBL615209,,
90,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,9,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",12083,D,,CHEMBL615210,2107.0,
91,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,9,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",12083,D,,CHEMBL615211,2107.0,
92,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,9,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",12083,D,,CHEMBL615212,2107.0,
93,,,BAO_0000357,,1,B,Expert,,8,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),11377,H,,CHEMBL615213,,
94,,,BAO_0000357,,1,B,Expert,,8,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,11377,H,,CHEMBL615273,,
95,726.0,Homo sapiens,BAO_0000219,HepG2,1,F,Expert,,1,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,81020,N,,CHEMBL615274,,
96,726.0,Homo sapiens,BAO_0000219,HepG2,1,F,Intermediate,,1,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,81020,N,,CHEMBL615275,,
97,726.0,Homo sapiens,BAO_0000219,HepG2,1,F,Intermediate,,1,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,81020,N,,CHEMBL615276,,
98,726.0,Homo sapiens,BAO_0000219,HepG2,1,F,Intermediate,,1,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,81020,N,,CHEMBL615277,,
99,726.0,Homo sapiens,BAO_0000219,HepG2,1,F,Intermediate,,1,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,81020,N,,CHEMBL615326,,
100,,Hepatitis B virus,BAO_0000218,,1,F,Expert,,1,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,50606,N,,CHEMBL883130,,
101,726.0,Homo sapiens,BAO_0000219,HepG2,1,F,Intermediate,,1,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,81020,N,,CHEMBL884519,,
102,726.0,Homo sapiens,BAO_0000219,HepG2,1,F,Intermediate,,1,Concentration required to inhibit 50% of 2.2.15 cell line,81020,N,,CHEMBL615327,,
103,726.0,Homo sapiens,BAO_0000219,HepG2,1,A,Intermediate,,1,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,81020,N,,CHEMBL615328,,
104,,Homo sapiens,BAO_0000218,2.2.15,1,F,Intermediate,,1,Cytotoxic activity of compound against uninfected 2.2.15 cells.,50587,N,,CHEMBL615329,,
105,,Homo sapiens,BAO_0000218,2.2.15,1,F,Intermediate,,1,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,50587,N,,CHEMBL615330,,
106,,Hepatitis B virus,BAO_0000218,2.2.15,1,F,Expert,,1,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",50606,N,,CHEMBL615331,,
107,,Homo sapiens,BAO_0000218,2.2.15,1,F,Intermediate,,1,In vitro anti-HBV activity in 2.2.15 cells,50587,N,,CHEMBL615332,,
108,,Homo sapiens,BAO_0000218,2.2.15,1,F,Intermediate,,1,In vitro anti-HBV activity in 2.2.15 cells; Not determined,50587,N,,CHEMBL615333,,
109,,Homo sapiens,BAO_0000218,2.2.15,1,F,Intermediate,,1,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,50587,N,,CHEMBL615334,,
110,,Homo sapiens,BAO_0000218,2.2.15,1,F,Intermediate,,1,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,50587,N,,CHEMBL615335,,
111,,Homo sapiens,BAO_0000218,2.2.15,1,F,Intermediate,,1,Cytotoxicity in 2.2.15 cells,50587,N,,CHEMBL615336,,
112,,Homo sapiens,BAO_0000218,2.2.15,1,F,Intermediate,,1,Cytotoxicity in 2.2.15 cells; Not determined,50587,N,,CHEMBL615337,,
113,,Homo sapiens,BAO_0000218,2.2.15,1,F,Intermediate,,1,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,50587,N,,CHEMBL615338,,
114,,Homo sapiens,BAO_0000218,2.2.15,1,F,Intermediate,,1,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,50587,N,,CHEMBL615339,,
115,,Homo sapiens,BAO_0000218,2.2.15,1,F,Intermediate,,1,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,50587,N,,CHEMBL615340,,
116,726.0,Homo sapiens,BAO_0000219,HepG2,1,F,Intermediate,,1,Antiviral activity against HBV was determined in 2.215 cell line,81020,N,,CHEMBL615341,,
117,,Homo sapiens,BAO_0000251,,1,B,Autocuration,,0,Inhibition of 20-HETE synthesis in human renal microsomes,22226,U,,CHEMBL615342,,
118,,,BAO_0000019,,1,B,Autocuration,,0,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,22226,U,,CHEMBL615343,,
119,388.0,Homo sapiens,BAO_0000219,2008,1,F,Intermediate,,1,Inhibitory concentration against 2008 (ovarian) cells,80612,N,,CHEMBL615344,,
120,388.0,Homo sapiens,BAO_0000219,2008,1,F,Intermediate,,1,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,80612,N,,CHEMBL615345,,
121,388.0,Homo sapiens,BAO_0000219,2008,1,F,Intermediate,,1,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),80612,N,,CHEMBL615346,,
122,388.0,Homo sapiens,BAO_0000219,2008,1,F,Intermediate,,1,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,80612,N,,CHEMBL615347,,
123,388.0,Homo sapiens,BAO_0000219,2008,1,F,Intermediate,,1,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,80612,N,,CHEMBL615348,,
124,561.0,Homo sapiens,BAO_0000219,2008/R,1,F,Intermediate,,1,In vitro inhibition of 2008/R ovarian cancer cell line,80613,N,,CHEMBL827085,,
125,561.0,Homo sapiens,BAO_0000219,2008/R,1,F,Intermediate,,1,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,80613,N,,CHEMBL615349,,
126,389.0,Homo sapiens,BAO_0000219,2008/S,1,F,Intermediate,,1,In vitro inhibition of 2008/S ovarian cancer cell line,80614,N,,CHEMBL615350,,
127,389.0,Homo sapiens,BAO_0000219,2008/S,1,F,Intermediate,,1,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,80614,N,,CHEMBL615351,,
128,,Homo sapiens,BAO_0000220,,1,B,Expert,,2,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,100256,S,,CHEMBL615352,,
129,,Homo sapiens,BAO_0000220,,1,B,Intermediate,,2,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,100256,S,,CHEMBL615353,,
130,,,BAO_0000220,,1,B,Expert,,2,Inhibition of chymotrypsin-like activity of 20S proteasome,100256,S,,CHEMBL615354,,
131,,,BAO_0000220,,1,B,Expert,,2,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,100256,S,,CHEMBL615355,,
132,,,BAO_0000220,,1,B,Intermediate,,2,Inhibitory activity against 20S proteosome,100256,S,,CHEMBL615356,,
133,,Homo sapiens,BAO_0000019,,1,B,Autocuration,,0,Compound was tested for inhibitory activity against tryptase,22226,U,,CHEMBL615357,,
134,726.0,Homo sapiens,BAO_0000219,HepG2,1,F,Intermediate,,1,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,81020,N,,CHEMBL615358,,
135,726.0,Homo sapiens,BAO_0000219,HepG2,1,F,Intermediate,,1,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,81020,N,,CHEMBL827086,,
136,,,BAO_0000019,,1,B,Autocuration,,0,Compound was tested for the inhibition of Alpha-glucosidase,22226,U,,CHEMBL615359,,
137,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory concentration against human neutrophil elastase (HNE),235,H,,CHEMBL615360,,
138,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,,0,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,22226,U,,CHEMBL615361,948.0,
139,,,BAO_0000019,,1,F,Autocuration,,8,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,19640,H,,CHEMBL615362,,
140,,,BAO_0000019,,1,F,Expert,,8,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,19640,H,,CHEMBL615363,,
141,,,BAO_0000357,,1,B,Autocuration,,8,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,19640,H,,CHEMBL615364,,
142,,,BAO_0000019,,1,F,Expert,,8,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,19640,H,,CHEMBL615365,,
143,524.0,Mus musculus,BAO_0000219,P338,1,F,Intermediate,,1,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,80360,N,,CHEMBL615366,,
144,524.0,Mus musculus,BAO_0000219,P338,1,F,Intermediate,,1,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,80360,N,,CHEMBL615367,,
145,554.0,Homo sapiens,BAO_0000219,PBL,1,F,Intermediate,,1,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,80384,N,,CHEMBL615368,,
146,,Ovis aries,BAO_0000019,,1,F,Autocuration,,0,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,22226,U,,CHEMBL615369,,
147,,Ovis aries,BAO_0000019,,1,F,Autocuration,,0,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,22226,U,,CHEMBL615370,,
148,,,BAO_0000357,,1,B,Autocuration,,8,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),191,H,,CHEMBL615673,,
149,,Homo sapiens,BAO_0000019,,1,F,Autocuration,,0,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,22226,U,,CHEMBL615674,,
150,,Homo sapiens,BAO_0000019,,1,F,Autocuration,,0,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,22226,U,,CHEMBL615675,,
151,635.0,Homo sapiens,BAO_0000219,CCRF-CEM,1,F,Autocuration,,0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,22226,U,,CHEMBL615676,,
152,635.0,Homo sapiens,BAO_0000219,CCRF-CEM,1,F,Autocuration,,0,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,22226,U,,CHEMBL615677,,
153,635.0,Homo sapiens,BAO_0000219,CCRF-CEM,1,F,Autocuration,,0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,22226,U,,CHEMBL615678,,
154,635.0,Homo sapiens,BAO_0000219,CCRF-CEM,1,F,Autocuration,,0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,22226,U,,CHEMBL615679,,
155,,Homo sapiens,BAO_0000019,,1,F,Autocuration,,0,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,22226,U,,CHEMBL615680,,
156,,Homo sapiens,BAO_0000019,,1,F,Autocuration,,0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,22226,U,,CHEMBL615681,,
157,,,BAO_0000249,,1,B,Autocuration,,6,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,104290,H,,CHEMBL857972,,
158,,Streptococcus pyogenes,BAO_0000218,,1,F,Intermediate,,1,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,50264,N,,CHEMBL857899,,
159,,Human herpesvirus 3,BAO_0000218,,1,F,Intermediate,,1,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),50527,N,,CHEMBL615371,,
160,468.0,vericilla zoster virus,BAO_0000218,HEL,1,F,Expert,,1,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,50527,N,,CHEMBL615372,,
161,,vericilla zoster virus,BAO_0000218,,1,F,Intermediate,,1,Antiviral activity against 07/1 strain of VZV; ND: No data,50527,N,,CHEMBL615373,,
162,,vericilla zoster virus,BAO_0000218,,1,F,Intermediate,,1,Antiviral activity against 07/1 strain of VZV; ND=No data,50527,N,,CHEMBL615374,,
163,,escherichia cloac,BAO_0000218,,1,F,Intermediate,,1,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",50145,N,,CHEMBL615375,,
164,,,BAO_0000019,,1,B,Autocuration,,0,Ratio of Ki at A2 to Ki at A1 receptors,22226,U,,CHEMBL615376,,
165,,Candida albicans,BAO_0000249,,1,B,Expert,,8,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",11143,H,,CHEMBL615377,,
166,,Candida glabrata CBS 138,BAO_0000357,,1,B,Expert,,8,"Inhibition of 1,3-beta-glucan synthase",18077,H,,CHEMBL615378,,
167,832.0,Homo sapiens,BAO_0000219,1-87 tumor cell line,1,F,Intermediate,,1,Inhibition of growth of 1-87 human tumor cell line,80609,N,,CHEMBL615379,,
168,,Rattus norvegicus,BAO_0000219,,1,B,Expert,,9,Inhibition of 1-lipoxygenase (LOX)in RBL cells,12166,D,,CHEMBL615380,,
169,,Glycine max,BAO_0000357,,1,B,Autocuration,,9,Inhibitory activity against soybean 1-lipoxygenase (SLO),100171,D,,CHEMBL615381,,
170,,Glycine max,BAO_0000357,,1,B,Autocuration,,9,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,100171,D,,CHEMBL615382,,
171,,Glycine max,BAO_0000357,,1,B,Autocuration,,9,% inhibition against soybean 1-lipoxygenase (SLO),100171,D,,CHEMBL615383,,
172,,Glycine max,BAO_0000357,,1,B,Autocuration,,9,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,100171,D,,CHEMBL615384,,
173,,Glycine max,BAO_0000357,,1,B,Autocuration,,9,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,100171,D,,CHEMBL615385,,
174,,Glycine max,BAO_0000357,,1,B,Autocuration,,9,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,100171,D,,CHEMBL615386,,
175,,Glycine max,BAO_0000357,,1,B,Autocuration,,9,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,100171,D,,CHEMBL615387,,
176,,Glycine max,BAO_0000357,,1,B,Autocuration,,9,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,100171,D,,CHEMBL615388,,
177,,Glycine max,BAO_0000357,,1,B,Autocuration,,9,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,100171,D,,CHEMBL615214,,
178,,Glycine max,BAO_0000357,,1,B,Autocuration,,9,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,100171,D,,CHEMBL827087,,
179,,Glycine max,BAO_0000357,,1,B,Autocuration,,9,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,100171,D,,CHEMBL615215,,
180,,Glycine max,BAO_0000357,,1,B,Autocuration,,9,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,100171,D,,CHEMBL615216,,
181,,Glycine max,BAO_0000357,,1,B,Autocuration,,9,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,100171,D,,CHEMBL615217,,
182,,Glycine max,BAO_0000357,,1,B,Autocuration,,9,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,100171,D,,CHEMBL615218,,
183,,Glycine max,BAO_0000357,,1,B,Autocuration,,9,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,100171,D,,CHEMBL615219,,
184,,Mus musculus,BAO_0000019,,1,B,Autocuration,,0,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,22226,U,,CHEMBL615220,,
185,294.0,Mus musculus,BAO_0000219,C3H 10T1/2,1,F,Intermediate,,1,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),80049,N,,CHEMBL615221,,
186,,,BAO_0000019,,1,F,Intermediate,,0,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,22226,U,,CHEMBL615222,,
187,,,BAO_0000357,,1,B,Autocuration,,8,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),11489,H,,CHEMBL615223,,
188,,,BAO_0000357,,1,B,Autocuration,,8,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),11862,H,,CHEMBL615224,,
189,,,BAO_0000357,,1,B,Autocuration,,8,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,11862,H,,CHEMBL615225,,
190,,,BAO_0000357,,1,B,Autocuration,,8,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,11489,H,,CHEMBL615226,,
191,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,11862,H,,CHEMBL615227,,
192,,Bos taurus,BAO_0000019,,1,F,Expert,,9,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,12347,D,,CHEMBL615228,,
193,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,100120,D,,CHEMBL615229,,
194,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Inhibition of 11 beta-hydroxylase from rat adrenal gland,100120,D,,CHEMBL615230,2369.0,
195,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Inhibition of rat adrenal 11-beta-hydroxylase,100120,D,,CHEMBL615231,,
196,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Inhibition of rat adrenal 11-beta-hydroxylase,100120,D,,CHEMBL884520,,
197,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,100120,D,,CHEMBL615232,,
198,,,BAO_0000019,,1,B,Autocuration,,8,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,10328,H,,CHEMBL615233,,
199,,,BAO_0000357,,1,B,Autocuration,,8,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,11490,H,,CHEMBL827088,,
200,,,BAO_0000357,,1,B,Autocuration,,8,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,11490,H,,CHEMBL615234,,
201,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for the percent of inhibition against 12-LO at 10 uM,11134,H,,CHEMBL615235,,
202,,,BAO_0000019,,1,B,Autocuration,,8,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,12052,H,,CHEMBL615236,,
203,,,BAO_0000019,,1,B,Autocuration,,8,Compound was tested in vitro for inhibition of 12-LO human platelet,11134,H,,CHEMBL615237,,
204,,,BAO_0000019,,1,F,Autocuration,,8,Inhibitory concentration against human platelet 12-lipoxygenase,11134,H,,CHEMBL615238,,
205,,,BAO_0000019,,1,B,Autocuration,,8,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,11134,H,,CHEMBL615239,,
206,,Homo sapiens,BAO_0000019,,1,F,Autocuration,,9,Inhibitory concentration against human platelet 12-lipoxygenase,11134,D,,CHEMBL615240,,
207,,,BAO_0000019,,1,B,Expert,,8,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,11835,H,,CHEMBL615241,,
208,,,BAO_0000357,,1,B,Expert,,8,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,11601,H,,CHEMBL615242,,
209,,,BAO_0000019,,1,B,Autocuration,,8,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),11134,H,,CHEMBL615243,,
210,,,BAO_0000019,,1,B,Autocuration,,8,Inhibitory activity against human platelet 12-lipoxygenase,11134,H,,CHEMBL615244,,
211,,,BAO_0000019,,1,B,Autocuration,,8,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,11134,H,,CHEMBL615245,,
212,,,BAO_0000019,,1,B,Autocuration,,8,% inhibition against human platelet 12-lipoxygenase (12-HLO),11134,H,,CHEMBL615246,,
213,,,BAO_0000019,,1,B,Autocuration,,8,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,11134,H,,CHEMBL615247,,
214,,,BAO_0000019,,1,B,Autocuration,,8,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,11134,H,,CHEMBL615248,,
215,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity towards porcine 12-lipoxygenase,11601,H,,CHEMBL615249,,
216,,,BAO_0000357,,1,B,Autocuration,,8,Tested for inhibition against porcine 12-LO,11601,H,,CHEMBL615250,,
217,,,BAO_0000019,,1,B,Autocuration,,8,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,12052,H,,CHEMBL615251,,
218,,,BAO_0000019,,1,B,Autocuration,,8,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,12052,H,,CHEMBL615252,,
219,,,BAO_0000019,,1,B,Expert,,8,In vitro inhibition of rat platelet 12-lipoxygenase,12052,H,,CHEMBL828340,,
220,,,BAO_0000019,,1,B,Autocuration,,8,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,12052,H,,CHEMBL615253,,
221,,,BAO_0000019,,1,B,Autocuration,,8,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,12052,H,,CHEMBL615254,,
222,,,BAO_0000019,,1,B,Autocuration,,8,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,12052,H,,CHEMBL615255,,
223,,,BAO_0000019,,1,B,Autocuration,,8,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,12052,H,,CHEMBL615256,,
224,,,BAO_0000019,,1,B,Autocuration,,8,In vitro inhibitory activity against rat platelet 12-lipoxygenase,12052,H,,CHEMBL615257,,
225,,,BAO_0000019,,1,B,Autocuration,,8,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,12052,H,,CHEMBL615258,,
226,621.0,Homo sapiens,BAO_0000219,41M,1,F,Intermediate,,1,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,80007,N,,CHEMBL615259,,
227,621.0,Homo sapiens,BAO_0000219,41M,1,F,Expert,,1,In vitro antitumor activity against 41M cell line.,80007,N,,CHEMBL615260,,
228,621.0,Homo sapiens,BAO_0000219,41M,1,F,Intermediate,,1,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,80007,N,,CHEMBL615261,,
229,621.0,Homo sapiens,BAO_0000219,41M,1,F,Intermediate,,1,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,80007,N,,CHEMBL615262,,
230,621.0,Homo sapiens,BAO_0000219,41M,1,F,Expert,,1,In vitro antitumor activity against 41McisR cell line.,80007,N,,CHEMBL615263,,
231,621.0,Homo sapiens,BAO_0000219,41M,1,F,Expert,,1,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,80007,N,,CHEMBL838393,,
232,621.0,Homo sapiens,BAO_0000219,41M,1,F,Intermediate,,1,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,80007,N,,CHEMBL615264,,
233,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),84,D,,CHEMBL615265,,
234,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),68,D,,CHEMBL615266,,
235,,,BAO_0000357,,1,B,Expert,,8,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),68,H,,CHEMBL615267,,
236,,,BAO_0000357,,1,B,Expert,,8,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,10201,H,,CHEMBL615268,,
237,,,BAO_0000357,,1,B,Expert,,8,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,10201,H,,CHEMBL615269,,
238,,,BAO_0000357,,1,B,Expert,,8,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,10201,H,,CHEMBL615270,,
239,,,BAO_0000357,,1,B,Autocuration,,8,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",12220,H,,CHEMBL615271,,
240,,Escherichia coli,BAO_0000357,,1,B,Autocuration,,8,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",11303,H,,CHEMBL615272,,
241,,Escherichia coli,BAO_0000357,,1,B,Autocuration,,8,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",11303,H,,CHEMBL615103,,
242,,Escherichia coli,BAO_0000357,,1,B,Autocuration,,8,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",11303,H,,CHEMBL615104,,
243,,,BAO_0000357,,1,B,Autocuration,,8,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",12220,H,,CHEMBL615105,,
244,,,BAO_0000357,,1,B,Autocuration,,8,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",12220,H,,CHEMBL872866,,
245,,Sus scrofa,BAO_0000357,,1,B,Autocuration,,8,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",11303,H,,CHEMBL615106,,
246,,Sus scrofa,BAO_0000019,,1,B,Autocuration,,8,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",11303,H,,CHEMBL615107,,
247,,Sus scrofa,BAO_0000357,,1,B,Autocuration,,8,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",11303,H,,CHEMBL615108,,
248,,Sus scrofa,BAO_0000357,,1,B,Autocuration,,8,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",11303,H,,CHEMBL615109,,
249,,Sus scrofa,BAO_0000357,,1,B,Autocuration,,8,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",11303,H,,CHEMBL615110,,
250,,Sus scrofa,BAO_0000019,,1,B,Autocuration,,8,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",11303,H,,CHEMBL840105,,
251,,Sus scrofa,BAO_0000019,,1,B,Autocuration,,8,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",11303,H,,CHEMBL615111,,
252,,Sus scrofa,BAO_0000019,,1,B,Autocuration,,8,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",11303,H,,CHEMBL615112,,
253,,Sus scrofa,BAO_0000019,,1,B,Autocuration,,8,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",11303,H,,CHEMBL615113,,
254,,Sus scrofa,BAO_0000019,,1,B,Autocuration,,8,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",11303,H,,CHEMBL615114,,
255,,Sus scrofa,BAO_0000357,,1,B,Autocuration,,8,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",11303,H,,CHEMBL615115,,
256,,Sus scrofa,BAO_0000019,,1,B,Autocuration,,8,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",11303,H,,CHEMBL615116,,
257,,,BAO_0000357,,1,B,Autocuration,,8,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",11303,H,,CHEMBL615698,,
258,,Sus scrofa,BAO_0000019,,1,B,Autocuration,,0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",22226,U,,CHEMBL615699,,
259,,Sus scrofa,BAO_0000019,,1,B,Autocuration,,0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",22226,U,,CHEMBL615700,,
260,,Saccharomyces cerevisiae,BAO_0000357,,1,B,Expert,,8,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,100249,H,,CHEMBL615701,,
261,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,0,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,22226,U,,CHEMBL615702,,
262,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,0,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,22226,U,,CHEMBL615703,,
263,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,0,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",22226,U,,CHEMBL615704,,
264,,,BAO_0000019,,1,F,Autocuration,,6,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",104698,H,,CHEMBL615705,,
265,,,BAO_0000019,,1,F,Autocuration,,6,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",104698,H,,CHEMBL615706,,
266,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,20033,D,,CHEMBL615707,2116.0,
267,,,BAO_0000019,,1,F,Expert,,8,Stimulatory activity of intragastric pressure was tested in the rat,10623,H,,CHEMBL615708,,
268,,,BAO_0000357,,1,B,Autocuration,,8,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,121,H,,CHEMBL615709,,
269,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,,0,Dose to reduce neuronal firing against 5-HT cells in rats (iv),22226,U,,CHEMBL615710,,
270,,,BAO_0000019,,1,F,Autocuration,,8,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,12688,H,,CHEMBL615711,,
271,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,121,D,,CHEMBL615712,,
272,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,121,D,,CHEMBL836325,,
273,,,BAO_0000019,,1,F,Autocuration,,8,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,12198,H,,CHEMBL615713,,
274,,,BAO_0000357,,1,B,Autocuration,,8,Inhibition constant of high-affinity 5-HT uptake,12198,H,,CHEMBL615714,,
275,,,BAO_0000019,,1,F,Autocuration,,8,Michaelis-Menten constant was reported for high affinity transport of 5-HT,12198,H,,CHEMBL615715,,
276,,,BAO_0000019,,1,F,Autocuration,,8,Maximum rate was determined for high affinity transport of 5-HT,12198,H,,CHEMBL615716,,
277,,,BAO_0000019,,1,F,Autocuration,,4,Compound was tested for agonistic activity against 5-HT uptake,104714,H,,CHEMBL615717,,
278,,,BAO_0000019,,1,B,Expert,,8,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,10577,H,,CHEMBL881818,,
279,,Bos taurus,BAO_0000357,,1,B,Expert,,8,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,105,H,,CHEMBL884540,,
280,,Rattus norvegicus,BAO_0000224,,1,B,Autocuration,,5,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,104744,D,,CHEMBL615718,,
281,,,BAO_0000224,,1,B,Autocuration,,4,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,104744,H,,CHEMBL615719,,
282,,,BAO_0000249,,1,B,Autocuration,,4,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,104744,H,,CHEMBL615720,,
283,,,BAO_0000249,,1,B,Autocuration,,4,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,104744,H,,CHEMBL615721,,
284,,,BAO_0000019,,1,B,Autocuration,,4,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,H,,CHEMBL615722,,
285,,,BAO_0000019,,1,F,Autocuration,,8,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,51,H,,CHEMBL615723,,
286,,,BAO_0000221,,1,B,Autocuration,,8,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,H,,CHEMBL615724,10000000.0,
287,,,BAO_0000221,,1,B,Autocuration,,8,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,51,H,,CHEMBL615725,10000000.0,
288,,,BAO_0000221,,1,B,Autocuration,,8,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,H,,CHEMBL615726,10000000.0,
289,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),10576,H,,CHEMBL615727,,
290,,Cavia porcellus,BAO_0000019,,1,F,Intermediate,,9,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,105570,D,,CHEMBL615728,,
291,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,279,H,,CHEMBL857971,,
292,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL615729,,
293,,Rattus norvegicus,BAO_0000019,,1,F,Expert,,9,Efficacy against 5-hydroxytryptamine 2A receptor,12687,D,,CHEMBL615730,,
294,,,BAO_0000019,,1,F,Expert,,8,Intrinsic activity towards 5-HT2A receptor of rat tail artery,12687,H,,CHEMBL615731,,
295,,,BAO_0000019,,1,F,Expert,,8,Relative potency towards 5-HT2A receptor of rat tail artery,12687,H,,CHEMBL615732,,
296,,,BAO_0000019,,1,F,Expert,,8,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,12687,H,,CHEMBL615733,,
297,,,BAO_0000019,,1,F,Expert,,8,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,12687,H,,CHEMBL615734,,
298,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,12687,H,,CHEMBL615735,,
299,,,BAO_0000019,,1,F,Expert,,8,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,12687,H,,CHEMBL615736,,
300,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,20033,D,,CHEMBL615737,2116.0,
301,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),20033,D,,CHEMBL615738,2116.0,
302,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,20033,D,,CHEMBL615739,2116.0,
303,,,BAO_0000357,,1,B,Autocuration,,8,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,10623,H,,CHEMBL615278,,
304,,Rattus norvegicus,BAO_0000019,,1,F,Expert,,9,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,10623,D,,CHEMBL615279,,
305,,,BAO_0000357,,1,B,Expert,,8,Binding affinity against 5-hydroxytryptamine 4 receptor,168,H,,CHEMBL615280,,
306,,Gallus gallus,BAO_0000019,,1,B,Autocuration,,0,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,22226,U,,CHEMBL615281,,
307,,Homo sapiens,BAO_0000019,,1,F,Autocuration,,0,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,22226,U,,CHEMBL615282,,
308,,Homo sapiens,BAO_0000019,,1,F,Autocuration,,0,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,22226,U,,CHEMBL615283,,
309,649.0,Homo sapiens,BAO_0000219,HL-60,1,B,Autocuration,,1,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,80156,N,,CHEMBL615284,,
310,,Homo sapiens,BAO_0000019,,1,B,Autocuration,,0,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,22226,U,,CHEMBL615285,,
311,,Homo sapiens,BAO_0000019,,1,B,Autocuration,,0,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,22226,U,,CHEMBL615286,,
312,,Homo sapiens,BAO_0000219,Oocytes,1,B,Autocuration,,7,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,104703,D,,CHEMBL615287,,
313,,,BAO_0000220,,1,F,Intermediate,,2,Chymotryptic inhibitory activity against 26S proteasome,100256,S,,CHEMBL615288,,
314,,,BAO_0000220,,1,B,Intermediate,,2,Inhibitory activity against 26S proteasome degradation of IkB,100256,S,,CHEMBL615289,,
315,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro inhibition of 2780/DOX ovarian cancer cell line,81034,N,,CHEMBL615290,,
316,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro inhibition of 2780/S ovarian cancer cell line,81034,N,,CHEMBL884522,,
317,,Homo sapiens,BAO_0000019,,1,F,Autocuration,,0,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,22226,U,,CHEMBL615291,,
318,,,BAO_0000225,,1,B,Intermediate,,3,Association constant for binding to AATT 28-mer AATT hairpin,22222,M,,CHEMBL615292,,
319,,,BAO_0000225,,1,B,Intermediate,,3,Kinetically Defined Association Constant for 28-mer AATT hairpin.,22222,M,,CHEMBL615293,,
320,,,BAO_0000225,,1,B,Intermediate,,3,Reaction Rate Parameter for 28-mer AATT hairpin,22222,M,,CHEMBL615294,,
321,,,BAO_0000225,,1,B,Intermediate,,3,Reaction Rate Parameter for 28-mer AATT hairpin,22222,M,,CHEMBL615295,,
322,,Homo sapiens,BAO_0000019,,1,F,Autocuration,,0,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),22226,U,,CHEMBL825021,,
323,,Homo sapiens,BAO_0000019,,1,F,Autocuration,,0,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),22226,U,,CHEMBL615296,,
324,,Homo sapiens,BAO_0000019,,1,F,Autocuration,,0,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,22226,U,,CHEMBL615297,,
325,,Cricetulus griseus,BAO_0000019,,1,F,Autocuration,,0,Cytotoxicity against cell line 2SC/20 determined by MTT test,22226,U,,CHEMBL615298,,
326,,Cricetulus griseus,BAO_0000019,,1,F,Autocuration,,0,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,22226,U,,CHEMBL615299,,
327,,Cricetulus griseus,BAO_0000019,,1,F,Autocuration,,0,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,22226,U,,CHEMBL615300,,
328,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,241,H,,CHEMBL615301,,
329,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,241,D,,CHEMBL615302,,
330,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,0,Selectivity ratio of ID50 in liver and heart,22226,U,,CHEMBL615303,,
331,,,BAO_0000019,,1,B,Autocuration,,8,"Selectivity, ratio of relative ID50 in liver and heart",12132,H,,CHEMBL615304,,
332,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,12132,H,,CHEMBL615305,,
333,,,BAO_0000218,,1,B,Autocuration,,8,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,H,,CHEMBL615306,,
334,,,BAO_0000218,,1,B,Autocuration,,8,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,H,,CHEMBL615307,,
335,,,BAO_0000218,,1,B,Autocuration,In vivo,8,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,H,,CHEMBL615308,,
336,,,BAO_0000218,,1,F,Autocuration,In vivo,8,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,H,,CHEMBL615309,,
337,,,BAO_0000019,,1,B,Autocuration,,0,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",22226,U,,CHEMBL615310,,
338,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,12132,H,,CHEMBL615311,,
339,,Homo sapiens,BAO_0000019,,1,B,Autocuration,,0,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",22226,U,,CHEMBL615312,,
340,,,BAO_0000019,,1,B,Autocuration,,8,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,12132,H,,CHEMBL615313,,
341,,,BAO_0000019,,1,F,Autocuration,,8,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,12132,H,,CHEMBL615314,,
342,,,BAO_0000019,,1,B,Autocuration,,8,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",12132,H,,CHEMBL615315,,
343,,Rattus norvegicus,BAO_0000218,,1,B,Autocuration,,0,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",22226,U,,CHEMBL615316,,
344,,,BAO_0000218,,1,B,Autocuration,In vivo,8,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,12132,H,,CHEMBL615317,,
345,,,BAO_0000218,,1,B,Autocuration,,8,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,H,,CHEMBL615318,,
346,,Rattus norvegicus,BAO_0000218,,1,B,Autocuration,,0,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",22226,U,,CHEMBL615319,,
347,,,BAO_0000019,,1,B,Autocuration,,8,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",12132,H,,CHEMBL615320,,
348,,,BAO_0000019,,1,F,Autocuration,,8,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",12132,H,,CHEMBL615321,,
349,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,0,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",22226,U,,CHEMBL615322,,
350,,Escherichia coli,BAO_0000357,,1,B,Autocuration,,8,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,19690,H,,CHEMBL615323,,
351,,Escherichia coli,BAO_0000357,,1,B,Autocuration,,8,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,19690,H,,CHEMBL615407,,
352,,Escherichia coli,BAO_0000357,,1,B,Autocuration,,8,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,19690,H,,CHEMBL857267,,
353,,Escherichia coli,BAO_0000357,,1,B,Autocuration,,8,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,19690,H,,CHEMBL615408,,
354,,,BAO_0000357,,1,B,Autocuration,,8,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,19690,H,,CHEMBL615409,,
355,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,19690,H,,CHEMBL615410,,
356,,,BAO_0000357,,1,B,Autocuration,,8,Inhibition constant against 3-dehydroquinate synthase,19690,H,,CHEMBL615411,,
357,,,BAO_0000357,,1,B,Autocuration,,8,Association rate constant against 3-dehydroquinate synthase,19690,H,,CHEMBL615412,,
358,,,BAO_0000357,,1,B,Autocuration,,8,Rate constant against 3-dehydroquinate synthase,19690,H,,CHEMBL615413,,
359,,,BAO_0000019,,1,B,Autocuration,,0,Inhibitory activity against fuc-TVII,22226,U,,CHEMBL615414,,
360,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,9,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,D,,CHEMBL615415,2107.0,
361,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,9,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,D,,CHEMBL615416,2107.0,
362,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,9,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,D,,CHEMBL615417,2107.0,
363,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,9,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,D,,CHEMBL615418,2107.0,
364,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,9,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,D,,CHEMBL615419,2107.0,
365,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,9,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,12236,D,,CHEMBL615420,2107.0,
366,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,9,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,12236,D,,CHEMBL615421,2107.0,
367,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,9,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,12236,D,,CHEMBL615422,2107.0,
368,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,9,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,12236,D,,CHEMBL615423,2107.0,
369,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,9,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,12236,D,,CHEMBL872868,2107.0,
370,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,9,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,12236,D,,CHEMBL615424,2107.0,
371,,,BAO_0000224,,1,B,Autocuration,,4,Inhibitory activity against 3-phosphoglycerate kinase.,104832,H,,CHEMBL825022,,
372,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,104832,H,,CHEMBL615425,,
373,,,BAO_0000224,,1,B,Autocuration,,4,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",104832,H,,CHEMBL615426,,
374,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,10612,D,,CHEMBL615427,,
375,844.0,Homo sapiens,BAO_0000219,3677 melanoma cell line,1,F,Intermediate,,1,Cytotoxicity on 3677 melanoma cells,80616,N,,CHEMBL615428,,
376,844.0,Homo sapiens,BAO_0000219,3677 melanoma cell line,1,F,Intermediate,,1,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,80616,N,,CHEMBL615429,,
377,700.0,Mus musculus,BAO_0000219,MC-38,1,F,Intermediate,,1,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,80617,N,,CHEMBL615430,,
378,,Homo sapiens,BAO_0000019,,1,F,Intermediate,,0,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,22226,U,,CHEMBL615431,,
379,798.0,,BAO_0000218,B16,1,F,Autocuration,,0,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,22226,U,,CHEMBL615432,,
380,798.0,,BAO_0000218,B16,1,F,Autocuration,,0,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,22226,U,,CHEMBL615433,,
381,,Human rhinovirus 14,BAO_0000019,,1,F,Expert,,9,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,12464,D,,CHEMBL615434,,
382,,Human rhinovirus sp.,BAO_0000218,,1,F,Intermediate,,1,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,50085,N,,CHEMBL615435,,
383,,human rhinovirus type 14,BAO_0000218,,1,F,Intermediate,,1,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,50679,N,,CHEMBL615436,,
384,,human rhinovirus type 14,BAO_0000218,,1,F,Intermediate,,1,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,50679,N,,CHEMBL615437,,
385,,Human rhinovirus 14,BAO_0000019,,1,F,Expert,,9,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12464,D,,CHEMBL615438,,
386,,Human rhinovirus 14,BAO_0000019,,1,F,Expert,,9,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12464,D,,CHEMBL615439,,
387,,Human rhinovirus 14,BAO_0000019,,1,F,Expert,,9,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12464,D,,CHEMBL615440,,
388,,Human rhinovirus 14,BAO_0000019,,1,F,Expert,,9,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,12464,D,,CHEMBL615441,,
389,,Enterovirus,BAO_0000218,,1,F,Intermediate,,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,50665,N,,CHEMBL615641,,
390,,Enterovirus,BAO_0000218,,1,F,Intermediate,,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,50665,N,,CHEMBL872065,,
391,,Enterovirus,BAO_0000218,,1,F,Intermediate,,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,50665,N,,CHEMBL825023,,
392,,Enterovirus,BAO_0000218,,1,F,Intermediate,,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,50665,N,,CHEMBL615642,,
393,,Human rhinovirus B,BAO_0000357,,1,B,Expert,,8,Inhibition of human rhinovirus 3C protease,12464,H,,CHEMBL615643,,
394,,Homo sapiens,BAO_0000019,,1,B,Autocuration,,0,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,22226,U,,CHEMBL615644,,
395,833.0,Mus musculus,BAO_0000218,3EM 37,1,F,Intermediate,,1,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),80619,N,,CHEMBL615645,,
396,833.0,Mus musculus,BAO_0000218,3EM 37,1,F,Intermediate,,1,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),80619,N,,CHEMBL615646,,
397,833.0,Mus musculus,BAO_0000218,3EM 37,1,F,Intermediate,,1,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),80619,N,,CHEMBL615647,,
398,833.0,Mus musculus,BAO_0000218,3EM 37,1,F,Intermediate,,1,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),80619,N,,CHEMBL615648,,
399,833.0,Mus musculus,BAO_0000218,3EM 37,1,F,Intermediate,,1,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,80619,N,,CHEMBL615649,,
400,833.0,Mus musculus,BAO_0000218,3EM 37,1,F,Intermediate,,1,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,80619,N,,CHEMBL615650,,
401,847.0,Mus musculus,BAO_0000218,3LL cell line,1,F,Intermediate,,1,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,80620,N,,CHEMBL615651,,
402,847.0,Mus musculus,BAO_0000218,3LL cell line,1,F,Intermediate,,1,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,80620,N,,CHEMBL615652,,
403,847.0,Mus musculus,BAO_0000218,3LL cell line,1,F,Expert,,1,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,80620,N,,CHEMBL615653,,
404,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,80620,N,,CHEMBL615654,,
405,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,80620,N,,CHEMBL615655,,
406,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,80620,N,,CHEMBL825024,,
407,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,80620,N,,CHEMBL615656,,
408,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,80620,N,,CHEMBL615657,,
409,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,80620,N,,CHEMBL615658,,
410,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,80620,N,,CHEMBL615659,,
411,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,80620,N,,CHEMBL615660,,
412,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,80620,N,,CHEMBL615661,,
413,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,80620,N,,CHEMBL615662,,
414,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,80620,N,,CHEMBL615663,,
415,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,80620,N,,CHEMBL615664,,
416,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,80620,N,,CHEMBL615665,,
417,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,80620,N,,CHEMBL615666,,
418,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,80620,N,,CHEMBL615667,,
419,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,80620,N,,CHEMBL615668,,
420,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,80620,N,,CHEMBL615669,,
421,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,80620,N,,CHEMBL615670,,
422,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,80620,N,,CHEMBL836739,,
423,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,80620,N,,CHEMBL615671,,
424,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,80620,N,,CHEMBL615672,,
425,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,80620,N,,CHEMBL615791,,
426,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,spermine levels in 3LL cells after the treatment of 1 uM of Compound,80620,N,,CHEMBL615792,,
427,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,spermine levels in 3LL cells after the treatment of 10 uM of Compound,80620,N,,CHEMBL615793,,
428,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,spermine levels in 3LL cells after the treatment of 250 uM of Compound,80620,N,,CHEMBL615794,,
429,847.0,Mus musculus,BAO_0000219,3LL cell line,1,F,Intermediate,,1,spermine levels in 3LL cells after the treatment of 50 uM of Compound,80620,N,,CHEMBL615795,,
430,971.0,Homo sapiens,BAO_0000219,3LLD122,1,F,Intermediate,,1,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,80621,N,,CHEMBL615590,,
431,,,BAO_0000218,,1,F,Autocuration,,0,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,22226,U,,CHEMBL615591,,
432,,,BAO_0000218,,1,F,Autocuration,,0,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,22226,U,,CHEMBL615592,,
433,,,BAO_0000218,,1,F,Autocuration,,0,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,22226,U,,CHEMBL615593,,
434,,,BAO_0000218,,1,F,Autocuration,,0,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,22226,U,,CHEMBL615594,,
435,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,80951,N,,CHEMBL615595,,
436,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,80951,N,,CHEMBL615596,,
437,723.0,,BAO_0000219,NIH3T3,1,F,Expert,,8,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,11169,H,,CHEMBL615597,,
438,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,80951,N,,CHEMBL615598,,
439,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,80951,N,,CHEMBL615599,,
440,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Expert,,1,Effective dose against murine 3T3 fibroblasts cells,80951,N,,CHEMBL615600,,
441,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Expert,,1,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,80951,N,,CHEMBL615601,,
442,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Expert,,1,Cytotoxic effect on 3T3 cells,80951,N,,CHEMBL615602,,
443,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Expert,,1,Cytotoxic effect on 3T3 cells,80951,N,,CHEMBL615603,,
444,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,80951,N,,CHEMBL615604,,
445,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,80951,N,,CHEMBL615605,,
446,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,80951,N,,CHEMBL615606,,
447,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Expert,,1,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,80951,N,,CHEMBL884526,,
448,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Expert,,1,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,80951,N,,CHEMBL615607,,
449,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,80951,N,,CHEMBL615608,,
450,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Expert,,1,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,80951,N,,CHEMBL615609,,
451,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Expert,,1,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,80951,N,,CHEMBL615682,,
452,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,80951,N,,CHEMBL615683,,
453,723.0,Mus musculus,BAO_0000218,NIH3T3,1,F,Expert,,1,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,80951,N,,CHEMBL615684,,
454,,Mus musculus,BAO_0000219,,1,F,Autocuration,,7,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,104860,D,,CHEMBL615685,,
455,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Expert,,1,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,80951,N,,CHEMBL615686,,
456,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,Inhibitory activity against 3T3 cell line,80951,N,,CHEMBL615687,,
457,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,80951,N,,CHEMBL884523,,
458,,,BAO_0000019,,1,F,Expert,,8,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,11169,H,,CHEMBL615688,,
459,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,80951,N,,CHEMBL615689,,
460,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,80951,N,,CHEMBL615690,,
461,,,BAO_0000019,,1,F,Expert,,8,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,11169,H,,CHEMBL615691,,
462,,,BAO_0000019,,1,F,Expert,,8,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,11169,H,,CHEMBL615692,,
463,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,80951,N,,CHEMBL615693,,
464,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Expert,,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,80951,N,,CHEMBL615324,,
465,723.0,Homo sapiens,BAO_0000219,NIH3T3,1,F,Expert,,9,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,9,D,,CHEMBL615325,,
466,723.0,Homo sapiens,BAO_0000219,NIH3T3,1,F,Expert,,9,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),9,D,,CHEMBL615490,,
467,723.0,Homo sapiens,BAO_0000219,NIH3T3,1,F,Expert,,9,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,188,D,,CHEMBL615491,,
468,723.0,Homo sapiens,BAO_0000219,NIH3T3,1,F,Expert,,9,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),188,D,,CHEMBL615492,,
469,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,80951,N,,CHEMBL615493,,
470,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,80951,N,,CHEMBL615494,,
471,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,80951,N,,CHEMBL615495,,
472,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,Inhibitory concentration was calculated on 3T3 cells by using growth assay,80951,N,,CHEMBL615496,,
473,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,80951,N,,CHEMBL615497,,
474,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Expert,,1,Inhibition of Swiss 3T3 mouse fibroblast proliferation,80951,N,,CHEMBL615498,,
475,723.0,Mus musculus,BAO_0000219,NIH3T3,1,A,Intermediate,,1,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,80951,N,,CHEMBL615499,,
476,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Expert,,1,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,80951,N,,CHEMBL835522,,
477,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,80951,N,,CHEMBL615500,,
478,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,N,,CHEMBL615501,,
479,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,N,,CHEMBL615502,,
480,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,N,,CHEMBL615503,,
481,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,N,,CHEMBL615504,,
482,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,N,,CHEMBL615505,,
483,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Expert,,1,Inhibition of swiss 3T3 mouse fibroblast proliferation,80951,N,,CHEMBL615506,,
484,723.0,Mus musculus,BAO_0000219,NIH3T3,1,F,Intermediate,,1,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,80951,N,,CHEMBL615507,,
485,620.0,,BAO_0000218,3T3-L1,1,F,Intermediate,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,80006,N,,CHEMBL615508,,
486,620.0,Mus musculus,BAO_0000219,3T3-L1,1,F,Intermediate,,1,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,80006,N,,CHEMBL615509,,
487,620.0,Mus musculus,BAO_0000219,3T3-L1,1,F,Intermediate,,1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,80006,N,,CHEMBL615510,,
488,620.0,Mus musculus,BAO_0000219,3T3-L1,1,F,Intermediate,,1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,80006,N,,CHEMBL615511,,
489,620.0,Mus musculus,BAO_0000219,3T3-L1,1,F,Intermediate,,1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,80006,N,,CHEMBL615512,,
490,620.0,Mus musculus,BAO_0000218,3T3-L1,1,F,Intermediate,,1,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",80006,N,,CHEMBL615513,,
491,620.0,Mus musculus,BAO_0000218,3T3-L1,1,F,Intermediate,,1,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",80006,N,,CHEMBL615514,,
492,620.0,,BAO_0000219,3T3-L1,1,F,Intermediate,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,80006,N,,CHEMBL615515,,
493,620.0,,BAO_0000219,3T3-L1,1,F,Intermediate,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,80006,N,,CHEMBL615516,,
494,620.0,,BAO_0000219,3T3-L1,1,F,Intermediate,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,80006,N,,CHEMBL615517,,
495,620.0,,BAO_0000219,3T3-L1,1,F,Intermediate,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,80006,N,,CHEMBL615518,,
496,620.0,,BAO_0000219,3T3-L1,1,F,Intermediate,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,80006,N,,CHEMBL615519,,
497,620.0,,BAO_0000218,3T3-L1,1,F,Intermediate,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,80006,N,,CHEMBL615520,,
498,620.0,,BAO_0000218,3T3-L1,1,F,Intermediate,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,80006,N,,CHEMBL615521,,
499,620.0,,BAO_0000218,3T3-L1,1,F,Intermediate,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,80006,N,,CHEMBL615522,,
500,620.0,,BAO_0000218,3T3-L1,1,F,Intermediate,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,80006,N,,CHEMBL615523,,
501,620.0,,BAO_0000218,3T3-L1,1,F,Expert,,1,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,80006,N,,CHEMBL615524,,
502,620.0,,BAO_0000218,3T3-L1,1,F,Expert,,1,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,80006,N,,CHEMBL615525,,
503,620.0,,BAO_0000218,3T3-L1,1,F,Intermediate,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,80006,N,,CHEMBL615526,,
504,620.0,,BAO_0000218,3T3-L1,1,F,Intermediate,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,80006,N,,CHEMBL615527,,
505,620.0,,BAO_0000218,3T3-L1,1,F,Intermediate,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,80006,N,,CHEMBL615528,,
506,620.0,,BAO_0000218,3T3-L1,1,F,Expert,,1,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,80006,N,,CHEMBL615529,,
507,620.0,,BAO_0000218,3T3-L1,1,F,Expert,,1,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,80006,N,,CHEMBL615530,,
508,620.0,,BAO_0000218,3T3-L1,1,F,Expert,,1,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,80006,N,,CHEMBL615531,,
509,620.0,,BAO_0000219,3T3-L1,1,F,Intermediate,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,80006,N,,CHEMBL615532,,
510,620.0,,BAO_0000219,3T3-L1,1,F,Intermediate,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,80006,N,,CHEMBL615533,,
511,620.0,,BAO_0000219,3T3-L1,1,F,Intermediate,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,80006,N,,CHEMBL615534,,
512,620.0,,BAO_0000218,3T3-L1,1,F,Intermediate,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,80006,N,,CHEMBL615535,,
513,620.0,,BAO_0000218,3T3-L1,1,F,Intermediate,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,80006,N,,CHEMBL615536,,
514,620.0,,BAO_0000218,3T3-L1,1,F,Intermediate,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,80006,N,,CHEMBL615537,,
515,620.0,,BAO_0000218,3T3-L1,1,F,Intermediate,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,80006,N,,CHEMBL615538,,
516,620.0,,BAO_0000218,3T3-L1,1,F,Intermediate,,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,80006,N,,CHEMBL836166,,
517,620.0,,BAO_0000219,3T3-L1,1,F,Expert,,8,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,11214,H,,CHEMBL615539,,
518,620.0,Mus musculus,BAO_0000219,3T3-L1,1,F,Intermediate,,1,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,80006,N,,CHEMBL615540,,
519,620.0,,BAO_0000219,3T3-L1,1,F,Expert,,8,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,11214,H,,CHEMBL615541,,
520,620.0,Mus musculus,BAO_0000219,3T3-L1,1,F,Expert,,1,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,80006,N,,CHEMBL615542,,
521,620.0,Mus musculus,BAO_0000219,3T3-L1,1,F,Intermediate,,1,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,80006,N,,CHEMBL615543,,
522,620.0,Mus musculus,BAO_0000219,3T3-L1,1,F,Expert,,1,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,80006,N,,CHEMBL615544,,
523,620.0,Mus musculus,BAO_0000219,3T3-L1,1,F,Expert,,1,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,80006,N,,CHEMBL615545,,
524,620.0,Mus musculus,BAO_0000219,3T3-L1,1,F,Expert,,1,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,80006,N,,CHEMBL615546,,
525,620.0,Mus musculus,BAO_0000219,3T3-L1,1,F,Expert,,1,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,80006,N,,CHEMBL615547,,
526,620.0,Mus musculus,BAO_0000219,3T3-L1,1,F,Expert,,1,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,80006,N,,CHEMBL615548,,
527,620.0,Mus musculus,BAO_0000219,3T3-L1,1,F,Expert,,1,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,80006,N,,CHEMBL615549,,
528,620.0,Mus musculus,BAO_0000219,3T3-L1,1,F,Expert,,1,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,80006,N,,CHEMBL615550,,
529,1118.0,Rattus norvegicus,BAO_0000219,3Y1 cell line,1,F,Intermediate,,1,Inhibitory activity against rat fibroblast (3Y1) cell line,80622,N,,CHEMBL615551,,
530,1118.0,Rattus norvegicus,BAO_0000219,3Y1 cell line,1,F,Expert,,1,Mean concentration causing inhibition of cell growth in 3Y1 cells.,80622,N,,CHEMBL615552,,
531,1118.0,Rattus norvegicus,BAO_0000219,3Y1 cell line,1,F,Expert,,1,Cytotoxicity in 3Y1 cells.,80622,N,,CHEMBL615553,,
532,1118.0,Rattus norvegicus,BAO_0000219,3Y1 cell line,1,F,Expert,,1,Cytostatic effect in 3Y1 cells.,80622,N,,CHEMBL615554,,
533,1118.0,Rattus norvegicus,BAO_0000219,3Y1 cell line,1,F,Intermediate,,1,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",80622,N,,CHEMBL615555,,
534,1118.0,Rattus norvegicus,BAO_0000219,3Y1 cell line,1,F,Expert,,1,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,80622,N,,CHEMBL615556,,
535,,,BAO_0000019,,1,B,Autocuration,,0,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,22226,U,,CHEMBL615557,,
536,,,BAO_0000019,,1,B,Autocuration,,0,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,22226,U,,CHEMBL615558,,
537,,,BAO_0000019,,1,B,Autocuration,,0,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,22226,U,,CHEMBL872066,,
538,,Sus scrofa,BAO_0000019,,1,B,Expert,,9,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,11607,D,,CHEMBL615559,,
539,,,BAO_0000019,,1,B,Autocuration,,8,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,11607,H,,CHEMBL615560,,
540,,,BAO_0000019,,1,B,Autocuration,,8,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,11607,H,,CHEMBL615561,,
541,,,BAO_0000019,,1,B,Expert,,8,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,11607,H,,CHEMBL857062,,
542,,,BAO_0000019,,1,B,Expert,,8,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),11607,H,,CHEMBL615562,,
543,,,BAO_0000019,,1,B,Autocuration,,8,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,11607,H,,CHEMBL615563,,
544,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),11607,H,,CHEMBL615564,,
545,,,BAO_0000019,,1,B,Autocuration,,8,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,11607,H,,CHEMBL615565,,
546,,,BAO_0000019,,1,B,Autocuration,,8,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,11607,H,,CHEMBL615566,,
547,,Sus scrofa,BAO_0000019,,1,B,Expert,,9,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,11607,D,,CHEMBL615567,,
548,,,BAO_0000019,,1,B,Autocuration,,8,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,11607,H,,CHEMBL615568,,
549,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),11607,H,,CHEMBL615569,,
550,,,BAO_0000019,,1,B,Autocuration,,8,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,11607,H,,CHEMBL615570,,
551,,,BAO_0000019,,1,B,Autocuration,,8,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),11607,H,,CHEMBL615571,,
552,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity against melatonin (MT1) receptor (pC1),104733,H,,CHEMBL615572,,
553,,,BAO_0000019,,1,B,Autocuration,,0,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,22226,U,,CHEMBL615573,,
554,,,BAO_0000019,,1,B,Autocuration,,0,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,22226,U,,CHEMBL615574,,
555,,,BAO_0000019,,1,B,Autocuration,,0,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,22226,U,,CHEMBL615575,,
556,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,10619,H,,CHEMBL615576,,
557,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,10619,H,,CHEMBL615577,,
558,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,51,H,,CHEMBL615578,10000000.0,
559,,,BAO_0000357,,1,B,Expert,,8,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,51,H,,CHEMBL615579,,
560,,,BAO_0000357,,1,B,Expert,,8,Binding affinity for 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL615580,,
561,,,BAO_0000019,,1,B,Expert,,8,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,51,H,,CHEMBL615581,,
562,,,BAO_0000221,,1,B,Autocuration,,8,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,H,,CHEMBL615582,10000000.0,
563,,,BAO_0000221,,1,B,Autocuration,,8,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,H,,CHEMBL615583,10000000.0,
564,,,BAO_0000221,,1,B,Autocuration,,8,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,51,H,,CHEMBL615584,10000000.0,
565,,,BAO_0000221,,1,B,Autocuration,,8,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,H,,CHEMBL833691,10000000.0,
566,,,BAO_0000221,,1,B,Autocuration,,8,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,51,H,,CHEMBL615585,10000000.0,
567,,,BAO_0000221,,1,B,Autocuration,,8,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,51,H,,CHEMBL615586,10000000.0,
568,,,BAO_0000221,,1,B,Autocuration,,8,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,H,,CHEMBL884524,10000000.0,
569,,,BAO_0000221,,1,B,Autocuration,,8,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,H,,CHEMBL615587,10000000.0,
570,,,BAO_0000221,,1,B,Autocuration,,8,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",51,H,,CHEMBL615588,10000000.0,
571,,Rattus norvegicus,BAO_0000249,,1,B,Expert,,9,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,10576,D,,CHEMBL615589,,
572,,Bos taurus,BAO_0000221,,1,B,Expert,,8,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,51,H,,CHEMBL615442,10000000.0,
573,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,51,H,,CHEMBL615443,10000000.0,
574,,,BAO_0000221,,1,B,Autocuration,,8,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,51,H,,CHEMBL615444,10000000.0,
575,,,BAO_0000221,,1,B,Expert,,8,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,51,H,,CHEMBL615445,10000000.0,
576,,,BAO_0000221,,1,B,Autocuration,,8,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,51,H,,CHEMBL615446,10000000.0,
577,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,51,H,,CHEMBL615447,,
578,,,BAO_0000221,,1,B,Expert,,8,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,H,,CHEMBL615448,10000000.0,
579,,,BAO_0000221,,1,B,Expert,,8,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,H,,CHEMBL615449,10000000.0,
580,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,51,H,,CHEMBL615450,,
581,,,BAO_0000221,,1,B,Expert,,8,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",51,H,,CHEMBL615451,10000000.0,
582,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,51,H,,CHEMBL615452,,
583,,,BAO_0000221,,1,B,Autocuration,,8,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,51,H,,CHEMBL615453,10000000.0,
584,,,BAO_0000221,,1,B,Autocuration,,8,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,H,,CHEMBL615454,10000000.0,
585,,,BAO_0000221,,1,B,Autocuration,,8,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,51,H,,CHEMBL615455,10000000.0,
586,,,BAO_0000221,,1,B,Autocuration,,8,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,H,,CHEMBL615456,10000000.0,
587,,,BAO_0000221,,1,B,Autocuration,,8,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,51,H,,CHEMBL615457,10000000.0,
588,,,BAO_0000218,,1,B,Expert,,8,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,51,H,,CHEMBL615458,10000000.0,
589,,,BAO_0000221,,1,B,Expert,,8,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,H,,CHEMBL615459,10000000.0,
590,449.0,Homo sapiens,BAO_0000219,CHO,1,B,Expert,,9,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",51,D,,CHEMBL615460,,
591,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,51,H,,CHEMBL615461,,
592,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,51,H,,CHEMBL615462,,
593,,Cavia porcellus,BAO_0000221,,1,F,Autocuration,,8,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,51,H,,CHEMBL615463,10000000.0,
594,,Cavia porcellus,BAO_0000221,,1,B,Autocuration,,8,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,51,H,,CHEMBL615464,2116.0,
595,,Cavia porcellus,BAO_0000221,,1,B,Autocuration,,8,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,51,H,,CHEMBL615465,2116.0,
596,,Cavia porcellus,BAO_0000221,,1,B,Autocuration,,8,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,51,H,,CHEMBL615466,2116.0,
597,,Cavia porcellus,BAO_0000221,,1,B,Autocuration,,8,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,51,H,,CHEMBL615467,2116.0,
598,,Cavia porcellus,BAO_0000221,,1,B,Autocuration,,8,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,51,H,,CHEMBL615468,2116.0,
599,,Cavia porcellus,BAO_0000221,,1,B,Autocuration,,8,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,51,H,,CHEMBL615469,2116.0,
600,,Cavia porcellus,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL615470,,
601,,Cavia porcellus,BAO_0000357,,1,B,Autocuration,,8,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL615471,,
602,,Cavia porcellus,BAO_0000357,,1,B,Autocuration,,8,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL615472,,
603,,Cavia porcellus,BAO_0000221,,1,B,Autocuration,,8,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,106,H,,CHEMBL883242,10000000.0,
604,,Cavia porcellus,BAO_0000221,,1,F,Autocuration,,8,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,106,H,,CHEMBL615473,10000000.0,
605,449.0,Cricetulus griseus,BAO_0000218,CHO,1,B,Autocuration,,8,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),11863,H,,CHEMBL615474,,
606,,,BAO_0000357,,1,B,Autocuration,,8,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL615475,,
607,308.0,,BAO_0000219,HeLa,1,F,Autocuration,,8,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,51,H,,CHEMBL615476,,
608,308.0,,BAO_0000219,HeLa,1,F,Autocuration,,8,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,51,H,,CHEMBL615477,,
609,,,BAO_0000019,,1,F,Autocuration,,8,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL615478,,
610,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL615160,,
611,449.0,,BAO_0000219,CHO,1,F,Expert,,8,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL615161,,
612,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,51,H,,CHEMBL615162,,
613,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,51,H,,CHEMBL615163,,
614,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,H,,CHEMBL615164,,
615,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,H,,CHEMBL615165,,
616,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,51,H,,CHEMBL615166,,
617,,,BAO_0000219,,1,F,Autocuration,,8,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,51,H,,CHEMBL615167,,
618,308.0,Homo sapiens,BAO_0000219,HeLa,1,B,Expert,,9,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,51,D,,CHEMBL615168,,
619,308.0,Homo sapiens,BAO_0000219,HeLa,1,B,Expert,,9,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,51,D,,CHEMBL615169,,
620,449.0,Homo sapiens,BAO_0000219,CHO,1,B,Expert,,9,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,51,D,,CHEMBL615170,,
621,449.0,Homo sapiens,BAO_0000219,CHO,1,B,Expert,,9,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,51,D,,CHEMBL615171,,
622,,,BAO_0000019,,1,F,Autocuration,,8,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL615694,,
623,,,BAO_0000019,,1,F,Autocuration,,8,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL615695,,
624,,,BAO_0000019,,1,F,Autocuration,,8,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",51,H,,CHEMBL615696,,
625,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,51,H,,CHEMBL615697,,
626,449.0,Homo sapiens,BAO_0000219,CHO,1,F,Expert,,9,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),51,D,,CHEMBL859410,,
627,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),51,H,,CHEMBL615841,,
628,449.0,Homo sapiens,BAO_0000219,CHO,1,F,Expert,,9,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),51,D,,CHEMBL615842,,
629,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,51,H,,CHEMBL835003,,
630,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),51,H,,CHEMBL615843,,
631,449.0,Homo sapiens,BAO_0000219,CHO,1,F,Expert,,9,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),51,D,,CHEMBL615979,,
632,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),51,H,,CHEMBL615980,,
633,449.0,Homo sapiens,BAO_0000219,CHO,1,F,Expert,,9,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),51,D,,CHEMBL615981,,
634,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,51,D,,CHEMBL615982,,
635,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",51,D,,CHEMBL615983,,
636,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",51,D,,CHEMBL615984,,
637,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",51,D,,CHEMBL615985,,
638,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,51,H,,CHEMBL615986,,
639,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,51,H,,CHEMBL615987,,
640,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,51,H,,CHEMBL615988,,
641,449.0,,BAO_0000219,CHO,1,F,Expert,,8,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,51,H,,CHEMBL615989,,
642,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,51,H,,CHEMBL615990,,
643,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,51,H,,CHEMBL615991,,
644,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,51,H,,CHEMBL615992,,
645,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,51,H,,CHEMBL615993,,
646,449.0,,BAO_0000219,CHO,1,F,Expert,,8,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,51,H,,CHEMBL615994,,
647,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,51,H,,CHEMBL615995,,
648,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,51,H,,CHEMBL615996,,
649,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,51,H,,CHEMBL615997,,
650,,,BAO_0000019,,1,F,Autocuration,,8,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,H,,CHEMBL615998,,
651,,,BAO_0000019,,1,F,Autocuration,,8,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,H,,CHEMBL615999,,
652,,,BAO_0000019,,1,F,Autocuration,,8,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,51,H,,CHEMBL616000,,
653,722.0,,BAO_0000219,HEK293,1,F,Autocuration,,8,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,H,,CHEMBL616001,,
654,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",51,D,,CHEMBL616002,,
655,,,BAO_0000019,,1,F,Expert,,8,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",51,H,,CHEMBL616003,,
656,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,51,D,,CHEMBL616004,,
657,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,51,D,,CHEMBL616005,,
658,,,BAO_0000019,,1,F,Autocuration,,8,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",51,H,,CHEMBL616006,,
659,,,BAO_0000019,,1,F,Expert,,8,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",51,H,,CHEMBL616007,,
660,,,BAO_0000019,,1,F,Autocuration,,8,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",51,H,,CHEMBL616008,,
661,,,BAO_0000019,,1,F,Autocuration,,8,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",51,H,,CHEMBL616009,,
662,,,BAO_0000019,,1,F,Expert,,8,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",51,H,,CHEMBL616010,,
663,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",51,D,,CHEMBL616011,,
664,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",51,D,,CHEMBL615740,,
665,,,BAO_0000019,,1,F,Autocuration,,8,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",51,H,,CHEMBL615741,,
666,,,BAO_0000019,,1,F,Expert,,8,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",51,H,,CHEMBL615742,,
667,,,BAO_0000019,,1,F,Autocuration,,8,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",51,H,,CHEMBL615743,,
668,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,51,H,,CHEMBL615744,,
669,449.0,,BAO_0000219,CHO,1,F,Expert,,8,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,51,H,,CHEMBL615745,,
670,,,BAO_0000357,,1,B,Autocuration,,8,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,51,H,,CHEMBL615746,,
671,,,BAO_0000357,,1,B,Autocuration,,8,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,51,H,,CHEMBL615747,,
672,,,BAO_0000019,,1,F,Autocuration,,8,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,H,,CHEMBL615748,,
673,,,BAO_0000019,,1,F,Autocuration,,8,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",51,H,,CHEMBL615749,,
674,,,BAO_0000019,,1,F,Autocuration,,8,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,51,H,,CHEMBL615750,,
675,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,51,D,,CHEMBL616259,,
676,,,BAO_0000019,,1,F,Autocuration,,8,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,H,,CHEMBL616260,,
677,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,51,D,,CHEMBL616261,,
678,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",51,D,,CHEMBL616262,,
679,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",51,D,,CHEMBL616263,,
680,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,51,D,,CHEMBL616264,,
681,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,51,D,,CHEMBL616265,,
682,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",51,D,,CHEMBL616266,,
683,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",51,D,,CHEMBL616267,,
684,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,51,D,,CHEMBL616268,,
685,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Inhibition of human 5-hydroxytryptamine 1A receptor,51,D,,CHEMBL616269,,
686,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,H,,CHEMBL884528,,
687,722.0,,BAO_0000219,HEK293,1,B,Expert,,9,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,105,D,,CHEMBL616270,,
688,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,51,H,,CHEMBL616271,,
689,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616272,,
690,,,BAO_0000357,,1,B,Expert,,8,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,51,H,,CHEMBL616273,,
691,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,51,D,,CHEMBL616274,,
692,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,51,H,,CHEMBL616275,,
693,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,H,,CHEMBL616276,,
694,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,In vivo,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,22226,U,,CHEMBL616277,,
695,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,In vivo,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,22226,U,,CHEMBL616278,,
696,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,In vivo,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,22226,U,,CHEMBL616279,,
697,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,In vivo,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,22226,U,,CHEMBL616280,,
698,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,In vivo,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,22226,U,,CHEMBL616281,,
699,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,In vivo,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,22226,U,,CHEMBL616282,,
700,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,In vivo,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,22226,U,,CHEMBL616283,,
701,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,In vivo,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,22226,U,,CHEMBL616284,,
702,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,In vivo,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,22226,U,,CHEMBL616285,,
703,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,In vivo,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,22226,U,,CHEMBL616286,,
704,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,In vivo,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,22226,U,,CHEMBL616287,,
705,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,In vivo,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,22226,U,,CHEMBL616288,,
706,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,In vivo,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,22226,U,,CHEMBL616289,,
707,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,In vivo,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,22226,U,,CHEMBL615610,,
708,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,In vivo,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,22226,U,,CHEMBL615611,,
709,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,In vivo,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,22226,U,,CHEMBL615612,,
710,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,In vivo,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,22226,U,,CHEMBL615613,,
711,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,In vivo,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,22226,U,,CHEMBL615614,,
712,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,In vivo,0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,22226,U,,CHEMBL615615,,
713,,,BAO_0000019,,1,B,Autocuration,,4,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,105093,H,,CHEMBL615616,,
714,,,BAO_0000249,,1,B,Autocuration,,8,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,11923,H,,CHEMBL615617,1898.0,
715,,,BAO_0000019,,1,B,Autocuration,,8,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,10577,H,,CHEMBL615618,,
716,,,BAO_0000019,,1,B,Autocuration,,8,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,10577,H,,CHEMBL615619,,
717,,,BAO_0000019,,1,B,Expert,,8,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,10577,H,,CHEMBL615620,,
718,,,BAO_0000357,,1,B,Autocuration,,8,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",55,H,,CHEMBL615621,,
719,,,BAO_0000357,,1,B,Autocuration,,8,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",55,H,,CHEMBL615622,,
720,,,BAO_0000019,,1,F,Autocuration,,8,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),12166,H,,CHEMBL615623,,
721,,,BAO_0000019,,1,F,Autocuration,,8,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,12166,H,,CHEMBL615624,,
722,,,BAO_0000019,,1,F,Autocuration,,8,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,12166,H,,CHEMBL615625,,
723,,,BAO_0000019,,1,F,Autocuration,,8,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,12166,H,,CHEMBL767045,,
724,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,8,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,55,H,,CHEMBL615626,,
725,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,8,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,55,H,,CHEMBL615627,,
726,,Cavia porcellus,BAO_0000019,,1,B,Autocuration,,8,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,55,H,,CHEMBL615628,,
727,,Cavia porcellus,BAO_0000357,,1,B,Autocuration,,8,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,55,H,,CHEMBL615629,,
728,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Inhibitory concentration against 5-lipoxygenase from human whole blood,55,D,,CHEMBL615630,,
729,,,BAO_0000219,,1,B,Autocuration,,8,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],55,H,,CHEMBL615631,,
730,,,BAO_0000218,,1,F,Autocuration,,8,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,17087,H,,CHEMBL615632,,
731,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,17087,H,,CHEMBL615633,,
732,,,BAO_0000218,,1,F,Autocuration,,8,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,17087,H,,CHEMBL615634,,
733,,Sus scrofa,BAO_0000019,,1,B,Expert,,8,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,55,H,,CHEMBL615635,,
734,,,BAO_0000357,,1,B,Expert,,8,In vitro inhibition of rat 5-Lipoxygenase,12166,H,,CHEMBL615636,,
735,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Inhibitory activity against 5-Lipoxygenase,12166,D,,CHEMBL615637,,
736,702.0,,BAO_0000219,RBL-1,1,B,Expert,,8,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,12166,H,,CHEMBL615638,,
737,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),12166,H,,CHEMBL615639,,
738,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,12166,H,,CHEMBL615640,,
739,,,BAO_0000019,,1,B,Autocuration,,8,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,12166,H,,CHEMBL615796,,
740,,,BAO_0000219,,1,B,Autocuration,,8,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],12166,H,,CHEMBL615845,,
741,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,12166,H,,CHEMBL615846,,
742,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,12166,H,,CHEMBL615847,,
743,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for inhibition of isolated 5-Lipoxygenase,12166,H,,CHEMBL615848,,
744,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,0,Ratio of IC50 against 5-LO and COX,22226,U,,CHEMBL615849,,
745,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,12166,H,,CHEMBL615850,,
746,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,12166,H,,CHEMBL615851,,
747,,,BAO_0000219,,1,B,Autocuration,,8,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,12166,H,,CHEMBL615852,,
748,,,BAO_0000019,,1,F,Autocuration,,8,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,12166,H,,CHEMBL615853,,
749,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,120,H,,CHEMBL884527,2367.0,
750,,Columba livia,BAO_0000019,,1,B,Autocuration,,0,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,22226,U,,CHEMBL872871,,
751,,Columba livia,BAO_0000019,,1,B,Autocuration,,0,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,22226,U,,CHEMBL615854,,
752,,Columba livia,BAO_0000019,,1,B,Autocuration,,0,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,22226,U,,CHEMBL767046,,
753,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,10732,H,,CHEMBL615855,,
754,,Rattus norvegicus,BAO_0000019,,1,F,Expert,,9,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,12198,D,,CHEMBL615856,,
755,,Rattus norvegicus,BAO_0000019,,1,F,Expert,,9,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),12198,D,,CHEMBL615857,,
756,,Rattus norvegicus,BAO_0000019,,1,F,Expert,,9,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),12198,D,,CHEMBL615858,,
757,,,BAO_0000221,,1,B,Expert,,8,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,10576,H,,CHEMBL615859,10000000.0,
758,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human 5-hydroxytryptamine 1 receptor,51,H,,CHEMBL615860,,
759,,Oryctolagus cuniculus,BAO_0000019,,1,B,Autocuration,,0,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,22226,U,,CHEMBL615861,,
760,,Oryctolagus cuniculus,BAO_0000019,,1,B,Autocuration,,0,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,22226,U,,CHEMBL615862,,
761,,Oryctolagus cuniculus,BAO_0000019,,1,B,Autocuration,,0,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,22226,U,,CHEMBL615863,,
762,,Oryctolagus cuniculus,BAO_0000019,,1,B,Autocuration,,0,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,22226,U,,CHEMBL615864,,
763,,,BAO_0000221,,1,B,Autocuration,,4,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,104744,H,,CHEMBL615865,10000000.0,
764,,,BAO_0000221,,1,B,Autocuration,,4,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,104744,H,,CHEMBL615866,10000000.0,
765,,,BAO_0000221,,1,B,Autocuration,,4,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,104744,H,,CHEMBL615867,10000000.0,
766,,,BAO_0000249,,1,B,Autocuration,,4,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,104744,H,,CHEMBL615868,,
767,,Rattus norvegicus,BAO_0000249,,1,B,Autocuration,,5,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,104744,D,,CHEMBL615869,,
768,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,5,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,104744,D,,CHEMBL615870,,
769,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,5,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,104744,D,,CHEMBL615871,,
770,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,104744,H,,CHEMBL615872,,
771,,,BAO_0000221,,1,B,Autocuration,,4,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,104744,H,,CHEMBL833492,10000000.0,
772,,,BAO_0000221,,1,B,Autocuration,,4,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,104744,H,,CHEMBL615873,10000000.0,
773,,,BAO_0000224,,1,B,Autocuration,,4,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,104744,H,,CHEMBL615479,,
774,,,BAO_0000019,,1,B,Autocuration,,4,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,104744,H,,CHEMBL615480,,
775,,Rattus norvegicus,BAO_0000249,,1,B,Autocuration,,5,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,104744,D,,CHEMBL615481,,
776,,,BAO_0000019,,1,B,Autocuration,,4,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,H,,CHEMBL872869,,
777,,,BAO_0000019,,1,B,Autocuration,,4,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,H,,CHEMBL615482,,
778,,,BAO_0000221,,1,B,Autocuration,,4,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,104744,H,,CHEMBL615483,955.0,
779,,,BAO_0000221,,1,B,Autocuration,,4,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,104744,H,,CHEMBL615484,955.0,
780,,,BAO_0000019,,1,B,Autocuration,,4,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,104744,H,,CHEMBL615485,,
781,,Rattus norvegicus,BAO_0000224,,1,B,Autocuration,,5,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,104744,D,,CHEMBL615486,,
782,,,BAO_0000224,,1,B,Autocuration,,4,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,104744,H,,CHEMBL615487,,
783,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,104744,H,,CHEMBL615488,,
784,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,104744,H,,CHEMBL615489,,
785,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,104744,H,,CHEMBL615389,,
786,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,104744,H,,CHEMBL615390,,
787,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,104744,H,,CHEMBL615391,,
788,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,104744,H,,CHEMBL615392,,
789,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,0,Affinity for 5-hydroxytryptamine 1 receptor,22226,U,,CHEMBL615393,,
790,,,BAO_0000221,,1,B,Autocuration,,4,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,104744,H,,CHEMBL615394,955.0,
791,,,BAO_0000221,,1,B,Autocuration,,4,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,104744,H,,CHEMBL615395,955.0,
792,,,BAO_0000224,,1,B,Autocuration,,4,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,104744,H,,CHEMBL615396,,
793,,,BAO_0000221,,1,B,Autocuration,,4,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,104744,H,,CHEMBL615397,955.0,
794,,,BAO_0000019,,1,B,Autocuration,,4,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,H,,CHEMBL615398,,
795,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,0,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,22226,U,,CHEMBL615399,,
796,,,BAO_0000019,,1,B,Autocuration,,4,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,104744,H,,CHEMBL615400,,
797,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,5,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,104744,D,,CHEMBL615401,,
798,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,0,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,22226,U,,CHEMBL615402,,
799,,,BAO_0000019,,1,B,Autocuration,,4,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,104744,H,,CHEMBL615403,,
800,,,BAO_0000221,,1,B,Autocuration,,4,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,104744,H,,CHEMBL615404,955.0,
801,,,BAO_0000019,,1,B,Autocuration,,4,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,104744,H,,CHEMBL615781,,
802,,,BAO_0000220,,1,B,Autocuration,,4,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,104744,H,,CHEMBL615782,955.0,
803,,,BAO_0000221,,1,B,Autocuration,,4,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,104744,H,,CHEMBL615783,955.0,
804,,,BAO_0000019,,1,B,Autocuration,,0,Compound was tested for binding affinity against 5-HT1 receptor,22226,U,,CHEMBL873481,,
805,,,BAO_0000019,,1,B,Autocuration,,0,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,22226,U,,CHEMBL615784,,
806,,,BAO_0000357,,1,B,Expert,,8,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,10576,H,,CHEMBL615785,,
807,,,BAO_0000249,,1,F,Autocuration,,8,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",10576,H,,CHEMBL615786,,
808,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,10576,H,,CHEMBL615787,,
809,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,10576,H,,CHEMBL615788,,
810,,,BAO_0000019,,1,F,Autocuration,,8,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL767044,,
811,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,10576,H,,CHEMBL615789,,
812,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,10576,H,,CHEMBL615790,,
813,,,BAO_0000019,,1,F,Autocuration,,8,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,10576,H,,CHEMBL615813,,
814,,,BAO_0000219,,1,F,Autocuration,,8,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,10576,H,,CHEMBL615814,,
815,,,BAO_0000219,,1,F,Expert,,8,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,51,H,,CHEMBL615815,,
816,,,BAO_0000219,,1,F,Autocuration,,8,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,10576,H,,CHEMBL615816,,
817,,,BAO_0000249,,1,B,Expert,,8,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,10576,H,,CHEMBL615817,,
818,,,BAO_0000221,,1,B,Autocuration,,8,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,10576,H,,CHEMBL615818,10000000.0,
819,,,BAO_0000221,,1,B,Autocuration,,8,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,10576,H,,CHEMBL615819,10000000.0,
820,,,BAO_0000249,,1,B,Expert,,8,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,10576,H,,CHEMBL615820,,
821,,Rattus norvegicus,BAO_0000221,,1,B,Expert,,9,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,10576,D,,CHEMBL615821,10000000.0,
822,,Rattus norvegicus,BAO_0000221,,1,B,Expert,,9,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10576,D,,CHEMBL615822,10000000.0,
823,,,BAO_0000221,,1,B,Expert,,8,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,10576,H,,CHEMBL615823,10000000.0,
824,,Rattus norvegicus,BAO_0000221,,1,B,Expert,,9,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,10576,D,,CHEMBL615824,10000000.0,
825,,Rattus norvegicus,BAO_0000221,,1,B,Expert,,9,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10576,D,,CHEMBL615825,10000000.0,
826,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,10576,H,,CHEMBL615826,,
827,,,BAO_0000249,,1,B,Expert,,8,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,10576,H,,CHEMBL615827,,
828,,,BAO_0000249,,1,B,Expert,,8,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,10576,H,,CHEMBL615828,10000000.0,
829,,,BAO_0000221,,1,B,Expert,,8,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,H,,CHEMBL615829,10000000.0,
830,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,10576,H,,CHEMBL615830,10000000.0,
831,,,BAO_0000221,,1,B,Expert,,8,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,10576,H,,CHEMBL615831,10000000.0,
832,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL615832,,
833,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,10576,H,,CHEMBL615833,,
834,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,10576,H,,CHEMBL615834,10000000.0,
835,,,BAO_0000249,,1,B,Intermediate,,8,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,10576,H,,CHEMBL615835,,
836,,,BAO_0000249,,1,B,Autocuration,,8,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,10576,H,,CHEMBL615836,10000000.0,
837,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,10576,D,,CHEMBL615837,,
838,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,10576,D,,CHEMBL615838,,
839,,,BAO_0000249,,1,B,Expert,,8,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",10576,H,,CHEMBL615839,,
840,,,BAO_0000019,,1,B,Autocuration,,8,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,10576,H,,CHEMBL884525,,
841,,,BAO_0000249,,1,B,Autocuration,,8,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,10576,H,,CHEMBL615840,,
842,,,BAO_0000221,,1,B,Expert,,8,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,H,,CHEMBL615405,10000000.0,
843,,,BAO_0000019,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,10576,H,,CHEMBL615406,,
844,,,BAO_0000221,,1,B,Expert,,8,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,10576,H,,CHEMBL615900,10000000.0,
845,,,BAO_0000221,,1,B,Expert,,8,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,10576,H,,CHEMBL615901,10000000.0,
846,,,BAO_0000357,,1,B,Expert,,8,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,10576,H,,CHEMBL615902,,
847,,,BAO_0000221,,1,B,Autocuration,,8,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,10576,H,,CHEMBL615903,10000000.0,
848,,,BAO_0000357,,1,B,Autocuration,,8,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,10576,H,,CHEMBL615904,,
849,,,BAO_0000357,,1,B,Expert,,8,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,10576,H,,CHEMBL615905,,
850,,,BAO_0000019,,1,B,Autocuration,,8,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,10576,H,,CHEMBL615906,,
851,,,BAO_0000019,,1,F,Autocuration,,8,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,10576,H,,CHEMBL615907,,
852,,,BAO_0000019,,1,B,Expert,,8,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,10576,H,,CHEMBL615908,,
853,,,BAO_0000221,,1,B,Autocuration,,8,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,10576,H,,CHEMBL615909,10000000.0,
854,,,BAO_0000019,,1,B,Autocuration,,8,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",10576,H,,CHEMBL615910,,
855,,,BAO_0000019,,1,B,Autocuration,,8,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",10576,H,,CHEMBL615911,,
856,,,BAO_0000019,,1,B,Autocuration,,8,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",10576,H,,CHEMBL615912,,
857,,,BAO_0000019,,1,B,Expert,,8,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,10576,H,,CHEMBL615913,,
858,,,BAO_0000357,,1,B,Expert,,8,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,10576,H,,CHEMBL615914,,
859,,,BAO_0000221,,1,B,Autocuration,,8,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,10576,H,,CHEMBL615915,10000000.0,
860,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,10576,H,,CHEMBL615916,,
861,,,BAO_0000357,,1,B,Expert,,8,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,10576,H,,CHEMBL615917,,
862,,,BAO_0000357,,1,B,Expert,,8,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL615918,,
863,,,BAO_0000249,,1,B,Expert,,8,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,10576,H,,CHEMBL615919,10000000.0,
864,,Rattus norvegicus,BAO_0000221,,1,B,Expert,,9,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10576,D,,CHEMBL615920,10000000.0,
865,,,BAO_0000357,,1,B,Autocuration,,8,Inhibition concentration against 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL615921,,
866,,,BAO_0000357,,1,B,Expert,,8,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),10576,H,,CHEMBL615922,,
867,,Rattus norvegicus,BAO_0000249,,1,F,Expert,,9,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",10576,D,,CHEMBL881290,,
868,,,BAO_0000221,,1,B,Autocuration,,8,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",10576,H,,CHEMBL615923,10000000.0,
869,,,BAO_0000221,,1,F,Autocuration,,8,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,H,,CHEMBL615924,10000000.0,
870,,,BAO_0000221,,1,F,Autocuration,,8,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,H,,CHEMBL615925,10000000.0,
871,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,10576,D,,CHEMBL615926,,
872,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,10576,D,,CHEMBL615927,,
873,,,BAO_0000221,,1,B,Autocuration,,8,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,H,,CHEMBL615928,10000000.0,
874,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,10576,D,,CHEMBL615929,,
875,,,BAO_0000221,,1,B,Autocuration,,8,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,10576,H,,CHEMBL615930,10000000.0,
876,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,H,,CHEMBL615931,,
877,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL615932,,
878,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL615933,,
879,,,BAO_0000357,,1,B,Autocuration,,8,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL615934,,
880,,,BAO_0000357,,1,B,Autocuration,,8,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,51,H,,CHEMBL615935,,
881,,,BAO_0000019,,1,F,Autocuration,,8,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,H,,CHEMBL615936,,
882,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,51,H,,CHEMBL615937,,
883,,,BAO_0000357,,1,B,Autocuration,,8,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL615938,,
884,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),51,H,,CHEMBL615797,,
885,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,H,,CHEMBL615798,,
886,,,BAO_0000357,,1,B,Autocuration,,8,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,51,H,,CHEMBL872870,,
887,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,51,H,,CHEMBL615799,,
888,,,BAO_0000357,,1,B,Autocuration,,8,Percent binding affinity against 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL615800,,
889,722.0,,BAO_0000219,HEK293,1,F,Autocuration,,8,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,H,,CHEMBL615801,,
890,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,51,H,,CHEMBL615802,,
891,,,BAO_0000357,,1,B,Autocuration,,8,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,51,H,,CHEMBL615803,,
892,,,BAO_0000019,,1,F,Expert,,8,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",51,H,,CHEMBL835002,,
893,,,BAO_0000019,,1,F,Autocuration,,8,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",51,H,,CHEMBL615804,,
894,308.0,,BAO_0000219,HeLa,1,B,Expert,,8,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL615805,,
895,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL615806,,
896,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,51,D,,CHEMBL615807,,
897,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,51,H,,CHEMBL615808,,
898,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity against 5-hydroxytryptamine 1A receptor,51,D,,CHEMBL615809,,
899,308.0,,BAO_0000219,HeLa,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,51,H,,CHEMBL615810,,
900,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,H,,CHEMBL615811,,
901,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,51,H,,CHEMBL615812,,
902,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,51,H,,CHEMBL615751,,
903,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against human 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL615752,,
904,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,51,H,,CHEMBL615753,,
905,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,51,H,,CHEMBL615754,,
906,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL615755,,
907,449.0,Homo sapiens,BAO_0000219,CHO,1,B,Expert,,9,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,51,D,,CHEMBL615756,,
908,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,51,H,,CHEMBL615757,,
909,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,51,H,,CHEMBL615758,,
910,,,BAO_0000357,,1,B,Expert,,8,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,51,H,,CHEMBL615759,,
911,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL615760,,
912,308.0,,BAO_0000219,HeLa,1,B,Expert,,8,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,51,H,,CHEMBL615761,,
913,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,51,H,,CHEMBL872104,,
914,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,51,H,,CHEMBL615762,,
915,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,51,H,,CHEMBL615763,,
916,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,51,H,,CHEMBL615764,,
917,1167.0,,BAO_0000219,Cell line,1,B,Autocuration,,8,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),51,H,,CHEMBL615765,,
918,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),51,H,,CHEMBL615766,,
919,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,51,H,,CHEMBL615767,,
920,,,BAO_0000357,,1,B,Expert,,8,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,H,,CHEMBL615768,,
921,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,H,,CHEMBL615769,,
922,,,BAO_0000357,,1,B,Expert,,8,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,51,H,,CHEMBL615770,,
923,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,H,,CHEMBL615771,,
924,,,BAO_0000357,,1,B,Expert,,8,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,51,H,,CHEMBL615772,,
925,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL615773,,
926,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,51,H,,CHEMBL615774,,
927,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,H,,CHEMBL615775,,
928,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,51,H,,CHEMBL615776,,
929,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,H,,CHEMBL615777,,
930,,,BAO_0000219,,1,B,Autocuration,,8,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,51,H,,CHEMBL615778,,
931,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,51,D,,CHEMBL615779,,
932,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,51,H,,CHEMBL615780,,
933,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616298,,
934,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616299,,
935,485.0,,BAO_0000219,CHO-K1,1,B,Autocuration,,8,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,51,H,,CHEMBL616300,,
936,485.0,,BAO_0000219,CHO-K1,1,F,Expert,,8,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,51,H,,CHEMBL616301,,
937,,,BAO_0000019,,1,B,Autocuration,,8,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616302,,
938,,,BAO_0000019,,1,B,Autocuration,,8,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),51,H,,CHEMBL616117,,
939,,,BAO_0000019,,1,B,Autocuration,,8,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),51,H,,CHEMBL616118,,
940,,,BAO_0000019,,1,B,Autocuration,,8,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,51,H,,CHEMBL616119,,
941,308.0,Homo sapiens,BAO_0000219,HeLa,1,B,Expert,,9,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,51,D,,CHEMBL616120,,
942,,,BAO_0000357,,1,B,Autocuration,,8,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616121,,
943,,,BAO_0000357,,1,B,Autocuration,,8,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,51,H,,CHEMBL616122,,
944,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616123,,
945,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,51,D,,CHEMBL616124,,
946,,,BAO_0000357,,1,B,Expert,,8,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,51,H,,CHEMBL616125,,
947,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,8,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,51,H,,CHEMBL616126,,
948,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,51,H,,CHEMBL616127,,
949,,,BAO_0000019,,1,B,Expert,,8,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616128,,
950,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,51,H,,CHEMBL616129,,
951,,,BAO_0000357,,1,B,Expert,,8,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616130,,
952,,,BAO_0000357,,1,B,Autocuration,,8,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,51,H,,CHEMBL616131,,
953,308.0,,BAO_0000219,HeLa,1,B,Autocuration,,8,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,51,H,,CHEMBL616132,,
954,308.0,Homo sapiens,BAO_0000219,HeLa,1,B,Expert,,9,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,51,D,,CHEMBL616133,,
955,,,BAO_0000357,,1,B,Autocuration,,8,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,H,,CHEMBL616134,,
956,,,BAO_0000357,,1,B,Autocuration,,8,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,51,H,,CHEMBL616135,,
957,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Affinity for 5-hydroxytryptamine 1A receptor subtype,51,D,,CHEMBL616136,,
958,,,BAO_0000019,,1,B,Autocuration,,8,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,51,H,,CHEMBL616137,,
959,,,BAO_0000019,,1,B,Autocuration,,8,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,51,H,,CHEMBL872105,,
960,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,51,H,,CHEMBL616138,,
961,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,51,D,,CHEMBL616139,,
962,,,BAO_0000019,,1,F,Autocuration,,8,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",51,H,,CHEMBL616140,,
963,,,BAO_0000019,,1,B,Expert,,8,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,51,H,,CHEMBL616141,,
964,,,BAO_0000357,,1,B,Autocuration,,8,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,H,,CHEMBL616142,,
965,,,BAO_0000357,,1,B,Autocuration,,8,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,51,H,,CHEMBL616143,,
966,308.0,,BAO_0000219,HeLa,1,B,Autocuration,,8,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,51,H,,CHEMBL616144,,
967,308.0,,BAO_0000219,HeLa,1,B,Autocuration,,8,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,51,H,,CHEMBL616145,,
968,308.0,,BAO_0000219,HeLa,1,B,Autocuration,,8,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,51,H,,CHEMBL616012,,
969,308.0,,BAO_0000219,HeLa,1,B,Autocuration,,8,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,51,H,,CHEMBL616013,,
970,,,BAO_0000019,,1,F,Autocuration,,8,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",51,H,,CHEMBL616014,,
971,,,BAO_0000019,,1,F,Autocuration,,8,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",51,H,,CHEMBL616015,,
972,,,BAO_0000019,,1,F,Autocuration,,8,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",51,H,,CHEMBL616016,,
973,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,51,H,,CHEMBL616017,,
974,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,51,H,,CHEMBL616018,,
975,,,BAO_0000019,,1,F,Autocuration,,8,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,51,H,,CHEMBL616019,,
976,,,BAO_0000019,,1,F,Autocuration,,8,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,51,H,,CHEMBL616020,,
977,,,BAO_0000357,,1,B,Autocuration,,8,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL858018,,
978,722.0,,BAO_0000219,HEK293,1,F,Autocuration,,8,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,H,,CHEMBL616021,,
979,,,BAO_0000019,,1,F,Expert,,8,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",51,H,,CHEMBL616022,,
980,,,BAO_0000019,,1,F,Autocuration,,8,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",51,H,,CHEMBL616023,,
981,,,BAO_0000019,,1,F,Autocuration,,8,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",51,H,,CHEMBL616024,,
982,,,BAO_0000019,,1,F,Autocuration,,8,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",51,H,,CHEMBL616025,,
983,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,51,H,,CHEMBL616026,,
984,,,BAO_0000019,,1,F,Autocuration,,8,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",51,H,,CHEMBL616027,,
985,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",51,D,,CHEMBL616028,,
986,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,51,D,,CHEMBL616029,,
987,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,51,H,,CHEMBL616030,,
988,,,BAO_0000019,,1,B,Expert,,8,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,51,H,,CHEMBL616031,,
989,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,51,D,,CHEMBL616032,,
990,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,51,D,,CHEMBL616033,,
991,,,BAO_0000019,,1,F,Autocuration,,8,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,H,,CHEMBL616034,,
992,,,BAO_0000019,,1,F,Autocuration,,8,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,H,,CHEMBL616035,,
993,,,BAO_0000019,,1,F,Autocuration,,8,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616036,,
994,,,BAO_0000019,,1,F,Autocuration,,8,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,H,,CHEMBL616037,,
995,,,BAO_0000019,,1,F,Autocuration,,8,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,H,,CHEMBL616038,,
996,,,BAO_0000019,,1,F,Autocuration,,8,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,H,,CHEMBL616039,,
997,,,BAO_0000019,,1,F,Autocuration,,8,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616040,,
998,308.0,Homo sapiens,BAO_0000219,HeLa,1,F,Expert,,9,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,51,D,,CHEMBL616041,,
999,308.0,Homo sapiens,BAO_0000219,HeLa,1,F,Expert,,9,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,51,D,,CHEMBL616042,,
1000,308.0,Homo sapiens,BAO_0000219,HeLa,1,F,Expert,,9,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,51,D,,CHEMBL616043,,
1001,,,BAO_0000019,,1,F,Autocuration,,8,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",51,H,,CHEMBL616044,,
1002,,,BAO_0000019,,1,F,Autocuration,,8,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",51,H,,CHEMBL616045,,
1003,722.0,,BAO_0000219,HEK293,1,F,Autocuration,,8,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,H,,CHEMBL616046,,
1004,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),51,H,,CHEMBL616047,,
1005,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,51,H,,CHEMBL616048,,
1006,449.0,Homo sapiens,BAO_0000219,CHO,1,F,Expert,,9,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),51,D,,CHEMBL616049,,
1007,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),51,H,,CHEMBL616050,,
1008,,,BAO_0000219,,1,F,Expert,,8,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,51,H,,CHEMBL616051,,
1009,,,BAO_0000219,,1,F,Autocuration,,8,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,51,H,,CHEMBL616212,,
1010,,,BAO_0000019,,1,F,Autocuration,,8,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",51,H,,CHEMBL616213,,
1011,,,BAO_0000219,,1,B,Expert,In vitro,8,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,51,H,,CHEMBL616214,,
1012,,,BAO_0000219,,1,B,Expert,In vitro,8,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,51,H,,CHEMBL616215,,
1013,,,BAO_0000357,,1,B,Autocuration,,8,Binding activity radioligand.,51,H,,CHEMBL616216,,
1014,,,BAO_0000019,,1,B,Autocuration,,8,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,51,H,,CHEMBL616217,,
1015,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616218,,
1016,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616219,,
1017,,,BAO_0000357,,1,B,Autocuration,,8,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616220,,
1018,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,51,D,,CHEMBL833493,,
1019,,,BAO_0000357,,1,B,Autocuration,,8,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616221,,
1020,449.0,Homo sapiens,BAO_0000219,CHO,1,B,Expert,,9,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,51,D,,CHEMBL616222,,
1021,,,BAO_0000019,,1,F,Autocuration,,8,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616223,,
1022,,,BAO_0000019,,1,F,Autocuration,,8,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,51,H,,CHEMBL616224,,
1023,,,BAO_0000019,,1,B,Expert,,8,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,51,H,,CHEMBL616225,,
1024,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,51,D,,CHEMBL616226,,
1025,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,51,H,,CHEMBL616227,,
1026,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,51,H,,CHEMBL616228,,
1027,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,51,H,,CHEMBL616229,,
1028,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,51,H,,CHEMBL616230,,
1029,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,51,H,,CHEMBL616231,,
1030,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,51,H,,CHEMBL616232,,
1031,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,51,H,,CHEMBL616233,,
1032,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,51,H,,CHEMBL857973,,
1033,,,BAO_0000219,,1,B,Autocuration,,8,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,51,H,,CHEMBL616234,,
1034,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616235,,
1035,308.0,,BAO_0000219,HeLa,1,B,Expert,,8,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,51,H,,CHEMBL616236,,
1036,,,BAO_0000019,,1,B,Expert,,8,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,51,H,,CHEMBL616237,,
1037,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,51,H,,CHEMBL616238,,
1038,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,51,H,,CHEMBL616239,,
1039,,,BAO_0000219,,1,B,Autocuration,,8,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,51,H,,CHEMBL616240,,
1040,308.0,Homo sapiens,BAO_0000219,HeLa,1,B,Expert,,9,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,51,D,,CHEMBL616241,,
1041,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,51,H,,CHEMBL616242,,
1042,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",51,H,,CHEMBL616243,,
1043,,,BAO_0000357,,1,B,Expert,,9,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,51,D,,CHEMBL616244,,
1044,,Homo sapiens,BAO_0000357,,1,B,Autocuration,,9,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,51,D,,CHEMBL616245,,
1045,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,106,H,,CHEMBL616246,,
1046,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-HT1D receptor,105,H,,CHEMBL616247,,
1047,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1A receptor,105,H,,CHEMBL616248,,
1048,,,BAO_0000357,,1,B,Autocuration,,8,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,107,H,,CHEMBL616249,,
1049,,Homo sapiens,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,10576,H,,CHEMBL616250,,
1050,,,BAO_0000357,,1,B,Autocuration,,8,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616251,,
1051,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,11863,H,,CHEMBL616252,,
1052,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,11863,H,,CHEMBL616253,,
1053,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,11863,H,,CHEMBL616254,,
1054,,Mus musculus,BAO_0000218,,1,F,Expert,,9,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,11863,D,,CHEMBL616255,,
1055,,Mus musculus,BAO_0000218,,1,F,Expert,,9,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,11863,D,,CHEMBL832872,,
1056,,Mus musculus,BAO_0000218,,1,F,Expert,,9,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,11863,D,,CHEMBL616256,,
1057,,Mus musculus,BAO_0000218,,1,F,Expert,,9,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,11863,D,,CHEMBL616257,,
1058,,Mus musculus,BAO_0000218,,1,F,Expert,,9,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,11863,D,,CHEMBL616258,,
1059,,Mus musculus,BAO_0000218,,1,F,Expert,,9,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,11863,D,,CHEMBL616384,,
1060,,,BAO_0000221,,1,B,Autocuration,,8,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,11863,H,,CHEMBL616385,10000000.0,
1061,,,BAO_0000357,,1,B,Expert,,8,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,11863,H,,CHEMBL616386,,
1062,,Mus musculus,BAO_0000221,,1,B,Expert,,9,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,11863,D,,CHEMBL616387,10000000.0,
1063,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,11863,H,,CHEMBL616388,10000000.0,
1064,,Mus musculus,BAO_0000221,,1,B,Expert,,9,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,11863,D,,CHEMBL616389,10000000.0,
1065,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,11863,H,,CHEMBL616390,10000000.0,
1066,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,11863,H,,CHEMBL616391,,
1067,,Mus musculus,BAO_0000221,,1,B,Expert,,9,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,11863,D,,CHEMBL616392,10000000.0,
1068,,Sus scrofa,BAO_0000357,,1,B,Autocuration,,8,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616393,,
1069,,Sus scrofa,BAO_0000357,,1,B,Autocuration,,8,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,51,H,,CHEMBL616394,,
1070,,Sus scrofa,BAO_0000019,,1,B,Autocuration,,8,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,51,H,,CHEMBL616395,,
1071,,Sus scrofa,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for the binding affinity at 5- HT1A receptor,51,H,,CHEMBL616396,,
1072,,Sus scrofa,BAO_0000019,,1,B,Autocuration,,8,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,51,H,,CHEMBL872907,,
1073,,Sus scrofa,BAO_0000019,,1,B,Autocuration,,8,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,51,H,,CHEMBL616397,,
1074,,Sus scrofa,BAO_0000019,,1,B,Autocuration,,8,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,51,H,,CHEMBL616398,,
1075,,Sus scrofa,BAO_0000357,,1,B,Expert,,8,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616399,,
1076,,Sus scrofa,BAO_0000357,,1,B,Autocuration,,8,Binding activity radioligand.,51,H,,CHEMBL857065,,
1077,,Sus scrofa,BAO_0000019,,1,B,Expert,,8,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,51,H,,CHEMBL616400,,
1078,,Sus scrofa,BAO_0000019,,1,B,Autocuration,,8,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,51,H,,CHEMBL616401,,
1079,,,BAO_0000019,,1,B,Expert,,8,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,10624,H,,CHEMBL616402,,
1080,,Sus scrofa,BAO_0000019,,1,B,Expert,,8,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616403,,
1081,,Sus scrofa,BAO_0000221,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,51,H,,CHEMBL616404,10000000.0,
1082,,Sus scrofa,BAO_0000249,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,51,H,,CHEMBL616405,,
1083,,Sus scrofa,BAO_0000019,,1,B,Autocuration,,8,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,51,H,,CHEMBL616406,,
1084,,Sus scrofa,BAO_0000019,,1,F,Expert,,8,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,51,H,,CHEMBL616407,,
1085,,Oryctolagus cuniculus,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,51,H,,CHEMBL616408,,
1086,,Rattus norvegicus,BAO_0000249,,1,B,Expert,,9,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,10576,D,,CHEMBL616409,,
1087,,Rattus norvegicus,BAO_0000221,,1,B,Expert,,9,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",10576,D,,CHEMBL616410,10000000.0,
1088,,,BAO_0000357,,1,B,Autocuration,,8,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,10576,H,,CHEMBL616411,,
1089,,Rattus norvegicus,BAO_0000249,,1,F,Expert,,9,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",10576,D,,CHEMBL616412,,
1090,,Rattus norvegicus,BAO_0000249,,1,F,Expert,,9,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",10576,D,,CHEMBL616413,10000000.0,
1091,,,BAO_0000221,,1,B,Autocuration,,8,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,H,,CHEMBL616414,10000000.0,
1092,,Rattus norvegicus,BAO_0000221,,1,B,Expert,,9,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,10576,D,,CHEMBL616415,10000000.0,
1093,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,10576,H,,CHEMBL616416,,
1094,,,BAO_0000357,,1,B,Expert,,8,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,10576,H,,CHEMBL616417,,
1095,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,10576,H,,CHEMBL616418,,
1096,,,BAO_0000219,,1,B,Autocuration,In vitro,8,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,10576,H,,CHEMBL616419,,
1097,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,10576,H,,CHEMBL616420,,
1098,,,BAO_0000249,,1,B,Autocuration,,8,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,10576,H,,CHEMBL616421,,
1099,,,BAO_0000249,,1,B,Autocuration,,8,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,10576,H,,CHEMBL616422,,
1100,,,BAO_0000249,,1,B,Expert,,8,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,10576,H,,CHEMBL616423,,
1101,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,10576,D,,CHEMBL616424,,
1102,,,BAO_0000357,,1,B,Expert,,8,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL616425,,
1103,,,BAO_0000357,,1,B,Expert,,8,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,10576,H,,CHEMBL616426,,
1104,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,10576,H,,CHEMBL616427,10000000.0,
1105,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,10576,H,,CHEMBL616428,10000000.0,
1106,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,H,,CHEMBL616290,10000000.0,
1107,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,10576,D,,CHEMBL616052,,
1108,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL616053,,
1109,,,BAO_0000249,,1,B,Autocuration,,8,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,10576,H,,CHEMBL616054,,
1110,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL616055,,
1111,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,10576,H,,CHEMBL616056,,
1112,,,BAO_0000019,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,10576,H,,CHEMBL616057,,
1113,,Rattus norvegicus,BAO_0000221,,1,B,Expert,,9,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10576,D,,CHEMBL616058,955.0,
1114,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10576,H,,CHEMBL616059,955.0,
1115,,,BAO_0000249,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,10576,H,,CHEMBL616060,,
1116,,Rattus norvegicus,BAO_0000221,,1,B,Expert,,9,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,10576,D,,CHEMBL616061,10000000.0,
1117,,,BAO_0000221,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,10576,H,,CHEMBL616062,10000000.0,
1118,,,BAO_0000249,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,10576,H,,CHEMBL616063,,
1119,,,BAO_0000249,,1,B,Autocuration,,8,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",10576,H,,CHEMBL616064,2435.0,
1120,,Rattus norvegicus,BAO_0000249,,1,B,Expert,,9,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,10576,D,,CHEMBL616065,,
1121,,Rattus norvegicus,BAO_0000249,,1,B,Expert,,9,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,10576,D,,CHEMBL616066,,
1122,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,10576,H,,CHEMBL616067,10000000.0,
1123,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,10576,H,,CHEMBL616068,10000000.0,
1124,,,BAO_0000221,,1,B,Intermediate,,8,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,10576,H,,CHEMBL616069,10000000.0,
1125,,,BAO_0000249,,1,B,Expert,,8,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,10576,H,,CHEMBL616070,,
1126,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,H,,CHEMBL616071,10000000.0,
1127,,,BAO_0000221,,1,B,Expert,,8,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,10576,H,,CHEMBL616072,10000000.0,
1128,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,10576,H,,CHEMBL616073,10000000.0,
1129,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,10576,H,,CHEMBL616074,10000000.0,
1130,,,BAO_0000019,,1,B,Expert,,8,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,10576,H,,CHEMBL616075,,
1131,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL616076,,
1132,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,10576,D,,CHEMBL616077,,
1133,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,10576,D,,CHEMBL616078,,
1134,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,10576,D,,CHEMBL616079,,
1135,485.0,Rattus norvegicus,BAO_0000219,CHO-K1,1,B,Expert,,9,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,10576,D,,CHEMBL616080,,
1136,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL616081,,
1137,,Rattus norvegicus,BAO_0000221,,1,B,Expert,,9,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,10576,D,,CHEMBL616082,10000000.0,
1138,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,10576,H,,CHEMBL616083,10000000.0,
1139,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,10576,H,,CHEMBL616084,,
1140,,,BAO_0000019,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,10576,H,,CHEMBL616085,,
1141,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,10576,H,,CHEMBL616086,,
1142,,,BAO_0000221,,1,B,Autocuration,,8,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",10576,H,,CHEMBL616087,10000000.0,
1143,,,BAO_0000357,,1,B,Expert,,8,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,10576,H,,CHEMBL616088,,
1144,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,10576,H,,CHEMBL616089,,
1145,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,10576,D,,CHEMBL616090,,
1146,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,10576,H,,CHEMBL616091,,
1147,,,BAO_0000249,,1,B,Autocuration,,8,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",10576,H,,CHEMBL616092,2435.0,
1148,,,BAO_0000357,,1,B,Autocuration,,8,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),10576,H,,CHEMBL616093,,
1149,,,BAO_0000218,,1,B,Autocuration,In vivo,8,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),10576,H,,CHEMBL616094,,
1150,,,BAO_0000221,,1,B,Autocuration,,8,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,10576,H,,CHEMBL616095,955.0,
1151,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,10576,D,,CHEMBL616096,,
1152,,,BAO_0000249,,1,B,Expert,,8,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,10576,H,,CHEMBL616097,,
1153,,Rattus norvegicus,BAO_0000249,,1,B,Expert,,9,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,10576,D,,CHEMBL616098,,
1154,,,BAO_0000221,,1,B,Autocuration,,8,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,H,,CHEMBL616099,10000000.0,
1155,,,BAO_0000221,,1,B,Autocuration,,8,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,H,,CHEMBL616100,10000000.0,
1156,,,BAO_0000357,,1,B,Expert,,8,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL616101,,
1157,,,BAO_0000249,,1,B,Expert,,8,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,10576,H,,CHEMBL616102,,
1158,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL616103,,
1159,,,BAO_0000019,,1,B,Expert,,8,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,10576,H,,CHEMBL616104,,
1160,,,BAO_0000019,,1,B,Expert,,8,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",10576,H,,CHEMBL616105,,
1161,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,10576,D,,CHEMBL616106,,
1162,,,BAO_0000019,,1,B,Autocuration,,8,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,10576,H,,CHEMBL616107,,
1163,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,10576,H,,CHEMBL616108,,
1164,,,BAO_0000221,,1,B,Expert,,8,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10576,H,,CHEMBL616109,10000000.0,
1165,,,BAO_0000357,,1,B,Autocuration,,8,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,10576,H,,CHEMBL616110,,
1166,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,10576,H,,CHEMBL616111,,
1167,,,BAO_0000019,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,10576,H,,CHEMBL616112,,
1168,,,BAO_0000221,,1,B,Autocuration,,8,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,10576,H,,CHEMBL616113,10000000.0,
1169,,,BAO_0000019,,1,B,Autocuration,,8,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL616114,,
1170,,,BAO_0000019,,1,B,Autocuration,,8,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL616115,,
1171,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL616116,,
1172,,,BAO_0000221,,1,B,Expert,,8,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,10576,H,,CHEMBL615844,955.0,
1173,,,BAO_0000221,,1,B,Expert,,8,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL615939,10000000.0,
1174,,,BAO_0000019,,1,B,Expert,,8,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,10576,H,,CHEMBL615940,,
1175,,,BAO_0000221,,1,B,Expert,,8,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,10576,H,,CHEMBL615941,10000000.0,
1176,,,BAO_0000221,,1,B,Autocuration,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,10576,H,,CHEMBL615942,10000000.0,
1177,,,BAO_0000221,,1,B,Autocuration,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10576,H,,CHEMBL615943,10000000.0,
1178,,,BAO_0000221,,1,B,Autocuration,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,10576,H,,CHEMBL615944,10000000.0,
1179,,,BAO_0000221,,1,B,Autocuration,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,10576,H,,CHEMBL615945,10000000.0,
1180,,,BAO_0000221,,1,B,Autocuration,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,10576,H,,CHEMBL615946,10000000.0,
1181,,,BAO_0000221,,1,B,Autocuration,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,10576,H,,CHEMBL615947,10000000.0,
1182,,,BAO_0000221,,1,B,Autocuration,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,10576,H,,CHEMBL615948,10000000.0,
1183,,,BAO_0000221,,1,B,Autocuration,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,10576,H,,CHEMBL615949,10000000.0,
1184,,,BAO_0000221,,1,B,Autocuration,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,10576,H,,CHEMBL615950,10000000.0,
1185,,,BAO_0000221,,1,B,Autocuration,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,10576,H,,CHEMBL615951,10000000.0,
1186,,,BAO_0000221,,1,B,Autocuration,,8,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,10576,H,,CHEMBL615952,10000000.0,
1187,,,BAO_0000221,,1,B,Autocuration,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,10576,H,,CHEMBL615953,10000000.0,
1188,,,BAO_0000221,,1,B,Autocuration,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,10576,H,,CHEMBL615954,10000000.0,
1189,,Rattus norvegicus,BAO_0000221,,1,B,Expert,,9,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10576,D,,CHEMBL615955,10000000.0,
1190,,,BAO_0000221,,1,B,Autocuration,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,10576,H,,CHEMBL615956,10000000.0,
1191,,,BAO_0000221,,1,B,Autocuration,,8,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,10576,H,,CHEMBL615957,10000000.0,
1192,,,BAO_0000019,,1,B,Expert,,8,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,10576,H,,CHEMBL615958,,
1193,,,BAO_0000019,,1,B,Expert,,8,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,10576,H,,CHEMBL615959,,
1194,,,BAO_0000019,,1,B,Autocuration,,8,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),10576,H,,CHEMBL615960,,
1195,,,BAO_0000019,,1,B,Autocuration,,8,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),10576,H,,CHEMBL615961,,
1196,,,BAO_0000221,,1,B,Expert,,8,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10576,H,,CHEMBL615962,955.0,
1197,,,BAO_0000019,,1,B,Expert,,8,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,10576,H,,CHEMBL615963,,
1198,,,BAO_0000019,,1,B,Autocuration,,8,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,10576,H,,CHEMBL615964,,
1199,,,BAO_0000019,,1,B,Autocuration,,8,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,10576,H,,CHEMBL615965,,
1200,449.0,,BAO_0000219,CHO,1,B,Expert,,8,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,10576,H,,CHEMBL615966,,
1201,,,BAO_0000249,,1,B,Expert,,8,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,10576,H,,CHEMBL615967,,
1202,,,BAO_0000019,,1,B,Expert,,8,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,10576,H,,CHEMBL615968,,
1203,449.0,,BAO_0000218,CHO,1,B,Autocuration,,8,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),10576,H,,CHEMBL615969,,
1204,,,BAO_0000218,,1,B,Autocuration,,8,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),10576,H,,CHEMBL615970,,
1205,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,10576,D,,CHEMBL615971,,
1206,,,BAO_0000249,,1,B,Expert,,8,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,10576,H,,CHEMBL615972,,
1207,,,BAO_0000249,,1,B,Autocuration,,8,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,10576,H,,CHEMBL615973,,
1208,,,BAO_0000249,,1,B,Autocuration,,8,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,10576,H,,CHEMBL615974,,
1209,449.0,Homo sapiens,BAO_0000219,CHO,1,B,Expert,,9,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,51,D,,CHEMBL615975,,
1210,,,BAO_0000249,,1,B,Expert,,8,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,10576,H,,CHEMBL615976,,
1211,,Rattus norvegicus,BAO_0000221,,1,B,Expert,,9,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,10576,D,,CHEMBL872106,10000000.0,
1212,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,10576,H,,CHEMBL615977,,
1213,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,10576,H,,CHEMBL615978,,
1214,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,10576,H,,CHEMBL616166,,
1215,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,10576,H,,CHEMBL616167,,
1216,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,10576,H,,CHEMBL616168,,
1217,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,10576,H,,CHEMBL616169,,
1218,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,10576,H,,CHEMBL616170,,
1219,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,10576,H,,CHEMBL616171,,
1220,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,10576,H,,CHEMBL616172,,
1221,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,10576,H,,CHEMBL616173,,
1222,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,10576,H,,CHEMBL616174,,
1223,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,10576,H,,CHEMBL616175,,
1224,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,10576,H,,CHEMBL616176,,
1225,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,10576,H,,CHEMBL616177,,
1226,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,10576,H,,CHEMBL616178,,
1227,,,BAO_0000019,,1,B,Autocuration,,8,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,10576,H,,CHEMBL616179,,
1228,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL616180,,
1229,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,10576,H,,CHEMBL616181,,
1230,,,BAO_0000019,,1,B,Autocuration,,8,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,10576,H,,CHEMBL616182,,
1231,,,BAO_0000221,,1,B,Autocuration,,8,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL616183,10000000.0,
1232,,,BAO_0000019,,1,B,Expert,,8,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,10576,H,,CHEMBL615874,,
1233,485.0,Rattus norvegicus,BAO_0000219,CHO-K1,1,B,Expert,,9,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,10576,D,,CHEMBL615875,,
1234,,,BAO_0000019,,1,B,Autocuration,,8,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,10576,H,,CHEMBL615876,,
1235,,,BAO_0000019,,1,B,Autocuration,,8,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,10576,H,,CHEMBL615877,,
1236,,,BAO_0000357,,1,B,Autocuration,,8,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),10576,H,,CHEMBL615878,,
1237,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,10576,H,,CHEMBL615879,,
1238,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,10576,H,,CHEMBL615880,,
1239,,,BAO_0000019,,1,B,Autocuration,,8,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",10576,H,,CHEMBL615881,,
1240,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",10576,D,,CHEMBL615882,,
1241,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,10576,H,,CHEMBL615883,,
1242,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),10576,H,,CHEMBL615884,,
1243,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),10576,H,,CHEMBL615885,,
1244,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),10576,H,,CHEMBL615886,,
1245,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),10576,H,,CHEMBL615887,,
1246,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),10576,H,,CHEMBL615888,,
1247,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),10576,H,,CHEMBL615889,,
1248,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),10576,H,,CHEMBL615890,,
1249,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),10576,H,,CHEMBL615891,,
1250,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),10576,H,,CHEMBL615892,,
1251,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),10576,H,,CHEMBL615893,,
1252,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),10576,H,,CHEMBL615894,,
1253,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),10576,H,,CHEMBL615895,,
1254,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),10576,H,,CHEMBL615896,,
1255,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,10576,H,,CHEMBL615897,,
1256,,Rattus norvegicus,BAO_0000249,,1,F,Expert,,9,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",10576,D,,CHEMBL615898,,
1257,,,BAO_0000019,,1,B,Autocuration,,8,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,10576,H,,CHEMBL615899,,
1258,,,BAO_0000019,,1,B,Autocuration,,8,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,10576,H,,CHEMBL616291,,
1259,,,BAO_0000357,,1,B,Autocuration,,8,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,10576,H,,CHEMBL616292,,
1260,,,BAO_0000249,,1,F,Autocuration,,8,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",10576,H,,CHEMBL616293,,
1261,,,BAO_0000221,,1,B,Expert,,8,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,H,,CHEMBL616294,10000000.0,
1262,,,BAO_0000249,,1,B,Autocuration,,8,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,10576,H,,CHEMBL616295,10000000.0,
1263,,,BAO_0000221,,1,B,Autocuration,,8,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,10576,H,,CHEMBL616296,955.0,
1264,,,BAO_0000019,,1,F,Autocuration,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,10576,H,,CHEMBL616297,,
1265,,,BAO_0000019,,1,F,Autocuration,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,10576,H,,CHEMBL616605,,
1266,,,BAO_0000019,,1,F,Autocuration,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,10576,H,,CHEMBL616606,,
1267,,,BAO_0000019,,1,F,Autocuration,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,10576,H,,CHEMBL616607,,
1268,,,BAO_0000019,,1,F,Expert,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,10576,H,,CHEMBL616608,,
1269,,,BAO_0000019,,1,F,Autocuration,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,10576,H,,CHEMBL616609,,
1270,,Rattus norvegicus,BAO_0000019,,1,F,Expert,,9,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,10576,D,,CHEMBL616610,,
1271,,,BAO_0000019,,1,F,Autocuration,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,10576,H,,CHEMBL616611,,
1272,,,BAO_0000019,,1,F,Expert,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,10576,H,,CHEMBL616612,,
1273,,,BAO_0000019,,1,F,Autocuration,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,10576,H,,CHEMBL616613,,
1274,,,BAO_0000019,,1,F,Expert,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,10576,H,,CHEMBL616614,,
1275,,,BAO_0000019,,1,F,Autocuration,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,10576,H,,CHEMBL616615,,
1276,,,BAO_0000019,,1,F,Expert,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,10576,H,,CHEMBL616616,,
1277,,,BAO_0000019,,1,F,Autocuration,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,10576,H,,CHEMBL616617,,
1278,,,BAO_0000019,,1,F,Autocuration,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,10576,H,,CHEMBL616618,,
1279,,,BAO_0000019,,1,F,Autocuration,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,10576,H,,CHEMBL616619,,
1280,,,BAO_0000019,,1,F,Expert,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,10576,H,,CHEMBL616620,,
1281,,,BAO_0000019,,1,F,Expert,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,10576,H,,CHEMBL616621,,
1282,,,BAO_0000019,,1,F,Autocuration,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,10576,H,,CHEMBL616622,,
1283,,,BAO_0000019,,1,F,Expert,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,10576,H,,CHEMBL616146,,
1284,,,BAO_0000019,,1,F,Autocuration,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,10576,H,,CHEMBL832873,,
1285,,,BAO_0000019,,1,F,Autocuration,,8,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,10576,H,,CHEMBL616147,,
1286,,,BAO_0000019,,1,F,Autocuration,,8,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,10576,H,,CHEMBL872872,,
1287,,,BAO_0000019,,1,F,Autocuration,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,10576,H,,CHEMBL616148,,
1288,,,BAO_0000221,,1,B,Autocuration,,8,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,10576,H,,CHEMBL616149,10000000.0,
1289,,,BAO_0000221,,1,B,Expert,,8,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,10576,H,,CHEMBL616150,10000000.0,
1290,,Rattus norvegicus,BAO_0000249,,1,B,Expert,,9,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,10576,D,,CHEMBL616151,,
1291,,,BAO_0000221,,1,B,Expert,,8,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,10576,H,,CHEMBL872873,10000000.0,
1292,,,BAO_0000221,,1,B,Autocuration,,8,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,10576,H,,CHEMBL616670,10000000.0,
1293,,,BAO_0000221,,1,B,Autocuration,,8,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,10576,H,,CHEMBL616671,10000000.0,
1294,,Rattus norvegicus,BAO_0000249,,1,F,Expert,,9,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",10576,D,,CHEMBL884861,,
1295,,,BAO_0000357,,1,B,Autocuration,,8,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,10576,H,,CHEMBL616672,,
1296,,,BAO_0000019,,1,B,Autocuration,,8,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,10576,H,,CHEMBL616673,,
1297,,,BAO_0000019,,1,F,Expert,,8,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,10576,H,,CHEMBL616674,,
1298,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,10576,H,,CHEMBL616675,,
1299,,,BAO_0000221,,1,B,Autocuration,,8,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,10576,H,,CHEMBL616676,10000000.0,
1300,,,BAO_0000221,,1,B,Autocuration,,8,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,H,,CHEMBL616677,10000000.0,
1301,,,BAO_0000221,,1,B,Autocuration,,8,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,H,,CHEMBL616678,10000000.0,
1302,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,10576,D,,CHEMBL616679,,
1303,,,BAO_0000221,,1,B,Expert,,8,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,10576,H,,CHEMBL616680,10000000.0,
1304,,,BAO_0000221,,1,B,Autocuration,,8,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,H,,CHEMBL616681,10000000.0,
1305,,,BAO_0000221,,1,B,Autocuration,,8,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,H,,CHEMBL616682,10000000.0,
1306,,,BAO_0000221,,1,B,Autocuration,,8,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL616683,10000000.0,
1307,,,BAO_0000221,,1,B,Autocuration,,8,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL616684,10000000.0,
1308,,,BAO_0000221,,1,B,Autocuration,,8,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,10576,H,,CHEMBL616685,10000000.0,
1309,,,BAO_0000221,,1,B,Autocuration,,8,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,10576,H,,CHEMBL616686,955.0,
1310,,,BAO_0000357,,1,B,Autocuration,,8,Affinity for 5-hydroxytryptamine 1A receptor site,10576,H,,CHEMBL616687,,
1311,,,BAO_0000357,,1,B,Autocuration,,8,Affinity for 5-hydroxytryptamine 1A receptor site,10576,H,,CHEMBL616688,,
1312,,,BAO_0000221,,1,B,Autocuration,,8,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,10576,H,,CHEMBL616689,10000000.0,
1313,,,BAO_0000357,,1,B,Autocuration,,8,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,10576,H,,CHEMBL616690,,
1314,,,BAO_0000357,,1,B,Expert,,8,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,10576,H,,CHEMBL616691,,
1315,,Rattus norvegicus,BAO_0000221,,1,B,Expert,,9,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,10576,D,,CHEMBL616692,10000000.0,
1316,,,BAO_0000249,,1,B,Expert,,8,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,10576,H,,CHEMBL616693,,
1317,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",10576,D,,CHEMBL616694,,
1318,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,10576,H,,CHEMBL616695,10000000.0,
1319,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,10576,H,,CHEMBL616696,,
1320,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,10576,H,,CHEMBL616697,,
1321,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against rat 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL616698,,
1322,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,10576,D,,CHEMBL616949,,
1323,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,10576,H,,CHEMBL616950,10000000.0,
1324,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,10576,H,,CHEMBL832875,,
1325,,,BAO_0000221,,1,B,Expert,,8,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10576,H,,CHEMBL616951,955.0,
1326,,,BAO_0000221,,1,B,Expert,,8,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10576,H,,CHEMBL616952,955.0,
1327,,,BAO_0000357,,1,B,Expert,,8,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,10576,H,,CHEMBL616953,,
1328,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,10576,H,,CHEMBL616954,,
1329,,,BAO_0000357,,1,B,Autocuration,,8,GTPgammaS radioligand binding assay,106,H,,CHEMBL616955,,
1330,,,BAO_0000357,,1,B,Autocuration,,8,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,106,H,,CHEMBL616956,,
1331,,,BAO_0000019,,1,F,Autocuration,,8,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,106,H,,CHEMBL616957,,
1332,,,BAO_0000019,,1,F,Autocuration,,8,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,106,H,,CHEMBL616958,,
1333,,,BAO_0000357,,1,B,Autocuration,,8,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,106,H,,CHEMBL616959,,
1334,,,BAO_0000357,,1,B,Autocuration,,8,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,106,H,,CHEMBL616960,,
1335,,,BAO_0000019,,1,F,Autocuration,,8,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,106,H,,CHEMBL616961,,
1336,308.0,,BAO_0000219,HeLa,1,B,Expert,,8,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,106,H,,CHEMBL616962,,
1337,308.0,,BAO_0000219,HeLa,1,B,Autocuration,,8,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,106,H,,CHEMBL616963,,
1338,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,106,D,,CHEMBL616524,,
1339,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,106,H,,CHEMBL616525,,
1340,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,106,H,,CHEMBL872908,,
1341,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,106,H,,CHEMBL616526,,
1342,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,106,D,,CHEMBL616527,,
1343,,,BAO_0000219,,1,B,Expert,,8,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,106,H,,CHEMBL616528,,
1344,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,106,H,,CHEMBL616529,,
1345,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,106,H,,CHEMBL616530,,
1346,,,BAO_0000357,,1,B,Expert,,8,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,106,H,,CHEMBL616531,,
1347,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,106,H,,CHEMBL616532,,
1348,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1B receptor,106,H,,CHEMBL616533,,
1349,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,106,H,,CHEMBL616534,,
1350,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,106,H,,CHEMBL616535,,
1351,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,106,H,,CHEMBL616536,,
1352,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,106,H,,CHEMBL616537,,
1353,485.0,,BAO_0000219,CHO-K1,1,F,Expert,,8,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,106,H,,CHEMBL616538,,
1354,,,BAO_0000019,,1,F,Expert,,8,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,106,H,,CHEMBL616539,,
1355,,,BAO_0000019,,1,B,Expert,,8,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,106,H,,CHEMBL616540,,
1356,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,106,H,,CHEMBL616429,,
1357,,,BAO_0000357,,1,B,Expert,,8,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,106,H,,CHEMBL616430,,
1358,,Homo sapiens,BAO_0000219,,1,B,Expert,,9,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,106,D,,CHEMBL616431,,
1359,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,106,D,,CHEMBL616432,,
1360,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Affinity for 5-hydroxytryptamine 1B receptor subtype,106,D,,CHEMBL616433,,
1361,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity for human 5-hydroxytryptamine 1B receptor,106,D,,CHEMBL616434,,
1362,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,106,H,,CHEMBL616435,,
1363,,,BAO_0000019,,1,B,Expert,,8,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,106,H,,CHEMBL616436,,
1364,308.0,,BAO_0000219,HeLa,1,B,Autocuration,,8,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,106,H,,CHEMBL616437,,
1365,308.0,,BAO_0000219,HeLa,1,B,Autocuration,,8,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,106,H,,CHEMBL616438,,
1366,308.0,,BAO_0000219,HeLa,1,B,Autocuration,,8,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,106,H,,CHEMBL616439,,
1367,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,106,D,,CHEMBL616440,,
1368,485.0,,BAO_0000219,CHO-K1,1,B,Autocuration,,8,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,106,H,,CHEMBL616441,,
1369,,,BAO_0000357,,1,B,Expert,,8,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,106,H,,CHEMBL616442,,
1370,,,BAO_0000357,,1,B,Autocuration,,8,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,106,H,,CHEMBL616443,,
1371,485.0,,BAO_0000219,CHO-K1,1,B,Expert,,8,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,106,H,,CHEMBL616444,,
1372,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding activity against human 5-hydroxytryptamine 1B receptor,106,D,,CHEMBL616445,,
1373,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding activity against human 5-hydroxytryptamine 1B receptor,106,D,,CHEMBL616446,,
1374,449.0,Homo sapiens,BAO_0000219,CHO,1,B,Expert,,9,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,106,D,,CHEMBL616447,,
1375,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,106,H,,CHEMBL616448,,
1376,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,106,H,,CHEMBL616449,,
1377,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,106,H,,CHEMBL616450,,
1378,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,106,H,,CHEMBL857974,,
1379,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,106,H,,CHEMBL616451,,
1380,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,106,H,,CHEMBL616452,,
1381,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,106,H,,CHEMBL616453,,
1382,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,106,H,,CHEMBL616454,,
1383,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity for human 5-hydroxytryptamine 1B receptor,106,D,,CHEMBL616455,,
1384,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,106,H,,CHEMBL616456,,
1385,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,106,H,,CHEMBL616457,,
1386,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,106,H,,CHEMBL616458,,
1387,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",106,H,,CHEMBL616459,,
1388,,,BAO_0000019,,1,F,Expert,,8,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,106,H,,CHEMBL616460,,
1389,,,BAO_0000019,,1,F,Expert,,8,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,106,H,,CHEMBL616461,,
1390,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",106,H,,CHEMBL616462,,
1391,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",106,H,,CHEMBL616463,,
1392,,,BAO_0000019,,1,F,Autocuration,,8,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",105,H,,CHEMBL616464,,
1393,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,105,H,,CHEMBL616465,,
1394,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,17105,H,,CHEMBL832874,,
1395,,Oryctolagus cuniculus,BAO_0000019,,1,F,Autocuration,,8,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,106,H,,CHEMBL616184,,
1396,,Oryctolagus cuniculus,BAO_0000019,,1,B,Autocuration,,8,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,106,H,,CHEMBL616185,,
1397,,Oryctolagus cuniculus,BAO_0000019,,1,B,Intermediate,,8,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",106,H,,CHEMBL616186,,
1398,,Oryctolagus cuniculus,BAO_0000019,,1,B,Autocuration,,8,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,106,H,,CHEMBL616187,,
1399,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,10577,H,,CHEMBL616188,,
1400,,,BAO_0000357,,1,B,Intermediate,,9,Binding affinity for 5-hydroxytryptamine 1B receptor,10577,D,,CHEMBL873475,,
1401,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,10577,D,,CHEMBL616189,2435.0,
1402,,,BAO_0000357,,1,B,Expert,,8,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,10577,H,,CHEMBL616190,,
1403,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,10576,H,,CHEMBL616191,,
1404,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,10576,H,,CHEMBL616192,,
1405,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,10576,H,,CHEMBL616193,,
1406,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,10576,H,,CHEMBL616194,,
1407,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,10576,H,,CHEMBL616195,,
1408,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,10576,H,,CHEMBL616196,,
1409,,,BAO_0000249,,1,B,Autocuration,,8,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,10576,H,,CHEMBL616197,10000000.0,
1410,,,BAO_0000019,,1,B,Intermediate,,8,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,10576,H,,CHEMBL616198,,
1411,,,BAO_0000221,,1,B,Autocuration,,8,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,10576,H,,CHEMBL616199,10000000.0,
1412,,,BAO_0000221,,1,B,Expert,,8,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,10576,H,,CHEMBL616200,10000000.0,
1413,,,BAO_0000221,,1,B,Expert,,8,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,10576,H,,CHEMBL616201,10000000.0,
1414,,,BAO_0000221,,1,B,Expert,,8,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,10576,H,,CHEMBL616202,10000000.0,
1415,,,BAO_0000221,,1,B,Expert,,8,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,10576,H,,CHEMBL616203,10000000.0,
1416,,,BAO_0000221,,1,B,Expert,,8,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,10576,H,,CHEMBL616204,10000000.0,
1417,,,BAO_0000221,,1,B,Expert,,8,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,10576,H,,CHEMBL616205,10000000.0,
1418,,,BAO_0000221,,1,B,Expert,,8,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,10576,H,,CHEMBL616206,10000000.0,
1419,,,BAO_0000249,,1,B,Expert,,8,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,10576,H,,CHEMBL616207,,
1420,,,BAO_0000249,,1,B,Autocuration,,8,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,10576,H,,CHEMBL616208,,
1421,,,BAO_0000249,,1,B,Autocuration,,8,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,10576,H,,CHEMBL616209,,
1422,,,BAO_0000357,,1,B,Expert,,8,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,10576,H,,CHEMBL616210,,
1423,,,BAO_0000221,,1,B,Expert,,8,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,10576,H,,CHEMBL616211,10000000.0,
1424,,,BAO_0000221,,1,B,Autocuration,,8,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,10576,H,,CHEMBL616504,10000000.0,
1425,,Rattus norvegicus,BAO_0000221,,1,B,Expert,,9,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,10576,D,,CHEMBL616505,10000000.0,
1426,,,BAO_0000019,,1,F,Autocuration,,8,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL616506,,
1427,,,BAO_0000221,,1,B,Autocuration,,8,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,H,,CHEMBL872107,10000000.0,
1428,,Rattus norvegicus,BAO_0000221,,1,B,Expert,,9,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,10576,D,,CHEMBL616507,10000000.0,
1429,,,BAO_0000249,,1,B,Autocuration,,8,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,10576,H,,CHEMBL616303,,
1430,,,BAO_0000221,,1,B,Autocuration,,8,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,10576,H,,CHEMBL616304,10000000.0,
1431,,,BAO_0000221,,1,B,Expert,,8,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10576,H,,CHEMBL616305,10000000.0,
1432,,,BAO_0000221,,1,F,Intermediate,,8,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL616306,10000000.0,
1433,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL616307,,
1434,,Rattus norvegicus,BAO_0000221,,1,B,Expert,,9,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,10576,D,,CHEMBL881829,10000000.0,
1435,,,BAO_0000357,,1,B,Expert,,8,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,10576,H,,CHEMBL616308,,
1436,,,BAO_0000019,,1,B,Autocuration,,8,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,10576,H,,CHEMBL616309,,
1437,,,BAO_0000019,,1,B,Expert,,8,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,10576,H,,CHEMBL616310,,
1438,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,10576,H,,CHEMBL616311,,
1439,,,BAO_0000357,,1,B,Expert,,8,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,10576,H,,CHEMBL616312,,
1440,,,BAO_0000357,,1,B,Autocuration,,8,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,10576,H,,CHEMBL616313,,
1441,,Rattus norvegicus,BAO_0000221,,1,B,Expert,,9,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,10576,D,,CHEMBL616314,10000000.0,
1442,,,BAO_0000221,,1,B,Autocuration,,8,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,H,,CHEMBL616315,10000000.0,
1443,,,BAO_0000221,,1,B,Autocuration,,8,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,10576,H,,CHEMBL616567,10000000.0,
1444,,,BAO_0000221,,1,B,Autocuration,,8,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,10576,H,,CHEMBL616568,10000000.0,
1445,,,BAO_0000019,,1,B,Intermediate,,8,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,10576,H,,CHEMBL616569,,
1446,,,BAO_0000357,,1,B,Expert,,8,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,10576,H,,CHEMBL616570,,
1447,,,BAO_0000357,,1,B,Autocuration,,8,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,10576,H,,CHEMBL616571,,
1448,,,BAO_0000221,,1,B,Autocuration,,8,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,10576,H,,CHEMBL616572,10000000.0,
1449,,,BAO_0000249,,1,B,Expert,,8,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,10576,H,,CHEMBL616573,,
1450,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,10576,D,,CHEMBL616574,,
1451,,,BAO_0000221,,1,B,Expert,,8,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,10576,H,,CHEMBL616575,10000000.0,
1452,,,BAO_0000221,,1,B,Autocuration,,8,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,10576,H,,CHEMBL872108,10000000.0,
1453,,,BAO_0000357,,1,B,Autocuration,,8,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,10576,H,,CHEMBL616576,,
1454,,,BAO_0000249,,1,B,Autocuration,,8,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,10576,H,,CHEMBL616577,,
1455,,,BAO_0000249,,1,B,Autocuration,,8,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,10576,H,,CHEMBL616578,,
1456,,,BAO_0000357,,1,B,Expert,,8,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,10576,H,,CHEMBL616579,,
1457,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,10576,D,,CHEMBL616580,,
1458,,,BAO_0000019,,1,B,Autocuration,,8,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,10576,H,,CHEMBL616581,,
1459,,,BAO_0000221,,1,B,Autocuration,,8,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,H,,CHEMBL616582,10000000.0,
1460,,,BAO_0000221,,1,B,Expert,,8,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,H,,CHEMBL616583,10000000.0,
1461,,Rattus norvegicus,BAO_0000221,,1,B,Expert,,9,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,10576,D,,CHEMBL616584,10000000.0,
1462,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL616585,,
1463,,Rattus norvegicus,BAO_0000221,,1,B,Expert,,9,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,10576,D,,CHEMBL616586,10000000.0,
1464,,,BAO_0000221,,1,B,Autocuration,,8,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,10576,H,,CHEMBL616587,10000000.0,
1465,,,BAO_0000221,,1,B,Autocuration,,8,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,10576,H,,CHEMBL616588,10000000.0,
1466,,,BAO_0000221,,1,B,Autocuration,,8,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,10576,H,,CHEMBL616589,10000000.0,
1467,,,BAO_0000221,,1,B,Expert,,8,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,H,,CHEMBL616590,10000000.0,
1468,449.0,,BAO_0000219,CHO,1,B,Expert,,8,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",10576,H,,CHEMBL616591,,
1469,,,BAO_0000357,,1,B,Expert,,8,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL616592,,
1470,,,BAO_0000357,,1,B,Autocuration,,8,The inhibition activity of 5-HT1A at 1 uM,10576,H,,CHEMBL616593,,
1471,485.0,,BAO_0000219,CHO-K1,1,B,Expert,,8,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",10576,H,,CHEMBL616594,,
1472,,,BAO_0000249,,1,B,Expert,,8,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,10576,H,,CHEMBL616595,,
1473,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,10576,H,,CHEMBL616596,,
1474,,,BAO_0000221,,1,B,Autocuration,,8,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10576,H,,CHEMBL616597,10000000.0,
1475,,,BAO_0000221,,1,B,Expert,,8,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10576,H,,CHEMBL616598,10000000.0,
1476,,Rattus norvegicus,BAO_0000249,,1,F,Expert,,9,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,10576,D,,CHEMBL616599,,
1477,,Rattus norvegicus,BAO_0000249,,1,F,Expert,,9,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",10576,D,,CHEMBL616600,10000000.0,
1478,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,10576,H,,CHEMBL616601,,
1479,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,10576,H,,CHEMBL616602,,
1480,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,10576,H,,CHEMBL616603,,
1481,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,10576,H,,CHEMBL616604,,
1482,,,BAO_0000249,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,10576,H,,CHEMBL616316,,
1483,,,BAO_0000249,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,10576,H,,CHEMBL616317,,
1484,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,10576,D,,CHEMBL616318,,
1485,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,10576,H,,CHEMBL616319,10000000.0,
1486,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,10576,H,,CHEMBL616320,10000000.0,
1487,,Rattus norvegicus,BAO_0000221,,1,B,Expert,,9,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,10576,D,,CHEMBL616321,10000000.0,
1488,,,BAO_0000019,,1,F,Autocuration,,8,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,10576,H,,CHEMBL616322,,
1489,,,BAO_0000019,,1,F,Autocuration,,8,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,10576,H,,CHEMBL616323,,
1490,,,BAO_0000357,,1,B,Autocuration,,8,Ratio of binding affinity to 5-HT 1A and D2 receptor,10576,H,,CHEMBL616324,,
1491,,,BAO_0000221,,1,B,Autocuration,,8,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,10576,H,,CHEMBL616325,10000000.0,
1492,,,BAO_0000221,,1,B,Autocuration,,8,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,10576,H,,CHEMBL616326,10000000.0,
1493,,,BAO_0000221,,1,B,Autocuration,,8,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,10576,H,,CHEMBL616327,10000000.0,
1494,,,BAO_0000357,,1,B,Autocuration,,8,Percentage inhibition against 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL616328,,
1495,,,BAO_0000249,,1,B,Autocuration,,8,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),10576,H,,CHEMBL858110,,
1496,,,BAO_0000249,,1,F,Autocuration,,8,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),10576,H,,CHEMBL616329,,
1497,,,BAO_0000249,,1,B,Autocuration,,8,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),10576,H,,CHEMBL616330,,
1498,,,BAO_0000249,,1,F,Autocuration,,8,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),10576,H,,CHEMBL616331,,
1499,,,BAO_0000249,,1,F,Autocuration,,8,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,10576,H,,CHEMBL616332,,
1500,,,BAO_0000249,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,10576,H,,CHEMBL857063,955.0,
1501,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,10576,H,,CHEMBL616333,,
1502,,,BAO_0000019,,1,F,Expert,,8,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,10576,H,,CHEMBL616334,,
1503,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10576,H,,CHEMBL616335,10000000.0,
1504,,,BAO_0000019,,1,B,Autocuration,,8,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,10576,H,,CHEMBL616336,,
1505,,,BAO_0000249,,1,B,Expert,,8,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,10576,H,,CHEMBL616337,,
1506,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,10576,H,,CHEMBL616338,,
1507,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,10576,H,,CHEMBL616339,10000000.0,
1508,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,10576,H,,CHEMBL616340,10000000.0,
1509,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,10576,H,,CHEMBL616341,,
1510,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Binding affinity against rat 5-hydroxytryptamine 1A receptor,10576,D,,CHEMBL616342,,
1511,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,10576,D,,CHEMBL616343,,
1512,,,BAO_0000019,,1,B,Expert,,8,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,10576,H,,CHEMBL616344,,
1513,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,10576,H,,CHEMBL616345,,
1514,,,BAO_0000019,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,10576,H,,CHEMBL616346,,
1515,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10576,H,,CHEMBL616347,10000000.0,
1516,,,BAO_0000019,,1,B,Expert,,8,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,10576,H,,CHEMBL616348,,
1517,,,BAO_0000357,,1,B,Expert,,8,Binding affinity at 5-hydroxytryptamine 1A receptor,10576,H,,CHEMBL616349,,
1518,,Rattus norvegicus,BAO_0000249,,1,B,Expert,,9,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,10576,D,,CHEMBL616152,,
1519,,,BAO_0000249,,1,B,Autocuration,,8,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,10576,H,,CHEMBL616153,,
1520,,,BAO_0000019,,1,B,Expert,,8,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",10576,H,,CHEMBL616154,,
1521,,,BAO_0000019,,1,B,Autocuration,,8,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,10576,H,,CHEMBL616155,,
1522,,Rattus norvegicus,BAO_0000221,,1,B,Expert,,9,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,10576,D,,CHEMBL616156,10000000.0,
1523,,Rattus norvegicus,BAO_0000221,,1,B,Expert,,9,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,10576,D,,CHEMBL616157,10000000.0,
1524,,,BAO_0000221,,1,B,Autocuration,,8,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,10576,H,,CHEMBL616158,10000000.0,
1525,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,10576,H,,CHEMBL616159,,
1526,,,BAO_0000357,,1,B,Expert,,8,pKi value against rat 5-hydroxytryptamine 1A receptor.,10576,H,,CHEMBL616160,,
1527,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,10576,H,,CHEMBL616161,,
1528,,,BAO_0000019,,1,F,Autocuration,,8,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,10576,H,,CHEMBL616162,,
1529,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,12687,D,,CHEMBL616163,,
1530,,,BAO_0000249,,1,B,Expert,,8,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,10626,H,,CHEMBL616164,,
1531,,,BAO_0000221,,1,B,Autocuration,,8,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,10576,H,,CHEMBL616165,955.0,
1532,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,8,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,51,H,,CHEMBL616355,,
1533,,,BAO_0000019,,1,F,Autocuration,,8,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,10576,H,,CHEMBL616356,,
1534,,,BAO_0000221,,1,B,Autocuration,,8,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10576,H,,CHEMBL616357,955.0,
1535,,,BAO_0000019,,1,B,Autocuration,,8,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",10576,H,,CHEMBL616358,,
1536,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616359,,
1537,,,BAO_0000357,,1,B,Expert,,8,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,51,H,,CHEMBL616360,,
1538,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616361,,
1539,,,BAO_0000357,,1,B,Autocuration,,8,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616362,,
1540,,,BAO_0000249,,1,B,Autocuration,,8,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,51,H,,CHEMBL616363,,
1541,,,BAO_0000357,,1,B,Autocuration,,8,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,51,H,,CHEMBL616364,,
1542,,,BAO_0000357,,1,B,Autocuration,,8,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616365,,
1543,,,BAO_0000357,,1,B,Expert,,8,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,51,H,,CHEMBL616366,,
1544,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL872906,,
1545,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,51,H,,CHEMBL616367,,
1546,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616368,,
1547,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,51,H,,CHEMBL616369,,
1548,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,51,D,,CHEMBL616370,,
1549,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,51,D,,CHEMBL616371,,
1550,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,51,H,,CHEMBL616372,,
1551,,,BAO_0000219,,1,B,Expert,,8,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,51,H,,CHEMBL616373,,
1552,,,BAO_0000218,,1,B,Autocuration,In vivo,8,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,H,,CHEMBL616374,,
1553,,,BAO_0000221,,1,B,Autocuration,,8,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,H,,CHEMBL616375,10000000.0,
1554,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,51,H,,CHEMBL616376,,
1555,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,51,H,,CHEMBL857064,,
1556,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,51,H,,CHEMBL616377,,
1557,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,51,H,,CHEMBL616378,,
1558,,,BAO_0000357,,1,B,Autocuration,,8,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,51,H,,CHEMBL616379,,
1559,,,BAO_0000357,,1,B,Autocuration,,8,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,11863,H,,CHEMBL616380,,
1560,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,11863,H,,CHEMBL616381,,
1561,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,11863,H,,CHEMBL616382,,
1562,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,11863,H,,CHEMBL616383,,
1563,449.0,Mus musculus,BAO_0000219,CHO,1,B,Expert,,9,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,11863,D,,CHEMBL616350,,
1564,,,BAO_0000357,,1,B,Autocuration,,8,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,11863,H,,CHEMBL616351,,
1565,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,11863,H,,CHEMBL616352,,
1566,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1A receptor,11863,H,,CHEMBL616353,,
1567,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against serotonergic 5-HT1a receptor,11863,H,,CHEMBL616354,,
1568,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,11863,H,,CHEMBL616508,,
1569,,Mus musculus,BAO_0000357,,1,B,Expert,,9,Binding affinity for 5-hydroxytryptamine 1A receptor,11863,D,,CHEMBL616559,,
1570,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity at 5-hydroxytryptamine 1A receptor,11863,H,,CHEMBL616560,,
1571,,,BAO_0000357,,1,B,Autocuration,,8,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",11863,H,,CHEMBL616561,,
1572,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,11863,H,,CHEMBL616562,,
1573,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,11863,H,,CHEMBL616563,,
1574,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,11863,H,,CHEMBL616564,,
1575,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,11863,H,,CHEMBL616565,,
1576,,,BAO_0000218,,1,B,Autocuration,,8,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,11863,H,,CHEMBL616566,,
1577,,,BAO_0000357,,1,B,Autocuration,,8,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,11863,H,,CHEMBL616989,,
1578,,,BAO_0000357,,1,B,Autocuration,,8,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,11863,H,,CHEMBL857975,,
1579,,Mus musculus,BAO_0000357,,1,B,Expert,,9,Binding affinity against 5-hydroxytryptamine 1A receptor,11863,D,,CHEMBL616990,,
1580,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,11863,H,,CHEMBL616991,,
1581,,,BAO_0000357,,1,B,Autocuration,,8,Tested against 5-hydroxytryptamine 1A receptor,11863,H,,CHEMBL616992,,
1582,,,BAO_0000357,,1,B,Autocuration,,8,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,11863,H,,CHEMBL616993,,
1583,,Oryctolagus cuniculus,BAO_0000019,,1,B,Expert,,8,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,106,H,,CHEMBL616994,,
1584,,Oryctolagus cuniculus,BAO_0000019,,1,B,Autocuration,,8,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,106,H,,CHEMBL616995,,
1585,722.0,Gorilla gorilla,BAO_0000219,HEK293,1,B,Intermediate,,9,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,105571,D,,CHEMBL616996,,
1586,,Cavia porcellus,BAO_0000218,,1,F,Autocuration,In vivo,8,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,106,H,,CHEMBL616997,,
1587,,Cavia porcellus,BAO_0000218,,1,F,Autocuration,In vivo,8,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,106,H,,CHEMBL616998,,
1588,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,8,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,106,H,,CHEMBL616999,,
1589,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,8,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,106,H,,CHEMBL617000,,
1590,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,8,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,106,H,,CHEMBL617001,,
1591,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,8,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,106,H,,CHEMBL858111,,
1592,,,BAO_0000019,,1,F,Autocuration,,8,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,106,H,,CHEMBL617002,,
1593,,,BAO_0000019,,1,F,Autocuration,,8,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),106,H,,CHEMBL617003,,
1594,,,BAO_0000019,,1,F,Autocuration,,8,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),106,H,,CHEMBL617004,,
1595,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,106,D,,CHEMBL617005,,
1596,485.0,Homo sapiens,BAO_0000219,CHO-K1,1,F,Expert,,9,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,106,D,,CHEMBL616623,,
1597,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,106,H,,CHEMBL616624,,
1598,,,BAO_0000357,,1,B,Autocuration,,8,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,106,H,,CHEMBL883243,,
1599,,,BAO_0000019,,1,F,Autocuration,,8,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,106,H,,CHEMBL616625,,
1600,449.0,,BAO_0000219,CHO,1,F,Expert,,8,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",106,H,,CHEMBL616626,,
1601,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,106,H,,CHEMBL616627,,
1602,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,106,H,,CHEMBL616628,,
1603,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,106,H,,CHEMBL616629,,
1604,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,106,H,,CHEMBL616630,,
1605,,,BAO_0000019,,1,F,Expert,,8,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",106,H,,CHEMBL616631,,
1606,,,BAO_0000019,,1,F,Autocuration,,8,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",106,H,,CHEMBL616632,,
1607,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,106,D,,CHEMBL616633,,
1608,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,106,H,,CHEMBL616634,,
1609,,,BAO_0000357,,1,B,Autocuration,,8,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,106,H,,CHEMBL616635,,
1610,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity against 5-hydroxytryptamine 1B receptor,106,D,,CHEMBL885358,,
1611,449.0,Homo sapiens,BAO_0000219,CHO,1,B,Expert,,9,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,106,D,,CHEMBL616636,,
1612,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,106,H,,CHEMBL616637,,
1613,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,106,H,,CHEMBL616638,,
1614,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,106,H,,CHEMBL616639,,
1615,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,106,H,,CHEMBL616640,,
1616,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,106,H,,CHEMBL616641,,
1617,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,106,H,,CHEMBL616642,,
1618,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,106,H,,CHEMBL616643,,
1619,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),106,H,,CHEMBL616644,,
1620,,,BAO_0000357,,1,B,Autocuration,,8,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,106,H,,CHEMBL616645,,
1621,,Oryctolagus cuniculus,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),105,H,,CHEMBL616646,,
1622,,Oryctolagus cuniculus,BAO_0000019,,1,F,Expert,,8,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),105,H,,CHEMBL616647,,
1623,,,BAO_0000357,,1,B,Autocuration,,8,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),105,H,,CHEMBL616509,,
1624,,,BAO_0000357,,1,B,Autocuration,,8,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),105,H,,CHEMBL616510,,
1625,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL616511,,
1626,,Bos taurus,BAO_0000357,,1,B,Expert,,8,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,105,H,,CHEMBL616512,,
1627,,Bos taurus,BAO_0000357,,1,B,Autocuration,,8,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,105,H,,CHEMBL616513,,
1628,,Bos taurus,BAO_0000019,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,105,H,,CHEMBL616514,2435.0,
1629,,Bos taurus,BAO_0000357,,1,B,Expert,,8,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,105,H,,CHEMBL616515,,
1630,,Bos taurus,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,105,H,,CHEMBL616516,,
1631,,Bos taurus,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,105,H,,CHEMBL616517,,
1632,,Bos taurus,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,105,H,,CHEMBL616518,,
1633,,Bos taurus,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,105,H,,CHEMBL616519,,
1634,,Bos taurus,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,105,H,,CHEMBL616520,,
1635,,Bos taurus,BAO_0000357,,1,B,Autocuration,,8,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,105,H,,CHEMBL616521,,
1636,,Bos taurus,BAO_0000357,,1,B,Autocuration,,8,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,105,H,,CHEMBL616522,,
1637,,Bos taurus,BAO_0000357,,1,B,Autocuration,,8,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,105,H,,CHEMBL884531,,
1638,,Bos taurus,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,105,H,,CHEMBL616523,,
1639,,Bos taurus,BAO_0000019,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,105,H,,CHEMBL616731,2435.0,
1640,,Bos taurus,BAO_0000019,,1,B,Autocuration,,8,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,105,H,,CHEMBL616732,,
1641,,Bos taurus,BAO_0000357,,1,B,Autocuration,,8,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,105,H,,CHEMBL616733,,
1642,,Bos taurus,BAO_0000357,,1,B,Autocuration,,8,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,105,H,,CHEMBL616734,,
1643,,Bos taurus,BAO_0000249,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,105,H,,CHEMBL616735,,
1644,,Bos taurus,BAO_0000249,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,105,H,,CHEMBL616736,,
1645,,Bos taurus,BAO_0000019,,1,F,Expert,,8,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,H,,CHEMBL616737,,
1646,,Bos taurus,BAO_0000019,,1,B,Autocuration,,8,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,105,H,,CHEMBL616738,,
1647,,Bos taurus,BAO_0000019,,1,F,Expert,,8,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,H,,CHEMBL616739,,
1648,,Bos taurus,BAO_0000019,,1,F,Expert,,8,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,H,,CHEMBL616740,,
1649,,Bos taurus,BAO_0000019,,1,F,Expert,,8,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,H,,CHEMBL616741,,
1650,722.0,Gorilla gorilla,BAO_0000219,HEK293,1,B,Autocuration,,8,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,105,H,,CHEMBL616742,,
1651,,Cavia porcellus,BAO_0000019,,1,B,Intermediate,,9,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,105570,D,,CHEMBL616743,,
1652,,Cavia porcellus,BAO_0000019,,1,B,Intermediate,,9,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,105570,D,,CHEMBL616744,,
1653,,Cavia porcellus,BAO_0000019,,1,F,Intermediate,,9,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,105570,D,,CHEMBL616745,,
1654,,Cavia porcellus,BAO_0000019,,1,F,Intermediate,,9,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,D,,CHEMBL616746,,
1655,,Cavia porcellus,BAO_0000019,,1,F,Intermediate,,9,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,105570,D,,CHEMBL616747,,
1656,,Cavia porcellus,BAO_0000019,,1,F,Intermediate,,9,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,105570,D,,CHEMBL616748,,
1657,,Cavia porcellus,BAO_0000019,,1,F,Intermediate,,9,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,105570,D,,CHEMBL616648,,
1658,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,Binding affinity against 5-hydroxytryptamine 1D receptor,105570,D,,CHEMBL616649,,
1659,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,105570,D,,CHEMBL616650,,
1660,,Cavia porcellus,BAO_0000218,,1,F,Intermediate,,9,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,D,,CHEMBL616651,,
1661,,Cavia porcellus,BAO_0000218,,1,F,Intermediate,,9,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,D,,CHEMBL616652,,
1662,,Cavia porcellus,BAO_0000218,,1,F,Intermediate,,9,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,D,,CHEMBL616653,,
1663,,Cavia porcellus,BAO_0000218,,1,F,Intermediate,,9,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,105570,D,,CHEMBL616654,,
1664,,Cavia porcellus,BAO_0000019,,1,B,Intermediate,,9,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,105570,D,,CHEMBL616655,,
1665,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,105570,D,,CHEMBL616656,,
1666,,Cavia porcellus,BAO_0000019,,1,B,Autocuration,,8,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,105,H,,CHEMBL616657,,
1667,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,105570,D,,CHEMBL616658,2435.0,
1668,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,105570,D,,CHEMBL616659,,
1669,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1D receptor,51,H,,CHEMBL616660,,
1670,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,106,H,,CHEMBL616661,,
1671,,,BAO_0000019,,1,F,Expert,,8,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL616662,,
1672,,,BAO_0000019,,1,F,Autocuration,,8,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL616663,,
1673,,,BAO_0000019,,1,F,Autocuration,,8,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL616664,,
1674,449.0,Homo sapiens,BAO_0000219,CHO,1,F,Expert,,9,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",105,D,,CHEMBL881820,,
1675,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",105,H,,CHEMBL616665,,
1676,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL616666,,
1677,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL616667,,
1678,449.0,,BAO_0000219,CHO,1,F,Expert,,8,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",105,H,,CHEMBL616668,,
1679,449.0,Homo sapiens,BAO_0000219,CHO,1,F,Expert,,9,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",105,D,,CHEMBL616669,,
1680,449.0,,BAO_0000219,CHO,1,F,Expert,,8,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",105,H,,CHEMBL617040,,
1681,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",105,H,,CHEMBL617041,,
1682,449.0,,BAO_0000219,CHO,1,F,Expert,,8,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",105,H,,CHEMBL617042,,
1683,449.0,,BAO_0000219,CHO,1,F,Expert,,8,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",105,H,,CHEMBL617043,,
1684,,,BAO_0000019,,1,F,Autocuration,,8,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL617044,,
1685,449.0,,BAO_0000219,CHO,1,F,Expert,,8,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL617045,,
1686,449.0,Homo sapiens,BAO_0000219,CHO,1,F,Expert,,9,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",105,D,,CHEMBL617046,,
1687,449.0,Homo sapiens,BAO_0000219,CHO,1,F,Expert,,9,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",105,D,,CHEMBL617047,,
1688,,,BAO_0000019,,1,F,Expert,,8,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",105,H,,CHEMBL617048,,
1689,,,BAO_0000019,,1,F,Autocuration,,8,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",105,H,,CHEMBL616897,,
1690,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",105,D,,CHEMBL616898,,
1691,449.0,Homo sapiens,BAO_0000219,CHO,1,F,Expert,,9,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,105,D,,CHEMBL858201,,
1692,,,BAO_0000019,,1,F,Autocuration,,8,Intrinsic activity for 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL616899,,
1693,,,BAO_0000219,,1,B,Autocuration,In vitro,8,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),105,H,,CHEMBL616900,,
1694,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,105,H,,CHEMBL616901,,
1695,,,BAO_0000357,,1,B,Autocuration,,8,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,105,H,,CHEMBL616902,,
1696,449.0,Homo sapiens,BAO_0000219,CHO,1,B,Expert,,9,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,D,,CHEMBL616903,,
1697,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,105,H,,CHEMBL616904,,
1698,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL616905,,
1699,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,105,H,,CHEMBL616906,,
1700,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,105,H,,CHEMBL616907,,
1701,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,105,H,,CHEMBL616908,,
1702,449.0,Homo sapiens,BAO_0000219,CHO,1,B,Expert,,9,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,D,,CHEMBL616909,,
1703,449.0,Homo sapiens,BAO_0000219,CHO,1,B,Expert,,9,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,D,,CHEMBL616910,,
1704,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,105,H,,CHEMBL616911,,
1705,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,H,,CHEMBL616912,,
1706,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),105,H,,CHEMBL616913,,
1707,449.0,Homo sapiens,BAO_0000219,CHO,1,B,Expert,,9,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,105,D,,CHEMBL616914,,
1708,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,105,H,,CHEMBL616915,,
1709,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,105,H,,CHEMBL616916,,
1710,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,105,D,,CHEMBL616917,,
1711,,,BAO_0000357,,1,B,Autocuration,,8,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",105,H,,CHEMBL616918,,
1712,,,BAO_0000219,,1,B,Expert,,8,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,105,H,,CHEMBL616919,,
1713,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,105,H,,CHEMBL616920,,
1714,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,105,H,,CHEMBL872914,,
1715,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,105,H,,CHEMBL616921,,
1716,,,BAO_0000357,,1,B,Expert,,8,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL616922,,
1717,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL616923,,
1718,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL616924,,
1719,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,105,H,,CHEMBL875909,,
1720,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,105,H,,CHEMBL616925,,
1721,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,105,H,,CHEMBL616926,,
1722,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL616927,,
1723,485.0,,BAO_0000219,CHO-K1,1,F,Expert,,8,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,105,H,,CHEMBL616928,,
1724,,Homo sapiens,BAO_0000219,,1,B,Expert,In vitro,9,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),105,D,,CHEMBL616929,,
1725,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,105,D,,CHEMBL616930,,
1726,,,BAO_0000019,,1,B,Expert,,8,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL616931,,
1727,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,105,H,,CHEMBL616932,,
1728,,,BAO_0000357,,1,B,Expert,,8,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL616933,,
1729,,Homo sapiens,BAO_0000219,,1,B,Expert,,9,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,105,D,,CHEMBL616934,,
1730,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity for human 5-hydroxytryptamine 1D receptor,105,D,,CHEMBL616935,,
1731,,,BAO_0000357,,1,B,Autocuration,,8,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,105,H,,CHEMBL616936,,
1732,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Affinity for 5-hydroxytryptamine 1D receptor subtype,105,D,,CHEMBL616937,,
1733,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity for human 5-hydroxytryptamine 1D receptor,105,D,,CHEMBL616938,,
1734,,,BAO_0000019,,1,B,Autocuration,,8,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL616939,,
1735,,,BAO_0000019,,1,B,Expert,,8,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,105,H,,CHEMBL616940,,
1736,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,105,D,,CHEMBL616941,,
1737,485.0,,BAO_0000219,CHO-K1,1,B,Autocuration,,8,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,105,H,,CHEMBL616942,,
1738,485.0,,BAO_0000219,CHO-K1,1,B,Autocuration,,8,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,105,H,,CHEMBL616943,,
1739,449.0,,BAO_0000219,CHO,1,B,Autocuration,,4,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,104802,H,,CHEMBL616944,,
1740,,,BAO_0000019,,1,F,Autocuration,,8,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",105,H,,CHEMBL616945,,
1741,,,BAO_0000357,,1,B,Autocuration,,8,Binding activity radioligand.,105,H,,CHEMBL616946,,
1742,,,BAO_0000019,,1,B,Autocuration,,8,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,105,H,,CHEMBL616947,,
1743,485.0,,BAO_0000219,CHO-K1,1,B,Expert,,8,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL616948,,
1744,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL616851,,
1745,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL616852,,
1746,,,BAO_0000357,,1,B,Autocuration,,8,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL616853,,
1747,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding activity against human 5-hydroxytryptamine 1D receptor,105,D,,CHEMBL616854,,
1748,449.0,Homo sapiens,BAO_0000219,CHO,1,B,Expert,,9,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,105,D,,CHEMBL616855,,
1749,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,105,H,,CHEMBL616856,,
1750,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,105,H,,CHEMBL616857,,
1751,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL616858,,
1752,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,105,H,,CHEMBL616859,,
1753,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,105,H,,CHEMBL616860,,
1754,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,105,H,,CHEMBL616861,,
1755,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,105,H,,CHEMBL616541,,
1756,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,105,H,,CHEMBL616542,,
1757,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,105,H,,CHEMBL616543,,
1758,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity for human 5-hydroxytryptamine 1D receptor,105,D,,CHEMBL616544,,
1759,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,105,H,,CHEMBL616545,,
1760,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,105,H,,CHEMBL616546,,
1761,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,105,H,,CHEMBL616547,,
1762,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",105,H,,CHEMBL616548,,
1763,,,BAO_0000019,,1,F,Expert,,8,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,105,H,,CHEMBL616549,,
1764,,,BAO_0000019,,1,F,Expert,,8,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,105,H,,CHEMBL616550,,
1765,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-HT2C receptor,108,H,,CHEMBL857066,,
1766,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1D receptor,108,H,,CHEMBL616551,,
1767,,,BAO_0000357,,1,B,Autocuration,,8,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,10577,H,,CHEMBL616552,,
1768,,,BAO_0000019,,1,F,Autocuration,,8,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,10577,H,,CHEMBL832876,,
1769,,,BAO_0000019,,1,B,Expert,,8,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",10577,H,,CHEMBL616553,,
1770,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-HT1B was determined,10577,H,,CHEMBL616554,,
1771,,,BAO_0000019,,1,B,Expert,,8,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,10577,H,,CHEMBL616555,,
1772,,,BAO_0000019,,1,B,Expert,,8,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",10577,H,,CHEMBL616556,,
1773,,,BAO_0000019,,1,B,Autocuration,,8,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",10577,H,,CHEMBL616557,,
1774,,,BAO_0000019,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,10577,H,,CHEMBL616558,,
1775,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,10577,D,,CHEMBL616749,,
1776,,,BAO_0000357,,1,B,Autocuration,,8,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,10577,H,,CHEMBL616750,,
1777,,,BAO_0000357,,1,B,Autocuration,,8,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",10577,H,,CHEMBL616751,,
1778,,,BAO_0000249,,1,B,Autocuration,,8,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,10577,H,,CHEMBL616752,,
1779,,,BAO_0000019,,1,B,Autocuration,,8,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,10577,H,,CHEMBL616753,2435.0,
1780,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,10577,D,,CHEMBL616754,,
1781,,,BAO_0000019,,1,B,Autocuration,,8,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,10577,H,,CHEMBL616755,,
1782,,,BAO_0000019,,1,B,Autocuration,,8,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,10577,H,,CHEMBL616756,2435.0,
1783,,,BAO_0000019,,1,B,Autocuration,,8,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,10577,H,,CHEMBL616757,2435.0,
1784,,,BAO_0000357,,1,B,Autocuration,,8,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,10577,H,,CHEMBL616758,2435.0,
1785,,,BAO_0000249,,1,B,Autocuration,,8,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,10577,H,,CHEMBL616759,,
1786,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,10577,H,,CHEMBL616760,,
1787,,,BAO_0000019,,1,B,Autocuration,,8,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,10577,H,,CHEMBL616761,2435.0,
1788,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-HT1B serotonin receptor in rat striatum,10577,H,,CHEMBL616762,2435.0,
1789,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,10577,H,,CHEMBL616763,,
1790,,,BAO_0000357,,1,B,Expert,,8,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,10577,H,,CHEMBL872909,,
1791,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,10577,H,,CHEMBL616764,,
1792,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,10577,D,,CHEMBL616765,,
1793,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,10577,H,,CHEMBL616766,2435.0,
1794,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,10577,H,,CHEMBL616767,2435.0,
1795,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,10577,H,,CHEMBL616768,,
1796,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,10577,H,,CHEMBL616769,,
1797,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,10577,H,,CHEMBL616770,,
1798,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,10577,H,,CHEMBL616771,,
1799,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,10577,H,,CHEMBL616772,2435.0,
1800,,,BAO_0000019,,1,B,Expert,,8,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,10577,H,,CHEMBL616773,,
1801,,,BAO_0000019,,1,B,Autocuration,,8,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,10577,H,,CHEMBL616774,,
1802,,,BAO_0000357,,1,B,Autocuration,,8,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,10577,H,,CHEMBL616775,,
1803,,,BAO_0000249,,1,B,Autocuration,,8,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,10577,H,,CHEMBL616776,,
1804,,,BAO_0000357,,1,B,Autocuration,,8,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,10577,H,,CHEMBL616777,,
1805,,,BAO_0000357,,1,B,Autocuration,,8,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,10577,H,,CHEMBL616778,,
1806,,Rattus norvegicus,BAO_0000249,,1,B,Expert,,9,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,10577,D,,CHEMBL616779,,
1807,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Binding affinity towards 5-hydroxytryptamine 1B receptor,10577,D,,CHEMBL616780,,
1808,,,BAO_0000019,,1,B,Autocuration,,8,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,10577,H,,CHEMBL616781,,
1809,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,10577,H,,CHEMBL616782,,
1810,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,10577,H,,CHEMBL616783,,
1811,,,BAO_0000019,,1,B,Expert,,8,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,10577,H,,CHEMBL616784,2435.0,
1812,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,10577,H,,CHEMBL616785,,
1813,,,BAO_0000249,,1,B,Autocuration,,8,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,10577,H,,CHEMBL857067,955.0,
1814,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,10577,H,,CHEMBL616786,,
1815,,,BAO_0000249,,1,B,Autocuration,,8,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,10577,H,,CHEMBL616787,955.0,
1816,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,10577,H,,CHEMBL616788,,
1817,,,BAO_0000357,,1,B,Autocuration,,8,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,10577,H,,CHEMBL616789,,
1818,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,10577,D,,CHEMBL616790,,
1819,,,BAO_0000357,,1,B,Expert,,8,Binding affinity at 5-hydroxytryptamine 1B receptor,10577,H,,CHEMBL616791,,
1820,,,BAO_0000019,,1,B,Autocuration,,8,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,10577,H,,CHEMBL616792,,
1821,,Rattus norvegicus,BAO_0000249,,1,B,Expert,,9,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,10577,D,,CHEMBL616793,,
1822,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,10577,H,,CHEMBL616794,,
1823,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,10577,H,,CHEMBL616795,,
1824,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,104686,H,,CHEMBL616796,,
1825,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,106,H,,CHEMBL616797,,
1826,,,BAO_0000249,,1,B,Autocuration,,8,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,106,H,,CHEMBL616798,,
1827,,,BAO_0000357,,1,B,Autocuration,,8,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,106,H,,CHEMBL616799,,
1828,,,BAO_0000357,,1,B,Autocuration,,8,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,106,H,,CHEMBL616800,,
1829,,,BAO_0000357,,1,B,Autocuration,,8,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,106,H,,CHEMBL616801,,
1830,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,106,H,,CHEMBL616802,,
1831,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,106,H,,CHEMBL616803,,
1832,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,106,H,,CHEMBL857068,,
1833,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,106,H,,CHEMBL616804,,
1834,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,106,H,,CHEMBL616805,,
1835,,,BAO_0000357,,1,B,Autocuration,,8,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,106,H,,CHEMBL616806,,
1836,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1B receptor,106,H,,CHEMBL616807,,
1837,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,106,H,,CHEMBL616808,,
1838,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,106,H,,CHEMBL616809,,
1839,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,106,H,,CHEMBL616810,,
1840,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,104802,H,,CHEMBL616811,,
1841,,Bos taurus,BAO_0000357,,1,B,Autocuration,,8,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,108,H,,CHEMBL616812,,
1842,,Sus scrofa,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,108,H,,CHEMBL616813,,
1843,,Sus scrofa,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,108,H,,CHEMBL616814,,
1844,,Sus scrofa,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,108,H,,CHEMBL616815,,
1845,,Sus scrofa,BAO_0000357,,1,B,Autocuration,,8,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,108,H,,CHEMBL616816,,
1846,,Sus scrofa,BAO_0000357,,1,B,Autocuration,,8,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,108,H,,CHEMBL616817,,
1847,,Sus scrofa,BAO_0000357,,1,B,Autocuration,,8,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,108,H,,CHEMBL616818,,
1848,,Sus scrofa,BAO_0000357,,1,B,Expert,,8,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,108,H,,CHEMBL616819,,
1849,,Sus scrofa,BAO_0000357,,1,B,Expert,,8,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,108,H,,CHEMBL616820,,
1850,,Sus scrofa,BAO_0000019,,1,B,Expert,,8,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,108,H,,CHEMBL616821,,
1851,,Sus scrofa,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,108,H,,CHEMBL616822,,
1852,,Oryctolagus cuniculus,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,108,H,,CHEMBL616823,,
1853,,Rattus norvegicus,BAO_0000357,,1,B,Autocuration,,9,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,12689,D,,CHEMBL616824,,
1854,,Rattus norvegicus,BAO_0000357,,1,B,Autocuration,,9,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,12689,D,,CHEMBL616825,,
1855,,Rattus norvegicus,BAO_0000357,,1,B,Autocuration,,9,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,12689,D,,CHEMBL616826,,
1856,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,12689,D,,CHEMBL616827,,
1857,,Rattus norvegicus,BAO_0000357,,1,B,Autocuration,,9,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,12689,D,,CHEMBL616828,,
1858,,Rattus norvegicus,BAO_0000357,,1,B,Autocuration,,9,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,12689,D,,CHEMBL616829,,
1859,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,9,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,12689,D,,CHEMBL616830,,
1860,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Binding affinity against 5-hydroxytryptamine 1C receptor,12689,D,,CHEMBL616831,,
1861,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,9,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,D,,CHEMBL616832,,
1862,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,9,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,D,,CHEMBL616833,,
1863,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,D,,CHEMBL616834,,
1864,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,9,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,D,,CHEMBL829595,,
1865,,Rattus norvegicus,BAO_0000357,,1,B,Autocuration,,9,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,12689,D,,CHEMBL616835,,
1866,,Rattus norvegicus,BAO_0000249,,1,B,Autocuration,,9,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,12689,D,,CHEMBL872910,,
1867,,,BAO_0000357,,1,B,Expert,,8,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,12689,H,,CHEMBL616836,,
1868,,Rattus norvegicus,BAO_0000357,,1,B,Autocuration,,9,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,12689,D,,CHEMBL616837,,
1869,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,9,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,12689,D,,CHEMBL616466,,
1870,722.0,Rattus norvegicus,BAO_0000219,HEK293,1,B,Autocuration,,9,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,12689,D,,CHEMBL616467,,
1871,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,108,H,,CHEMBL616468,,
1872,,,BAO_0000357,,1,B,Autocuration,,8,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,108,H,,CHEMBL616469,,
1873,,,BAO_0000357,,1,B,Autocuration,,8,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,108,H,,CHEMBL616470,,
1874,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1C receptor,12689,H,,CHEMBL616471,,
1875,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,12689,H,,CHEMBL616472,,
1876,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1C receptor,12689,H,,CHEMBL616473,,
1877,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against serotonergic 5-HT1c receptor,12689,H,,CHEMBL616474,,
1878,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,12689,H,,CHEMBL616475,,
1879,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,12689,H,,CHEMBL616476,,
1880,,Oryctolagus cuniculus,BAO_0000019,,1,B,Autocuration,,8,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),105,H,,CHEMBL616477,,
1881,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,104686,H,,CHEMBL616478,,
1882,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,104686,H,,CHEMBL616479,,
1883,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,104686,H,,CHEMBL616480,,
1884,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,5,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,104686,D,,CHEMBL616481,,
1885,,Rattus norvegicus,BAO_0000249,,1,B,Autocuration,,5,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,104686,D,,CHEMBL616482,,
1886,,Rattus norvegicus,BAO_0000221,,1,B,Autocuration,,5,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,104686,D,,CHEMBL884713,955.0,
1887,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,104686,H,,CHEMBL616483,,
1888,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,104686,H,,CHEMBL616484,,
1889,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,104686,H,,CHEMBL616485,,
1890,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,104686,H,,CHEMBL616486,,
1891,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,104686,H,,CHEMBL616487,,
1892,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,104686,H,,CHEMBL616488,,
1893,,,BAO_0000019,,1,B,Autocuration,,4,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,H,,CHEMBL616489,,
1894,,,BAO_0000019,,1,B,Autocuration,,4,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,H,,CHEMBL616490,,
1895,,,BAO_0000019,,1,B,Autocuration,,4,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,104686,H,,CHEMBL616491,,
1896,,,BAO_0000019,,1,B,Autocuration,,4,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,104686,H,,CHEMBL616492,,
1897,,,BAO_0000019,,1,B,Autocuration,,4,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,H,,CHEMBL616493,,
1898,,,BAO_0000019,,1,B,Autocuration,,4,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,104686,H,,CHEMBL616494,,
1899,,,BAO_0000019,,1,B,Autocuration,,4,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,104686,H,,CHEMBL616495,,
1900,,,BAO_0000019,,1,B,Autocuration,,4,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,104686,H,,CHEMBL616496,,
1901,,,BAO_0000019,,1,B,Autocuration,,4,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,H,,CHEMBL616497,,
1902,,,BAO_0000019,,1,B,Autocuration,,4,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,H,,CHEMBL616498,,
1903,,,BAO_0000019,,1,B,Autocuration,,4,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,104686,H,,CHEMBL616499,,
1904,,,BAO_0000019,,1,B,Autocuration,,4,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,104686,H,,CHEMBL616500,,
1905,,Rattus norvegicus,BAO_0000221,,1,B,Autocuration,,5,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,104686,D,,CHEMBL616501,955.0,
1906,,,BAO_0000221,,1,B,Autocuration,,4,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,104686,H,,CHEMBL616502,955.0,
1907,,,BAO_0000249,,1,B,Autocuration,,4,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,104686,H,,CHEMBL884529,,
1908,,,BAO_0000249,,1,B,Autocuration,,4,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,104686,H,,CHEMBL616503,,
1909,,,BAO_0000224,,1,B,Autocuration,,4,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,104686,H,,CHEMBL616964,,
1910,,,BAO_0000249,,1,B,Autocuration,,4,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,104686,H,,CHEMBL616965,,
1911,,,BAO_0000224,,1,B,Autocuration,,4,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,104686,H,,CHEMBL616966,,
1912,,,BAO_0000224,,1,B,Autocuration,,4,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,104686,H,,CHEMBL616967,,
1913,,Rattus norvegicus,BAO_0000224,,1,B,Autocuration,,5,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,104686,D,,CHEMBL616968,,
1914,,,BAO_0000224,,1,B,Autocuration,,4,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,104686,H,,CHEMBL616969,,
1915,,,BAO_0000019,,1,B,Autocuration,,4,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,104686,H,,CHEMBL884530,,
1916,,,BAO_0000224,,1,B,Autocuration,,4,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,104686,H,,CHEMBL616970,,
1917,,,BAO_0000224,,1,B,Autocuration,,4,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,104686,H,,CHEMBL616971,,
1918,,,BAO_0000224,,1,B,Autocuration,,4,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",104686,H,,CHEMBL616972,,
1919,,,BAO_0000224,,1,B,Autocuration,,4,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,104686,H,,CHEMBL616973,,
1920,,,BAO_0000224,,1,B,Autocuration,,4,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,104686,H,,CHEMBL616974,,
1921,,,BAO_0000019,,1,B,Autocuration,,4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,104686,H,,CHEMBL616975,,
1922,,,BAO_0000019,,1,B,Autocuration,,4,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,104686,H,,CHEMBL616976,,
1923,,,BAO_0000224,,1,B,Autocuration,,4,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,104686,H,,CHEMBL616977,,
1924,,,BAO_0000224,,1,B,Autocuration,,4,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,104686,H,,CHEMBL616978,,
1925,,,BAO_0000224,,1,B,Autocuration,,4,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,104686,H,,CHEMBL616979,,
1926,,,BAO_0000224,,1,B,Autocuration,,4,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,104686,H,,CHEMBL616980,,
1927,,,BAO_0000249,,1,B,Autocuration,,4,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,104686,H,,CHEMBL616981,,
1928,,,BAO_0000249,,1,B,Autocuration,,4,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,104686,H,,CHEMBL616982,,
1929,,,BAO_0000224,,1,B,Autocuration,,4,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,104686,H,,CHEMBL616983,,
1930,,,BAO_0000019,,1,B,Autocuration,,4,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,104686,H,,CHEMBL616984,,
1931,,Rattus norvegicus,BAO_0000224,,1,B,Autocuration,,5,Inhibitory activity against 5-hydroxytryptamine 2 receptor,104686,D,,CHEMBL616985,,
1932,,,BAO_0000224,,1,B,Autocuration,,4,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,104686,H,,CHEMBL616986,,
1933,,,BAO_0000224,,1,B,Autocuration,,4,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,104686,H,,CHEMBL616987,,
1934,,,BAO_0000019,,1,B,Autocuration,,4,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,104686,H,,CHEMBL616988,,
1935,,,BAO_0000019,,1,B,Autocuration,,4,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,104686,H,,CHEMBL617243,,
1936,,,BAO_0000019,,1,B,Autocuration,,4,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,104686,H,,CHEMBL617244,,
1937,485.0,Rattus norvegicus,BAO_0000219,CHO-K1,1,B,Autocuration,,5,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,104686,D,,CHEMBL617245,,
1938,,,BAO_0000249,,1,B,Autocuration,,4,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,104686,H,,CHEMBL617246,,
1939,,,BAO_0000224,,1,B,Autocuration,,4,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),104686,H,,CHEMBL617546,,
1940,,,BAO_0000249,,1,B,Autocuration,,4,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),104686,H,,CHEMBL617547,,
1941,,,BAO_0000219,,1,B,Autocuration,In vitro,4,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,104686,H,,CHEMBL617548,,
1942,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor,104686,H,,CHEMBL617549,,
1943,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,104686,H,,CHEMBL617550,,
1944,,,BAO_0000224,,1,B,Autocuration,,4,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,104686,H,,CHEMBL617551,,
1945,,,BAO_0000249,,1,B,Autocuration,,4,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,104686,H,,CHEMBL617552,,
1946,,,BAO_0000249,,1,B,Autocuration,,4,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,104686,H,,CHEMBL617553,,
1947,,,BAO_0000019,,1,F,Autocuration,,4,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,104686,H,,CHEMBL617554,1515.0,
1948,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,104686,H,,CHEMBL617555,,
1949,,,BAO_0000224,,1,B,Autocuration,,4,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,104686,H,,CHEMBL617556,,
1950,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,10624,H,,CHEMBL617557,,
1951,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,10624,H,,CHEMBL617558,,
1952,,,BAO_0000357,,1,B,Expert,,8,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,17106,H,,CHEMBL617559,,
1953,,,BAO_0000357,,1,B,Expert,,9,Binding affinity for 5-hydroxytryptamine 1D receptor,17106,D,,CHEMBL617560,,
1954,,,BAO_0000249,,1,B,Autocuration,,8,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,17106,H,,CHEMBL617561,,
1955,,,BAO_0000249,,1,B,Autocuration,,8,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,17106,H,,CHEMBL617562,,
1956,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,17106,H,,CHEMBL617563,2435.0,
1957,,,BAO_0000019,,1,F,Autocuration,,8,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,17106,H,,CHEMBL617564,,
1958,,,BAO_0000019,,1,B,Expert,,8,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,17106,H,,CHEMBL617565,,
1959,,,BAO_0000357,,1,B,Autocuration,,8,Binding activity radioligand.,17106,H,,CHEMBL856076,,
1960,,,BAO_0000019,,1,B,Autocuration,,8,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,17106,H,,CHEMBL617566,,
1961,,,BAO_0000019,,1,B,Expert,,8,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,17106,H,,CHEMBL875911,,
1962,,,BAO_0000019,,1,B,Autocuration,,8,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,17106,H,,CHEMBL617567,,
1963,,,BAO_0000249,,1,B,Autocuration,,8,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,17106,H,,CHEMBL617568,,
1964,,,BAO_0000019,,1,B,Expert,,8,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,17106,H,,CHEMBL617569,,
1965,,,BAO_0000249,,1,B,Expert,,8,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,17106,H,,CHEMBL617570,,
1966,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,17106,H,,CHEMBL617571,,
1967,,Sus scrofa,BAO_0000357,,1,B,Autocuration,,8,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,105,H,,CHEMBL617572,,
1968,,Oryctolagus cuniculus,BAO_0000357,,1,B,Expert,,8,The compound was tested for intrinsic activity against 5-HT1D receptor,105,H,,CHEMBL617573,,
1969,,Oryctolagus cuniculus,BAO_0000019,,1,B,Autocuration,,8,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,105,H,,CHEMBL617574,,
1970,,Oryctolagus cuniculus,BAO_0000357,,1,B,Expert,,8,The compound was tested for binding affinity against 5-HT1D receptor,105,H,,CHEMBL617575,,
1971,,,BAO_0000357,,1,B,Autocuration,,8,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,10578,H,,CHEMBL617576,,
1972,,,BAO_0000019,,1,F,Autocuration,,8,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,10578,H,,CHEMBL617577,,
1973,,,BAO_0000019,,1,F,Autocuration,,8,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,10578,H,,CHEMBL617578,,
1974,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,10578,H,,CHEMBL617579,,
1975,,,BAO_0000019,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,10578,H,,CHEMBL617580,,
1976,,,BAO_0000249,,1,B,Autocuration,,8,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,10578,H,,CHEMBL617581,,
1977,,,BAO_0000357,,1,B,Autocuration,,8,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,10578,H,,CHEMBL617582,,
1978,,,BAO_0000019,,1,B,Expert,,8,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,10578,H,,CHEMBL617583,,
1979,,,BAO_0000357,,1,B,Autocuration,,8,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,105,H,,CHEMBL617584,,
1980,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL617585,,
1981,,,BAO_0000357,,1,B,Autocuration,,8,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,105,H,,CHEMBL875912,,
1982,,,BAO_0000357,,1,B,Autocuration,,8,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL617586,,
1983,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,105,H,,CHEMBL617587,,
1984,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,105,H,,CHEMBL617588,,
1985,,,BAO_0000357,,1,B,Autocuration,,8,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL857980,,
1986,,,BAO_0000357,,1,B,Autocuration,,8,Tested against 5-hydroxytryptamine 1D receptor,105,H,,CHEMBL617589,,
1987,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,105,H,,CHEMBL617590,,
1988,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,105,H,,CHEMBL617591,,
1989,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity against 5-Hydroxytryptamine 1D receptor,105,D,,CHEMBL617592,,
1990,,,BAO_0000357,,1,B,Autocuration,,8,,105,H,,CHEMBL617593,,
1991,485.0,,BAO_0000219,CHO-K1,1,B,Autocuration,,8,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,106,H,,CHEMBL617594,,
1992,485.0,,BAO_0000219,CHO-K1,1,B,Autocuration,,8,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,105,H,,CHEMBL617595,,
1993,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,105,H,,CHEMBL617596,,
1994,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,105,H,,CHEMBL617597,,
1995,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,105,H,,CHEMBL617598,,
1996,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,105,H,,CHEMBL872916,,
1997,,,BAO_0000357,,1,B,Expert,,8,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,105,H,,CHEMBL617599,,
1998,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,105,H,,CHEMBL617091,,
1999,485.0,,BAO_0000219,CHO-K1,1,B,Expert,,8,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",105,H,,CHEMBL617092,,
2000,485.0,,BAO_0000219,CHO-K1,1,B,Autocuration,,8,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,105,H,,CHEMBL617093,,
2001,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,105,H,,CHEMBL617094,,
2002,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,105,H,,CHEMBL617095,,
2003,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,105,H,,CHEMBL617096,,
2004,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,105,H,,CHEMBL617097,,
2005,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,105,H,,CHEMBL617098,,
2006,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,105,H,,CHEMBL617301,,
2007,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,105,H,,CHEMBL617302,,
2008,,,BAO_0000357,,1,B,Autocuration,,8,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,105,H,,CHEMBL617303,,
2009,,,BAO_0000357,,1,B,Expert,,8,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,105,H,,CHEMBL617304,,
2010,449.0,,BAO_0000219,CHO,1,B,Expert,,8,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",105,H,,CHEMBL617305,,
2011,,Homo sapiens,BAO_0000219,,1,B,Autocuration,,9,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,105,D,,CHEMBL617306,,
2012,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,17106,H,,CHEMBL617307,,
2013,,Oryctolagus cuniculus,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,105,H,,CHEMBL617308,,
2014,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,105,H,,CHEMBL617309,,
2015,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,105,H,,CHEMBL617310,,
2016,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,105,H,,CHEMBL617311,,
2017,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,105,H,,CHEMBL617312,,
2018,,,BAO_0000357,,1,B,Autocuration,,8,Affinity against 5-hydroxytryptamine 1D receptor alpha,105,H,,CHEMBL617313,,
2019,,,BAO_0000357,,1,B,Expert,,8,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,105,H,,CHEMBL617314,,
2020,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,106,H,,CHEMBL617315,,
2021,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,106,H,,CHEMBL617316,,
2022,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,106,H,,CHEMBL617317,,
2023,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",106,H,,CHEMBL617318,,
2024,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,106,H,,CHEMBL617319,,
2025,,,BAO_0000357,,1,B,Expert,,9,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,106,D,,CHEMBL617320,,
2026,,,BAO_0000357,,1,B,Expert,,9,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,106,D,,CHEMBL617321,,
2027,,,BAO_0000357,,1,B,Expert,,9,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,106,D,,CHEMBL617322,,
2028,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,106,H,,CHEMBL616862,,
2029,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,106,H,,CHEMBL616863,,
2030,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,106,H,,CHEMBL616864,,
2031,485.0,,BAO_0000219,CHO-K1,1,B,Autocuration,,8,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,106,H,,CHEMBL616865,,
2032,485.0,,BAO_0000219,CHO-K1,1,B,Autocuration,,8,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,106,H,,CHEMBL616866,,
2033,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,106,H,,CHEMBL616867,,
2034,485.0,,BAO_0000219,CHO-K1,1,B,Expert,,8,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",106,H,,CHEMBL616868,,
2035,,,BAO_0000357,,1,B,Expert,,8,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,105,H,,CHEMBL616869,,
2036,449.0,,BAO_0000219,CHO,1,B,Expert,,8,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",106,H,,CHEMBL616870,,
2037,485.0,,BAO_0000219,CHO-K1,1,F,Autocuration,,8,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,105,H,,CHEMBL616871,,
2038,485.0,,BAO_0000219,CHO-K1,1,F,Autocuration,,8,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,105,H,,CHEMBL616872,,
2039,485.0,,BAO_0000219,CHO-K1,1,F,Autocuration,,8,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,105,H,,CHEMBL616873,,
2040,485.0,,BAO_0000219,CHO-K1,1,F,Autocuration,,8,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,105,H,,CHEMBL616838,,
2041,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,105,H,,CHEMBL616839,,
2042,,Oryctolagus cuniculus,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,106,H,,CHEMBL616840,,
2043,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,105,H,,CHEMBL616841,,
2044,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,105,H,,CHEMBL616842,,
2045,,,BAO_0000357,,1,B,Expert,,8,Binding affinity against 5-hydroxytryptamine 1D receptor beta,105,H,,CHEMBL857976,,
2046,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,10618,H,,CHEMBL616843,,
2047,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,10618,D,,CHEMBL616844,,
2048,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,10618,H,,CHEMBL616845,,
2049,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,10618,D,,CHEMBL616846,,
2050,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,10618,H,,CHEMBL616847,,
2051,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,10618,H,,CHEMBL616848,,
2052,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,10618,H,,CHEMBL616849,,
2053,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,10618,H,,CHEMBL872911,,
2054,,,BAO_0000019,,1,B,Autocuration,,8,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,10618,H,,CHEMBL616850,,
2055,449.0,Homo sapiens,BAO_0000219,CHO,1,B,Expert,,9,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,10618,D,,CHEMBL616699,,
2056,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,10618,H,,CHEMBL616700,,
2057,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,10618,H,,CHEMBL616701,,
2058,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,10618,H,,CHEMBL616702,,
2059,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,10618,H,,CHEMBL616703,,
2060,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,10618,H,,CHEMBL616704,,
2061,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,10618,H,,CHEMBL616705,,
2062,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,10618,H,,CHEMBL616706,,
2063,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,10618,H,,CHEMBL616707,,
2064,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,10618,H,,CHEMBL616708,,
2065,,,BAO_0000357,,1,B,Autocuration,,8,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,10618,H,,CHEMBL616709,,
2066,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,10618,H,,CHEMBL616710,,
2067,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,10618,H,,CHEMBL616711,,
2068,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",10618,H,,CHEMBL616712,,
2069,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,10618,H,,CHEMBL616713,,
2070,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,10618,H,,CHEMBL616714,,
2071,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,10618,H,,CHEMBL616715,,
2072,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1E receptor,10618,H,,CHEMBL616716,,
2073,,,BAO_0000019,,1,F,Autocuration,,8,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",279,H,,CHEMBL616717,,
2074,,,BAO_0000019,,1,F,Expert,,8,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",279,H,,CHEMBL616718,,
2075,,,BAO_0000019,,1,F,Autocuration,,8,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,279,H,,CHEMBL875905,,
2076,,,BAO_0000019,,1,F,Autocuration,,8,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,279,H,,CHEMBL616719,,
2077,,,BAO_0000019,,1,F,Expert,,8,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",279,H,,CHEMBL616720,,
2078,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,279,H,,CHEMBL616721,,
2079,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,279,H,,CHEMBL616722,,
2080,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),279,H,,CHEMBL616723,,
2081,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,279,H,,CHEMBL616724,,
2082,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,279,H,,CHEMBL616725,,
2083,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human 5-hydroxytryptamine 1F receptor,279,H,,CHEMBL616726,,
2084,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,279,H,,CHEMBL616727,,
2085,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,279,H,,CHEMBL616728,,
2086,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,279,H,,CHEMBL616729,,
2087,,,BAO_0000019,,1,B,Expert,,8,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,279,H,,CHEMBL616730,,
2088,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,279,H,,CHEMBL617125,,
2089,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,279,H,,CHEMBL857977,,
2090,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,279,H,,CHEMBL617126,,
2091,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,279,H,,CHEMBL617127,,
2092,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,279,H,,CHEMBL617128,,
2093,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,279,H,,CHEMBL617129,,
2094,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,279,H,,CHEMBL617130,,
2095,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,279,H,,CHEMBL617131,,
2096,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",279,H,,CHEMBL617132,,
2097,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",279,H,,CHEMBL617133,,
2098,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,279,H,,CHEMBL617134,,
2099,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,279,H,,CHEMBL617135,,
2100,,,BAO_0000357,,1,B,Autocuration,,8,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,279,H,,CHEMBL617136,,
2101,,,BAO_0000019,,1,B,Autocuration,,4,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",104686,H,,CHEMBL617137,,
2102,,,BAO_0000019,,1,B,Autocuration,,4,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",104686,H,,CHEMBL617138,,
2103,,,BAO_0000019,,1,B,Autocuration,,4,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",104686,H,,CHEMBL617139,,
2104,,,BAO_0000019,,1,B,Autocuration,,8,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL617140,,
2105,,,BAO_0000218,,1,F,Autocuration,In vivo,4,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",104686,H,,CHEMBL617141,,
2106,,,BAO_0000019,,1,F,Autocuration,,4,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,H,,CHEMBL858112,,
2107,,,BAO_0000019,,1,B,Intermediate,,8,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,17005,H,,CHEMBL617142,,
2108,,Bos taurus,BAO_0000019,,1,B,Autocuration,,0,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",22226,U,,CHEMBL617143,,
2109,,Bos taurus,BAO_0000019,,1,B,Autocuration,,0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,22226,U,,CHEMBL617144,,
2110,,Bos taurus,BAO_0000019,,1,B,Autocuration,,0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,22226,U,,CHEMBL617145,,
2111,,,BAO_0000019,,1,B,Autocuration,,0,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,22226,U,,CHEMBL617146,,
2112,,Cavia porcellus,BAO_0000019,,1,B,Autocuration,,4,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,104784,H,,CHEMBL617147,,
2113,,Cavia porcellus,BAO_0000019,,1,B,Autocuration,,4,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,104784,H,,CHEMBL617148,,
2114,,Cavia porcellus,BAO_0000019,,1,B,Autocuration,,4,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,104784,H,,CHEMBL617149,,
2115,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,104784,H,,CHEMBL617150,,
2116,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,104784,H,,CHEMBL617151,,
2117,,,BAO_0000224,,1,B,Autocuration,,4,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,104784,H,,CHEMBL617201,,
2118,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,10209,H,,CHEMBL617202,,
2119,,,BAO_0000218,,1,B,Autocuration,In vivo,4,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,104826,H,,CHEMBL617203,,
2120,,,BAO_0000019,,1,B,Autocuration,,4,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,104826,H,,CHEMBL617204,,
2121,,,BAO_0000224,,1,B,Autocuration,,4,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,104826,H,,CHEMBL617205,,
2122,,Mus musculus,BAO_0000019,,1,B,Autocuration,,5,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,104826,D,,CHEMBL617206,,
2123,,,BAO_0000218,,1,B,Autocuration,In vivo,4,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,104826,H,,CHEMBL617207,,
2124,,Mus musculus,BAO_0000019,,1,B,Autocuration,,5,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,104826,D,,CHEMBL617208,,
2125,,,BAO_0000224,,1,B,Autocuration,,4,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,104826,H,,CHEMBL617209,,
2126,,,BAO_0000224,,1,B,Autocuration,,4,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,104826,H,,CHEMBL617210,,
2127,,,BAO_0000224,,1,B,Autocuration,,4,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,104826,H,,CHEMBL617211,,
2128,,Mus musculus,BAO_0000019,,1,B,Autocuration,,5,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,104826,D,,CHEMBL617212,,
2129,,Sus scrofa,BAO_0000224,,1,B,Autocuration,,4,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,104784,H,,CHEMBL617213,,
2130,,Sus scrofa,BAO_0000224,,1,B,Autocuration,,4,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,104784,H,,CHEMBL617214,,
2131,,,BAO_0000221,,1,B,Autocuration,,0,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,22226,U,,CHEMBL617215,,
2132,,,BAO_0000221,,1,B,Autocuration,,0,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,22226,U,,CHEMBL617216,,
2133,,Sus scrofa,BAO_0000357,,1,B,Autocuration,,8,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,17005,H,,CHEMBL617217,,
2134,,,BAO_0000019,,1,B,Autocuration,,4,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,104686,H,,CHEMBL617218,,
2135,,,BAO_0000019,,1,B,Autocuration,,4,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,104686,H,,CHEMBL872913,,
2136,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,104826,H,,CHEMBL617219,,
2137,,,BAO_0000224,,1,B,Autocuration,,4,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,104686,H,,CHEMBL873482,,
2138,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,5,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,104686,D,,CHEMBL617220,,
2139,,,BAO_0000019,,1,B,Autocuration,,4,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,104686,H,,CHEMBL617221,,
2140,,,BAO_0000019,,1,B,Autocuration,,4,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,104686,H,,CHEMBL617222,,
2141,,,BAO_0000019,,1,F,Autocuration,,4,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,104686,H,,CHEMBL875906,,
2142,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,104686,H,,CHEMBL617223,,
2143,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,104686,H,,CHEMBL617224,,
2144,,Rattus norvegicus,BAO_0000224,,1,B,Autocuration,,5,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,104686,D,,CHEMBL617225,,
2145,,,BAO_0000224,,1,B,Autocuration,,4,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,104686,H,,CHEMBL617226,,
2146,,,BAO_0000224,,1,B,Autocuration,,4,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,104686,H,,CHEMBL617227,,
2147,,,BAO_0000224,,1,B,Autocuration,,4,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,104686,H,,CHEMBL617228,,
2148,,,BAO_0000224,,1,B,Autocuration,,4,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,104686,H,,CHEMBL617229,,
2149,,,BAO_0000224,,1,B,Autocuration,,4,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,104686,H,,CHEMBL617230,,
2150,,,BAO_0000224,,1,B,Autocuration,,4,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",104686,H,,CHEMBL617231,,
2151,,,BAO_0000224,,1,B,Autocuration,,4,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,104686,H,,CHEMBL617232,,
2152,,,BAO_0000224,,1,B,Autocuration,,4,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,104686,H,,CHEMBL617233,,
2153,,,BAO_0000224,,1,B,Autocuration,,4,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,104686,H,,CHEMBL617234,,
2154,,,BAO_0000019,,1,F,Autocuration,,4,Compound was tested for the inhibition of quipazine induced head twitches in rats,104686,H,,CHEMBL617235,,
2155,,,BAO_0000019,,1,F,Autocuration,,4,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,104686,H,,CHEMBL617236,,
2156,,,BAO_0000221,,1,B,Autocuration,,4,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,104686,H,,CHEMBL617237,10000000.0,
2157,,,BAO_0000221,,1,B,Autocuration,,4,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,104686,H,,CHEMBL617238,10000000.0,
2158,,Rattus norvegicus,BAO_0000221,,1,B,Autocuration,,5,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,104686,D,,CHEMBL617239,955.0,
2159,,,BAO_0000019,,1,B,Autocuration,,4,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,104686,H,,CHEMBL617240,,
2160,,,BAO_0000249,,1,B,Autocuration,,4,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,104686,H,,CHEMBL617241,,
2161,,,BAO_0000249,,1,B,Autocuration,,4,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,104686,H,,CHEMBL875907,,
2162,,,BAO_0000019,,1,B,Autocuration,,4,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,104686,H,,CHEMBL617242,,
2163,,,BAO_0000019,,1,F,Autocuration,,4,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,104686,H,,CHEMBL617152,,
2164,,Rattus norvegicus,BAO_0000221,,1,B,Autocuration,,5,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,104686,D,,CHEMBL617153,955.0,
2165,,Rattus norvegicus,BAO_0000249,,1,B,Autocuration,,5,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,104686,D,,CHEMBL617154,,
2166,,,BAO_0000221,,1,B,Autocuration,,4,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,104686,H,,CHEMBL617155,955.0,
2167,,,BAO_0000019,,1,F,Autocuration,,4,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,104686,H,,CHEMBL617156,,
2168,,,BAO_0000019,,1,F,Autocuration,,4,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,104686,H,,CHEMBL617157,,
2169,,,BAO_0000019,,1,F,Autocuration,,4,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,H,,CHEMBL617158,,
2170,,,BAO_0000019,,1,F,Autocuration,,4,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,104686,H,,CHEMBL617159,,
2171,,,BAO_0000019,,1,F,Autocuration,,4,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,104686,H,,CHEMBL617160,,
2172,,,BAO_0000019,,1,F,Autocuration,,4,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,H,,CHEMBL858113,,
2173,,,BAO_0000220,,1,B,Autocuration,,4,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,104686,H,,CHEMBL617247,955.0,
2174,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,104686,H,,CHEMBL617248,,
2175,,,BAO_0000249,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,104686,H,,CHEMBL617249,955.0,
2176,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,104686,H,,CHEMBL617250,,
2177,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,104686,H,,CHEMBL617251,,
2178,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,5,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,104686,D,,CHEMBL617252,,
2179,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,104686,H,,CHEMBL617006,,
2180,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,104686,H,,CHEMBL617007,,
2181,,,BAO_0000019,,1,F,Autocuration,,4,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",104686,H,,CHEMBL617008,,
2182,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,104686,H,,CHEMBL617009,,
2183,,Rattus norvegicus,BAO_0000224,,1,B,Autocuration,,5,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,104686,D,,CHEMBL617010,,
2184,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,5,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,104686,D,,CHEMBL857978,,
2185,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,5,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,104686,D,,CHEMBL617011,,
2186,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,5,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,104686,D,,CHEMBL617012,,
2187,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,104686,H,,CHEMBL617013,,
2188,,,BAO_0000249,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,104686,H,,CHEMBL617014,,
2189,,,BAO_0000019,,1,B,Autocuration,,4,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,104686,H,,CHEMBL617015,,
2190,,,BAO_0000019,,1,B,Autocuration,,4,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,104686,H,,CHEMBL617016,,
2191,,,BAO_0000224,,1,B,Autocuration,,4,pKi value for 5-hydroxytryptamine 2 receptor binding site,104686,H,,CHEMBL617017,,
2192,,,BAO_0000221,,1,B,Autocuration,,4,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,104686,H,,CHEMBL617018,955.0,
2193,,,BAO_0000019,,1,F,Autocuration,,4,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,104686,H,,CHEMBL617019,,
2194,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,105075,H,,CHEMBL617020,,
2195,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,105075,H,,CHEMBL617021,,
2196,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,105075,H,,CHEMBL617022,,
2197,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,105075,H,,CHEMBL617023,,
2198,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,105075,H,,CHEMBL617024,,
2199,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,105075,H,,CHEMBL617025,,
2200,,,BAO_0000224,,1,B,Autocuration,,4,Hill coefficient of compound was determined,105075,H,,CHEMBL617026,,
2201,,,BAO_0000019,,1,B,Autocuration,,0,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,22226,U,,CHEMBL617027,,
2202,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,5,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,104686,D,,CHEMBL617028,,
2203,,,BAO_0000019,,1,B,Expert,,8,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,12687,H,,CHEMBL617029,,
2204,,,BAO_0000019,,1,B,Expert,,8,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,12687,H,,CHEMBL875908,,
2205,,,BAO_0000357,,1,B,Autocuration,,8,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),12687,H,,CHEMBL617030,,
2206,,,BAO_0000019,,1,B,Autocuration,,8,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),12687,H,,CHEMBL617031,,
2207,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,12687,H,,CHEMBL617032,,
2208,,Rattus norvegicus,BAO_0000224,,1,B,Autocuration,,5,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,104686,D,,CHEMBL617033,,
2209,,,BAO_0000224,,1,B,Autocuration,,4,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",104686,H,,CHEMBL617034,,
2210,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,104686,H,,CHEMBL617035,,
2211,,,BAO_0000019,,1,B,Autocuration,,4,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",104686,H,,CHEMBL617036,,
2212,,,BAO_0000224,,1,B,Autocuration,,4,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,104784,H,,CHEMBL617037,,
2213,,,BAO_0000219,,1,B,Autocuration,,0,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,22226,U,,CHEMBL617038,,
2214,,,BAO_0000219,,1,B,Autocuration,,4,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",104784,H,,CHEMBL617039,,
2215,,,BAO_0000224,,1,B,Autocuration,,4,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,104784,H,,CHEMBL617161,,
2216,,,BAO_0000224,,1,B,Autocuration,,4,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,104784,H,,CHEMBL617162,,
2217,,,BAO_0000224,,1,B,Autocuration,,4,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,104784,H,,CHEMBL617163,,
2218,,,BAO_0000224,,1,B,Autocuration,,4,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,104784,H,,CHEMBL617164,,
2219,,,BAO_0000249,,1,B,Autocuration,,4,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,104784,H,,CHEMBL617165,,
2220,,,BAO_0000224,,1,B,Autocuration,,4,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,104784,H,,CHEMBL617166,,
2221,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity towards 5-HT2 receptor,104784,H,,CHEMBL617167,,
2222,,,BAO_0000224,,1,B,Autocuration,,4,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,104784,H,,CHEMBL872912,,
2223,,,BAO_0000224,,1,B,Autocuration,,4,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,104784,H,,CHEMBL617168,,
2224,,,BAO_0000224,,1,B,Autocuration,,4,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,104686,H,,CHEMBL617169,,
2225,,,BAO_0000224,,1,B,Autocuration,,4,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,104784,H,,CHEMBL617170,,
2226,,,BAO_0000224,,1,B,Autocuration,,4,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,104784,H,,CHEMBL617171,,
2227,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,104784,H,,CHEMBL617172,,
2228,,,BAO_0000224,,1,B,Autocuration,,4,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,104784,H,,CHEMBL617173,,
2229,,,BAO_0000019,,1,B,Autocuration,,0,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,22226,U,,CHEMBL617174,,
2230,,,BAO_0000224,,1,B,Autocuration,,4,5-hydroxytryptamine 2 receptor binding affinity,104784,H,,CHEMBL617175,,
2231,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,17005,H,,CHEMBL617176,,
2232,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,17005,H,,CHEMBL617177,,
2233,,,BAO_0000224,,1,B,Autocuration,,4,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,104784,H,,CHEMBL617178,,
2234,,,BAO_0000224,,1,B,Autocuration,,4,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,104784,H,,CHEMBL617179,,
2235,,,BAO_0000224,,1,B,Autocuration,,4,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,104784,H,,CHEMBL617180,,
2236,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,17005,H,,CHEMBL617181,,
2237,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 2 receptor,17005,H,,CHEMBL617182,,
2238,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 2 receptor,17005,H,,CHEMBL617183,,
2239,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,17005,H,,CHEMBL617184,,
2240,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against serotonergic 5-HT2 receptor,17005,H,,CHEMBL617185,,
2241,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,17005,H,,CHEMBL617186,,
2242,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for the binding affinity at 5- HT2 receptor,17005,H,,CHEMBL617187,,
2243,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,17005,H,,CHEMBL617188,,
2244,,,BAO_0000218,,1,B,Autocuration,,8,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,17005,H,,CHEMBL617189,,
2245,,Homo sapiens,BAO_0000224,,1,B,Autocuration,,5,Inhibitory activity against cloned human 5-HT2 receptor,104784,D,,CHEMBL617190,,
2246,449.0,Homo sapiens,BAO_0000219,CHO,1,B,Autocuration,,5,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",104784,D,,CHEMBL617191,,
2247,449.0,Homo sapiens,BAO_0000219,CHO,1,B,Autocuration,,5,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",104784,D,,CHEMBL617192,,
2248,449.0,Homo sapiens,BAO_0000219,CHO,1,B,Autocuration,,5,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",104784,D,,CHEMBL617193,,
2249,449.0,Homo sapiens,BAO_0000219,CHO,1,B,Autocuration,,5,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",104784,D,,CHEMBL617194,,
2250,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor,104784,H,,CHEMBL617195,,
2251,,,BAO_0000224,,1,B,Autocuration,,4,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,104784,H,,CHEMBL881830,,
2252,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 2 receptor,17005,H,,CHEMBL617196,,
2253,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,104686,H,,CHEMBL617197,,
2254,,,BAO_0000357,,1,B,Expert,,8,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,17005,H,,CHEMBL617198,,
2255,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor,17005,H,,CHEMBL873476,,
2256,,,BAO_0000019,,1,B,Expert,,8,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,17005,H,,CHEMBL617199,,
2257,,Cavia porcellus,BAO_0000357,,1,B,Autocuration,,8,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617200,,
2258,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,51,H,,CHEMBL617484,,
2259,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,107,H,,CHEMBL617485,,
2260,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,51,H,,CHEMBL617486,,
2261,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,107,H,,CHEMBL858022,,
2262,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,107,H,,CHEMBL617049,,
2263,449.0,Homo sapiens,BAO_0000219,CHO,1,F,Expert,,9,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,107,D,,CHEMBL617050,,
2264,,,BAO_0000219,,1,F,Autocuration,,8,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,107,H,,CHEMBL617051,,
2265,,,BAO_0000219,,1,F,Autocuration,,8,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,107,H,,CHEMBL617052,,
2266,,,BAO_0000219,,1,F,Autocuration,,8,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,107,H,,CHEMBL617053,,
2267,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",107,H,,CHEMBL617054,,
2268,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",107,H,,CHEMBL617055,,
2269,,,BAO_0000357,,1,B,Autocuration,,8,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,107,H,,CHEMBL882924,,
2270,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Inhibition of human 5-hydroxytryptamine 2A receptor,107,D,,CHEMBL617056,,
2271,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,107,H,,CHEMBL617057,,
2272,,,BAO_0000219,,1,B,Expert,,8,Inhibitory concentration against human 5-HT2A receptor in BEK cells,107,H,,CHEMBL617058,,
2273,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),107,H,,CHEMBL617059,,
2274,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,107,H,,CHEMBL617060,,
2275,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,107,H,,CHEMBL617061,,
2276,307.0,,BAO_0000219,L929,1,B,Expert,,8,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,107,H,,CHEMBL617062,,
2277,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,107,H,,CHEMBL617063,,
2278,,,BAO_0000019,,1,F,Autocuration,,8,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,107,H,,CHEMBL617064,,
2279,,,BAO_0000019,,1,F,Autocuration,,8,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,107,H,,CHEMBL617065,,
2280,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,107,H,,CHEMBL617066,,
2281,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,107,H,,CHEMBL617067,,
2282,,,BAO_0000019,,1,F,Autocuration,,8,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,107,H,,CHEMBL617068,,
2283,,,BAO_0000019,,1,F,Autocuration,,8,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,107,H,,CHEMBL617069,,
2284,,,BAO_0000019,,1,F,Autocuration,,8,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,107,H,,CHEMBL617070,,
2285,,,BAO_0000357,,1,B,Autocuration,,8,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,107,H,,CHEMBL617071,,
2286,,,BAO_0000357,,1,B,Autocuration,,8,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,107,H,,CHEMBL872915,,
2287,,,BAO_0000357,,1,B,Autocuration,,8,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,107,H,,CHEMBL617072,,
2288,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,107,H,,CHEMBL617073,,
2289,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,107,H,,CHEMBL617074,,
2290,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,107,H,,CHEMBL617075,,
2291,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617076,,
2292,,Homo sapiens,BAO_0000019,,1,B,Expert,,9,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,107,D,,CHEMBL617077,,
2293,,,BAO_0000357,,1,B,Expert,,8,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,107,H,,CHEMBL617078,,
2294,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,107,D,,CHEMBL617079,,
2295,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,107,H,,CHEMBL617080,,
2296,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,107,H,,CHEMBL617081,,
2297,,,BAO_0000219,,1,B,Expert,,8,Binding affinity towards human 5-HT2A receptor in BEK cells,107,H,,CHEMBL617082,,
2298,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617083,,
2299,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,107,H,,CHEMBL617084,,
2300,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity for human 5-hydroxytryptamine 2A receptor,107,D,,CHEMBL617085,,
2301,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,107,H,,CHEMBL617086,,
2302,,,BAO_0000219,,1,B,Autocuration,,8,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,107,H,,CHEMBL617087,,
2303,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617088,,
2304,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617089,,
2305,,,BAO_0000019,,1,B,Expert,,8,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",107,H,,CHEMBL617090,,
2306,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,107,H,,CHEMBL617513,,
2307,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,107,H,,CHEMBL617514,,
2308,,,BAO_0000019,,1,B,Autocuration,,8,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617515,,
2309,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,107,H,,CHEMBL617516,,
2310,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,107,D,,CHEMBL617517,,
2311,449.0,Homo sapiens,BAO_0000219,CHO,1,B,Expert,,9,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,107,D,,CHEMBL617518,,
2312,,,BAO_0000357,,1,B,Autocuration,,8,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617519,,
2313,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,107,D,,CHEMBL617520,,
2314,,,BAO_0000357,,1,B,Autocuration,,8,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,107,H,,CHEMBL617521,,
2315,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,107,D,,CHEMBL617522,,
2316,,,BAO_0000357,,1,B,Autocuration,,8,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,107,H,,CHEMBL617523,,
2317,,,BAO_0000357,,1,B,Autocuration,,8,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,107,H,,CHEMBL617524,,
2318,,,BAO_0000019,,1,B,Autocuration,,4,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,104686,H,,CHEMBL617525,,
2319,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,5,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,104686,D,,CHEMBL617526,,
2320,,,BAO_0000224,,1,B,Autocuration,,4,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,104686,H,,CHEMBL617527,,
2321,,,BAO_0000019,,1,B,Autocuration,,4,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,104686,H,,CHEMBL617528,,
2322,,,BAO_0000019,,1,B,Autocuration,,4,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,104686,H,,CHEMBL617529,,
2323,,,BAO_0000224,,1,B,Autocuration,,4,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,104686,H,,CHEMBL617530,,
2324,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,104686,H,,CHEMBL617531,,
2325,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,104686,H,,CHEMBL617532,,
2326,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,104686,H,,CHEMBL617533,,
2327,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,104686,H,,CHEMBL617534,,
2328,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,104686,H,,CHEMBL617535,,
2329,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,104686,H,,CHEMBL617536,,
2330,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,104686,H,,CHEMBL617537,,
2331,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,104686,H,,CHEMBL617538,,
2332,,,BAO_0000219,,1,B,Autocuration,In vitro,4,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,104686,H,,CHEMBL617539,,
2333,,Rattus norvegicus,BAO_0000224,,1,B,Autocuration,,5,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,104686,D,,CHEMBL617540,,
2334,,Rattus norvegicus,BAO_0000224,,1,B,Autocuration,,5,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,104686,D,,CHEMBL617541,,
2335,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,104686,H,,CHEMBL617542,,
2336,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,104686,H,,CHEMBL617543,,
2337,485.0,Rattus norvegicus,BAO_0000219,CHO-K1,1,B,Autocuration,,5,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,104686,D,,CHEMBL617544,,
2338,485.0,Rattus norvegicus,BAO_0000219,CHO-K1,1,B,Autocuration,,5,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,104686,D,,CHEMBL617545,,
2339,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,5,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,104686,D,,CHEMBL617413,,
2340,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,104686,H,,CHEMBL617414,,
2341,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,5,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,104686,D,,CHEMBL617415,,
2342,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor,104686,H,,CHEMBL617416,,
2343,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,104686,H,,CHEMBL617417,,
2344,,,BAO_0000019,,1,B,Autocuration,,4,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",104686,H,,CHEMBL617418,,
2345,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,104686,H,,CHEMBL617419,,
2346,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,104686,H,,CHEMBL617420,,
2347,,Rattus norvegicus,BAO_0000224,,1,B,Autocuration,,5,Affinity for 5-hydroxytryptamine 2 receptor,104686,D,,CHEMBL617421,,
2348,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,104686,H,,CHEMBL617422,,
2349,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,104686,H,,CHEMBL617423,,
2350,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,104686,H,,CHEMBL617424,,
2351,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,104686,H,,CHEMBL617425,,
2352,,,BAO_0000224,,1,B,Autocuration,,4,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),104686,H,,CHEMBL617426,,
2353,,,BAO_0000218,,1,B,Autocuration,In vivo,4,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),104686,H,,CHEMBL617427,,
2354,,,BAO_0000221,,1,B,Autocuration,,4,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,104686,H,,CHEMBL617428,955.0,
2355,,,BAO_0000224,,1,B,Autocuration,,4,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,104686,H,,CHEMBL617429,,
2356,,,BAO_0000019,,1,B,Autocuration,,4,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,104686,H,,CHEMBL617430,,
2357,,,BAO_0000019,,1,B,Autocuration,,4,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,104686,H,,CHEMBL617431,,
2358,,,BAO_0000019,,1,B,Autocuration,,4,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,104686,H,,CHEMBL617432,1870.0,
2359,,,BAO_0000224,,1,B,Autocuration,,4,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,104686,H,,CHEMBL617433,,
2360,,,BAO_0000224,,1,B,Autocuration,,4,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,104686,H,,CHEMBL617434,,
2361,,Rattus norvegicus,BAO_0000224,,1,B,Autocuration,,5,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,104686,D,,CHEMBL617435,,
2362,,,BAO_0000019,,1,B,Autocuration,,4,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,104686,H,,CHEMBL617436,,
2363,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,5,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,104686,D,,CHEMBL617437,2435.0,
2364,,,BAO_0000019,,1,B,Autocuration,,4,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",104686,H,,CHEMBL617438,,
2365,,,BAO_0000019,,1,B,Autocuration,,4,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",104686,H,,CHEMBL617439,,
2366,,,BAO_0000224,,1,B,Autocuration,,4,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,104686,H,,CHEMBL617440,,
2367,,,BAO_0000224,,1,B,Autocuration,,4,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,104686,H,,CHEMBL617441,,
2368,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,5,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,104686,D,,CHEMBL872918,,
2369,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,5,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,104686,D,,CHEMBL617442,,
2370,,,BAO_0000019,,1,B,Autocuration,,4,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,104686,H,,CHEMBL617443,,
2371,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,104686,H,,CHEMBL617444,,
2372,,,BAO_0000019,,1,B,Autocuration,,4,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,104686,H,,CHEMBL617445,,
2373,,,BAO_0000019,,1,B,Autocuration,,4,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,104686,H,,CHEMBL617446,,
2374,,,BAO_0000249,,1,B,Autocuration,,4,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,104686,H,,CHEMBL617447,,
2375,,,BAO_0000019,,1,B,Autocuration,,4,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,104686,H,,CHEMBL617448,,
2376,,,BAO_0000019,,1,B,Autocuration,,4,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,104686,H,,CHEMBL617449,,
2377,,,BAO_0000019,,1,B,Autocuration,,4,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,104686,H,,CHEMBL617450,,
2378,,,BAO_0000019,,1,B,Autocuration,,4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,104686,H,,CHEMBL617451,,
2379,,,BAO_0000019,,1,B,Autocuration,,4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,104686,H,,CHEMBL617452,,
2380,,,BAO_0000019,,1,B,Autocuration,,4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,104686,H,,CHEMBL617453,,
2381,,,BAO_0000019,,1,B,Autocuration,,4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,104686,H,,CHEMBL617660,,
2382,,,BAO_0000019,,1,B,Autocuration,,4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,104686,H,,CHEMBL617661,,
2383,,,BAO_0000019,,1,B,Autocuration,,4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,104686,H,,CHEMBL617662,,
2384,,,BAO_0000019,,1,B,Autocuration,,4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,104686,H,,CHEMBL872919,,
2385,,,BAO_0000019,,1,B,Autocuration,,4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,104686,H,,CHEMBL617663,,
2386,,,BAO_0000019,,1,B,Autocuration,,4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,104686,H,,CHEMBL617664,,
2387,,,BAO_0000019,,1,B,Autocuration,,4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,104686,H,,CHEMBL617665,,
2388,,,BAO_0000019,,1,B,Autocuration,,4,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,104686,H,,CHEMBL617666,,
2389,,,BAO_0000019,,1,B,Autocuration,,4,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,104686,H,,CHEMBL617667,,
2390,,,BAO_0000249,,1,B,Autocuration,,4,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,104686,H,,CHEMBL617668,,
2391,,,BAO_0000249,,1,B,Autocuration,,4,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,104686,H,,CHEMBL617669,,
2392,,,BAO_0000224,,1,B,Autocuration,,4,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,104686,H,,CHEMBL617670,,
2393,,Rattus norvegicus,BAO_0000224,,1,B,Autocuration,,5,Inhibitory constant against 5-hydroxytryptamine 2 receptor,104686,D,,CHEMBL617671,,
2394,,,BAO_0000224,,1,B,Autocuration,,4,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,104686,H,,CHEMBL617672,,
2395,,,BAO_0000019,,1,B,Autocuration,,4,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,104686,H,,CHEMBL617673,,
2396,,,BAO_0000224,,1,B,Autocuration,,4,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,104686,H,,CHEMBL617674,,
2397,,,BAO_0000019,,1,B,Autocuration,,4,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,104686,H,,CHEMBL617675,,
2398,,,BAO_0000019,,1,B,Autocuration,,4,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,104686,H,,CHEMBL617676,,
2399,,,BAO_0000019,,1,B,Autocuration,,4,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,104686,H,,CHEMBL617677,,
2400,,,BAO_0000019,,1,B,Autocuration,,5,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,104686,D,,CHEMBL617678,,
2401,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,104686,H,,CHEMBL617679,,
2402,,,BAO_0000224,,1,B,Autocuration,,4,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,104686,H,,CHEMBL617680,,
2403,,,BAO_0000019,,1,B,Autocuration,,4,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,104686,H,,CHEMBL617681,,
2404,,,BAO_0000221,,1,B,Autocuration,,4,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,104686,H,,CHEMBL617682,955.0,
2405,,,BAO_0000224,,1,B,Autocuration,,4,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,104686,H,,CHEMBL617683,,
2406,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,104686,H,,CHEMBL617684,,
2407,,Rattus norvegicus,BAO_0000224,,1,B,Autocuration,,5,Binding affinity towards 5-hydroxytryptamine 2 receptor,104686,D,,CHEMBL617685,,
2408,,,BAO_0000019,,1,B,Autocuration,,4,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,104686,H,,CHEMBL617686,,
2409,,,BAO_0000224,,1,B,Autocuration,,4,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,104686,H,,CHEMBL617687,,
2410,,,BAO_0000224,,1,B,Autocuration,,4,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,104686,H,,CHEMBL617688,,
2411,,,BAO_0000019,,1,F,Autocuration,,4,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,H,,CHEMBL617689,,
2412,,,BAO_0000019,,1,F,Autocuration,,4,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,H,,CHEMBL617690,,
2413,,,BAO_0000218,,1,F,Autocuration,In vivo,4,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",104686,H,,CHEMBL617691,,
2414,,,BAO_0000218,,1,F,Autocuration,In vivo,4,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",104686,H,,CHEMBL617692,,
2415,,,BAO_0000218,,1,F,Autocuration,In vivo,4,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",104686,H,,CHEMBL617693,,
2416,,,BAO_0000218,,1,F,Autocuration,In vivo,4,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",104686,H,,CHEMBL617694,,
2417,,,BAO_0000221,,1,B,Expert,,8,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,12687,H,,CHEMBL857985,955.0,
2418,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,12687,D,,CHEMBL617695,,
2419,,,BAO_0000019,,1,B,Autocuration,,8,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,12687,H,,CHEMBL617696,,
2420,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,12687,H,,CHEMBL617697,,
2421,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,12687,D,,CHEMBL617257,,
2422,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,12687,D,,CHEMBL617258,,
2423,,,BAO_0000019,,1,B,Expert,,8,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,12687,H,,CHEMBL617259,,
2424,,,BAO_0000357,,1,B,Autocuration,,8,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,12687,H,,CHEMBL617260,,
2425,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,12687,D,,CHEMBL617261,,
2426,,,BAO_0000019,,1,B,Autocuration,,8,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,12687,H,,CHEMBL617262,,
2427,,,BAO_0000019,,1,B,Expert,,8,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,12687,H,,CHEMBL617263,,
2428,,,BAO_0000019,,1,B,Autocuration,,8,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,12687,H,,CHEMBL617264,,
2429,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,12687,D,,CHEMBL617265,,
2430,,,BAO_0000249,,1,B,Autocuration,,8,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL617266,,
2431,,,BAO_0000019,,1,B,Autocuration,,8,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,12687,H,,CHEMBL617267,,
2432,,,BAO_0000019,,1,B,Expert,,8,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,12687,H,,CHEMBL617268,,
2433,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,12687,H,,CHEMBL617269,,
2434,,,BAO_0000357,,1,B,Expert,,8,Kinetic inhibition constant evaluated by measuring serotonergic activity,12687,H,,CHEMBL617323,,
2435,,,BAO_0000357,,1,B,Autocuration,,8,Serotonergic activity of the compound.,12687,H,,CHEMBL617324,,
2436,,,BAO_0000249,,1,B,Autocuration,,8,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,12687,H,,CHEMBL617325,,
2437,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,12687,D,,CHEMBL617326,,
2438,,,BAO_0000249,,1,B,Expert,,8,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,12687,H,,CHEMBL617327,,
2439,,Rattus norvegicus,BAO_0000019,,1,F,Expert,,9,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,D,,CHEMBL617328,,
2440,,Rattus norvegicus,BAO_0000019,,1,F,Expert,,9,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,D,,CHEMBL617329,,
2441,,Rattus norvegicus,BAO_0000019,,1,F,Expert,,9,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,D,,CHEMBL617330,,
2442,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,H,,CHEMBL617331,,
2443,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,12687,H,,CHEMBL617332,,
2444,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617333,,
2445,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,107,H,,CHEMBL617334,,
2446,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,107,H,,CHEMBL617335,,
2447,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,107,H,,CHEMBL617336,,
2448,,,BAO_0000357,,1,B,Autocuration,,8,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,107,H,,CHEMBL617337,,
2449,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,107,D,,CHEMBL617338,,
2450,,,BAO_0000357,,1,B,Autocuration,,8,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617339,,
2451,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617340,,
2452,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,107,H,,CHEMBL617341,,
2453,,,BAO_0000357,,1,B,Expert,,8,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617342,,
2454,,,BAO_0000357,,1,B,Expert,,8,Affinity for 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617343,,
2455,723.0,,BAO_0000219,NIH3T3,1,B,Expert,,8,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,107,H,,CHEMBL617344,,
2456,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,107,H,,CHEMBL617345,,
2457,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,107,H,,CHEMBL617346,,
2458,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617347,,
2459,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,107,H,,CHEMBL617348,,
2460,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,107,H,,CHEMBL617349,,
2461,,,BAO_0000019,,1,F,Autocuration,,8,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617350,,
2462,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,107,H,,CHEMBL872339,,
2463,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,107,H,,CHEMBL617351,,
2464,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617352,,
2465,,,BAO_0000357,,1,B,Autocuration,,8,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617353,,
2466,,,BAO_0000357,,1,B,Autocuration,,8,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617354,,
2467,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617355,,
2468,449.0,Mus musculus,BAO_0000219,CHO,1,B,Expert,,8,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,107,H,,CHEMBL617356,,
2469,,,BAO_0000357,,1,B,Autocuration,,8,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617357,,
2470,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity at 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617358,,
2471,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617359,,
2472,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,107,H,,CHEMBL617360,,
2473,,,BAO_0000357,,1,B,Autocuration,,8,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,107,H,,CHEMBL875913,,
2474,,,BAO_0000357,,1,B,Autocuration,,8,Affinity against 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617361,,
2475,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity against 5-Hydroxytryptamine 2A receptor,107,D,,CHEMBL617362,,
2476,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,107,H,,CHEMBL617363,,
2477,,,BAO_0000357,,1,B,Autocuration,,8,Tested against 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617364,,
2478,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,105075,H,,CHEMBL617365,,
2479,,,BAO_0000224,,1,B,Autocuration,,4,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,105075,H,,CHEMBL617366,,
2480,,,BAO_0000224,,1,B,Autocuration,,4,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,105075,H,,CHEMBL617367,,
2481,,,BAO_0000224,,1,B,Autocuration,,4,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,105075,H,,CHEMBL617368,,
2482,,,BAO_0000357,,1,B,Autocuration,,8,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),107,H,,CHEMBL617369,,
2483,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,227,D,,CHEMBL617370,,
2484,449.0,Homo sapiens,BAO_0000219,CHO,1,F,Expert,,9,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,227,D,,CHEMBL617371,,
2485,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),227,H,,CHEMBL617372,,
2486,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,227,D,,CHEMBL617373,,
2487,,,BAO_0000019,,1,F,Autocuration,,8,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,227,H,,CHEMBL617374,,
2488,,,BAO_0000019,,1,F,Autocuration,,8,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,227,H,,CHEMBL617375,,
2489,,,BAO_0000019,,1,F,Autocuration,,8,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,227,H,,CHEMBL617376,,
2490,,,BAO_0000019,,1,F,Autocuration,,8,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,227,H,,CHEMBL617377,,
2491,,,BAO_0000019,,1,F,Autocuration,,8,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,227,H,,CHEMBL617378,,
2492,,,BAO_0000019,,1,F,Autocuration,,8,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,227,H,,CHEMBL617379,,
2493,,,BAO_0000357,,1,B,Autocuration,,8,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,227,H,,CHEMBL617380,,
2494,,,BAO_0000357,,1,B,Autocuration,,8,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,227,H,,CHEMBL617381,,
2495,,,BAO_0000357,,1,B,Autocuration,,8,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,227,H,,CHEMBL617382,,
2496,,,BAO_0000357,,1,B,Autocuration,,8,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617383,,
2497,,,BAO_0000357,,1,B,Expert,,8,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,107,H,,CHEMBL617384,,
2498,,,BAO_0000357,,1,B,Expert,,8,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,107,H,,CHEMBL617385,,
2499,,,BAO_0000019,,1,B,Autocuration,,8,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,107,H,,CHEMBL617386,,
2500,,,BAO_0000019,,1,B,Autocuration,,8,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,107,H,,CHEMBL617387,,
2501,723.0,,BAO_0000219,NIH3T3,1,B,Autocuration,,8,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,107,H,,CHEMBL617388,,
2502,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,107,H,,CHEMBL617389,,
2503,449.0,Homo sapiens,BAO_0000219,CHO,1,F,Expert,,9,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,107,D,,CHEMBL617390,,
2504,,,BAO_0000224,,1,B,Autocuration,,4,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,104817,H,,CHEMBL617391,,
2505,,,BAO_0000357,,1,B,Autocuration,,8,Binding activity radioligand.,107,H,,CHEMBL617392,,
2506,,,BAO_0000019,,1,B,Autocuration,,8,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,107,H,,CHEMBL617393,,
2507,307.0,,BAO_0000219,L929,1,B,Autocuration,,8,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,107,H,,CHEMBL617394,,
2508,307.0,,BAO_0000219,L929,1,B,Expert,,8,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,107,H,,CHEMBL617395,,
2509,307.0,,BAO_0000219,L929,1,B,Expert,,8,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,107,H,,CHEMBL617396,,
2510,307.0,,BAO_0000219,L929,1,B,Autocuration,,8,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,107,H,,CHEMBL617397,,
2511,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-HT2A receptor,107,H,,CHEMBL617398,,
2512,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 2A receptor,107,H,,CHEMBL617399,,
2513,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,107,H,,CHEMBL617400,,
2514,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,107,H,,CHEMBL617401,,
2515,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,107,D,,CHEMBL617402,,
2516,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,D,,CHEMBL617403,,
2517,,,BAO_0000357,,1,B,Expert,,8,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,107,H,,CHEMBL617404,,
2518,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,D,,CHEMBL857981,,
2519,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,D,,CHEMBL617405,,
2520,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,107,D,,CHEMBL617253,,
2521,,,BAO_0000357,,1,B,Expert,,8,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,107,H,,CHEMBL617254,,
2522,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,107,H,,CHEMBL617255,,
2523,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,107,H,,CHEMBL617256,,
2524,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,107,H,,CHEMBL616874,,
2525,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,107,D,,CHEMBL616875,,
2526,722.0,,BAO_0000219,HEK293,1,B,Expert,,8,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,107,H,,CHEMBL616876,,
2527,722.0,,BAO_0000219,HEK293,1,B,Expert,,8,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",107,H,,CHEMBL616877,,
2528,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,107,D,,CHEMBL616878,,
2529,722.0,,BAO_0000219,HEK293,1,B,Expert,,8,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,107,H,,CHEMBL616879,,
2530,722.0,,BAO_0000219,HEK293,1,B,Expert,,8,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,107,H,,CHEMBL616880,,
2531,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,D,,CHEMBL616881,,
2532,723.0,,BAO_0000219,NIH3T3,1,B,Autocuration,,8,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,107,H,,CHEMBL616882,,
2533,723.0,,BAO_0000219,NIH3T3,1,B,Autocuration,,8,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,107,H,,CHEMBL616883,,
2534,723.0,,BAO_0000219,NIH3T3,1,B,Autocuration,,8,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,107,H,,CHEMBL616884,,
2535,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,107,H,,CHEMBL616885,,
2536,485.0,,BAO_0000219,CHO-K1,1,B,Autocuration,,8,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,107,H,,CHEMBL616886,,
2537,485.0,,BAO_0000219,CHO-K1,1,B,Expert,,8,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,107,H,,CHEMBL616887,,
2538,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity for human 5-hydroxytryptamine 2A receptor,107,D,,CHEMBL616888,,
2539,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,107,H,,CHEMBL616889,,
2540,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,107,H,,CHEMBL616890,,
2541,449.0,Homo sapiens,BAO_0000219,CHO,1,B,Expert,,9,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,107,D,,CHEMBL616891,,
2542,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,107,H,,CHEMBL616892,,
2543,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",107,H,,CHEMBL616893,,
2544,723.0,,BAO_0000219,NIH3T3,1,F,Autocuration,,8,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,10620,H,,CHEMBL616894,,
2545,723.0,,BAO_0000219,NIH3T3,1,B,Expert,,8,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,107,H,,CHEMBL616895,,
2546,,,BAO_0000019,,1,F,Autocuration,,8,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,10620,H,,CHEMBL616896,,
2547,,,BAO_0000357,,1,B,Autocuration,,8,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,10621,H,,CHEMBL617099,,
2548,,,BAO_0000357,,1,B,Autocuration,,8,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,10621,H,,CHEMBL617100,,
2549,,Oryctolagus cuniculus,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against rabbit aorta 5-HT2A receptor,107,H,,CHEMBL884532,,
2550,,Oryctolagus cuniculus,BAO_0000357,,1,B,Expert,,8,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,107,H,,CHEMBL617101,,
2551,,Oryctolagus cuniculus,BAO_0000357,,1,B,Expert,,8,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,107,H,,CHEMBL617102,,
2552,,Oryctolagus cuniculus,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,107,H,,CHEMBL617103,,
2553,,Oryctolagus cuniculus,BAO_0000357,,1,B,Expert,,8,The compound was tested for binding affinity against 5-HT2A receptor,107,H,,CHEMBL617104,,
2554,485.0,,BAO_0000219,CHO-K1,1,B,Autocuration,,8,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,10576,H,,CHEMBL857979,,
2555,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity analysed towards 5-HT 2A in rat jugular vein,12687,H,,CHEMBL857502,,
2556,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,12687,H,,CHEMBL617105,,
2557,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,12687,H,,CHEMBL858021,945.0,
2558,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Binding affinity for 5-HT 2A in rat stomach fundus,12687,D,,CHEMBL875910,945.0,
2559,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,12687,H,,CHEMBL617106,,
2560,723.0,,BAO_0000219,NIH3T3,1,B,Expert,,8,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL617107,,
2561,,,BAO_0000019,,1,F,Autocuration,,8,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL617108,,
2562,,,BAO_0000019,,1,F,Autocuration,,8,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL617109,,
2563,,,BAO_0000357,,1,B,Autocuration,,8,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL617110,,
2564,,,BAO_0000357,,1,B,Autocuration,,8,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,12687,H,,CHEMBL617111,,
2565,,Rattus norvegicus,BAO_0000019,,1,F,Expert,,9,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,12687,D,,CHEMBL617112,,
2566,,,BAO_0000357,,1,B,Autocuration,,8,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL617113,,
2567,,,BAO_0000357,,1,B,Autocuration,,8,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL617114,,
2568,,,BAO_0000357,,1,B,Autocuration,,8,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL617115,,
2569,,,BAO_0000219,,1,F,Autocuration,,8,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,12687,H,,CHEMBL617116,,
2570,,,BAO_0000019,,1,F,Autocuration,,8,Efficacy at 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL617117,,
2571,,,BAO_0000357,,1,B,Autocuration,,8,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),12687,H,,CHEMBL617118,,
2572,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),12687,D,,CHEMBL617119,,
2573,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),12687,D,,CHEMBL617120,,
2574,,Rattus norvegicus,BAO_0000219,,1,F,Expert,,9,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,12687,D,,CHEMBL617121,,
2575,,,BAO_0000219,,1,F,Autocuration,,8,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,12687,H,,CHEMBL617122,,
2576,,,BAO_0000019,,1,B,Autocuration,,8,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL617123,,
2577,,,BAO_0000019,,1,B,Expert,,8,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,12687,H,,CHEMBL617124,,
2578,,,BAO_0000249,,1,B,Expert,,8,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,12687,H,,CHEMBL617600,,
2579,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,12687,H,,CHEMBL617601,,
2580,,,BAO_0000019,,1,B,Expert,,8,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,12687,H,,CHEMBL882923,,
2581,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL617602,,
2582,,,BAO_0000019,,1,B,Autocuration,,8,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,12687,H,,CHEMBL617603,,
2583,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL617604,,
2584,,,BAO_0000019,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,12687,H,,CHEMBL617605,,
2585,,,BAO_0000019,,1,B,Expert,,8,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,12687,H,,CHEMBL617606,,
2586,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,12687,D,,CHEMBL617607,,
2587,,,BAO_0000249,,1,B,Autocuration,,8,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,H,,CHEMBL617455,,
2588,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,12687,D,,CHEMBL617456,,
2589,,,BAO_0000357,,1,B,Expert,,8,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),12687,H,,CHEMBL617457,,
2590,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,12687,D,,CHEMBL617458,,
2591,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,12687,D,,CHEMBL617459,,
2592,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,12687,H,,CHEMBL617460,,
2593,,,BAO_0000357,,1,B,Expert,,8,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",12687,H,,CHEMBL617461,,
2594,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,12687,D,,CHEMBL617462,,
2595,,,BAO_0000357,,1,B,Autocuration,,8,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,12687,H,,CHEMBL617463,,
2596,,,BAO_0000019,,1,B,Autocuration,,8,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",12687,H,,CHEMBL617464,,
2597,,,BAO_0000019,,1,B,Autocuration,,8,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",12687,H,,CHEMBL617465,,
2598,,,BAO_0000019,,1,B,Expert,,8,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,12687,H,,CHEMBL617466,,
2599,,,BAO_0000019,,1,B,Autocuration,,8,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,12687,H,,CHEMBL617467,,
2600,,,BAO_0000019,,1,B,Expert,,8,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,12687,H,,CHEMBL617468,,
2601,,,BAO_0000019,,1,B,Autocuration,,8,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,12687,H,,CHEMBL617469,,
2602,,,BAO_0000019,,1,B,Autocuration,,8,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL617470,,
2603,,,BAO_0000019,,1,B,Autocuration,,8,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,12687,H,,CHEMBL617471,,
2604,723.0,,BAO_0000219,NIH3T3,1,B,Expert,,8,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,12687,H,,CHEMBL617472,,
2605,,,BAO_0000357,,1,B,Expert,,8,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,12687,H,,CHEMBL617473,,
2606,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,12687,D,,CHEMBL617474,,
2607,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,12687,D,,CHEMBL617475,,
2608,,,BAO_0000221,,1,B,Autocuration,,8,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,12687,H,,CHEMBL617476,955.0,
2609,,,BAO_0000357,,1,B,Expert,,8,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL617477,,
2610,723.0,,BAO_0000219,NIH3T3,1,B,Expert,,8,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL617478,,
2611,,,BAO_0000221,,1,F,Autocuration,,8,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",12687,H,,CHEMBL617479,,
2612,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,12687,H,,CHEMBL617480,,
2613,,,BAO_0000357,,1,B,Expert,,8,Binding affinity against 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL617481,,
2614,,,BAO_0000019,,1,B,Expert,,8,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,12687,H,,CHEMBL617482,,
2615,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,12687,H,,CHEMBL617483,,
2616,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,12687,H,,CHEMBL621528,,
2617,723.0,Rattus norvegicus,BAO_0000219,NIH3T3,1,B,Expert,,9,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,12687,D,,CHEMBL621529,,
2618,,,BAO_0000357,,1,B,Expert,,8,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,12687,H,,CHEMBL621530,,
2619,,,BAO_0000357,,1,B,Expert,,8,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,H,,CHEMBL621531,,
2620,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,12687,D,,CHEMBL621532,,
2621,,,BAO_0000357,,1,B,Expert,,8,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,12687,H,,CHEMBL621533,,
2622,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,12687,H,,CHEMBL621534,,
2623,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,12687,H,,CHEMBL621535,,
2624,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,12687,H,,CHEMBL621536,,
2625,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL621537,,
2626,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Binding affinity for 5-hydroxytryptamine 2A receptor,12687,D,,CHEMBL621538,,
2627,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,12687,H,,CHEMBL621539,,
2628,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,12687,H,,CHEMBL621540,,
2629,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,12687,H,,CHEMBL621541,,
2630,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,12687,H,,CHEMBL621542,,
2631,,,BAO_0000357,,1,B,Expert,,8,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,12687,H,,CHEMBL621543,,
2632,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,12687,H,,CHEMBL621544,,
2633,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,12687,D,,CHEMBL621545,,
2634,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,H,,CHEMBL621546,,
2635,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,12687,H,,CHEMBL621547,,
2636,723.0,,BAO_0000219,NIH3T3,1,B,Expert,,8,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL618692,,
2637,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL618693,,
2638,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,12687,H,,CHEMBL872922,,
2639,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,12687,H,,CHEMBL618694,,
2640,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,12687,D,,CHEMBL618695,,
2641,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,12687,H,,CHEMBL618696,,
2642,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,12687,H,,CHEMBL618697,,
2643,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,12687,H,,CHEMBL618892,,
2644,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,12687,H,,CHEMBL618893,,
2645,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL618894,,
2646,723.0,,BAO_0000219,NIH3T3,1,B,Expert,,8,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,12687,H,,CHEMBL618895,,
2647,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,12687,D,,CHEMBL618896,,
2648,,,BAO_0000019,,1,B,Autocuration,,8,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,12687,H,,CHEMBL618897,5383.0,
2649,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,12687,H,,CHEMBL618898,,
2650,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,12687,H,,CHEMBL618899,,
2651,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,12687,H,,CHEMBL618900,,
2652,,,BAO_0000019,,1,B,Autocuration,,8,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,12687,H,,CHEMBL618901,,
2653,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL618902,,
2654,,Rattus norvegicus,BAO_0000221,,1,B,Expert,,9,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,12687,D,,CHEMBL618903,10000000.0,
2655,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL618904,,
2656,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,12687,H,,CHEMBL618905,,
2657,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,12687,H,,CHEMBL618906,,
2658,723.0,,BAO_0000219,NIH3T3,1,B,Expert,,8,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,12687,H,,CHEMBL618907,,
2659,,,BAO_0000019,,1,B,Autocuration,,8,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,12687,H,,CHEMBL618908,,
2660,,,BAO_0000357,,1,B,Autocuration,,8,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL617909,,
2661,,,BAO_0000019,,1,B,Expert,,8,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,12687,H,,CHEMBL617910,,
2662,,,BAO_0000221,,1,B,Autocuration,,8,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,12687,H,,CHEMBL617911,955.0,
2663,,,BAO_0000249,,1,B,Autocuration,,8,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,H,,CHEMBL872923,,
2664,,,BAO_0000249,,1,B,Autocuration,,8,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,H,,CHEMBL617912,,
2665,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,12687,D,,CHEMBL617913,,
2666,,,BAO_0000249,,1,B,Expert,,8,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,H,,CHEMBL617914,,
2667,,,BAO_0000249,,1,B,Autocuration,,8,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,H,,CHEMBL617915,,
2668,,,BAO_0000249,,1,B,Autocuration,,8,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,H,,CHEMBL617916,,
2669,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,12687,D,,CHEMBL617917,,
2670,,,BAO_0000019,,1,B,Expert,,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,12687,H,,CHEMBL617918,,
2671,,,BAO_0000019,,1,B,Autocuration,,8,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,12687,H,,CHEMBL617919,,
2672,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,12687,D,,CHEMBL617920,,
2673,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,12687,D,,CHEMBL617921,,
2674,,Rattus norvegicus,BAO_0000224,,1,B,Expert,,5,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",105102,D,,CHEMBL617922,,
2675,,,BAO_0000357,,1,B,Autocuration,,8,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,12687,H,,CHEMBL617923,,
2676,,,BAO_0000357,,1,B,Autocuration,,8,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,H,,CHEMBL617924,,
2677,,,BAO_0000357,,1,B,Autocuration,,8,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,12687,H,,CHEMBL617925,,
2678,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,12687,D,,CHEMBL617926,,
2679,,,BAO_0000357,,1,B,Autocuration,,8,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,12687,H,,CHEMBL617927,,
2680,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,12687,H,,CHEMBL617928,,
2681,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,D,,CHEMBL617929,,
2682,,,BAO_0000019,,1,B,Expert,,8,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,12687,H,,CHEMBL617930,,
2683,,,BAO_0000019,,1,B,Autocuration,,8,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,12687,H,,CHEMBL617931,,
2684,,,BAO_0000019,,1,B,Autocuration,,8,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,12687,H,,CHEMBL617932,,
2685,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,12687,H,,CHEMBL617933,,
2686,,,BAO_0000019,,1,B,Autocuration,,8,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,12687,H,,CHEMBL617934,,
2687,,,BAO_0000019,,1,B,Autocuration,,8,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,12687,H,,CHEMBL617935,,
2688,,,BAO_0000357,,1,B,Autocuration,,8,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,12687,H,,CHEMBL617936,,
2689,,,BAO_0000019,,1,B,Autocuration,,8,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,12687,H,,CHEMBL617937,,
2690,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,12687,H,,CHEMBL617938,,
2691,,,BAO_0000218,,1,B,Autocuration,,8,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,12687,H,,CHEMBL617939,,
2692,,,BAO_0000218,,1,B,Autocuration,,8,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,12687,H,,CHEMBL617940,,
2693,,,BAO_0000218,,1,B,Autocuration,,8,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,12687,H,,CHEMBL617941,,
2694,,,BAO_0000357,,1,B,Expert,,8,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,12687,H,,CHEMBL617942,,
2695,,,BAO_0000357,,1,B,Expert,,8,Ratio of pKi of 5-HT2A to that of D2 receptor,12687,H,,CHEMBL617943,,
2696,,,BAO_0000224,,1,B,Expert,,4,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,105093,H,,CHEMBL617944,,
2697,,,BAO_0000224,,1,B,Expert,,4,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,105093,H,,CHEMBL617945,,
2698,,,BAO_0000224,,1,B,Expert,,4,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,105075,H,,CHEMBL617946,,
2699,,,BAO_0000357,,1,B,Autocuration,,8,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,12687,H,,CHEMBL617947,,
2700,,,BAO_0000357,,1,B,Expert,,8,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,12687,H,,CHEMBL617948,,
2701,,,BAO_0000019,,1,F,Autocuration,,8,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,12687,H,,CHEMBL858116,,
2702,,,BAO_0000019,,1,F,Autocuration,,8,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,12687,H,,CHEMBL617949,,
2703,,,BAO_0000019,,1,F,Autocuration,,8,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,12687,H,,CHEMBL617950,,
2704,,,BAO_0000019,,1,F,Expert,,8,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,12687,H,,CHEMBL617951,1515.0,
2705,,,BAO_0000019,,1,F,Expert,,8,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,12687,H,,CHEMBL617952,1515.0,
2706,,,BAO_0000019,,1,F,Autocuration,,8,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,12687,H,,CHEMBL617953,1515.0,
2707,,,BAO_0000357,,1,B,Autocuration,,8,Binding activity radioligand.,12687,H,,CHEMBL617954,,
2708,,,BAO_0000019,,1,B,Expert,,8,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,12687,H,,CHEMBL617955,,
2709,,,BAO_0000019,,1,B,Autocuration,,8,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,12687,H,,CHEMBL857071,,
2710,,,BAO_0000019,,1,B,Expert,,8,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,12687,H,,CHEMBL617270,,
2711,339.0,,BAO_0000219,N1E-115,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,12687,H,,CHEMBL617271,,
2712,339.0,,BAO_0000219,N1E-115,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,12687,H,,CHEMBL617272,,
2713,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,12687,H,,CHEMBL617273,,
2714,,Rattus norvegicus,BAO_0000019,,1,F,Expert,,9,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,12687,D,,CHEMBL617274,,
2715,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL617275,,
2716,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL617276,,
2717,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL617277,,
2718,,,BAO_0000019,,1,B,Expert,,8,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL617278,,
2719,,,BAO_0000019,,1,B,Expert,,8,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,108,H,,CHEMBL617279,,
2720,,,BAO_0000019,,1,B,Expert,,8,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL617280,,
2721,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL617281,,
2722,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL617282,,
2723,,,BAO_0000019,,1,B,Expert,,8,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,108,H,,CHEMBL617283,,
2724,,,BAO_0000019,,1,B,Expert,,8,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,108,H,,CHEMBL617284,,
2725,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,108,H,,CHEMBL617285,,
2726,,,BAO_0000019,,1,B,Autocuration,,8,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL617286,,
2727,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,108,D,,CHEMBL617287,,
2728,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,108,H,,CHEMBL617288,,
2729,,,BAO_0000357,,1,B,Autocuration,,8,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,108,H,,CHEMBL617289,,
2730,,,BAO_0000357,,1,B,Autocuration,,8,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,108,H,,CHEMBL872917,,
2731,,,BAO_0000357,,1,B,Autocuration,,8,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,108,H,,CHEMBL617290,,
2732,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,108,H,,CHEMBL617291,,
2733,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,108,H,,CHEMBL617292,,
2734,723.0,,BAO_0000219,NIH3T3,1,B,Autocuration,,8,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,108,H,,CHEMBL617293,,
2735,449.0,Homo sapiens,BAO_0000219,CHO,1,F,Expert,,9,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,108,D,,CHEMBL617294,,
2736,,,BAO_0000019,,1,B,Expert,,8,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,108,H,,CHEMBL617295,,
2737,,,BAO_0000357,,1,B,Autocuration,,8,Binding activity radioligand.,108,H,,CHEMBL617296,,
2738,,,BAO_0000019,,1,B,Autocuration,,8,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,108,H,,CHEMBL617297,,
2739,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,108,H,,CHEMBL617298,,
2740,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,108,H,,CHEMBL617299,,
2741,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,108,H,,CHEMBL617300,,
2742,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-HT2C receptor,108,H,,CHEMBL617454,,
2743,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,108,H,,CHEMBL617505,,
2744,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,108,D,,CHEMBL617506,,
2745,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,108,D,,CHEMBL617507,,
2746,,,BAO_0000357,,1,B,Expert,,8,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,108,H,,CHEMBL617508,,
2747,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,108,D,,CHEMBL857982,,
2748,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,108,D,,CHEMBL617509,,
2749,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,108,D,,CHEMBL617510,,
2750,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,108,H,,CHEMBL617511,,
2751,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,108,H,,CHEMBL617512,,
2752,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,108,H,,CHEMBL617749,,
2753,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,108,H,,CHEMBL617750,,
2754,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,108,H,,CHEMBL617751,,
2755,722.0,,BAO_0000219,HEK293,1,B,Expert,,8,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,108,H,,CHEMBL617752,,
2756,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",108,H,,CHEMBL617753,,
2757,722.0,,BAO_0000219,HEK293,1,B,Expert,,8,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",108,H,,CHEMBL617754,,
2758,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,108,D,,CHEMBL617755,,
2759,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",108,H,,CHEMBL617756,,
2760,722.0,,BAO_0000219,HEK293,1,B,Expert,,8,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,108,H,,CHEMBL617757,,
2761,722.0,,BAO_0000219,HEK293,1,B,Expert,,8,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,108,H,,CHEMBL617758,,
2762,723.0,,BAO_0000219,NIH3T3,1,B,Autocuration,,8,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,108,H,,CHEMBL617759,,
2763,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,108,H,,CHEMBL617760,,
2764,485.0,,BAO_0000219,CHO-K1,1,B,Expert,,8,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,108,H,,CHEMBL617761,,
2765,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity against 5-hydroxytryptamine 2C receptor,108,D,,CHEMBL617762,,
2766,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL617763,,
2767,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,108,H,,CHEMBL857983,,
2768,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,108,H,,CHEMBL617764,,
2769,308.0,,BAO_0000219,HeLa,1,B,Autocuration,,8,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,108,H,,CHEMBL617765,,
2770,,,BAO_0000019,,1,F,Autocuration,,8,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,108,H,,CHEMBL617766,,
2771,,,BAO_0000221,,1,F,Autocuration,,8,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,108,H,,CHEMBL617767,10000000.0,
2772,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,108,H,,CHEMBL617768,,
2773,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",108,H,,CHEMBL617769,,
2774,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,11864,H,,CHEMBL858023,,
2775,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity analysed on 5-HT 2C in rat stomach fundus,11864,H,,CHEMBL617770,945.0,
2776,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,11864,H,,CHEMBL617771,945.0,
2777,625.0,,BAO_0000219,A9,1,F,Autocuration,,8,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,11864,H,,CHEMBL617772,,
2778,723.0,,BAO_0000219,NIH3T3,1,B,Autocuration,,8,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,11864,H,,CHEMBL617773,,
2779,723.0,,BAO_0000219,NIH3T3,1,B,Autocuration,,8,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,11864,H,,CHEMBL617850,,
2780,723.0,,BAO_0000219,NIH3T3,1,B,Autocuration,,8,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,11864,H,,CHEMBL617851,,
2781,,,BAO_0000019,,1,F,Autocuration,,8,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,11864,H,,CHEMBL617852,,
2782,,Mus musculus,BAO_0000019,,1,B,Autocuration,,8,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,12689,H,,CHEMBL858024,945.0,
2783,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,12689,D,,CHEMBL617853,945.0,
2784,,,BAO_0000357,,1,B,Expert,,8,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,108,H,,CHEMBL617854,,
2785,,Sus scrofa,BAO_0000357,,1,B,Expert,,8,Binding affinity for 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL873477,,
2786,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL617855,,
2787,,,BAO_0000019,,1,B,Expert,,8,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,108,H,,CHEMBL617856,,
2788,,,BAO_0000019,,1,B,Autocuration,,8,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,108,H,,CHEMBL617857,,
2789,,,BAO_0000249,,1,B,Autocuration,,8,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,108,H,,CHEMBL617858,,
2790,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL617859,,
2791,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL617860,,
2792,,,BAO_0000357,,1,B,Autocuration,,8,Binding activity radioligand.,108,H,,CHEMBL617861,,
2793,,,BAO_0000019,,1,B,Expert,,8,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,108,H,,CHEMBL617862,,
2794,,,BAO_0000019,,1,B,Autocuration,,8,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,108,H,,CHEMBL617863,,
2795,,,BAO_0000249,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,108,H,,CHEMBL617864,,
2796,,,BAO_0000249,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,108,H,,CHEMBL617649,,
2797,,Sus scrofa,BAO_0000019,,1,F,Expert,,8,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,108,H,,CHEMBL617650,,
2798,,Sus scrofa,BAO_0000019,,1,F,Expert,,8,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,108,H,,CHEMBL617651,,
2799,,Sus scrofa,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,108,H,,CHEMBL617652,,
2800,,Sus scrofa,BAO_0000019,,1,B,Autocuration,,8,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,108,H,,CHEMBL857072,,
2801,,Sus scrofa,BAO_0000357,,1,B,Autocuration,,8,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL617653,,
2802,,,BAO_0000019,,1,B,Autocuration,,8,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,12687,H,,CHEMBL617654,,
2803,,,BAO_0000019,,1,F,Autocuration,,8,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,12689,H,,CHEMBL617655,,
2804,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,12689,H,,CHEMBL617656,,
2805,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,12689,H,,CHEMBL617657,,
2806,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,12689,H,,CHEMBL617658,,
2807,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,12689,D,,CHEMBL617659,,
2808,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,12689,D,,CHEMBL617838,,
2809,,Rattus norvegicus,BAO_0000249,,1,B,Expert,,9,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,12689,D,,CHEMBL617839,,
2810,,,BAO_0000357,,1,B,Autocuration,,8,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,12689,H,,CHEMBL617840,,
2811,,,BAO_0000019,,1,B,Autocuration,,8,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,12689,H,,CHEMBL617841,,
2812,,,BAO_0000019,,1,B,Autocuration,,8,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,12689,H,,CHEMBL875915,,
2813,,,BAO_0000219,,1,B,Expert,In vitro,8,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,12689,H,,CHEMBL617842,,
2814,723.0,,BAO_0000219,NIH3T3,1,B,Expert,,8,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,12689,H,,CHEMBL617843,,
2815,,,BAO_0000357,,1,B,Expert,,8,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,12689,H,,CHEMBL617844,,
2816,,,BAO_0000357,,1,B,Expert,,8,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,12689,H,,CHEMBL617845,,
2817,723.0,,BAO_0000219,NIH3T3,1,B,Expert,,8,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,12689,H,,CHEMBL617846,,
2818,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,12689,H,,CHEMBL617847,,
2819,,,BAO_0000357,,1,B,Expert,,8,Binding affinity against 5-hydroxytryptamine 2C receptor,12689,H,,CHEMBL617848,,
2820,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,12689,H,,CHEMBL617849,,
2821,,,BAO_0000357,,1,B,Expert,,8,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,12689,H,,CHEMBL621507,,
2822,,,BAO_0000357,,1,B,Expert,,8,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,12689,H,,CHEMBL621508,,
2823,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,12689,H,,CHEMBL621509,,
2824,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,12689,H,,CHEMBL621510,,
2825,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,12689,H,,CHEMBL621511,,
2826,625.0,,BAO_0000219,A9,1,B,Expert,,8,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,12689,H,,CHEMBL621512,,
2827,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,12689,H,,CHEMBL621513,,
2828,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,12689,H,,CHEMBL621514,,
2829,,,BAO_0000219,,1,B,Expert,In vitro,8,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,12689,H,,CHEMBL621515,,
2830,,,BAO_0000219,,1,B,Autocuration,,8,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,12689,H,,CHEMBL621516,,
2831,,,BAO_0000019,,1,B,Autocuration,,8,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,12689,H,,CHEMBL621517,5383.0,
2832,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,12689,H,,CHEMBL621518,,
2833,,,BAO_0000019,,1,B,Autocuration,,8,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,12689,H,,CHEMBL621519,,
2834,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,12689,H,,CHEMBL621520,,
2835,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,12689,H,,CHEMBL621521,,
2836,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,12689,H,,CHEMBL621522,,
2837,,,BAO_0000219,,1,B,Expert,,8,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,12689,H,,CHEMBL621523,,
2838,,,BAO_0000357,,1,B,Autocuration,,8,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,12689,H,,CHEMBL621524,,
2839,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,12689,D,,CHEMBL621525,,
2840,,,BAO_0000357,,1,B,Autocuration,,8,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,12689,H,,CHEMBL872921,,
2841,,,BAO_0000357,,1,B,Autocuration,,8,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,12689,H,,CHEMBL621526,,
2842,,,BAO_0000219,,1,B,Expert,,8,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,12689,H,,CHEMBL621527,,
2843,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,12689,D,,CHEMBL617865,,
2844,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,12689,H,,CHEMBL617866,,
2845,,,BAO_0000019,,1,B,Autocuration,,8,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,12689,H,,CHEMBL617867,,
2846,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,12689,H,,CHEMBL617487,,
2847,,,BAO_0000357,,1,B,Expert,,8,Binding affinity for 5-hydroxytryptamine 2C receptor,12689,H,,CHEMBL617488,,
2848,,,BAO_0000357,,1,B,Autocuration,,8,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,12689,H,,CHEMBL617489,,
2849,,,BAO_0000019,,1,B,Autocuration,,8,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,12689,H,,CHEMBL617490,,
2850,,,BAO_0000019,,1,B,Autocuration,,8,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,12689,H,,CHEMBL617491,,
2851,,,BAO_0000019,,1,B,Autocuration,,8,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,12689,H,,CHEMBL617492,,
2852,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,12689,H,,CHEMBL617493,,
2853,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,12689,H,,CHEMBL617494,,
2854,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,12689,D,,CHEMBL617495,,
2855,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,12689,H,,CHEMBL617496,,
2856,485.0,,BAO_0000219,CHO-K1,1,B,Autocuration,,8,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,12689,H,,CHEMBL617497,,
2857,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,12689,H,,CHEMBL617498,,
2858,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,12689,H,,CHEMBL617499,,
2859,,,BAO_0000019,,1,F,Autocuration,,8,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,12689,H,,CHEMBL617500,,
2860,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL617501,,
2861,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL617502,,
2862,,,BAO_0000357,,1,B,Autocuration,,8,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,227,H,,CHEMBL617503,,
2863,,,BAO_0000357,,1,B,Autocuration,,8,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,227,H,,CHEMBL617504,,
2864,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,227,H,,CHEMBL617406,,
2865,,Homo sapiens,BAO_0000019,,1,B,Expert,,9,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,227,D,,CHEMBL617407,,
2866,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,227,H,,CHEMBL617408,,
2867,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,227,H,,CHEMBL617409,,
2868,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,227,H,,CHEMBL617410,,
2869,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,227,H,,CHEMBL617411,,
2870,,,BAO_0000019,,1,B,Autocuration,,8,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,227,H,,CHEMBL617412,,
2871,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,227,D,,CHEMBL617774,,
2872,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,227,D,,CHEMBL617775,,
2873,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,227,D,,CHEMBL617776,,
2874,449.0,Homo sapiens,BAO_0000219,CHO,1,F,Expert,,9,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,227,D,,CHEMBL617777,,
2875,449.0,Homo sapiens,BAO_0000219,CHO,1,F,Expert,,9,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,227,D,,CHEMBL617778,,
2876,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",227,H,,CHEMBL617779,,
2877,722.0,,BAO_0000219,HEK293,1,B,Expert,,8,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,227,H,,CHEMBL617780,,
2878,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",227,H,,CHEMBL617781,,
2879,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,227,D,,CHEMBL617782,,
2880,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,227,D,,CHEMBL617783,,
2881,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,227,H,,CHEMBL617784,,
2882,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,227,H,,CHEMBL617785,,
2883,722.0,,BAO_0000219,HEK293,1,B,Expert,,8,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,227,H,,CHEMBL857984,,
2884,722.0,,BAO_0000219,HEK293,1,B,Expert,,8,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,227,H,,CHEMBL617786,,
2885,722.0,,BAO_0000219,HEK293,1,B,Expert,,8,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,227,H,,CHEMBL617787,,
2886,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,227,D,,CHEMBL617788,,
2887,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,227,D,,CHEMBL617789,,
2888,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,227,H,,CHEMBL617790,,
2889,485.0,,BAO_0000219,CHO-K1,1,B,Expert,,8,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,227,H,,CHEMBL617791,,
2890,,,BAO_0000357,,1,B,Expert,,8,Binding affinity against 5-hydroxytryptamine 2B receptor,227,H,,CHEMBL617608,,
2891,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,227,H,,CHEMBL617609,,
2892,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,227,H,,CHEMBL617610,,
2893,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,227,H,,CHEMBL617611,,
2894,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",227,H,,CHEMBL617612,,
2895,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",227,H,,CHEMBL617613,,
2896,,Oryctolagus cuniculus,BAO_0000019,,1,B,Autocuration,,8,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,227,H,,CHEMBL617614,,
2897,,,BAO_0000019,,1,B,Expert,,8,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,12688,H,,CHEMBL617615,945.0,
2898,,,BAO_0000357,,1,B,Expert,,8,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,12688,H,,CHEMBL858114,945.0,
2899,,,BAO_0000357,,1,B,Autocuration,,8,Affinity against serotonergic receptor in the isolated rat stomach fundus,12688,H,,CHEMBL617616,945.0,
2900,,Rattus norvegicus,BAO_0000019,,1,F,Expert,,9,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,12688,D,,CHEMBL617617,945.0,
2901,,Rattus norvegicus,BAO_0000019,,1,F,Expert,,9,Antagonistic against 5-hydroxytryptamine 2B receptor,12688,D,,CHEMBL875914,,
2902,,,BAO_0000019,,1,F,Autocuration,,8,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,12688,H,,CHEMBL617618,945.0,
2903,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,12688,D,,CHEMBL617619,945.0,
2904,,,BAO_0000019,,1,F,Autocuration,,8,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,12688,H,,CHEMBL617620,,
2905,,,BAO_0000019,,1,F,Autocuration,,8,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,12688,H,,CHEMBL617621,,
2906,,,BAO_0000019,,1,F,Autocuration,,8,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,12688,H,,CHEMBL617622,,
2907,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,D,,CHEMBL617623,945.0,
2908,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,D,,CHEMBL617624,945.0,
2909,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,D,,CHEMBL617625,945.0,
2910,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,D,,CHEMBL617626,945.0,
2911,,,BAO_0000019,,1,F,Autocuration,,8,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,12688,H,,CHEMBL617627,945.0,
2912,,,BAO_0000019,,1,F,Expert,,8,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,12688,H,,CHEMBL617628,945.0,
2913,,,BAO_0000019,,1,F,Autocuration,,8,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,12688,H,,CHEMBL617629,945.0,
2914,,,BAO_0000019,,1,F,Autocuration,,8,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,12688,H,,CHEMBL858115,945.0,
2915,,Rattus norvegicus,BAO_0000019,,1,F,Expert,,9,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,12688,D,,CHEMBL617630,945.0,
2916,,,BAO_0000019,,1,F,Autocuration,,8,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,12688,H,,CHEMBL617631,1515.0,
2917,,,BAO_0000357,,1,B,Autocuration,,8,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,12688,H,,CHEMBL617632,,
2918,,,BAO_0000357,,1,B,Expert,,8,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,12688,H,,CHEMBL617633,,
2919,,,BAO_0000357,,1,B,Autocuration,,8,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,12688,H,,CHEMBL617634,,
2920,,,BAO_0000357,,1,B,Autocuration,,8,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,12688,H,,CHEMBL617635,,
2922,,Rattus norvegicus,BAO_0000019,,1,F,Autocuration,,9,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,12688,D,,CHEMBL617637,945.0,
2923,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 1A receptor,227,H,,CHEMBL617638,,
2924,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,227,H,,CHEMBL617639,,
2925,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,227,H,,CHEMBL617640,,
2926,,,BAO_0000357,,1,B,Autocuration,,8,Evaluated for the binding affinity to 5-HT 2B receptor,227,H,,CHEMBL617641,,
2927,,,BAO_0000357,,1,B,Autocuration,,8,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,227,H,,CHEMBL617642,,
2928,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinities against 5-hydroxytryptamine 2B receptor,227,H,,CHEMBL617643,,
2929,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinities towards 5-hydroxytryptamine 2B receptor,227,H,,CHEMBL617644,,
2930,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,227,H,,CHEMBL617645,,
2931,,,BAO_0000357,,1,B,Expert,,8,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,108,H,,CHEMBL617646,,
2932,,Bos taurus,BAO_0000357,,1,B,Autocuration,,8,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,108,H,,CHEMBL617647,,
2933,,Bos taurus,BAO_0000357,,1,B,Autocuration,,8,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,108,H,,CHEMBL617648,,
2934,,Bos taurus,BAO_0000357,,1,B,Autocuration,,8,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,108,H,,CHEMBL617875,,
2935,,Bos taurus,BAO_0000357,,1,B,Autocuration,,8,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,108,H,,CHEMBL617876,,
2936,,Bos taurus,BAO_0000357,,1,B,Expert,,8,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,108,H,,CHEMBL617877,,
2937,,Bos taurus,BAO_0000357,,1,B,Expert,,8,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,108,H,,CHEMBL617878,,
2938,,Bos taurus,BAO_0000357,,1,B,Autocuration,,8,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,108,H,,CHEMBL617879,,
2939,,Cavia porcellus,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,108,H,,CHEMBL617880,,
2940,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,20033,D,,CHEMBL617881,2435.0,
2941,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-HT1A receptor,51,H,,CHEMBL857073,,
2942,449.0,,BAO_0000219,CHO,1,F,Expert,,8,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,108,H,,CHEMBL617882,,
2943,449.0,Homo sapiens,BAO_0000219,CHO,1,F,Expert,,9,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,108,D,,CHEMBL617883,,
2944,,,BAO_0000219,,1,F,Autocuration,,8,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,108,H,,CHEMBL617884,,
2945,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,108,H,,CHEMBL617885,,
2946,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",108,H,,CHEMBL617886,,
2947,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Inhibition of human 5-hydroxytryptamine 2C receptor,108,D,,CHEMBL617887,,
2948,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),108,H,,CHEMBL617888,,
2949,,,BAO_0000019,,1,B,Autocuration,,8,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,108,H,,CHEMBL617889,,
2950,,,BAO_0000357,,1,B,Autocuration,,8,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL617890,,
2951,,,BAO_0000357,,1,B,Autocuration,,8,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,108,H,,CHEMBL617891,,
2952,,,BAO_0000357,,1,B,Autocuration,,8,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,108,H,,CHEMBL617892,,
2953,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,108,H,,CHEMBL617893,,
2954,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,108,H,,CHEMBL617894,,
2955,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,108,H,,CHEMBL617895,,
2956,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL617896,,
2957,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,108,D,,CHEMBL617897,,
2958,,,BAO_0000019,,1,F,Autocuration,,8,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,108,H,,CHEMBL617898,,
2959,,,BAO_0000019,,1,F,Autocuration,,8,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,108,H,,CHEMBL617899,,
2960,449.0,Rattus norvegicus,BAO_0000219,CHO,1,B,Expert,,8,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,108,H,,CHEMBL617900,,
2961,,,BAO_0000019,,1,F,Autocuration,,8,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,108,H,,CHEMBL617901,,
2962,,,BAO_0000019,,1,F,Autocuration,,8,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,108,H,,CHEMBL617902,,
2963,,,BAO_0000019,,1,F,Autocuration,,8,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,108,H,,CHEMBL617903,,
2964,,,BAO_0000357,,1,B,Autocuration,,8,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,108,H,,CHEMBL617904,,
2965,,,BAO_0000357,,1,B,Autocuration,,8,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,108,H,,CHEMBL617905,,
2966,,,BAO_0000357,,1,B,Autocuration,,8,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,108,H,,CHEMBL617906,,
2967,,,BAO_0000357,,1,B,Autocuration,,8,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,108,H,,CHEMBL617907,,
2968,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,108,H,,CHEMBL617908,,
2969,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,108,H,,CHEMBL620617,,
2970,,Homo sapiens,BAO_0000019,,1,B,Expert,,9,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,108,D,,CHEMBL620618,,
2971,,,BAO_0000357,,1,B,Expert,,8,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,108,H,,CHEMBL620619,,
2972,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,108,D,,CHEMBL620620,,
2973,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,108,H,,CHEMBL620621,,
2974,,Rattus norvegicus,BAO_0000249,,1,B,Autocuration,,7,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,104698,D,,CHEMBL872920,,
2975,,,BAO_0000223,,1,B,Autocuration,,6,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,104698,H,,CHEMBL620622,,
2976,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,7,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,104698,D,,CHEMBL620623,,
2977,,,BAO_0000019,,1,B,Autocuration,,6,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,104698,H,,CHEMBL620624,,
2978,,,BAO_0000019,,1,B,Autocuration,,6,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,104698,H,,CHEMBL620625,,
2979,,,BAO_0000219,,1,B,Autocuration,,6,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,104698,H,,CHEMBL620626,,
2980,,,BAO_0000019,,1,B,Autocuration,,6,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,104698,H,,CHEMBL621307,,
2981,,,BAO_0000019,,1,B,Autocuration,,6,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,104698,H,,CHEMBL621308,,
2982,,,BAO_0000223,,1,B,Autocuration,,6,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,104698,H,,CHEMBL621309,,
2983,,,BAO_0000223,,1,B,Autocuration,,6,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,104698,H,,CHEMBL621310,,
2984,,,BAO_0000223,,1,B,Autocuration,,6,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,104698,H,,CHEMBL621311,,
2985,,,BAO_0000249,,1,B,Autocuration,,6,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",104698,H,,CHEMBL621502,,
2986,,,BAO_0000249,,1,B,Autocuration,,6,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",104698,H,,CHEMBL621503,,
2987,,,BAO_0000249,,1,B,Autocuration,,6,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,104698,H,,CHEMBL621504,,
2988,,,BAO_0000223,,1,B,Autocuration,,6,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,104698,H,,CHEMBL621505,,
2989,,,BAO_0000019,,1,B,Autocuration,,6,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,104698,H,,CHEMBL621506,,
2990,,,BAO_0000223,,1,B,Autocuration,,6,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,104698,H,,CHEMBL619781,,
2991,,,BAO_0000223,,1,B,Autocuration,,6,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,104698,H,,CHEMBL619782,,
2992,,,BAO_0000019,,1,B,Autocuration,,6,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,104698,H,,CHEMBL619783,,
2993,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,7,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,104698,D,,CHEMBL619784,,
2994,,,BAO_0000249,,1,B,Autocuration,,6,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,104698,H,,CHEMBL619785,,
2995,,,BAO_0000223,,1,B,Autocuration,,6,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,104698,H,,CHEMBL619786,,
2996,,,BAO_0000019,,1,B,Autocuration,,6,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,104698,H,,CHEMBL619787,,
2997,,,BAO_0000019,,1,B,Autocuration,,6,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,104698,H,,CHEMBL872925,,
2998,,,BAO_0000019,,1,B,Autocuration,,6,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,104698,H,,CHEMBL619788,,
2999,,,BAO_0000249,,1,B,Autocuration,,6,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,104698,H,,CHEMBL619789,,
3000,,,BAO_0000249,,1,B,Autocuration,,6,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,104698,H,,CHEMBL619790,,
3001,,,BAO_0000019,,1,B,Autocuration,,6,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,104698,H,,CHEMBL619791,,
3002,,,BAO_0000019,,1,B,Autocuration,,6,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,104698,H,,CHEMBL619792,,
3003,,,BAO_0000249,,1,B,Autocuration,,6,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,104698,H,,CHEMBL619793,,
3004,,Rattus norvegicus,BAO_0000223,,1,B,Autocuration,,7,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,104698,D,,CHEMBL619794,,
3005,,,BAO_0000221,,1,B,Autocuration,,6,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,104698,H,,CHEMBL619795,955.0,
3006,,,BAO_0000019,,1,B,Autocuration,,6,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,104698,H,,CHEMBL619796,,
3007,,,BAO_0000223,,1,B,Autocuration,,6,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,104698,H,,CHEMBL620448,,
3008,,,BAO_0000223,,1,B,Autocuration,,6,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,104698,H,,CHEMBL620449,,
3009,,,BAO_0000223,,1,B,Autocuration,,6,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,104698,H,,CHEMBL620450,,
3010,,,BAO_0000223,,1,B,Autocuration,,6,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,104698,H,,CHEMBL620451,,
3011,,,BAO_0000223,,1,B,Autocuration,,6,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,104698,H,,CHEMBL620631,,
3012,,,BAO_0000019,,1,B,Autocuration,,6,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,104698,H,,CHEMBL620632,,
3013,,,BAO_0000019,,1,B,Autocuration,,6,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,104698,H,,CHEMBL620633,,
3014,,,BAO_0000223,,1,B,Autocuration,,6,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,104698,H,,CHEMBL620634,,
3015,,,BAO_0000019,,1,B,Autocuration,,6,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,104698,H,,CHEMBL620635,,
3016,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,H,,CHEMBL620636,,
3017,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,104698,H,,CHEMBL620637,,
3018,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,104698,H,,CHEMBL620638,,
3019,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,104698,H,,CHEMBL620639,,
3020,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,H,,CHEMBL620640,,
3021,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,104698,H,,CHEMBL620641,,
3022,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,104698,H,,CHEMBL620642,,
3023,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,104698,H,,CHEMBL620643,,
3024,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,104698,H,,CHEMBL620644,,
3025,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,H,,CHEMBL620645,,
3026,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,104698,H,,CHEMBL620646,,
3027,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,104698,H,,CHEMBL620647,,
3028,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,104698,H,,CHEMBL620648,,
3029,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,H,,CHEMBL620649,,
3030,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,104698,H,,CHEMBL620650,,
3031,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,104698,H,,CHEMBL620651,,
3032,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,104698,H,,CHEMBL872875,,
3033,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,104698,H,,CHEMBL620652,,
3034,,,BAO_0000019,,1,F,Autocuration,,6,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,104698,H,,CHEMBL620653,,
3035,,,BAO_0000019,,1,B,Autocuration,,6,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,104698,H,,CHEMBL857076,,
3036,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,7,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,104698,D,,CHEMBL620654,,
3037,,,BAO_0000223,,1,B,Autocuration,,6,Binding activity radioligand.,104698,H,,CHEMBL620655,,
3038,,,BAO_0000249,,1,B,Autocuration,,6,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,104698,H,,CHEMBL620656,,
3039,,,BAO_0000249,,1,B,Autocuration,,6,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,104698,H,,CHEMBL620657,,
3040,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,108,H,,CHEMBL620658,,
3041,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,108,H,,CHEMBL620659,,
3042,,,BAO_0000357,,1,B,Autocuration,,8,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,108,H,,CHEMBL620660,,
3043,,,BAO_0000357,,1,B,Autocuration,,8,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL620661,,
3044,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL620662,,
3045,,,BAO_0000357,,1,B,Expert,,8,Affinity for 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL620663,,
3046,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,108,H,,CHEMBL620664,,
3047,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,108,H,,CHEMBL620665,,
3048,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,108,H,,CHEMBL620666,,
3049,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,108,H,,CHEMBL620667,,
3050,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,108,H,,CHEMBL620668,,
3051,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,108,H,,CHEMBL620669,,
3052,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL620670,,
3053,,,BAO_0000357,,1,B,Autocuration,,8,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL620671,,
3054,,,BAO_0000357,,1,B,Autocuration,,8,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,108,H,,CHEMBL620672,,
3055,,,BAO_0000357,,1,B,Autocuration,,8,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,108,H,,CHEMBL620673,,
3056,,,BAO_0000357,,1,B,Autocuration,,8,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL620674,,
3057,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL620675,,
3058,,,BAO_0000357,,1,B,Autocuration,,8,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,108,H,,CHEMBL620676,,
3059,,,BAO_0000357,,1,B,Autocuration,,8,Affinity against 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL621382,,
3060,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity against 5-hydroxytryptamine 2C receptor,108,D,,CHEMBL621383,,
3061,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,108,H,,CHEMBL621384,,
3062,,Bos taurus,BAO_0000357,,1,B,Autocuration,,8,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,144,H,,CHEMBL621385,,
3063,,Bos taurus,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,144,H,,CHEMBL617989,,
3064,,Cavia porcellus,BAO_0000019,,1,F,Expert,,4,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,104714,H,,CHEMBL617990,,
3065,,Cavia porcellus,BAO_0000221,,1,B,Autocuration,,4,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,104714,H,,CHEMBL875085,2116.0,
3066,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,4,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,104714,H,,CHEMBL617991,,
3067,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,4,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,104714,H,,CHEMBL617992,,
3068,,Cavia porcellus,BAO_0000221,,1,B,Autocuration,,4,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,104714,H,,CHEMBL617993,2116.0,
3069,,Cavia porcellus,BAO_0000221,,1,B,Autocuration,,4,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,104714,H,,CHEMBL617994,2116.0,
3070,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,4,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,104714,H,,CHEMBL617995,,
3071,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,4,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,104714,H,,CHEMBL617996,,
3072,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,4,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,104714,H,,CHEMBL617997,,
3073,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,4,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,104714,H,,CHEMBL617998,,
3074,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,4,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,104714,H,,CHEMBL617999,,
3075,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,4,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,104714,H,,CHEMBL618000,,
3076,,Cavia porcellus,BAO_0000221,,1,F,Autocuration,,4,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",104714,H,,CHEMBL617815,2116.0,
3077,,Cavia porcellus,BAO_0000221,,1,F,Autocuration,,4,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",104714,H,,CHEMBL617816,2116.0,
3078,,Cavia porcellus,BAO_0000221,,1,F,Autocuration,,4,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,104714,H,,CHEMBL617817,2116.0,
3079,,Cavia porcellus,BAO_0000221,,1,B,Autocuration,,4,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,104714,H,,CHEMBL617818,2116.0,
3080,,Cavia porcellus,BAO_0000221,,1,B,Autocuration,,4,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,104714,H,,CHEMBL617819,2116.0,
3081,,Cavia porcellus,BAO_0000223,,1,B,Autocuration,,4,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,104714,H,,CHEMBL617820,,
3082,,Cavia porcellus,BAO_0000221,,1,B,Autocuration,,4,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,104714,H,,CHEMBL617821,2116.0,
3083,,Cavia porcellus,BAO_0000221,,1,F,Autocuration,,4,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),104714,H,,CHEMBL617822,2116.0,
3084,,Cavia porcellus,BAO_0000221,,1,F,Autocuration,,4,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),104714,H,,CHEMBL617823,2116.0,
3085,,Cavia porcellus,BAO_0000221,,1,F,Autocuration,,4,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,104714,H,,CHEMBL617824,2116.0,
3086,,Cavia porcellus,BAO_0000221,,1,F,Autocuration,,4,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,104714,H,,CHEMBL617825,2116.0,
3087,,Cavia porcellus,BAO_0000221,,1,F,Autocuration,,4,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,104714,H,,CHEMBL617826,2116.0,
3088,,Cavia porcellus,BAO_0000221,,1,B,Autocuration,,4,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,104714,H,,CHEMBL617827,2116.0,
3089,,Cavia porcellus,BAO_0000221,,1,F,Autocuration,,4,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),104714,H,,CHEMBL617828,2116.0,
3090,,Cavia porcellus,BAO_0000221,,1,B,Autocuration,,4,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,104714,H,,CHEMBL617829,2116.0,
3091,,Cavia porcellus,BAO_0000221,,1,B,Autocuration,,4,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,104714,H,,CHEMBL617830,2116.0,
3092,,Cavia porcellus,BAO_0000221,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,104714,H,,CHEMBL617831,2116.0,
3093,,Cavia porcellus,BAO_0000221,,1,B,Autocuration,,4,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,104714,H,,CHEMBL617832,2116.0,
3094,,Cavia porcellus,BAO_0000019,,1,B,Autocuration,,0,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,22226,U,,CHEMBL617833,,
3095,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,51,H,,CHEMBL617834,,
3096,,Homo sapiens,BAO_0000223,,1,B,Expert,,5,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,104714,D,,CHEMBL617835,,
3097,,,BAO_0000223,,1,B,Autocuration,,4,Binding affinity towards 5-HT3 receptor,104714,H,,CHEMBL617836,,
3098,,,BAO_0000223,,1,B,Autocuration,,4,Binding activity radioligand.,104714,H,,CHEMBL617837,,
3099,,,BAO_0000019,,1,B,Autocuration,,4,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,104714,H,,CHEMBL620392,,
3100,,,BAO_0000223,,1,B,Autocuration,,4,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,104714,H,,CHEMBL620393,,
3101,,,BAO_0000223,,1,B,Autocuration,,4,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,104714,H,,CHEMBL620394,,
3102,,,BAO_0000223,,1,B,Autocuration,,4,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,104714,H,,CHEMBL620395,,
3103,,,BAO_0000019,,1,B,Autocuration,,0,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,22226,U,,CHEMBL620396,,
3104,433.0,,BAO_0000219,NG108-15,1,B,Expert,,4,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,105030,H,,CHEMBL620582,,
3105,,,BAO_0000218,,1,B,Autocuration,In vivo,4,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",105030,H,,CHEMBL620583,,
3106,,,BAO_0000019,,1,B,Autocuration,,4,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),105030,H,,CHEMBL620584,,
3107,,,BAO_0000224,,1,B,Autocuration,,4,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,105030,H,,CHEMBL620585,,
3108,,,BAO_0000224,,1,B,Autocuration,,4,Compound was evaluated for the binding affinity at 5- HT3 receptor,105030,H,,CHEMBL620586,,
3109,,,BAO_0000019,,1,B,Autocuration,,4,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),105030,H,,CHEMBL620587,,
3110,,,BAO_0000019,,1,B,Autocuration,,4,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,105030,H,,CHEMBL620588,,
3111,,,BAO_0000218,,1,F,Autocuration,,4,5-hydroxytryptamine 3 receptor agonism in mouse,105030,H,,CHEMBL620589,,
3112,,,BAO_0000219,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,105030,H,,CHEMBL620590,,
3113,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,105030,H,,CHEMBL617956,,
3114,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,105030,H,,CHEMBL617957,,
3115,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,105030,H,,CHEMBL617958,,
3116,,,BAO_0000219,,1,B,Autocuration,,4,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,105030,H,,CHEMBL617959,,
3117,,,BAO_0000219,,1,B,Autocuration,,4,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,105030,H,,CHEMBL617960,,
3118,,,BAO_0000224,,1,B,Autocuration,,4,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,105030,H,,CHEMBL617961,,
3119,,,BAO_0000219,,1,B,Autocuration,In vitro,4,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,105030,H,,CHEMBL617962,,
3120,339.0,,BAO_0000219,N1E-115,1,B,Autocuration,,4,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,105030,H,,CHEMBL617963,,
3121,,,BAO_0000019,,1,B,Autocuration,,8,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,11765,H,,CHEMBL617964,,
3122,,,BAO_0000219,,1,B,Autocuration,,8,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,11765,H,,CHEMBL617965,,
3123,,Mus musculus,BAO_0000357,,1,B,Autocuration,,9,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,10630,D,,CHEMBL617966,,
3124,,,BAO_0000019,,1,B,Autocuration,,8,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,17106,H,,CHEMBL857074,,
3125,,Sus scrofa,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,144,H,,CHEMBL617967,,
3126,,Sus scrofa,BAO_0000357,,1,B,Autocuration,,8,Binding activity radioligand.,144,H,,CHEMBL617968,,
3127,,Oryctolagus cuniculus,BAO_0000223,,1,B,Autocuration,,4,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,104714,H,,CHEMBL617969,,
3128,,Oryctolagus cuniculus,BAO_0000223,,1,B,Autocuration,,4,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,104714,H,,CHEMBL617970,,
3129,,Oryctolagus cuniculus,BAO_0000223,,1,B,Autocuration,,4,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,104714,H,,CHEMBL617971,,
3130,,Oryctolagus cuniculus,BAO_0000019,,1,B,Autocuration,,4,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,104714,H,,CHEMBL617972,,
3131,,Oryctolagus cuniculus,BAO_0000019,,1,F,Autocuration,,4,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),104714,H,,CHEMBL617973,,
3132,,Oryctolagus cuniculus,BAO_0000019,,1,F,Autocuration,,4,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),104714,H,,CHEMBL617974,,
3133,,Oryctolagus cuniculus,BAO_0000221,,1,F,Autocuration,,4,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),104714,H,,CHEMBL617975,2116.0,
3134,,Oryctolagus cuniculus,BAO_0000019,,1,F,Autocuration,,4,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),104714,H,,CHEMBL617976,,
3135,,Oryctolagus cuniculus,BAO_0000019,,1,F,Autocuration,,4,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),104714,H,,CHEMBL617977,,
3136,,Oryctolagus cuniculus,BAO_0000019,,1,F,Autocuration,,4,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),104714,H,,CHEMBL617978,,
3137,,Oryctolagus cuniculus,BAO_0000019,,1,F,Autocuration,,4,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),104714,H,,CHEMBL617979,,
3138,449.0,Oryctolagus cuniculus,BAO_0000219,CHO,1,B,Autocuration,,4,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,104714,H,,CHEMBL617980,,
3139,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,7,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,104698,D,,CHEMBL617981,,
3140,,,BAO_0000019,,1,B,Autocuration,,8,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),12020,H,,CHEMBL617982,,
3141,,,BAO_0000357,,1,B,Autocuration,,8,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),12020,H,,CHEMBL617983,,
3142,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,7,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,104698,D,,CHEMBL617984,,
3143,,,BAO_0000019,,1,B,Autocuration,,6,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",104698,H,,CHEMBL617985,,
3144,,,BAO_0000218,,1,F,Autocuration,In vivo,6,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",104698,H,,CHEMBL617986,948.0,
3145,,,BAO_0000019,,1,F,Autocuration,,6,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",104698,H,,CHEMBL617987,948.0,
3146,,,BAO_0000019,,1,F,Autocuration,,6,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",104698,H,,CHEMBL617988,948.0,
3147,,,BAO_0000019,,1,F,Autocuration,,6,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",104698,H,,CHEMBL617792,948.0,
3148,,,BAO_0000019,,1,F,Autocuration,,6,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",104698,H,,CHEMBL617793,948.0,
3149,,,BAO_0000019,,1,F,Autocuration,,6,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",104698,H,,CHEMBL617794,,
3150,,,BAO_0000019,,1,F,Autocuration,,6,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",104698,H,,CHEMBL617795,,
3151,,,BAO_0000019,,1,F,Autocuration,,6,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",104698,H,,CHEMBL617796,,
3152,,,BAO_0000019,,1,F,Autocuration,,6,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",104698,H,,CHEMBL617797,,
3153,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,In vivo,7,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),104698,D,,CHEMBL617798,,
3154,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),104698,H,,CHEMBL617799,,
3155,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,In vivo,7,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,D,,CHEMBL617800,,
3156,,Rattus norvegicus,BAO_0000019,,1,F,Autocuration,,7,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,104698,D,,CHEMBL617801,,
3157,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,In vivo,7,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,104698,D,,CHEMBL617802,,
3158,,Rattus norvegicus,BAO_0000019,,1,F,Autocuration,,7,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),104698,D,,CHEMBL617803,,
3159,,,BAO_0000019,,1,B,Autocuration,,6,Binding affinity towards 5-HT3 receptor in rat was evaluated,104698,H,,CHEMBL617804,,
3160,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,7,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,104698,D,,CHEMBL617805,,
3161,,,BAO_0000223,,1,B,Autocuration,,6,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,104698,H,,CHEMBL617806,,
3162,,,BAO_0000019,,1,B,Autocuration,,6,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,104698,H,,CHEMBL617807,,
3163,,,BAO_0000019,,1,B,Autocuration,,6,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,104698,H,,CHEMBL617808,,
3164,,,BAO_0000249,,1,B,Autocuration,,6,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,104698,H,,CHEMBL617809,,
3165,,,BAO_0000019,,1,B,Autocuration,,6,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,104698,H,,CHEMBL617810,,
3166,,,BAO_0000249,,1,B,Autocuration,,6,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,104698,H,,CHEMBL617811,955.0,
3167,,,BAO_0000221,,1,B,Autocuration,,6,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,104698,H,,CHEMBL617812,955.0,
3168,,,BAO_0000249,,1,B,Autocuration,,6,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,104698,H,,CHEMBL617813,,
3169,,,BAO_0000249,,1,B,Autocuration,,6,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,104698,H,,CHEMBL617814,,
3170,,,BAO_0000019,,1,B,Autocuration,,6,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,104698,H,,CHEMBL617698,,
3171,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,7,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,104698,D,,CHEMBL617699,,
3172,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,7,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,104698,D,,CHEMBL617700,,
3173,,Rattus norvegicus,BAO_0000223,,1,B,Autocuration,,7,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,104698,D,,CHEMBL617701,,
3174,,,BAO_0000019,,1,B,Autocuration,,6,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,104698,H,,CHEMBL617702,,
3175,,,BAO_0000249,,1,B,Autocuration,,6,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",104698,H,,CHEMBL617703,,
3176,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,7,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,104698,D,,CHEMBL617704,,
3177,,,BAO_0000223,,1,B,Autocuration,,6,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,104698,H,,CHEMBL617705,,
3178,,Rattus norvegicus,BAO_0000223,,1,B,Autocuration,,7,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,104698,D,,CHEMBL617706,,
3179,433.0,,BAO_0000219,NG108-15,1,B,Autocuration,,6,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),104698,H,,CHEMBL617707,,
3180,433.0,,BAO_0000219,NG108-15,1,B,Autocuration,,6,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,104698,H,,CHEMBL617708,,
3181,,,BAO_0000019,,1,B,Autocuration,,6,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,104698,H,,CHEMBL617709,,
3182,,,BAO_0000019,,1,B,Autocuration,,6,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,104698,H,,CHEMBL617710,,
3183,,,BAO_0000019,,1,B,Autocuration,,6,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,104698,H,,CHEMBL882925,,
3184,,,BAO_0000019,,1,B,Autocuration,,6,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,104698,H,,CHEMBL617711,,
3185,,,BAO_0000019,,1,F,Autocuration,,6,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,104698,H,,CHEMBL617712,,
3186,,Rattus norvegicus,BAO_0000019,,1,F,Autocuration,,7,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,104698,D,,CHEMBL617713,,
3187,,,BAO_0000019,,1,F,Autocuration,,6,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",104698,H,,CHEMBL617714,,
3188,,,BAO_0000218,,1,F,Autocuration,,6,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,104698,H,,CHEMBL617715,,
3189,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,104698,H,,CHEMBL617716,,
3190,,,BAO_0000218,,1,F,Autocuration,,6,Inhibition of 5-HT evoked reflex bradycardia in rat.,104698,H,,CHEMBL617717,,
3191,,,BAO_0000218,,1,F,Autocuration,In vivo,6,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,H,,CHEMBL617718,,
3192,,,BAO_0000218,,1,F,Autocuration,In vivo,6,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,104698,H,,CHEMBL617719,,
3193,,,BAO_0000218,,1,F,Autocuration,In vivo,6,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),104698,H,,CHEMBL617720,,
3194,,Rattus norvegicus,BAO_0000218,,1,F,Autocuration,In vivo,7,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,104698,D,,CHEMBL617721,,
3195,,,BAO_0000218,,1,F,Autocuration,In vivo,6,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,H,,CHEMBL617722,,
3196,,,BAO_0000218,,1,F,Autocuration,In vivo,6,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,104698,H,,CHEMBL617723,,
3197,,,BAO_0000218,,1,F,Autocuration,In vivo,6,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,104698,H,,CHEMBL617724,,
3198,,,BAO_0000218,,1,F,Autocuration,In vivo,6,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,104698,H,,CHEMBL617725,,
3199,,,BAO_0000218,,1,F,Autocuration,In vivo,6,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,104698,H,,CHEMBL617726,,
3200,,,BAO_0000218,,1,F,Autocuration,In vivo,6,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,H,,CHEMBL617727,,
3201,,,BAO_0000218,,1,F,Autocuration,In vivo,6,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,104698,H,,CHEMBL617728,,
3202,,,BAO_0000218,,1,F,Autocuration,In vivo,6,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,104698,H,,CHEMBL617729,,
3203,,,BAO_0000218,,1,F,Autocuration,In vivo,6,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,104698,H,,CHEMBL617730,,
3204,,,BAO_0000218,,1,F,Autocuration,In vivo,6,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,H,,CHEMBL617731,,
3205,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,104698,H,,CHEMBL617732,,
3206,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,104698,H,,CHEMBL617733,,
3207,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,104698,H,,CHEMBL617734,,
3208,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,104698,H,,CHEMBL872874,,
3209,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,104698,H,,CHEMBL617735,,
3210,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,104698,H,,CHEMBL617736,,
3211,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,104698,H,,CHEMBL617737,,
3212,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,104698,H,,CHEMBL617738,,
3213,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,104698,H,,CHEMBL617739,,
3214,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,104698,H,,CHEMBL617740,,
3215,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,H,,CHEMBL617741,,
3216,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,104698,H,,CHEMBL617742,,
3217,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,104698,H,,CHEMBL617743,,
3218,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,104698,H,,CHEMBL617744,,
3219,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,104698,H,,CHEMBL617745,,
3220,,,BAO_0000218,,1,F,Autocuration,,6,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",104698,H,,CHEMBL617746,,
3221,,,BAO_0000218,,1,F,Autocuration,,6,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",104698,H,,CHEMBL617747,,
3222,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,104698,H,,CHEMBL617748,,
3223,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,104698,H,,CHEMBL618909,,
3224,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,104698,H,,CHEMBL618910,,
3225,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,104698,H,,CHEMBL618911,,
3226,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,104698,H,,CHEMBL618912,,
3227,,,BAO_0000218,,1,F,Autocuration,In vivo,6,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),104698,H,,CHEMBL618913,,
3228,,,BAO_0000019,,1,F,Autocuration,,6,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,104698,H,,CHEMBL618914,,
3229,,,BAO_0000019,,1,F,Autocuration,,6,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,104698,H,,CHEMBL618915,,
3230,,Rattus norvegicus,BAO_0000223,,1,B,Autocuration,,7,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,104698,D,,CHEMBL618916,,
3231,,,BAO_0000019,,1,F,Autocuration,,6,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,104698,H,,CHEMBL618917,,
3232,,,BAO_0000221,,1,B,Intermediate,,7,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,104698,D,,CHEMBL618918,10000000.0,
3233,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,7,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,104698,D,,CHEMBL618919,,
3234,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,7,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,104698,D,,CHEMBL618920,,
3235,,,BAO_0000223,,1,B,Autocuration,,6,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,104698,H,,CHEMBL618921,,
3236,,,BAO_0000019,,1,B,Autocuration,,6,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,104698,H,,CHEMBL618922,,
3237,,,BAO_0000019,,1,B,Autocuration,,6,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,104698,H,,CHEMBL618923,,
3238,,,BAO_0000019,,1,B,Autocuration,,6,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,104698,H,,CHEMBL618924,,
3239,,,BAO_0000019,,1,B,Autocuration,,6,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,104698,H,,CHEMBL618925,,
3240,,,BAO_0000019,,1,B,Autocuration,,6,Binding affinity towards 5-HT3 receptor in rat was evaluated,104698,H,,CHEMBL618926,,
3241,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,20033,D,,CHEMBL618927,2116.0,
3242,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,20033,D,,CHEMBL618928,2116.0,
3243,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",20033,D,,CHEMBL618929,2116.0,
3244,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",20033,D,,CHEMBL618930,2116.0,
3245,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",20033,D,,CHEMBL618931,2116.0,
3246,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",20033,D,,CHEMBL619594,2116.0,
3247,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",20033,D,,CHEMBL619595,2116.0,
3248,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,20033,D,,CHEMBL619596,2116.0,
3249,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,20033,D,,CHEMBL619755,2116.0,
3250,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,20033,D,,CHEMBL619756,2116.0,
3251,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,20033,D,,CHEMBL619757,2116.0,
3252,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,20033,D,,CHEMBL619758,2116.0,
3253,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",20033,D,,CHEMBL619759,2116.0,
3254,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",20033,D,,CHEMBL619760,2116.0,
3255,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",20033,D,,CHEMBL619761,2116.0,
3256,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,20033,D,,CHEMBL619762,2116.0,
3257,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",20033,D,,CHEMBL619763,2116.0,
3258,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",20033,D,,CHEMBL617868,2116.0,
3259,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,20033,D,,CHEMBL617869,,
3260,,Cavia porcellus,BAO_0000249,,1,B,Intermediate,,9,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,D,,CHEMBL882926,2435.0,
3261,,Cavia porcellus,BAO_0000249,,1,B,Intermediate,,9,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,D,,CHEMBL617870,2435.0,
3262,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,20033,D,,CHEMBL617871,2435.0,
3263,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,20033,D,,CHEMBL617872,2435.0,
3264,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,20033,D,,CHEMBL617873,2435.0,
3265,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,20033,D,,CHEMBL617874,2435.0,
3266,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,20033,D,,CHEMBL619067,2116.0,
3267,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,20033,D,,CHEMBL619068,2116.0,
3268,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,20033,D,,CHEMBL619069,2116.0,
3269,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,20033,D,,CHEMBL619070,,
3270,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,20033,D,,CHEMBL619071,,
3271,,Cavia porcellus,BAO_0000019,,1,F,Intermediate,,9,Agonistic activity against 5-hydroxytryptamine 4 receptor,20033,D,,CHEMBL619072,,
3272,,Cavia porcellus,BAO_0000019,,1,F,Intermediate,,9,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,20033,D,,CHEMBL619073,,
3273,,Cavia porcellus,BAO_0000019,,1,F,Intermediate,,9,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,20033,D,,CHEMBL619074,,
3274,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,20033,D,,CHEMBL619075,,
3275,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,20033,D,,CHEMBL619076,2435.0,
3276,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,20033,D,,CHEMBL619077,2435.0,
3277,,Cavia porcellus,BAO_0000249,,1,B,Intermediate,,9,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,D,,CHEMBL619078,2435.0,
3278,,Cavia porcellus,BAO_0000249,,1,B,Intermediate,,9,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,D,,CHEMBL619079,2435.0,
3279,,Cavia porcellus,BAO_0000221,,1,B,Intermediate,,9,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,20033,D,,CHEMBL619080,2116.0,
3280,,Cavia porcellus,BAO_0000357,,1,B,Expert,,9,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,20033,D,,CHEMBL619081,,
3281,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,20033,D,,CHEMBL619082,,
3282,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,20033,D,,CHEMBL619083,,
3283,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,20033,D,,CHEMBL619084,,
3284,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,20033,D,,CHEMBL859397,2116.0,
3285,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,20033,D,,CHEMBL619085,2116.0,
3286,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,20033,D,,CHEMBL619086,2116.0,
3287,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,20033,D,,CHEMBL619087,2116.0,
3288,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,20033,D,,CHEMBL619088,2116.0,
3289,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,20033,D,,CHEMBL619089,,
3290,,Cavia porcellus,BAO_0000357,,1,B,Autocuration,,8,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,168,H,,CHEMBL619090,,
3291,,Cavia porcellus,BAO_0000019,,1,F,Intermediate,,9,Antagonistic activity against 5-hydroxytryptamine 4 receptor,20033,D,,CHEMBL619091,,
3292,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,20033,D,,CHEMBL619092,,
3293,,Cavia porcellus,BAO_0000019,,1,B,Intermediate,,9,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,20033,D,,CHEMBL619093,,
3294,722.0,Cavia porcellus,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,168,H,,CHEMBL619094,,
3295,,Cavia porcellus,BAO_0000019,,1,B,Intermediate,,9,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,20033,D,,CHEMBL619095,,
3296,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,20033,D,,CHEMBL857988,,
3297,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,20033,D,,CHEMBL619096,,
3298,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,20033,D,,CHEMBL619097,2435.0,
3299,,Cavia porcellus,BAO_0000221,,1,B,Intermediate,,9,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,20033,D,,CHEMBL619098,10000000.0,
3300,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,20033,D,,CHEMBL619751,,
3301,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,20033,D,,CHEMBL619752,,
3302,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,20033,D,,CHEMBL875096,2116.0,
3303,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,108,H,,CHEMBL619004,,
3304,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,168,H,,CHEMBL619005,,
3305,,,BAO_0000019,,1,B,Autocuration,,8,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,168,H,,CHEMBL619006,,
3306,308.0,,BAO_0000219,HeLa,1,B,Autocuration,,8,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,168,H,,CHEMBL619007,,
3307,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,168,H,,CHEMBL619008,,
3308,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,168,H,,CHEMBL619009,,
3309,308.0,,BAO_0000219,HeLa,1,B,Autocuration,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",168,H,,CHEMBL619010,,
3310,,,BAO_0000357,,1,B,Autocuration,,8,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,10622,H,,CHEMBL619011,,
3311,,,BAO_0000357,,1,B,Autocuration,,8,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,10622,H,,CHEMBL619012,,
3312,,,BAO_0000219,,1,B,Autocuration,,8,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,10622,H,,CHEMBL619013,,
3313,,,BAO_0000357,,1,B,Autocuration,,8,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,10622,H,,CHEMBL619014,,
3314,,,BAO_0000019,,1,F,Autocuration,,8,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,11249,H,,CHEMBL857503,2081.0,
3315,,,BAO_0000019,,1,F,Autocuration,,8,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,11249,H,,CHEMBL619015,2081.0,
3316,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,11249,H,,CHEMBL619016,,
3317,,,BAO_0000221,,1,B,Autocuration,,8,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,11249,H,,CHEMBL619017,10000000.0,
3318,,Sus scrofa,BAO_0000221,,1,B,Autocuration,,8,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,168,H,,CHEMBL619018,10000000.0,
3319,,Oryctolagus cuniculus,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,168,H,,CHEMBL619019,,
3320,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,10623,D,,CHEMBL619020,,
3321,,,BAO_0000019,,1,F,Autocuration,,8,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,10623,H,,CHEMBL619021,,
3322,,,BAO_0000357,,1,B,Autocuration,,8,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,10623,H,,CHEMBL619022,,
3323,,,BAO_0000357,,1,B,Autocuration,,8,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,10623,H,,CHEMBL619023,,
3324,,,BAO_0000019,,1,F,Autocuration,,8,lntrinsic activity relative to 5-HT receptor,10623,H,,CHEMBL619024,,
3325,,,BAO_0000019,,1,F,Autocuration,,8,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,10623,H,,CHEMBL619025,,
3326,,,BAO_0000019,,1,F,Expert,,8,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,10623,H,,CHEMBL619026,,
3327,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,10623,H,,CHEMBL619027,,
3328,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,10623,H,,CHEMBL619028,,
3329,,,BAO_0000019,,1,F,Autocuration,,8,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,10623,H,,CHEMBL619029,,
3330,,,BAO_0000019,,1,F,Autocuration,,8,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,10623,H,,CHEMBL619030,,
3331,,,BAO_0000357,,1,B,Expert,,8,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,10623,H,,CHEMBL619031,,
3332,,,BAO_0000019,,1,F,Autocuration,,8,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,10623,H,,CHEMBL619032,,
3333,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,10623,D,,CHEMBL619033,,
3334,,,BAO_0000357,,1,B,Autocuration,,8,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,10623,H,,CHEMBL619034,,
3335,,,BAO_0000357,,1,B,Autocuration,,8,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,10623,H,,CHEMBL619035,,
3336,,,BAO_0000357,,1,B,Autocuration,,8,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,10623,H,,CHEMBL619036,,
3337,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,10623,D,,CHEMBL619037,,
3338,,,BAO_0000249,,1,B,Autocuration,,8,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,10623,H,,CHEMBL619038,2435.0,
3339,,,BAO_0000249,,1,B,Autocuration,,8,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,10623,H,,CHEMBL619039,,
3340,,,BAO_0000249,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,10623,H,,CHEMBL619040,,
3341,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,10623,D,,CHEMBL619041,2435.0,
3342,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,10623,H,,CHEMBL619042,2435.0,
3343,,,BAO_0000249,,1,B,Expert,,8,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,10623,H,,CHEMBL619043,2435.0,
3344,,,BAO_0000019,,1,B,Expert,,8,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,10623,H,,CHEMBL619044,2435.0,
3345,,,BAO_0000249,,1,B,Expert,,8,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,10623,H,,CHEMBL619045,2435.0,
3346,,,BAO_0000249,,1,B,Expert,,8,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,10623,H,,CHEMBL619046,2435.0,
3347,,,BAO_0000249,,1,B,Expert,,8,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,10623,H,,CHEMBL619047,,
3348,,,BAO_0000221,,1,F,Autocuration,,8,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,10623,H,,CHEMBL619048,955.0,
3349,,,BAO_0000019,,1,F,Autocuration,,8,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,10623,H,,CHEMBL859398,,
3350,,,BAO_0000019,,1,F,Autocuration,,8,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,10623,H,,CHEMBL619049,,
3351,,,BAO_0000019,,1,F,Autocuration,,8,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,10623,H,,CHEMBL857886,,
3352,,,BAO_0000019,,1,F,Autocuration,,8,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,10623,H,,CHEMBL619050,,
3353,,,BAO_0000019,,1,F,Autocuration,,8,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,10623,H,,CHEMBL620591,,
3354,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Binding affinity against rat 5-hydroxytryptamine 4 receptor,10623,D,,CHEMBL620592,,
3355,,,BAO_0000249,,1,B,Expert,,8,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,10623,H,,CHEMBL620593,2435.0,
3356,,Rattus norvegicus,BAO_0000019,,1,F,Expert,,9,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,10623,D,,CHEMBL620594,,
3357,,,BAO_0000019,,1,F,Expert,,8,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,10623,H,,CHEMBL875079,,
3358,,,BAO_0000019,,1,F,Expert,,8,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,10623,H,,CHEMBL620595,,
3359,,Rattus norvegicus,BAO_0000019,,1,F,Expert,,9,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,10623,D,,CHEMBL620596,,
3360,,,BAO_0000019,,1,F,Autocuration,,8,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,10623,H,,CHEMBL620597,,
3361,,,BAO_0000019,,1,F,Expert,,8,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,10623,H,,CHEMBL620598,,
3362,,,BAO_0000218,,1,F,Expert,,8,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),10623,H,,CHEMBL620599,,
3363,,,BAO_0000019,,1,F,Autocuration,,8,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,10623,H,,CHEMBL620600,,
3364,,Rattus norvegicus,BAO_0000019,,1,F,Autocuration,,8,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,168,H,,CHEMBL620601,,
3365,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,168,H,,CHEMBL620602,,
3366,,,BAO_0000357,,1,B,Autocuration,,8,Tested for affinity towards 5-hydroxytryptamine 4 receptor,168,H,,CHEMBL620603,,
3367,,,BAO_0000357,,1,B,Autocuration,,8,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,168,H,,CHEMBL620604,,
3368,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for 5-hydroxytryptamine 4 binding affinity,168,H,,CHEMBL620605,,
3369,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,168,H,,CHEMBL620606,,
3370,,,BAO_0000019,,1,F,Autocuration,,8,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,168,H,,CHEMBL620607,,
3371,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity towards 5-HT4 receptor was determined,168,H,,CHEMBL620608,,
3372,,,BAO_0000019,,1,F,Autocuration,,8,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,168,H,,CHEMBL620609,,
3373,,,BAO_0000019,,1,F,Autocuration,,8,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,168,H,,CHEMBL620610,,
3374,,,BAO_0000357,,1,B,Autocuration,,8,Tested for selectivity for 5-hydroxytryptamine 4 receptor,168,H,,CHEMBL620611,,
3375,,,BAO_0000357,,1,B,Autocuration,,8,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,168,H,,CHEMBL620612,,
3376,,,BAO_0000357,,1,B,Autocuration,,8,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,168,H,,CHEMBL620613,,
3377,,,BAO_0000357,,1,B,Autocuration,,8,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,168,H,,CHEMBL620614,,
3378,,,BAO_0000357,,1,B,Expert,,8,Binding affinity against 5-Hydroxytryptamine 4 receptor,168,H,,CHEMBL620615,,
3379,,,BAO_0000249,,1,B,Autocuration,,6,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,104698,H,,CHEMBL857075,,
3380,,,BAO_0000249,,1,B,Autocuration,,6,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,104698,H,,CHEMBL620616,,
3381,,,BAO_0000249,,1,B,Autocuration,,6,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,104698,H,,CHEMBL619411,,
3382,,,BAO_0000019,,1,B,Autocuration,,6,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,104698,H,,CHEMBL619412,,
3383,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,7,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,104698,D,,CHEMBL619413,,
3384,,,BAO_0000221,,1,B,Autocuration,,6,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,104698,H,,CHEMBL619414,10000000.0,
3385,,,BAO_0000019,,1,B,Autocuration,,6,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,104698,H,,CHEMBL619415,,
3386,,,BAO_0000019,,1,B,Autocuration,,6,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,104698,H,,CHEMBL619416,,
3387,,,BAO_0000019,,1,F,Autocuration,,6,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,104698,H,,CHEMBL619417,,
3388,,Rattus norvegicus,BAO_0000223,,1,B,Autocuration,,7,Binding affinity against rat 5-hydroxytryptamine 3 receptor,104698,D,,CHEMBL619418,,
3389,,Rattus norvegicus,BAO_0000223,,1,B,Autocuration,,7,Binding affinity against 5-Hydroxytryptamine 3 receptor,104698,D,,CHEMBL619419,,
3390,,,BAO_0000019,,1,B,Autocuration,,6,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,104698,H,,CHEMBL619420,,
3391,,,BAO_0000249,,1,B,Autocuration,,6,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,104698,H,,CHEMBL619421,,
3392,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,7,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,104698,D,,CHEMBL619422,,
3393,,,BAO_0000019,,1,B,Autocuration,,6,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,104698,H,,CHEMBL619423,,
3394,,,BAO_0000019,,1,B,Autocuration,,6,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,104698,H,,CHEMBL875080,,
3395,,,BAO_0000019,,1,B,Autocuration,,6,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,104698,H,,CHEMBL619424,,
3396,,,BAO_0000249,,1,B,Autocuration,,6,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,104698,H,,CHEMBL619425,,
3397,,,BAO_0000223,,1,B,Autocuration,,6,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,104698,H,,CHEMBL619426,,
3398,,,BAO_0000223,,1,B,Autocuration,,6,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,104698,H,,CHEMBL619427,,
3399,,Rattus norvegicus,BAO_0000223,,1,B,Autocuration,,7,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,104698,D,,CHEMBL619645,,
3400,,,BAO_0000249,,1,B,Expert,,9,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",10576,D,,CHEMBL619646,,
3401,,,BAO_0000221,,1,F,Autocuration,,8,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,12020,H,,CHEMBL619647,955.0,
3402,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,12020,H,,CHEMBL619648,,
3403,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,12020,H,,CHEMBL619165,,
3404,,,BAO_0000218,,1,F,Autocuration,In vivo,8,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,12020,H,,CHEMBL620719,,
3405,,,BAO_0000019,,1,B,Autocuration,,8,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,12020,H,,CHEMBL872924,,
3406,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,12020,H,,CHEMBL620720,,
3407,,,BAO_0000019,,1,B,Autocuration,,8,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,12020,H,,CHEMBL620721,,
3408,,,BAO_0000019,,1,B,Autocuration,,8,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,12020,H,,CHEMBL620722,,
3409,,,BAO_0000019,,1,B,Autocuration,,6,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",104698,H,,CHEMBL620723,,
3410,,,BAO_0000019,,1,B,Autocuration,,8,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,12020,H,,CHEMBL620724,,
3411,,,BAO_0000249,,1,B,Autocuration,,6,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,104698,H,,CHEMBL620725,,
3412,,Rattus norvegicus,BAO_0000019,,1,F,Autocuration,,9,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,12020,D,,CHEMBL620726,,
3413,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 3 receptor,144,H,,CHEMBL620727,,
3414,,,BAO_0000223,,1,B,Autocuration,,4,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,104714,H,,CHEMBL620728,,
3415,,,BAO_0000019,,1,B,Autocuration,,0,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,22226,U,,CHEMBL620729,,
3416,,,BAO_0000019,,1,F,Autocuration,,4,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,104714,H,,CHEMBL858288,,
3417,,,BAO_0000223,,1,B,Autocuration,,4,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,104714,H,,CHEMBL620730,,
3418,,,BAO_0000223,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 3 receptor,104714,H,,CHEMBL620731,,
3419,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,4,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,104714,H,,CHEMBL620732,,
3420,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,4,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,104714,H,,CHEMBL618042,,
3421,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,4,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,104714,H,,CHEMBL618043,,
3422,,,BAO_0000223,,1,B,Autocuration,,4,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,104714,H,,CHEMBL618044,,
3423,,,BAO_0000019,,1,F,Autocuration,,4,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,104714,H,,CHEMBL618045,,
3424,,,BAO_0000223,,1,B,Autocuration,,4,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,104714,H,,CHEMBL618046,,
3425,,,BAO_0000019,,1,F,Autocuration,,4,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,104714,H,,CHEMBL618047,,
3426,,,BAO_0000019,,1,F,Autocuration,,4,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,104714,H,,CHEMBL875084,,
3427,,,BAO_0000019,,1,F,Autocuration,,4,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,104714,H,,CHEMBL618048,,
3428,,,BAO_0000223,,1,B,Autocuration,,4,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,104714,H,,CHEMBL618049,,
3429,,,BAO_0000019,,1,F,Autocuration,,4,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,104714,H,,CHEMBL619764,,
3430,,,BAO_0000019,,1,F,Autocuration,,4,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,104714,H,,CHEMBL619765,,
3431,,,BAO_0000019,,1,F,Autocuration,,4,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,104714,H,,CHEMBL619766,,
3432,,,BAO_0000223,,1,B,Autocuration,,4,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,104714,H,,CHEMBL619767,,
3433,,,BAO_0000223,,1,B,Autocuration,,4,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,104714,H,,CHEMBL619768,,
3434,,,BAO_0000019,,1,F,Autocuration,,4,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,104714,H,,CHEMBL619769,,
3435,,,BAO_0000223,,1,B,Autocuration,,4,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,104714,H,,CHEMBL619770,,
3436,,,BAO_0000223,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 3 receptor,104714,H,,CHEMBL619771,,
3437,,,BAO_0000219,,1,B,Autocuration,,4,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,104714,H,,CHEMBL619772,,
3438,,,BAO_0000223,,1,B,Autocuration,,4,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,104714,H,,CHEMBL619773,,
3439,433.0,,BAO_0000219,NG108-15,1,B,Autocuration,,4,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,104714,H,,CHEMBL619774,,
3440,,,BAO_0000019,,1,B,Autocuration,,4,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,104714,H,,CHEMBL875083,,
3441,433.0,,BAO_0000219,NG108-15,1,B,Autocuration,,4,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,104714,H,,CHEMBL620718,,
3442,,,BAO_0000223,,1,B,Autocuration,,4,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,104714,H,,CHEMBL618127,,
3443,,,BAO_0000223,,1,B,Autocuration,,4,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,104714,H,,CHEMBL618128,,
3444,,,BAO_0000219,,1,B,Autocuration,In vitro,4,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,104714,H,,CHEMBL618129,,
3445,,,BAO_0000223,,1,B,Autocuration,,4,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,104714,H,,CHEMBL618130,,
3446,,,BAO_0000019,,1,F,Autocuration,,4,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,104714,H,,CHEMBL618131,,
3447,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,4,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,104714,H,,CHEMBL618132,,
3448,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,4,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,104714,H,,CHEMBL618133,,
3449,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,4,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,104714,H,,CHEMBL618134,,
3450,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,4,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,104714,H,,CHEMBL618135,,
3451,,,BAO_0000223,,1,B,Autocuration,,4,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,104714,H,,CHEMBL618136,,
3452,,,BAO_0000223,,1,B,Autocuration,,4,Binding affinity towards 5-hydroxytryptamine 3 receptor,104714,H,,CHEMBL618137,,
3453,,,BAO_0000223,,1,B,Autocuration,,4,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,104714,H,,CHEMBL618138,,
3454,,,BAO_0000223,,1,B,Autocuration,,4,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,104714,H,,CHEMBL618139,,
3455,,,BAO_0000223,,1,B,Autocuration,,4,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,104714,H,,CHEMBL618140,,
3456,,,BAO_0000223,,1,B,Autocuration,,4,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,104714,H,,CHEMBL618141,,
3457,,,BAO_0000357,,1,B,Expert,,8,Binding affinity for 5-hydroxytryptamine 2C receptor,108,H,,CHEMBL873478,,
3458,,,BAO_0000223,,1,B,Autocuration,,6,Binding affinity towards 5-hydroxytryptamine 3 receptor,104698,H,,CHEMBL618142,,
3459,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,144,H,,CHEMBL618143,,
3460,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,144,H,,CHEMBL618144,,
3461,,,BAO_0000357,,1,B,Autocuration,,8,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,144,H,,CHEMBL618145,,
3462,,,BAO_0000223,,1,B,Autocuration,,4,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,104714,H,,CHEMBL618146,,
3463,,,BAO_0000223,,1,B,Autocuration,,4,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,104714,H,,CHEMBL618147,,
3464,,,BAO_0000223,,1,B,Autocuration,,4,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,104714,H,,CHEMBL618148,,
3465,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,144,H,,CHEMBL618149,,
3466,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,144,H,,CHEMBL872927,,
3467,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,144,H,,CHEMBL618150,,
3468,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,144,H,,CHEMBL618151,,
3469,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,144,H,,CHEMBL875094,,
3470,,,BAO_0000019,,1,B,Autocuration,,8,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,144,H,,CHEMBL618152,,
3471,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,144,H,,CHEMBL618153,,
3472,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,144,H,,CHEMBL618888,,
3473,,,BAO_0000019,,1,F,Autocuration,,8,Tested for 5-hydroxytryptamine 3 receptor agonist activity,144,H,,CHEMBL618889,,
3474,,,BAO_0000357,,1,B,Autocuration,,8,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,144,H,,CHEMBL618890,,
3475,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,144,H,,CHEMBL618891,,
3476,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,144,H,,CHEMBL619054,,
3477,,,BAO_0000223,,1,B,Autocuration,,4,Binding affinity against the 5-hydroxytryptamine 3 receptor,104714,H,,CHEMBL619055,,
3478,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against human 5-hydroxytryptamine 3A receptor,144,H,,CHEMBL619056,,
3479,,,BAO_0000019,,1,F,Autocuration,,8,Percent efficacy against 5-hydroxytryptamine 3A receptor,144,H,,CHEMBL619057,,
3480,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against human 5-hydroxytryptamine 3A receptor,144,H,,CHEMBL619058,,
3481,,Rattus norvegicus,BAO_0000219,Oocytes,1,F,Expert,,9,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,12020,D,,CHEMBL619059,,
3482,,Rattus norvegicus,BAO_0000219,Oocytes,1,F,Expert,,9,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,12020,D,,CHEMBL619060,,
3483,,Rattus norvegicus,BAO_0000219,Oocytes,1,F,Expert,,9,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,12020,D,,CHEMBL875095,,
3484,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,20033,D,,CHEMBL619061,2116.0,
3485,,Cavia porcellus,BAO_0000221,,1,F,Intermediate,,9,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,20033,D,,CHEMBL619062,2116.0,
3486,,Cavia porcellus,BAO_0000019,,1,F,Intermediate,,9,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,20033,D,,CHEMBL619063,,
3487,,Cavia porcellus,BAO_0000221,,1,B,Intermediate,,9,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,20033,D,,CHEMBL619064,2116.0,
3488,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,20033,D,,CHEMBL619065,,
3489,,Cavia porcellus,BAO_0000221,,1,B,Intermediate,,9,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,20033,D,,CHEMBL619066,2116.0,
3490,,,BAO_0000221,,1,B,Autocuration,,8,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,10209,H,,CHEMBL619775,2116.0,
3491,,,BAO_0000357,,1,B,Autocuration,,8,Affinity against 5-hydroxytryptamine 7 receptor,10209,H,,CHEMBL619776,,
3492,,Cavia porcellus,BAO_0000224,,1,B,Autocuration,,4,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,104841,H,,CHEMBL619777,,
3493,,Cavia porcellus,BAO_0000224,,1,B,Autocuration,,4,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,104841,H,,CHEMBL619778,,
3494,,Cavia porcellus,BAO_0000221,,1,B,Autocuration,,4,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,104841,H,,CHEMBL619779,2116.0,
3495,,Cavia porcellus,BAO_0000224,,1,B,Autocuration,,4,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",104841,H,,CHEMBL619780,,
3496,,Cavia porcellus,BAO_0000224,,1,B,Autocuration,,4,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",104841,H,,CHEMBL619166,,
3497,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,4,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,104841,H,,CHEMBL619167,,
3498,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,4,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,104841,H,,CHEMBL619168,,
3499,,Homo sapiens,BAO_0000219,,1,B,Expert,,9,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,168,D,,CHEMBL619169,2081.0,
3500,,Homo sapiens,BAO_0000219,,1,B,Expert,,9,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,168,D,,CHEMBL619170,2081.0,
3501,,Homo sapiens,BAO_0000019,,1,F,Autocuration,,5,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",104841,D,,CHEMBL619171,,
3502,,Homo sapiens,BAO_0000219,,1,F,Expert,,9,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",168,D,,CHEMBL619172,2081.0,
3503,,Mus musculus,BAO_0000019,,1,B,Autocuration,,0,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,22226,U,,CHEMBL619173,,
3504,,Mus musculus,BAO_0000019,,1,B,Autocuration,,0,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,22226,U,,CHEMBL619174,,
3505,,,BAO_0000019,,1,B,Autocuration,,4,5-hydroxytryptamine receptor binding affinity was determined in rats,104705,H,,CHEMBL619175,,
3506,,,BAO_0000224,,1,B,Autocuration,,4,Binding affinity at rat 5-hydroxytryptamine receptor.,104705,H,,CHEMBL619176,,
3507,,,BAO_0000019,,1,B,Autocuration,,4,Affinity against 5-hydroxytryptamine receptors in rat fundus model,104705,H,,CHEMBL619177,,
3508,,,BAO_0000224,,1,B,Autocuration,,4,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,104705,H,,CHEMBL619178,,
3509,,,BAO_0000224,,1,B,Autocuration,,4,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,104705,H,,CHEMBL619179,,
3510,,,BAO_0000019,,1,F,Autocuration,,4,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,104705,H,,CHEMBL619180,945.0,
3511,,,BAO_0000019,,1,F,Autocuration,,4,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,104705,H,,CHEMBL619181,945.0,
3512,,,BAO_0000019,,1,F,Autocuration,,4,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,104705,H,,CHEMBL619182,,
3513,,,BAO_0000224,,1,B,Autocuration,,4,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,104705,H,,CHEMBL619183,,
3514,,,BAO_0000224,,1,B,Autocuration,,4,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",104705,H,,CHEMBL619184,,
3515,,,BAO_0000221,,1,B,Autocuration,,8,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,10576,H,,CHEMBL619185,10000000.0,
3516,,,BAO_0000357,,1,B,Expert,,8,Binding affinity for rat 5-hydroxytryptamine transporter.,12198,H,,CHEMBL619186,,
3517,,,BAO_0000019,,1,B,Autocuration,,4,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,104705,H,,CHEMBL619187,,
3518,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,5,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,104705,D,,CHEMBL619188,,
3519,,Rattus norvegicus,BAO_0000224,,1,B,Autocuration,,5,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,104705,D,,CHEMBL619189,,
3520,,Rattus norvegicus,BAO_0000019,,1,F,Expert,,9,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,12198,D,,CHEMBL619190,955.0,
3521,,Rattus norvegicus,BAO_0000221,,1,F,Expert,,9,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,12198,D,,CHEMBL619191,2037.0,
3522,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,5,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,104705,D,,CHEMBL619192,,
3523,,Rattus norvegicus,BAO_0000224,,1,B,Autocuration,,5,Percent binding affinity against 5-hydroxytryptamine receptor,104705,D,,CHEMBL619193,,
3524,,,BAO_0000019,,1,B,Autocuration,,0,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,22226,U,,CHEMBL619194,,
3525,,Rattus norvegicus,BAO_0000224,,1,B,Autocuration,,5,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,104705,D,,CHEMBL619195,,
3526,,Rattus norvegicus,BAO_0000224,,1,B,Autocuration,,5,Affinity against 5-hydroxytryptamine receptor was determined,104705,D,,CHEMBL619196,,
3527,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,5,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,104705,D,,CHEMBL619197,945.0,
3528,,Homo sapiens,BAO_0000219,,1,B,Expert,In vitro,9,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,121,D,,CHEMBL619198,,
3529,,Homo sapiens,BAO_0000219,,1,B,Expert,In vitro,9,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,121,D,,CHEMBL875081,,
3530,,,BAO_0000357,,1,B,Autocuration,,8,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,18065,H,,CHEMBL884712,,
3531,,,BAO_0000357,,1,B,Expert,,8,Inhibition of 5-hydroxytryptamine reuptake,121,H,,CHEMBL884710,,
3532,,,BAO_0000019,,1,F,Autocuration,,8,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",18065,H,,CHEMBL619199,,
3533,,,BAO_0000019,,1,F,Autocuration,,8,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",18065,H,,CHEMBL619200,,
3534,,,BAO_0000019,,1,F,Autocuration,,8,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",18065,H,,CHEMBL619201,,
3535,,,BAO_0000019,,1,F,Autocuration,,8,Tested for 5-hydroxytryptamine receptor uptake,18065,H,,CHEMBL619202,,
3536,449.0,Homo sapiens,BAO_0000219,CHO,1,B,Expert,,9,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,51,D,,CHEMBL619203,,
3537,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,51,D,,CHEMBL619204,,
3538,,Homo sapiens,BAO_0000249,,1,B,Autocuration,,8,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,10576,H,,CHEMBL619205,,
3539,,,BAO_0000357,,1,B,Autocuration,,8,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,10576,H,,CHEMBL619206,,
3540,,,BAO_0000249,,1,B,Expert,,8,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,10576,H,,CHEMBL619207,,
3541,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,10825,H,,CHEMBL619208,2435.0,
3542,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,10825,H,,CHEMBL619209,2435.0,
3543,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,10825,H,,CHEMBL619210,2435.0,
3544,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,10825,H,,CHEMBL619211,2435.0,
3545,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,10825,H,,CHEMBL619212,2435.0,
3546,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,10825,H,,CHEMBL620681,2435.0,
3547,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,10825,H,,CHEMBL620682,2435.0,
3548,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,10825,H,,CHEMBL620683,2435.0,
3549,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,10825,H,,CHEMBL620684,2435.0,
3550,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,10825,H,,CHEMBL620685,2435.0,
3551,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,10825,H,,CHEMBL620686,2435.0,
3552,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,10825,H,,CHEMBL620687,349.0,
3553,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,10825,H,,CHEMBL620688,349.0,
3554,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,10825,H,,CHEMBL620689,349.0,
3555,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,10825,H,,CHEMBL620690,349.0,
3556,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,10825,H,,CHEMBL620691,349.0,
3557,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,10825,H,,CHEMBL620692,349.0,
3558,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,10825,H,,CHEMBL620693,349.0,
3559,,,BAO_0000357,,1,B,Expert,,8,Binding affinity against 5-hydroxytryptamine 4 receptor,168,H,,CHEMBL620694,,
3560,,,BAO_0000019,,1,F,Autocuration,,8,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,168,H,,CHEMBL857986,,
3561,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,168,H,,CHEMBL620695,,
3562,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,168,H,,CHEMBL620696,,
3563,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,168,H,,CHEMBL620697,,
3564,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 4 receptor,168,H,,CHEMBL620698,,
3565,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,168,H,,CHEMBL620699,,
3566,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,168,H,,CHEMBL620700,,
3567,643.0,,BAO_0000219,COS-7,1,B,Autocuration,,8,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,168,H,,CHEMBL620701,,
3568,643.0,,BAO_0000219,COS-7,1,B,Autocuration,,8,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,168,H,,CHEMBL875082,,
3569,643.0,,BAO_0000219,COS-7,1,B,Autocuration,,8,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,168,H,,CHEMBL620702,,
3570,643.0,,BAO_0000219,COS-7,1,B,Autocuration,,8,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,168,H,,CHEMBL620703,,
3571,673.0,,BAO_0000219,C6,1,B,Autocuration,,8,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,168,H,,CHEMBL620704,,
3572,673.0,,BAO_0000219,C6,1,B,Expert,,8,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,168,H,,CHEMBL620705,,
3573,673.0,,BAO_0000219,C6,1,B,Expert,,8,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,168,H,,CHEMBL620706,,
3574,673.0,,BAO_0000219,C6,1,B,Expert,,8,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,168,H,,CHEMBL620707,,
3575,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 5 receptor,10624,H,,CHEMBL620708,,
3576,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,105,H,,CHEMBL620709,,
3577,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity against 5-hydroxytryptamine 5A receptor,10624,D,,CHEMBL620710,,
3578,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,10624,H,,CHEMBL620711,,
3579,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,10624,D,,CHEMBL620712,,
3580,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity towards human 5-hydroxytryptamine 5A receptor,10624,D,,CHEMBL620713,,
3581,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,10624,D,,CHEMBL620714,,
3582,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,10624,D,,CHEMBL620715,,
3583,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-HT5A receptor,10624,H,,CHEMBL620716,,
3584,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,10624,H,,CHEMBL620717,,
3585,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,10624,H,,CHEMBL618072,,
3586,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards cloned human 5-HT5A receptor was determined,10624,H,,CHEMBL857987,,
3587,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,10624,H,,CHEMBL618073,,
3588,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,10624,H,,CHEMBL618074,,
3589,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),10624,H,,CHEMBL618075,,
3590,,Mus musculus,BAO_0000357,,1,B,Expert,,9,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,10625,D,,CHEMBL618076,,
3591,,Mus musculus,BAO_0000357,,1,B,Expert,,9,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,10625,D,,CHEMBL618077,,
3592,,Mus musculus,BAO_0000357,,1,B,Expert,,9,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,10625,D,,CHEMBL618078,,
3593,,Mus musculus,BAO_0000357,,1,B,Expert,,9,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,10625,D,,CHEMBL881821,,
3594,,Mus musculus,BAO_0000357,,1,B,Expert,,9,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,10625,D,,CHEMBL618079,,
3595,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,10625,H,,CHEMBL618080,,
3596,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,10576,H,,CHEMBL618081,,
3597,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,10626,H,,CHEMBL618082,,
3598,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-HT5a receptor,10624,H,,CHEMBL618083,,
3599,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity towards 5-hydroxytryptamine 5A receptor,10624,D,,CHEMBL618084,,
3600,,,BAO_0000357,,1,B,Expert,,8,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,10624,H,,CHEMBL618085,,
3601,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,10624,H,,CHEMBL618086,,
3602,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinities against 5-hydroxytryptamine 5A receptor,10624,H,,CHEMBL875092,,
3603,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinities towards 5-hydroxytryptamine 5A receptor,10624,H,,CHEMBL618087,,
3604,,,BAO_0000357,,1,B,Autocuration,,8,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,10624,H,,CHEMBL872926,,
3605,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,4,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,104714,H,,CHEMBL618088,,
3606,,,BAO_0000223,,1,B,Autocuration,,4,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,104714,H,,CHEMBL618089,,
3607,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Inhibition of human 5-hydroxytryptamine 6 receptor,10627,D,,CHEMBL618090,,
3608,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,10627,D,,CHEMBL618091,,
3609,,,BAO_0000357,,1,B,Autocuration,,8,Inhibition against human 5-hydroxytryptamine 6 receptor,10627,H,,CHEMBL618092,,
3610,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,10627,D,,CHEMBL618093,,
3611,308.0,,BAO_0000219,HeLa,1,B,Expert,,8,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,10627,H,,CHEMBL618094,,
3612,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,10627,D,,CHEMBL618095,,
3613,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,D,,CHEMBL875093,,
3614,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,10627,D,,CHEMBL618096,,
3615,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,10627,D,,CHEMBL618118,,
3616,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity against 5-hydroxytryptamine 6 receptor,10627,D,,CHEMBL618119,,
3617,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,H,,CHEMBL618120,,
3618,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,H,,CHEMBL618121,,
3619,722.0,,BAO_0000219,HEK293,1,B,Expert,,8,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",10627,H,,CHEMBL618122,,
3620,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,10627,H,,CHEMBL618123,,
3621,722.0,,BAO_0000219,HEK293,1,B,Expert,,8,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,10627,H,,CHEMBL618124,,
3622,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,H,,CHEMBL618125,,
3623,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,10627,D,,CHEMBL618126,,
3624,,,BAO_0000019,,1,B,Expert,,8,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,10627,H,,CHEMBL618236,,
3625,,,BAO_0000019,,1,B,Expert,,8,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,10627,H,,CHEMBL618237,,
3626,643.0,,BAO_0000219,COS-7,1,B,Expert,,8,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,10627,H,,CHEMBL618238,,
3627,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,10627,D,,CHEMBL618239,,
3628,,,BAO_0000019,,1,B,Autocuration,,8,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,10627,H,,CHEMBL618240,,
3629,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,10627,H,,CHEMBL618241,,
3630,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,10627,H,,CHEMBL859399,,
3631,,,BAO_0000019,,1,F,Autocuration,,8,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,10627,H,,CHEMBL618242,,
3632,,,BAO_0000357,,1,B,Autocuration,,8,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,10627,H,,CHEMBL857991,,
3633,,,BAO_0000357,,1,B,Expert,,8,Binding affinity against human 5-hydroxytryptamine 6 receptor,10627,H,,CHEMBL619951,,
3634,308.0,Homo sapiens,BAO_0000219,HeLa,1,B,Expert,,9,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,10627,D,,CHEMBL619952,,
3635,308.0,Homo sapiens,BAO_0000219,HeLa,1,B,Expert,,9,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,10627,D,,CHEMBL619953,,
3636,308.0,,BAO_0000219,HeLa,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,10627,H,,CHEMBL619954,,
3637,308.0,,BAO_0000219,HeLa,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,10627,H,,CHEMBL619955,,
3638,308.0,,BAO_0000219,HeLa,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,10627,H,,CHEMBL619956,,
3639,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,10627,H,,CHEMBL619957,,
3640,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,10627,H,,CHEMBL619958,,
3641,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,10627,H,,CHEMBL620627,,
3642,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,10627,H,,CHEMBL620628,,
3643,308.0,,BAO_0000219,HeLa,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,10627,H,,CHEMBL620629,,
3644,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,H,,CHEMBL620630,,
3645,308.0,,BAO_0000219,HeLa,1,B,Autocuration,,8,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,10627,H,,CHEMBL620782,,
3646,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,10627,H,,CHEMBL620783,,
3647,,,BAO_0000357,,1,B,Expert,,8,Binding affinity against human 5-hydroxytryptamine 6 receptor,10627,H,,CHEMBL620784,,
3648,308.0,,BAO_0000219,HeLa,1,B,Expert,,8,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,10627,H,,CHEMBL620785,,
3649,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),10627,H,,CHEMBL857992,,
3650,,,BAO_0000219,,1,B,Autocuration,,8,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,10627,H,,CHEMBL620786,,
3651,308.0,,BAO_0000219,HeLa,1,B,Autocuration,,8,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,10627,H,,CHEMBL620787,,
3652,308.0,,BAO_0000219,HeLa,1,B,Autocuration,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",10627,H,,CHEMBL620788,,
3653,308.0,,BAO_0000219,HeLa,1,B,Autocuration,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",10627,H,,CHEMBL620789,,
3654,308.0,,BAO_0000219,HeLa,1,B,Autocuration,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",10627,H,,CHEMBL620790,,
3655,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,10628,H,,CHEMBL620791,,
3656,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,10628,H,,CHEMBL620792,,
3657,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,10628,H,,CHEMBL620793,,
3658,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,10628,H,,CHEMBL620794,,
3659,308.0,Homo sapiens,BAO_0000219,HeLa,1,B,Autocuration,,9,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,10627,D,,CHEMBL620795,,
3660,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,H,,CHEMBL620796,,
3661,,,BAO_0000357,,1,B,Autocuration,,8,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,10627,H,,CHEMBL620797,,
3662,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,10627,D,,CHEMBL620798,,
3663,,,BAO_0000357,,1,B,Autocuration,,8,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,10627,H,,CHEMBL620799,,
3664,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,H,,CHEMBL620800,,
3665,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,10627,H,,CHEMBL620801,,
3666,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,10627,H,,CHEMBL875100,,
3667,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,10627,H,,CHEMBL620802,,
3668,,,BAO_0000019,,1,F,Expert,,8,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,10627,H,,CHEMBL620803,,
3669,,,BAO_0000019,,1,F,Expert,,8,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,10627,H,,CHEMBL620804,,
3670,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,10627,H,,CHEMBL620805,,
3671,,,BAO_0000357,,1,B,Autocuration,,8,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,10627,H,,CHEMBL620806,,
3672,,,BAO_0000357,,1,B,Autocuration,,8,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,10627,H,,CHEMBL620807,,
3673,,,BAO_0000357,,1,B,Autocuration,,8,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,10627,H,,CHEMBL620808,,
3674,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinities against 5-hydroxytryptamine 6 receptor,10627,H,,CHEMBL620809,,
3675,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinities towards 5-hydroxytryptamine 6 receptor,10627,H,,CHEMBL620810,,
3676,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity towards 5-hydroxytryptamine 6 receptor,10627,D,,CHEMBL620811,,
3677,,,BAO_0000357,,1,B,Autocuration,,8,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,10627,H,,CHEMBL620812,,
3678,,,BAO_0000357,,1,B,Autocuration,,8,Affinity against 5-hydroxytryptamine 6 receptor,10627,H,,CHEMBL620813,,
3679,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],10627,H,,CHEMBL620814,,
3680,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Inhibition of human 5-hydroxytryptamine 7 receptor,10209,D,,CHEMBL620815,,
3681,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,10209,H,,CHEMBL620816,,
3682,,,BAO_0000357,,1,B,Autocuration,,8,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,10209,H,,CHEMBL620817,,
3683,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),10209,H,,CHEMBL620818,,
3684,722.0,,BAO_0000219,HEK293,1,B,Expert,,8,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,10209,H,,CHEMBL620819,,
3685,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,10209,D,,CHEMBL620820,,
3686,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,10209,H,,CHEMBL620821,,
3687,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity towards human 5-hydroxytryptamine 7 receptor,10209,D,,CHEMBL620822,,
3688,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,10209,D,,CHEMBL620823,,
3689,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity against 5-hydroxytryptamine 7 receptor,10209,D,,CHEMBL620824,,
3690,449.0,,BAO_0000219,CHO,1,B,Expert,,8,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,10209,H,,CHEMBL620825,,
3691,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,10209,H,,CHEMBL872930,,
3692,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 7 receptor,10209,H,,CHEMBL620826,,
3693,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,10209,H,,CHEMBL620827,,
3694,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,10209,H,,CHEMBL620828,,
3695,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,10209,H,,CHEMBL620829,,
3696,722.0,,BAO_0000219,HEK293,1,B,Expert,,8,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,10209,H,,CHEMBL620830,,
3697,,,BAO_0000019,,1,B,Expert,,8,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,10209,H,,CHEMBL620831,,
3698,,,BAO_0000019,,1,B,Expert,,8,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,10209,H,,CHEMBL620832,,
3699,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,10209,D,,CHEMBL621548,,
3700,,,BAO_0000019,,1,B,Autocuration,,8,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,10209,H,,CHEMBL621549,,
3701,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,10209,H,,CHEMBL621550,,
3702,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,10209,H,,CHEMBL621551,,
3703,,,BAO_0000019,,1,B,Autocuration,,8,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,10209,H,,CHEMBL621552,,
3704,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,10209,H,,CHEMBL857077,,
3705,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,10209,H,,CHEMBL618158,,
3706,643.0,Homo sapiens,BAO_0000219,COS-7,1,B,Expert,,9,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,10209,D,,CHEMBL618159,,
3707,643.0,,BAO_0000219,COS-7,1,B,Autocuration,,8,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,10209,H,,CHEMBL875101,,
3708,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,10209,D,,CHEMBL618160,,
3709,,,BAO_0000357,,1,B,Expert,,8,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,10209,H,,CHEMBL618161,,
3710,722.0,,BAO_0000219,HEK293,1,B,Expert,,8,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,10209,H,,CHEMBL618162,,
3711,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,10209,H,,CHEMBL618163,,
3712,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 7 human receptors,10209,H,,CHEMBL618164,,
3713,,,BAO_0000219,,1,B,Expert,,8,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,10209,H,,CHEMBL618165,,
3714,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,10209,H,,CHEMBL618166,,
3715,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,10209,H,,CHEMBL857989,,
3716,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,10209,H,,CHEMBL619888,,
3717,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,10209,H,,CHEMBL619889,,
3718,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,10209,H,,CHEMBL619890,,
3719,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,10209,H,,CHEMBL619891,,
3720,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),10209,H,,CHEMBL619892,,
3721,722.0,,BAO_0000219,HEK293,1,B,Expert,,9,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,10209,D,,CHEMBL619893,,
3722,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),10209,H,,CHEMBL619894,,
3723,722.0,,BAO_0000219,HEK293,1,B,Intermediate,,9,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,10209,D,,CHEMBL619895,,
3724,,,BAO_0000357,,1,B,Intermediate,,9,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,10209,D,,CHEMBL619896,,
3725,643.0,,BAO_0000219,COS-7,1,B,Autocuration,,8,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,10209,H,,CHEMBL619897,,
3726,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,10209,H,,CHEMBL619898,,
3727,722.0,,BAO_0000219,HEK293,1,B,Expert,,8,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,10209,H,,CHEMBL619899,,
3728,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),10209,H,,CHEMBL619900,,
3729,722.0,Homo sapiens,BAO_0000219,HEK293,1,B,Expert,,9,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,10209,D,,CHEMBL619901,,
3730,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,10209,H,,CHEMBL620580,,
3731,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,10209,H,,CHEMBL620581,,
3732,722.0,,BAO_0000219,HEK293,1,B,Autocuration,,8,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",10209,H,,CHEMBL620733,,
3733,,Homo sapiens,BAO_0000357,,1,B,Autocuration,,9,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,10209,D,,CHEMBL620734,,
3734,,Mus musculus,BAO_0000357,,1,B,Expert,,9,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,10022,D,,CHEMBL620735,,
3735,,Oryctolagus cuniculus,BAO_0000019,,1,B,Autocuration,,8,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,10209,H,,CHEMBL620736,,
3736,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,11923,H,,CHEMBL620737,,
3737,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,11923,H,,CHEMBL620738,,
3738,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,11923,H,,CHEMBL620739,,
3739,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,11923,H,,CHEMBL620740,,
3740,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,11923,H,,CHEMBL620741,,
3741,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,11923,H,,CHEMBL620742,,
3742,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,11923,H,,CHEMBL620743,,
3743,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,11923,H,,CHEMBL620744,,
3744,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,11923,H,,CHEMBL620745,,
3745,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,11923,H,,CHEMBL620746,,
3746,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,11923,H,,CHEMBL620747,,
3747,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,11923,H,,CHEMBL620748,,
3748,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,11923,H,,CHEMBL620749,,
3749,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,11923,H,,CHEMBL620750,,
3750,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,11923,D,,CHEMBL620751,,
3751,,,BAO_0000357,,1,B,Expert,,8,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,11923,H,,CHEMBL620752,,
3752,,,BAO_0000019,,1,B,Autocuration,,8,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,11923,H,,CHEMBL872929,,
3753,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,11923,D,,CHEMBL620753,,
3754,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,11923,D,,CHEMBL620754,,
3755,449.0,Rattus norvegicus,BAO_0000219,CHO,1,B,Expert,,9,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,11923,D,,CHEMBL620755,,
3756,,,BAO_0000357,,1,B,Autocuration,,8,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,11923,H,,CHEMBL620756,,
3757,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,11923,H,,CHEMBL620757,,
3758,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",11923,H,,CHEMBL620758,,
3759,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",11923,H,,CHEMBL620759,,
3760,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,11923,H,,CHEMBL620760,,
3761,449.0,,BAO_0000219,CHO,1,B,Autocuration,,8,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,11923,H,,CHEMBL620761,,
3762,,,BAO_0000221,,1,F,Autocuration,,8,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,11923,H,,CHEMBL620762,2116.0,
3763,,,BAO_0000221,,1,F,Autocuration,,8,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,11923,H,,CHEMBL620763,2116.0,
3764,,,BAO_0000221,,1,F,Autocuration,,8,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,11923,H,,CHEMBL620764,2116.0,
3765,,Rattus norvegicus,BAO_0000249,,1,B,Expert,,9,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,11923,D,,CHEMBL857990,,
3766,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,11923,H,,CHEMBL620765,,
3767,,,BAO_0000357,,1,B,Expert,,8,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,11923,H,,CHEMBL620766,,
3768,,,BAO_0000019,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,11923,H,,CHEMBL620767,1898.0,
3769,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,11923,H,,CHEMBL620768,,
3770,,,BAO_0000249,,1,B,Expert,,8,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,11923,H,,CHEMBL619051,1898.0,
3771,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 7 receptor,11923,H,,CHEMBL619052,,
3772,722.0,Rattus norvegicus,BAO_0000219,HEK293,1,F,Expert,,9,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,11923,D,,CHEMBL619053,,
3773,722.0,Rattus norvegicus,BAO_0000219,HEK293,1,F,Expert,,9,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,11923,D,,CHEMBL619703,,
3774,722.0,Rattus norvegicus,BAO_0000219,HEK293,1,F,Autocuration,,9,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,11923,D,,CHEMBL619704,,
3775,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards 5-hydroxytryptamine 7 receptor,10209,H,,CHEMBL619851,,
3776,,,BAO_0000357,,1,B,Autocuration,,8,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,10209,H,,CHEMBL619852,,
3777,,,BAO_0000357,,1,B,Autocuration,,8,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,10209,H,,CHEMBL619853,,
3778,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Binding affinity towards human 5-hydroxytryptamine 7 receptor,10209,D,,CHEMBL619854,,
3779,,,BAO_0000357,,1,B,Expert,,8,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,10209,H,,CHEMBL619855,,
3780,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,10209,H,,CHEMBL619856,,
3781,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,10209,H,,CHEMBL619857,,
3782,,,BAO_0000019,,1,F,Expert,,8,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,10209,H,,CHEMBL619858,,
3783,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,10209,H,,CHEMBL619859,,
3784,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,10209,H,,CHEMBL619860,,
3785,,,BAO_0000357,,1,B,Autocuration,,8,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,10209,H,,CHEMBL619861,,
3786,,,BAO_0000357,,1,B,Expert,,8,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,10209,H,,CHEMBL619862,,
3787,,,BAO_0000357,,1,B,Autocuration,,8,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,10209,H,,CHEMBL619863,,
3788,,,BAO_0000357,,1,B,Autocuration,,8,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,10209,H,,CHEMBL619864,,
3789,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinities against 5-hydroxytryptamine 7 receptor,10209,H,,CHEMBL872928,,
3790,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinities towards 5-hydroxytryptamine 7 receptor,10209,H,,CHEMBL619865,,
3791,,,BAO_0000357,,1,B,Expert,,8,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,10209,H,,CHEMBL619866,,
3792,,,BAO_0000357,,1,B,Autocuration,,8,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,10209,H,,CHEMBL619867,,
3793,,,BAO_0000221,,1,B,Autocuration,,8,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,10209,H,,CHEMBL619868,2116.0,
3794,,,BAO_0000019,,1,F,Autocuration,,8,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,55,H,,CHEMBL619869,,
3795,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,55,D,,CHEMBL619870,,
3796,,,BAO_0000357,,1,B,Autocuration,,8,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,55,H,,CHEMBL619871,,
3797,,,BAO_0000357,,1,B,Autocuration,,8,In vitro inhibition of human recombinant lipoxygenase enzyme,55,H,,CHEMBL619872,,
3798,,,BAO_0000357,,1,B,Autocuration,,8,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,55,H,,CHEMBL619873,,
3799,,,BAO_0000357,,1,B,Expert,,8,Inhibition of 5-lipoxygenase in human whole blood.,55,H,,CHEMBL619874,178.0,
3800,,,BAO_0000357,,1,B,Expert,,8,Inhibition of 5-lipoxygenase in human whole blood.,55,H,,CHEMBL619875,178.0,
3801,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,55,H,,CHEMBL619876,,
3802,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),55,H,,CHEMBL619877,,
3803,,,BAO_0000219,,1,F,Expert,,8,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,55,H,,CHEMBL619878,,
3804,,,BAO_0000019,,1,F,Autocuration,,8,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,55,H,,CHEMBL619879,178.0,
3805,,,BAO_0000357,,1,B,Autocuration,,8,In vitro inhibition of 5-lipoxygenase from human polymorphs,55,H,,CHEMBL619880,,
3806,,,BAO_0000357,,1,B,Autocuration,,8,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),55,H,,CHEMBL619881,,
3807,,,BAO_0000357,,1,B,Expert,,8,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,55,H,,CHEMBL619882,,
3808,,,BAO_0000357,,1,B,Autocuration,,8,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,55,H,,CHEMBL619883,,
3809,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),55,D,,CHEMBL619884,178.0,
3810,,,BAO_0000357,,1,B,Autocuration,,8,In vitro potency against human 5-Lipoxygenase,55,H,,CHEMBL619885,,
3811,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,55,D,,CHEMBL619886,,
3812,,,BAO_0000019,,1,F,Autocuration,,8,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,55,H,,CHEMBL619887,178.0,
3813,,,BAO_0000019,,1,F,Autocuration,,8,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,55,H,,CHEMBL875097,,
3814,,,BAO_0000219,,1,B,Autocuration,,8,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,55,H,,CHEMBL618001,,
3815,,,BAO_0000219,,1,B,Autocuration,,8,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,55,H,,CHEMBL618002,,
3816,,,BAO_0000219,,1,B,Autocuration,,8,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,55,H,,CHEMBL618003,,
3817,,,BAO_0000219,,1,B,Autocuration,,8,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,55,H,,CHEMBL618004,,
3818,,,BAO_0000219,,1,B,Autocuration,,8,Inhibition of human 5-lipoxygenase in human cells,55,H,,CHEMBL618005,,
3819,,,BAO_0000357,,1,B,Expert,,8,Inhibition of human neutrophil 5-lipoxygenase,55,H,,CHEMBL618006,,
3820,,,BAO_0000019,,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,55,H,,CHEMBL875086,,
3821,,,BAO_0000357,,1,B,Expert,,8,Inhibition of 5-lipoxygenase from human whole blood,55,H,,CHEMBL618007,178.0,
3822,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,55,H,,CHEMBL618008,,
3823,,,BAO_0000219,,1,B,Autocuration,,8,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,55,H,,CHEMBL618009,,
3824,,,BAO_0000357,,1,B,Expert,,8,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,55,H,,CHEMBL618010,,
3825,,,BAO_0000357,,1,B,Autocuration,,8,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,55,H,,CHEMBL618011,,
3826,,,BAO_0000357,,1,B,Expert,,8,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,55,H,,CHEMBL618012,,
3827,,,BAO_0000357,,1,B,Autocuration,,8,Tested against 5-lipoxygenase,55,H,,CHEMBL882927,,
3828,,,BAO_0000357,,1,B,Autocuration,,8,Tested for activity against 5-Lipoxygenase (5-LO),55,H,,CHEMBL618013,,
3829,,,BAO_0000357,,1,B,Autocuration,,8,Tested for activity against 5-lipoxygenase,55,H,,CHEMBL618014,,
3830,,,BAO_0000357,,1,B,Autocuration,,8,Tested for inhibition of 5-HPETE production by human 5-LO,55,H,,CHEMBL618015,,
3831,,,BAO_0000019,,1,F,Autocuration,,8,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,55,H,,CHEMBL618016,,
3832,,,BAO_0000357,,1,B,Expert,,8,Inhibition of Human 5-lipoxygenase,55,H,,CHEMBL618017,,
3833,,,BAO_0000019,,1,B,Autocuration,,8,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,55,H,,CHEMBL618018,,
3834,,,BAO_0000219,,1,B,Autocuration,,8,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],55,H,,CHEMBL875087,,
3835,,,BAO_0000219,,1,B,Autocuration,,8,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],55,H,,CHEMBL618019,,
3836,,,BAO_0000019,,1,B,Autocuration,,8,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,55,H,,CHEMBL618020,,
3837,,,BAO_0000019,,1,B,Autocuration,,8,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,55,H,,CHEMBL618021,,
3838,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),55,H,,CHEMBL618022,178.0,
3839,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,55,H,,CHEMBL618023,,
3840,,,BAO_0000357,,1,B,Autocuration,,8,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),55,H,,CHEMBL618024,,
3841,,,BAO_0000019,,1,B,Expert,,8,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,55,H,,CHEMBL873950,,
3842,,,BAO_0000357,,1,B,Autocuration,,8,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,55,H,,CHEMBL618025,,
3843,,,BAO_0000219,,1,B,Autocuration,,8,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,55,H,,CHEMBL618026,,
3844,,,BAO_0000219,,1,B,Autocuration,,8,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,55,H,,CHEMBL618027,,
3845,,,BAO_0000219,,1,B,Autocuration,,8,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,55,H,,CHEMBL618028,,
3846,,,BAO_0000219,,1,B,Autocuration,,8,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,55,H,,CHEMBL618029,,
3847,,,BAO_0000357,,1,B,Expert,,8,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,55,H,,CHEMBL618030,,
3848,,,BAO_0000357,,1,B,Expert,,8,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,55,H,,CHEMBL618031,,
3849,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,55,H,,CHEMBL618032,,
3850,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,55,H,,CHEMBL618033,,
3851,,,BAO_0000357,,1,B,Autocuration,,8,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,55,H,,CHEMBL618034,,
3852,,,BAO_0000357,,1,B,Autocuration,,8,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,55,H,,CHEMBL875088,,
3853,,,BAO_0000019,,1,B,Autocuration,,8,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,55,H,,CHEMBL618035,,
3854,,,BAO_0000019,,1,B,Autocuration,,8,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,55,H,,CHEMBL618036,,
3855,,,BAO_0000357,,1,B,Expert,,8,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,55,H,,CHEMBL618037,,
3856,,,BAO_0000357,,1,B,Expert,,8,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,55,H,,CHEMBL618038,,
3857,,,BAO_0000019,,1,F,Autocuration,,8,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,55,H,,CHEMBL618761,,
3858,,,BAO_0000357,,1,B,Expert,,8,Inhibition of lipoxygenase at the concentration of 0.1 uM,55,H,,CHEMBL618762,,
3859,,,BAO_0000357,,1,B,Expert,,8,Inhibition of lipoxygenase at the concentration of 1 uM,55,H,,CHEMBL618763,,
3860,,,BAO_0000357,,1,B,Autocuration,,8,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,55,H,,CHEMBL618764,,
3861,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Inhibition of 5-Lipoxygenase (5-LOX),55,D,,CHEMBL618765,,
3862,,,BAO_0000357,,1,B,Expert,,8,Inhibition of 5-lipoxygenase in mouse macrophages.,17087,H,,CHEMBL618766,,
3863,,,BAO_0000357,,1,B,Expert,,8,Inhibition of 5-lipoxygenase in mouse macrophages.,17087,H,,CHEMBL618767,,
3864,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against lipoxygenase-2 in mice,17087,H,,CHEMBL619380,,
3865,,,BAO_0000357,,1,B,Expert,,8,Inhibitory activity against murine lipoxygenase-2.,17087,H,,CHEMBL619381,,
3866,,Mus musculus,BAO_0000357,,1,B,Expert,,9,Inhibition of 5-lipoxygenase from mouse macrophage,17087,D,,CHEMBL619382,,
3867,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,17087,H,,CHEMBL619383,,
3868,,Sus scrofa,BAO_0000019,,1,B,Autocuration,,8,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,55,H,,CHEMBL619384,,
3869,,Sus scrofa,BAO_0000019,,1,B,Autocuration,,8,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,55,H,,CHEMBL619385,,
3870,,Oryctolagus cuniculus,BAO_0000019,,1,B,Autocuration,,8,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,55,H,,CHEMBL882928,,
3871,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,12166,D,,CHEMBL619386,,
3872,,,BAO_0000019,,1,B,Autocuration,,8,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",12166,H,,CHEMBL619387,,
3873,,,BAO_0000019,,1,B,Autocuration,,8,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",12166,H,,CHEMBL619388,,
3874,,,BAO_0000019,,1,B,Autocuration,,8,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",12166,H,,CHEMBL619389,,
3875,,,BAO_0000019,,1,B,Expert,,8,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),12166,H,,CHEMBL619390,,
3876,,,BAO_0000019,,1,B,Expert,,8,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",12166,H,,CHEMBL619391,,
3877,,,BAO_0000019,,1,B,Autocuration,,8,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,12166,H,,CHEMBL619392,,
3878,,,BAO_0000019,,1,B,Autocuration,,8,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),12166,H,,CHEMBL619393,,
3879,,,BAO_0000019,,1,B,Autocuration,,8,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,12166,H,,CHEMBL619394,,
3880,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",12166,H,,CHEMBL619395,,
3881,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",12166,H,,CHEMBL619396,,
3882,,,BAO_0000357,,1,B,Autocuration,,8,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),12166,H,,CHEMBL619397,,
3883,,,BAO_0000357,,1,B,Autocuration,,8,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",12166,H,,CHEMBL619398,,
3884,,,BAO_0000357,,1,B,Autocuration,,8,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",12166,H,,CHEMBL619399,,
3885,,,BAO_0000357,,1,B,Autocuration,,8,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,12166,H,,CHEMBL619400,,
3886,,,BAO_0000019,,1,B,Autocuration,,8,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",12166,H,,CHEMBL619401,,
3887,,,BAO_0000019,,1,B,Autocuration,,8,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",12166,H,,CHEMBL619402,,
3888,663.0,Rattus norvegicus,BAO_0000219,RBL-2H3,1,B,Expert,,9,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,12166,D,,CHEMBL619403,,
3889,,,BAO_0000357,,1,B,Autocuration,,8,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,12166,H,,CHEMBL619404,,
3890,,,BAO_0000357,,1,B,Autocuration,,8,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,12166,H,,CHEMBL619405,,
3891,702.0,,BAO_0000219,RBL-1,1,B,Expert,,8,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,12166,H,,CHEMBL619406,,
3892,702.0,Rattus norvegicus,BAO_0000219,RBL-1,1,B,Expert,,9,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,12166,D,,CHEMBL619407,,
3893,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),12166,H,,CHEMBL619408,,
3894,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,12166,H,,CHEMBL619409,,
3895,702.0,,BAO_0000219,RBL-1,1,B,Expert,,8,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,12166,H,,CHEMBL619410,,
3896,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,12166,H,,CHEMBL619753,,
3897,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,12166,H,,CHEMBL619754,,
3898,,,BAO_0000357,,1,B,Expert,,8,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,12166,H,,CHEMBL619903,,
3899,,,BAO_0000357,,1,B,Expert,,8,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",12166,H,,CHEMBL619904,,
3900,,,BAO_0000357,,1,B,Expert,,8,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,12166,H,,CHEMBL619905,,
3901,,,BAO_0000019,,1,B,Autocuration,,8,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,12166,H,,CHEMBL619906,,
3902,,,BAO_0000019,,1,B,Autocuration,,8,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,12166,H,,CHEMBL619907,,
3903,,,BAO_0000019,,1,B,Autocuration,,8,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,12166,H,,CHEMBL619908,,
3904,,,BAO_0000019,,1,B,Autocuration,,8,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,12166,H,,CHEMBL619909,,
3905,702.0,,BAO_0000219,RBL-1,1,F,Expert,,8,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,12166,H,,CHEMBL619910,,
3906,702.0,,BAO_0000219,RBL-1,1,B,Expert,,8,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,12166,H,,CHEMBL882929,,
3907,702.0,,BAO_0000219,RBL-1,1,B,Expert,,8,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,12166,H,,CHEMBL619911,,
3908,,,BAO_0000019,,1,B,Autocuration,,8,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,12166,H,,CHEMBL619912,,
3909,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,12166,D,,CHEMBL619913,,
3910,702.0,,BAO_0000219,RBL-1,1,B,Expert,,8,In vitro inhibitory activity against RBL-1 5-LO,12166,H,,CHEMBL619914,,
3911,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),12166,H,,CHEMBL619915,,
3912,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),12166,H,,CHEMBL619916,,
3913,,,BAO_0000218,,1,B,Autocuration,,8,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,12166,H,,CHEMBL619917,,
3914,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,12166,H,,CHEMBL619918,,
3915,,,BAO_0000218,,1,B,Autocuration,,8,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,12166,H,,CHEMBL619919,,
3916,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,12166,H,,CHEMBL883710,,
3917,,,BAO_0000019,,1,B,Autocuration,,8,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,12166,H,,CHEMBL619920,178.0,
3918,,,BAO_0000357,,1,B,Expert,,8,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,12166,H,,CHEMBL619921,,
3919,,,BAO_0000019,,1,F,Autocuration,,8,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,12166,H,,CHEMBL619922,,
3920,,,BAO_0000219,,1,F,Autocuration,,8,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,12166,H,,CHEMBL619923,,
3921,702.0,,BAO_0000219,RBL-1,1,B,Expert,,8,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,12166,H,,CHEMBL619924,,
3922,,,BAO_0000357,,1,B,Expert,,8,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,12166,H,,CHEMBL619925,,
3923,702.0,,BAO_0000219,RBL-1,1,B,Expert,,8,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,12166,H,,CHEMBL619926,,
3924,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,12166,H,,CHEMBL619927,,
3925,702.0,,BAO_0000219,RBL-1,1,B,Expert,,8,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,12166,H,,CHEMBL619928,,
3926,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase,12166,H,,CHEMBL619929,,
3927,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,12166,H,,CHEMBL875089,,
3928,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,12166,H,,CHEMBL619930,,
3929,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,12166,H,,CHEMBL619931,,
3930,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,12166,H,,CHEMBL619932,,
3931,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,12166,H,,CHEMBL619933,,
3932,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,12166,H,,CHEMBL619934,,
3933,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,12166,H,,CHEMBL619935,,
3934,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,12166,H,,CHEMBL619936,,
3935,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,12166,H,,CHEMBL619937,,
3936,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,12166,H,,CHEMBL619938,,
3937,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,12166,H,,CHEMBL619939,,
3938,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,12166,H,,CHEMBL619940,,
3939,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,12166,H,,CHEMBL875090,,
3940,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,12166,H,,CHEMBL619941,,
3941,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,12166,H,,CHEMBL619942,,
3942,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,12166,H,,CHEMBL883711,,
3943,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,12166,H,,CHEMBL619943,,
3944,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,12166,H,,CHEMBL619944,,
3945,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,12166,H,,CHEMBL619945,,
3946,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,12166,H,,CHEMBL619946,,
3947,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,12166,H,,CHEMBL619947,,
3948,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,12166,H,,CHEMBL619948,,
3949,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,12166,H,,CHEMBL619949,,
3950,,,BAO_0000019,,1,B,Expert,,8,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,12166,H,,CHEMBL619950,,
3951,,,BAO_0000019,,1,B,Autocuration,,8,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,12166,H,,CHEMBL618050,,
3952,663.0,,BAO_0000219,RBL-2H3,1,F,Expert,,8,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,12166,H,,CHEMBL875091,,
3953,663.0,,BAO_0000219,RBL-2H3,1,F,Expert,,8,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,12166,H,,CHEMBL618051,,
3954,702.0,Rattus norvegicus,BAO_0000219,RBL-1,1,B,Expert,,9,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,12166,D,,CHEMBL618052,,
3955,,,BAO_0000019,,1,B,Autocuration,,8,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,12166,H,,CHEMBL618053,,
3956,,,BAO_0000019,,1,B,Expert,,8,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),12166,H,,CHEMBL618054,,
3957,702.0,Rattus norvegicus,BAO_0000219,RBL-1,1,B,Expert,,9,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,12166,D,,CHEMBL618055,,
3958,702.0,,BAO_0000219,RBL-1,1,B,Expert,,8,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,12166,H,,CHEMBL618056,,
3959,,,BAO_0000357,,1,B,Autocuration,,8,In vitro inhibitory activity against 5-lipoxygenase was determined,12166,H,,CHEMBL618057,,
3960,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,12166,H,,CHEMBL618058,,
3961,702.0,,BAO_0000219,RBL-1,1,B,Expert,,8,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,12166,H,,CHEMBL618059,,
3962,,Rattus norvegicus,BAO_0000019,,1,F,Expert,,9,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,12166,D,,CHEMBL618060,,
3963,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,12166,H,,CHEMBL618061,,
3964,,,BAO_0000019,,1,B,Autocuration,,8,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,12166,H,,CHEMBL618062,,
3965,702.0,,BAO_0000219,RBL-1,1,B,Expert,,8,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,12166,H,,CHEMBL618063,,
3966,,,BAO_0000357,,1,B,Autocuration,,8,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,12166,H,,CHEMBL618064,,
3967,702.0,Rattus norvegicus,BAO_0000219,RBL-1,1,B,Expert,,9,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,12166,D,,CHEMBL618065,,
3968,702.0,Rattus norvegicus,BAO_0000219,RBL-1,1,B,Expert,,9,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,12166,D,,CHEMBL618066,,
3969,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),12166,H,,CHEMBL618067,,
3970,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),12166,H,,CHEMBL618068,,
3971,702.0,Rattus norvegicus,BAO_0000219,RBL-1,1,B,Expert,,9,Inhibition of 5-lipoxygenase in rat RBL-1 cells,12166,D,,CHEMBL618069,,
3972,702.0,,BAO_0000219,RBL-1,1,B,Expert,,8,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12166,H,,CHEMBL618070,,
3973,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,10825,H,,CHEMBL618071,349.0,
3974,,,BAO_0000019,,1,F,Autocuration,,8,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,10825,H,,CHEMBL619247,349.0,
3975,,,BAO_0000019,,1,F,Autocuration,,8,Approximate dose levels for a half maximal reduction of 5-HTP levels,10825,H,,CHEMBL619248,,
3976,,,BAO_0000221,,1,B,Autocuration,,8,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10576,H,,CHEMBL619249,10000000.0,
3977,,,BAO_0000221,,1,B,Autocuration,,8,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10576,H,,CHEMBL619250,10000000.0,
3978,,,BAO_0000019,,1,B,Autocuration,,8,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,10577,H,,CHEMBL619251,,
3979,,Canis lupus familiaris,BAO_0000019,,1,F,Autocuration,,8,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,55,H,,CHEMBL619252,178.0,
3980,,,BAO_0000019,,1,F,Autocuration,,8,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,55,H,,CHEMBL619253,178.0,
3981,,,BAO_0000219,,1,B,Autocuration,,8,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],12166,H,,CHEMBL619254,,
3982,,,BAO_0000219,,1,B,Expert,,8,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,17140,H,,CHEMBL619255,,
3983,,,BAO_0000219,,1,B,Expert,,8,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,17140,H,,CHEMBL619256,,
3984,,,BAO_0000219,,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),17140,H,,CHEMBL875418,,
3985,,,BAO_0000219,,1,B,Expert,,8,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,17140,H,,CHEMBL619257,,
3986,,,BAO_0000219,,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,17140,H,,CHEMBL619258,,
3987,,,BAO_0000357,,1,B,Expert,,8,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,17140,H,,CHEMBL619259,,
3988,,,BAO_0000357,,1,B,Expert,,8,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,17140,H,,CHEMBL619260,,
3989,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL619261,178.0,
3990,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL619263,178.0,
3991,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL619264,178.0,
3992,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL619265,178.0,
3993,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL619266,178.0,
3994,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL619902,178.0,
3995,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL620058,178.0,
3996,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL620059,178.0,
3997,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL620060,178.0,
3998,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL620061,178.0,
3999,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",55,H,,CHEMBL620062,178.0,
4000,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",55,H,,CHEMBL620063,178.0,
4001,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",55,H,,CHEMBL620064,178.0,
4002,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL620065,178.0,
4003,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",55,H,,CHEMBL620066,178.0,
4004,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",55,H,,CHEMBL620067,178.0,
4005,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",55,H,,CHEMBL620068,178.0,
4006,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL620069,178.0,
4007,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",55,H,,CHEMBL620070,178.0,
4008,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",55,H,,CHEMBL620071,178.0,
4009,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",55,H,,CHEMBL620072,178.0,
4010,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL620036,178.0,
4011,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",55,H,,CHEMBL857702,178.0,
4012,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",55,H,,CHEMBL620037,178.0,
4013,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",55,H,,CHEMBL620038,178.0,
4014,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL620039,178.0,
4015,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",55,H,,CHEMBL620040,178.0,
4016,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",55,H,,CHEMBL620041,178.0,
4017,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",55,H,,CHEMBL620042,178.0,
4018,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL620043,178.0,
4019,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",55,H,,CHEMBL620044,178.0,
4020,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",55,H,,CHEMBL620045,178.0,
4021,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",55,H,,CHEMBL620046,178.0,
4022,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL620047,178.0,
4023,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",55,H,,CHEMBL620048,178.0,
4024,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",55,H,,CHEMBL857703,178.0,
4025,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",55,H,,CHEMBL620049,178.0,
4026,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL620050,178.0,
4027,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL620051,178.0,
4028,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL619213,178.0,
4029,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL619214,178.0,
4030,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL619804,178.0,
4031,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",55,H,,CHEMBL619805,178.0,
4032,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL619806,178.0,
4033,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL619807,178.0,
4034,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,8,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL619808,178.0,
4035,,Canis lupus familiaris,BAO_0000218,,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,55,H,,CHEMBL619809,,
4036,,Canis lupus familiaris,BAO_0000218,,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,55,H,,CHEMBL619810,,
4037,,Canis lupus familiaris,BAO_0000218,,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,55,H,,CHEMBL619811,,
4038,,Canis lupus familiaris,BAO_0000218,,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,55,H,,CHEMBL620769,,
4039,,Canis lupus familiaris,BAO_0000218,,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,55,H,,CHEMBL620770,,
4040,,Canis lupus familiaris,BAO_0000218,,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,55,H,,CHEMBL620771,,
4041,,Canis lupus familiaris,BAO_0000218,,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,55,H,,CHEMBL620772,,
4042,,Canis lupus familiaris,BAO_0000218,,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,55,H,,CHEMBL620773,,
4043,,Cavia porcellus,BAO_0000357,,1,B,Autocuration,,8,Ability to inhibit 5-lipoxygenase in guinea pig,55,H,,CHEMBL620774,,
4044,,Cavia porcellus,BAO_0000357,,1,B,Expert,,8,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),55,H,,CHEMBL620775,,
4045,,Cavia porcellus,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,55,H,,CHEMBL620776,,
4046,,Cavia porcellus,BAO_0000218,,1,B,Autocuration,,8,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",55,H,,CHEMBL620777,178.0,
4047,,Cavia porcellus,BAO_0000357,,1,B,Autocuration,,8,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,55,H,,CHEMBL620778,,
4048,,Cavia porcellus,BAO_0000357,,1,B,Autocuration,,8,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,55,H,,CHEMBL620779,,
4049,,Cavia porcellus,BAO_0000019,,1,B,Expert,,8,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,55,H,,CHEMBL621500,,
4050,,Cavia porcellus,BAO_0000019,,1,B,Expert,,8,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,55,H,,CHEMBL621501,,
4051,,Cavia porcellus,BAO_0000019,,1,B,Autocuration,,8,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,55,H,,CHEMBL618098,,
4052,,Cavia porcellus,BAO_0000019,,1,B,Autocuration,,8,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,55,H,,CHEMBL618099,,
4053,,Cavia porcellus,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase,55,H,,CHEMBL618100,,
4054,,Cavia porcellus,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,55,H,,CHEMBL618101,,
4055,,Cavia porcellus,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,55,H,,CHEMBL618102,,
4056,,Cavia porcellus,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,55,H,,CHEMBL618103,,
4057,,Cavia porcellus,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity uM,55,H,,CHEMBL618104,,
4058,,Cavia porcellus,BAO_0000219,,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,55,H,,CHEMBL883712,,
4059,,Cavia porcellus,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase at 10 uM,55,H,,CHEMBL618105,,
4060,,Cavia porcellus,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,55,H,,CHEMBL618106,,
4061,,Cavia porcellus,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,55,H,,CHEMBL618107,,
4062,,Cavia porcellus,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,55,H,,CHEMBL618108,,
4063,,Cavia porcellus,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity uM,55,H,,CHEMBL618109,,
4064,,Cavia porcellus,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,55,H,,CHEMBL618110,,
4065,,Cavia porcellus,BAO_0000357,,1,B,Expert,,8,Inhibitory activity uM,55,H,,CHEMBL618111,,
4066,,Cavia porcellus,BAO_0000019,,1,F,Autocuration,,8,Inhibitory activity uM,55,H,,CHEMBL618112,,
4067,,Cavia porcellus,BAO_0000019,,1,B,Autocuration,,8,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,55,H,,CHEMBL618113,,
4068,,Cavia porcellus,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,55,H,,CHEMBL618114,,
4069,,Cavia porcellus,BAO_0000221,,1,F,Expert,,8,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,55,H,,CHEMBL620871,2116.0,
4070,,,BAO_0000357,,1,B,Autocuration,,8,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),55,H,,CHEMBL620872,,
4071,,,BAO_0000357,,1,B,Autocuration,,8,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),55,H,,CHEMBL620873,,
4072,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),55,H,,CHEMBL620874,,
4073,,,BAO_0000357,,1,B,Expert,,8,In vitro inhibition of human 5-Lipoxygenase.,55,H,,CHEMBL620875,,
4074,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,22226,U,,CHEMBL620876,2107.0,
4075,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,22226,U,,CHEMBL620877,2107.0,
4076,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,22226,U,,CHEMBL857854,2107.0,
4077,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,22226,U,,CHEMBL620878,2107.0,
4078,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,22226,U,,CHEMBL620879,2107.0,
4079,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,22226,U,,CHEMBL620880,2107.0,
4080,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,22226,U,,CHEMBL620881,2107.0,
4081,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,22226,U,,CHEMBL620882,2107.0,
4082,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,22226,U,,CHEMBL620883,2107.0,
4083,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,22226,U,,CHEMBL620884,2107.0,
4084,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,22226,U,,CHEMBL620885,2107.0,
4085,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,22226,U,,CHEMBL620886,2107.0,
4086,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,22226,U,,CHEMBL620887,2107.0,
4087,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,22226,U,,CHEMBL618039,2107.0,
4088,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,22226,U,,CHEMBL618040,2107.0,
4089,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,22226,U,,CHEMBL618041,2107.0,
4090,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",22226,U,,CHEMBL618216,2107.0,
4091,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",22226,U,,CHEMBL618217,2107.0,
4092,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,22226,U,,CHEMBL618218,2107.0,
4093,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,22226,U,,CHEMBL618219,2107.0,
4094,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,22226,U,,CHEMBL618220,2107.0,
4095,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,22226,U,,CHEMBL618221,2107.0,
4096,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,22226,U,,CHEMBL618222,2107.0,
4097,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,22226,U,,CHEMBL618223,2107.0,
4098,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,22226,U,,CHEMBL618224,2107.0,
4099,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,22226,U,,CHEMBL618225,2107.0,
4100,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,22226,U,,CHEMBL618226,2107.0,
4101,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,22226,U,,CHEMBL618227,2107.0,
4102,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,22226,U,,CHEMBL618228,2107.0,
4103,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,22226,U,,CHEMBL618229,2107.0,
4104,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,22226,U,,CHEMBL618230,2107.0,
4105,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,22226,U,,CHEMBL618231,2107.0,
4106,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,22226,U,,CHEMBL618232,2107.0,
4107,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,22226,U,,CHEMBL618233,2107.0,
4108,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,22226,U,,CHEMBL618234,2107.0,
4109,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,22226,U,,CHEMBL618235,2107.0,
4110,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,22226,U,,CHEMBL618115,2107.0,
4111,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,22226,U,,CHEMBL618116,2107.0,
4112,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,22226,U,,CHEMBL618117,2107.0,
4113,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,22226,U,,CHEMBL619968,2107.0,
4114,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,22226,U,,CHEMBL619969,2107.0,
4115,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,22226,U,,CHEMBL619970,2107.0,
4116,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,22226,U,,CHEMBL619971,2107.0,
4117,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,22226,U,,CHEMBL619972,2107.0,
4118,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,22226,U,,CHEMBL619973,2107.0,
4119,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,22226,U,,CHEMBL619974,2107.0,
4120,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,22226,U,,CHEMBL619975,2107.0,
4121,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,22226,U,,CHEMBL619976,,
4122,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",22226,U,,CHEMBL619977,2107.0,
4123,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",22226,U,,CHEMBL619978,2107.0,
4124,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",22226,U,,CHEMBL619979,2107.0,
4125,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",22226,U,,CHEMBL619980,2107.0,
4126,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",22226,U,,CHEMBL619981,2107.0,
4127,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,In vitro inhibition of 7226/S myeloma cancer cell line,80433,N,,CHEMBL619982,,
4128,993.0,Homo sapiens,BAO_0000219,BEL-7404 tumor cell line,1,F,Intermediate,,1,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),80698,N,,CHEMBL619983,,
4129,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,80640,N,,CHEMBL620031,,
4130,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,80640,N,,CHEMBL620032,,
4131,505.0,Cricetulus griseus,BAO_0000219,V79,1,F,Expert,,1,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,81264,N,,CHEMBL620033,,
4132,505.0,Cricetulus griseus,BAO_0000219,V79,1,F,Expert,,1,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,81264,N,,CHEMBL620034,,
4133,1119.0,Rattus norvegicus,BAO_0000219,7800C1 cell line,1,F,Intermediate,,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,80635,N,,CHEMBL620035,,
4134,1119.0,Rattus norvegicus,BAO_0000219,7800C1 cell line,1,F,Intermediate,,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,80635,N,,CHEMBL618318,,
4135,1119.0,Rattus norvegicus,BAO_0000219,7800C1 cell line,1,F,Intermediate,,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,80635,N,,CHEMBL618319,,
4136,1119.0,Rattus norvegicus,BAO_0000219,7800C1 cell line,1,F,Intermediate,,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,80635,N,,CHEMBL618320,,
4137,1119.0,Rattus norvegicus,BAO_0000219,7800C1 cell line,1,F,Intermediate,,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,80635,N,,CHEMBL618321,,
4138,1119.0,Rattus norvegicus,BAO_0000219,7800C1 cell line,1,F,Intermediate,,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,80635,N,,CHEMBL883118,,
4139,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,In vitro antitumor activity against renal 786-0 tumor cell lines,80640,N,,CHEMBL883795,,
4140,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,Cytotoxic activity against 786-0 Renal cancer cell line,80640,N,,CHEMBL618322,,
4141,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,80640,N,,CHEMBL618323,,
4142,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,80640,N,,CHEMBL618324,,
4143,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,In vitro antitumor activity against human renal 786-0 cell line,80640,N,,CHEMBL618325,,
4144,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,Inhibition of Renal cancer in 786-0 cancer cell lines,80640,N,,CHEMBL875416,,
4145,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,80640,N,,CHEMBL618326,,
4146,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,80640,N,,CHEMBL618327,,
4147,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,inhibition of the growth of renal cancer(786-0) cell line,80640,N,,CHEMBL619215,,
4148,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),80640,N,,CHEMBL619216,,
4149,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,80640,N,,CHEMBL619217,,
4150,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,The IC50 value was measured on 786-0 cell line in ovarian tumor,80640,N,,CHEMBL619218,,
4151,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,The IC50 value was measured on 786-0 cell line in ovarian tumor t,80640,N,,CHEMBL619219,,
4152,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,The IC50 value was measured on 786-0 cell line in renal tumor type.,80640,N,,CHEMBL619220,,
4153,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,80640,N,,CHEMBL619221,,
4154,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,Tested for cytotoxic activity against renal cancer 786-0 cell line,80640,N,,CHEMBL619222,,
4155,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,Compound was tested for growth inhibitory activity against 786-0 cell line,80640,N,,CHEMBL857454,,
4156,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,12166,H,,CHEMBL619223,,
4157,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,12166,H,,CHEMBL619224,,
4158,,,BAO_0000019,,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,12166,H,,CHEMBL619225,,
4159,702.0,,BAO_0000219,RBL-1,1,B,Expert,,8,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),12166,H,,CHEMBL619226,,
4160,702.0,,BAO_0000219,RBL-1,1,B,Expert,,8,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),12166,H,,CHEMBL619227,,
4161,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,12166,H,,CHEMBL619228,,
4162,,,BAO_0000219,,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,12166,H,,CHEMBL619229,,
4163,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,12166,H,,CHEMBL619230,,
4164,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,12166,H,,CHEMBL619231,,
4165,,,BAO_0000357,,1,B,Autocuration,,8,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",12166,H,,CHEMBL619232,,
4166,,,BAO_0000357,,1,B,Expert,,8,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,12166,H,,CHEMBL619233,,
4167,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,12166,H,,CHEMBL619234,,
4168,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),12166,H,,CHEMBL619235,,
4169,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",12166,D,,CHEMBL619236,,
4170,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,12166,H,,CHEMBL619237,,
4171,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,12166,H,,CHEMBL619238,,
4172,,,BAO_0000357,,1,B,Expert,,8,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,12166,H,,CHEMBL619239,,
4173,,,BAO_0000357,,1,B,Autocuration,,8,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,12166,H,,CHEMBL619240,,
4174,,,BAO_0000019,,1,B,Autocuration,,8,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,12166,H,,CHEMBL875417,,
4175,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),12166,H,,CHEMBL619241,,
4176,,,BAO_0000019,,1,F,Expert,,8,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,12166,H,,CHEMBL619242,,
4177,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,12166,H,,CHEMBL883796,,
4178,,,BAO_0000357,,1,B,Autocuration,,8,Tested for its inhibitory activity against 5-lipoxygenase,12166,H,,CHEMBL619243,,
4179,,,BAO_0000357,,1,B,Autocuration,,8,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,12166,H,,CHEMBL619244,,
4180,,,BAO_0000019,,1,B,Expert,,8,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",12166,H,,CHEMBL619245,,
4181,,,BAO_0000019,,1,B,Expert,,8,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,12166,H,,CHEMBL619246,,
4182,702.0,,BAO_0000219,RBL-1,1,B,Expert,,8,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,12166,H,,CHEMBL619984,,
4183,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,12166,H,,CHEMBL619985,,
4184,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,12166,H,,CHEMBL619986,,
4185,702.0,,BAO_0000219,RBL-1,1,B,Expert,,8,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,12166,H,,CHEMBL619987,,
4186,,,BAO_0000218,,1,B,Autocuration,,8,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,12166,H,,CHEMBL619988,,
4187,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,12166,H,,CHEMBL619989,,
4188,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,12166,H,,CHEMBL619990,,
4189,,,BAO_0000219,,1,B,Autocuration,,8,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],12166,H,,CHEMBL619991,,
4190,,,BAO_0000219,,1,B,Autocuration,,8,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),12166,H,,CHEMBL619992,,
4191,,,BAO_0000218,,1,B,Autocuration,In vivo,8,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),12166,H,,CHEMBL619993,,
4192,663.0,,BAO_0000219,RBL-2H3,1,F,Autocuration,,8,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,12166,H,,CHEMBL619994,,
4193,663.0,,BAO_0000219,RBL-2H3,1,F,Autocuration,,8,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,12166,H,,CHEMBL619995,,
4194,,,BAO_0000019,,1,B,Autocuration,,8,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],12166,H,,CHEMBL619996,,
4195,,,BAO_0000019,,1,B,Autocuration,,8,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,12166,H,,CHEMBL619997,,
4196,,,BAO_0000019,,1,B,Expert,,8,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,12166,H,,CHEMBL619998,,
4197,,,BAO_0000019,,1,B,Expert,,8,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,12166,H,,CHEMBL619999,,
4198,,,BAO_0000019,,1,B,Autocuration,,8,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,12166,H,,CHEMBL620000,,
4199,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,12166,H,,CHEMBL620001,,
4200,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,12166,D,,CHEMBL620002,,
4201,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,12166,H,,CHEMBL620003,,
4202,702.0,,BAO_0000219,RBL-1,1,F,Expert,,8,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,12166,H,,CHEMBL620004,,
4203,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for the inhibition of 5-lipoxygenase,12166,H,,CHEMBL874063,,
4204,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,12166,H,,CHEMBL620005,,
4205,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,12166,H,,CHEMBL620006,,
4206,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,12166,H,,CHEMBL620007,,
4207,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,12166,H,,CHEMBL620008,,
4208,702.0,Rattus norvegicus,BAO_0000219,RBL-1,1,B,Expert,,9,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,12166,D,,CHEMBL620009,,
4209,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,12166,H,,CHEMBL620010,,
4210,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,12166,H,,CHEMBL620011,,
4211,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,12166,H,,CHEMBL620677,,
4212,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,12166,H,,CHEMBL620678,,
4213,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,12166,H,,CHEMBL620679,,
4214,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,12166,H,,CHEMBL620680,,
4215,,Rattus norvegicus,BAO_0000357,,1,B,Expert,,9,Inhibitory activity against 5-lipoxygenase at 10 uM,12166,D,,CHEMBL620838,,
4216,,,BAO_0000357,,1,B,Autocuration,,8,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,12166,H,,CHEMBL620839,,
4217,,,BAO_0000357,,1,B,Expert,,8,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,12166,H,,CHEMBL620840,,
4218,702.0,,BAO_0000219,RBL-1,1,B,Expert,,8,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,12166,H,,CHEMBL620841,,
4219,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,12166,H,,CHEMBL620842,,
4220,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,12166,H,,CHEMBL620843,,
4221,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,12166,H,,CHEMBL620844,,
4222,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,12166,H,,CHEMBL620845,,
4223,,,BAO_0000019,,1,B,Autocuration,,8,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,12166,H,,CHEMBL620846,,
4224,,,BAO_0000357,,1,B,Autocuration,,8,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,12166,H,,CHEMBL873951,,
4225,,,BAO_0000357,,1,B,Autocuration,,8,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,12166,H,,CHEMBL620847,,
4226,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,12166,H,,CHEMBL620848,,
4227,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,12166,H,,CHEMBL620849,,
4228,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,12166,H,,CHEMBL620850,,
4229,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,12166,H,,CHEMBL620851,,
4230,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,12166,H,,CHEMBL620852,,
4231,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12166,H,,CHEMBL875098,,
4232,702.0,Rattus norvegicus,BAO_0000219,RBL-1,1,B,Expert,,9,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,12166,D,,CHEMBL620853,,
4233,,,BAO_0000019,,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,12166,H,,CHEMBL620854,,
4234,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,12166,H,,CHEMBL620855,,
4235,702.0,,BAO_0000219,RBL-1,1,B,Expert,,8,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,12166,H,,CHEMBL839884,,
4236,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12166,H,,CHEMBL620856,,
4237,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,12166,H,,CHEMBL620857,,
4238,,,BAO_0000019,,1,B,Autocuration,,8,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,12166,H,,CHEMBL620858,,
4239,,,BAO_0000019,,1,B,Autocuration,,8,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,12166,H,,CHEMBL620859,,
4240,,,BAO_0000019,,1,B,Autocuration,,8,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,12166,H,,CHEMBL620860,,
4241,,,BAO_0000019,,1,B,Autocuration,,8,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,12166,H,,CHEMBL620861,,
4242,,,BAO_0000357,,1,B,Expert,,8,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),12166,H,,CHEMBL620862,,
4243,,,BAO_0000357,,1,B,Autocuration,,8,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,12166,H,,CHEMBL620863,,
4244,,,BAO_0000019,,1,B,Autocuration,,8,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,12166,H,,CHEMBL620864,,
4245,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,12166,H,,CHEMBL620865,,
4246,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,12166,H,,CHEMBL620866,,
4247,663.0,,BAO_0000219,RBL-2H3,1,B,Autocuration,,8,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,12166,H,,CHEMBL620867,,
4248,663.0,,BAO_0000219,RBL-2H3,1,B,Autocuration,,8,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,12166,H,,CHEMBL620868,,
4249,663.0,,BAO_0000219,RBL-2H3,1,F,Autocuration,,8,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,12166,H,,CHEMBL620869,,
4250,,,BAO_0000019,,1,F,Autocuration,,8,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,12166,H,,CHEMBL873952,,
4251,,,BAO_0000357,,1,B,Autocuration,,8,The compound was tested for inhibition of isolated 5-lipoxygenase,12166,H,,CHEMBL875099,,
4252,663.0,,BAO_0000219,RBL-2H3,1,F,Autocuration,,8,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,12166,H,,CHEMBL620870,,
4253,,,BAO_0000019,,1,B,Autocuration,,8,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,12166,H,,CHEMBL618261,,
4254,,,BAO_0000019,,1,B,Autocuration,,8,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,12166,H,,CHEMBL618262,,
4255,,,BAO_0000019,,1,B,Autocuration,,8,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,12166,H,,CHEMBL619428,,
4256,,,BAO_0000019,,1,B,Autocuration,,8,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,12166,H,,CHEMBL619429,,
4257,,,BAO_0000019,,1,B,Autocuration,,8,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,12166,H,,CHEMBL619430,,
4258,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,12166,H,,CHEMBL620017,,
4259,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,12166,H,,CHEMBL620018,,
4260,702.0,,BAO_0000219,RBL-1,1,F,Autocuration,,8,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,12166,H,,CHEMBL620019,,
4261,702.0,,BAO_0000219,RBL-1,1,F,Autocuration,,8,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,12166,H,,CHEMBL620020,,
4262,702.0,,BAO_0000219,RBL-1,1,F,Autocuration,,8,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,12166,H,,CHEMBL620021,,
4263,702.0,,BAO_0000219,RBL-1,1,F,Autocuration,,8,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,12166,H,,CHEMBL620022,,
4264,702.0,,BAO_0000219,RBL-1,1,F,Autocuration,,8,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,12166,H,,CHEMBL620023,,
4265,702.0,,BAO_0000219,RBL-1,1,F,Autocuration,,8,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,12166,H,,CHEMBL620024,,
4266,702.0,,BAO_0000219,RBL-1,1,F,Autocuration,,8,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,12166,H,,CHEMBL620025,,
4267,702.0,,BAO_0000219,RBL-1,1,F,Autocuration,,8,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,12166,H,,CHEMBL620026,,
4268,702.0,,BAO_0000219,RBL-1,1,F,Autocuration,,8,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,12166,H,,CHEMBL620027,,
4269,,Rattus norvegicus,BAO_0000019,,1,F,Expert,,9,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,12166,D,,CHEMBL620028,,
4270,,,BAO_0000357,,1,B,Autocuration,,8,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,12166,H,,CHEMBL620029,,
4271,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for the percent of inhibition against 5-LO at 10 uM,12166,H,,CHEMBL620030,,
4272,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,12166,H,,CHEMBL875415,,
4273,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,12166,H,,CHEMBL618256,,
4274,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,12166,H,,CHEMBL618257,,
4275,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,12166,H,,CHEMBL618258,,
4276,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,12166,H,,CHEMBL618259,,
4277,,,BAO_0000019,,1,B,Autocuration,,8,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,12166,H,,CHEMBL618260,,
4278,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,12166,H,,CHEMBL618215,,
4279,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,12166,H,,CHEMBL618390,,
4280,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,12166,H,,CHEMBL618391,,
4281,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,12166,H,,CHEMBL618392,,
4282,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,12166,H,,CHEMBL618393,,
4283,,,BAO_0000219,,1,B,Autocuration,,8,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,12166,H,,CHEMBL618394,,
4284,702.0,Homo sapiens,BAO_0000219,RBL-1,1,B,Expert,,8,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),12166,H,,CHEMBL618395,,
4285,702.0,Rattus norvegicus,BAO_0000219,RBL-1,1,B,Expert,,9,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),12166,D,,CHEMBL618396,,
4286,702.0,Rattus norvegicus,BAO_0000219,RBL-1,1,B,Expert,,9,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),12166,D,,CHEMBL858253,,
4287,,Rattus norvegicus,BAO_0000019,,1,B,Autocuration,,9,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,12166,D,,CHEMBL618397,,
4288,,Glycine max,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),12054,H,,CHEMBL618398,,
4289,,,BAO_0000019,,1,B,Autocuration,,0,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",22226,U,,CHEMBL618399,,
4290,,,BAO_0000357,,1,B,Expert,,8,In vitro inhibition of 5-Lipoxygenase; Inactive.,55,H,,CHEMBL618400,,
4291,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,55,H,,CHEMBL618401,,
4292,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory concentration against 5-lipoxygenase; No inhibition,55,H,,CHEMBL618402,,
4293,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,55,H,,CHEMBL876400,,
4294,,,BAO_0000357,,1,B,Expert,,8,Inhibitory activity against 5-lipoxygenase.,55,H,,CHEMBL618403,,
4295,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,55,H,,CHEMBL618404,,
4296,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,55,H,,CHEMBL618405,,
4297,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,55,H,,CHEMBL618406,,
4298,,,BAO_0000019,,1,F,Expert,,8,Inhibitory concentration against arachidonic acid 5-lipoxygenation,55,H,,CHEMBL618407,,
4299,,,BAO_0000357,,1,B,Autocuration,,8,Tested for the inhibitory activity against 5-lipoxygenase,55,H,,CHEMBL618408,,
4300,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for its inhibitory activity against 5-lipoxygenase,55,H,,CHEMBL618409,,
4301,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,55,H,,CHEMBL618410,,
4302,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,55,H,,CHEMBL618411,,
4303,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,55,H,,CHEMBL618412,,
4304,702.0,,BAO_0000219,RBL-1,1,B,Autocuration,,8,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,12166,H,,CHEMBL618413,,
4305,,,BAO_0000357,,1,B,Autocuration,,8,,12166,H,,CHEMBL618414,,
4306,,,BAO_0000357,,1,B,Autocuration,,8,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),10102,H,,CHEMBL618415,,
4307,,,BAO_0000019,,1,B,Autocuration,,8,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,10102,H,,CHEMBL618416,,
4308,,,BAO_0000357,,1,B,Autocuration,,8,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,10102,H,,CHEMBL876401,,
4309,,,BAO_0000357,,1,B,Expert,,8,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,10102,H,,CHEMBL618417,,
4310,,,BAO_0000357,,1,B,Autocuration,,8,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,10102,H,,CHEMBL618418,,
4311,,,BAO_0000357,,1,B,Autocuration,,8,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",10102,H,,CHEMBL618419,,
4312,,,BAO_0000357,,1,B,Autocuration,,8,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",10102,H,,CHEMBL618420,,
4313,,,BAO_0000357,,1,B,Autocuration,,8,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,10102,H,,CHEMBL618421,,
4314,,,BAO_0000019,,1,B,Autocuration,,8,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,11238,H,,CHEMBL618422,,
4315,,,BAO_0000019,,1,B,Autocuration,,8,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),11238,H,,CHEMBL618423,,
4316,,,BAO_0000019,,1,B,Autocuration,,8,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),11238,H,,CHEMBL618424,,
4317,,,BAO_0000220,,1,B,Intermediate,,2,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,100284,S,,CHEMBL618425,,
4318,,Homo sapiens,BAO_0000019,,1,F,Autocuration,,0,The dark toxicity against 543 human galactophore carcinoma cells,22226,U,,CHEMBL618426,,
4319,390.0,Homo sapiens,BAO_0000219,Panel (56 tumour cell lines),1,F,Expert,,1,Tested in vitro for cytotoxicity against 56 human tumor cell lines,80623,N,,CHEMBL618427,,
4320,345.0,Homo sapiens,BAO_0000219,5637,1,F,Expert,,1,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,80008,N,,CHEMBL618428,,
4321,345.0,Homo sapiens,BAO_0000219,5637,1,F,Intermediate,,1,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,80008,N,,CHEMBL618429,,
4322,345.0,Homo sapiens,BAO_0000219,5637,1,F,Intermediate,,1,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",80008,N,,CHEMBL618430,,
4323,345.0,Homo sapiens,BAO_0000219,5637,1,F,Expert,,1,Growth inhibition against human 5637 cell lines,80008,N,,CHEMBL618431,,
4324,345.0,Homo sapiens,BAO_0000219,5637,1,F,Expert,,1,Antitumor activity against human bladder carcinoma 5637 cells.,80008,N,,CHEMBL883799,,
4325,345.0,Homo sapiens,BAO_0000219,5637,1,F,Intermediate,,1,Antitumor activity against human bladder carcinoma 5637 cells,80008,N,,CHEMBL618432,,
4326,345.0,Homo sapiens,BAO_0000219,5637,1,F,Intermediate,,1,Antitumor activity against human bladder carcinoma 5637 cells,80008,N,,CHEMBL618433,,
4327,,Bos taurus,BAO_0000357,,1,B,Expert,,9,In vitro inhibition of bovine trypsin(Trp).,10443,D,,CHEMBL618434,,
4328,407.0,Cercopithecidae,BAO_0000219,CV-1,1,B,Expert,,8,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,240,H,,CHEMBL618435,,
4329,,,BAO_0000357,,1,B,Autocuration,,8,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,10577,H,,CHEMBL876402,,
4330,,,BAO_0000019,,1,F,Autocuration,,6,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,104698,H,,CHEMBL618436,,
4331,,,BAO_0000218,,1,F,Autocuration,In vivo,0,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,22226,U,,CHEMBL618437,,
4332,,Cavia porcellus,BAO_0000357,,1,B,Intermediate,,9,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,20033,D,,CHEMBL618438,,
4333,,Rattus norvegicus,BAO_0000251,,1,A,Expert,,8,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,17045,H,,CHEMBL883800,,
4334,,Rattus norvegicus,BAO_0000251,,1,A,Expert,,8,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,17045,H,,CHEMBL618439,,
4335,,,BAO_0000019,,1,F,Intermediate,,0,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,22226,U,,CHEMBL618440,,
4336,,,BAO_0000019,,1,F,Intermediate,,0,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,22226,U,,CHEMBL618441,,
4337,,Trypanosoma brucei,BAO_0000019,,1,B,Expert,,8,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,11938,H,,CHEMBL618442,,
4338,,Trypanosoma brucei,BAO_0000019,,1,B,Autocuration,,8,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,11938,H,,CHEMBL618443,,
4339,,Ovis aries,BAO_0000019,,1,B,Expert,,8,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,11938,H,,CHEMBL619158,,
4340,,Ovis aries,BAO_0000019,,1,B,Autocuration,,8,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,11938,H,,CHEMBL620974,,
4341,,,BAO_0000357,,1,B,Autocuration,,8,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,11938,H,,CHEMBL620975,,
4342,,Homo sapiens,BAO_0000019,,1,F,Intermediate,,0,Average inhibitory concentration against 60 human cell lines was reported,22226,U,,CHEMBL620976,,
4343,,Homo sapiens,BAO_0000019,,1,F,Expert,,0,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,22226,U,,CHEMBL620977,,
4344,542.0,Homo sapiens,BAO_0000219,Panel NCI-60 (60 carcinoma cell lines),1,F,Intermediate,,1,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,80315,N,,CHEMBL620978,,
4345,542.0,Homo sapiens,BAO_0000219,Panel NCI-60 (60 carcinoma cell lines),1,F,Intermediate,,1,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,80315,N,,CHEMBL620979,,
4346,542.0,,BAO_0000219,Panel NCI-60 (60 carcinoma cell lines),1,F,Expert,,1,In vitro mean growth inhibitory activity against 60-cell panel,80315,N,,CHEMBL620980,,
4347,542.0,,BAO_0000219,Panel NCI-60 (60 carcinoma cell lines),1,F,Expert,,1,In vitro mean growth lethal concentration against 60-cell panel,80315,N,,CHEMBL620981,,
4348,542.0,,BAO_0000219,Panel NCI-60 (60 carcinoma cell lines),1,F,Expert,,1,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,80315,N,,CHEMBL620982,,
4349,542.0,,BAO_0000219,Panel NCI-60 (60 carcinoma cell lines),1,F,Expert,,1,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,80315,N,,CHEMBL620983,,
4350,,,BAO_0000019,,1,F,Autocuration,,4,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,104775,H,,CHEMBL620984,,
4351,,,BAO_0000019,,1,F,Autocuration,,4,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,104775,H,,CHEMBL620985,,
4352,,,BAO_0000357,,1,B,Expert,,8,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,275,H,,CHEMBL620986,,
4353,,Plasmodium falciparum,BAO_0000218,,1,F,Expert,,1,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,50425,N,,CHEMBL620987,,
4354,,Plasmodium falciparum,BAO_0000218,,1,F,Expert,,1,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,50425,N,,CHEMBL620988,,
4355,,Plasmodium falciparum,BAO_0000218,,1,F,Expert,,1,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,50425,N,,CHEMBL620989,,
4356,,Plasmodium falciparum,BAO_0000218,,1,F,Expert,,1,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,50425,N,,CHEMBL620990,,
4357,,Plasmodium falciparum,BAO_0000218,,1,F,Intermediate,,1,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,50425,N,,CHEMBL620991,,
4358,850.0,Mus musculus,BAO_0000218,6C3HED,1,F,Intermediate,,1,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,80628,N,,CHEMBL620992,,
4359,850.0,Mus musculus,BAO_0000218,6C3HED,1,F,Intermediate,,1,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,80628,N,,CHEMBL620993,,
4360,850.0,Mus musculus,BAO_0000218,6C3HED,1,F,Intermediate,,1,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,80628,N,,CHEMBL620994,,
4361,850.0,Mus musculus,BAO_0000218,6C3HED,1,F,Intermediate,,1,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,80628,N,,CHEMBL620995,,
4362,850.0,Mus musculus,BAO_0000218,6C3HED,1,F,Intermediate,,1,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,80628,N,,CHEMBL620996,,
4363,850.0,Mus musculus,BAO_0000218,6C3HED,1,F,Intermediate,,1,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,80628,N,,CHEMBL875581,,
4364,,Mus musculus,BAO_0000218,,1,F,Autocuration,In vivo,0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,22224,U,,CHEMBL620997,,
4365,,Mus musculus,BAO_0000218,,1,F,Autocuration,In vivo,0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,22224,U,,CHEMBL620998,,
4366,,Mus musculus,BAO_0000218,,1,F,Autocuration,In vivo,0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),22224,U,,CHEMBL620999,,
4367,,Mus musculus,BAO_0000218,,1,F,Autocuration,In vivo,0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,22224,U,,CHEMBL621000,,
4368,,Mus musculus,BAO_0000218,,1,F,Autocuration,In vivo,0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,22224,U,,CHEMBL621001,,
4369,,Mus musculus,BAO_0000218,,1,F,Autocuration,In vivo,0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,22224,U,,CHEMBL621002,,
4370,,Mus musculus,BAO_0000218,,1,F,Autocuration,In vivo,0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,22224,U,,CHEMBL621003,,
4371,,Mus musculus,BAO_0000218,,1,F,Autocuration,In vivo,0,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",22224,U,,CHEMBL621004,,
4372,,Mus musculus,BAO_0000218,,1,F,Autocuration,In vivo,0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),22224,U,,CHEMBL621005,,
4373,,Mus musculus,BAO_0000218,,1,F,Autocuration,In vivo,0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),22224,U,,CHEMBL621006,,
4374,,Mus musculus,BAO_0000218,,1,F,Autocuration,In vivo,0,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,22224,U,,CHEMBL621007,,
4375,,Mus musculus,BAO_0000218,,1,F,Autocuration,,0,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,22224,U,,CHEMBL621008,,
4376,,Mus musculus,BAO_0000218,,1,F,Autocuration,,0,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,22224,U,,CHEMBL621009,,
4377,,Mus musculus,BAO_0000218,,1,F,Autocuration,,0,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,22224,U,,CHEMBL857705,,
4378,,Mus musculus,BAO_0000218,,1,F,Autocuration,,0,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,22224,U,,CHEMBL619828,,
4379,,Mus musculus,BAO_0000218,,1,F,Autocuration,,0,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,22224,U,,CHEMBL619829,,
4380,,Mus musculus,BAO_0000218,,1,F,Autocuration,,0,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,22224,U,,CHEMBL619830,,
4381,,Mus musculus,BAO_0000218,,1,F,Autocuration,,0,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,22224,U,,CHEMBL619831,,
4382,,Mus musculus,BAO_0000218,,1,F,Autocuration,,0,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,22224,U,,CHEMBL619832,,
4383,,Mus musculus,BAO_0000218,,1,A,Autocuration,,0,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,22224,U,,CHEMBL619833,,
4384,,Mus musculus,BAO_0000218,,1,A,Autocuration,,0,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,22224,U,,CHEMBL619834,,
4385,,Mus musculus,BAO_0000218,,1,A,Autocuration,,0,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,22224,U,,CHEMBL619835,,
4386,,Mus musculus,BAO_0000218,,1,A,Autocuration,,0,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,22224,U,,CHEMBL619836,,
4387,850.0,Mus musculus,BAO_0000218,6C3HED,1,F,Intermediate,,1,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",80628,N,,CHEMBL619837,,
4388,,,BAO_0000218,,1,F,Autocuration,In vivo,0,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,22224,U,,CHEMBL619838,,
4389,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,50594,N,,CHEMBL619839,,
4390,850.0,Mus musculus,BAO_0000218,6C3HED,1,F,Intermediate,In vivo,1,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,80628,N,,CHEMBL619840,,
4391,850.0,Mus musculus,BAO_0000218,6C3HED,1,F,Intermediate,In vivo,1,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,80628,N,,CHEMBL619841,,
4392,850.0,Mus musculus,BAO_0000218,6C3HED,1,F,Expert,,1,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),80628,N,,CHEMBL857704,,
4393,850.0,Mus musculus,BAO_0000218,6C3HED,1,F,Intermediate,,1,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),80628,N,,CHEMBL619842,,
4394,850.0,Mus musculus,BAO_0000218,6C3HED,1,F,Expert,,1,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),80628,N,,CHEMBL619843,,
4395,,Staphylococcus aureus,BAO_0000019,,1,B,Autocuration,,0,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",22226,U,,CHEMBL619844,,
4396,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,22226,U,,CHEMBL857855,2107.0,
4397,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,22226,U,,CHEMBL619845,2107.0,
4398,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,22226,U,,CHEMBL619846,2107.0,
4399,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,22226,U,,CHEMBL619847,2107.0,
4400,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,22226,U,,CHEMBL619848,2107.0,
4401,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,22226,U,,CHEMBL620893,2107.0,
4402,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,22226,U,,CHEMBL620894,2107.0,
4403,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,22226,U,,CHEMBL620895,2107.0,
4404,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,22226,U,,CHEMBL620896,2107.0,
4405,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,22226,U,,CHEMBL620897,2107.0,
4406,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,22226,U,,CHEMBL620898,2107.0,
4407,,Rattus norvegicus,BAO_0000251,,1,B,Autocuration,,0,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,22226,U,,CHEMBL620899,2107.0,
4408,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,The apparent total plasma clearance in monkey,22224,U,,CHEMBL620900,1969.0,
4409,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound was evaluated for Hepatic clearance in monkey,22224,U,,CHEMBL620901,,
4410,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Lower clearance in monkey (i.v.) at 0.5 mpk,22224,U,,CHEMBL620902,,
4411,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance in rhesus monkey,22224,U,,CHEMBL620903,,
4412,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,22224,U,,CHEMBL620904,,
4413,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance of compound was determined in monkey,22224,U,,CHEMBL620905,,
4414,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance was calculated in rhesus monkey,22224,U,,CHEMBL620906,,
4415,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance in rhesus monkey,22224,U,,CHEMBL875420,,
4416,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),22224,U,,CHEMBL620907,,
4417,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance was evaluated in rhesus,22224,U,,CHEMBL620908,,
4418,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,22224,U,,CHEMBL620909,,
4419,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,22224,U,,CHEMBL620910,,
4420,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),22224,U,,CHEMBL620911,,
4421,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),22224,U,,CHEMBL620912,,
4422,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax 24 hr after 2 mg/kg oral administration in monkeys,22224,U,,CHEMBL620913,,
4423,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax in monkey after administration of 1 mg/kg iv,22224,U,,CHEMBL620914,,
4424,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax was determine after peroral administration at 10 mpk in Rhesus,22224,U,,CHEMBL620915,,
4425,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax in cynomolgus monkey by iv administration,22224,U,,CHEMBL620916,,
4426,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax in cynomolgus monkey by po administration,22224,U,,CHEMBL620917,,
4427,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax value evaluated in monkey,22224,U,,CHEMBL620918,,
4428,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,22224,U,,CHEMBL620919,,
4429,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,22224,U,,CHEMBL620920,1969.0,
4430,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,22224,U,,CHEMBL620921,1969.0,
4431,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximal plasma concentration in squirrel monkeys,22224,U,,CHEMBL620922,1969.0,
4432,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,U,,CHEMBL620923,,
4433,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,22224,U,,CHEMBL620924,1969.0,
4434,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),22224,U,,CHEMBL620925,,
4435,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,22224,U,,CHEMBL620926,,
4436,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,22224,U,,CHEMBL620927,,
4437,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,22224,U,,CHEMBL620928,,
4438,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,22224,U,,CHEMBL620929,,
4439,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,22224,U,,CHEMBL620930,1969.0,
4440,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,22224,U,,CHEMBL620931,,
4441,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,22224,U,,CHEMBL620932,,
4442,,monkey,BAO_0000218,,1,A,Autocuration,In vivo,0,Absolute bioavailability was evaluated in monkey,22224,U,,CHEMBL620933,,
4443,,monkey,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,22224,U,,CHEMBL620934,,
4444,,monkey,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,22224,U,,CHEMBL620935,,
4445,,Macaca mulatta,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability of compound was determined in rhesus monkey,22224,U,,CHEMBL620936,,
4446,,marmosets,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability determined after oral administration in marmoset,22224,U,,CHEMBL620937,,
4447,,Macaca fascicularis,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in cynomolgus monkey,22224,U,,CHEMBL620938,,
4448,,monkey,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in monkey (p.o.) at 2.0 mpk,22224,U,,CHEMBL620939,,
4449,,monkey,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability was evaluated after oral administration in monkey,22224,U,,CHEMBL620940,,
4450,,Macaca fascicularis,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,U,,CHEMBL620941,,
4451,,Macaca mulatta,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),22224,U,,CHEMBL620942,,
4452,,Macaca mulatta,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),22224,U,,CHEMBL620943,,
4453,,monkey,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability of the compound was determined in monkey,22224,U,,CHEMBL620944,,
4454,,Saimiri sciureus,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in squirrel monkey (dose 5 mg/kg),22224,U,,CHEMBL620945,,
4455,,monkey,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),22224,U,,CHEMBL620946,,
4456,,monkey,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in monkey,22224,U,,CHEMBL620947,,
4457,,Saimiri sciureus,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound was tested for bioavailability in squirrel monkey,22224,U,,CHEMBL620948,,
4458,,Macaca mulatta,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in Rhesus monkey,22224,U,,CHEMBL620949,,
4459,,Macaca mulatta,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),22224,U,,CHEMBL620950,,
4460,,Macaca fascicularis,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,22224,U,,CHEMBL620951,,
4461,,Macaca fascicularis,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,22224,U,,CHEMBL620952,,
4462,,monkey,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in monkey (dose 5 mg/kg),22224,U,,CHEMBL875421,,
4463,,monkey,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability of compound at 5 mg/kg in monkey,22224,U,,CHEMBL620953,,
4464,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,50588,N,,CHEMBL873491,,
4465,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,50588,N,,CHEMBL620954,,
4466,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Plasma half life determined,50588,N,,CHEMBL620955,1969.0,
4467,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Plasma half life in dog,50588,N,,CHEMBL618097,1969.0,
4468,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Plasma half-life in Beagle dogs,50588,N,,CHEMBL618268,1969.0,
4469,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),50588,N,,CHEMBL618269,1969.0,
4470,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),50588,N,,CHEMBL618270,1969.0,
4471,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,50588,N,,CHEMBL618271,,
4472,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,50588,N,,CHEMBL873493,,
4473,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Tested for the half life period in dog,50588,N,,CHEMBL621031,,
4474,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for the half life period in dog at dosage of 10 mpk,50588,N,,CHEMBL621032,,
4475,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,The compound was tested for half life in dog,50588,N,,CHEMBL621033,,
4476,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",50588,N,,CHEMBL621034,1969.0,
4477,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,The half life was determined,50588,N,,CHEMBL621035,,
4478,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,The plasma half-life in dogs,50588,N,,CHEMBL621036,1969.0,
4479,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,50588,N,,CHEMBL621037,1969.0,
4480,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life in dog,50588,N,,CHEMBL619812,,
4481,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,50588,N,,CHEMBL619813,,
4482,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,tmax upon peroral administration of 10.0 mg/Kg dose in dog,50588,N,,CHEMBL873335,,
4483,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,50588,N,,CHEMBL619814,,
4484,,Mustela putorius furo,BAO_0000218,,1,A,Expert,In vivo,1,Cmax in ferrets after 30 mg/kg oral dose,50506,N,,CHEMBL619815,,
4485,,Mustela putorius furo,BAO_0000218,,1,F,Expert,In vivo,1,Emesis in ferrets at 30 mg/kg oral dose,50506,N,,CHEMBL619816,,
4486,,Macaca fascicularis,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in cynomolgus monkey,22224,U,,CHEMBL619817,,
4487,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution in cynomolgus,100710,N,,CHEMBL619818,,
4488,,Cavia porcellus,BAO_0000218,,1,A,Autocuration,,0,AUC tested in guinea pig when 3 mg/kg dose was given perorally,22224,U,,CHEMBL619819,1969.0,
4489,,Cavia porcellus,BAO_0000218,,1,A,Autocuration,,0,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,22224,U,,CHEMBL619820,,
4490,,Cavia porcellus,BAO_0000218,,1,A,Autocuration,,0,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",22224,U,,CHEMBL875419,,
4491,,Cavia porcellus,BAO_0000218,,1,A,Autocuration,In vivo,0,AUC in guinea pig after 3mg/kg oral dose,22224,U,,CHEMBL619821,1969.0,
4492,,Cavia porcellus,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in guinea pig was tested,22224,U,,CHEMBL619822,,
4493,,Cavia porcellus,BAO_0000218,,1,A,Autocuration,In vivo,0,Tested for oral bioavailability in guinea pig at 5 mg/kg,22224,U,,CHEMBL619823,,
4494,,Cavia porcellus,BAO_0000218,,1,A,Autocuration,In vivo,0,Tested for the oral bioavailability of the compound,22224,U,,CHEMBL619824,,
4495,,Cavia porcellus,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,22224,U,,CHEMBL619825,,
4496,,Cavia porcellus,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,22224,U,,CHEMBL619826,,
4497,,Cavia porcellus,BAO_0000218,,1,A,Autocuration,In vivo,0,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,22224,U,,CHEMBL619827,2048.0,
4498,,Cavia porcellus,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax in guinea pig after 3mg/kg oral dose,22224,U,,CHEMBL618167,,
4499,,Cavia porcellus,BAO_0000019,,1,A,Autocuration,,0,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,22224,U,,CHEMBL618168,178.0,
4500,,Cavia porcellus,BAO_0000019,,1,A,Autocuration,,0,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,22224,U,,CHEMBL618169,955.0,
4501,,Cavia porcellus,BAO_0000019,,1,A,Autocuration,,0,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,22224,U,,CHEMBL618170,,
4502,,Cavia porcellus,BAO_0000019,,1,A,Autocuration,,0,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,22224,U,,CHEMBL618171,160.0,
4503,,Cavia porcellus,BAO_0000019,,1,A,Autocuration,,0,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,22224,U,,CHEMBL618172,2113.0,
4504,,Cavia porcellus,BAO_0000019,,1,A,Autocuration,,0,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,22224,U,,CHEMBL618173,2107.0,
4505,,Cavia porcellus,BAO_0000019,,1,A,Autocuration,,0,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,22224,U,,CHEMBL618174,,
4506,,Cavia porcellus,BAO_0000019,,1,A,Autocuration,,0,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,22224,U,,CHEMBL875408,2106.0,
4507,,Cavia porcellus,BAO_0000218,,1,A,Autocuration,In vivo,0,Elimination T1/2 in Guinea pig (PO dose),22224,U,,CHEMBL839827,,
4508,,Cavia porcellus,BAO_0000019,,1,A,Autocuration,,0,Partition coefficient was measured as -log (counts per min ),22224,U,,CHEMBL618175,,
4509,,Cavia porcellus,BAO_0000218,,1,A,Autocuration,In vivo,0,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,22224,U,,CHEMBL618176,,
4510,,Cavia porcellus,BAO_0000218,,1,A,Autocuration,In vivo,0,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,22224,U,,CHEMBL618177,,
4511,,Cavia porcellus,BAO_0000218,,1,A,Autocuration,In vivo,0,Elimination T1/2 in Guinea pig (PO dose),22224,U,,CHEMBL618178,,
4512,,Cavia porcellus,BAO_0000218,,1,A,Autocuration,In vivo,0,"Tested for the half life period of the compound, intravenously",22224,U,,CHEMBL618179,,
4513,,Cavia porcellus,BAO_0000019,,1,A,Autocuration,,0,Half-life was measured,22224,U,,CHEMBL873489,,
4514,,Cavia porcellus,BAO_0000019,,1,A,Autocuration,,0,The time required for onset of inotropy after addition of a single dose of delta F75,22224,U,,CHEMBL618180,,
4515,,Cavia porcellus,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,22224,U,,CHEMBL618181,,
4516,,Cavia porcellus,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,22224,U,,CHEMBL618182,,
4517,,Cricetulus griseus,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,22224,U,,CHEMBL618183,,
4518,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,N,,CHEMBL618184,,
4519,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,N,,CHEMBL618185,,
4520,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,N,,CHEMBL618186,,
4521,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,N,,CHEMBL618187,,
4522,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,50594,N,,CHEMBL618188,,
4523,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,N,,CHEMBL875409,,
4524,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,N,,CHEMBL618189,,
4525,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,50594,N,,CHEMBL618190,178.0,
4526,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,50594,N,,CHEMBL618191,178.0,
4527,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,50594,N,,CHEMBL618192,178.0,
4528,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,50594,N,,CHEMBL618193,10000001.0,
4529,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,50594,N,,CHEMBL618194,10000001.0,
4530,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,50594,N,,CHEMBL618195,10000001.0,
4531,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,50594,N,,CHEMBL618196,955.0,
4532,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,50594,N,,CHEMBL618197,955.0,
4533,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,50594,N,,CHEMBL618198,955.0,
4534,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,50594,N,,CHEMBL618199,948.0,
4535,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,50594,N,,CHEMBL618200,948.0,
4536,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,50594,N,,CHEMBL618201,948.0,
4537,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,50594,N,,CHEMBL618202,160.0,
4538,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,50594,N,,CHEMBL618203,160.0,
4539,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,50594,N,,CHEMBL618204,160.0,
4540,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,50594,N,,CHEMBL618205,2113.0,
4541,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,50594,N,,CHEMBL618206,2113.0,
4542,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,50594,N,,CHEMBL618207,2113.0,
4543,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,50594,N,,CHEMBL618208,2107.0,
4544,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,50594,N,,CHEMBL618932,2107.0,
4545,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,50594,N,,CHEMBL618933,2107.0,
4546,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,50594,N,,CHEMBL618934,2048.0,
4547,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,50594,N,,CHEMBL618935,2048.0,
4548,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,50594,N,,CHEMBL618936,2048.0,
4549,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,50594,N,,CHEMBL618937,2385.0,
4550,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,50594,N,,CHEMBL618938,2385.0,
4551,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,50594,N,,CHEMBL619104,2385.0,
4552,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,50594,N,,CHEMBL619105,2106.0,
4553,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,50594,N,,CHEMBL619106,2106.0,
4554,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,50594,N,,CHEMBL619107,2106.0,
4555,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,50594,N,,CHEMBL875410,945.0,
4556,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,50594,N,,CHEMBL619108,945.0,
4557,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,50594,N,,CHEMBL619109,945.0,
4558,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,50594,N,,CHEMBL619110,,
4559,,Mus musculus,BAO_0000218,,1,F,Intermediate,In vivo,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,50594,N,,CHEMBL619111,,
4560,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,MRT value at a dose of 10 mg/kg intravenous administration in mice.,50594,N,,CHEMBL619112,,
4561,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,MRT value at a dose of 10 mg/kg peroral administration in mice.,50594,N,,CHEMBL619113,,
4562,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,50594,N,,CHEMBL619114,,
4563,,Mus musculus,BAO_0000218,,1,F,Intermediate,In vivo,1,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,50594,N,,CHEMBL619115,,
4564,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,81034,N,,CHEMBL619116,,
4565,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,81034,N,,CHEMBL619117,,
4566,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Compound was evaluated for cytotoxicity against A2780 cell lines.,81034,N,,CHEMBL619118,,
4567,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,81034,N,,CHEMBL619119,,
4568,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,81034,N,,CHEMBL619120,,
4569,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,81034,N,,CHEMBL619121,,
4570,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,81034,N,,CHEMBL619122,,
4571,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,81034,N,,CHEMBL619123,,
4572,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,81034,N,,CHEMBL619124,,
4573,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Compound was evaluated for cytotoxicity against A2780 cell line,81034,N,,CHEMBL619125,,
4574,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro inhibitory activity against human tumor cell line A2780,81034,N,,CHEMBL875411,,
4575,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,81034,N,,CHEMBL619126,,
4576,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,81034,N,,CHEMBL619127,,
4577,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,81034,N,,CHEMBL619128,,
4578,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,81034,N,,CHEMBL619129,,
4579,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,81034,N,,CHEMBL619130,,
4580,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,81034,N,,CHEMBL619131,,
4581,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,81034,N,,CHEMBL619132,,
4582,478.0,Homo sapiens,BAO_0000218,A2780,1,F,Expert,,1,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,81034,N,,CHEMBL619133,,
4583,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,81034,N,,CHEMBL619134,,
4584,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,81034,N,,CHEMBL619135,,
4585,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,81034,N,,CHEMBL619136,,
4586,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Relative resistance factor in A2780 cisplatin-resistant line,81034,N,,CHEMBL619137,,
4587,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,81034,N,,CHEMBL883713,,
4588,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,81034,N,,CHEMBL875412,,
4589,478.0,Homo sapiens,BAO_0000218,A2780,1,F,Expert,,1,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,81034,N,,CHEMBL619138,,
4590,478.0,Homo sapiens,BAO_0000218,A2780,1,F,Expert,,1,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,81034,N,,CHEMBL619262,,
4591,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,81034,N,,CHEMBL619139,,
4592,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,81034,N,,CHEMBL619140,,
4593,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,81034,N,,CHEMBL619141,,
4594,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,81034,N,,CHEMBL619142,,
4595,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,81034,N,,CHEMBL619143,,
4596,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,81034,N,,CHEMBL619144,,
4597,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,81034,N,,CHEMBL619145,,
4598,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,81034,N,,CHEMBL619146,,
4599,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,81034,N,,CHEMBL619147,,
4600,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Antiproliferative effect of compound on A2780/DX cell line,81034,N,,CHEMBL619148,,
4601,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,81034,N,,CHEMBL619149,,
4602,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),81034,N,,CHEMBL619150,,
4603,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),81034,N,,CHEMBL619151,,
4604,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,81034,N,,CHEMBL883794,,
4605,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,81034,N,,CHEMBL619152,,
4606,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro cytotoxicity against A2780ADR cell line,81034,N,,CHEMBL619153,,
4607,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro cytotoxicity against A2780CIS cell line,81034,N,,CHEMBL619154,,
4608,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,81034,N,,CHEMBL619155,,
4609,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,81034,N,,CHEMBL619156,,
4610,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",81034,N,,CHEMBL619157,,
4611,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",81034,N,,CHEMBL619797,,
4612,,Macaca mulatta,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability of compound in rhesus macaques,22224,U,,CHEMBL619798,,
4613,,monkey,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in monkey,22224,U,,CHEMBL619799,,
4614,,monkey,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability evaluated in monkey,22224,U,,CHEMBL619800,,
4615,,monkey,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in monkey (dose 1 mg/kg p.o.),22224,U,,CHEMBL619801,,
4616,,Macaca mulatta,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in Rhesus monkey,22224,U,,CHEMBL619802,,
4617,,Macaca mulatta,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability was calculated in rhesus monkey,22224,U,,CHEMBL619803,,
4618,,Macaca fascicularis,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in cynomolgus monkey,22224,U,,CHEMBL619965,,
4619,,monkey,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in monkey,22224,U,,CHEMBL619966,,
4620,,monkey,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in monkey,22224,U,,CHEMBL619967,,
4621,,monkey,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in monkey (dose 1 mg/kg),22224,U,,CHEMBL620073,,
4622,,monkey,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in monkey (dose 5 mg/kg),22224,U,,CHEMBL620074,,
4623,,monkey,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in monkey,22224,U,,CHEMBL620075,,
4624,,monkey,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in monkey,22224,U,,CHEMBL620076,,
4625,,Macaca mulatta,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in rhesus monkey,22224,U,,CHEMBL620077,,
4626,,Macaca mulatta,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,22224,U,,CHEMBL620078,,
4627,,Saimiri sciureus,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,22224,U,,CHEMBL620079,,
4628,,monkey,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),22224,U,,CHEMBL620080,,
4629,,Macaca mulatta,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in Rhesus monkey,22224,U,,CHEMBL620081,,
4630,,Macaca mulatta,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),22224,U,,CHEMBL620082,,
4631,,monkey,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in monkey at 10 mg/kg of the compound,22224,U,,CHEMBL620083,,
4632,,Macaca mulatta,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in Rhesus monkey,22224,U,,CHEMBL620084,,
4633,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,U,,CHEMBL620085,,
4634,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,U,,CHEMBL874595,,
4635,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,22224,U,,CHEMBL873352,,
4636,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,22224,U,,CHEMBL620086,,
4637,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Mean residence time was determined after intravenous administration in cynomolgus monkeys,22224,U,,CHEMBL620087,,
4638,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,22224,U,,CHEMBL620088,,
4639,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,22224,U,,CHEMBL620089,,
4640,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),22224,U,,CHEMBL620090,,
4641,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),22224,U,,CHEMBL620091,,
4642,,Cercopithecidae,BAO_0000251,,1,A,Autocuration,,0,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),22224,U,,CHEMBL620092,,
4643,,Cercopithecidae,BAO_0000251,,1,A,Autocuration,,0,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),22224,U,,CHEMBL620093,,
4644,,Cercopithecidae,BAO_0000251,,1,A,Autocuration,,0,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),22224,U,,CHEMBL620094,,
4645,,Cercopithecidae,BAO_0000251,,1,A,Autocuration,,0,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),22224,U,,CHEMBL620095,,
4646,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,U,,CHEMBL620096,,
4647,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,U,,CHEMBL620097,,
4648,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,22224,U,,CHEMBL620098,,
4649,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,U,,CHEMBL620099,,
4650,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,U,,CHEMBL620100,,
4651,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Elimination Half-life of compound was determined in monkey,22224,U,,CHEMBL620101,,
4652,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Half life of compound was determined in rhesus monkey,22224,U,,CHEMBL620102,,
4653,,Cercopithecidae,BAO_0000366,,1,A,Autocuration,,0,Half life in monkey plasma,22224,U,,CHEMBL620103,1969.0,
4654,,Cercopithecidae,BAO_0000366,,1,A,Autocuration,,0,Half life in monkey plasma; Not detected,22224,U,,CHEMBL620104,1969.0,
4655,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,U,,CHEMBL874596,,
4656,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Half-life 24 hr after 2 mg/kg iv administration in monkeys,22224,U,,CHEMBL873490,,
4657,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Terminal half life of the compound.,22224,U,,CHEMBL620105,,
4658,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,U,,CHEMBL620780,,
4659,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),22224,U,,CHEMBL620781,,
4660,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,22224,U,,CHEMBL620956,,
4661,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,U,,CHEMBL620957,1088.0,
4662,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,U,,CHEMBL620958,1088.0,
4663,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,22224,U,,CHEMBL620959,,
4664,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,22224,U,,CHEMBL620960,,
4665,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Volume of distribution was evaluated in rhesus,22224,U,,CHEMBL620961,,
4666,,Cricetulus griseus,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,22224,U,,CHEMBL620962,,
4667,,Cricetulus griseus,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,22224,U,,CHEMBL620963,,
4668,,Cricetulus griseus,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in hamster was determined,22224,U,,CHEMBL620964,,
4669,,Cricetulus griseus,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,22224,U,,CHEMBL620965,,
4670,,Cricetulus griseus,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,22224,U,,CHEMBL620966,,
4671,,Cricetulus griseus,BAO_0000221,,1,A,Autocuration,,0,Half life of compound was determined in hamster blood,22224,U,,CHEMBL620967,178.0,
4672,,Sus scrofa,BAO_0000019,,1,A,Autocuration,,0,Michaelis-Menten constant of the compound.,22224,U,,CHEMBL620968,,
4673,,Sus scrofa,BAO_0000019,,1,A,Autocuration,,0,Vmax value was measured at 0 uM concentration of silyl ether.,22224,U,,CHEMBL874597,,
4674,,Sus scrofa,BAO_0000019,,1,A,Autocuration,,0,Vmax value was measured at 10 uM concentration of silyl ether.,22224,U,,CHEMBL620969,,
4675,,Sus scrofa,BAO_0000019,,1,A,Autocuration,,0,Vmax value was measured at 5 uM concentration of silyl ether.,22224,U,,CHEMBL620970,,
4676,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,235,D,,CHEMBL620971,,
4677,,Homo sapiens,BAO_0000218,,1,A,Autocuration,,0,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,22224,U,,CHEMBL620972,,
4678,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Compound was evaluated for area under the curve expressed as (h*ug/ml),22224,U,,CHEMBL620973,,
4679,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Active metabolite of ifosfamide determined in humans; A-Active,22224,U,,CHEMBL618243,,
4680,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,22224,U,,CHEMBL618244,,
4681,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,22224,U,,CHEMBL618245,,
4682,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,22224,U,,CHEMBL618246,,
4683,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,22224,U,,CHEMBL618247,,
4684,,Homo sapiens,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for oral bioavailability in human,22224,U,,CHEMBL618248,,
4685,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Metabolite of ifosfamide determined in urine; NF-Not found,22224,U,,CHEMBL618249,1088.0,
4686,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),22224,U,,CHEMBL618250,,
4687,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,22224,U,,CHEMBL874598,,
4688,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,22224,U,,CHEMBL618251,,
4689,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,22224,U,,CHEMBL618252,,
4690,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,22224,U,,CHEMBL618253,,
4691,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),22224,U,,CHEMBL618254,,
4692,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Percent of compound in healthy individuals (Group D),22224,U,,CHEMBL618255,,
4693,,Homo sapiens,BAO_0000251,,1,A,Autocuration,,0,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,22224,U,,CHEMBL618983,2107.0,
4694,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Binding towards human plasma protein at 10 uM,22224,U,,CHEMBL618984,,
4695,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Binding towards human plasma protein at 100 uM,22224,U,,CHEMBL618985,,
4696,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Human plasma protein binding activity was determined,22224,U,,CHEMBL618986,,
4697,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),22224,U,,CHEMBL618987,,
4698,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Percent binding of compound towards human plasma protein was determined,22224,U,,CHEMBL618988,,
4699,,Homo sapiens,BAO_0000251,,1,A,Autocuration,In vitro,0,Plasma clearance in human liver microsomes,22224,U,,CHEMBL618989,2107.0,
4700,,Homo sapiens,BAO_0000251,,1,A,Autocuration,In vitro,0,In vitro intrinsic clearance in human liver microsome,22224,U,,CHEMBL618990,2107.0,
4701,,Homo sapiens,BAO_0000251,,1,A,Autocuration,In vitro,0,In vitro intrinsic clearance in human liver microsome,22224,U,,CHEMBL618991,2107.0,
4702,,Homo sapiens,BAO_0000251,,1,A,Autocuration,In vitro,0,In vitro microsome metabolism clearance in human was determined,22224,U,,CHEMBL876725,,
4703,,Homo sapiens,BAO_0000251,,1,A,Autocuration,In vitro,0,In vitro microsome metabolism clearance in human was determined; High,22224,U,,CHEMBL618992,,
4704,,Homo sapiens,BAO_0000251,,1,A,Autocuration,In vitro,0,In vitro microsome metabolism clearance in human was determined; ND denotes no data,22224,U,,CHEMBL618993,,
4705,,Homo sapiens,BAO_0000251,,1,A,Autocuration,In vitro,0,Pharmacokinetic property (clearance) in human liver microsome,22224,U,,CHEMBL618994,2107.0,
4706,,Homo sapiens,BAO_0000251,,1,A,Autocuration,In vitro,0,Plasma clearance in human liver microsomes,22224,U,,CHEMBL618995,2107.0,
4707,,Homo sapiens,BAO_0000251,,1,A,Autocuration,In vitro,0,In vitro clearance in human liver microsomes,22224,U,,CHEMBL618996,2107.0,
4708,,Homo sapiens,BAO_0000251,,1,A,Autocuration,In vitro,0,Intrinsic clearance in human liver microsomes was determined,22224,U,,CHEMBL618997,2107.0,
4709,,Homo sapiens,BAO_0000251,,1,A,Autocuration,In vitro,0,Intrinsic clearance in human liver microsomes was determined,22224,U,,CHEMBL618998,2107.0,
4710,,Homo sapiens,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,22224,U,,CHEMBL618999,,
4711,,Homo sapiens,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,22224,U,,CHEMBL620223,,
4712,,Homo sapiens,BAO_0000218,,1,A,Autocuration,,0,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,22224,U,,CHEMBL620224,,
4713,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Stability in human plasma 2 hr after incubation expressed as percent concentration,22224,U,,CHEMBL620225,,
4714,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Stability in human plasma 4 hr after incubation expressed as percent concentration,22224,U,,CHEMBL620226,,
4715,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,U,,CHEMBL620227,1088.0,
4716,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,U,,CHEMBL876726,1088.0,
4717,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,U,,CHEMBL620228,1088.0,
4718,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,U,,CHEMBL620229,1088.0,
4719,,Mus musculus,BAO_0000218,,1,F,Intermediate,In vivo,1,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,50594,N,,CHEMBL620230,,
4720,,Mus musculus,BAO_0000218,,1,F,Intermediate,In vivo,1,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,50594,N,,CHEMBL620231,,
4721,,Mus musculus,BAO_0000218,,1,F,Intermediate,In vivo,1,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,50594,N,,CHEMBL620232,,
4722,,Mus musculus,BAO_0000218,,1,F,Intermediate,In vivo,1,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,50594,N,,CHEMBL620233,,
4723,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),50594,N,,CHEMBL620234,,
4724,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),50594,N,,CHEMBL620235,,
4725,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),50594,N,,CHEMBL620236,,
4726,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vitro metabolic potential in mouse liver microsomes,50594,N,,CHEMBL620237,2107.0,
4727,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Ability of compound to bind to plasma protein was evaluated in HSA cells,50594,N,,CHEMBL620238,,
4728,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),50594,N,,CHEMBL620239,2369.0,
4729,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,50594,N,,CHEMBL620240,955.0,
4730,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,50594,N,,CHEMBL620241,955.0,
4731,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),50594,N,,CHEMBL876727,,
4732,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),50594,N,,CHEMBL620242,2113.0,
4733,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),50594,N,,CHEMBL620243,,
4734,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,50594,N,,CHEMBL620244,,
4735,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,50594,N,,CHEMBL620245,1977.0,
4736,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,50594,N,,CHEMBL620246,1977.0,
4737,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,50594,N,,CHEMBL620247,1977.0,
4738,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life of compound was determined in plasma of mice at 24 mg/Kg,50594,N,,CHEMBL620248,1969.0,
4739,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life of compound was determined in plasma of mice at 40 mg/Kg,50594,N,,CHEMBL873497,1969.0,
4740,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life of compound was determined in plasma of mice at 5 mg/Kg,50594,N,,CHEMBL620249,1969.0,
4741,,Mus musculus,BAO_0000218,,1,F,Intermediate,In vivo,1,Half life after intraperitoneal administration in mice at 18 uM/kg,50594,N,,CHEMBL620250,,
4742,,Mus musculus,BAO_0000218,,1,F,Intermediate,In vivo,1,Half life after intraperitoneal administration in mice at 23 uM/kg,50594,N,,CHEMBL620251,,
4743,,Mus musculus,BAO_0000218,,1,F,Intermediate,In vivo,1,Half life after intraperitoneal administration in mice at 25 uM/kg,50594,N,,CHEMBL620252,,
4744,,Mus musculus,BAO_0000218,,1,F,Intermediate,In vivo,1,Half life after intraperitoneal administration in mice at 26 uM/kg,50594,N,,CHEMBL620253,,
4745,,Mus musculus,BAO_0000218,,1,F,Intermediate,In vivo,1,Half life after intravenous administration in mice at 23 uM/kg,50594,N,,CHEMBL620254,,
4746,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life after intravenous administration in mice at 24 uM/kg,50594,N,,CHEMBL620255,,
4747,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,50594,N,,CHEMBL620256,,
4748,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,50594,N,,CHEMBL876728,,
4749,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum time required to reach Cp max was evaluated in mice after oral administration,50594,N,,CHEMBL620257,,
4750,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),50594,N,,CHEMBL620258,,
4751,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",50594,N,,CHEMBL620259,,
4752,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,50594,N,,CHEMBL620260,,
4753,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,50594,N,,CHEMBL620261,178.0,
4754,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life at a dose of 10 mg/kg intravenous administration in mice.,50594,N,,CHEMBL620262,,
4755,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life at a dose of 10 mg/kg peroral administration in mice.,50594,N,,CHEMBL620263,,
4756,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Half life in ob/ob mice,50594,N,,CHEMBL620264,,
4757,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life at a single subcutaneous administration of 40 mg/kg in mice,50594,N,,CHEMBL620265,,
4758,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Half-life was measured in mouse,50594,N,,CHEMBL620266,,
4759,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,50594,N,,CHEMBL620267,,
4760,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,50594,N,,CHEMBL619364,,
4761,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,50594,N,,CHEMBL619365,,
4762,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,T2 in brain of mice at the oral dose of 50 mg/kg,50594,N,,CHEMBL619366,955.0,
4763,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,T2 in kidney of mice at the oral dose of 50 mg/kg,50594,N,,CHEMBL619367,2113.0,
4764,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,T2 in liver of mice at the oral dose of 50 mg/kg,50594,N,,CHEMBL619368,2107.0,
4765,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,T2 in lungs of mice at the oral dose of 50 mg/kg,50594,N,,CHEMBL619369,2048.0,
4766,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,T2 in spleen of mice at the oral dose of 50 mg/kg,50594,N,,CHEMBL876729,2106.0,
4767,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,50594,N,,CHEMBL619370,,
4768,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",50594,N,,CHEMBL619371,,
4769,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,50594,N,,CHEMBL619372,,
4770,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,50594,N,,CHEMBL620012,,
4771,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,50594,N,,CHEMBL620013,,
4772,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",81034,N,,CHEMBL620014,,
4773,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",81034,N,,CHEMBL620015,,
4774,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",81034,N,,CHEMBL621010,,
4775,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",81034,N,,CHEMBL621011,,
4776,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",81034,N,,CHEMBL621012,,
4777,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",81034,N,,CHEMBL621013,,
4778,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro cytotoxicity against A2780TAX cell line,81034,N,,CHEMBL621014,,
4779,481.0,Homo sapiens,BAO_0000219,A2780cisR,1,F,Intermediate,,1,In vitro inhibitory activity against human tumor cell line A2780cis,80017,N,,CHEMBL618154,,
4780,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,81034,N,,CHEMBL618155,,
4781,481.0,Homo sapiens,BAO_0000219,A2780cisR,1,F,Intermediate,,1,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,80017,N,,CHEMBL618156,,
4782,481.0,Homo sapiens,BAO_0000219,A2780cisR,1,F,Intermediate,,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),80017,N,,CHEMBL618157,,
4783,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,81034,N,,CHEMBL618328,,
4784,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,81034,N,,CHEMBL618329,,
4785,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,81034,N,,CHEMBL618330,,
4786,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,In vitro antitumor activity against A2780cisR cell line.,81034,N,,CHEMBL618331,,
4787,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),81034,N,,CHEMBL618332,,
4788,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,81034,N,,CHEMBL618333,,
4789,481.0,Homo sapiens,BAO_0000219,A2780cisR,1,F,Intermediate,,1,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,80017,N,,CHEMBL618334,,
4790,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,81034,N,,CHEMBL618335,,
4791,,Rattus norvegicus,BAO_0000019,,1,B,Expert,,9,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,11736,D,,CHEMBL618336,,
4792,,,BAO_0000019,,1,F,Expert,,8,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),11736,H,,CHEMBL618337,,
4793,,Rattus norvegicus,BAO_0000019,,1,F,Expert,,9,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),11736,D,,CHEMBL618338,,
4794,722.0,Homo sapiens,BAO_0000219,HEK293,1,F,Expert,,9,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,278,D,,CHEMBL618339,,
4795,722.0,Homo sapiens,BAO_0000219,HEK293,1,F,Expert,,9,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,278,D,,CHEMBL618340,,
4796,,Mus musculus,BAO_0000019,,1,B,Expert,,9,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,11831,D,,CHEMBL618341,,
4797,,,BAO_0000019,,1,F,Expert,,8,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),11831,H,,CHEMBL618342,,
4798,,Mus musculus,BAO_0000019,,1,F,Expert,,9,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),11831,D,,CHEMBL618343,,
4799,,,BAO_0000357,,1,B,Expert,,8,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,280,H,,CHEMBL621038,,
4800,574.0,Homo sapiens,BAO_0000219,T-cells,1,F,Autocuration,,0,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),22226,U,,CHEMBL621039,,
4801,574.0,Homo sapiens,BAO_0000219,T-cells,1,F,Autocuration,,0,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,22226,U,,CHEMBL621040,,
4802,455.0,Homo sapiens,BAO_0000219,A-375,1,F,Intermediate,,1,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,80018,N,,CHEMBL621041,,
4803,455.0,Homo sapiens,BAO_0000219,A-375,1,F,Intermediate,,1,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,80018,N,,CHEMBL621042,,
4804,455.0,Homo sapiens,BAO_0000219,A-375,1,F,Intermediate,,1,In vitro antitumor activity against A375cell line extracted form melanoma,80018,N,,CHEMBL621043,,
4805,455.0,Homo sapiens,BAO_0000219,A-375,1,F,Expert,,1,Inhibition of cell growth in (A375) melan cell line,80018,N,,CHEMBL621044,,
4806,455.0,Homo sapiens,BAO_0000219,A-375,1,F,Intermediate,,1,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,80018,N,,CHEMBL621045,,
4807,455.0,Homo sapiens,BAO_0000219,A-375,1,F,Intermediate,,1,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,80018,N,,CHEMBL621046,,
4808,455.0,Homo sapiens,BAO_0000219,A-375,1,F,Intermediate,,1,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,80018,N,,CHEMBL621047,,
4809,797.0,Homo sapiens,BAO_0000219,A-427,1,F,Intermediate,,1,Antiproliferative activity measured against A427 human lung carcinoma,80019,N,,CHEMBL621048,,
4810,797.0,Homo sapiens,BAO_0000219,A-427,1,F,Intermediate,,1,Antiproliferative activity measured against A427 human lung carcinoma,80019,N,,CHEMBL883798,,
4811,797.0,Homo sapiens,BAO_0000219,A-427,1,F,Intermediate,,1,Cytotoxicity against lung carcinoma A427 tumor cell lines,80019,N,,CHEMBL621049,,
4812,797.0,Homo sapiens,BAO_0000219,A-427,1,F,Intermediate,,1,Inhibition of large cell lung carcinoma (A427),80019,N,,CHEMBL621050,,
4813,797.0,Homo sapiens,BAO_0000219,A-427,1,F,Intermediate,,1,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,80019,N,,CHEMBL621051,,
4814,797.0,Homo sapiens,BAO_0000219,A-427,1,F,Intermediate,,1,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,80019,N,,CHEMBL621052,,
4815,797.0,Homo sapiens,BAO_0000219,A-427,1,F,Intermediate,,1,Inhibitory concentration in human lung carcinoma A427 cell line,80019,N,,CHEMBL621053,,
4816,797.0,Homo sapiens,BAO_0000219,A-427,1,F,Intermediate,,1,Inhibitory concentration in human lung carcinoma A427/VCR cell line,80019,N,,CHEMBL621054,,
4817,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,22224,U,,CHEMBL621055,,
4818,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Tested for volume of distribution upon iv administration to african green monkey,22224,U,,CHEMBL876398,,
4819,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Volume of distribution in monkey,22224,U,,CHEMBL621056,,
4820,,Macaca mulatta,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,U,,CHEMBL621057,,
4821,,Macaca mulatta,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,22224,U,,CHEMBL621058,,
4822,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Pharmacokinetic property(Vdss) in cynomolgus monkey,22224,U,,CHEMBL621059,,
4823,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,The distribution volume after intravenous administration in cynomolgus monkeys,22224,U,,CHEMBL621060,,
4824,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,22224,U,,CHEMBL621061,,
4825,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,22224,U,,CHEMBL621062,,
4826,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Volume displacement was calculated in rhesus monkey,22224,U,,CHEMBL621063,,
4827,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Volume of distribution in steady state was determined in rhesus monkey,22224,U,,CHEMBL621064,,
4828,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Volume of distribution of compound was determined in monkey,22224,U,,CHEMBL621065,,
4829,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),22224,U,,CHEMBL621066,,
4830,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),22224,U,,CHEMBL621067,,
4831,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),22224,U,,CHEMBL621068,,
4832,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,22224,U,,CHEMBL876399,,
4833,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Volume distribution in monkey after administration of 1 mg/kg iv,22224,U,,CHEMBL621069,,
4834,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),22224,U,,CHEMBL621070,,
4835,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,22224,U,,CHEMBL621071,,
4836,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,U,,CHEMBL621072,,
4837,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral systemic bioavailability upon iv administration to african green monkey,22224,U,,CHEMBL618209,,
4838,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),22224,U,,CHEMBL618210,,
4839,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Baboon plasma free fraction. ,22224,U,,CHEMBL618211,,
4840,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,Area under the curve was calculated in rhesus monkey after iv administration,22224,U,,CHEMBL618212,,
4841,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Area under the curve was calculated in rhesus monkey after peroral administration,22224,U,,CHEMBL618213,,
4842,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,22224,U,,CHEMBL618214,,
4843,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Half life period in monkey after 5 mg/kg dose,22224,U,,CHEMBL873492,,
4844,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Half-life was determined in monkey after 3 mg/kg of i.v. dose,22224,U,,CHEMBL618272,,
4845,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,22224,U,,CHEMBL618273,,
4846,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,22224,U,,CHEMBL618274,1969.0,
4847,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,22224,U,,CHEMBL618275,,
4848,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,22224,U,,CHEMBL618276,,
4849,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Compound was evaluated for terminal half life in monkey,22224,U,,CHEMBL618277,,
4850,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,22224,U,,CHEMBL618278,,
4851,,Macaca mulatta,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,U,,CHEMBL618279,1969.0,
4852,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Half life of compound was determined in squirrel monkey,22224,U,,CHEMBL618280,,
4853,,Macaca fascicularis,BAO_0000218,,1,A,Autocuration,In vivo,0,Half life after iv administration in cynomolgus monkey,22224,U,,CHEMBL618281,,
4854,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Half life in monkey plasma after administration of 1 mg/kg iv,22224,U,,CHEMBL618282,1969.0,
4855,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Half life was calculated in rhesus monkey,22224,U,,CHEMBL618283,,
4856,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Half life in monkey,22224,U,,CHEMBL618284,,
4857,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),22224,U,,CHEMBL618285,,
4858,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Half life was evaluated in rhesus,22224,U,,CHEMBL618286,,
4859,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Half life period after oral administration (2.5 mg/kg) in monkey was determined,22224,U,,CHEMBL618287,,
4860,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Half life period was determine after peroral administration at 10 mpk in Rhesus,22224,U,,CHEMBL618288,,
4861,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),22224,U,,CHEMBL876393,,
4862,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,22224,U,,CHEMBL618289,,
4863,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,22224,U,,CHEMBL618290,,
4864,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Half-life was calculated in monkey,22224,U,,CHEMBL618291,,
4865,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Half-life in Squirrel monkey,22224,U,,CHEMBL618292,,
4866,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Half-life in rhesus monkey,22224,U,,CHEMBL618293,,
4867,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Half-life was measured in monkey after an iv dose of 1 mg/kg,22224,U,,CHEMBL618294,,
4868,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Half-life period after intravenous administration in cynomolgus monkeys,22224,U,,CHEMBL618295,,
4869,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Half-life period after oral administration in cynomolgus monkeys,22224,U,,CHEMBL618296,,
4870,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,22224,U,,CHEMBL618297,,
4871,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,U,,CHEMBL618298,1088.0,
4872,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,U,,CHEMBL618299,1088.0,
4873,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,U,,CHEMBL618300,1088.0,
4874,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,22224,U,,CHEMBL618301,1088.0,
4875,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,22224,U,,CHEMBL618302,1088.0,
4876,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,22224,U,,CHEMBL876394,1088.0,
4877,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,22224,U,,CHEMBL618303,1088.0,
4878,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,22224,U,,CHEMBL618304,1088.0,
4879,,Homo sapiens,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,22224,U,,CHEMBL618305,,
4880,,Homo sapiens,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in human,22224,U,,CHEMBL618306,,
4881,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Compound was tested for human plasma protein binding,22224,U,,CHEMBL618307,,
4882,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Compound was tested for human plasma protein binding; Not determined,22224,U,,CHEMBL618308,,
4883,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Protein binding activity of compound in human plasma; % Free,22224,U,,CHEMBL618309,,
4884,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Unbound fraction (plasma),22224,U,,CHEMBL618310,,
4885,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,Half life for the hydrolysis of compound in human blood serum,22224,U,,CHEMBL873353,1969.0,
4886,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,Half life period in human plasma using phosphate buffer (0.08 M),22224,U,,CHEMBL618311,1969.0,
4887,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,Half life period in human plasma using phosphate buffer (0.1 M),22224,U,,CHEMBL618312,1969.0,
4888,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,Half-life in human plasma was determined,22224,U,,CHEMBL618313,1969.0,
4889,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,22224,U,,CHEMBL618314,,
4890,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),22224,U,,CHEMBL618315,,
4891,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",22224,U,,CHEMBL618316,,
4892,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",22224,U,,CHEMBL618317,,
4893,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",22224,U,,CHEMBL620138,,
4894,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Partition coefficient (logP),22224,U,,CHEMBL858280,,
4895,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,In vitro metabolic stability in human was measured as pmol/min/mg/protein,22224,U,,CHEMBL620139,,
4896,,Homo sapiens,BAO_0000251,,1,A,Autocuration,,0,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,22224,U,,CHEMBL620140,,
4897,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),22224,U,,CHEMBL620141,,
4898,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),22224,U,,CHEMBL620142,,
4899,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),22224,U,,CHEMBL620143,,
4900,,Homo sapiens,BAO_0000251,,1,A,Autocuration,,0,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),22224,U,,CHEMBL620144,,
4901,,Homo sapiens,BAO_0000251,,1,A,Autocuration,,0,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),22224,U,,CHEMBL620145,,
4902,,Homo sapiens,BAO_0000251,,1,A,Autocuration,,0,Metabolism of compound in human microsomes; Trace,22224,U,,CHEMBL620146,,
4903,,Homo sapiens,BAO_0000251,,1,A,Autocuration,,0,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,22224,U,,CHEMBL620147,2107.0,
4904,,Homo sapiens,BAO_0000251,,1,A,Autocuration,,0,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,22224,U,,CHEMBL620148,,
4905,,Homo sapiens,BAO_0000251,,1,A,Autocuration,,0,In vitro metabolic potential in human liver microsomes,22224,U,,CHEMBL620149,2107.0,
4906,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,22224,U,,CHEMBL876412,,
4907,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Tested for human plasma protein binding of the compound; Not tested,22224,U,,CHEMBL619352,,
4908,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Compound was tested for percent protein binding (PB) in human,22224,U,,CHEMBL619353,,
4909,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Protein binding in human plasma,22224,U,,CHEMBL619354,1969.0,
4910,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Permeability coefficient (B to A) in Caco-2 cell,22224,U,,CHEMBL619355,,
4911,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,22224,U,,CHEMBL619356,,
4912,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),22224,U,,CHEMBL619357,,
4913,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,In vitro rate of absorption observed as Caco-2 permeability in humans,22224,U,,CHEMBL619358,,
4914,495.0,Homo sapiens,BAO_0000219,Caco-2,1,A,Autocuration,,0,Cellular permeability of compound was determined in Caco-2 cells; High,22224,U,,CHEMBL619359,,
4915,495.0,Homo sapiens,BAO_0000219,Caco-2,1,A,Autocuration,,0,Permeability in Caco-2 cells of compound,22224,U,,CHEMBL619360,,
4916,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Permeability coefficient (A to B) in Caco-2 cell,22224,U,,CHEMBL619361,,
4917,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Permeability coefficient (B to A) in Caco-2 cell,22224,U,,CHEMBL619362,,
4918,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Permeability coefficient (Papp) (Caco-2 cell monolayer),22224,U,,CHEMBL619363,,
4919,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,22224,U,,CHEMBL618942,,
4920,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Compound was tested for protein binding in human plasma,22224,U,,CHEMBL618943,,
4921,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,22224,U,,CHEMBL618944,,
4922,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,22224,U,,CHEMBL618945,1088.0,
4923,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,50594,N,,CHEMBL618946,,
4924,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),50594,N,,CHEMBL876413,,
4925,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,50594,N,,CHEMBL618947,,
4926,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time taken to reach maximum concentration in plasma upon oral administration in mouse,50594,N,,CHEMBL618948,1969.0,
4927,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,N,,CHEMBL618949,1969.0,
4928,,Mus musculus,BAO_0000218,,1,F,Intermediate,In vivo,1,Tmax after intraperitoneal administration in mice at 23 uM/kg,50594,N,,CHEMBL618950,,
4929,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax after oral administration at 30 mg/kg in ICR mouse,50594,N,,CHEMBL618951,,
4930,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax after peroral administration in mice at 2.4 uM/kg,50594,N,,CHEMBL618952,,
4931,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax at a single subcutaneous administration of 40 mg/kg in mice,50594,N,,CHEMBL618953,,
4932,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax in brain of mice at the oral dose of 50 mg/kg,50594,N,,CHEMBL618954,955.0,
4933,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax in kidney of mice at the oral dose of 50 mg/kg,50594,N,,CHEMBL618955,2113.0,
4934,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax in liver of mice at the oral dose of 50 mg/kg,50594,N,,CHEMBL618956,2107.0,
4935,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax in lungs of mice at the oral dose of 50 mg/kg,50594,N,,CHEMBL618957,2048.0,
4936,,Mus musculus,BAO_0000218,,1,F,Intermediate,In vivo,1,Tmax in mice at 18 uM/kg i.p. administration,50594,N,,CHEMBL618958,,
4937,,Mus musculus,BAO_0000218,,1,F,Intermediate,In vivo,1,Tmax in mice at 23 uM/kg i.v. administration,50594,N,,CHEMBL618959,,
4938,,Mus musculus,BAO_0000218,,1,F,Intermediate,In vivo,1,Tmax in mice at 25 uM/kg i.p. administration,50594,N,,CHEMBL618960,,
4939,,Mus musculus,BAO_0000218,,1,F,Intermediate,In vivo,1,Tmax in mice at 26 uM/kg i.p. administration,50594,N,,CHEMBL876723,,
4940,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax in spleen of mice at the oral dose of 50 mg/kg,50594,N,,CHEMBL618961,2106.0,
4941,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,50594,N,,CHEMBL618962,,
4942,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax value at a dose of 10 mg/kg peroral administration in mice.,50594,N,,CHEMBL618963,,
4943,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Tmax value in IRC mice,50594,N,,CHEMBL618964,,
4944,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,50594,N,,CHEMBL618965,,
4945,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,50594,N,,CHEMBL618966,,
4946,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),50594,N,,CHEMBL618967,1088.0,
4947,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),50594,N,,CHEMBL618968,1088.0,
4948,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),50594,N,,CHEMBL618969,1088.0,
4949,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,50594,N,,CHEMBL618970,,
4950,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,50594,N,,CHEMBL618971,,
4951,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,50594,N,,CHEMBL618972,,
4952,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,50594,N,,CHEMBL618973,,
4953,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,50594,N,,CHEMBL618974,,
4954,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,50594,N,,CHEMBL618975,,
4955,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Vd in mice,50594,N,,CHEMBL618976,,
4956,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution in mouse,50594,N,,CHEMBL618977,,
4957,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,N,,CHEMBL876724,,
4958,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution of compound in plasma was determined at 24 mg/Kg,50594,N,,CHEMBL618978,,
4959,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution of compound in plasma was determined at 40 mg/Kg,50594,N,,CHEMBL618979,,
4960,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution of compound in plasma was determined at 5 mg/Kg,50594,N,,CHEMBL618980,,
4961,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (vdss) was measured in mouse,50594,N,,CHEMBL618981,,
4962,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Value distribution upon iv administration in mouse,50594,N,,CHEMBL618982,,
4963,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,50594,N,,CHEMBL620150,,
4964,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution was evaluated in mice after intravenous administration,50594,N,,CHEMBL620151,,
4965,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution was evaluated in mice after oral administration,50594,N,,CHEMBL620152,,
4966,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,50594,N,,CHEMBL620153,,
4967,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Steady state volume of distribution was determined in mice,50594,N,,CHEMBL876395,,
4968,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution (steady state) of compound was determined in mouse,50594,N,,CHEMBL620154,,
4969,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,50594,N,,CHEMBL620155,,
4970,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Vss value at a dose of 10 mg/kg intravenous administration in mice.,50594,N,,CHEMBL620156,,
4971,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,50594,N,,CHEMBL620157,,
4972,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound (oxidized form) in in kidney tissue,50594,N,,CHEMBL620158,2113.0,
4973,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,50594,N,,CHEMBL620159,178.0,
4974,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",50594,N,,CHEMBL620160,178.0,
4975,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,N,,CHEMBL620161,178.0,
4976,797.0,Homo sapiens,BAO_0000219,A-427,1,F,Intermediate,,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,80019,N,,CHEMBL620162,,
4977,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,1,Inhibition of A431 human squamous cell carcinoma cell proliferation,80852,N,,CHEMBL620163,,
4978,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,1,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,80852,N,,CHEMBL620833,,
4979,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,1,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,80852,N,,CHEMBL876396,,
4980,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,1,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,80852,N,,CHEMBL620834,,
4981,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,1,Inhibition of A431 human carcinoma cell proliferation,80852,N,,CHEMBL620835,,
4982,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,1,In vitro inhibition of A431 (human carcinoma) cell basal growth.,80852,N,,CHEMBL620836,,
4983,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,80852,N,,CHEMBL620837,,
4984,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,In vitro cytotoxicity against epidermoid carcinoma cell line,80852,N,,CHEMBL621017,,
4985,500.0,Homo sapiens,BAO_0000218,A-431,1,F,Expert,,9,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",9,D,,CHEMBL621018,,
4986,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,Antiproliferative activity of compound was measured on human tumor cell line A431.,80852,N,,CHEMBL621019,,
4987,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,Antiproliferative effect of compound on A431 cell line expressing mutant p53,80852,N,,CHEMBL621020,,
4988,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,80852,N,,CHEMBL621021,,
4989,500.0,,BAO_0000219,A-431,1,F,Expert,,8,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,9,H,,CHEMBL621022,,
4990,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,1,Tested for antiproliferative activity against human A431 cells,80852,N,,CHEMBL621023,,
4991,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,9,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,9,D,,CHEMBL621024,,
4992,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,1,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,80852,N,,CHEMBL621025,,
4993,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,1,Inhibition of A431 cell proliferation,80852,N,,CHEMBL621026,,
4994,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,1,Cytotoxic effect on A431 human epidermoid carcinoma cells,80852,N,,CHEMBL621027,,
4995,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,1,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),80852,N,,CHEMBL876397,,
4996,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,80852,N,,CHEMBL883797,,
4997,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,80852,N,,CHEMBL621028,,
4998,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,80852,N,,CHEMBL621029,,
4999,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,80852,N,,CHEMBL621030,,
5000,500.0,,BAO_0000219,A-431,1,F,Expert,,8,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,9,H,,CHEMBL621147,,
5001,500.0,Homo sapiens,BAO_0000218,A-431,1,F,Intermediate,,1,In vivo antiproliferative activity against A431 cell line,80852,N,,CHEMBL621148,,
5002,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,9,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,9,D,,CHEMBL621149,,
5003,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,1,Inhibition of A431 human epidermoid carcinoma cell proliferation,80852,N,,CHEMBL621150,,
5004,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,9,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,9,D,,CHEMBL621151,,
5005,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),80852,N,,CHEMBL621152,,
5006,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),80852,N,,CHEMBL621153,,
5007,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),80852,N,,CHEMBL884000,,
5008,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,Inhibition of EGFR overexpressing A431 cell proliferation,9,D,,CHEMBL621154,,
5009,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,1,Inhibition of A431 cell proliferation,80852,N,,CHEMBL621155,,
5010,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,9,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,9,D,,CHEMBL621156,,
5011,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,9,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",9,D,,CHEMBL621157,,
5012,500.0,,BAO_0000219,A-431,1,F,Expert,,8,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),9,H,,CHEMBL621158,,
5013,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,80852,N,,CHEMBL621159,,
5014,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,80852,N,,CHEMBL621160,,
5015,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,80852,N,,CHEMBL621161,,
5016,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,80852,N,,CHEMBL621162,,
5017,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,80852,N,,CHEMBL621163,,
5018,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,80852,N,,CHEMBL621164,,
5019,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,80852,N,,CHEMBL621165,,
5020,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Half-life period in cynomolgus monkey,22224,U,,CHEMBL619159,,
5021,,Cercopithecidae,BAO_0000366,,1,A,Autocuration,In vitro,0,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",22224,U,,CHEMBL619160,1969.0,
5022,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Longer half-life in monkey (i.v.) at 0.5 mpk,22224,U,,CHEMBL619161,,
5023,,Cercopithecidae,BAO_0000366,,1,A,Autocuration,,0,Plasma half life in monkey,22224,U,,CHEMBL619162,1969.0,
5024,,Cercopithecidae,BAO_0000366,,1,A,Autocuration,,0,Plasma half-life in rhesus monkey,22224,U,,CHEMBL619163,1969.0,
5025,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),22224,U,,CHEMBL619164,1969.0,
5026,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),22224,U,,CHEMBL619320,1969.0,
5027,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Tested for half life upon iv administration to african green monkey,22224,U,,CHEMBL619321,,
5028,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,22224,U,,CHEMBL873336,,
5029,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,22224,U,,CHEMBL619322,,
5030,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,22224,U,,CHEMBL619323,,
5031,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,The time for peak concentration value after oral administration in cynomolgus monkeys,22224,U,,CHEMBL619324,,
5032,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,22224,U,,CHEMBL619325,,
5033,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,22224,U,,CHEMBL876411,,
5034,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,22224,U,,CHEMBL619326,,
5035,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,22224,U,,CHEMBL619327,,
5036,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,22224,U,,CHEMBL619328,,
5037,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,22224,U,,CHEMBL619329,,
5038,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,22224,U,,CHEMBL619330,,
5039,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,22224,U,,CHEMBL619331,,
5040,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,22224,U,,CHEMBL619332,,
5041,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,22224,U,,CHEMBL619333,,
5042,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,22224,U,,CHEMBL619334,,
5043,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,22224,U,,CHEMBL619335,,
5044,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,22224,U,,CHEMBL619336,,
5045,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,22224,U,,CHEMBL619337,,
5046,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,22224,U,,CHEMBL619338,,
5047,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,22224,U,,CHEMBL619339,,
5048,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (cannulated) (dose 2 mg/kg),50597,N,,CHEMBL619340,,
5049,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,N,,CHEMBL873496,1969.0,
5050,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC value in rat after IV administration at a dose of 10 mg/kg,50597,N,,CHEMBL619341,1969.0,
5051,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC value in rat after oral administration at a dose of 10 mg/kg,50597,N,,CHEMBL619342,1969.0,
5052,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value in rat after oral administration at a dose of 10 mg/kg,50597,N,,CHEMBL619343,,
5053,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat after oral administration at a dose of 10 mg/kg,50597,N,,CHEMBL619344,,
5054,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax value in rat after oral administration at a dose of 10 mg/kg,50597,N,,CHEMBL619345,,
5055,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Vc value in rat after IV administration at a dose of 10 mg/kg,50597,N,,CHEMBL619346,,
5056,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period in rat after IV administration at a dose of 10 mg/kg,50597,N,,CHEMBL619347,,
5057,,Papio hamadryas,BAO_0000019,,1,A,Autocuration,,0,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,22224,U,,CHEMBL619348,,
5058,,Papio hamadryas,BAO_0000019,,1,A,Autocuration,,0,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),22224,U,,CHEMBL619349,,
5059,,Papio hamadryas,BAO_0000019,,1,A,Autocuration,,0,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),22224,U,,CHEMBL619350,,
5060,,Papio hamadryas,BAO_0000019,,1,A,Autocuration,,0,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,22224,U,,CHEMBL619351,,
5061,,Papio hamadryas,BAO_0000019,,1,A,Autocuration,,0,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,22224,U,,CHEMBL875953,,
5062,,Papio hamadryas,BAO_0000019,,1,A,Autocuration,,0,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,22224,U,,CHEMBL621716,,
5063,,Papio hamadryas,BAO_0000019,,1,A,Autocuration,,0,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,22224,U,,CHEMBL621717,,
5064,,Papio hamadryas,BAO_0000019,,1,A,Autocuration,,0,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,22224,U,,CHEMBL621718,,
5065,,beagle,BAO_0000019,,1,A,Autocuration,,0,Area under curve after 1 mpk peroral administration to beagles,22224,U,,CHEMBL621719,,
5066,,beagle,BAO_0000019,,1,A,Autocuration,,0,Area under curve after 2 mpk peroral administration to beagles,22224,U,,CHEMBL621720,,
5067,,beagle,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax value after 1 mpk peroral administration to beagles,22224,U,,CHEMBL621721,,
5068,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,22224,U,,CHEMBL621722,1088.0,
5069,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,22224,U,,CHEMBL621723,1088.0,
5070,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,22224,U,,CHEMBL621724,1088.0,
5071,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,22224,U,,CHEMBL623443,1088.0,
5072,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,22224,U,,CHEMBL623444,1088.0,
5073,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,22224,U,,CHEMBL623445,1088.0,
5074,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,22224,U,,CHEMBL623446,1088.0,
5075,,Homo sapiens,BAO_0000251,,1,A,Autocuration,,0,Metabolic stability observed at 30 min after administration in human liver microsomes,22224,U,,CHEMBL623447,2107.0,
5076,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,22224,U,,CHEMBL623448,,
5077,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,22224,U,,CHEMBL623449,,
5078,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,22224,U,,CHEMBL623450,,
5079,,Homo sapiens,BAO_0000251,,1,A,Autocuration,,0,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",22224,U,,CHEMBL623451,2107.0,
5080,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Metabolic stability (% remaining at 30 mins) in human S9.,22224,U,,CHEMBL623452,,
5081,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,22224,U,,CHEMBL623453,,
5082,,Homo sapiens,BAO_0000251,,1,A,Autocuration,,0,Percent parent compound remaining after 20 min incubation with human liver microsomes,22224,U,,CHEMBL623454,2107.0,
5083,,Homo sapiens,BAO_0000251,,1,A,Autocuration,,0,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,22224,U,,CHEMBL623455,2107.0,
5084,,Homo sapiens,BAO_0000251,,1,A,Autocuration,,0,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,22224,U,,CHEMBL624371,2107.0,
5085,,Homo sapiens,BAO_0000218,,1,A,Autocuration,,0,First pass metabolism and metabolic bioavailability using human hepatic microsomes,22224,U,,CHEMBL624372,,
5086,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,22224,U,,CHEMBL624373,,
5087,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Percent remaining in human plasma after incubation for 60 min at 37 C.,22224,U,,CHEMBL624374,,
5088,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,The percent remaining in human plasma after 30 min was determined,22224,U,,CHEMBL624556,,
5089,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,Conversion rate of the prodrug in human plasma,22224,U,,CHEMBL624557,1969.0,
5090,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,Conversion rate of the prodrug in human plasma; ND means no data,22224,U,,CHEMBL624558,1969.0,
5091,,Homo sapiens,BAO_0000221,,1,A,Autocuration,,0,Half life of compound was determined in human blood,22224,U,,CHEMBL624559,178.0,
5092,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Half life of compound was determined in man with once daily dosing,22224,U,,CHEMBL624560,,
5093,,Homo sapiens,BAO_0000251,,1,A,Autocuration,In vitro,0,Half life in human microsomes,22224,U,,CHEMBL624561,,
5094,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,Half life in human plasma,22224,U,,CHEMBL624562,1969.0,
5095,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,Half life in human plasma; Not detected,22224,U,,CHEMBL624563,1969.0,
5096,,Homo sapiens,BAO_0000218,,1,A,Autocuration,In vivo,0,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,22224,U,,CHEMBL624564,,
5097,,Homo sapiens,BAO_0000251,,1,A,Autocuration,In vitro,0,Half-life for oxidative metabolic stability was determined using rat liver microsomes,22224,U,,CHEMBL624565,2107.0,
5098,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,Half-life in human plasma,22224,U,,CHEMBL875152,1969.0,
5099,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,Half-life of the parent prodrug in plasma,22224,U,,CHEMBL624566,1969.0,
5100,,Homo sapiens,BAO_0000366,,1,A,Autocuration,In vitro,0,In vitro half life in human plasma was determined,22224,U,,CHEMBL873805,1969.0,
5101,,Homo sapiens,BAO_0000251,,1,A,Autocuration,In vitro,0,The compound was tested In Vitro for half life in human liver microsomes.,22224,U,,CHEMBL624567,2107.0,
5102,,Homo sapiens,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,22224,U,,CHEMBL624568,,
5103,,Homo sapiens,BAO_0000218,,1,A,Autocuration,In vivo,0,Observed volume of distribution,22224,U,,CHEMBL624569,,
5104,,Homo sapiens,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in human,22224,U,,CHEMBL624570,,
5105,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Tested for human plasma protein binding of the compound,22224,U,,CHEMBL624571,,
5106,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,"First order rate constant, k was determined in human plasma",22224,U,,CHEMBL624572,,
5107,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Observed rate constant in 80% human plasma at 37 degree Centigrade,22224,U,,CHEMBL624573,,
5108,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Observed rate constant in 80% human plasma at 37 degree Centigrade,22224,U,,CHEMBL875153,,
5109,,Homo sapiens,BAO_0000251,,1,A,Autocuration,,0,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,22224,U,,CHEMBL624574,2107.0,
5110,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,The compound was tested for the plasma binding in human,22224,U,,CHEMBL624575,,
5111,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Plasma protein binding (human),22224,U,,CHEMBL624576,,
5112,,Homo sapiens,BAO_0000251,,1,A,Autocuration,In vitro,0,Compound was evaluated for half-life in human liver microsomes,22224,U,,CHEMBL624577,2107.0,
5113,,Homo sapiens,BAO_0000221,,1,A,Autocuration,In vitro,0,Half life measured in vitro for its stability in human blood,22224,U,,CHEMBL624578,178.0,
5114,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Half life in human serum,22224,U,,CHEMBL622796,1977.0,
5115,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Half life in human serum; ND=not determined,22224,U,,CHEMBL622797,1977.0,
5116,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Half life were determined in CEM-SS cell extract in decomposition step 1,22224,U,,CHEMBL622798,,
5117,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Half life were determined in CEM-SS cell extract in decomposition step 2,22224,U,,CHEMBL622799,,
5118,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,Half life of the in human plasma,22224,U,,CHEMBL622800,1969.0,
5119,,Homo sapiens,BAO_0000220,,1,A,Autocuration,In vitro,0,Half life period in human hepatic S9 fraction was determined,22224,U,,CHEMBL622801,,
5120,,Homo sapiens,BAO_0000251,,1,A,Autocuration,In vitro,0,Half life period in human liver microsome was determined,22224,U,,CHEMBL622802,2107.0,
5121,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Half life period was determined; 6-7,22224,U,,CHEMBL622803,,
5122,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Half life period was evaluated in human,22224,U,,CHEMBL875154,,
5123,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,Half life time in human plasma,22224,U,,CHEMBL622804,1969.0,
5124,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,N,,CHEMBL622805,955.0,
5125,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,N,,CHEMBL622611,948.0,
5126,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,N,,CHEMBL622612,948.0,
5127,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,N,,CHEMBL875160,2113.0,
5128,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",50594,N,,CHEMBL622613,2113.0,
5129,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,N,,CHEMBL622614,2113.0,
5130,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,N,,CHEMBL622615,2107.0,
5131,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,50594,N,,CHEMBL622616,2107.0,
5132,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,N,,CHEMBL622617,2107.0,
5133,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,50594,N,,CHEMBL622618,2106.0,
5134,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",50594,N,,CHEMBL622619,2106.0,
5135,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,N,,CHEMBL622620,2106.0,
5136,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,N,,CHEMBL622621,955.0,
5137,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound (oxidized form) in blood tissue,50594,N,,CHEMBL622622,178.0,
5138,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,N,,CHEMBL622623,178.0,
5139,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",50594,N,,CHEMBL622624,178.0,
5140,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,N,,CHEMBL622625,178.0,
5141,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,N,,CHEMBL622626,178.0,
5142,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,N,,CHEMBL622627,178.0,
5143,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound (oxidized form) in brain tissue of mice,50594,N,,CHEMBL622628,955.0,
5144,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,N,,CHEMBL622629,955.0,
5145,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",50594,N,,CHEMBL622630,955.0,
5146,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,N,,CHEMBL622631,955.0,
5147,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,N,,CHEMBL622632,955.0,
5148,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",50594,N,,CHEMBL622633,955.0,
5149,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound (oxidized form) in heart tissue of mice,50594,N,,CHEMBL622634,948.0,
5150,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,N,,CHEMBL622635,948.0,
5151,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,N,,CHEMBL875161,948.0,
5152,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",50594,N,,CHEMBL622636,948.0,
5153,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,N,,CHEMBL623335,948.0,
5154,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,N,,CHEMBL623336,948.0,
5155,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,N,,CHEMBL623337,2113.0,
5156,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",50594,N,,CHEMBL623338,2113.0,
5157,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",50594,N,,CHEMBL623339,2113.0,
5158,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,N,,CHEMBL623524,2113.0,
5159,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,N,,CHEMBL623525,2113.0,
5160,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound (oxidized form) in liver tissue,50594,N,,CHEMBL623526,2107.0,
5161,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,N,,CHEMBL623527,2107.0,
5162,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,N,,CHEMBL623528,2107.0,
5163,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,80852,N,,CHEMBL624615,,
5164,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,80852,N,,CHEMBL621672,,
5165,500.0,,BAO_0000218,A-431,1,F,Expert,,1,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",80852,N,,CHEMBL621673,,
5166,500.0,,BAO_0000218,A-431,1,F,Expert,,1,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",80852,N,,CHEMBL621674,,
5167,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,9,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,9,D,,CHEMBL884002,,
5168,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",80852,N,,CHEMBL621850,,
5169,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,80852,N,,CHEMBL621851,,
5170,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,9,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,9,D,,CHEMBL621852,,
5171,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,9,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,9,D,,CHEMBL621853,,
5172,500.0,,BAO_0000218,A-431,1,F,Expert,,1,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",80852,N,,CHEMBL621854,,
5173,500.0,,BAO_0000218,A-431,1,F,Expert,,1,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",80852,N,,CHEMBL621855,,
5174,500.0,,BAO_0000218,A-431,1,F,Expert,,1,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",80852,N,,CHEMBL623724,,
5175,500.0,,BAO_0000218,A-431,1,F,Expert,,1,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",80852,N,,CHEMBL623725,,
5176,500.0,,BAO_0000218,A-431,1,F,Expert,,1,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",80852,N,,CHEMBL623726,,
5177,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,9,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",9,D,,CHEMBL623727,,
5178,500.0,,BAO_0000219,A-431,1,F,Expert,,8,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,9,H,,CHEMBL623728,,
5179,500.0,,BAO_0000218,A-431,1,F,Expert,,1,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",80852,N,,CHEMBL623729,,
5180,500.0,,BAO_0000218,A-431,1,F,Expert,,1,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",80852,N,,CHEMBL623730,,
5181,500.0,,BAO_0000218,A-431,1,F,Expert,,1,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",80852,N,,CHEMBL623731,,
5182,500.0,Mus musculus,BAO_0000218,A-431,1,F,Expert,,1,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",80852,N,,CHEMBL623732,,
5183,500.0,Mus musculus,BAO_0000218,A-431,1,F,Expert,,1,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",80852,N,,CHEMBL623733,,
5184,500.0,Mus musculus,BAO_0000218,A-431,1,F,Expert,,1,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",80852,N,,CHEMBL623734,,
5185,500.0,Mus musculus,BAO_0000218,A-431,1,F,Expert,,1,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",80852,N,,CHEMBL623735,,
5186,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,1,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,80852,N,,CHEMBL623736,,
5187,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,80852,N,,CHEMBL623737,,
5188,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,80852,N,,CHEMBL623738,,
5189,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Intermediate,,1,Dose giving a 50% decrease in the living cell number (A437 cells),80852,N,,CHEMBL875168,,
5190,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro inhibitory concentration against proliferation of A459 cell line.,80682,N,,CHEMBL623739,,
5191,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,80682,N,,CHEMBL623740,,
5192,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,80682,N,,CHEMBL624424,,
5193,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,In vitro antitumor activity against renal A498 tumor cell lines,80021,N,,CHEMBL624425,,
5194,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",80021,N,,CHEMBL624426,,
5195,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",80021,N,,CHEMBL624427,,
5196,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,80021,N,,CHEMBL624428,,
5197,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,80021,N,,CHEMBL624429,,
5198,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,80021,N,,CHEMBL624620,,
5199,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Cytotoxicity on kidney carcinoma (A-498) cell line,80021,N,,CHEMBL624621,,
5200,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Compound was evaluated against Human cell line renal A498,80021,N,,CHEMBL624622,,
5201,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Compound was tested for inhibition of A498 human renal cancer cell line,80021,N,,CHEMBL624623,,
5202,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Growth inhibitory activity against A498 human cancer cell line,80021,N,,CHEMBL874365,,
5203,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,In vitro antitumor activity against human renal A498 cell line,80021,N,,CHEMBL624624,,
5204,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,In vitro cytotoxic activity against renal (A498) cell line,80021,N,,CHEMBL624625,,
5205,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,In vitro cytotoxic activity against human renal cancer (A498) cell line,80021,N,,CHEMBL624626,,
5206,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Tested for cytostatic activity against renal A498 cell line,80021,N,,CHEMBL624627,,
5207,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,80021,N,,CHEMBL883157,,
5208,624.0,Homo sapiens,BAO_0000219,A498,1,F,Expert,,1,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,80021,N,,CHEMBL624628,,
5209,,beagle,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax value after 2 mpk peroral administration to beagles,22224,U,,CHEMBL624629,,
5210,,Canis lupus familiaris,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability,22224,U,,CHEMBL623551,,
5211,,Canis lupus familiaris,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability after 1 mpk peroral administration to beagles,22224,U,,CHEMBL623552,,
5212,,Canis lupus familiaris,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability after 2 mpk peroral administration to beagles,22224,U,,CHEMBL623553,,
5213,,Bos taurus,BAO_0000019,,1,A,Autocuration,,0,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,22224,U,,CHEMBL623554,,
5214,,Bos taurus,BAO_0000019,,1,A,Autocuration,,0,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,22224,U,,CHEMBL623555,,
5215,,Bos taurus,BAO_0000019,,1,A,Autocuration,,0,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,22224,U,,CHEMBL623556,,
5216,,Bos taurus,BAO_0000019,,1,A,Autocuration,,0,Solubility against bovine alpha-chymotrypsin,22224,U,,CHEMBL623557,,
5217,,Bos taurus,BAO_0000019,,1,A,Autocuration,,0,Rate constant of the bovine serum albumin catalyzed reaction of the compound,22224,U,,CHEMBL623558,,
5218,,Bos taurus,BAO_0000019,,1,A,Autocuration,,0,Rate constant of the bovine serum albumin catalyzed reaction of the compound,22224,U,,CHEMBL623559,,
5219,,Bos taurus,BAO_0000221,,1,A,Autocuration,,0,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,22224,U,,CHEMBL623560,2106.0,
5220,,Bos taurus,BAO_0000019,,1,A,Autocuration,,0,Half life in culture medium containing 10% of heat inactivated foetal calf serum,22224,U,,CHEMBL623561,,
5221,,Bos taurus,BAO_0000019,,1,A,Autocuration,,0,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,22224,U,,CHEMBL623562,,
5222,,Bos taurus,BAO_0000019,,1,A,Autocuration,,0,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,22224,U,,CHEMBL623563,,
5223,,Bos taurus,BAO_0000221,,1,A,Autocuration,,0,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,22224,U,,CHEMBL623564,2106.0,
5224,,Bos taurus,BAO_0000019,,1,A,Autocuration,,0,Half life in presence of 2 mg/mL BSA at pH 8.8,22224,U,,CHEMBL873806,,
5225,,Bos taurus,BAO_0000019,,1,A,Autocuration,,0,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,22224,U,,CHEMBL623565,,
5226,,Bos taurus,BAO_0000019,,1,A,Autocuration,,0,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,22224,U,,CHEMBL623566,,
5227,,Bos taurus,BAO_0000019,,1,A,Autocuration,,0,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,22224,U,,CHEMBL623567,,
5228,,Bos taurus,BAO_0000019,,1,A,Autocuration,,0,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),22224,U,,CHEMBL623568,,
5229,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,50588,N,,CHEMBL623569,1969.0,
5230,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,AUC after administration at 100 mg/kg/day in dogs,50588,N,,CHEMBL623570,1969.0,
5231,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,AUC in dog at 0-24 hr by peroral administration at 3 mpk,50588,N,,CHEMBL624254,1969.0,
5232,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,AUC value after 15 mg/kg iv dose in Dogs,50588,N,,CHEMBL624255,1969.0,
5233,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,AUC value after 30 mg/kg po dose in Dogs,50588,N,,CHEMBL624256,1969.0,
5234,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,AUC value after administration of 4 mg/Kg oral dose in dog,50588,N,,CHEMBL624257,1969.0,
5235,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,50588,N,,CHEMBL624258,1969.0,
5236,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,50588,N,,CHEMBL875277,,
5237,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,50588,N,,CHEMBL622667,,
5238,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,50588,N,,CHEMBL622668,,
5239,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,50588,N,,CHEMBL622669,,
5240,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve determined in dogs after intravenous administration of 3 mg/kg,50588,N,,CHEMBL622670,,
5241,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve determined in dogs after oral administration of 10 mg/kg,50588,N,,CHEMBL622671,,
5242,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,50588,N,,CHEMBL622672,,
5243,,Canis lupus familiaris,BAO_0000218,,1,A,Expert,,1,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,N,,CHEMBL622673,,
5244,,Canis lupus familiaris,BAO_0000218,,1,A,Expert,,1,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,50588,N,,CHEMBL622674,,
5245,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),50588,N,,CHEMBL622675,,
5246,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,50588,N,,CHEMBL622676,,
5247,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),50588,N,,CHEMBL622677,,
5248,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,50588,N,,CHEMBL622678,,
5249,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve in dog after administration of 20 mg/kg dose through peroral route,50588,N,,CHEMBL622679,,
5250,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),50588,N,,CHEMBL622680,,
5251,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determine after peroral administration at 10 mpk in dog,50588,N,,CHEMBL622681,,
5252,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determine after peroral administration at 5 mpk in dog,50588,N,,CHEMBL875278,,
5253,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined,50588,N,,CHEMBL622682,,
5254,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve in dogs,50588,N,,CHEMBL622683,,
5255,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve in dogs at 10 mg/kg dose fo oral administration,50588,N,,CHEMBL622684,,
5256,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),50588,N,,CHEMBL622685,,
5257,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,50588,N,,CHEMBL622686,,
5258,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,N,,CHEMBL618344,,
5259,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve value in dog at a dose of 5 mg/kg,50588,N,,CHEMBL875582,,
5260,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined after 0.1 mg/kg iv administration in dog,50588,N,,CHEMBL618345,,
5261,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined after 0.3 mg/kg po administration in dog,50588,N,,CHEMBL618346,,
5262,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,50588,N,,CHEMBL618347,,
5263,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,50588,N,,CHEMBL618348,,
5264,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,22224,U,,CHEMBL618349,,
5265,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,22224,U,,CHEMBL618350,,
5266,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,22224,U,,CHEMBL618351,,
5267,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,22224,U,,CHEMBL618352,,
5268,,Homo sapiens,BAO_0000221,,1,A,Autocuration,,0,Time taken to reduce 50% of the concentration of compound in blood plasma,22224,U,,CHEMBL873494,178.0,
5269,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",22224,U,,CHEMBL618353,1969.0,
5270,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,Half life in human plasma,22224,U,,CHEMBL618354,1969.0,
5271,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,Half life in human plasma was reported,22224,U,,CHEMBL875583,1969.0,
5272,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Half life in human serum,22224,U,,CHEMBL618355,1977.0,
5273,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,Half life upon exposure to human plasma,22224,U,,CHEMBL618356,1969.0,
5274,,Homo sapiens,BAO_0000251,,1,A,Autocuration,In vitro,0,t1/2 in human microsomes,22224,U,,CHEMBL618357,,
5275,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,Half life period in 80% human plasma at 37 degree Centigrade,22224,U,,CHEMBL618358,1969.0,
5276,,Homo sapiens,BAO_0000221,,1,A,Autocuration,,0,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),22224,U,,CHEMBL618359,14.0,
5277,,Homo sapiens,BAO_0000366,,1,A,Autocuration,In vitro,0,Half-life measured in in vitro Cathepsin B assay in human plasma,22224,U,,CHEMBL618360,1969.0,
5278,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,22224,U,,CHEMBL618361,,
5279,,Homo sapiens,BAO_0000251,,1,A,Autocuration,In vitro,0,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,22224,U,,CHEMBL618362,2107.0,
5280,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",22224,U,,CHEMBL618363,1969.0,
5281,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",22224,U,,CHEMBL618364,1969.0,
5282,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",22224,U,,CHEMBL875584,1969.0,
5283,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Half-life in the CEM cell extracts,22224,U,,CHEMBL618365,,
5284,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,22224,U,,CHEMBL873495,1969.0,
5285,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,22224,U,,CHEMBL618366,1969.0,
5286,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Half-life was determined,22224,U,,CHEMBL618367,,
5287,,Homo sapiens,BAO_0000221,,1,A,Autocuration,,0,Half-life (human blood stability),22224,U,,CHEMBL618368,178.0,
5288,,Homo sapiens,BAO_0000221,,1,A,Autocuration,,0,Half-life (human blood stability); no data,22224,U,,CHEMBL618369,178.0,
5289,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,Half-life in human plasma,22224,U,,CHEMBL618370,1969.0,
5290,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,CYP3A4 metabolism half-life (t1/2),22224,U,,CHEMBL618371,,
5291,,Homo sapiens,BAO_0000221,,1,A,Autocuration,,0,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),22224,U,,CHEMBL618372,178.0,
5292,,Homo sapiens,BAO_0000366,,1,A,Autocuration,In vitro,0,In vitro half life in human plasma,22224,U,,CHEMBL618373,1969.0,
5293,,Homo sapiens,BAO_0000366,,1,A,Autocuration,In vitro,0,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",22224,U,,CHEMBL618374,1969.0,
5294,,Homo sapiens,BAO_0000366,,1,A,Autocuration,In vitro,0,In vitro hydrolysis in human plasma,22224,U,,CHEMBL618375,1969.0,
5295,,Homo sapiens,BAO_0000366,,1,A,Autocuration,In vitro,0,In vitro hydrolysis in human plasma; no data,22224,U,,CHEMBL618376,1969.0,
5296,,Homo sapiens,BAO_0000251,,1,A,Autocuration,In vitro,0,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,22224,U,,CHEMBL618377,2107.0,
5297,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,Plasma half life in human,22224,U,,CHEMBL618378,1969.0,
5298,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,Stability after incubation with human plasma (at 37 degree C),22224,U,,CHEMBL618379,1969.0,
5299,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,T1/2 was evaluated in human plasma,22224,U,,CHEMBL618380,1969.0,
5300,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",22224,U,,CHEMBL618381,1969.0,
5301,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",22224,U,,CHEMBL618382,1969.0,
5302,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,22224,U,,CHEMBL618383,,
5303,,Homo sapiens,BAO_0000019,,1,A,Autocuration,In vitro,0,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,22224,U,,CHEMBL618384,,
5304,,Homo sapiens,BAO_0000019,,1,A,Autocuration,In vitro,0,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,22224,U,,CHEMBL618385,,
5305,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,22224,U,,CHEMBL619099,1969.0,
5306,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,22224,U,,CHEMBL619100,1969.0,
5307,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Time taken for 50% to be consumed by serum PON1 was determined,22224,U,,CHEMBL619101,,
5308,,Homo sapiens,BAO_0000019,,1,A,Autocuration,,0,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,22224,U,,CHEMBL619102,,
5309,,Homo sapiens,BAO_0000251,,1,A,Autocuration,,0,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,22224,U,,CHEMBL619103,2107.0,
5310,,Mus sp.,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,U,,CHEMBL619268,,
5311,,Mus sp.,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,U,,CHEMBL619269,,
5312,,Mus sp.,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,U,,CHEMBL619270,,
5313,,Mus sp.,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,U,,CHEMBL619271,,
5314,,Mus sp.,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,U,,CHEMBL875585,,
5315,,Mus sp.,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,U,,CHEMBL619272,,
5316,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,Compound tested for growth inhibition of renal cancer cell line 786-0,80640,N,,CHEMBL619273,,
5317,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,80640,N,,CHEMBL619274,,
5318,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Expert,,1,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,80640,N,,CHEMBL619275,,
5319,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",80640,N,,CHEMBL619276,,
5320,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",80640,N,,CHEMBL619277,,
5321,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",80640,N,,CHEMBL619278,,
5322,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,Tested for cytotoxicity against 786-0 cell lines in renal cancer,80640,N,,CHEMBL619279,,
5323,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,80640,N,,CHEMBL858458,,
5324,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Expert,,1,Cytotoxic effect on renal cancer line 786-0,80640,N,,CHEMBL619280,,
5325,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,80640,N,,CHEMBL619281,,
5326,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),80640,N,,CHEMBL619282,,
5327,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",80640,N,,CHEMBL619283,,
5328,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,80640,N,,CHEMBL619284,,
5329,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,80640,N,,CHEMBL619285,,
5330,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),80640,N,,CHEMBL619286,,
5331,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,80640,N,,CHEMBL619287,,
5332,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,80640,N,,CHEMBL857455,,
5333,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),80640,N,,CHEMBL883801,,
5334,972.0,Homo sapiens,BAO_0000219,791T cell line,1,F,Intermediate,,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,80641,N,,CHEMBL619288,,
5335,972.0,Homo sapiens,BAO_0000219,791T cell line,1,F,Intermediate,,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),80641,N,,CHEMBL619289,,
5336,972.0,Homo sapiens,BAO_0000219,791T cell line,1,F,Intermediate,,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,80641,N,,CHEMBL619290,,
5337,972.0,Homo sapiens,BAO_0000219,791T cell line,1,F,Intermediate,,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),80641,N,,CHEMBL619291,,
5338,972.0,Homo sapiens,BAO_0000219,791T cell line,1,F,Intermediate,,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),80641,N,,CHEMBL619292,,
5339,972.0,Homo sapiens,BAO_0000219,791T cell line,1,F,Intermediate,,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,80641,N,,CHEMBL619293,,
5340,972.0,Homo sapiens,BAO_0000219,791T cell line,1,F,Intermediate,,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),80641,N,,CHEMBL619294,,
5341,972.0,Homo sapiens,BAO_0000219,791T cell line,1,F,Intermediate,,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),80641,N,,CHEMBL619295,,
5342,972.0,Homo sapiens,BAO_0000219,791T cell line,1,F,Intermediate,,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),80641,N,,CHEMBL619296,,
5343,972.0,Homo sapiens,BAO_0000219,791T cell line,1,F,Intermediate,,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,80641,N,,CHEMBL619297,,
5344,391.0,Homo sapiens,BAO_0000219,786-0,1,F,Intermediate,,1,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,80640,N,,CHEMBL619298,,
5345,,,BAO_0000019,,1,F,Intermediate,,0,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,22226,U,,CHEMBL619299,,
5346,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Expert,,1,Inhibition of cell growth in drug resistant 8226 myeloma cell line,80433,N,,CHEMBL619300,,
5347,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Expert,,1,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,80433,N,,CHEMBL619301,,
5348,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,80433,N,,CHEMBL619302,,
5349,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,80433,N,,CHEMBL619303,,
5350,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,80433,N,,CHEMBL619304,,
5351,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),80433,N,,CHEMBL857706,,
5352,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),80433,N,,CHEMBL619305,,
5353,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),80433,N,,CHEMBL619306,,
5354,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),80433,N,,CHEMBL619307,,
5355,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),80433,N,,CHEMBL619308,,
5356,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),80433,N,,CHEMBL619309,,
5357,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),80433,N,,CHEMBL619310,,
5358,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),80021,N,,CHEMBL619311,,
5359,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Compound was tested for the growth inhibition of A498 renal tumor cell line,80021,N,,CHEMBL619312,,
5360,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),80021,N,,CHEMBL619313,,
5361,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,In vitro inhibitory concentration against renal cancer cell line A498,80021,N,,CHEMBL619314,,
5362,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Cytotoxicity against A 498 tumor cell line,80021,N,,CHEMBL619959,,
5363,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,In vitro antitumor activity against A498 human cancer cell line,80021,N,,CHEMBL619960,,
5364,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),80021,N,,CHEMBL619961,,
5365,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Inhibitory dose required against A498 human tumor cell lines,80021,N,,CHEMBL619962,,
5366,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Anticancer activity against one renal cancer (A498 cell line),80021,N,,CHEMBL875586,,
5367,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,In vitro cytotoxicity against melanoma A498 cell line,80021,N,,CHEMBL619963,,
5368,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Compound was tested for growth inhibitory activity against A498 cell line,80021,N,,CHEMBL619964,,
5369,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Compound tested for growth inhibition of renal cancer cell line A498,80021,N,,CHEMBL620108,,
5370,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,80021,N,,CHEMBL620109,,
5371,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,80021,N,,CHEMBL620110,,
5372,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,80021,N,,CHEMBL620111,,
5373,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Tested for cytotoxicity against A498 cell lines in renal cancer,80021,N,,CHEMBL620112,,
5374,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,80021,N,,CHEMBL620113,,
5375,624.0,Homo sapiens,BAO_0000219,A498,1,F,Expert,,1,Cytotoxic effect on renal cancer lines A498,80021,N,,CHEMBL620114,,
5376,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,80021,N,,CHEMBL620115,,
5377,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),80021,N,,CHEMBL620116,,
5378,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,80021,N,,CHEMBL620117,,
5379,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,80021,N,,CHEMBL620118,,
5380,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Cytotoxicity against human kidney carcinoma cell lines A4982LM,80021,N,,CHEMBL620119,,
5381,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,80021,N,,CHEMBL620120,,
5382,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,80682,N,,CHEMBL620121,,
5383,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Antitumor activity against A549 human lung carcinoma cell line,80682,N,,CHEMBL620122,,
5384,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,80682,N,,CHEMBL620123,,
5385,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,80682,N,,CHEMBL620124,,
5386,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",80682,N,,CHEMBL620125,,
5387,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,80682,N,,CHEMBL620126,,
5388,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80682,N,,CHEMBL883027,,
5389,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro cytotoxic activity against human lung A549 cell line,80682,N,,CHEMBL620127,,
5390,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),80682,N,,CHEMBL620128,,
5391,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxic activity against human lung A549 cell line),80682,N,,CHEMBL620129,,
5392,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,80682,N,,CHEMBL620130,,
5393,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro cytotoxicity against human non small-cell-lung cell line A549.,80682,N,,CHEMBL620131,,
5394,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",80682,N,,CHEMBL620132,,
5395,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",80682,N,,CHEMBL620133,,
5396,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Inhibition of A549 human lung carcinoma cell proliferation,80682,N,,CHEMBL620134,,
5397,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibitory activity against A549 lung adenocarcinoma cell line,80682,N,,CHEMBL620135,,
5398,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,80682,N,,CHEMBL620136,,
5399,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,80682,N,,CHEMBL620137,,
5400,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,80682,N,,CHEMBL620268,,
5401,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80682,N,,CHEMBL620269,,
5402,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,80682,N,,CHEMBL620270,,
5403,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,80682,N,,CHEMBL620271,,
5404,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Inhibition of A549 cancer cell proliferation,80682,N,,CHEMBL620272,,
5405,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Inhibition of A549 cancer cell proliferation (Not tested),80682,N,,CHEMBL620273,,
5406,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,80682,N,,CHEMBL620274,,
5407,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,80682,N,,CHEMBL620275,,
5408,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Antiproliferative potency determined as inhibitory concentration against A549 cells,80682,N,,CHEMBL620276,,
5409,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,80682,N,,CHEMBL620277,,
5410,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity against Renal cell lines A549 was determined,80682,N,,CHEMBL620278,,
5411,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined in dog after a 3 mg/kg of oral dose,50588,N,,CHEMBL620279,,
5412,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined in dog after oral administration at 1 mg/kg,50588,N,,CHEMBL620280,,
5413,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,50588,N,,CHEMBL620281,,
5414,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,50588,N,,CHEMBL620282,,
5415,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),50588,N,,CHEMBL621134,,
5416,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),50588,N,,CHEMBL621135,,
5417,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),50588,N,,CHEMBL621136,,
5418,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),50588,N,,CHEMBL621137,,
5419,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under plasma concentration time curve in dog upon oral administration,50588,N,,CHEMBL621138,1969.0,
5420,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,50588,N,,CHEMBL875587,1969.0,
5421,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,50588,N,,CHEMBL621139,,
5422,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,50588,N,,CHEMBL621140,,
5423,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under the curve for the compound was obtained when tested in dog,50588,N,,CHEMBL621141,,
5424,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under the curve at a dose of 1 mg/kg,50588,N,,CHEMBL621142,,
5425,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under the curve at a dose of 1 mg/kg (oral),50588,N,,CHEMBL621143,,
5426,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under the curve at i.v. dose of 0.2 mg/kg,50588,N,,CHEMBL621144,,
5427,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was measured in dog after an iv dose of 1 mg/kg,50588,N,,CHEMBL621145,,
5428,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,50588,N,,CHEMBL621146,,
5429,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,50588,N,,CHEMBL622567,,
5430,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,50588,N,,CHEMBL622568,,
5431,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for area under the curve in dog blood.,50588,N,,CHEMBL622569,,
5432,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,50588,N,,CHEMBL622570,,
5433,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,AUC in dog after oral dose (1 mg/kg),50588,N,,CHEMBL622571,1969.0,
5434,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,50588,N,,CHEMBL622572,,
5435,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",50588,N,,CHEMBL622573,,
5436,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC after intravenous administration to dogs,50588,N,,CHEMBL622574,,
5437,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC after oral administration to dogs,50588,N,,CHEMBL622575,,
5438,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,50588,N,,CHEMBL622576,,
5439,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,50588,N,,CHEMBL622577,,
5440,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,50588,N,,CHEMBL622578,,
5441,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,50588,N,,CHEMBL622579,,
5442,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",50588,N,,CHEMBL622580,,
5443,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",50588,N,,CHEMBL622581,,
5444,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,N,,CHEMBL622582,,
5445,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,N,,CHEMBL622583,,
5446,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral AUCN in dog (dosed at 0.5 mpk iv ),50588,N,,CHEMBL622584,,
5447,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral AUCN in dog (dosed at 0.5 mpk iv ),50588,N,,CHEMBL622585,,
5448,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for oral bioavailability in dog; 90-100,50588,N,,CHEMBL622586,,
5449,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,50588,N,,CHEMBL623281,,
5450,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,50588,N,,CHEMBL623282,,
5451,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,PAPP (membrane permeability) in dog kidney cell monolayer assay,50588,N,,CHEMBL623283,,
5452,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral bioavailability in dog,50588,N,,CHEMBL623284,,
5453,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Bioavailability administered orally at a dose of 10 mg/kg to dogs,50588,N,,CHEMBL623285,,
5454,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Plasma protein binding towards dog plasma at 10 uM,50588,N,,CHEMBL623463,1969.0,
5455,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Plasma protein binding towards dog plasma at 100 uM,50588,N,,CHEMBL875952,1969.0,
5456,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog (dose 4 mg/kg p.o.),50588,N,,CHEMBL621705,,
5457,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,50588,N,,CHEMBL621706,,
5458,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,50588,N,,CHEMBL621707,,
5459,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dogs,50588,N,,CHEMBL621708,,
5460,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability,50588,N,,CHEMBL621709,,
5461,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (dose 10 mg/kg),50588,N,,CHEMBL621710,,
5462,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,50588,N,,CHEMBL621711,,
5463,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog (dose 10.0 mg/kg p.o.),50588,N,,CHEMBL621712,,
5464,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,50588,N,,CHEMBL621713,,
5465,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,50588,N,,CHEMBL621714,,
5466,,Mus sp.,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,U,,CHEMBL621715,,
5467,,Mus sp.,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,U,,CHEMBL623717,2107.0,
5468,,Mus sp.,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,U,,CHEMBL623718,2107.0,
5469,,Mus sp.,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,U,,CHEMBL623719,2107.0,
5470,,Mus sp.,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,U,,CHEMBL623720,,
5471,,Mus sp.,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,U,,CHEMBL623721,,
5472,,Mus sp.,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,U,,CHEMBL623722,2385.0,
5473,,Mus sp.,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,U,,CHEMBL623723,2385.0,
5474,,Mus sp.,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,U,,CHEMBL618543,2385.0,
5475,,Mus sp.,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,U,,CHEMBL618544,2106.0,
5476,,Mus sp.,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,U,,CHEMBL875155,2106.0,
5477,,Mus sp.,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,22224,U,,CHEMBL618545,,
5478,,Mus sp.,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,U,,CHEMBL618546,,
5479,,Mus sp.,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,U,,CHEMBL623529,,
5480,,Mus sp.,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,22224,U,,CHEMBL623530,,
5481,,Mus sp.,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,22224,U,,CHEMBL621764,,
5482,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),22224,U,,CHEMBL621765,,
5483,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),22224,U,,CHEMBL621766,2037.0,
5484,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),22224,U,,CHEMBL621767,1870.0,
5485,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),22224,U,,CHEMBL621768,,
5486,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),22224,U,,CHEMBL621769,2435.0,
5487,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),22224,U,,CHEMBL621770,,
5488,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),22224,U,,CHEMBL621771,2037.0,
5489,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),22224,U,,CHEMBL621772,1870.0,
5490,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),22224,U,,CHEMBL621773,,
5491,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),22224,U,,CHEMBL621774,2435.0,
5492,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for oral bioavailability in rats,22224,U,,CHEMBL621775,,
5493,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,22224,U,,CHEMBL621776,1969.0,
5494,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Half life period was evaluated in monkey,22224,U,,CHEMBL621777,,
5495,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Half-life in rhesus monkeys by intravenous administration of dose,22224,U,,CHEMBL875162,,
5496,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,50594,N,,CHEMBL621778,1969.0,
5497,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,AUC after intraperitoneal administration of 100 mg/kg in mice,50594,N,,CHEMBL621779,1969.0,
5498,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,AUC value was determined after oral administration,50594,N,,CHEMBL622479,1969.0,
5499,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,50594,N,,CHEMBL622480,,
5500,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),50594,N,,CHEMBL622481,,
5501,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve by ioral administration in mouse,50594,N,,CHEMBL622482,,
5502,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve by iv administration in mouse,50594,N,,CHEMBL622483,,
5503,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve at 0-8 hr in IRC mice after peroral administration,50594,N,,CHEMBL622484,,
5504,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,50594,N,,CHEMBL622641,,
5505,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,50594,N,,CHEMBL622642,,
5506,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,50594,N,,CHEMBL622643,,
5507,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,50594,N,,CHEMBL622644,,
5508,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,80433,N,,CHEMBL622645,,
5509,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,80433,N,,CHEMBL622646,,
5510,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),80433,N,,CHEMBL621238,,
5511,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),80433,N,,CHEMBL621239,,
5512,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),80433,N,,CHEMBL621240,,
5513,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),80433,N,,CHEMBL621241,,
5514,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),80433,N,,CHEMBL621242,,
5515,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),80433,N,,CHEMBL620350,,
5516,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,80433,N,,CHEMBL620351,,
5517,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,80433,N,,CHEMBL620352,,
5518,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),80433,N,,CHEMBL620353,,
5519,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),80433,N,,CHEMBL620354,,
5520,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),80433,N,,CHEMBL620355,,
5521,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),80433,N,,CHEMBL620356,,
5522,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),80433,N,,CHEMBL620357,,
5523,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),80433,N,,CHEMBL620358,,
5524,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Expert,,1,In vitro inhibition of human 8226 myeloma tumor cell line growth.,80433,N,,CHEMBL620359,,
5525,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,80433,N,,CHEMBL620360,,
5526,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Cytotoxicity of compound against 8226/DOX1V cells,80433,N,,CHEMBL620361,,
5527,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Cytotoxicity of compound against 8226/S cells,80433,N,,CHEMBL620362,,
5528,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Inhibitory concentration against 8226 myeloma cancer cell line,80433,N,,CHEMBL620363,,
5529,741.0,Homo sapiens,BAO_0000219,RPMI-8226,1,F,Intermediate,,1,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,80433,N,,CHEMBL620364,,
5530,854.0,Homo sapiens,BAO_0000219,833K,1,F,Intermediate,,1,Inhibition of cell growth was studied in human teratocarcinoma (833K).,80647,N,,CHEMBL620365,,
5531,854.0,Homo sapiens,BAO_0000219,833K,1,F,Intermediate,,1,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',80647,N,,CHEMBL620366,,
5532,854.0,Homo sapiens,BAO_0000219,833K,1,F,Expert,,1,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,80647,N,,CHEMBL620367,,
5533,854.0,Homo sapiens,BAO_0000219,833K,1,F,Intermediate,,1,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,80647,N,,CHEMBL620368,,
5534,,,BAO_0000019,,1,B,Autocuration,,0,Inhibitory activity against caspase-1,22226,U,,CHEMBL620369,,
5535,,Enterococcus faecalis,BAO_0000357,,1,B,Autocuration,,8,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,45,H,,CHEMBL620370,,
5536,705.0,Homo sapiens,BAO_0000219,8701-BC,1,F,Intermediate,,1,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,80648,N,,CHEMBL620371,,
5537,705.0,Homo sapiens,BAO_0000219,8701-BC,1,F,Intermediate,,1,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,80648,N,,CHEMBL620372,,
5538,,,BAO_0000019,,1,F,Intermediate,,0,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,22226,U,,CHEMBL876492,,
5539,,,BAO_0000019,,1,F,Intermediate,,0,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,22226,U,,CHEMBL620373,,
5540,,,BAO_0000019,,1,F,Intermediate,,0,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,22226,U,,CHEMBL620374,,
5541,,,BAO_0000019,,1,B,Autocuration,,0,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,22226,U,,CHEMBL620375,,
5542,,Streptococcus pyogenes,BAO_0000019,,1,F,Autocuration,,0,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,22226,U,,CHEMBL857902,,
5543,,Streptococcus pyogenes,BAO_0000019,,1,F,Autocuration,,0,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,22226,U,,CHEMBL620376,,
5544,,,BAO_0000357,,1,B,Autocuration,,8,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,11922,H,,CHEMBL620377,,
5545,324.0,Homo sapiens,BAO_0000219,KB ,1,F,Intermediate,,1,Tested for in vitro cytotoxic potency of compound in 9KB assay,81115,N,,CHEMBL620378,,
5546,324.0,Homo sapiens,BAO_0000219,KB ,1,A,Intermediate,,1,Tested for in vitro cytotoxic potency of compound in 9KB assay,81115,N,,CHEMBL620379,,
5547,,Homo sapiens,BAO_0000219,,1,F,Autocuration,,0,In vitro cytotoxicity of compound was tested against 9KB cells.,22226,U,,CHEMBL620380,,
5548,392.0,Rattus norvegicus,BAO_0000219,9L,1,F,Intermediate,,1,Cytotoxic concentration against 9L cells was determined on day 3,80653,N,,CHEMBL884006,,
5549,392.0,Rattus norvegicus,BAO_0000219,9L,1,F,Expert,,1,Tested in vitro for anticancer activity against 9L cells,80653,N,,CHEMBL620381,,
5550,392.0,Rattus norvegicus,BAO_0000219,9L,1,F,Expert,,1,Tested in vitro for anticancer activity against 9L cells; Not determined,80653,N,,CHEMBL620382,,
5551,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,80682,N,,CHEMBL620383,,
5552,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,80682,N,,CHEMBL876493,,
5553,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,80682,N,,CHEMBL620384,,
5554,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,80682,N,,CHEMBL620385,,
5555,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Cytotoxicity against human lung carcinoma A549 cell line,80682,N,,CHEMBL620386,,
5556,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,9,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,25,D,,CHEMBL620387,,
5557,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,9,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",25,D,,CHEMBL621404,,
5558,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,"In vitro growth inhibition of A549, lung carcinoma",80682,N,,CHEMBL621405,,
5559,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,"In vitro growth inhibition of A549, lung carcinoma.",80682,N,,CHEMBL621406,,
5560,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,80682,N,,CHEMBL621407,,
5561,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxic activity against human lung cancer A549 cell line was determined,80682,N,,CHEMBL621408,,
5562,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,80682,N,,CHEMBL885345,,
5563,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity concentration against human lung carcinoma A-549 cell line,80682,N,,CHEMBL621409,,
5564,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Cytotoxicity in A549 (human carcinoma) cell line.,80682,N,,CHEMBL876034,,
5565,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity on lung carcinoma (A-549) cell line,80682,N,,CHEMBL621410,,
5566,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,80682,N,,CHEMBL621411,,
5567,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Effective dose of compound against replication of A549 cell line was evaluated,80682,N,,CHEMBL621412,,
5568,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,80682,N,,CHEMBL621413,,
5569,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),80682,N,,CHEMBL621414,,
5570,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,80682,N,,CHEMBL621415,,
5571,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,The compound was evaluated for antiproliferative activity against A549 cell line,80682,N,,CHEMBL621416,,
5572,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,80682,N,,CHEMBL621417,,
5573,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Concentration required for growth inhibition of human lung carcinoma cell line A549,80682,N,,CHEMBL621418,,
5574,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,80682,N,,CHEMBL621419,,
5575,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Growth inhibition against A549 cell line was evaluated,80682,N,,CHEMBL621420,,
5576,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,80682,N,,CHEMBL875823,,
5577,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,80682,N,,CHEMBL621421,,
5578,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,80682,N,,CHEMBL621422,,
5579,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Chemosensitivity against DT-diaphorase rich A549 cell lines,80682,N,,CHEMBL884014,,
5580,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,80682,N,,CHEMBL621423,,
5581,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro cytotoxicity against human A549 (lung cancer) cell line.,80682,N,,CHEMBL621424,,
5582,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro antitumor activity against A549 (lung) human tumor cell lines.,80682,N,,CHEMBL621425,,
5583,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro cytotoxic activity against human lung carcinoma A549 cell line,80682,N,,CHEMBL621426,,
5584,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,80682,N,,CHEMBL621427,,
5585,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,80682,N,,CHEMBL621428,,
5586,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Tested against A549 lung carcinoma in the sulforhodamine B assay.,80682,N,,CHEMBL621429,,
5587,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),80682,N,,CHEMBL621430,,
5588,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,80682,N,,CHEMBL621431,,
5589,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,80682,N,,CHEMBL621432,,
5590,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,80682,N,,CHEMBL621433,,
5591,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,80682,N,,CHEMBL875824,,
5592,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,80682,N,,CHEMBL621434,,
5593,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,80682,N,,CHEMBL621435,,
5594,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,80682,N,,CHEMBL621436,,
5595,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,80682,N,,CHEMBL621437,,
5596,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was tested for the growth inhibition of A549 lung tumor cell line,80682,N,,CHEMBL621438,,
5597,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Growth inhibition of human non-small-lung carcinoma (A549) cell line,80682,N,,CHEMBL621439,,
5598,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,80682,N,,CHEMBL621440,,
5599,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (conscious),50588,N,,CHEMBL621441,,
5600,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for the oral bioavailability after oral administration in dog.,50588,N,,CHEMBL621442,,
5601,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,50588,N,,CHEMBL621443,,
5602,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL621444,,
5603,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL625133,,
5604,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL625134,,
5605,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (fasted),50588,N,,CHEMBL625135,,
5606,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,50588,N,,CHEMBL625136,,
5607,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL625137,,
5608,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL625138,,
5609,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Percent bioavailability in dog,50588,N,,CHEMBL625139,,
5610,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,50588,N,,CHEMBL872264,,
5611,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL625140,,
5612,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,The compound was evaluated for bioavailability in dogs; 34-44,50588,N,,CHEMBL624436,,
5613,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog (dose 4 mg/kg p.o.),50588,N,,CHEMBL624437,,
5614,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL872261,,
5615,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,8 hour trough Blood level in dog was measured after administration of compound,50588,N,,CHEMBL624438,,
5616,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,50588,N,,CHEMBL624439,1969.0,
5617,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,C24 after oral administration at 5 mg/kg,50588,N,,CHEMBL624440,,
5618,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Clearance after oral and iv dosing in dogs,50588,N,,CHEMBL624441,,
5619,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Clearance of the drug was measured in the plasma of dog,50588,N,,CHEMBL624442,1969.0,
5620,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,50588,N,,CHEMBL624443,,
5621,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,50588,N,,CHEMBL624444,,
5622,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance of compound was determined in dogs,50588,N,,CHEMBL624445,,
5623,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance on i.v. administration of 2 mg/kg was measured in dog,50588,N,,CHEMBL624446,,
5624,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,50588,N,,CHEMBL624447,,
5625,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in dog was determined,50588,N,,CHEMBL624448,,
5626,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,50588,N,,CHEMBL624449,,
5627,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in dog after administration of 0.25 mg/kg iv,50588,N,,CHEMBL624450,,
5628,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in dog after administration of 1 mg/kg iv,50588,N,,CHEMBL875942,,
5629,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in dogs,50588,N,,CHEMBL624451,,
5630,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,50588,N,,CHEMBL624452,,
5631,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,50588,N,,CHEMBL624453,,
5632,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance after 15 mg/kg iv dose in Dogs,50588,N,,CHEMBL624454,,
5633,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance after 30 mg/kg po dose in Dogs,50588,N,,CHEMBL624455,,
5634,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma administration to dogs,50588,N,,CHEMBL624456,,
5635,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was determined,50588,N,,CHEMBL624457,,
5636,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,50588,N,,CHEMBL624458,,
5637,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,50588,N,,CHEMBL624459,,
5638,,Homo sapiens,BAO_0000251,,1,A,Intermediate,In vitro,2,Intrinsic clearance in human liver microsomes,102164,S,,CHEMBL624460,2107.0,
5639,,Homo sapiens,BAO_0000251,,1,A,Intermediate,In vitro,2,Intrinsic clearance in human liver microsomes,102164,S,,CHEMBL624461,2107.0,
5640,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,50588,N,,CHEMBL875943,,
5641,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,50588,N,,CHEMBL624462,,
5642,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance in dog (dose 1 mg/kg i.v.),50588,N,,CHEMBL624463,,
5643,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,50588,N,,CHEMBL624464,,
5644,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),50588,N,,CHEMBL624465,,
5645,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance after peroral administration at 10 mpk in dog,50588,N,,CHEMBL624466,,
5646,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance after peroral administration at 5 mpk in dog,50588,N,,CHEMBL624467,,
5647,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance after peroral administration at 5 mg/kg in dog,50588,N,,CHEMBL624468,,
5648,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was measured in dog,50588,N,,CHEMBL624469,,
5649,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was measured in dog,50588,N,,CHEMBL624470,,
5650,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,50588,N,,CHEMBL624471,,
5651,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Total clearance was determined after 0.1 mg/kg iv administration in dog,50588,N,,CHEMBL624472,,
5652,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,50588,N,,CHEMBL622775,,
5653,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,50588,N,,CHEMBL622776,,
5654,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,50588,N,,CHEMBL622777,,
5655,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance after peroral administration of 0.2 mg/kg in dog was determined,50588,N,,CHEMBL622778,,
5656,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance by intravenous administration of 1.2 mg/kg in dog,50588,N,,CHEMBL622779,,
5657,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance by iv administration in dogs at a dose of 1 mg/kg,50588,N,,CHEMBL622780,,
5658,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance value was evaluated in dog plasma,50588,N,,CHEMBL622781,1969.0,
5659,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,50588,N,,CHEMBL622782,,
5660,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for plasma clearance in dog,50588,N,,CHEMBL622783,1969.0,
5661,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (Plasma clearance) was measured in dog,50588,N,,CHEMBL622784,,
5662,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve when injected perorally in mice at a dose of 50 mg/kg,50594,N,,CHEMBL622785,,
5663,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,50594,N,,CHEMBL622786,,
5664,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve value in mouse at a dose of 10 mg/kg,50594,N,,CHEMBL622787,,
5665,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,50594,N,,CHEMBL875949,,
5666,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,50594,N,,CHEMBL622788,,
5667,,Mus musculus,BAO_0000218,,1,F,Intermediate,,1,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,50594,N,,CHEMBL622789,,
5668,,Mus musculus,BAO_0000218,,1,F,Intermediate,,1,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,50594,N,,CHEMBL622790,,
5669,,Mus musculus,BAO_0000218,,1,F,Intermediate,,1,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,50594,N,,CHEMBL622791,,
5670,,Mus musculus,BAO_0000218,,1,F,Intermediate,,1,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,50594,N,,CHEMBL622792,,
5671,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,50594,N,,CHEMBL622793,,
5672,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined for the compound at 24 mg/Kg,50594,N,,CHEMBL622794,,
5673,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined for the compound at 40 mg/Kg,50594,N,,CHEMBL622795,,
5674,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined for the compound at 5 mg/Kg,50594,N,,CHEMBL621803,,
5675,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve for the compound is obtained at dose 25 mg/kg,50594,N,,CHEMBL621804,,
5676,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve for the compound was obtained when tested in mouse,50594,N,,CHEMBL621805,,
5677,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,50594,N,,CHEMBL621806,,
5678,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,50594,N,,CHEMBL621807,,
5679,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,50594,N,,CHEMBL621808,,
5680,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,50594,N,,CHEMBL621809,,
5681,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),50594,N,,CHEMBL621810,,
5682,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,50594,N,,CHEMBL875164,,
5683,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,50594,N,,CHEMBL621811,,
5684,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Compound was evaluated for the pharmacokinetic parameter, area under curve",50594,N,,CHEMBL621812,,
5685,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),50594,N,,CHEMBL621813,,
5686,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),50594,N,,CHEMBL621814,,
5687,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,50594,N,,CHEMBL621815,,
5688,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,50594,N,,CHEMBL621816,,
5689,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,50594,N,,CHEMBL621817,,
5690,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,50594,N,,CHEMBL621818,,
5691,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,50594,N,,CHEMBL621819,,
5692,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,50594,N,,CHEMBL621820,,
5693,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,50594,N,,CHEMBL621821,,
5694,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,50594,N,,CHEMBL621822,,
5695,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,50594,N,,CHEMBL619474,,
5696,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",50594,N,,CHEMBL619475,,
5697,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",50594,N,,CHEMBL619476,,
5698,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",50594,N,,CHEMBL619477,,
5699,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",50594,N,,CHEMBL619478,,
5700,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",50594,N,,CHEMBL619479,,
5701,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",50594,N,,CHEMBL619480,,
5702,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,50594,N,,CHEMBL619481,,
5703,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,50594,N,,CHEMBL619482,,
5704,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was evaluated in mice after intravenous administration,50594,N,,CHEMBL619483,,
5705,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was evaluated in mice after oral administration,50594,N,,CHEMBL619484,,
5706,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,50594,N,,CHEMBL619485,1969.0,
5707,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,AUC total value at a dose of 10 mg/kg peroral administration in mice.,50594,N,,CHEMBL619486,1969.0,
5708,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),50594,N,,CHEMBL619487,,
5709,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,AUMC after intraperitoneal administration of 100 mg/kg in mice,50594,N,,CHEMBL619488,,
5710,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,50594,N,,CHEMBL620106,178.0,
5711,392.0,,BAO_0000219,9L,1,F,Intermediate,,1,The compound was tested in vitro for anticancer activity against 9L cells,80653,N,,CHEMBL620107,,
5712,,Rattus norvegicus,BAO_0000019,,1,F,Autocuration,,0,Anti proliferation activity determined; Weak effect,22226,U,,CHEMBL620283,,
5713,,Rattus norvegicus,BAO_0000219,,1,F,Autocuration,,0,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,22226,U,,CHEMBL875176,,
5714,,Rattus norvegicus,BAO_0000219,,1,F,Autocuration,,0,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,22226,U,,CHEMBL620284,,
5715,,Rattus norvegicus,BAO_0000219,,1,F,Autocuration,,0,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,22226,U,,CHEMBL623515,,
5716,,Mus musculus,BAO_0000019,,1,F,Autocuration,,0,The cytotoxic activity was in vitro tested by 9PS assay method,22226,U,,CHEMBL623516,,
5717,,Mus musculus,BAO_0000019,,1,F,Autocuration,,0,The cytotoxic activity was in vitro tested by 9PS assay method.,22226,U,,CHEMBL623517,,
5718,,,BAO_0000019,,1,A,Autocuration,,0,Partition coefficient (logD6.5),22224,U,,CHEMBL857878,,
5719,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,81034,N,,CHEMBL623518,,
5720,455.0,Homo sapiens,BAO_0000219,A-375,1,F,Intermediate,,1,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),80018,N,,CHEMBL624195,,
5721,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,1,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,80852,N,,CHEMBL624196,,
5722,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,9,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,9,D,,CHEMBL624197,,
5723,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,80021,N,,CHEMBL624198,,
5724,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,in vitro cytotoxicity against A 498 cancer cell line,80021,N,,CHEMBL621287,,
5725,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,In vitro cytotoxic activity against renal (A 498) cancer cell line.,80021,N,,CHEMBL621288,,
5726,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Cytotoxic activity against A 498 renal cancer cell lines.,80021,N,,CHEMBL876496,,
5727,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,80021,N,,CHEMBL621289,,
5728,,Staphylococcus aureus,BAO_0000019,,1,F,Autocuration,,0,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,22226,U,,CHEMBL621290,,
5729,,Staphylococcus aureus,BAO_0000019,,1,F,Autocuration,,0,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,22226,U,,CHEMBL621291,,
5730,,Staphylococcus aureus,BAO_0000019,,1,F,Autocuration,,0,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,22226,U,,CHEMBL621292,,
5731,,Staphylococcus aureus,BAO_0000019,,1,F,Autocuration,,0,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,22226,U,,CHEMBL621293,,
5732,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibitory concentration required against A 549 lung cancer cell line,80682,N,,CHEMBL621294,,
5733,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,80682,N,,CHEMBL621295,,
5734,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,80682,N,,CHEMBL884007,,
5735,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxicity against lung cancer A 549 cell lines,80682,N,,CHEMBL621296,,
5736,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was tested for its cytotoxicity against A 549 cell line,80682,N,,CHEMBL621297,,
5737,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",80682,N,,CHEMBL839828,,
5738,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",80682,N,,CHEMBL620397,,
5739,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,80682,N,,CHEMBL620398,,
5740,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,80682,N,,CHEMBL620399,,
5741,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro inhibition of A549 (human lung cancer) cell growth.,80682,N,,CHEMBL620400,,
5742,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,80682,N,,CHEMBL620401,,
5743,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,80682,N,,CHEMBL620402,,
5744,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),80682,N,,CHEMBL620403,,
5745,,,BAO_0000218,,1,F,Autocuration,,0,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,22226,U,,CHEMBL620404,,
5746,,,BAO_0000218,,1,F,Autocuration,In vivo,4,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,104694,H,,CHEMBL620405,,
5747,,,BAO_0000218,,1,F,Autocuration,In vivo,4,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,104694,H,,CHEMBL620406,,
5748,,,BAO_0000218,,1,F,Autocuration,In vivo,4,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,104694,H,,CHEMBL620407,,
5749,,,BAO_0000218,,1,F,Autocuration,In vivo,4,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,104694,H,,CHEMBL620408,,
5750,,,BAO_0000218,,1,F,Autocuration,In vivo,4,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,104694,H,,CHEMBL620409,,
5751,624.0,Homo sapiens,BAO_0000219,A498,1,F,Expert,,1,Inhibition of A-498 human Renal cell proliferation,80021,N,,CHEMBL620410,,
5752,,Rattus norvegicus,BAO_0000019,,1,F,Autocuration,,0,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",22226,U,,CHEMBL620411,,
5753,,Rattus norvegicus,BAO_0000019,,1,F,Autocuration,,0,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",22226,U,,CHEMBL620412,,
5754,,Rattus norvegicus,BAO_0000019,,1,F,Autocuration,,0,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",22226,U,,CHEMBL876596,,
5755,622.0,Homo sapiens,BAO_0000219,A 172,1,F,Expert,,1,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,80012,N,,CHEMBL620413,,
5756,622.0,Homo sapiens,BAO_0000219,A 172,1,F,Intermediate,,1,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80012,N,,CHEMBL620414,,
5757,622.0,Homo sapiens,BAO_0000219,A 172,1,F,Intermediate,,1,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80012,N,,CHEMBL620415,,
5758,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,80682,N,,CHEMBL620416,,
5759,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,80682,N,,CHEMBL620417,,
5760,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Cytotoxic activity evaluated against A549 tumor cells,80682,N,,CHEMBL620418,,
5761,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,80682,N,,CHEMBL620419,,
5762,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,80682,N,,CHEMBL620420,,
5763,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,80682,N,,CHEMBL620421,,
5764,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,80682,N,,CHEMBL620422,,
5765,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity of compound against A549 cell line,80682,N,,CHEMBL620423,,
5766,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Cytotoxicity against human lung cell carcinoma A549 cell line,80682,N,,CHEMBL620424,,
5767,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,80682,N,,CHEMBL620425,,
5768,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,80682,N,,CHEMBL620426,,
5769,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,80682,N,,CHEMBL620427,,
5770,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,80682,N,,CHEMBL620428,,
5771,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,80682,N,,CHEMBL620429,,
5772,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,80682,N,,CHEMBL620430,,
5773,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,80682,N,,CHEMBL839887,,
5774,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,80682,N,,CHEMBL620431,,
5775,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,80682,N,,CHEMBL884010,,
5776,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxicity against A549 (human lung cancer),80682,N,,CHEMBL620538,,
5777,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,80682,N,,CHEMBL620539,,
5778,646.0,Homo sapiens,BAO_0000218,A549,1,F,Intermediate,,1,In vivo antiproliferative activity against A549 cell line,80682,N,,CHEMBL623373,,
5779,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibition of non-small-cell lung adenocarcinoma (A549),80682,N,,CHEMBL623374,,
5780,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,80682,N,,CHEMBL623375,,
5781,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,80682,N,,CHEMBL623376,,
5782,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),80682,N,,CHEMBL623377,,
5783,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,80682,N,,CHEMBL623378,,
5784,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibitory activity of compound against human A549 lung carcinoma cell line.,80682,N,,CHEMBL623379,,
5785,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibitory activity against A549 lung cancer cell line,80682,N,,CHEMBL623380,,
5786,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,80682,N,,CHEMBL623381,,
5787,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,80682,N,,CHEMBL623382,,
5788,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibitory concentration against A549 (lung cancer) cell line,80682,N,,CHEMBL623383,,
5789,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,80682,N,,CHEMBL623384,,
5790,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,80682,N,,CHEMBL623385,,
5791,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Activity against A549 cancer cell line.,80682,N,,CHEMBL623386,,
5792,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,The compound was evaluated for cytotoxicity against A549 cell line,80682,N,,CHEMBL884105,,
5793,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,80682,N,,CHEMBL623387,,
5794,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,80682,N,,CHEMBL621568,,
5795,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Growth inhibitory activity was measured for human A549 tumor cell line.,80682,N,,CHEMBL621569,,
5796,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibitory activity against A549 lung cancer cell line,80682,N,,CHEMBL621570,,
5797,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibitory activity against A549 cell line; inactive,80682,N,,CHEMBL621571,,
5798,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,80682,N,,CHEMBL621572,,
5799,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,80682,N,,CHEMBL621573,,
5800,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,80682,N,,CHEMBL621574,,
5801,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),80682,N,,CHEMBL621575,,
5802,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),80682,N,,CHEMBL621576,,
5803,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),80682,N,,CHEMBL621577,,
5804,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),80682,N,,CHEMBL621578,,
5805,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),80682,N,,CHEMBL621579,,
5806,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,80682,N,,CHEMBL621580,,
5807,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance (in vivo) in mongrel dogs was determined,50588,N,,CHEMBL621581,,
5808,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was measured in dog,50588,N,,CHEMBL621582,,
5809,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,50588,N,,CHEMBL621583,,
5810,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,50588,N,,CHEMBL621584,,
5811,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for plasma clearance in dog,50588,N,,CHEMBL621585,1969.0,
5812,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,The compound was tested for clearance in dog plasma.,50588,N,,CHEMBL621586,,
5813,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",50588,N,,CHEMBL875835,,
5814,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,50588,N,,CHEMBL621587,,
5815,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),50588,N,,CHEMBL621588,1969.0,
5816,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vitro,1,In vitro clearance in dog liver microsomes,50588,N,,CHEMBL621589,2107.0,
5817,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,50588,N,,CHEMBL621590,,
5818,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,50588,N,,CHEMBL621591,,
5819,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in dog,50588,N,,CHEMBL621592,,
5820,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance rate in dog,50588,N,,CHEMBL621593,,
5821,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,50588,N,,CHEMBL621594,1969.0,
5822,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance in dogs,50588,N,,CHEMBL621595,,
5823,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in dogs,50588,N,,CHEMBL621596,,
5824,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was determined,50588,N,,CHEMBL621597,,
5825,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Lower clearance in dog (i.v.) at 0.5 mpk,50588,N,,CHEMBL621598,,
5826,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in Beagle dogs,50588,N,,CHEMBL621599,,
5827,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance (Clp) in dog,50588,N,,CHEMBL875836,,
5828,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,50588,N,,CHEMBL621600,,
5829,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance (pharmacokinetic parameter) in dog was determined,50588,N,,CHEMBL621601,,
5830,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,50588,N,,CHEMBL618474,,
5831,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance of compound was determined in dog,50588,N,,CHEMBL618475,,
5832,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance after intravenous administration of 1 mg/kg in dog,50588,N,,CHEMBL624524,,
5833,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,50588,N,,CHEMBL624525,,
5834,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in dog was determined,50588,N,,CHEMBL624526,,
5835,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was calculated in dog,50588,N,,CHEMBL624527,,
5836,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance at the dose of 2 mg/kg in dog,50588,N,,CHEMBL624528,,
5837,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in dog,50588,N,,CHEMBL624529,,
5838,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in dog,50588,N,,CHEMBL624530,,
5839,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in dog; Unable to calculate,50588,N,,CHEMBL624531,,
5840,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rhesus monkey,50588,N,,CHEMBL624532,,
5841,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,N,,CHEMBL624533,,
5842,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,N,,CHEMBL624534,,
5843,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,N,,CHEMBL624535,,
5844,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was evaluated in dog,50588,N,,CHEMBL624536,,
5845,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was evaluated in dog; Not tested,50588,N,,CHEMBL624537,,
5846,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was evaluated in rhesus,50588,N,,CHEMBL624538,,
5847,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was evaluated in rhesus; Not tested,50588,N,,CHEMBL624539,,
5848,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,50588,N,,CHEMBL624540,,
5849,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50588,N,,CHEMBL624541,,
5850,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,50588,N,,CHEMBL624542,,
5851,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,N,,CHEMBL624543,,
5852,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance value at a dose of 0.2 mg/kg i.v.,50588,N,,CHEMBL624544,,
5853,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,50588,N,,CHEMBL624545,1969.0,
5854,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax after oral dose of compound at 3 mg/kg in dogs,50588,N,,CHEMBL624546,,
5855,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax after single intravenous bolus of 1 mg/kg in dogs,50588,N,,CHEMBL875957,,
5856,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,50588,N,,CHEMBL624547,,
5857,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,50588,N,,CHEMBL624548,,
5858,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in dog after administration of 1 mg/kg iv,50588,N,,CHEMBL624549,,
5859,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,50588,N,,CHEMBL624550,1969.0,
5860,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax on p.o. administration of 10 mg/kg was measured in dog,50588,N,,CHEMBL621613,,
5861,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax was determine after peroral administration at 10 mpk in dog,50588,N,,CHEMBL621614,,
5862,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax was determine after peroral administration at 5 mpk in dog,50588,N,,CHEMBL623431,,
5863,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax was determine after peroral administration at 5 mg/kg in dog,50588,N,,CHEMBL623432,,
5864,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax after 0.3 mg/kg po administration in dog,50588,N,,CHEMBL623433,,
5865,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax after peroral administration in dogs at 2.4 uM/kg,50588,N,,CHEMBL623434,,
5866,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in dog after oral administration at 1 mg/kg,50588,N,,CHEMBL623435,,
5867,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,50588,N,,CHEMBL623436,,
5868,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax upon oral administration in male Beagle dog at 10 mg/kg,50588,N,,CHEMBL875958,,
5869,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value after 15 mg/kg iv dose in Dogs,50588,N,,CHEMBL623437,,
5870,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL623438,178.0,
5871,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL623439,178.0,
5872,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,N,,CHEMBL623440,10000001.0,
5873,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL623441,10000001.0,
5874,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL623442,10000001.0,
5875,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,N,,CHEMBL623469,,
5876,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL623470,,
5877,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL623471,,
5878,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,N,,CHEMBL623472,948.0,
5879,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL623473,948.0,
5880,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL623474,948.0,
5881,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,N,,CHEMBL623475,2113.0,
5882,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL623476,2113.0,
5883,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL623477,2113.0,
5884,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL621896,160.0,
5885,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,N,,CHEMBL621897,160.0,
5886,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL621898,160.0,
5887,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,N,,CHEMBL621899,2107.0,
5888,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL621900,2107.0,
5889,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL621901,2107.0,
5890,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,N,,CHEMBL621902,2048.0,
5891,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL621903,2048.0,
5892,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL622587,2048.0,
5893,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,N,,CHEMBL620285,2385.0,
5894,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL875285,2385.0,
5895,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL620286,2385.0,
5896,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,N,,CHEMBL620287,,
5897,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL620288,,
5898,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL620289,,
5899,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,N,,CHEMBL620290,160.0,
5900,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL620291,160.0,
5901,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL620292,160.0,
5902,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,N,,CHEMBL620293,2106.0,
5903,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL620294,2106.0,
5904,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL618614,2106.0,
5905,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,N,,CHEMBL618615,945.0,
5906,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL618616,945.0,
5907,622.0,Homo sapiens,BAO_0000219,A 172,1,F,Expert,,1,Cytotoxicity against A-172 human tumor cell lines,80012,N,,CHEMBL618617,,
5908,622.0,Homo sapiens,BAO_0000219,A 172,1,F,Intermediate,,1,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,80012,N,,CHEMBL618618,,
5909,623.0,Homo sapiens,BAO_0000219,A204,1,F,Intermediate,,1,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,80014,N,,CHEMBL618619,,
5910,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Tested for antiproliferative activity against A-2780 tumoral cell line,81034,N,,CHEMBL618620,,
5911,455.0,Homo sapiens,BAO_0000219,A-375,1,F,Intermediate,,1,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,80018,N,,CHEMBL618621,,
5912,455.0,Homo sapiens,BAO_0000219,A-375,1,F,Intermediate,,1,Tested in vitro against A-375 cell line human melanoma,80018,N,,CHEMBL618622,,
5913,797.0,Homo sapiens,BAO_0000219,A-427,1,F,Expert,,1,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,80019,N,,CHEMBL618623,,
5914,797.0,Homo sapiens,BAO_0000219,A-427,1,F,Intermediate,,1,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80019,N,,CHEMBL618624,,
5915,797.0,Homo sapiens,BAO_0000219,A-427,1,F,Expert,,1,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,80019,N,,CHEMBL618625,,
5916,797.0,Homo sapiens,BAO_0000219,A-427,1,F,Intermediate,,1,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,80019,N,,CHEMBL618626,,
5917,797.0,Homo sapiens,BAO_0000219,A-427,1,F,Intermediate,,1,Antitumor activity on A-427 lung carcinoma cell lines,80019,N,,CHEMBL618627,,
5918,797.0,Homo sapiens,BAO_0000219,A-427,1,F,Intermediate,,1,Cytotoxic activity against human A-427 lung tumor cell line,80019,N,,CHEMBL618628,,
5919,797.0,Homo sapiens,BAO_0000219,A-427,1,F,Expert,,1,In vitro antitumor effects against human A-427 cell lines.,80019,N,,CHEMBL618629,,
5920,797.0,Homo sapiens,BAO_0000219,A-427,1,F,Expert,,1,In vitro inhibition of A-427 (human lung cancer) cell growth.,80019,N,,CHEMBL618630,,
5921,797.0,Homo sapiens,BAO_0000219,A-427,1,F,Intermediate,,1,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,80019,N,,CHEMBL618631,,
5922,797.0,Homo sapiens,BAO_0000219,A-427,1,F,Intermediate,,1,Cytotoxic activity of compound against A-427 lung human tumor cell line,80019,N,,CHEMBL618632,,
5923,500.0,Homo sapiens,BAO_0000219,A-431,1,F,Expert,,1,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,80852,N,,CHEMBL618633,,
5924,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,80021,N,,CHEMBL619315,,
5925,624.0,Homo sapiens,BAO_0000219,A498,1,F,Expert,,1,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,80021,N,,CHEMBL619316,,
5926,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Cytotoxicity against human kidney carcinoma A-498cell lines,80021,N,,CHEMBL619317,,
5927,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,80021,N,,CHEMBL619318,,
5928,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,80021,N,,CHEMBL619319,,
5929,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Antitumor cytotoxic activity against A-498 cell line was determined,80021,N,,CHEMBL619739,,
5930,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,80021,N,,CHEMBL619740,,
5931,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,80021,N,,CHEMBL883158,,
5932,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,80021,N,,CHEMBL884012,,
5933,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,In vitro inhibitory activity against A-498 ovarian cancer cell lines,80021,N,,CHEMBL619741,,
5934,624.0,Homo sapiens,BAO_0000219,A498,1,F,Intermediate,,1,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",80021,N,,CHEMBL619742,,
5935,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibition of growth lung non-small cell carcinoma A-549 cell line,80682,N,,CHEMBL876610,,
5936,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,80682,N,,CHEMBL619743,,
5937,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro antiproliferative activity against human A-549 NSCL cell line,80682,N,,CHEMBL619744,,
5938,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,80682,N,,CHEMBL619745,,
5939,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,80682,N,,CHEMBL619746,,
5940,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,80682,N,,CHEMBL619747,,
5941,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,80682,N,,CHEMBL619748,,
5942,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,80682,N,,CHEMBL619749,,
5943,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,80682,N,,CHEMBL619750,,
5944,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,80682,N,,CHEMBL624014,,
5945,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,80682,N,,CHEMBL624015,,
5946,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,80682,N,,CHEMBL885344,,
5947,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,80682,N,,CHEMBL623224,,
5948,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxic activity against A-549 cell line,80682,N,,CHEMBL623225,,
5949,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,80682,N,,CHEMBL622698,,
5950,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,80682,N,,CHEMBL622699,,
5951,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",80682,N,,CHEMBL622700,,
5952,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),80682,N,,CHEMBL622701,,
5953,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),80682,N,,CHEMBL622702,,
5954,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxic activity against human lung carcinoma (A-549) cell line,80682,N,,CHEMBL622703,,
5955,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Cytotoxic activity towards A-549 cells,80682,N,,CHEMBL622704,,
5956,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,"In vitro percent inhibition of A549, lung carcinoma.",80682,N,,CHEMBL622705,,
5957,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,"In vitro percent inhibition of A549, lung carcinoma",80682,N,,CHEMBL622706,,
5958,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,"In vitro percent inhibition of A549, lung carcinoma.",80682,N,,CHEMBL622707,,
5959,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",80682,N,,CHEMBL622708,,
5960,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,80682,N,,CHEMBL622709,,
5961,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,80682,N,,CHEMBL622710,,
5962,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,80682,N,,CHEMBL622711,,
5963,646.0,Homo sapiens,BAO_0000218,A549,1,F,Intermediate,,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,N,,CHEMBL622712,,
5964,646.0,Homo sapiens,BAO_0000218,A549,1,F,Intermediate,,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,N,,CHEMBL622713,,
5965,646.0,Homo sapiens,BAO_0000218,A549,1,F,Intermediate,,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,N,,CHEMBL622714,,
5966,646.0,Homo sapiens,BAO_0000218,A549,1,F,Intermediate,,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,N,,CHEMBL622715,,
5967,646.0,Homo sapiens,BAO_0000218,A549,1,F,Intermediate,,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",80682,N,,CHEMBL622716,,
5968,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",80682,N,,CHEMBL622717,,
5969,646.0,Homo sapiens,BAO_0000218,A549,1,F,Intermediate,,1,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),80682,N,,CHEMBL622718,,
5970,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,80682,N,,CHEMBL622719,,
5971,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,80682,N,,CHEMBL622720,,
5972,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,80682,N,,CHEMBL622721,,
5973,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,80682,N,,CHEMBL622722,,
5974,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,80682,N,,CHEMBL876030,,
5975,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",80682,N,,CHEMBL620206,,
5976,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,80682,N,,CHEMBL620207,,
5977,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,80682,N,,CHEMBL620208,,
5978,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,80682,N,,CHEMBL620209,,
5979,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,80682,N,,CHEMBL620210,,
5980,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,80682,N,,CHEMBL621639,,
5981,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,80682,N,,CHEMBL621640,,
5982,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,80682,N,,CHEMBL621641,,
5983,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,80682,N,,CHEMBL621642,,
5984,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,80682,N,,CHEMBL621643,,
5985,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,80682,N,,CHEMBL621644,,
5986,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,80682,N,,CHEMBL621645,,
5987,646.0,Mus musculus,BAO_0000219,A549,1,F,Intermediate,,1,In vitro antiproliferative activity against A549 cell line,80682,N,,CHEMBL621646,,
5988,646.0,,BAO_0000219,A549,1,F,Intermediate,,1,Synergism with indomethacin in A549 cells,80682,N,,CHEMBL621647,,
5989,646.0,,BAO_0000219,A549,1,F,Intermediate,,1,Synergism with tolmetin in A549 cells,80682,N,,CHEMBL621648,,
5990,646.0,,BAO_0000219,A549,1,F,Intermediate,,1,Synergism with sulindac in A549 cells,80682,N,,CHEMBL621649,,
5991,646.0,,BAO_0000219,A549,1,F,Intermediate,,1,Antagonism of indomethacin in A549 cells,80682,N,,CHEMBL621650,,
5992,646.0,,BAO_0000219,A549,1,F,Intermediate,,1,Antagonism of sulindac in A549 cells,80682,N,,CHEMBL621651,,
5993,646.0,,BAO_0000219,A549,1,F,Intermediate,,1,Antagonism of tolmetin in A549 cells,80682,N,,CHEMBL621652,,
5994,646.0,,BAO_0000219,A549,1,F,Intermediate,,1,Synergism with indomethacin in A549 cells,80682,N,,CHEMBL621653,,
5995,646.0,,BAO_0000219,A549,1,F,Intermediate,,1,Synergism with sulindac in A549 cells,80682,N,,CHEMBL621654,,
5996,646.0,,BAO_0000219,A549,1,F,Intermediate,,1,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,80682,N,,CHEMBL621655,,
5997,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value after 30 mg/kg po dose in Dogs,50588,N,,CHEMBL621656,,
5998,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),50588,N,,CHEMBL621657,,
5999,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,50588,N,,CHEMBL621658,,
6000,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),50588,N,,CHEMBL621659,,
6001,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,50588,N,,CHEMBL621660,,
6002,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value after administration of 4 mg/Kg oral dose in dog,50588,N,,CHEMBL621661,,
6003,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value in dog,50588,N,,CHEMBL621662,,
6004,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value in dogs after oral administration at 1 mg/kg,50588,N,,CHEMBL621663,,
6005,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,50588,N,,CHEMBL621664,,
6006,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,50588,N,,CHEMBL621665,1969.0,
6007,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,50588,N,,CHEMBL621666,1969.0,
6008,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Concentration maxima after oral dosing in dogs,50588,N,,CHEMBL621667,,
6009,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Concentration maxima after oral dosing in dogs; not available,50588,N,,CHEMBL876738,,
6010,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Concentration maxima after oral dosing in dogs; not available,50588,N,,CHEMBL621668,,
6011,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,50588,N,,CHEMBL621669,,
6012,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,50588,N,,CHEMBL621670,,
6013,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo maximal concentration was calculated at 1 mg/kg in dog,50588,N,,CHEMBL621671,,
6014,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,50588,N,,CHEMBL622360,,
6015,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,50588,N,,CHEMBL622361,,
6016,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in dog plasma after oral dose (1 mg/kg),50588,N,,CHEMBL622362,1969.0,
6017,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,50588,N,,CHEMBL622363,1969.0,
6018,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal plasma concentration at a dose of 1 mg/kg,50588,N,,CHEMBL622364,1969.0,
6019,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal plasma concentration at a dose of 1 mg/kg (oral),50588,N,,CHEMBL622365,1969.0,
6020,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,50588,N,,CHEMBL622533,1969.0,
6021,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration of compound in dog was evaluated.,50588,N,,CHEMBL622534,,
6022,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,50588,N,,CHEMBL622535,,
6023,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,50588,N,,CHEMBL876739,,
6024,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),50588,N,,CHEMBL622536,,
6025,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration obtained in dog plasma was determined,50588,N,,CHEMBL622537,1969.0,
6026,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration was determined,50588,N,,CHEMBL622538,,
6027,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration at the dose of 2 mg/kg in dog,50588,N,,CHEMBL627867,,
6028,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,N,,CHEMBL627868,,
6029,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration was evaluated in dog plasma,50588,N,,CHEMBL627869,1969.0,
6030,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration was evaluated after 75 min after administration in dog,50588,N,,CHEMBL627870,,
6031,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration determined in dog after oral administration of 17b,50588,N,,CHEMBL627871,1969.0,
6032,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration determined in dog after oral administration of 2b,50588,N,,CHEMBL627872,1969.0,
6033,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration in dog,50588,N,,CHEMBL627873,1969.0,
6034,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,50588,N,,CHEMBL627874,1969.0,
6035,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,50588,N,,CHEMBL627875,1969.0,
6036,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,50588,N,,CHEMBL627876,1969.0,
6037,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,50588,N,,CHEMBL627877,1969.0,
6038,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,N,,CHEMBL627878,1969.0,
6039,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,50588,N,,CHEMBL627879,1969.0,
6040,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,50588,N,,CHEMBL875355,1969.0,
6041,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,50588,N,,CHEMBL627880,1969.0,
6042,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,50588,N,,CHEMBL627881,1969.0,
6043,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,50588,N,,CHEMBL627882,1969.0,
6044,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,50588,N,,CHEMBL627883,1969.0,
6045,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,50588,N,,CHEMBL628526,1969.0,
6046,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,50588,N,,CHEMBL628527,1969.0,
6047,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,50588,N,,CHEMBL628528,1969.0,
6048,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,50588,N,,CHEMBL628529,1969.0,
6049,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,50588,N,,CHEMBL628530,1969.0,
6050,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,50588,N,,CHEMBL625243,1969.0,
6051,,Canis lupus familiaris,BAO_0000218,,1,A,Expert,In vivo,1,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,N,,CHEMBL625244,1969.0,
6052,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,50588,N,,CHEMBL625245,,
6053,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,50588,N,,CHEMBL625246,,
6054,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,50594,N,,CHEMBL625247,945.0,
6055,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,50594,N,,CHEMBL625248,1088.0,
6056,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,50594,N,,CHEMBL625249,1088.0,
6057,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,50594,N,,CHEMBL625250,1088.0,
6058,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,50594,N,,CHEMBL625251,,
6059,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,50594,N,,CHEMBL875356,,
6060,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),50594,N,,CHEMBL625252,,
6061,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),50594,N,,CHEMBL625253,178.0,
6062,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),50594,N,,CHEMBL625254,,
6063,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),50594,N,,CHEMBL625255,,
6064,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),50594,N,,CHEMBL625256,,
6065,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),50594,N,,CHEMBL625257,178.0,
6066,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),50594,N,,CHEMBL625258,178.0,
6067,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for washout rate in mice (Radiolabeled compound),50594,N,,CHEMBL625259,,
6068,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,50594,N,,CHEMBL625260,,
6069,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",50594,N,,CHEMBL625261,,
6070,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",50594,N,,CHEMBL625262,,
6071,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",50594,N,,CHEMBL622639,,
6072,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,50594,N,,CHEMBL622640,,
6073,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,50594,N,,CHEMBL622812,,
6074,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,50594,N,,CHEMBL622813,,
6075,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,50594,N,,CHEMBL622814,,
6076,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Time at maximum activity in mice (Radiolabeled compound),50594,N,,CHEMBL622815,,
6077,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,50594,N,,CHEMBL625342,,
6078,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,50594,N,,CHEMBL625343,,
6079,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Binding towards mouse plasma protein at 10 uM,50594,N,,CHEMBL877591,,
6080,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Binding towards mouse plasma protein at 100 uM,50594,N,,CHEMBL625344,,
6081,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was evaluated in mice after intravenous administration,50594,N,,CHEMBL625345,,
6082,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was evaluated in mice after oral administration,50594,N,,CHEMBL625346,,
6083,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,50594,N,,CHEMBL625347,,
6084,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,50594,N,,CHEMBL625348,,
6085,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,50594,N,,CHEMBL625349,,
6086,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in mouse,50594,N,,CHEMBL625350,,
6087,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability after intravenous administration in mice at 24 uM/kg,50594,N,,CHEMBL882952,,
6088,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL625351,955.0,
6089,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL625352,955.0,
6090,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL877592,955.0,
6091,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL625353,955.0,
6092,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL625354,955.0,
6093,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL626019,955.0,
6094,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL626020,948.0,
6095,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL626021,948.0,
6096,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL626022,948.0,
6097,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL626192,948.0,
6098,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),80682,N,,CHEMBL626193,,
6099,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,80682,N,,CHEMBL626194,,
6100,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity against human lung carcinoma A-549 cell lines,80682,N,,CHEMBL626195,,
6101,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,80682,N,,CHEMBL626196,,
6102,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxicity against human lung carcinoma cell line A-549,80682,N,,CHEMBL626197,,
6103,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,80682,N,,CHEMBL626198,,
6104,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,80682,N,,CHEMBL626199,,
6105,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,80682,N,,CHEMBL626200,,
6106,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,80682,N,,CHEMBL626201,,
6107,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,80682,N,,CHEMBL626202,,
6108,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,80682,N,,CHEMBL626203,,
6109,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxicity against A-549 human lung cancer cells,80682,N,,CHEMBL626204,,
6110,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,80682,N,,CHEMBL624701,,
6111,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,80682,N,,CHEMBL624702,,
6112,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,80682,N,,CHEMBL624703,,
6113,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Tested in vitro for cytotoxicity against A-549 lung cancer cells,80682,N,,CHEMBL624704,,
6114,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,80682,N,,CHEMBL624705,,
6115,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,80682,N,,CHEMBL624706,,
6116,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Antitumor cytotoxic activity against A-549 cell line was determined,80682,N,,CHEMBL624707,,
6117,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",80682,N,,CHEMBL624708,,
6118,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,80682,N,,CHEMBL624709,,
6119,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,80682,N,,CHEMBL884107,,
6120,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Antitumoral activity was assayed against A-549 cell line,80682,N,,CHEMBL624710,,
6121,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,80682,N,,CHEMBL624711,,
6122,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,80682,N,,CHEMBL624712,,
6123,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,80682,N,,CHEMBL624713,,
6124,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was tested for inhibition of cell growth of A-549 cells,80682,N,,CHEMBL624714,,
6125,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,80682,N,,CHEMBL624715,,
6126,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,80682,N,,CHEMBL624716,,
6127,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro cytotoxicity against A549-human lung carcinoma cells.,80682,N,,CHEMBL619505,,
6128,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,80682,N,,CHEMBL619506,,
6129,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxic activity against A-549 cell lines.,80682,N,,CHEMBL619507,,
6130,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,80682,N,,CHEMBL619508,,
6131,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity against human A549 non small cell lung cell lines,80682,N,,CHEMBL619509,,
6132,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Inhibition of cell growth in (A-549) lung cell line,80682,N,,CHEMBL619510,,
6133,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,80682,N,,CHEMBL619511,,
6134,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro antitumor activity against A-549 tumor cells.,80682,N,,CHEMBL619512,,
6135,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro antitumor effects against human A-549 cell lines.,80682,N,,CHEMBL619513,,
6136,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxic activity of compound against A-549 cell line,80682,N,,CHEMBL619514,,
6137,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxicity against human lung carcinoma A-549 cell line,80682,N,,CHEMBL619515,,
6138,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxicity against human non-small cell lung carcinoma A549,80682,N,,CHEMBL619516,,
6139,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,80682,N,,CHEMBL884005,,
6140,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,80682,N,,CHEMBL619517,,
6141,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibitory concentration of compound against A-549 cell line,80682,N,,CHEMBL619518,,
6142,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,80682,N,,CHEMBL619519,,
6143,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,cytotoxic activity against leukemia (A-549) cancer cell line,80682,N,,CHEMBL876489,,
6144,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,80682,N,,CHEMBL619520,,
6145,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,80682,N,,CHEMBL619521,,
6146,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),80682,N,,CHEMBL619522,,
6147,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),80682,N,,CHEMBL619523,,
6148,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),80682,N,,CHEMBL619524,,
6149,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),80682,N,,CHEMBL619525,,
6150,646.0,,BAO_0000219,A549,1,F,Intermediate,,1,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,80682,N,,CHEMBL619526,,
6151,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,80682,N,,CHEMBL619527,,
6152,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity against A549 cells; No cytotoxicity,80682,N,,CHEMBL619528,,
6153,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Cytotoxicity against human lung carcinoma (A549) cell lines,80682,N,,CHEMBL619529,,
6154,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,80682,N,,CHEMBL619530,,
6155,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro anticancer activity against human lung (A549) cell line,80682,N,,CHEMBL876490,,
6156,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,80682,N,,CHEMBL619531,,
6157,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,80682,N,,CHEMBL619532,,
6158,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,80682,N,,CHEMBL619533,,
6159,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,80682,N,,CHEMBL619534,,
6160,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,80682,N,,CHEMBL620164,,
6161,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,80682,N,,CHEMBL620165,,
6162,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Inhibition of A549 human lung tumor cell proliferation,80682,N,,CHEMBL620166,,
6163,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",80682,N,,CHEMBL620167,,
6164,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro cytotoxicity against human tumor cell line A549,80682,N,,CHEMBL620168,,
6165,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,80682,N,,CHEMBL620338,,
6166,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,80682,N,,CHEMBL620339,,
6167,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,80682,N,,CHEMBL620340,,
6168,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,80682,N,,CHEMBL620341,,
6169,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,80682,N,,CHEMBL876491,,
6170,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,80682,N,,CHEMBL620342,,
6171,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,80682,N,,CHEMBL620343,,
6172,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,% inhibition against A549 cells (lung cancer) at 4 ug/mL,80682,N,,CHEMBL620344,,
6173,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro anticancer activity against human lung (A549) cell line,80682,N,,CHEMBL620345,,
6174,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,80682,N,,CHEMBL620346,,
6175,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,80682,N,,CHEMBL620347,,
6176,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,80682,N,,CHEMBL620348,,
6177,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,80682,N,,CHEMBL620349,,
6178,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,80682,N,,CHEMBL618667,,
6179,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Percentage inhibition of human lung carcinoma (A549) cell lines,80682,N,,CHEMBL618668,,
6180,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,80682,N,,CHEMBL876031,,
6181,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",80682,N,,CHEMBL618759,,
6182,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,80682,N,,CHEMBL618760,,
6183,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,80682,N,,CHEMBL619000,,
6184,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",80682,N,,CHEMBL619001,,
6185,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",80682,N,,CHEMBL619002,,
6186,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",80682,N,,CHEMBL619003,,
6187,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",80682,N,,CHEMBL619597,,
6188,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",80682,N,,CHEMBL619598,,
6189,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,80682,N,,CHEMBL619599,,
6190,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,80682,N,,CHEMBL619600,,
6191,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,80682,N,,CHEMBL619601,,
6192,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,80682,N,,CHEMBL619602,,
6193,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,80682,N,,CHEMBL619603,,
6194,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,80682,N,,CHEMBL619604,,
6195,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,80682,N,,CHEMBL619605,,
6196,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,50588,N,,CHEMBL619606,,
6197,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic activity (Cmax) in dog,50588,N,,CHEMBL876032,,
6198,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),50588,N,,CHEMBL619607,,
6199,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,50588,N,,CHEMBL619608,,
6200,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,50588,N,,CHEMBL619609,,
6201,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in dog plasma after 30mg/kg oral dose,50588,N,,CHEMBL619610,1969.0,
6202,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for the peak blood level in dog,50588,N,,CHEMBL619611,178.0,
6203,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",50588,N,,CHEMBL619612,,
6204,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",50588,N,,CHEMBL619613,,
6205,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,50588,N,,CHEMBL619614,178.0,
6206,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,50588,N,,CHEMBL619615,,
6207,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,50588,N,,CHEMBL619616,,
6208,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Final plasma concentration in dogs after oral administration at 1 mg/kg,50588,N,,CHEMBL619617,1969.0,
6209,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,50588,N,,CHEMBL619618,,
6210,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,50588,N,,CHEMBL876033,,
6211,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,50588,N,,CHEMBL619619,,
6212,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,50588,N,,CHEMBL619620,,
6213,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,50588,N,,CHEMBL619621,1088.0,
6214,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,50588,N,,CHEMBL619622,1088.0,
6215,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,50588,N,,CHEMBL618874,1088.0,
6216,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Absolute bioavailability was evaluated in dog,50588,N,,CHEMBL618875,,
6217,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,50588,N,,CHEMBL618876,,
6218,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability after peroral administration (1 mg/kg) was determined in dog,50588,N,,CHEMBL618877,,
6219,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog,50588,N,,CHEMBL618878,,
6220,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog,50588,N,,CHEMBL618879,,
6221,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability after intravenous administration in dogs,50588,N,,CHEMBL618880,,
6222,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability after peroral administration in dogs,50588,N,,CHEMBL618881,,
6223,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),50588,N,,CHEMBL618882,,
6224,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,50588,N,,CHEMBL624226,,
6225,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,50588,N,,CHEMBL624227,1969.0,
6226,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability,50588,N,,CHEMBL624228,,
6227,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability,50588,N,,CHEMBL624229,,
6228,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability by intravenous administration of 1.2 mg/kg in dog,50588,N,,CHEMBL624230,,
6229,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog,50588,N,,CHEMBL624231,,
6230,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog,50588,N,,CHEMBL624232,,
6231,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog,50588,N,,CHEMBL625127,,
6232,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog,50588,N,,CHEMBL625128,,
6233,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog,50588,N,,CHEMBL621675,,
6234,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog (p.o.) at 2.0 mpk,50588,N,,CHEMBL621676,,
6235,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),50588,N,,CHEMBL621677,,
6236,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,50588,N,,CHEMBL621678,,
6237,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog,50588,N,,CHEMBL621679,,
6238,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was evaluated after oral administration in dog,50588,N,,CHEMBL621680,,
6239,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,N,,CHEMBL621681,,
6240,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was evaluated in dog,50588,N,,CHEMBL876740,,
6241,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog,50588,N,,CHEMBL621682,,
6242,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog,50588,N,,CHEMBL621683,,
6243,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),50588,N,,CHEMBL621684,,
6244,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),50588,N,,CHEMBL621685,,
6245,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),50588,N,,CHEMBL621686,,
6246,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,N,,CHEMBL621687,,
6247,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,50588,N,,CHEMBL621688,,
6248,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability of compound in dog was determined after peroral administration,50588,N,,CHEMBL621689,,
6249,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL621690,,
6250,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,50588,N,,CHEMBL621691,,
6251,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,50588,N,,CHEMBL875941,,
6252,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for oral bioavailability in dogs; 37-38 %,50588,N,,CHEMBL621692,,
6253,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog,50588,N,,CHEMBL621693,,
6254,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),50588,N,,CHEMBL621694,,
6255,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL621695,948.0,
6256,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL621696,948.0,
6257,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL621697,2113.0,
6258,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL621698,2113.0,
6259,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL623420,2113.0,
6260,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL623421,2113.0,
6261,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL623422,2113.0,
6262,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL623423,2113.0,
6263,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL623424,2107.0,
6264,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL623425,2107.0,
6265,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL623426,2107.0,
6266,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL623427,2107.0,
6267,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL623428,2107.0,
6268,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL875947,2107.0,
6269,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL623429,2048.0,
6270,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL623430,2048.0,
6271,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL622588,2048.0,
6272,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL622589,2048.0,
6273,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL622751,2048.0,
6274,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,50594,N,,CHEMBL622752,2048.0,
6275,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,50594,N,,CHEMBL622753,,
6276,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,50594,N,,CHEMBL622647,,
6277,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,50594,N,,CHEMBL875163,,
6278,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,50594,N,,CHEMBL622648,,
6279,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,50594,N,,CHEMBL622649,,
6280,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,50594,N,,CHEMBL622650,955.0,
6281,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,50594,N,,CHEMBL622651,955.0,
6282,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,50594,N,,CHEMBL622652,955.0,
6283,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,50594,N,,CHEMBL622653,955.0,
6284,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,50594,N,,CHEMBL622654,955.0,
6285,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,50594,N,,CHEMBL622655,948.0,
6286,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,50594,N,,CHEMBL622656,948.0,
6287,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,50594,N,,CHEMBL622657,948.0,
6288,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,50594,N,,CHEMBL622658,948.0,
6289,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,50594,N,,CHEMBL622659,948.0,
6290,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,50594,N,,CHEMBL624630,2113.0,
6291,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,50594,N,,CHEMBL624631,2113.0,
6292,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,50594,N,,CHEMBL624632,2113.0,
6293,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,80682,N,,CHEMBL624633,,
6294,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,80682,N,,CHEMBL624634,,
6295,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),80682,N,,CHEMBL624635,,
6296,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),80682,N,,CHEMBL624636,,
6297,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,80682,N,,CHEMBL857055,,
6298,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,80682,N,,CHEMBL624637,,
6299,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,80682,N,,CHEMBL624638,,
6300,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,80682,N,,CHEMBL874366,,
6301,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,80682,N,,CHEMBL624639,,
6302,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,80682,N,,CHEMBL624640,,
6303,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,80682,N,,CHEMBL624641,,
6304,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,80682,N,,CHEMBL624642,,
6305,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,80682,N,,CHEMBL624643,,
6306,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,80682,N,,CHEMBL624644,,
6307,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,80682,N,,CHEMBL624645,,
6308,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,The compound was evaluated for its cytotoxic potency against A-549 cell line,80682,N,,CHEMBL619445,,
6309,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,80682,N,,CHEMBL839886,,
6310,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxic activity of compound against A-549 tumor cell line.,80682,N,,CHEMBL619446,,
6311,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,80682,N,,CHEMBL619447,,
6312,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,80682,N,,CHEMBL619448,,
6313,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,80682,N,,CHEMBL619449,,
6314,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,80682,N,,CHEMBL619450,,
6315,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),80682,N,,CHEMBL619451,,
6316,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,80682,N,,CHEMBL619452,,
6317,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,80682,N,,CHEMBL619453,,
6318,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,80682,N,,CHEMBL874367,,
6319,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxic concentration against A-549 tumor cells.,80682,N,,CHEMBL619454,,
6320,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,80682,N,,CHEMBL619455,,
6321,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",80682,N,,CHEMBL619456,,
6322,,Acinetobacter baumannii,BAO_0000218,,1,F,Expert,,1,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,50191,N,,CHEMBL619457,,
6323,,Acinetobacter calcoaceticus,BAO_0000218,,1,F,Intermediate,,1,Activity against Acinetobacter calcoaceticus (AC54),50192,N,,CHEMBL619458,,
6324,,Aspergillus flavus,BAO_0000218,,1,F,Expert,,1,In vitro antifungal activity against Aspergillus flavus CM74,50274,N,,CHEMBL619459,,
6325,,Aspergillus flavus,BAO_0000218,,1,F,Expert,,1,In vitro antifungal activity against Aspergillus flavus CM74,50274,N,,CHEMBL619460,,
6326,,Aspergillus fumigatus,BAO_0000218,,1,F,Intermediate,,1,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,50416,N,,CHEMBL619461,,
6327,,Aspergillus fumigatus,BAO_0000218,,1,F,Intermediate,,1,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),50416,N,,CHEMBL619462,,
6328,,Aspergillus fumigatus,BAO_0000218,,1,F,Intermediate,,1,Antimicrobial activity against Aspergillus fumigatus (MIC),50416,N,,CHEMBL620388,,
6329,,Aspergillus fumigatus,BAO_0000218,,1,F,Intermediate,,1,Antimicrobial activity against Aspergillus fumigatus (MIC),50416,N,,CHEMBL620389,,
6330,,Aspergillus fumigatus,BAO_0000218,,1,F,Intermediate,,1,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),50416,N,,CHEMBL620390,,
6331,,Aspergillus fumigatus,BAO_0000218,,1,F,Expert,,1,In vitro antifungal activity against Aspergillus fumigatus 48238E,50416,N,,CHEMBL620391,,
6332,,Aspergillus fumigatus,BAO_0000218,,1,F,Expert,,1,In vitro antifungal activity against Aspergillus fumigatus 48238E,50416,N,,CHEMBL621073,,
6333,,Actinomyces naeslundii,BAO_0000218,,1,F,Intermediate,,1,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,50296,N,,CHEMBL621074,,
6334,,Actinomyces viscosus,BAO_0000218,,1,F,Intermediate,,1,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,50366,N,,CHEMBL621075,,
6335,,Acanthocheilonema viteae,BAO_0000218,,1,F,Intermediate,,1,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),50535,N,,CHEMBL619554,,
6336,,Acanthocheilonema viteae,BAO_0000218,,1,F,Intermediate,,1,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),50535,N,,CHEMBL619555,,
6337,,Aggregatibacter actinomycetemcomitans,BAO_0000218,,1,F,Intermediate,,1,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,50169,N,,CHEMBL619556,,
6338,,Aggregatibacter actinomycetemcomitans,BAO_0000218,,1,F,Intermediate,,1,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,50169,N,,CHEMBL619557,,
6339,,Aggregatibacter actinomycetemcomitans,BAO_0000218,,1,F,Intermediate,,1,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,50169,N,,CHEMBL619558,,
6340,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,80682,N,,CHEMBL619559,,
6341,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,80682,N,,CHEMBL619560,,
6342,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,80682,N,,CHEMBL619561,,
6343,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,80682,N,,CHEMBL619562,,
6344,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,% inhibition against A549 cells (lung cancer) at 4 ug/mL,80682,N,,CHEMBL619563,,
6345,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,GI values against A549 cells (lung cancer),80682,N,,CHEMBL857457,,
6346,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,80682,N,,CHEMBL619564,,
6347,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibitory activity against A549 human adenocarcinoma,80682,N,,CHEMBL619565,,
6348,646.0,Homo sapiens,BAO_0000218,A549,1,F,Intermediate,,1,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,80682,N,,CHEMBL619566,,
6349,646.0,Homo sapiens,BAO_0000218,A549,1,F,Intermediate,,1,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,80682,N,,CHEMBL619567,,
6350,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibitory activity against A549 lung adenocarcinoma cell line,80682,N,,CHEMBL619568,,
6351,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,80682,N,,CHEMBL619569,,
6352,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity against human A549 lung cells,80682,N,,CHEMBL619570,,
6353,646.0,Homo sapiens,BAO_0000218,A549,1,F,Intermediate,,1,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,80682,N,,CHEMBL619571,,
6354,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Growth inhibition of A549 (human lung carcinoma) cell line.,80682,N,,CHEMBL619572,,
6355,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Effective dose required for inhibitory activity against A549 human tumor cell line.,80682,N,,CHEMBL619573,,
6356,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,80682,N,,CHEMBL619574,,
6357,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,80682,N,,CHEMBL619575,,
6358,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,80682,N,,CHEMBL619576,,
6359,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,80682,N,,CHEMBL619577,,
6360,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro inhibitory activity against A549 tumor cell culture,80682,N,,CHEMBL619578,,
6361,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,80682,N,,CHEMBL884009,,
6362,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),80682,N,,CHEMBL619579,,
6363,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,80682,N,,CHEMBL619580,,
6364,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,80682,N,,CHEMBL619581,,
6365,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,80682,N,,CHEMBL619582,,
6366,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,80682,N,,CHEMBL619583,,
6367,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,80682,N,,CHEMBL876502,,
6368,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,80682,N,,CHEMBL619584,,
6369,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,80682,N,,CHEMBL619585,,
6370,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,80682,N,,CHEMBL619586,,
6371,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,80682,N,,CHEMBL619587,,
6372,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,80682,N,,CHEMBL619588,,
6373,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Tested in vitro for cytotoxicity in A549/ATCC cell lines,80682,N,,CHEMBL619589,,
6374,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,80682,N,,CHEMBL619590,,
6375,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),80682,N,,CHEMBL619591,,
6376,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,80682,N,,CHEMBL619592,,
6377,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,80682,N,,CHEMBL619593,,
6378,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,80682,N,,CHEMBL620217,,
6379,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,80682,N,,CHEMBL620218,,
6380,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,80682,N,,CHEMBL620219,,
6381,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Antitumor activity against A549/ATCC cell line,80682,N,,CHEMBL620220,,
6382,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,80682,N,,CHEMBL625141,,
6383,646.0,Homo sapiens,BAO_0000219,A549,1,F,Expert,,1,In vitro cytotoxicity against A549/ATCC cell line.,80682,N,,CHEMBL625142,,
6384,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,80682,N,,CHEMBL625143,,
6385,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,80682,N,,CHEMBL625144,,
6386,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,80682,N,,CHEMBL622474,,
6387,646.0,Homo sapiens,BAO_0000219,A549,1,F,Intermediate,,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,80682,N,,CHEMBL884104,,
6388,,Homo sapiens,BAO_0000219,,1,F,Autocuration,,0,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,22226,U,,CHEMBL622475,,
6389,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,0,Compound was tested for oral bioavailability in dogs,22224,U,,CHEMBL622476,,
6390,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,50588,N,,CHEMBL875831,,
6391,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,50588,N,,CHEMBL622477,,
6392,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL622478,,
6393,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for the oral bioavailability in dog; No availability,50588,N,,CHEMBL623172,,
6394,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (dose 5 mg/kg),50588,N,,CHEMBL623173,,
6395,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,50588,N,,CHEMBL623174,,
6396,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,50588,N,,CHEMBL623175,,
6397,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),50588,N,,CHEMBL623340,,
6398,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (dose 5 mg/kg),50588,N,,CHEMBL623341,,
6399,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),50588,N,,CHEMBL623342,,
6400,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability of active FTIs in dogs,50588,N,,CHEMBL623343,,
6401,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),50588,N,,CHEMBL623344,,
6402,,Canis lupus familiaris,BAO_0000218,,1,A,Expert,In vivo,1,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,N,,CHEMBL623345,,
6403,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL875832,,
6404,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL623346,,
6405,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL623347,,
6406,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability of compound was determined in dog; Not tested,50588,N,,CHEMBL623348,,
6407,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL623349,,
6408,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability (10 mg/kg) was determined in dog,50588,N,,CHEMBL623350,,
6409,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability,50588,N,,CHEMBL623351,,
6410,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),50588,N,,CHEMBL623352,,
6411,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability administered in solution in rats,50588,N,,CHEMBL623353,,
6412,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability after 30 mg/kg po dose in Dogs,50588,N,,CHEMBL875833,,
6413,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability at a dose of 1 mg/kg in dogs,50588,N,,CHEMBL623354,,
6414,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (dose 1 mg/kg p.o.),50588,N,,CHEMBL623355,,
6415,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in Dog; ND = not determined,50588,N,,CHEMBL623356,,
6416,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL623357,,
6417,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL623358,,
6418,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL623359,,
6419,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL623360,,
6420,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dogs; No data,50588,N,,CHEMBL623361,,
6421,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability measured in dogs,50588,N,,CHEMBL623362,,
6422,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL623363,,
6423,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability was calculated in dog,50588,N,,CHEMBL623364,,
6424,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability after 0.3 mg/kg po administration in dog,50588,N,,CHEMBL875834,,
6425,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (i.v. dosing),50588,N,,CHEMBL623365,,
6426,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL623366,,
6427,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,50588,N,,CHEMBL623367,,
6428,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in Beagle dogs,50588,N,,CHEMBL623368,,
6429,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL623369,,
6430,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL623370,,
6431,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL623371,,
6432,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL623372,,
6433,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL621351,,
6434,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL621352,,
6435,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL621353,,
6436,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL621354,,
6437,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL621355,,
6438,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL621356,,
6439,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL621357,,
6440,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL621358,,
6441,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),50588,N,,CHEMBL621359,,
6442,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),50588,N,,CHEMBL621360,,
6443,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),50588,N,,CHEMBL621361,,
6444,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL621362,,
6445,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL621363,,
6446,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL621364,,
6447,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),50588,N,,CHEMBL621166,,
6448,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (dose 1 mg/kg i.v.),50588,N,,CHEMBL621167,,
6449,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability (F) in dogs,50588,N,,CHEMBL621168,,
6450,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL621169,,
6451,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog,50588,N,,CHEMBL875950,,
6452,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (dose 10 mg/kg),50588,N,,CHEMBL621170,,
6453,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability after peroral administration at 5 mpk in Dog,50588,N,,CHEMBL621171,,
6454,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (dose 5 mg/kg),50588,N,,CHEMBL621172,,
6455,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (dose 10 mg/kg),50588,N,,CHEMBL621173,,
6456,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,50594,N,,CHEMBL621174,2113.0,
6457,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,50594,N,,CHEMBL621175,2113.0,
6458,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,50594,N,,CHEMBL621176,2107.0,
6459,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,50594,N,,CHEMBL621177,2107.0,
6460,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,50594,N,,CHEMBL621178,2107.0,
6461,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,50594,N,,CHEMBL621179,2107.0,
6462,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,50594,N,,CHEMBL621180,2107.0,
6463,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,50594,N,,CHEMBL875951,2048.0,
6464,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,50594,N,,CHEMBL621181,2048.0,
6465,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,50594,N,,CHEMBL621182,2048.0,
6466,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,50594,N,,CHEMBL621183,2048.0,
6467,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,50594,N,,CHEMBL621184,2048.0,
6468,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,50594,N,,CHEMBL621185,,
6469,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,50594,N,,CHEMBL621186,,
6470,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,50594,N,,CHEMBL621187,,
6471,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,50594,N,,CHEMBL621188,,
6472,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,50594,N,,CHEMBL621189,,
6473,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,50594,N,,CHEMBL621190,2106.0,
6474,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,50594,N,,CHEMBL618520,2106.0,
6475,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,50594,N,,CHEMBL621739,2106.0,
6476,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,50594,N,,CHEMBL621740,2106.0,
6477,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,50594,N,,CHEMBL621741,2106.0,
6478,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,50594,N,,CHEMBL621742,,
6479,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,50594,N,,CHEMBL621743,,
6480,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,50594,N,,CHEMBL621744,,
6481,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,50594,N,,CHEMBL621745,,
6482,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,50594,N,,CHEMBL621746,,
6483,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,50594,N,,CHEMBL621747,,
6484,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,50594,N,,CHEMBL621748,,
6485,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,50594,N,,CHEMBL621749,,
6486,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,50594,N,,CHEMBL621750,,
6487,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,50594,N,,CHEMBL621751,,
6488,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,50594,N,,CHEMBL621752,948.0,
6489,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,50594,N,,CHEMBL621753,948.0,
6490,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,50594,N,,CHEMBL875955,948.0,
6491,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,50594,N,,CHEMBL621754,948.0,
6492,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,50594,N,,CHEMBL621755,948.0,
6493,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,50594,N,,CHEMBL621756,2107.0,
6494,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,50594,N,,CHEMBL624199,2107.0,
6495,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,50594,N,,CHEMBL624200,2107.0,
6496,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,50594,N,,CHEMBL624375,2107.0,
6497,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,50594,N,,CHEMBL624376,2107.0,
6498,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,50594,N,,CHEMBL624377,2048.0,
6499,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,50594,N,,CHEMBL624378,2048.0,
6500,,aeinetobacter anitrotap,BAO_0000218,,1,F,Intermediate,,1,Compound tested for the antimicrobial activity against Acinetobacter anitratus,50067,N,,CHEMBL857901,,
6501,,Acinetobacter calcoaceticus subsp. anitratus,BAO_0000218,,1,F,Intermediate,,1,Compound tested for the antimicrobial activity against Acinetobacter anitratus,50067,N,,CHEMBL875274,,
6502,,Acinetobacter calcoaceticus subsp. anitratus,BAO_0000218,,1,F,Intermediate,,1,Compound tested for the antimicrobial activity against Acinetobacter anitratus,50067,N,,CHEMBL624379,,
6503,,aeinetobacter anitrotap,BAO_0000218,,1,F,Intermediate,,1,Compound tested for the antimicrobial activity against Acinetobacter anitratus,50067,N,,CHEMBL624380,,
6504,,Acinetobacter calcoaceticus,BAO_0000218,,1,F,Intermediate,,1,Activity against Acinetobacter calcoaceticus (AC54),50192,N,,CHEMBL624381,,
6505,,Anolis carolinensis,BAO_0000218,,1,F,Intermediate,,1,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,50714,N,,CHEMBL624382,,
6506,,Anolis carolinensis,BAO_0000218,,1,F,Intermediate,,1,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,50714,N,,CHEMBL624383,,
6507,,Actinomyces naeslundii,BAO_0000218,,1,F,Intermediate,,1,Chlorohexidine coefficient for Actinomyces naeslundii 631,50296,N,,CHEMBL624384,,
6508,,Actinomyces naeslundii,BAO_0000218,,1,F,Intermediate,,1,Chlorohexidine coefficient for Actinomyces naeslundii B74,50296,N,,CHEMBL624385,,
6509,,Actinomyces naeslundii,BAO_0000218,,1,F,Intermediate,,1,Chlorohexidine coefficient for Actinomyces naeslundii N/3,50296,N,,CHEMBL624386,,
6510,,Actinomyces naeslundii,BAO_0000218,,1,F,Intermediate,,1,Chlorohexidine coefficient for Actinomyces naeslundii N/9,50296,N,,CHEMBL624387,,
6511,,Actinomyces naeslundii,BAO_0000218,,1,F,Intermediate,,1,Plaque bactericidal index against Actinomyces naeslundii 631,50296,N,,CHEMBL624388,,
6512,,Actinomyces naeslundii,BAO_0000218,,1,F,Intermediate,,1,Plaque bactericidal index against Actinomyces naeslundii N/9,50296,N,,CHEMBL624389,,
6513,,Actinomyces naeslundii,BAO_0000218,,1,F,Intermediate,,1,Plaque bactericidal index against Actinomyces naeslundii B74,50296,N,,CHEMBL624390,,
6514,,Actinomyces naeslundii,BAO_0000218,,1,F,Intermediate,,1,Plaque bactericidal index against Actinomyces naeslundii N/3,50296,N,,CHEMBL875275,,
6515,,Artemia salina,BAO_0000218,,1,F,Intermediate,,1,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,50056,N,,CHEMBL624391,,
6516,,Artemia salina,BAO_0000218,,1,F,Intermediate,,1,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",50056,N,,CHEMBL623636,,
6517,,Ascaris suum,BAO_0000218,,1,F,Intermediate,,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,50532,N,,CHEMBL623637,,
6518,,Ascaris suum,BAO_0000218,,1,F,Intermediate,,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,50532,N,,CHEMBL623638,,
6519,,Ascaris suum,BAO_0000218,,1,F,Intermediate,,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,50532,N,,CHEMBL623639,,
6520,,Ascaris suum,BAO_0000218,,1,F,Intermediate,,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,50532,N,,CHEMBL623640,,
6521,,Ascaris suum,BAO_0000218,,1,F,Intermediate,,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,50532,N,,CHEMBL623641,,
6522,,Ascaris suum,BAO_0000218,,1,F,Intermediate,,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,50532,N,,CHEMBL623642,,
6523,,Ascaris suum,BAO_0000218,,1,F,Intermediate,,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,50532,N,,CHEMBL623643,,
6524,,Ascaris suum,BAO_0000218,,1,F,Intermediate,,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,50532,N,,CHEMBL623644,,
6525,,Ascaris suum,BAO_0000218,,1,F,Intermediate,,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,50532,N,,CHEMBL623645,,
6526,,Ascaris suum,BAO_0000218,,1,F,Intermediate,,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,50532,N,,CHEMBL623646,,
6527,,Ascaris suum,BAO_0000218,,1,F,Intermediate,,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,50532,N,,CHEMBL623647,,
6528,,Ascaris suum,BAO_0000218,,1,F,Intermediate,,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,50532,N,,CHEMBL623648,,
6529,,Actinomyces viscosus,BAO_0000218,,1,F,Intermediate,,1,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,50366,N,,CHEMBL623649,,
6530,,Actinomyces viscosus,BAO_0000218,,1,F,Intermediate,,1,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,50366,N,,CHEMBL623650,,
6531,,Actinomyces viscosus,BAO_0000218,,1,F,Intermediate,,1,Chlorohexidine coefficient for Actinomyces viscosus 8A06,50366,N,,CHEMBL623651,,
6532,,Actinomyces viscosus,BAO_0000218,,1,F,Expert,,1,Chlorohexidine coefficient for Actinomyces viscosus M-100,50366,N,,CHEMBL623652,,
6533,,Actinomyces viscosus,BAO_0000218,,1,F,Intermediate,,1,Chlorohexidine coefficient for Actinomyces viscosus M-626,50366,N,,CHEMBL623653,,
6534,,Actinomyces viscosus,BAO_0000218,,1,F,Intermediate,,1,Chlorohexidine coefficient for Actinomyces viscosus T14V,50366,N,,CHEMBL623654,,
6535,,Actinomyces viscosus,BAO_0000218,,1,F,Intermediate,,1,Plaque bactericidal index against Actinomyces viscosus 8A06,50366,N,,CHEMBL623655,,
6536,,Actinomyces viscosus,BAO_0000218,,1,F,Intermediate,,1,Plaque bactericidal index against Actinomyces viscosus M-100,50366,N,,CHEMBL623656,,
6537,,Actinomyces viscosus,BAO_0000218,,1,F,Expert,,1,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,50366,N,,CHEMBL623657,,
6538,,Actinomyces viscosus,BAO_0000218,,1,F,Intermediate,,1,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",50366,N,,CHEMBL623658,,
6539,,Actinomyces viscosus,BAO_0000218,,1,F,Intermediate,,1,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",50366,N,,CHEMBL623659,,
6540,,Actinomyces viscosus,BAO_0000218,,1,F,Intermediate,,1,Plaque bactericidal index against Actinomyces viscosus 626,50366,N,,CHEMBL623660,,
6541,,Actinomyces viscosus,BAO_0000218,,1,F,Intermediate,,1,Plaque bactericidal index against Actinomyces viscosus T14V,50366,N,,CHEMBL623661,,
6542,,Acanthocheilonema viteae,BAO_0000218,,1,F,Intermediate,,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,50535,N,,CHEMBL875281,,
6543,,Acanthocheilonema viteae,BAO_0000218,,1,F,Intermediate,,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,50535,N,,CHEMBL623662,,
6544,,Acanthocheilonema viteae,BAO_0000218,,1,F,Intermediate,,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,50535,N,,CHEMBL623663,,
6545,,Acanthocheilonema viteae,BAO_0000218,,1,F,Intermediate,,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,50535,N,,CHEMBL623664,,
6546,,Acanthocheilonema viteae,BAO_0000218,,1,F,Intermediate,,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,50535,N,,CHEMBL623665,,
6547,165.0,Homo sapiens,BAO_0000219,A673,1,F,Intermediate,,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,80023,N,,CHEMBL621856,,
6548,645.0,Homo sapiens,BAO_0000219,A704,1,F,Intermediate,,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,80661,N,,CHEMBL620432,,
6549,,Rattus norvegicus,BAO_0000219,,1,F,Autocuration,,0,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,22226,U,,CHEMBL620433,,
6550,625.0,Mus musculus,BAO_0000219,A9,1,F,Intermediate,,1,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,80024,N,,CHEMBL620434,,
6551,625.0,Mus musculus,BAO_0000219,A9,1,F,Intermediate,,1,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,80024,N,,CHEMBL620435,,
6552,625.0,Homo sapiens,BAO_0000219,A9,1,F,Intermediate,,1,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,80024,N,,CHEMBL620436,,
6553,625.0,Homo sapiens,BAO_0000219,A9,1,F,Intermediate,,1,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,80024,N,,CHEMBL876597,,
6554,874.0,Homo sapiens,BAO_0000219,Human ovarian carcinoma cell line,1,F,Expert,,1,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,81037,N,,CHEMBL620437,,
6555,625.0,Mus musculus,BAO_0000219,A9,1,F,Expert,,1,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",80024,N,,CHEMBL620438,,
6556,625.0,Mus musculus,BAO_0000219,A9,1,F,Expert,,1,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,80024,N,,CHEMBL620439,,
6557,625.0,Mus musculus,BAO_0000219,A9,1,F,Expert,,1,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,80024,N,,CHEMBL619657,,
6558,625.0,Mus musculus,BAO_0000219,A9,1,F,Intermediate,,1,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,80024,N,,CHEMBL619658,,
6559,625.0,Mus musculus,BAO_0000219,A9,1,F,Intermediate,,1,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,80024,N,,CHEMBL619659,,
6560,,,BAO_0000019,,1,F,Expert,,8,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",10649,H,,CHEMBL619660,,
6561,625.0,Mus musculus,BAO_0000219,A9,1,F,Intermediate,,1,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,80024,N,,CHEMBL619661,,
6562,625.0,Mus musculus,BAO_0000219,A9,1,F,Intermediate,,1,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,80024,N,,CHEMBL619662,,
6563,975.0,Cricetulus griseus,BAO_0000219,AA6,1,F,Intermediate,,1,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,80663,N,,CHEMBL619663,,
6564,,Homo sapiens,BAO_0000219,,1,F,Autocuration,,0,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,22226,U,,CHEMBL619664,,
6565,,Homo sapiens,BAO_0000219,,1,F,Autocuration,,0,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",22226,U,,CHEMBL619665,,
6566,974.0,Homo sapiens,BAO_0000219,AA5,1,F,Intermediate,,1,Anti -HIV activity was measured against AA5/HIV-1(IIIB),80662,N,,CHEMBL883244,,
6567,974.0,Homo sapiens,BAO_0000219,AA5,1,F,Intermediate,,1,Cytotoxicity was measured against AA5/HIV-1(IIIB),80662,N,,CHEMBL884011,,
6568,974.0,Homo sapiens,BAO_0000219,AA5,1,F,Intermediate,,1,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,80662,N,,CHEMBL619666,,
6569,379.0,Homo sapiens,BAO_0000219,U-937,1,F,Intermediate,,1,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,80566,N,,CHEMBL619667,,
6570,274.0,Cricetulus griseus,BAO_0000219,UV4,1,F,Intermediate,,1,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,80578,N,,CHEMBL619668,,
6571,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Expert,,1,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",80089,N,,CHEMBL619669,,
6572,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,Average intracellular compound concentration when the hypoxic SER=1.6,80089,N,,CHEMBL876608,,
6573,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,Average intracellular compound concentration when the hypoxic SER=1.6.,80089,N,,CHEMBL619670,,
6574,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,80089,N,,CHEMBL619671,,
6575,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,80089,N,,CHEMBL619672,,
6576,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,80089,N,,CHEMBL619673,,
6577,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",80089,N,,CHEMBL619674,,
6578,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",80089,N,,CHEMBL619675,,
6579,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,80089,N,,CHEMBL619676,,
6580,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,80089,N,,CHEMBL619677,,
6581,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,A,Intermediate,,1,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,80089,N,,CHEMBL619678,,
6582,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,A,Intermediate,,1,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,80089,N,,CHEMBL619679,,
6583,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,A,Expert,,1,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,80089,N,,CHEMBL619680,,
6584,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,A,Intermediate,,1,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,80089,N,,CHEMBL621457,,
6585,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Expert,,1,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,80089,N,,CHEMBL876609,,
6586,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,80089,N,,CHEMBL621458,,
6587,185.0,hampster,BAO_0000219,CHO-AA8,1,F,Expert,,1,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,80089,N,,CHEMBL621459,,
6588,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Expert,,1,Aerobic growth inhibition in Chinese hamster cell line AA8,80089,N,,CHEMBL621460,,
6589,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Expert,,1,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,80089,N,,CHEMBL621461,,
6590,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Expert,,1,Inhibition of growth under aerobic conditions in AA8 cells,80089,N,,CHEMBL621462,,
6591,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (dose 10 mg/kg),50588,N,,CHEMBL621463,,
6592,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog at 10 mg/kg of the compound,50588,N,,CHEMBL621464,,
6593,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (dose 5 uM/kg),50588,N,,CHEMBL621465,,
6594,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (dose 5 uM/kg),50588,N,,CHEMBL621466,,
6595,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (mongrel),50588,N,,CHEMBL621467,,
6596,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (dose 10 mg/kg),50588,N,,CHEMBL621468,,
6597,,Canis lupus familiaris,BAO_0000218,,1,F,Intermediate,In vivo,1,Oral bioavailability in dog (dose 10 mg/kg),50588,N,,CHEMBL876734,,
6598,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog,50588,N,,CHEMBL618476,,
6599,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog (dose 1 mg/kg i.v.),50588,N,,CHEMBL618477,,
6600,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),50588,N,,CHEMBL618478,,
6601,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,50588,N,,CHEMBL618479,,
6602,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog,50588,N,,CHEMBL618480,,
6603,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog (dose 3-10 mg/kg),50588,N,,CHEMBL618481,,
6604,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,The compound was tested for bioavailability of compound in plasma of dog; Complete,50588,N,,CHEMBL618482,1969.0,
6605,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL618483,,
6606,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL618484,,
6607,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog,50588,N,,CHEMBL618485,,
6608,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,oral bioavailability was measured in dogs,50588,N,,CHEMBL618486,,
6609,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for plasma protein binding in dog; Not determined,50588,N,,CHEMBL618487,,
6610,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for plasma protein binding of dog,50588,N,,CHEMBL618488,,
6611,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for plasma protein binding of dog; Not determined,50588,N,,CHEMBL876735,,
6612,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,50588,N,,CHEMBL618489,,
6613,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,50588,N,,CHEMBL618490,,
6614,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life was determined,50588,N,,CHEMBL618491,,
6615,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,50588,N,,CHEMBL618492,,
6616,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life was evaluated in dog,50588,N,,CHEMBL873354,,
6617,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life was determined,50588,N,,CHEMBL618493,,
6618,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,N,,CHEMBL618494,,
6619,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,N,,CHEMBL618495,948.0,
6620,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,N,,CHEMBL618496,2113.0,
6621,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,N,,CHEMBL618497,2107.0,
6622,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,N,,CHEMBL618498,2048.0,
6623,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),50588,N,,CHEMBL618499,2106.0,
6624,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,LogP in dog,50588,N,,CHEMBL876736,,
6625,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Partition coefficient (logP),50588,N,,CHEMBL618500,,
6626,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Partition coefficient in dog,50588,N,,CHEMBL857831,,
6627,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,50588,N,,CHEMBL618501,,
6628,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),50588,N,,CHEMBL618502,,
6629,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,50588,N,,CHEMBL618503,,
6630,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),50588,N,,CHEMBL618504,,
6631,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),50588,N,,CHEMBL618505,,
6632,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Metabolism of compound in dog S9 microsomes; Trace,50588,N,,CHEMBL618506,,
6633,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,In vitro metabolic potential in dog liver microsomes,50588,N,,CHEMBL618507,2107.0,
6634,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,50588,N,,CHEMBL876737,,
6635,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL618508,,
6636,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL618509,,
6637,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50588,N,,CHEMBL618510,,
6638,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,The compound was tested for bioavailability in dogs,50588,N,,CHEMBL618511,,
6639,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,The compound was tested for oral bioavailability in dogs,50588,N,,CHEMBL618512,,
6640,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog,50588,N,,CHEMBL618513,,
6641,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for percent protein binding (PB) in dog,50588,N,,CHEMBL618514,,
6642,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,50588,N,,CHEMBL620052,,
6643,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for plasma clearance.,50588,N,,CHEMBL620053,1969.0,
6644,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,The compound was tested for plasma clearance in dog,50588,N,,CHEMBL620054,1969.0,
6645,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,50588,N,,CHEMBL620055,1969.0,
6646,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,50588,N,,CHEMBL620056,,
6647,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,In vitro relative rate of metabolism was determined in dog liver microsomes,50588,N,,CHEMBL620057,2107.0,
6648,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,50588,N,,CHEMBL618939,,
6649,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,50588,N,,CHEMBL618940,,
6650,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life after intravenous administration in dogs at 1.2 uM/kg,50588,N,,CHEMBL618941,,
6651,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,50594,N,,CHEMBL624473,2048.0,
6652,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,50594,N,,CHEMBL624474,2048.0,
6653,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,50594,N,,CHEMBL624475,2048.0,
6654,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,50594,N,,CHEMBL624476,,
6655,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,50594,N,,CHEMBL623478,,
6656,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,50594,N,,CHEMBL623479,,
6657,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,50594,N,,CHEMBL623480,,
6658,42.0,Mus musculus,BAO_0000218,CCRF S-180,1,A,Intermediate,,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,50594,N,,CHEMBL623481,,
6659,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,C2 in brain of mice at the oral dose of 50 mg/kg,50594,N,,CHEMBL623482,955.0,
6660,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,C2 in kidney of mice at the oral dose of 50 mg/kg,50594,N,,CHEMBL623483,2113.0,
6661,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,C2 in liver of mice at the oral dose of 50 mg/kg,50594,N,,CHEMBL623484,2107.0,
6662,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,C2 in lungs of mice at the oral dose of 50 mg/kg,50594,N,,CHEMBL623485,2048.0,
6663,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,C2 in spleen of mice at the oral dose of 50 mg/kg,50594,N,,CHEMBL623486,2106.0,
6664,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in mouse,50594,N,,CHEMBL623487,,
6665,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance of compound after intravenous administration in mice at 24 uM/kg,50594,N,,CHEMBL623488,,
6666,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance from mouse blood following i.v. administration of 10 mg/kg,50594,N,,CHEMBL623489,,
6667,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance was evaluated in mice after intravenous administration,50594,N,,CHEMBL875157,,
6668,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance was evaluated in mice after oral administration,50594,N,,CHEMBL623490,,
6669,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (Plasma clearance) was measured in mouse,50594,N,,CHEMBL623491,,
6670,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance of compound was determined at 40 mg/Kg,50594,N,,CHEMBL623492,,
6671,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance of at 24 mg/Kg,50594,N,,CHEMBL623493,,
6672,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance at 24 mg/Kg,50594,N,,CHEMBL623494,,
6673,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance at 5 mg/Kg,50594,N,,CHEMBL623495,,
6674,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in mice,50594,N,,CHEMBL623496,,
6675,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance value upon iv administration in mouse,50594,N,,CHEMBL623497,,
6676,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Total plasma clearance in mice,50594,N,,CHEMBL623498,1969.0,
6677,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance in mouse,50594,N,,CHEMBL623499,,
6678,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance value was determined,50594,N,,CHEMBL623500,,
6679,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,50594,N,,CHEMBL623501,,
6680,,,BAO_0000100,,1,P,Intermediate,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL875158,,
6681,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,50594,N,,CHEMBL623502,,
6682,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,50594,N,,CHEMBL623503,,
6683,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,N,,CHEMBL623504,,
6684,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,50594,N,,CHEMBL623505,,
6685,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,50594,N,,CHEMBL623506,,
6686,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,50594,N,,CHEMBL623507,,
6687,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,50594,N,,CHEMBL623508,,
6688,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax after oral administration at 30 mg/kg in ICR mouse,50594,N,,CHEMBL623509,,
6689,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax after peroral administration in mice at 2.4 uM/kg,50594,N,,CHEMBL875159,,
6690,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in brain of mice at the oral dose of 50 mg/kg,50594,N,,CHEMBL623510,955.0,
6691,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in kidney of mice at the oral dose of 50 mg/kg,50594,N,,CHEMBL623511,2113.0,
6692,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in liver of mice at the oral dose of 50 mg/kg,50594,N,,CHEMBL623512,2107.0,
6693,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in lungs of mice at the oral dose of 50 mg/kg,50594,N,,CHEMBL623513,2048.0,
6694,,Mus musculus,BAO_0000218,,1,F,Intermediate,In vivo,1,Cmax in mice at 18 uM/kg i.p. administration,50594,N,,CHEMBL623514,,
6695,,Mus musculus,BAO_0000218,,1,F,Intermediate,In vivo,1,Cmax in mice at 23 uM/kg i.v. administration,50594,N,,CHEMBL622609,,
6696,,Mus musculus,BAO_0000218,,1,F,Intermediate,In vivo,1,Cmax in mice at 24 uM/kg i.p. administration,50594,N,,CHEMBL622610,,
6697,,Mus musculus,BAO_0000218,,1,F,Intermediate,In vivo,1,Cmax in mice at 25 uM/kg i.p. administration,50594,N,,CHEMBL621823,,
6698,,Mus musculus,BAO_0000218,,1,F,Intermediate,In vivo,1,Cmax in mice at 26 uM/kg i.p. administration,50594,N,,CHEMBL621824,,
6699,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in spleen of mice at the oral dose of 50 mg/kg,50594,N,,CHEMBL621825,2106.0,
6700,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,50594,N,,CHEMBL621826,,
6701,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value at a dose of 10 mg/kg peroral administration in mice.,50594,N,,CHEMBL621827,,
6702,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value was determined,50594,N,,CHEMBL621828,,
6703,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value in IRC mice,50594,N,,CHEMBL621829,,
6704,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,50594,N,,CHEMBL621830,,
6705,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,50594,N,,CHEMBL621831,,
6706,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,50594,N,,CHEMBL621832,1969.0,
6707,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",50594,N,,CHEMBL624579,1969.0,
6708,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,50594,N,,CHEMBL624580,,
6709,,Acanthocheilonema viteae,BAO_0000218,,1,F,Intermediate,,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,50535,N,,CHEMBL624581,,
6710,,Acanthocheilonema viteae,BAO_0000218,,1,F,Intermediate,,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,50535,N,,CHEMBL624582,,
6711,,Acanthocheilonema viteae,BAO_0000218,,1,F,Intermediate,,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,50535,N,,CHEMBL624583,,
6712,455.0,Homo sapiens,BAO_0000219,A-375,1,F,Intermediate,,1,Inhibitory activity against human tumor cell line A0375 melanoma.,80018,N,,CHEMBL624584,,
6713,,Rattus norvegicus,BAO_0000249,,1,B,Expert,,9,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,12512,D,,CHEMBL624585,,
6714,,Homo sapiens,BAO_0000019,,1,F,Expert,,9,Forskolin-induced cAMP production at human A1 adenosine receptor,114,D,,CHEMBL875165,,
6715,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,114,H,,CHEMBL619490,,
6716,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,114,H,,CHEMBL619491,,
6717,449.0,,BAO_0000219,CHO,1,F,Expert,,8,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,114,H,,CHEMBL619492,,
6718,449.0,,BAO_0000219,CHO,1,F,Expert,,8,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,114,H,,CHEMBL619493,,
6719,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,114,H,,CHEMBL619494,,
6720,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,114,H,,CHEMBL619495,,
6721,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,114,H,,CHEMBL619496,,
6722,449.0,Homo sapiens,BAO_0000219,CHO,1,F,Expert,,9,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,114,D,,CHEMBL619497,,
6723,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,114,H,,CHEMBL619498,,
6724,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,114,H,,CHEMBL619499,,
6725,449.0,,BAO_0000219,CHO,1,F,Expert,,8,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,114,H,,CHEMBL619500,,
6726,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,114,H,,CHEMBL619501,,
6727,449.0,,BAO_0000219,CHO,1,F,Expert,,8,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,114,H,,CHEMBL619502,,
6728,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,114,H,,CHEMBL619503,,
6729,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,114,H,,CHEMBL619504,,
6730,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,114,H,,CHEMBL621298,,
6731,449.0,,BAO_0000219,CHO,1,F,Expert,,8,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,114,H,,CHEMBL621299,,
6732,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,114,H,,CHEMBL621300,,
6733,449.0,,BAO_0000219,CHO,1,F,Autocuration,,8,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,114,H,,CHEMBL621301,,
6734,449.0,,BAO_0000219,CHO,1,F,Expert,,8,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,114,H,,CHEMBL621302,,
6735,164.0,Oryctolagus cuniculus,BAO_0000219,A10,1,F,Intermediate,,1,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,80013,N,,CHEMBL621303,,
6736,164.0,Rattus norvegicus,BAO_0000219,A10,1,F,Autocuration,,0,In vitro potassium channel opening activity in A10 (smooth muscle) cells,22226,U,,CHEMBL621304,,
6737,164.0,Rattus norvegicus,BAO_0000219,A10,1,F,Autocuration,,0,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,22226,U,,CHEMBL621305,,
6738,164.0,Rattus norvegicus,BAO_0000219,A10,1,F,Intermediate,,1,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,80013,N,,CHEMBL621306,,
6739,164.0,Rattus norvegicus,BAO_0000219,A10,1,F,Intermediate,,1,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,80013,N,,CHEMBL618444,,
6740,164.0,Rattus norvegicus,BAO_0000219,A10,1,F,Intermediate,,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,80013,N,,CHEMBL618445,,
6741,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,80089,N,,CHEMBL618446,,
6742,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,80089,N,,CHEMBL618447,,
6743,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,80089,N,,CHEMBL618448,,
6744,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,80089,N,,CHEMBL618449,,
6745,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,80089,N,,CHEMBL618637,,
6746,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",80089,N,,CHEMBL618638,,
6747,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),80089,N,,CHEMBL618639,,
6748,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Expert,,1,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",80089,N,,CHEMBL618640,,
6749,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Expert,,1,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,80089,N,,CHEMBL618641,,
6750,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,80089,N,,CHEMBL618642,,
6751,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,Inhibitory activity against aerobic growth of AA8 cells.,80089,N,,CHEMBL618643,,
6752,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,A,Intermediate,,1,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,80089,N,,CHEMBL884013,,
6753,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Expert,,1,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,80089,N,,CHEMBL622723,,
6754,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,80089,N,,CHEMBL622724,,
6755,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Expert,,1,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,80089,N,,CHEMBL622725,,
6756,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Expert,,1,Cytotoxicity against AA8 cell line,80089,N,,CHEMBL622726,,
6757,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),80089,N,,CHEMBL622727,,
6758,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,A,Intermediate,,1,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),80089,N,,CHEMBL622728,,
6759,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),80089,N,,CHEMBL622729,,
6760,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,A,Intermediate,,1,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),80089,N,,CHEMBL622730,,
6761,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,80089,N,,CHEMBL622731,,
6762,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,80089,N,,CHEMBL622732,,
6763,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Intermediate,,1,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,80089,N,,CHEMBL622733,,
6764,,Cricetulus griseus,BAO_0000218,,1,F,Autocuration,,0,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),22224,U,,CHEMBL622734,,
6765,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Expert,,1,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,80089,N,,CHEMBL622735,,
6766,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Autocuration,,0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,22224,U,,CHEMBL618746,,
6767,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Autocuration,,0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,22224,U,,CHEMBL618747,,
6768,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Autocuration,,0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,22224,U,,CHEMBL620540,,
6769,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Autocuration,,0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,22224,U,,CHEMBL620541,,
6770,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Autocuration,,0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,22224,U,,CHEMBL620542,,
6771,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Autocuration,,0,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,22224,U,,CHEMBL620543,,
6772,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Autocuration,,0,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,22224,U,,CHEMBL618832,,
6773,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Expert,,1,Concentration required to reduce AA8 cell survival by 10%,80089,N,,CHEMBL618833,,
6774,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Autocuration,,0,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",22224,U,,CHEMBL618834,,
6775,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Autocuration,,0,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,22224,U,,CHEMBL618835,,
6776,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Autocuration,,0,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,22224,U,,CHEMBL618836,,
6777,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Autocuration,,0,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,22224,U,,CHEMBL618837,,
6778,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Autocuration,,0,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,22224,U,,CHEMBL618838,,
6779,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Autocuration,,0,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,22224,U,,CHEMBL618839,,
6780,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Autocuration,,0,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,22224,U,,CHEMBL618840,,
6781,,Cricetulus griseus,BAO_0000019,,1,F,Autocuration,,0,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",22224,U,,CHEMBL618841,,
6782,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Autocuration,,0,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,22224,U,,CHEMBL618842,,
6783,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Autocuration,,0,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,22224,U,,CHEMBL618843,,
6784,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period after 15 mg/kg iv dose in Dogs,50588,N,,CHEMBL618844,,
6785,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period after 30 mg/kg po dose in Dogs,50588,N,,CHEMBL618845,,
6786,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life was measured after oral 2b administration (tested in 6 dogs),50588,N,,CHEMBL618846,,
6787,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life was measured in dog after oral 17b administration,50588,N,,CHEMBL618847,,
6788,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,50588,N,,CHEMBL618848,,
6789,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,50588,N,,CHEMBL618849,,
6790,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax value after 15 mg/kg iv dose in Dogs,50588,N,,CHEMBL618850,,
6791,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax value after 30 mg/kg po dose in Dogs,50588,N,,CHEMBL618851,,
6792,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for its half life when administered intravenously in dog,50588,N,,CHEMBL873815,,
6793,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),50588,N,,CHEMBL618852,1969.0,
6794,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Elimination Half-life of compound was determined in dog,50588,N,,CHEMBL618853,,
6795,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life of compound in dog following oral administration,50588,N,,CHEMBL618854,,
6796,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life of compound was determined in dog,50588,N,,CHEMBL618855,,
6797,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life of compound was determined in dog blood,50588,N,,CHEMBL618856,178.0,
6798,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life after oral and iv dosing in dogs,50588,N,,CHEMBL875827,,
6799,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life in dogs in hours,50588,N,,CHEMBL618857,,
6800,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life on i.v. administration of 2 mg/kg was measured in dog,50588,N,,CHEMBL618858,,
6801,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,t1/2 in dog after oral dose (1 mg/kg),50588,N,,CHEMBL618859,,
6802,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life was evaluated in dog,50588,N,,CHEMBL618860,,
6803,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period of compound was determined after intravenous administration at 2 mg/kg,50588,N,,CHEMBL618861,,
6804,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period of compound was determined after peroral administration at 2 mg/kg,50588,N,,CHEMBL622539,,
6805,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period (10 mg/kg) was determined in dog,50588,N,,CHEMBL622540,,
6806,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period (10 mg/kg) was determined in dog,50588,N,,CHEMBL873803,,
6807,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period by iv administration in dog at a dose of 0.3 mg/kg,50588,N,,CHEMBL873804,,
6808,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period by po administration in dog at a dose of 0.3 mg/kg,50588,N,,CHEMBL624311,,
6809,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life period in dog,50588,N,,CHEMBL624312,,
6810,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period in dogs after oral administration at 1 mg/kg,50588,N,,CHEMBL624313,,
6811,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,N,,CHEMBL624314,,
6812,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half-life of compound was determined in dogs,50588,N,,CHEMBL624315,,
6813,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half-life in dog plasma,50588,N,,CHEMBL624316,1969.0,
6814,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half-life in mongrel dogs was determined,50588,N,,CHEMBL624317,,
6815,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life in dog upon oral administration,50588,N,,CHEMBL624318,,
6816,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life in dog upon oral administration; Unable to calculate,50588,N,,CHEMBL624319,,
6817,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half-life was measured in dog,50588,N,,CHEMBL624496,,
6818,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half-life was measured in dog,50588,N,,CHEMBL624497,,
6819,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,50588,N,,CHEMBL624498,,
6820,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral half life was determined,50588,N,,CHEMBL624499,,
6821,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,50588,N,,CHEMBL624500,1969.0,
6822,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Plasma half life was evaluated,50588,N,,CHEMBL624501,1969.0,
6823,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Plasma half life was evaluated in Dog,50588,N,,CHEMBL623666,1969.0,
6824,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Plasma half life was evaluated in dog,50588,N,,CHEMBL623667,1969.0,
6825,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,T1/2 (Half-life) was after oral administration at 5 mg/kg,50588,N,,CHEMBL623668,,
6826,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Tested for the half life value in dog,50588,N,,CHEMBL623669,,
6827,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum time at the dose of 2 mg/kg in dog,50588,N,,CHEMBL623670,,
6828,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,50588,N,,CHEMBL623671,,
6829,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,50588,N,,CHEMBL875945,178.0,
6830,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,50588,N,,CHEMBL623672,178.0,
6831,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,50588,N,,CHEMBL623673,,
6832,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),50588,N,,CHEMBL623674,,
6833,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,50588,N,,CHEMBL623675,,
6834,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",50588,N,,CHEMBL872526,,
6835,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",50588,N,,CHEMBL623676,,
6836,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,50588,N,,CHEMBL623677,1969.0,
6837,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,50588,N,,CHEMBL623678,1969.0,
6838,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Time taken for maximum plasma concentration in dog,50588,N,,CHEMBL623679,1969.0,
6839,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Time to reach Cmax after oral administration to dogs,50588,N,,CHEMBL623680,,
6840,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,N,,CHEMBL623681,1969.0,
6841,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,50588,N,,CHEMBL623682,,
6842,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax after peroral administration (1 mg/kg) was determined in dog,50588,N,,CHEMBL623683,,
6843,,Canis lupus familiaris,BAO_0000218,,1,A,Expert,In vivo,1,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,N,,CHEMBL623684,,
6844,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,50588,N,,CHEMBL622745,,
6845,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax after peroral administration in dogs at 2.4 uM/kg,50588,N,,CHEMBL622746,,
6846,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo Cmax in mice at dose of 100 mg/kg,50594,N,,CHEMBL622747,,
6847,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo Cmax in mice at dose of 50 mg/kg,50594,N,,CHEMBL622748,,
6848,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,50594,N,,CHEMBL622749,,
6849,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),50594,N,,CHEMBL622750,1969.0,
6850,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,50594,N,,CHEMBL623411,1969.0,
6851,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration obtained in mouse plasma was determined,50594,N,,CHEMBL875946,1969.0,
6852,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,50594,N,,CHEMBL623412,1969.0,
6853,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,N,,CHEMBL623413,1969.0,
6854,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,50594,N,,CHEMBL623414,1969.0,
6855,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,50594,N,,CHEMBL623415,1969.0,
6856,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,50594,N,,CHEMBL623416,1969.0,
6857,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,50594,N,,CHEMBL623417,1969.0,
6858,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,50594,N,,CHEMBL623418,1969.0,
6859,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,50594,N,,CHEMBL623419,1969.0,
6860,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,50594,N,,CHEMBL622816,,
6861,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,50594,N,,CHEMBL623313,,
6862,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,50594,N,,CHEMBL623314,,
6863,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,50594,N,,CHEMBL876788,,
6864,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,50594,N,,CHEMBL623315,,
6865,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,50594,N,,CHEMBL623316,,
6866,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,50594,N,,CHEMBL623317,,
6868,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in male mice after 2 mg/kg oral dose,50594,N,,CHEMBL623319,,
6869,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,50594,N,,CHEMBL623320,,
6870,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,50594,N,,CHEMBL623321,,
6871,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,50594,N,,CHEMBL623322,,
6872,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,50594,N,,CHEMBL623323,,
6873,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,50594,N,,CHEMBL623324,,
6874,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,50594,N,,CHEMBL623325,,
6875,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,50594,N,,CHEMBL623326,,
6876,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,50594,N,,CHEMBL623327,,
6877,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Maximum concentration in plasma upon oral administration in mouse,50594,N,,CHEMBL623328,1969.0,
6878,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Maximum plasma concentration was evaluated in mice after oral administration,50594,N,,CHEMBL623329,1969.0,
6879,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,50594,N,,CHEMBL623330,1969.0,
6880,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Dose at which the compound induced fecal excretion in mice,50594,N,,CHEMBL876789,,
6893,164.0,Rattus norvegicus,BAO_0000219,A10,1,F,Expert,,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,80013,N,,CHEMBL623333,,
6894,164.0,Rattus norvegicus,BAO_0000219,A10,1,F,Expert,,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,80013,N,,CHEMBL623334,,
6895,164.0,Rattus norvegicus,BAO_0000219,A10,1,F,Expert,,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,80013,N,,CHEMBL627536,,
6896,164.0,Rattus norvegicus,BAO_0000219,A10,1,F,Expert,,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,80013,N,,CHEMBL627537,,
6897,164.0,Rattus norvegicus,BAO_0000219,A10,1,F,Intermediate,,1,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),80013,N,,CHEMBL627538,,
6898,393.0,Homo sapiens,BAO_0000219,A121,1,F,Intermediate,,1,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,80655,N,,CHEMBL884106,,
6899,393.0,Homo sapiens,BAO_0000219,A121,1,F,Intermediate,,1,Anticancer activity against human ovarian carcinoma A121 cells,80655,N,,CHEMBL625294,,
6900,393.0,Homo sapiens,BAO_0000219,A121,1,F,Intermediate,,1,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,80655,N,,CHEMBL625295,,
6901,393.0,Homo sapiens,BAO_0000219,A121,1,F,Intermediate,,1,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,80655,N,,CHEMBL625296,,
6902,393.0,Homo sapiens,BAO_0000219,A121,1,F,Expert,,1,Growth inhibition of human ovarian carcinoma (A121) cell line,80655,N,,CHEMBL625297,,
6903,393.0,Homo sapiens,BAO_0000219,A121,1,F,Expert,,1,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,80655,N,,CHEMBL625298,,
6904,393.0,Homo sapiens,BAO_0000219,A121,1,F,Intermediate,,1,Cytotoxicity against human A121 ovarian cells,80655,N,,CHEMBL625960,,
6905,393.0,Homo sapiens,BAO_0000219,A121,1,F,Intermediate,,1,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,80655,N,,CHEMBL625961,,
6906,393.0,Homo sapiens,BAO_0000219,A121,1,F,Intermediate,,1,In vitro cytotoxicity against human ovarian carcinoma A21,80655,N,,CHEMBL625962,,
6907,393.0,Homo sapiens,BAO_0000219,A121,1,F,Intermediate,,1,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,80655,N,,CHEMBL624717,,
6908,393.0,Homo sapiens,BAO_0000219,A121,1,F,Intermediate,,1,Inhibitory activity of compound against human A121 ovarian cell line.,80655,N,,CHEMBL624718,,
6909,393.0,Homo sapiens,BAO_0000219,A121,1,F,Intermediate,,1,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,80655,N,,CHEMBL624719,,
6910,393.0,Homo sapiens,BAO_0000219,A121,1,F,Intermediate,,1,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,80655,N,,CHEMBL624720,,
6911,622.0,Homo sapiens,BAO_0000219,A 172,1,F,Intermediate,,1,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,80012,N,,CHEMBL624721,,
6912,622.0,Homo sapiens,BAO_0000219,A 172,1,F,Expert,,1,In vitro cytotoxicity against A172 human tumor cell lines.,80012,N,,CHEMBL624722,,
6913,622.0,Homo sapiens,BAO_0000219,A 172,1,F,Intermediate,,1,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,80012,N,,CHEMBL877597,,
6914,622.0,Homo sapiens,BAO_0000219,A 172,1,F,Intermediate,,1,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,80012,N,,CHEMBL624723,,
6915,622.0,Homo sapiens,BAO_0000219,A 172,1,F,Intermediate,,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,80012,N,,CHEMBL624724,,
6916,,Canis lupus familiaris,BAO_0000224,,1,B,Autocuration,,4,Association constant against A2 adenosine receptor,104729,H,,CHEMBL624725,,
6917,1085.0,fish,BAO_0000219,A2,1,F,Intermediate,,1,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,80656,N,,CHEMBL624726,,
6918,,Rattus norvegicus,BAO_0000224,,1,B,Autocuration,,5,Ratio of Ki for adenosine A2 and A1 receptor binding,104713,D,,CHEMBL857535,,
6919,623.0,Homo sapiens,BAO_0000219,A204,1,F,Expert,,1,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,80014,N,,CHEMBL624727,,
6920,623.0,Homo sapiens,BAO_0000219,A204,1,F,Expert,,1,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,80014,N,,CHEMBL624728,,
6921,404.0,Homo sapiens,BAO_0000219,A2058,1,F,Intermediate,,1,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,80015,N,,CHEMBL624729,,
6922,973.0,Homo sapiens,BAO_0000219,A253 cell line,1,F,Intermediate,,1,Growth inhibition against Human squamous cell line(A 253),80657,N,,CHEMBL624730,,
6923,973.0,Homo sapiens,BAO_0000219,A253 cell line,1,F,Intermediate,,1,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,80657,N,,CHEMBL624731,,
6924,973.0,Homo sapiens,BAO_0000219,A253 cell line,1,F,Intermediate,,1,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,80657,N,,CHEMBL624732,,
6925,973.0,Homo sapiens,BAO_0000219,A253 cell line,1,F,Intermediate,,1,Growth inhibition of A253 cell lines.,80657,N,,CHEMBL883245,,
6926,973.0,Homo sapiens,BAO_0000219,A253 cell line,1,F,Intermediate,,1,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),80657,N,,CHEMBL624733,,
6927,973.0,Homo sapiens,BAO_0000219,A253 cell line,1,F,Intermediate,,1,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,80657,N,,CHEMBL624734,,
6928,973.0,Homo sapiens,BAO_0000219,A253 cell line,1,F,Intermediate,,1,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,80657,N,,CHEMBL624735,,
6929,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,81034,N,,CHEMBL621780,,
6930,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,81034,N,,CHEMBL877598,,
6931,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,Cytotoxic activity against A2780 human ovarian carcinoma cell line,81034,N,,CHEMBL621781,,
6932,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Cytotoxicity against human cancer cell lines A2780 (ovarian),81034,N,,CHEMBL621782,,
6933,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,81034,N,,CHEMBL621783,,
6934,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,81034,N,,CHEMBL621784,,
6935,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),81034,N,,CHEMBL621785,,
6936,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,81034,N,,CHEMBL621968,,
6937,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,81034,N,,CHEMBL621969,,
6938,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,81034,N,,CHEMBL621970,,
6939,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,81034,N,,CHEMBL621971,,
6940,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,81034,N,,CHEMBL621972,,
6941,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,81034,N,,CHEMBL884108,,
6942,,Cricetulus griseus,BAO_0000019,,1,F,Autocuration,,0,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,22224,U,,CHEMBL623826,,
6943,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,A,Autocuration,,0,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,22224,U,,CHEMBL623827,,
6944,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Autocuration,,0,Evaluated for growth inhibition of AA8 cells under aerobic conditions,22224,U,,CHEMBL623828,,
6945,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Autocuration,,0,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,22224,U,,CHEMBL623829,,
6946,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Autocuration,,0,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),22224,U,,CHEMBL623830,,
6947,,Cricetulus griseus,BAO_0000019,,1,F,Autocuration,,0,Growth inhibition against CHO-derived cell line AA8,22224,U,,CHEMBL623831,,
6948,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Autocuration,,0,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],22224,U,,CHEMBL623832,,
6949,185.0,hampster,BAO_0000219,CHO-AA8,1,F,Expert,,1,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,80089,N,,CHEMBL623833,,
6950,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Expert,,1,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,80089,N,,CHEMBL623834,,
6951,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Autocuration,,0,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,22224,U,,CHEMBL623835,,
6952,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Autocuration,,0,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,22224,U,,CHEMBL623836,,
6953,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Autocuration,,0,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,22224,U,,CHEMBL623837,,
6954,185.0,Cricetulus griseus,BAO_0000219,CHO-AA8,1,F,Expert,,1,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,80089,N,,CHEMBL623838,,
6955,,,BAO_0000019,,1,F,Autocuration,,8,compound was evaluated for association constant (Ka) of isolated serum protein AAG,12675,H,,CHEMBL623839,,
6956,,,BAO_0000019,,1,F,Autocuration,,8,Number of binding sites (n) of isolated serum protein AAG,12675,H,,CHEMBL623840,,
6957,,,BAO_0000225,,1,B,Intermediate,,3,Association constant for binding to AATT duplex,22222,M,,CHEMBL623841,,
6958,416.0,Homo sapiens,BAO_0000219,ABAE,1,F,Expert,,1,Inhibition of ABAE human fibroblast cell proliferation,100090,N,,CHEMBL623842,,
6959,1064.0,Mus musculus,BAO_0000218,AC755,1,F,Intermediate,,1,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",80668,N,,CHEMBL623843,,
6960,,Oryctolagus cuniculus,BAO_0000218,,1,F,Expert,,9,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,102444,D,,CHEMBL618669,,
6961,,Oryctolagus cuniculus,BAO_0000218,,1,F,Expert,In vivo,9,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,102444,D,,CHEMBL618670,,
6962,,,BAO_0000357,,1,B,Autocuration,,8,Inhibitory activity against angiotensin-converting enzyme (ACE).,69,H,,CHEMBL618671,,
6963,,,BAO_0000357,,1,B,Autocuration,,8,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,69,H,,CHEMBL618672,,
6964,978.0,Homo sapiens,BAO_0000219,ACH-2 cell line,1,F,Intermediate,,1,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,80669,N,,CHEMBL618673,,
6965,978.0,Homo sapiens,BAO_0000219,ACH-2 cell line,1,F,Intermediate,,1,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),80669,N,,CHEMBL618674,,
6966,998.0,Human immunodeficiency virus 1,BAO_0000219,T cell line,1,F,Autocuration,,0,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,22224,U,,CHEMBL618675,,
6967,998.0,Human immunodeficiency virus 1,BAO_0000219,T cell line,1,F,Autocuration,,0,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),22224,U,,CHEMBL618676,,
6968,998.0,Human immunodeficiency virus 1,BAO_0000219,T cell line,1,F,Autocuration,,0,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),22224,U,,CHEMBL618677,,
6969,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Inhibition of growth of renal cancer ACHN cell line,80025,N,,CHEMBL618678,,
6970,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Inhibition of growth of ACHN renal cancer cell line,80025,N,,CHEMBL618679,,
6971,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Inhibitory concentration required against ACHN renal cancer cell line,80025,N,,CHEMBL618680,,
6972,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Expert,,1,Concentration required to inhibit growth of human renal (ACHN) cell line,80025,N,,CHEMBL618681,,
6973,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,80025,N,,CHEMBL618682,,
6974,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Cytotoxic activity against ACHN Renal cancer cell line,80025,N,,CHEMBL618683,,
6975,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Cytotoxicity evaluation against ACHN renal cancer cells,80025,N,,CHEMBL618684,,
6976,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,In vitro antitumor activity against human renal ACHN cell line,80025,N,,CHEMBL618685,,
6977,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,80025,N,,CHEMBL876499,,
6978,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,80025,N,,CHEMBL618686,,
6979,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",80025,N,,CHEMBL618687,,
6980,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,80025,N,,CHEMBL618688,,
6981,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Expert,,1,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,80025,N,,CHEMBL618689,,
6982,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,80025,N,,CHEMBL618690,,
6983,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,80025,N,,CHEMBL618691,,
6984,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),80025,N,,CHEMBL619373,,
6985,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",80025,N,,CHEMBL884008,,
6986,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,80025,N,,CHEMBL619374,,
6987,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Compound was tested for the growth inhibition of ACHN renal tumor cell line,80025,N,,CHEMBL619375,,
6988,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,80025,N,,CHEMBL619376,,
6989,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,80025,N,,CHEMBL619377,,
6990,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,80025,N,,CHEMBL619378,,
6991,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax value after administration of 4 mg/Kg oral dose in dog,50588,N,,CHEMBL872527,,
6992,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",50588,N,,CHEMBL876500,,
6993,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,50588,N,,CHEMBL619379,,
6994,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution after 15 mg/kg iv dose in Dogs,50588,N,,CHEMBL619538,,
6995,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution after 30 mg/kg po dose in Dogs,50588,N,,CHEMBL619539,,
6996,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,50588,N,,CHEMBL619540,,
6997,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,50588,N,,CHEMBL619541,,
6998,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution was evaluated in dog,50588,N,,CHEMBL619542,,
6999,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,50588,N,,CHEMBL619543,,
7000,,Canis lupus familiaris,BAO_0000218,,1,A,Expert,,1,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,50588,N,,CHEMBL619544,,
7001,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,The compound was tested for volume of distribution in dog,50588,N,,CHEMBL619545,,
7002,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,50588,N,,CHEMBL619546,,
7003,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Vd (1 mg/kg) was determined in dog (in vivo),50588,N,,CHEMBL619547,,
7004,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Vd in dog,50588,N,,CHEMBL619548,,
7005,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution was determined,50588,N,,CHEMBL619549,,
7006,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution in dog,50588,N,,CHEMBL619550,,
7007,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution by as 4 fold increase by iv administration in dogs,50588,N,,CHEMBL876501,,
7008,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,50588,N,,CHEMBL619551,,
7009,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,N,,CHEMBL619552,,
7010,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution at the dose of 2 mg/kg in dog,50588,N,,CHEMBL619553,,
7011,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Steady state volume of distribution was determined,50588,N,,CHEMBL618722,,
7012,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,50588,N,,CHEMBL618723,,
7013,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,50588,N,,CHEMBL618724,,
7014,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,50588,N,,CHEMBL618725,,
7015,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog (dose 1 mg/kg i.v.),50588,N,,CHEMBL618726,,
7016,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),50588,N,,CHEMBL618727,,
7017,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (vdss) was measured in dog,50588,N,,CHEMBL624233,,
7018,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,50588,N,,CHEMBL624234,,
7019,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Vdss was determined after iv 0.1 mg/kg administration in dog,50588,N,,CHEMBL624235,,
7020,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume displacement was calculated in dog,50588,N,,CHEMBL624236,,
7021,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,50588,N,,CHEMBL624237,,
7022,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution constant was determined,50588,N,,CHEMBL624238,,
7023,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution at a dose of 1 uM/kg in dog was determined,50588,N,,CHEMBL624239,,
7024,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,50588,N,,CHEMBL875829,,
7025,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,50588,N,,CHEMBL624240,,
7026,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution (Vdss) was measured in dog,50588,N,,CHEMBL624241,,
7027,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution (Vdss) was measured in dog,50588,N,,CHEMBL624242,,
7028,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50588,N,,CHEMBL624243,,
7029,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution in steady state was determined in dog,50588,N,,CHEMBL624244,,
7030,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution of compound was determined in dog,50588,N,,CHEMBL624245,,
7031,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,50588,N,,CHEMBL624246,,
7032,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),50588,N,,CHEMBL624247,,
7033,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution (Vdss) was measured in dog,50588,N,,CHEMBL624248,,
7034,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,N,,CHEMBL624249,,
7035,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,N,,CHEMBL624250,,
7036,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,N,,CHEMBL624251,,
7037,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Maximum rate of depolarization of the upstroke of the action potential,50588,N,,CHEMBL624252,,
7038,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Steady state volume distribution in dog,50588,N,,CHEMBL624253,,
7039,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,50588,N,,CHEMBL624950,,
7040,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,50588,N,,CHEMBL624951,,
7041,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,50588,N,,CHEMBL875830,,
7042,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution in dog after administration of 1 mg/kg iv,50588,N,,CHEMBL624952,,
7043,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,50588,N,,CHEMBL624953,,
7044,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Vss after intravenous administration (0.5 mg/kg) was determined in dog,50588,N,,CHEMBL624954,,
7045,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Vss on i.v. administration of 2 mg/kg was measured in dog,50588,N,,CHEMBL624955,,
7046,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Vss was determined,50588,N,,CHEMBL624956,,
7047,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Vss in dog,50588,N,,CHEMBL625129,,
7048,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,50588,N,,CHEMBL625130,,
7049,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution in dogs,50588,N,,CHEMBL625131,,
7050,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution in dog,50588,N,,CHEMBL625132,,
7051,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for the oral bioavailability in dog,50588,N,,CHEMBL872263,,
7060,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,50594,N,,CHEMBL624336,,
7061,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,50594,N,,CHEMBL624337,,
7062,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability after peroral administration of 50 mg/kg of dose in mice,50594,N,,CHEMBL624338,,
7063,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was measured in mouse,50594,N,,CHEMBL624339,,
7064,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in mouse,50594,N,,CHEMBL624340,,
7065,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,N,,CHEMBL624341,,
7066,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in mouse,50594,N,,CHEMBL624342,,
7067,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,50594,N,,CHEMBL624343,,
7068,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in mouse,50594,N,,CHEMBL624344,,
7069,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral availability at 50 mg/kg po in male mice,50594,N,,CHEMBL624345,,
7070,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in mouse (dose 10 mg/kg),50594,N,,CHEMBL624346,,
7071,,Mus musculus,BAO_0000218,,1,A,Expert,In vivo,1,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,50594,N,,CHEMBL624347,,
7072,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",50594,N,,CHEMBL624348,,
7074,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in mouse,50594,N,,CHEMBL622754,,
7075,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in vivo in mice;ND=Not determined,50594,N,,CHEMBL622755,,
7076,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in mouse at 10 mg/kg of the compound,50594,N,,CHEMBL622756,,
7077,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),50594,N,,CHEMBL622757,,
7078,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),50594,N,,CHEMBL622758,,
7079,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for bioavailability of the compound,50594,N,,CHEMBL622759,,
7080,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for half life at the dose of 10 mg/kg when administered intravenously,50594,N,,CHEMBL622760,,
7081,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,50594,N,,CHEMBL622761,1969.0,
7082,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,The plasma half life of compound was determined on heparin prepared by human plasma. ,50594,N,,CHEMBL622762,1969.0,
7083,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,50594,N,,CHEMBL622763,1969.0,
7084,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,50594,N,,CHEMBL622764,1969.0,
7085,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,50594,N,,CHEMBL622765,1969.0,
7086,,Mus musculus,BAO_0000218,,1,F,Intermediate,,1,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,50594,N,,CHEMBL622766,,
7087,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,50594,N,,CHEMBL622767,,
7088,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,50594,N,,CHEMBL622768,,
7089,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,N,,CHEMBL875948,178.0,
7090,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,N,,CHEMBL622769,178.0,
7091,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,N,,CHEMBL622770,178.0,
7092,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,N,,CHEMBL622771,178.0,
7093,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,N,,CHEMBL622772,178.0,
7094,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,N,,CHEMBL622773,178.0,
7095,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,N,,CHEMBL622774,178.0,
7096,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,N,,CHEMBL621725,10000001.0,
7097,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,50594,N,,CHEMBL621726,10000001.0,
7098,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,81034,N,,CHEMBL621727,,
7099,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,81034,N,,CHEMBL622413,,
7100,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Compound was evaluated for cytotoxicity against A2780 cell line,81034,N,,CHEMBL622414,,
7101,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,Inhibition of A2780 cell clonogenic assay,81034,N,,CHEMBL622415,,
7102,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,Cytotoxic effect on ovarian cancer cell line (A2780),81034,N,,CHEMBL884001,,
7103,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,81034,N,,CHEMBL622416,,
7104,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",81034,N,,CHEMBL622417,,
7105,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,81034,N,,CHEMBL622590,,
7106,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,Antiproliferative activity against human A2780 cells,81034,N,,CHEMBL622591,,
7107,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,Inhibition of human A2780 cell proliferation,81034,N,,CHEMBL622592,,
7108,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,81034,N,,CHEMBL622593,,
7109,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,Inhibition of human A2780 cell proliferation (No data),81034,N,,CHEMBL622594,,
7110,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,81034,N,,CHEMBL622595,,
7111,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Compound was evaluated against human Ovarian carcinoma cell line A2780,81034,N,,CHEMBL622596,,
7112,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,Growth inhibition against A2780 wild-type ovarian cell lines,81034,N,,CHEMBL622597,,
7113,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,81034,N,,CHEMBL622598,,
7114,,Homo sapiens,BAO_0000019,,1,F,Autocuration,,5,Inhibition of tubulin polymerization in human ovarian cancer cell lines,104766,D,,CHEMBL622599,,
7115,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,81034,N,,CHEMBL622600,,
7116,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,81034,N,,CHEMBL622601,,
7117,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,81034,N,,CHEMBL622602,,
7118,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,81034,N,,CHEMBL622603,,
7119,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,81034,N,,CHEMBL622604,,
7120,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,81034,N,,CHEMBL622605,,
7121,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,In vitro inhibition of human ovarian cell line A2780,81034,N,,CHEMBL622606,,
7122,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",81034,N,,CHEMBL619463,,
7123,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),81034,N,,CHEMBL619464,,
7124,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,Concentration required to inhibit A2780-cell growth by 50%,81034,N,,CHEMBL619465,,
7125,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,81034,N,,CHEMBL619466,,
7126,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,Cytotoxic effect on human ovarian (A2780) cancer cell line,81034,N,,CHEMBL619467,,
7127,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,81034,N,,CHEMBL619468,,
7128,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,81034,N,,CHEMBL619469,,
7129,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,81034,N,,CHEMBL619470,,
7130,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,81034,N,,CHEMBL619471,,
7131,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Cytotoxicity against human ovarian carcinoma A2780 cell line,81034,N,,CHEMBL619472,,
7132,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",81034,N,,CHEMBL619473,,
7133,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",81034,N,,CHEMBL874368,,
7134,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",81034,N,,CHEMBL884003,,
7135,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",81034,N,,CHEMBL622690,,
7136,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,81034,N,,CHEMBL622691,,
7137,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,81034,N,,CHEMBL622692,,
7138,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,81034,N,,CHEMBL623406,,
7139,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",81034,N,,CHEMBL884004,,
7140,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,81034,N,,CHEMBL623407,,
7141,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,81034,N,,CHEMBL623408,,
7142,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,In vitro antitumor activity against A2780 cell line.,81034,N,,CHEMBL623409,,
7143,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,81034,N,,CHEMBL623410,,
7144,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,In vitro cytotoxicity against A2780 human ovarian cancer cell line,81034,N,,CHEMBL623576,,
7145,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Inhibitory activity against kidney A-CHN tumor cell growth in culture,80025,N,,CHEMBL623577,,
7146,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,The IC50 value was measured on ACHN cell line in renal tumor type.,80025,N,,CHEMBL623578,,
7147,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,80025,N,,CHEMBL623579,,
7148,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Expert,,1,In vitro lethal concentration against most sensitive ACHN cell line,80025,N,,CHEMBL623580,,
7149,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Tested for cytotoxic activity against renal cancer ACHN cell line,80025,N,,CHEMBL623581,,
7150,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Compound tested for growth inhibition of renal cancer cell line ACHN,80025,N,,CHEMBL857456,,
7151,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,80025,N,,CHEMBL623582,,
7152,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,80025,N,,CHEMBL623583,,
7153,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,In vitro anticancer activity against ACHN renal cancer cell line,80025,N,,CHEMBL623584,,
7154,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,80025,N,,CHEMBL623585,,
7155,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Percent selectivity was evaluated in renal ACHN cell lines,80025,N,,CHEMBL623586,,
7156,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,In vitro inhibitory activity against renal ACHN cancer cell line,80025,N,,CHEMBL623587,,
7157,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Tested for cytotoxicity against ACHN cell lines in renal cancer,80025,N,,CHEMBL875279,,
7158,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,80025,N,,CHEMBL623588,,
7159,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,80025,N,,CHEMBL623589,,
7160,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,80025,N,,CHEMBL623590,,
7161,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Expert,,1,Cytotoxic effect on renal cancer line ACHN,80025,N,,CHEMBL623591,,
7162,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,80025,N,,CHEMBL623592,,
7163,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,In vitro inhibition of Renal Cancer ACHN cell lines,80025,N,,CHEMBL623593,,
7164,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Antitumor activity against human renal adenocarcinoma ACHN cells,80025,N,,CHEMBL623594,,
7165,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Expert,,1,Antitumor activity against human renal adenocarcinoma ACHN cells.,80025,N,,CHEMBL621833,,
7166,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,80025,N,,CHEMBL621834,,
7167,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),80025,N,,CHEMBL621835,,
7168,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",80025,N,,CHEMBL621836,,
7169,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,80025,N,,CHEMBL621837,,
7170,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,80025,N,,CHEMBL875280,,
7171,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,80025,N,,CHEMBL621838,,
7172,626.0,Homo sapiens,BAO_0000219,ACHN,1,F,Intermediate,,1,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,80025,N,,CHEMBL621839,,
7173,,,BAO_0000019,,1,A,Autocuration,,0,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,22224,U,,CHEMBL621840,,
7174,,,BAO_0000019,,1,F,Autocuration,,8,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,10647,H,,CHEMBL621841,,
7175,468.0,Cytomegalovirus,BAO_0000218,HEL,1,F,Expert,,1,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,50529,N,,CHEMBL622979,,
7176,,Cytomegalovirus,BAO_0000218,,1,F,Intermediate,,1,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,50529,N,,CHEMBL876595,,
7177,,,BAO_0000357,,1,B,Autocuration,,8,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),12159,H,,CHEMBL620221,,
7178,,,BAO_0000357,,1,B,Autocuration,,8,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),12159,H,,CHEMBL620222,,
7179,979.0,Bos taurus,BAO_0000219,ADDP cell line,1,F,Intermediate,,1,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,80670,N,,CHEMBL620506,,
7180,980.0,Mus musculus,BAO_0000219,ADJ/PC6,1,F,Intermediate,,1,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,80671,N,,CHEMBL620507,,
7181,980.0,Mus musculus,BAO_0000219,ADJ/PC6,1,F,Intermediate,,1,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,80671,N,,CHEMBL620508,,
7182,980.0,Mus musculus,BAO_0000219,ADJ/PC6,1,F,Intermediate,,1,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",80671,N,,CHEMBL620509,,
7183,980.0,Mus musculus,BAO_0000219,ADJ/PC6,1,F,Intermediate,,1,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,80671,N,,CHEMBL620510,,
7184,980.0,Mus musculus,BAO_0000219,ADJ/PC6,1,A,Intermediate,,1,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,80671,N,,CHEMBL620511,,
7185,980.0,Mus musculus,BAO_0000219,ADJ/PC6,1,F,Intermediate,,1,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,80671,N,,CHEMBL620512,,
7186,,Mus musculus,BAO_0000019,,1,F,Autocuration,,0,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,22224,U,,CHEMBL620513,,
7187,,Mus musculus,BAO_0000019,,1,F,Autocuration,,0,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,22224,U,,CHEMBL620514,,
7188,,Mus musculus,BAO_0000019,,1,F,Autocuration,,0,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,22224,U,,CHEMBL620515,,
7189,,Bacillus subtilis,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),22224,U,,CHEMBL620516,,
7190,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,AUC value in dog after IV administration at a dose of 5 mg/kg,50588,N,,CHEMBL620517,1969.0,
7191,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,AUC value in dog after oral administration at a dose of 5 mg/kg,50588,N,,CHEMBL620518,1969.0,
7192,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value in dog after oral administration at a dose of 5 mg/kg,50588,N,,CHEMBL620519,,
7193,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog after oral administration at a dose of 5 mg/kg,50588,N,,CHEMBL621386,,
7194,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax value in dog after oral administration at a dose of 5 mg/kg,50588,N,,CHEMBL621387,,
7195,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for its clearance when administered intravenously in dog,50588,N,,CHEMBL621388,,
7196,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,50588,N,,CHEMBL621389,,
7197,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),50588,N,,CHEMBL621390,,
7198,,,BAO_0000100,,1,P,Intermediate,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL621391,,
7199,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life in dog,50588,N,,CHEMBL621392,,
7200,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Time taken for EC90 was determined when tested in dog,50588,N,,CHEMBL621393,,
7201,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life (iv) was determined,50588,N,,CHEMBL621394,,
7202,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,50588,N,,CHEMBL621395,2107.0,
7203,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was calculated in dog after iv administration,50588,N,,CHEMBL621396,,
7204,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was calculated in dog after peroral administration,50588,N,,CHEMBL621397,,
7205,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,50588,N,,CHEMBL621398,,
7206,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,pKa was evaluated in dog,50588,N,,CHEMBL618818,,
7207,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,50588,N,,CHEMBL618819,,
7208,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,50588,N,,CHEMBL618820,,
7209,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,50588,N,,CHEMBL873810,,
7210,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,50588,N,,CHEMBL876606,,
7211,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for the half-life (t 1/2) in hours,50588,N,,CHEMBL618821,,
7212,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,50588,N,,CHEMBL618822,178.0,
7213,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,50588,N,,CHEMBL618823,178.0,
7214,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life after intravenous administration of 1 mg/kg in dog,50588,N,,CHEMBL618824,,
7215,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life was measured in dog,50588,N,,CHEMBL618825,,
7216,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period in dog after 5 mg/kg dose,50588,N,,CHEMBL618826,,
7217,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life period was evaluated in dog; 4-4.8,50588,N,,CHEMBL618827,,
7218,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,50588,N,,CHEMBL618828,,
7219,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life was determined in dog after a3 mg/kg of iv dose,50588,N,,CHEMBL618829,,
7220,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half-life was determined,50588,N,,CHEMBL618830,,
7221,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life in dogs,50588,N,,CHEMBL618831,,
7222,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,50588,N,,CHEMBL619489,1969.0,
7223,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,50588,N,,CHEMBL619649,,
7224,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for the half life period after iv administration in Beagle dog.,50588,N,,CHEMBL876607,,
7225,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for the half life period after oral administration in conscious dog.,50588,N,,CHEMBL619650,,
7226,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for half life in dog,50588,N,,CHEMBL619651,,
7227,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for its half life in dog,50588,N,,CHEMBL619652,,
7228,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,50588,N,,CHEMBL619653,,
7229,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life of compound in dog was determined,50588,N,,CHEMBL619654,,
7230,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life (iv) was determined,50588,N,,CHEMBL619655,,
7231,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),50588,N,,CHEMBL619656,178.0,
7232,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,50588,N,,CHEMBL873812,1969.0,
7233,,Canis lupus familiaris,BAO_0000218,,1,F,Intermediate,In vivo,1,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,50588,N,,CHEMBL621365,1969.0,
7234,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life in dog,50588,N,,CHEMBL621366,,
7235,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life in dog plasma,50588,N,,CHEMBL621367,1969.0,
7236,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in dog plasma after administration of 0.25 mg/kg iv,50588,N,,CHEMBL621368,1969.0,
7237,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in dog plasma after administration of 1 mg/kg iv,50588,N,,CHEMBL621369,1969.0,
7238,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in dog plasma was determined at dose 10 mg/kg,50588,N,,CHEMBL621370,1969.0,
7239,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life in dog was determined,50588,N,,CHEMBL621371,,
7240,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),50588,N,,CHEMBL621372,,
7241,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life upon exposure to human plasma,50588,N,,CHEMBL621373,1969.0,
7242,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life was calculated in dog,50588,N,,CHEMBL621374,,
7243,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life was determined,50588,N,,CHEMBL621375,,
7244,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life was determined,50588,N,,CHEMBL621376,,
7245,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life by intravenous administration of 1.2 mg/kg in dog,50588,N,,CHEMBL619624,,
7246,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life in dog,50588,N,,CHEMBL875840,,
7247,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life in dog after intra venous administration of the compound,50588,N,,CHEMBL619625,,
7248,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life in dog after intra venous administration of the compound; ND means Not determined,50588,N,,CHEMBL619626,,
7249,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in dog after po administration of the compound,50588,N,,CHEMBL619627,,
7250,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in dog after po administration of the compound; ND means Not determined,50588,N,,CHEMBL873817,,
7251,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in dog at the single oral dose of 1 mg/kg,50588,N,,CHEMBL619628,,
7252,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life in dogs,50588,N,,CHEMBL619629,,
7253,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,50588,N,,CHEMBL619630,,
7254,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life in rat,50588,N,,CHEMBL619631,,
7255,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),50588,N,,CHEMBL619632,,
7256,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,N,,CHEMBL619633,10000001.0,
7257,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,N,,CHEMBL875841,10000001.0,
7258,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,N,,CHEMBL619634,10000001.0,
7259,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,N,,CHEMBL619635,10000001.0,
7260,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,N,,CHEMBL619636,10000001.0,
7261,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,N,,CHEMBL619637,10000004.0,
7262,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,N,,CHEMBL619638,10000004.0,
7263,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,N,,CHEMBL619639,10000004.0,
7264,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,N,,CHEMBL619640,10000004.0,
7265,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,N,,CHEMBL619641,10000004.0,
7266,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,N,,CHEMBL619642,10000004.0,
7267,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,N,,CHEMBL619643,10000004.0,
7268,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,N,,CHEMBL619644,948.0,
7269,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,N,,CHEMBL621112,948.0,
7270,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,N,,CHEMBL621113,948.0,
7271,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,N,,CHEMBL621114,948.0,
7272,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,N,,CHEMBL621115,948.0,
7273,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,N,,CHEMBL621116,948.0,
7274,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,N,,CHEMBL621117,948.0,
7275,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,N,,CHEMBL621118,2113.0,
7276,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,50594,N,,CHEMBL621119,2113.0,
7277,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,N,,CHEMBL621120,2113.0,
7278,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,N,,CHEMBL621757,2113.0,
7279,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,N,,CHEMBL621758,2113.0,
7280,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,N,,CHEMBL621759,2113.0,
7281,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,N,,CHEMBL621760,2113.0,
7282,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,N,,CHEMBL621761,2107.0,
7283,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,N,,CHEMBL621762,2107.0,
7284,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,N,,CHEMBL621763,2107.0,
7285,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,N,,CHEMBL624502,2107.0,
7286,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,N,,CHEMBL624503,2107.0,
7287,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,N,,CHEMBL624504,2107.0,
7288,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,N,,CHEMBL624505,2107.0,
7289,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,N,,CHEMBL624506,2048.0,
7290,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro cytotoxicity against A2780 (human ovarian cancer),81034,N,,CHEMBL624507,,
7291,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,81034,N,,CHEMBL624508,,
7292,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,81034,N,,CHEMBL624509,,
7293,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,81034,N,,CHEMBL624510,,
7294,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,81034,N,,CHEMBL875956,,
7295,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,81034,N,,CHEMBL839885,,
7296,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,81034,N,,CHEMBL624511,,
7297,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro cytotoxicity against A2780 cell line,81034,N,,CHEMBL624512,,
7298,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,81034,N,,CHEMBL624513,,
7299,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro inhibitory activity against human ovarian cancer A2780 cell line,81034,N,,CHEMBL624514,,
7300,478.0,Homo sapiens,BAO_0000218,A2780,1,F,Intermediate,,1,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,81034,N,,CHEMBL618547,,
7301,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",81034,N,,CHEMBL618548,,
7302,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Inhibition of tubulin polymerization in analogy of ca.,81034,N,,CHEMBL618549,,
7303,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,81034,N,,CHEMBL618550,,
7304,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,Cytotoxic effect in ovarian cancer cell line (A2780),81034,N,,CHEMBL618551,,
7305,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,81034,N,,CHEMBL618552,,
7306,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Tested for the cytotoxicity in A2780 ovarian cell line,81034,N,,CHEMBL618553,,
7307,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),81034,N,,CHEMBL618554,,
7308,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,81034,N,,CHEMBL618555,,
7309,481.0,,BAO_0000219,A2780cisR,1,F,Intermediate,,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,80017,N,,CHEMBL618556,,
7310,481.0,,BAO_0000219,A2780cisR,1,F,Intermediate,,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),80017,N,,CHEMBL618557,,
7311,481.0,,BAO_0000219,A2780cisR,1,F,Intermediate,,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,80017,N,,CHEMBL618558,,
7312,481.0,,BAO_0000219,A2780cisR,1,F,Intermediate,,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),80017,N,,CHEMBL618559,,
7313,478.0,Homo sapiens,BAO_0000218,A2780,1,F,Intermediate,,1,In vivo log of cells killed after administration of compound in A2780 cell line,81034,N,,CHEMBL618560,,
7314,478.0,Homo sapiens,BAO_0000218,A2780,1,F,Intermediate,In vivo,1,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,81034,N,,CHEMBL618561,,
7315,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,81034,N,,CHEMBL618562,,
7316,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,81034,N,,CHEMBL618563,,
7317,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,81034,N,,CHEMBL618564,,
7318,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,81034,N,,CHEMBL618565,,
7319,478.0,Homo sapiens,BAO_0000218,A2780,1,F,Intermediate,,1,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),81034,N,,CHEMBL618566,,
7320,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,81034,N,,CHEMBL618567,,
7321,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,81034,N,,CHEMBL618568,,
7322,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,81034,N,,CHEMBL618569,,
7323,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,81034,N,,CHEMBL621857,,
7324,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,81034,N,,CHEMBL621858,,
7325,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,81034,N,,CHEMBL621859,,
7326,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",81034,N,,CHEMBL621860,,
7327,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),81034,N,,CHEMBL621861,,
7328,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Expert,,1,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",81034,N,,CHEMBL621862,,
7329,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),81034,N,,CHEMBL621863,,
7330,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),81034,N,,CHEMBL621864,,
7331,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),81034,N,,CHEMBL621865,,
7332,478.0,Mus musculus,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro antiproliferative activity against A2780 cell line,81034,N,,CHEMBL621866,,
7333,478.0,Mus musculus,BAO_0000219,A2780,1,F,Expert,,1,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,81034,N,,CHEMBL621867,,
7334,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,81034,N,,CHEMBL621868,,
7335,478.0,Homo sapiens,BAO_0000219,A2780,1,F,Intermediate,,1,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,81034,N,,CHEMBL875282,,
7336,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Vc value in dog after IV administration at a dose of 5 mg/kg,50588,N,,CHEMBL621869,,
7337,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period in dog after IV administration at a dose of 5 mg/kg,50588,N,,CHEMBL621870,,
7338,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Area under curve was determine after peroral administration at 10 mpk in Rhesus,22224,U,,CHEMBL621871,,
7339,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,U,,CHEMBL621243,1969.0,
7340,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,U,,CHEMBL621244,1969.0,
7341,,Macaca fascicularis,BAO_0000218,,1,A,Autocuration,In vivo,0,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,22224,U,,CHEMBL621245,,
7342,,Macaca fascicularis,BAO_0000218,,1,A,Autocuration,In vivo,0,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,22224,U,,CHEMBL621246,,
7343,,Macaca fascicularis,BAO_0000218,,1,A,Autocuration,In vivo,0,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,22224,U,,CHEMBL621247,,
7344,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral Bioavailability in rat,22224,U,,CHEMBL618386,,
7345,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,22224,U,,CHEMBL618387,,
7346,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,Area under curve value in monkey at a dose of 5 mg/kg,22224,U,,CHEMBL618388,,
7347,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,Area under curve was determined in monkey after a 3 mg/kg of oral dose,22224,U,,CHEMBL618389,,
7348,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,22224,U,,CHEMBL618574,,
7349,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,22224,U,,CHEMBL618575,,
7350,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,22224,U,,CHEMBL618576,,
7351,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,22224,U,,CHEMBL618577,,
7352,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,22224,U,,CHEMBL876487,,
7353,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,22224,U,,CHEMBL618578,,
7354,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,22224,U,,CHEMBL618579,,
7355,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,22224,U,,CHEMBL618580,,
7356,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,22224,U,,CHEMBL618581,,
7357,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,22224,U,,CHEMBL618582,,
7358,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,22224,U,,CHEMBL618583,,
7359,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,22224,U,,CHEMBL618584,,
7360,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral AUCN in monkey (dosed at 0.5 mpk iv ),22224,U,,CHEMBL618585,,
7361,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,,0,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),22224,U,,CHEMBL618586,,
7362,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,U,,CHEMBL618587,,
7363,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,22224,U,,CHEMBL618588,,
7364,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Binding towards monkey plasma protein at 10 uM,22224,U,,CHEMBL618589,,
7365,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Binding towards monkey plasma protein at 100 uM,22224,U,,CHEMBL618590,,
7366,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Apparent bioavailability in squirrel monkey was determined,22224,U,,CHEMBL872262,,
7367,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,22224,U,,CHEMBL618591,,
7368,,monkey,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in monkey (dose 2 mg/kg),22224,U,,CHEMBL618592,,
7369,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,22224,U,,CHEMBL876488,,
7370,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,22224,U,,CHEMBL618593,,
7371,,monkey,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in monkey (i.d. dosing),22224,U,,CHEMBL618594,,
7372,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,22224,U,,CHEMBL618595,,
7373,,Cercopithecidae,BAO_0000019,,1,A,Autocuration,,0,Clearance of the drug was measured in cynomolgus,22224,U,,CHEMBL621469,,
7374,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,22224,U,,CHEMBL621470,,
7375,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,22224,U,,CHEMBL621471,,
7376,,Macaca mulatta,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,U,,CHEMBL621472,1969.0,
7377,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance in rhesus monkey was determined,22224,U,,CHEMBL621473,,
7378,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance in monkey after administration of 1 mg/kg iv,22224,U,,CHEMBL621474,,
7379,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance in cynomolgus monkey,22224,U,,CHEMBL621475,,
7380,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,22224,U,,CHEMBL621476,,
7381,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance after peroral administration at 10 mpk in Rhesus,22224,U,,CHEMBL624290,,
7382,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,The total clearance was determined after intravenous administration in cynomolgus monkeys,22224,U,,CHEMBL624291,,
7383,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,22224,U,,CHEMBL624292,,
7384,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,22224,U,,CHEMBL624293,,
7385,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Tested for Clearance upon iv administration to african green monkey,22224,U,,CHEMBL624294,,
7386,,Cercopithecidae,BAO_0000218,,1,A,Autocuration,In vivo,0,Clearance in monkey,22224,U,,CHEMBL624295,,
7387,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,N,,CHEMBL624296,,
7388,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),50588,N,,CHEMBL624297,,
7389,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life was evaluated after intravenous administration to dogs,50588,N,,CHEMBL624298,,
7390,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life was evaluated in dog,50588,N,,CHEMBL624299,,
7391,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life was evaluated in dog,50588,N,,CHEMBL624300,,
7392,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,50588,N,,CHEMBL624301,,
7393,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),50588,N,,CHEMBL624302,,
7394,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period after intravenous administration in dog,50588,N,,CHEMBL876026,,
7395,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period after oral administration (2.5 mg/kg) in dog was determined,50588,N,,CHEMBL624303,,
7396,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life period at a dose of 1 uM/kg in dog was determined,50588,N,,CHEMBL624304,,
7397,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period was determine after peroral administration at 10 mpk in dog,50588,N,,CHEMBL624305,,
7398,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period was determine after peroral administration at 5 mpk in dog,50588,N,,CHEMBL624306,,
7399,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life period was determined,50588,N,,CHEMBL624307,,
7400,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life period was determined,50588,N,,CHEMBL624308,,
7401,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period by iv administration in dog at a dose of 6 mg/kg,50588,N,,CHEMBL624309,,
7402,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half life period was evaluated in dog,50588,N,,CHEMBL624310,,
7403,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,50588,N,,CHEMBL625003,,
7404,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),50588,N,,CHEMBL625004,,
7405,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,50588,N,,CHEMBL625005,,
7406,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,50588,N,,CHEMBL873813,,
7407,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life after oral dose of compound at 3 mg/kg in dogs,50588,N,,CHEMBL625006,,
7408,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,50588,N,,CHEMBL625007,,
7409,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,50588,N,,CHEMBL876027,,
7410,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,50588,N,,CHEMBL625008,,
7411,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life of compound in dog following p.o. administration of 1 mg/kg,50588,N,,CHEMBL625009,,
7412,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half-life of compound in plasma of dog was determined,50588,N,,CHEMBL625010,1969.0,
7413,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half-life of compound was determined in dogs,50588,N,,CHEMBL625011,,
7414,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life after administration of 4 mg/Kg oral dose in dog,50588,N,,CHEMBL621553,,
7415,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life after intravenous administration of 1 mg/kg/h in dog,50588,N,,CHEMBL621554,,
7416,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half-life in Dog,50588,N,,CHEMBL621555,,
7417,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half-life in Dog,50588,N,,CHEMBL621556,,
7418,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half-life in dog,50588,N,,CHEMBL621557,,
7419,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life in dog after oral administration at 1 mg/kg,50588,N,,CHEMBL621558,,
7420,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,50588,N,,CHEMBL621559,,
7421,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half-life in dogs,50588,N,,CHEMBL621560,,
7422,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half-life in dogs; ND indicates not determined,50588,N,,CHEMBL876028,,
7423,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half-life in plasma of dog,50588,N,,CHEMBL621561,1969.0,
7424,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half-life in plasma of dog at dose of 3-10 mgkg,50588,N,,CHEMBL621562,1969.0,
7425,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,50588,N,,CHEMBL621563,,
7426,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life was measured in dog after an iv dose of 1 mg/kg,50588,N,,CHEMBL621564,,
7427,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life was measured in dogs after an oral dose of 10 uM/kg,50588,N,,CHEMBL621565,,
7428,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,50588,N,,CHEMBL621566,,
7429,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,50588,N,,CHEMBL621567,,
7430,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life of the compound after 0.3 mg/kg po administration in dog,50588,N,,CHEMBL622978,,
7431,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,50588,N,,CHEMBL873814,,
7432,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,50588,N,,CHEMBL623219,,
7433,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,50588,N,,CHEMBL624477,,
7434,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,t1/2 in dog,50588,N,,CHEMBL624478,,
7435,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Half-life period measured in dogs,50588,N,,CHEMBL624479,,
7436,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,50588,N,,CHEMBL624480,,
7437,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,50588,N,,CHEMBL623595,,
7438,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50588,N,,CHEMBL623596,,
7439,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vitro,1,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",50588,N,,CHEMBL623597,1969.0,
7440,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo half life period was calculated at 1 mg/kg in dog,50588,N,,CHEMBL623598,,
7441,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,50588,N,,CHEMBL623599,,
7442,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Longer half-life in dog (i.v.) at 0.5 mpk,50588,N,,CHEMBL623600,,
7443,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog (dose 5 uM/kg),50588,N,,CHEMBL623601,,
7444,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,50588,N,,CHEMBL623602,,
7445,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,50588,N,,CHEMBL623603,,
7446,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dog (dose 1 mg/kg i.v.),50588,N,,CHEMBL623604,,
7447,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,50594,N,,CHEMBL623605,2048.0,
7448,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,N,,CHEMBL623606,2048.0,
7449,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,N,,CHEMBL623607,2048.0,
7450,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,N,,CHEMBL623608,2048.0,
7451,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,N,,CHEMBL623609,2048.0,
7452,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,N,,CHEMBL623610,2048.0,
7453,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,N,,CHEMBL623611,2385.0,
7454,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,50594,N,,CHEMBL623612,2385.0,
7455,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,N,,CHEMBL623613,2385.0,
7456,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,N,,CHEMBL623614,2385.0,
7457,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,N,,CHEMBL623615,2385.0,
7458,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,N,,CHEMBL623616,2385.0,
7459,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,N,,CHEMBL623617,2385.0,
7460,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,N,,CHEMBL875944,14.0,
7461,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,N,,CHEMBL623618,14.0,
7462,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,N,,CHEMBL623619,14.0,
7463,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,N,,CHEMBL623620,14.0,
7464,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,N,,CHEMBL623621,14.0,
7465,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,N,,CHEMBL623622,14.0,
7466,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,N,,CHEMBL623623,14.0,
7467,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,N,,CHEMBL623624,2106.0,
7468,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,N,,CHEMBL618521,2106.0,
7469,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,N,,CHEMBL618522,2106.0,
7470,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,N,,CHEMBL618523,2106.0,
7471,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,N,,CHEMBL618524,2106.0,
7472,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,N,,CHEMBL618525,2106.0,
7473,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,N,,CHEMBL624586,2106.0,
7474,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,50594,N,,CHEMBL624587,945.0,
7475,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,50594,N,,CHEMBL624588,945.0,
7476,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,50594,N,,CHEMBL624589,945.0,
7477,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,50594,N,,CHEMBL624590,945.0,
7478,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,50594,N,,CHEMBL624591,945.0,
7479,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,50594,N,,CHEMBL624592,945.0,
7480,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,50594,N,,CHEMBL624593,945.0,
7481,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL624594,,
7482,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for the bioavailability in rat,50597,N,,CHEMBL624595,,
7483,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),50597,N,,CHEMBL624596,,
7484,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat,50597,N,,CHEMBL624597,,
7485,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat,50597,N,,CHEMBL624598,,
7486,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (dose 3-10 mg/kg),50597,N,,CHEMBL624599,,
7487,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat,50597,N,,CHEMBL875166,,
7488,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,N,,CHEMBL624600,1969.0,
7489,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,50597,N,,CHEMBL624601,1969.0,
7490,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life after oral administration was determined in rats at 6 mg/kg,50597,N,,CHEMBL624602,,
7491,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life was determined,50597,N,,CHEMBL624603,,
7492,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,50597,N,,CHEMBL624604,,
7493,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma half life in rat at oral dose 2.8 mg/mk body weight,50597,N,,CHEMBL624605,1969.0,
7494,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life in rats,50597,N,,CHEMBL624606,,
7495,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,50597,N,,CHEMBL624607,178.0,
7496,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Hill coefficient of the compound,50597,N,,CHEMBL624608,,
7497,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,50597,N,,CHEMBL624609,178.0,
7498,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,50597,N,,CHEMBL624610,178.0,
7499,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,50597,N,,CHEMBL624611,178.0,
7500,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,50597,N,,CHEMBL624612,178.0,
7501,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,50597,N,,CHEMBL875167,178.0,
7502,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,50597,N,,CHEMBL624613,178.0,
7503,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",50597,N,,CHEMBL624614,178.0,
7504,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,50597,N,,CHEMBL624392,,
7505,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,50597,N,,CHEMBL624393,955.0,
7506,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,50597,N,,CHEMBL624394,955.0,
7507,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,50597,N,,CHEMBL624395,955.0,
7508,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,50597,N,,CHEMBL624396,955.0,
7509,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,50597,N,,CHEMBL624397,955.0,
7510,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,50597,N,,CHEMBL624398,2046.0,
7511,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,50597,N,,CHEMBL624399,2046.0,
7512,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,50597,N,,CHEMBL624400,2046.0,
7513,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,50597,N,,CHEMBL624401,2046.0,
7514,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,50597,N,,CHEMBL624402,2046.0,
7515,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,N,,CHEMBL624403,178.0,
7516,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,50597,N,,CHEMBL624404,178.0,
7517,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,50597,N,,CHEMBL624405,178.0,
7518,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,N,,CHEMBL624406,10000001.0,
7519,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,50597,N,,CHEMBL624407,10000001.0,
7520,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,50597,N,,CHEMBL624408,10000001.0,
7521,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,N,,CHEMBL618644,948.0,
7522,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,50597,N,,CHEMBL618645,948.0,
7523,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,50597,N,,CHEMBL618646,948.0,
7524,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,N,,CHEMBL618647,2113.0,
7525,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,50597,N,,CHEMBL618648,2113.0,
7526,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,50597,N,,CHEMBL618649,2113.0,
7527,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,N,,CHEMBL618650,2107.0,
7528,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,50597,N,,CHEMBL618651,2107.0,
7529,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,50597,N,,CHEMBL876497,2107.0,
7530,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,N,,CHEMBL618652,2048.0,
7531,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,50597,N,,CHEMBL618653,2048.0,
7532,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,50597,N,,CHEMBL618654,2048.0,
7533,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,50597,N,,CHEMBL618655,,
7534,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for solubility in water,50597,N,,CHEMBL618656,,
7535,,,BAO_0000100,,1,P,Intermediate,,0,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),22229,U,,CHEMBL618657,,
7536,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Solubility was determined,50597,N,,CHEMBL618658,,
7537,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,solubility in water (ug/mL) at 37 degree C.,50597,N,,CHEMBL618659,,
7538,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,50597,N,,CHEMBL618660,,
7539,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,50597,N,,CHEMBL618661,,
7540,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life in rats,50597,N,,CHEMBL873807,,
7541,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life in Dawley rat,50597,N,,CHEMBL618662,,
7542,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period after 3 mg/kg iv administration,50597,N,,CHEMBL618663,,
7543,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period after 3 mg/kg iv administration in rat,50597,N,,CHEMBL618664,,
7544,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period after 3 mg/kg iv administration in the rat,50597,N,,CHEMBL618665,,
7545,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period in female Sprague-Dawley rats,50597,N,,CHEMBL876498,,
7546,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period in rat,50597,N,,CHEMBL618666,,
7547,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in rats was determined,50597,N,,CHEMBL620440,,
7548,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in rats with metabolic oxidation,50597,N,,CHEMBL620441,,
7549,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in rats,50597,N,,CHEMBL620442,,
7550,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,N,,CHEMBL620443,,
7551,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,N,,CHEMBL620444,,
7552,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,N,,CHEMBL620445,,
7553,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,N,,CHEMBL620446,,
7554,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Biological half-life measured in plasma of rat,50597,N,,CHEMBL620447,1969.0,
7555,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Biological half-life measured in plasma of rat; 22-25,50597,N,,CHEMBL621129,1969.0,
7556,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Biological half-life measured in plasma of rat; 9-16,50597,N,,CHEMBL621130,1969.0,
7557,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for its half life when administered intravenously in rat,50597,N,,CHEMBL873808,,
7558,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,50597,N,,CHEMBL876598,,
7559,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,50597,N,,CHEMBL621131,,
7560,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life (T1/2) after oral administration in rat,50597,N,,CHEMBL621132,,
7561,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life of compound after iv administration of 20 mg/kg dose in rat,50597,N,,CHEMBL621133,,
7562,,Rattus norvegicus,BAO_0000218,,1,A,Expert,In vivo,1,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,N,,CHEMBL621312,,
7563,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life of compound was determined in rat,50597,N,,CHEMBL621313,,
7564,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life of compound was determined in rat blood,50597,N,,CHEMBL621314,178.0,
7565,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life at 1 mg/kg was determined in rat,50597,N,,CHEMBL621315,,
7566,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life at 10 mg/kg was determined in rat,50597,N,,CHEMBL621316,,
7567,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life in rats,50597,N,,CHEMBL621317,,
7568,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life in rats in hours,50597,N,,CHEMBL621318,,
7569,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,50597,N,,CHEMBL621319,,
7570,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,50597,N,,CHEMBL621377,,
7571,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life was determined,50597,N,,CHEMBL621378,,
7572,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life after i.v. administration,50597,N,,CHEMBL876599,,
7573,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,50597,N,,CHEMBL621379,,
7574,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life in rat plasma,50597,N,,CHEMBL621380,1969.0,
7575,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life in rat plasma; Not detected,50597,N,,CHEMBL621381,1969.0,
7576,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life in rats,50597,N,,CHEMBL618515,,
7577,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period of compound was determined after peroral administration,50597,N,,CHEMBL618516,,
7578,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,50597,N,,CHEMBL618517,,
7579,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period in rat,50597,N,,CHEMBL618518,,
7580,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,50597,N,,CHEMBL618519,,
7581,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,50597,N,,CHEMBL618698,,
7582,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,50597,N,,CHEMBL618862,,
7583,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,50597,N,,CHEMBL618863,,
7584,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,50597,N,,CHEMBL618864,,
7585,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life time in rat the dose of 2 mg/kg,50597,N,,CHEMBL618865,,
7586,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life 24 hr after 10 mg/kg iv administration in rats,50597,N,,CHEMBL618866,,
7587,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life 24 hr after 2 mg/kg iv administration in rats,50597,N,,CHEMBL618867,,
7588,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life consistent with the observed metabolic steady state in rats,50597,N,,CHEMBL875828,,
7589,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,50597,N,,CHEMBL618868,,
7590,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life for oxidative metabolic stability was determined using male human,50597,N,,CHEMBL618869,,
7591,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",50597,N,,CHEMBL618870,,
7592,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in rat plasma,50597,N,,CHEMBL618871,1969.0,
7593,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in rat plasma was determined,50597,N,,CHEMBL618872,1969.0,
7594,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in rats was determined,50597,N,,CHEMBL873816,,
7595,,,BAO_0000218,,1,A,Autocuration,,0,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,22224,U,,CHEMBL618873,,
7596,,,BAO_0000019,,1,A,Autocuration,,0,Area under curve after oral dose of 0.1 mg//kg,22224,U,,CHEMBL621602,,
7597,,,BAO_0000218,,1,A,Autocuration,,0,Area under curve after oral dose of 0.3 mg/kg,22224,U,,CHEMBL621603,,
7598,,,BAO_0000218,,1,A,Autocuration,,0,Area under curve after oral dose of 1 mg/kg,22224,U,,CHEMBL621604,,
7599,,,BAO_0000218,,1,A,Autocuration,,0,Area under curve after oral dose of 10 mg/kg,22224,U,,CHEMBL621605,,
7600,,,BAO_0000218,,1,A,Autocuration,,0,Area under curve after oral dose of 23.4 mg/kg,22224,U,,CHEMBL621606,,
7601,,,BAO_0000218,,1,A,Autocuration,,0,Area under curve after oral dose of 3 mg/kg,22224,U,,CHEMBL621607,,
7602,,,BAO_0000218,,1,A,Autocuration,,0,Area under curve after oral dose of 3.87 mg/kg,22224,U,,CHEMBL621608,,
7603,,,BAO_0000019,,1,A,Autocuration,,0,Area under curve was determined,22224,U,,CHEMBL621609,,
7604,,,BAO_0000218,,1,A,Autocuration,,0,Area under curve at a dose of 10 mg/kg,22224,U,,CHEMBL621610,,
7605,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined; ND=No data,50597,N,,CHEMBL621611,,
7606,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,50597,N,,CHEMBL621612,,
7607,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,50597,N,,CHEMBL622308,,
7608,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,50597,N,,CHEMBL622309,,
7609,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,50597,N,,CHEMBL622310,,
7610,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,50597,N,,CHEMBL622311,,
7611,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,50597,N,,CHEMBL622312,,
7612,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,50597,N,,CHEMBL622931,,
7613,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,50597,N,,CHEMBL622932,,
7614,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,50597,N,,CHEMBL622736,1969.0,
7615,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,50597,N,,CHEMBL622737,1969.0,
7616,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,50597,N,,CHEMBL622738,1969.0,
7617,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,50597,N,,CHEMBL622739,1969.0,
7618,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,50597,N,,CHEMBL622740,1969.0,
7619,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,50597,N,,CHEMBL622741,1969.0,
7620,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,50597,N,,CHEMBL622742,1969.0,
7621,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,50597,N,,CHEMBL622743,1969.0,
7622,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,AUC in mice,50594,N,,CHEMBL622744,1969.0,
7623,,,BAO_0000019,,1,A,Autocuration,,0,Area under curve was measured from the graph obtained from concentration Vs time,22224,U,,CHEMBL624134,,
7624,,,BAO_0000019,,1,A,Autocuration,,0,Area under curve value of compound per hour after oral administration,22224,U,,CHEMBL624135,,
7625,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined after oral administration in rats,50597,N,,CHEMBL624136,,
7626,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined after oral administration in rats; No data,50597,N,,CHEMBL624137,,
7627,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined after oral administration in rats;No data,50597,N,,CHEMBL624320,,
7628,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,50588,N,,CHEMBL624321,,
7629,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,50597,N,,CHEMBL624322,,
7630,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined for the compound after iv dose of 5.06 in rats,50597,N,,CHEMBL624323,,
7631,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,50597,N,,CHEMBL624324,,
7632,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,50597,N,,CHEMBL624325,,
7633,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,50597,N,,CHEMBL624326,,
7634,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,50597,N,,CHEMBL624327,,
7635,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,50597,N,,CHEMBL624328,,
7636,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined in Dogs after peroral administration,50588,N,,CHEMBL627848,,
7637,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined in Rats after peroral administration,50597,N,,CHEMBL627849,,
7638,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined in carotid blood of rat when administered intradermally,50597,N,,CHEMBL627850,,
7639,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined in portal blood of rat when administered intradermally,50597,N,,CHEMBL627851,,
7640,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,50594,N,,CHEMBL627852,,
7641,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,50594,N,,CHEMBL627853,,
7642,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),50594,N,,CHEMBL627854,,
7643,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,50594,N,,CHEMBL627855,,
7644,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),50594,N,,CHEMBL627856,,
7645,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,50594,N,,CHEMBL875339,,
7646,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),50594,N,,CHEMBL627857,,
7647,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,50597,N,,CHEMBL627858,2106.0,
7648,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,50597,N,,CHEMBL627859,178.0,
7649,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,50597,N,,CHEMBL627860,955.0,
7650,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,50597,N,,CHEMBL627019,948.0,
7651,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,50597,N,,CHEMBL627020,2107.0,
7652,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,50597,N,,CHEMBL627021,2048.0,
7653,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,50597,N,,CHEMBL627022,2385.0,
7654,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,50597,N,,CHEMBL627023,,
7655,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,50597,N,,CHEMBL627024,2106.0,
7656,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,50597,N,,CHEMBL627025,2046.0,
7657,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,50597,N,,CHEMBL627026,2113.0,
7658,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,50597,N,,CHEMBL627027,178.0,
7659,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,50597,N,,CHEMBL627028,955.0,
7660,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,50597,N,,CHEMBL627029,948.0,
7661,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,50597,N,,CHEMBL627030,2113.0,
7662,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,50597,N,,CHEMBL627031,2107.0,
7663,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,50597,N,,CHEMBL627032,2048.0,
7664,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,50597,N,,CHEMBL627033,2385.0,
7665,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,50597,N,,CHEMBL627034,,
7666,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,50597,N,,CHEMBL627035,2106.0,
7667,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,50597,N,,CHEMBL627036,2046.0,
7668,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,50597,N,,CHEMBL875340,178.0,
7669,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,50597,N,,CHEMBL627037,948.0,
7670,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,50597,N,,CHEMBL627038,2113.0,
7671,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,50597,N,,CHEMBL627039,2107.0,
7672,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,50597,N,,CHEMBL627040,2385.0,
7673,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,50597,N,,CHEMBL624663,2106.0,
7674,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,50597,N,,CHEMBL625963,2046.0,
7675,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,50597,N,,CHEMBL876799,955.0,
7676,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,50597,N,,CHEMBL626133,2048.0,
7677,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,50597,N,,CHEMBL626134,,
7678,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,50597,N,,CHEMBL626135,,
7679,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,50597,N,,CHEMBL626136,,
7680,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,50597,N,,CHEMBL626137,,
7681,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,50597,N,,CHEMBL626138,,
7682,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,50597,N,,CHEMBL626139,,
7683,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,N,,CHEMBL626140,,
7684,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,N,,CHEMBL626141,,
7685,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,C24h in rat p.o. at 20 mg/kg concentration,50597,N,,CHEMBL626142,,
7686,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,N,,CHEMBL627930,2385.0,
7687,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,50597,N,,CHEMBL627931,2385.0,
7688,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,50597,N,,CHEMBL627932,2385.0,
7689,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,N,,CHEMBL627933,2106.0,
7690,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,50597,N,,CHEMBL627934,2106.0,
7691,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,50597,N,,CHEMBL627935,2106.0,
7692,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,50597,N,,CHEMBL627936,178.0,
7693,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,50597,N,,CHEMBL627937,178.0,
7694,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,50597,N,,CHEMBL627938,178.0,
7695,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,50597,N,,CHEMBL627939,178.0,
7696,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,50597,N,,CHEMBL627940,178.0,
7697,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,50597,N,,CHEMBL627941,178.0,
7698,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,N,,CHEMBL876800,178.0,
7699,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,50597,N,,CHEMBL627942,178.0,
7700,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,50597,N,,CHEMBL627943,178.0,
7701,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,50597,N,,CHEMBL627944,178.0,
7702,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,50597,N,,CHEMBL627945,178.0,
7703,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,50597,N,,CHEMBL628584,178.0,
7704,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of GdDTPA at 15 min,50597,N,,CHEMBL628585,178.0,
7705,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,50597,N,,CHEMBL628586,178.0,
7706,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of GdDTPA at 30 min,50597,N,,CHEMBL628587,178.0,
7707,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,50597,N,,CHEMBL628588,178.0,
7708,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,50597,N,,CHEMBL628589,178.0,
7709,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,50597,N,,CHEMBL625304,178.0,
7710,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,50597,N,,CHEMBL625305,178.0,
7711,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,50597,N,,CHEMBL625306,178.0,
7712,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,50597,N,,CHEMBL625307,178.0,
7713,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,50597,N,,CHEMBL625308,178.0,
7714,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,50597,N,,CHEMBL627740,178.0,
7715,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,50597,N,,CHEMBL627741,178.0,
7716,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,N,,CHEMBL627742,178.0,
7717,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,50597,N,,CHEMBL627743,178.0,
7718,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,50597,N,,CHEMBL627744,178.0,
7719,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,50597,N,,CHEMBL627745,10000001.0,
7720,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,50597,N,,CHEMBL627746,10000001.0,
7721,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,50597,N,,CHEMBL627747,10000001.0,
7722,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,50597,N,,CHEMBL876810,10000001.0,
7723,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,50597,N,,CHEMBL627748,10000001.0,
7724,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,50597,N,,CHEMBL627749,10000001.0,
7725,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,N,,CHEMBL627750,10000001.0,
7726,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,50597,N,,CHEMBL618728,10000001.0,
7727,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,50597,N,,CHEMBL618729,10000001.0,
7728,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat bone in the presence of GdDTPA at 15 min,50597,N,,CHEMBL618730,10000001.0,
7729,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,50597,N,,CHEMBL618731,10000001.0,
7730,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat bone in the presence of GdDTPA at 30 min,50597,N,,CHEMBL618732,10000001.0,
7731,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,50597,N,,CHEMBL618733,10000001.0,
7732,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,50597,N,,CHEMBL618734,10000001.0,
7733,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,50597,N,,CHEMBL618735,10000001.0,
7734,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,50597,N,,CHEMBL876602,10000001.0,
7735,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,50597,N,,CHEMBL618736,10000001.0,
7736,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,50597,N,,CHEMBL618737,10000001.0,
7737,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,50597,N,,CHEMBL618738,10000001.0,
7738,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,50597,N,,CHEMBL618739,10000001.0,
7739,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,50597,N,,CHEMBL618740,10000001.0,
7740,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,N,,CHEMBL618741,10000001.0,
7741,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,50597,N,,CHEMBL618742,10000001.0,
7742,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,50597,N,,CHEMBL618743,10000001.0,
7743,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life from rat plasma at a single oral dose of 25 mg/kg,50597,N,,CHEMBL618744,1969.0,
7744,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in male rat,50597,N,,CHEMBL618745,,
7745,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life in rat after peroral administration at 10 mg/kg concentration,50597,N,,CHEMBL620479,,
7746,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life in rat after peroral administration at 5 mg/kg concentration,50597,N,,CHEMBL620480,,
7747,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life in rat at a dose of 3 mg/kg,50597,N,,CHEMBL620481,,
7748,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life was evaluated in rats,50597,N,,CHEMBL620482,,
7749,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life was measured in rat,50597,N,,CHEMBL876603,,
7750,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life period for the compound was determined in rats at 50 mg/kg dose,50597,N,,CHEMBL620483,,
7751,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life period in rats after intravenous administration at 5 mg/kg,50597,N,,CHEMBL620484,,
7752,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life period in rat at 10 mg/kg,50597,N,,CHEMBL620485,,
7753,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",50597,N,,CHEMBL620486,,
7754,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",50597,N,,CHEMBL620487,,
7755,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",50597,N,,CHEMBL620488,,
7756,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life time in rat the dose of 2 mg/kg,50597,N,,CHEMBL620489,,
7757,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,50597,N,,CHEMBL620490,,
7758,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,50597,N,,CHEMBL620491,,
7759,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",50597,N,,CHEMBL876604,1969.0,
7760,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral half life was determined,50597,N,,CHEMBL620492,,
7761,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",50597,N,,CHEMBL620493,,
7762,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (t1/2) in rat,50597,N,,CHEMBL620494,,
7763,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma elimination half-life was determined,50597,N,,CHEMBL620495,1969.0,
7764,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,50597,N,,CHEMBL620496,1969.0,
7765,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma half life was observed after intravenous administration in rat,50597,N,,CHEMBL620497,1969.0,
7766,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma half-life was determined,50597,N,,CHEMBL620498,1969.0,
7767,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma half-life following oral administration in Fisher rats,50597,N,,CHEMBL620499,1969.0,
7768,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma half-life in rat,50597,N,,CHEMBL620500,1969.0,
7769,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasmatic Half-life after intravenous administration to rat,50597,N,,CHEMBL873809,1969.0,
7770,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,50597,N,,CHEMBL620501,,
7771,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Terminal half life after intravenous administration (1 mg/kg) in rat,50597,N,,CHEMBL620502,,
7772,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Terminal half life in Rat at a oral dose of 5 mg/kg,50597,N,,CHEMBL620503,,
7773,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,50597,N,,CHEMBL620504,,
7774,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,50597,N,,CHEMBL876605,,
7775,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,50597,N,,CHEMBL620505,,
7776,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,plasma half life was observed after intravenous administration in rat,50597,N,,CHEMBL873811,1969.0,
7777,,Rattus norvegicus,BAO_0000218,,1,A,Expert,In vivo,1,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,N,,CHEMBL624016,,
7778,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life of compound determined in rat,50597,N,,CHEMBL624017,,
7779,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean residence time determined in rat,50597,N,,CHEMBL624018,,
7780,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma half life determined in rat,50597,N,,CHEMBL624019,,
7781,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for Tmax in brain after intravenous administration in male rats,50597,N,,CHEMBL624020,955.0,
7782,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for pharmacokinetic parameter maximum time period,50597,N,,CHEMBL624201,,
7783,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,50597,N,,CHEMBL872528,,
7784,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,N,,CHEMBL624202,,
7785,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,N,,CHEMBL624203,,
7786,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,N,,CHEMBL624350,,
7787,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,N,,CHEMBL621320,,
7788,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,50597,N,,CHEMBL621321,,
7789,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Maximum time (Tmax) required to reach Cmax in rats,50597,N,,CHEMBL621322,,
7790,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,50597,N,,CHEMBL621323,,
7791,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum time of clearance of compound in rats after peroral administration,50597,N,,CHEMBL621324,,
7792,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Maximum time at the dose of 2 mg/kg in rat,50597,N,,CHEMBL621325,,
7793,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,50597,N,,CHEMBL875837,1969.0,
7794,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,50597,N,,CHEMBL621326,1969.0,
7795,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax in Guinea pig (PO dose),50597,N,,CHEMBL621327,,
7796,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",50597,N,,CHEMBL621328,,
7797,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter (Tmax) in rat,50597,N,,CHEMBL621329,,
7798,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter (Tmax) was estimated,50597,N,,CHEMBL621330,,
7799,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (Tmax) in rat,50597,N,,CHEMBL621331,,
7800,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,50597,N,,CHEMBL621332,,
7801,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,T max in Rat at a oral dose of 5 mg/kg,50597,N,,CHEMBL621333,,
7802,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,T max was determined at 10 mg/kg po dose in rats,50597,N,,CHEMBL621334,,
7803,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),50594,N,,CHEMBL621335,,
7804,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,50588,N,,CHEMBL621336,,
7805,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,50597,N,,CHEMBL621337,,
7806,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve was measured after i.v. administration into Beagle dog.,50588,N,,CHEMBL621338,,
7807,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve was measured after iv administration into Beagle dog,50588,N,,CHEMBL875838,,
7808,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve was measured after po administration into Beagle dog,50588,N,,CHEMBL621339,,
7809,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve was measured after po administration into Beagle dog.,50588,N,,CHEMBL621340,,
7810,,,BAO_0000218,,1,A,Autocuration,,0,Area under curve was measured at peroral dose of 3 mg/kg,22224,U,,CHEMBL621341,,
7811,,,BAO_0000019,,1,A,Autocuration,,0,Area under curve was measured by using concentration Vs time,22224,U,,CHEMBL621342,,
7812,,,BAO_0000019,,1,A,Autocuration,,0,Area under curve was measured by using concentration Vs time; not tested,22224,U,,CHEMBL621343,,
7813,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),50594,N,,CHEMBL621344,,
7814,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve(AUC) was measured in mice after oral administration.,50594,N,,CHEMBL621345,,
7815,,,BAO_0000019,,1,A,Autocuration,,0,Area under curve(AUC) value of the compound,22224,U,,CHEMBL621346,,
7816,,,BAO_0000218,,1,A,Autocuration,,0,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,22224,U,,CHEMBL621347,,
7817,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,50588,N,,CHEMBL621348,,
7818,,,BAO_0000019,,1,A,Autocuration,,0,Area under curve(carotid artery) was determined by the availability in blood,22224,U,,CHEMBL621349,178.0,
7819,,,BAO_0000019,,1,A,Autocuration,,0,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,22224,U,,CHEMBL621350,178.0,
7820,,,BAO_0000019,,1,A,Autocuration,,0,Area under curve(carotid artery) was determined by the availability in blood; No data,22224,U,,CHEMBL875839,178.0,
7821,,,BAO_0000019,,1,A,Autocuration,,0,Area under curve(portal vein) was determined by the availability in blood,22224,U,,CHEMBL620211,178.0,
7822,,,BAO_0000019,,1,A,Autocuration,,0,Area under curve(portal vein) was determined by the availability in blood; ND means no data,22224,U,,CHEMBL620212,178.0,
7823,,,BAO_0000019,,1,A,Autocuration,,0,Area under curve(portal vein) was determined by the availability in blood; No data,22224,U,,CHEMBL620213,178.0,
7824,,Macaca mulatta,BAO_0000218,,1,A,Intermediate,,1,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",50797,N,,CHEMBL620214,1969.0,
7825,,Macaca mulatta,BAO_0000218,,1,A,Intermediate,,1,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",50797,N,,CHEMBL620215,1969.0,
7826,,Macaca mulatta,BAO_0000218,,1,A,Intermediate,,1,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,50797,N,,CHEMBL620216,1969.0,
7827,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",50588,N,,CHEMBL620888,1969.0,
7828,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",50588,N,,CHEMBL620889,1969.0,
7829,,,BAO_0000019,,1,A,Autocuration,,0,Area under plasma concentration vs time curve observed in rats for 0-3 h,22224,U,,CHEMBL620890,1969.0,
7830,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under plasma time curve determined in male rat,50597,N,,CHEMBL620891,1969.0,
7831,,,BAO_0000019,,1,A,Autocuration,,0,Area under the MAP curve measured over 5 min.,22224,U,,CHEMBL620892,,
7832,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,50594,N,,CHEMBL621079,,
7833,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,50594,N,,CHEMBL621080,,
7834,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,50588,N,,CHEMBL621081,,
7835,,Cricetinae,BAO_0000218,,1,A,Intermediate,,1,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,100712,N,,CHEMBL621082,,
7836,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,50597,N,,CHEMBL621083,,
7837,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,50588,N,,CHEMBL621084,,
7838,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,50588,N,,CHEMBL621085,,
7839,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,50588,N,,CHEMBL621086,,
7840,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),50588,N,,CHEMBL621087,,
7841,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),50588,N,,CHEMBL622607,,
7842,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Serum AUC in marmosets (IV dose),50588,N,,CHEMBL622608,,
7843,,,BAO_0000019,,1,A,Autocuration,,0,Area under the curve after intravenous administration at a dose of 10 umol/kg,22224,U,,CHEMBL624481,,
7844,,,BAO_0000019,,1,A,Autocuration,,0,Area under the curve after intravenous administration at a dose of 2 umol/kg,22224,U,,CHEMBL624482,,
7845,,,BAO_0000019,,1,A,Autocuration,,0,Area under the curve after intravenous administration at a dose of 4 umol/kg,22224,U,,CHEMBL624483,,
7846,,,BAO_0000019,,1,A,Autocuration,,0,Area under the curve after intravenous administration at a dose of 40 umol/kg,22224,U,,CHEMBL624484,,
7847,,,BAO_0000019,,1,A,Autocuration,,0,Area under the curve after intravenous administration at a dose of 5 umol/kg,22224,U,,CHEMBL624485,,
7848,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve for fumarate salt was evaluated in F344 Rats.,50597,N,,CHEMBL624486,,
7849,,,BAO_0000019,,1,A,Autocuration,,0,Area under the curve for the compound was calculated.,22224,U,,CHEMBL624487,,
7850,,,BAO_0000019,,1,A,Autocuration,,0,Area under the curve in concentration/ time,22224,U,,CHEMBL624488,,
7851,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve administered intraintestinal in rats.,50597,N,,CHEMBL624489,,
7852,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve administered intravenously in rats.,50597,N,,CHEMBL625184,,
7853,,,BAO_0000019,,1,A,Autocuration,,0,Area under the curve during intravenous administration,22224,U,,CHEMBL625185,,
7854,,,BAO_0000019,,1,A,Autocuration,,0,Area under the curve during intravenous administration; Not determined,22224,U,,CHEMBL875954,,
7855,,,BAO_0000019,,1,A,Autocuration,,0,Area under the curve during systemic administration,22224,U,,CHEMBL625186,,
7856,,,BAO_0000019,,1,A,Autocuration,,0,Area under the curve during systemic administration; Not determined,22224,U,,CHEMBL625187,,
7857,,,BAO_0000019,,1,A,Autocuration,,0,Area under the curve was calculated for the compound.,22224,U,,CHEMBL625188,,
7858,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,50588,N,,CHEMBL625189,,
7859,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,50588,N,,CHEMBL625190,,
7860,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,50597,N,,CHEMBL621733,,
7861,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,50597,N,,CHEMBL621734,,
7862,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,50597,N,,CHEMBL621735,,
7863,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Clearance of the drug was measured in the plasma of rat; No data,50597,N,,CHEMBL621736,1969.0,
7864,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The pharmacokinetic parameter plasma clearance in vivo in rats,50597,N,,CHEMBL621737,1969.0,
7865,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma clearance at the dose of 2 mg/kg in rat,50597,N,,CHEMBL621738,,
7866,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,50597,N,,CHEMBL622806,,
7867,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,50597,N,,CHEMBL623519,,
7868,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,N,,CHEMBL623520,,
7869,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,N,,CHEMBL623521,,
7870,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,N,,CHEMBL623522,,
7871,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance rate in rat,50597,N,,CHEMBL623523,,
7872,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance rate in rat,50597,N,,CHEMBL623690,,
7873,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,N,,CHEMBL623691,,
7874,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,N,,CHEMBL623692,,
7875,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,N,,CHEMBL623693,,
7876,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,N,,CHEMBL623694,,
7877,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance of compound after iv administration of 20 mg/kg dose in rat,50597,N,,CHEMBL623695,,
7878,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,50597,N,,CHEMBL623696,,
7879,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,50597,N,,CHEMBL623697,,
7880,,Macaca mulatta,BAO_0000218,,1,A,Intermediate,In vivo,0,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,U,,CHEMBL623698,1969.0,
7881,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,0,Compound was tested for its plasma clearance rate in Sprague Dawley rats,22224,U,,CHEMBL623699,1969.0,
7882,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Mean (%CV) PK parameters for CL(mL/min/kg).,50597,N,,CHEMBL623700,,
7883,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,50597,N,,CHEMBL623701,,
7884,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,50597,N,,CHEMBL623702,1969.0,
7885,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,50597,N,,CHEMBL623703,,
7886,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rat was determined,50597,N,,CHEMBL623704,,
7887,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rat after administration of 2 mg/kg iv,50597,N,,CHEMBL623705,,
7888,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rat after administration of 2 mg/kg iv,50597,N,,CHEMBL623706,,
7889,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was determined,50597,N,,CHEMBL623707,,
7890,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rat,50597,N,,CHEMBL623708,,
7891,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,50597,N,,CHEMBL623709,,
7892,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rat by iv administration,50597,N,,CHEMBL623710,,
7893,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,50597,N,,CHEMBL623711,,
7894,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rat p.o.,50597,N,,CHEMBL623712,,
7895,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rats,50597,N,,CHEMBL623713,,
7896,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was determined; ND denotes no data,50597,N,,CHEMBL623714,,
7897,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was determined; ND denotes not determined,50597,N,,CHEMBL623715,,
7898,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,50597,N,,CHEMBL623716,,
7899,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,50597,N,,CHEMBL622980,,
7900,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma administration to rats,50597,N,,CHEMBL622981,,
7901,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance of the compound in female Sprague-Dawley rats,50597,N,,CHEMBL622982,,
7902,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was observed after intravenous administration in rat,50597,N,,CHEMBL622983,,
7903,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,50597,N,,CHEMBL622984,,
7904,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,50597,N,,CHEMBL622985,,
7905,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,plasma clearance was observed after intravenous administration in rat,50597,N,,CHEMBL623631,1969.0,
7906,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo CL/F determined,50597,N,,CHEMBL623632,,
7907,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,50597,N,,CHEMBL623633,1969.0,
7908,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,50597,N,,CHEMBL623634,1969.0,
7909,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for the lower blood clearance in rat,50597,N,,CHEMBL623635,,
7910,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Evaluated for the low clearance in rat (in vivo),50597,N,,CHEMBL621195,,
7911,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (CLb)of the compound was determined in rat,50597,N,,CHEMBL621196,,
7912,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Rapid clearance after intravenous administration in rat was determined,50597,N,,CHEMBL875287,,
7913,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance measured in rat,50597,N,,CHEMBL621197,,
7914,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for plasma clearance in rat,50597,N,,CHEMBL621198,1969.0,
7915,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Low plasma clearance was calculated in rat,50597,N,,CHEMBL621199,1969.0,
7916,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (Clp) in rat,50597,N,,CHEMBL621200,,
7917,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,50597,N,,CHEMBL621201,,
7918,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,50597,N,,CHEMBL621202,,
7919,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance after IV dosing at 0.5 mg/kg in rat,50597,N,,CHEMBL621203,,
7920,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance after IV dosing at 1 mg/kg in rat,50597,N,,CHEMBL621204,,
7921,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,50597,N,,CHEMBL621205,948.0,
7922,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,50597,N,,CHEMBL621206,948.0,
7923,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,50597,N,,CHEMBL621207,948.0,
7924,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,50597,N,,CHEMBL621208,948.0,
7925,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,50597,N,,CHEMBL621209,948.0,
7926,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,50597,N,,CHEMBL876484,948.0,
7927,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,N,,CHEMBL621210,948.0,
7928,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,50597,N,,CHEMBL621211,948.0,
7929,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,50597,N,,CHEMBL621212,948.0,
7930,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart in the presence of GdDTPA at 15 min,50597,N,,CHEMBL621213,948.0,
7931,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,50597,N,,CHEMBL621214,948.0,
7932,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart in the presence of GdDTPA at 30 min,50597,N,,CHEMBL621215,948.0,
7933,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,50597,N,,CHEMBL621216,948.0,
7934,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,50597,N,,CHEMBL621217,948.0,
7935,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,50597,N,,CHEMBL621218,948.0,
7936,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,50597,N,,CHEMBL621219,948.0,
7937,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,50597,N,,CHEMBL621220,948.0,
7938,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,50597,N,,CHEMBL621221,948.0,
7939,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,50597,N,,CHEMBL621222,948.0,
7940,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,50597,N,,CHEMBL621223,948.0,
7941,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,50597,N,,CHEMBL876485,948.0,
7942,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,N,,CHEMBL621224,948.0,
7943,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,50597,N,,CHEMBL621225,948.0,
7944,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,50597,N,,CHEMBL621226,948.0,
7945,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,50597,N,,CHEMBL621227,2113.0,
7946,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,50597,N,,CHEMBL621228,2113.0,
7947,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,50597,N,,CHEMBL621229,2113.0,
7948,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,50597,N,,CHEMBL621230,2113.0,
7949,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,50597,N,,CHEMBL621231,2113.0,
7950,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,50597,N,,CHEMBL621232,2113.0,
7951,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,N,,CHEMBL621233,2113.0,
7952,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,50597,N,,CHEMBL621234,2113.0,
7953,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,50597,N,,CHEMBL621235,2113.0,
7954,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,N,,CHEMBL621236,2113.0,
7955,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,50597,N,,CHEMBL621237,2113.0,
7956,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,50597,N,,CHEMBL876486,2113.0,
7957,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,50597,N,,CHEMBL622436,160.0,
7958,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,50597,N,,CHEMBL622437,160.0,
7959,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,50597,N,,CHEMBL622438,160.0,
7960,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,50597,N,,CHEMBL622439,2107.0,
7961,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,50597,N,,CHEMBL622440,2107.0,
7962,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,50597,N,,CHEMBL622441,2107.0,
7963,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,50597,N,,CHEMBL622442,2107.0,
7964,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,50597,N,,CHEMBL622443,2107.0,
7965,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,50597,N,,CHEMBL622444,2107.0,
7966,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,50597,N,,CHEMBL622445,2107.0,
7967,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,50597,N,,CHEMBL622446,2107.0,
7968,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,N,,CHEMBL622447,2107.0,
7969,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,50597,N,,CHEMBL622448,2107.0,
7970,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,50597,N,,CHEMBL622449,2107.0,
7971,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,50597,N,,CHEMBL622450,2107.0,
7972,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,50597,N,,CHEMBL622451,2107.0,
7973,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver in the presence of GdDTPA at 15 min,50597,N,,CHEMBL622452,2107.0,
7974,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,50597,N,,CHEMBL622453,2107.0,
7975,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver in the presence of GdDTPA at 30 min,50597,N,,CHEMBL622454,2107.0,
7976,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,50597,N,,CHEMBL622455,2107.0,
7977,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,50597,N,,CHEMBL876024,2107.0,
7978,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,T max was determined at 3 mg/kg po dose in rats,50597,N,,CHEMBL622456,,
7979,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",50597,N,,CHEMBL622457,,
7980,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",50597,N,,CHEMBL622458,,
7981,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,50597,N,,CHEMBL622459,,
7982,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,50597,N,,CHEMBL873343,,
7983,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,50597,N,,CHEMBL622460,,
7984,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Time for maximum plasma concentration determined in rat,50597,N,,CHEMBL622461,1969.0,
7985,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,50597,N,,CHEMBL622462,1969.0,
7986,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,50597,N,,CHEMBL622463,,
7987,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,50597,N,,CHEMBL622464,,
7988,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,50597,N,,CHEMBL622465,,
7989,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,50597,N,,CHEMBL622466,,
7990,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,50597,N,,CHEMBL622467,,
7991,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Time of maximum plasma concentration in rat,50597,N,,CHEMBL622468,1969.0,
7992,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",50597,N,,CHEMBL876025,1969.0,
7993,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",50597,N,,CHEMBL622469,1969.0,
7994,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",50597,N,,CHEMBL622470,1969.0,
7995,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time required to reach maximum concentration (Cmax) after oral administration in rat,50597,N,,CHEMBL622471,,
7996,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Time required to reach maximum concentration in rat plasma,50597,N,,CHEMBL622472,1969.0,
7997,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,50597,N,,CHEMBL622473,1969.0,
7998,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,50597,N,,CHEMBL624282,1969.0,
7999,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,50597,N,,CHEMBL624283,1969.0,
8000,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,50597,N,,CHEMBL624284,1969.0,
8001,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,50597,N,,CHEMBL624285,1969.0,
8002,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time to reach Cmax after oral administration to rats,50597,N,,CHEMBL624286,,
8003,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time to reach Cmax when a dose of 1 mg/kg is administered orally,50597,N,,CHEMBL624287,,
8004,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,50597,N,,CHEMBL624288,,
8005,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,50597,N,,CHEMBL624289,1969.0,
8006,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,50597,N,,CHEMBL873344,1969.0,
8007,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax after peroral administration (10 mg/kg) was determined in rat,50597,N,,CHEMBL619623,,
8008,,Rattus norvegicus,BAO_0000218,,1,A,Expert,In vivo,1,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,N,,CHEMBL621399,,
8009,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,50597,N,,CHEMBL621400,,
8010,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",50597,N,,CHEMBL621401,,
8011,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tmax was determined,50597,N,,CHEMBL621402,,
8012,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tmax was determined,50597,N,,CHEMBL621403,,
8013,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax after oral administration in rat,50597,N,,CHEMBL621121,,
8014,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax after peroral administration in rats at 2.4 uM/kg,50597,N,,CHEMBL872525,,
8015,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tmax in male rat,50597,N,,CHEMBL621122,,
8016,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax in rat at 10 mg/kg,50597,N,,CHEMBL621123,,
8017,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax in rat by po administration at a dose of 40 mg/kg,50597,N,,CHEMBL621124,,
8018,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tmax in rats,50597,N,,CHEMBL621125,,
8019,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax was measured in rats after peroral administration at 5 mg/kg,50597,N,,CHEMBL621126,,
8020,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax value after oral dose at a dose of 10 mg/kg in rats.,50597,N,,CHEMBL621127,,
8021,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax value after administration of 20 mg/Kg oral dose in rat,50597,N,,CHEMBL621128,,
8022,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax value at a dose of 10 mg/kg in male SD rats,50597,N,,CHEMBL618263,,
8023,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax value at a dose of 100 mg/kg in male SD rats,50597,N,,CHEMBL618264,,
8024,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax value at a dose of 50 mg/kg in male SD rats,50597,N,,CHEMBL618265,,
8025,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,N,,CHEMBL618266,1969.0,
8026,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,time required to reach maximum concentration (Cmax) after oral administration in rat,50597,N,,CHEMBL618267,,
8027,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),50597,N,,CHEMBL618450,1088.0,
8028,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),50597,N,,CHEMBL618451,1088.0,
8029,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,50597,N,,CHEMBL618452,,
8030,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,50597,N,,CHEMBL618453,1088.0,
8031,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,50597,N,,CHEMBL618454,1088.0,
8032,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,50597,N,,CHEMBL618455,1088.0,
8033,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,50597,N,,CHEMBL618456,,
8034,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound distribution in rat tissues was determined,50597,N,,CHEMBL618457,,
8035,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution was evaluated in rat,50597,N,,CHEMBL618458,,
8036,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,50597,N,,CHEMBL618459,,
8037,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,50597,N,,CHEMBL876733,,
8038,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,50588,N,,CHEMBL618460,,
8039,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,50597,N,,CHEMBL618461,,
8040,,,BAO_0000019,,1,A,Autocuration,,0,Area under the curve was determined after oral administration (300 uM/Kg),22224,U,,CHEMBL618462,,
8041,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,50597,N,,CHEMBL618463,,
8042,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,50597,N,,CHEMBL618464,,
8043,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,50597,N,,CHEMBL618465,,
8044,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,50597,N,,CHEMBL618466,,
8045,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,50597,N,,CHEMBL618467,,
8046,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,50597,N,,CHEMBL618468,,
8047,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,50588,N,,CHEMBL618469,1969.0,
8048,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,50588,N,,CHEMBL618470,1969.0,
8049,,,BAO_0000218,,1,A,Autocuration,,0,Plasma drug AUC in rat (PO dose),22224,U,,CHEMBL618471,,
8050,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,50594,N,,CHEMBL618472,,
8051,,,BAO_0000218,,1,A,Autocuration,,0,Area under was determined at a dose of 30 mg/kg,22224,U,,CHEMBL618473,,
8052,,Mustela putorius furo,BAO_0000218,,1,A,Intermediate,,1,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,50506,N,,CHEMBL621699,,
8053,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,50597,N,,CHEMBL621700,,
8054,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,50597,N,,CHEMBL621701,,
8055,,Mustela putorius furo,BAO_0000218,,1,A,Intermediate,,1,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,50506,N,,CHEMBL621702,,
8056,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,50588,N,,CHEMBL621703,,
8057,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,50588,N,,CHEMBL621704,,
8058,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",50597,N,,CHEMBL624259,,
8059,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",50597,N,,CHEMBL624260,,
8060,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",50597,N,,CHEMBL624430,,
8061,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",50597,N,,CHEMBL624431,,
8062,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",50597,N,,CHEMBL624432,,
8063,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",50597,N,,CHEMBL624433,,
8064,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",50597,N,,CHEMBL624434,,
8065,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",50597,N,,CHEMBL624435,,
8066,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,50594,N,,CHEMBL618570,,
8067,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),50594,N,,CHEMBL618571,,
8068,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,50594,N,,CHEMBL618572,,
8069,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),50594,N,,CHEMBL618573,,
8070,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,50594,N,,CHEMBL619267,,
8071,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),50594,N,,CHEMBL619431,,
8072,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,50594,N,,CHEMBL619432,,
8073,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),50594,N,,CHEMBL619433,,
8074,,,BAO_0000218,,1,A,Autocuration,,0,AUC in mice after oral dose (50 mg/kg),22224,U,,CHEMBL619434,1969.0,
8075,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,50594,N,,CHEMBL619435,1977.0,
8076,,,BAO_0000019,,1,A,Autocuration,,0,AUC (0-4 hr) ug/ml/h,22224,U,,CHEMBL619436,1969.0,
8077,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,50597,N,,CHEMBL619437,,
8078,,,BAO_0000218,,1,A,Autocuration,,0,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,22224,U,,CHEMBL619438,,
8079,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for Area under curve in mice,50594,N,,CHEMBL619439,,
8080,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,50597,N,,CHEMBL619440,,
8081,,,BAO_0000218,,1,F,Autocuration,,0,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,22224,U,,CHEMBL619441,,
8082,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,50597,N,,CHEMBL619442,,
8083,,,BAO_0000019,,1,A,Autocuration,,0,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,22224,U,,CHEMBL875156,,
8084,,,BAO_0000019,,1,A,Autocuration,,0,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,22224,U,,CHEMBL619443,,
8085,,,BAO_0000019,,1,A,Autocuration,,0,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,22224,U,,CHEMBL619444,,
8086,,,BAO_0000019,,1,A,Autocuration,,0,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,22224,U,,CHEMBL623464,,
8087,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for area under curve when administered through oral route in mouse,50594,N,,CHEMBL623465,,
8088,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,50597,N,,CHEMBL623466,,
8089,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,50597,N,,CHEMBL623467,,
8090,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rat,50597,N,,CHEMBL623468,,
8091,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,50597,N,,CHEMBL622660,,
8092,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance rate in Sprague-Dawley rats,50597,N,,CHEMBL622661,,
8093,,Rattus norvegicus,BAO_0000218,,1,F,Intermediate,In vivo,1,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,N,,CHEMBL622662,,
8094,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (total body clearance) in rat,50597,N,,CHEMBL622663,,
8095,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,50597,N,,CHEMBL622664,,
8096,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,50597,N,,CHEMBL622665,,
8097,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,50597,N,,CHEMBL622666,,
8098,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cl in rat i.v. at 2 mg/kg concentration,50597,N,,CHEMBL621615,,
8099,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance of compound after intravenous administration in rats at 24 uM/kg,50597,N,,CHEMBL621616,,
8100,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance was determined,50597,N,,CHEMBL621617,,
8101,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance by intravenous administration of 3.4 mg/kg in rat,50597,N,,CHEMBL621618,,
8102,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,50597,N,,CHEMBL621619,,
8103,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance rate after i.v. administration in rats,50597,N,,CHEMBL621620,,
8104,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,50597,N,,CHEMBL621786,,
8105,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,50597,N,,CHEMBL621787,,
8106,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,50597,N,,CHEMBL621788,,
8107,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance (Cl) after oral administration in rat,50597,N,,CHEMBL621789,,
8108,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,50597,N,,CHEMBL621790,,
8109,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for plasma clearance in rat,50597,N,,CHEMBL621791,1969.0,
8110,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vitro,1,In vitro microsome metabolism clearance in rat was determined,50597,N,,CHEMBL621792,,
8111,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vitro,1,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,50597,N,,CHEMBL621793,,
8112,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,N,,CHEMBL621794,,
8113,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo plasma clearance was determined,50597,N,,CHEMBL621795,1969.0,
8114,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,50597,N,,CHEMBL621796,,
8115,401.0,Rattus norvegicus,BAO_0000218,Hepatocyte,1,A,Intermediate,In vivo,1,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,50597,N,,CHEMBL621797,2107.0,
8116,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (Plasma clearance) was measured in rat,50597,N,,CHEMBL621798,,
8117,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (clearance) in rat i.v.,50597,N,,CHEMBL621799,,
8118,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Plasma Clearance was evaluated in rats, iv",50597,N,,CHEMBL621800,,
8119,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance (in vivo) in rats was determined,50597,N,,CHEMBL621801,,
8120,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,50597,N,,CHEMBL621802,,
8121,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was determined,50597,N,,CHEMBL618596,,
8122,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,50597,N,,CHEMBL618597,,
8123,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,50597,N,,CHEMBL618598,,
8124,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rats,50597,N,,CHEMBL618599,,
8125,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance rate determined in rat,50597,N,,CHEMBL618600,,
8126,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was determined in rat,50597,N,,CHEMBL618601,,
8127,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was determined,50597,N,,CHEMBL618602,,
8128,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance value in rat,50597,N,,CHEMBL618603,,
8129,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,Ex vivo,1,Clearance rate constant using isolated perfused rat liver (IPRL) assay,50597,N,,CHEMBL618604,2107.0,
8130,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance in rat,50597,N,,CHEMBL618605,,
8131,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Total body clearance in rat i.v. at 2 mg/kg concentration,50597,N,,CHEMBL618606,,
8132,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance of compound in rats after intravenous administration,50597,N,,CHEMBL618607,,
8133,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance after iv administration to rats,50597,N,,CHEMBL618608,,
8134,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,50597,N,,CHEMBL618609,,
8135,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,50597,N,,CHEMBL618610,,
8136,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,50597,N,,CHEMBL618611,,
8137,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,50597,N,,CHEMBL618612,,
8138,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,50597,N,,CHEMBL618613,,
8139,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,50597,N,,CHEMBL621076,,
8140,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,50597,N,,CHEMBL621077,,
8141,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",50597,N,,CHEMBL621078,,
8142,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance in rat,50597,N,,CHEMBL621251,,
8143,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance in rat after oral administration at 10 mg/kg,50597,N,,CHEMBL621252,,
8144,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance in rat.,50597,N,,CHEMBL621253,,
8145,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance rate following an oral dose of 20 mg/kg in rats,50597,N,,CHEMBL621254,,
8146,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,50597,N,,CHEMBL621255,,
8147,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,50597,N,,CHEMBL621256,1969.0,
8148,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,50597,N,,CHEMBL621257,2107.0,
8149,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,50597,N,,CHEMBL621258,2107.0,
8150,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,50597,N,,CHEMBL621259,2107.0,
8151,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,50597,N,,CHEMBL621260,2107.0,
8152,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,50597,N,,CHEMBL876494,2107.0,
8153,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,50597,N,,CHEMBL621261,2107.0,
8154,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,50597,N,,CHEMBL621262,2107.0,
8155,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,N,,CHEMBL621263,2107.0,
8156,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,50597,N,,CHEMBL621264,2107.0,
8157,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,50597,N,,CHEMBL621265,2385.0,
8158,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,50597,N,,CHEMBL621266,2385.0,
8159,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,50597,N,,CHEMBL621267,2385.0,
8160,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,50597,N,,CHEMBL621268,2385.0,
8161,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,50597,N,,CHEMBL621269,2385.0,
8162,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,50597,N,,CHEMBL621270,2385.0,
8163,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,50597,N,,CHEMBL621271,2385.0,
8164,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,50597,N,,CHEMBL621272,2385.0,
8165,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,50597,N,,CHEMBL621273,2385.0,
8166,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,50597,N,,CHEMBL621274,2385.0,
8167,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,50597,N,,CHEMBL876495,2385.0,
8168,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,50597,N,,CHEMBL621275,2385.0,
8169,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,50597,N,,CHEMBL621276,2385.0,
8170,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,50597,N,,CHEMBL621277,2385.0,
8171,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,50597,N,,CHEMBL621278,160.0,
8172,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,50597,N,,CHEMBL621279,160.0,
8173,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),50597,N,,CHEMBL621280,160.0,
8174,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,50597,N,,CHEMBL621281,2106.0,
8175,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,50597,N,,CHEMBL621282,2106.0,
8176,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,50597,N,,CHEMBL621283,2106.0,
8177,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,50597,N,,CHEMBL621284,2106.0,
8178,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,50597,N,,CHEMBL621285,2106.0,
8179,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,50597,N,,CHEMBL621286,2106.0,
8180,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,50597,N,,CHEMBL623220,2106.0,
8181,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,50597,N,,CHEMBL623221,2106.0,
8182,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,50597,N,,CHEMBL876029,2106.0,
8183,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,50597,N,,CHEMBL623222,945.0,
8184,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,50597,N,,CHEMBL623223,945.0,
8185,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,50597,N,,CHEMBL621445,945.0,
8186,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL621446,178.0,
8187,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL621447,178.0,
8188,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL619681,178.0,
8189,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL619682,178.0,
8190,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL619683,178.0,
8191,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL619684,955.0,
8192,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL619685,955.0,
8193,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL619686,955.0,
8194,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL619687,955.0,
8195,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL619688,955.0,
8196,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL619689,948.0,
8197,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL619690,948.0,
8198,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL619691,948.0,
8199,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,50597,N,,CHEMBL619692,,
8200,,Rattus norvegicus,BAO_0000218,,1,A,Expert,,1,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,N,,CHEMBL619693,,
8201,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Vc value after IV dose at a dose of 5 mg/kg in rats.,50597,N,,CHEMBL619694,,
8202,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,50597,N,,CHEMBL619695,,
8203,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for pharmacokinetic parameter volume of distribution,50597,N,,CHEMBL619696,,
8204,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for volume of distribution in rat,50597,N,,CHEMBL619697,,
8205,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Steady state volume distribution was determined; steady state(ss),50597,N,,CHEMBL619698,,
8206,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Steady state volume of distribution after iv administration to rats,50597,N,,CHEMBL619699,,
8207,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Steady state volume of distribution dosing at 3 mg/kg iv,50597,N,,CHEMBL619700,,
8208,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The compound was evaluated for volume of distribution in rat,50597,N,,CHEMBL619701,,
8209,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The compound was tested for volume of distribution in rat,50597,N,,CHEMBL619702,,
8210,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,50597,N,,CHEMBL620335,,
8211,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution (VD) after oral administration in rat,50597,N,,CHEMBL620336,,
8212,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,N,,CHEMBL620337,,
8213,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution in rat,50597,N,,CHEMBL620520,,
8214,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution in rat,50597,N,,CHEMBL620521,,
8215,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution in rat after peroral administration at 10 mg/kg,50597,N,,CHEMBL875825,,
8216,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution in rat after peroral administration at 5 mg/kg,50597,N,,CHEMBL620522,,
8217,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,50597,N,,CHEMBL620523,,
8218,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution in rat.,50597,N,,CHEMBL620524,,
8219,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution in rat,50597,N,,CHEMBL620525,,
8220,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution in rat,50597,N,,CHEMBL620526,,
8221,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution in rat by iv administration,50597,N,,CHEMBL620527,,
8222,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution in rats,50597,N,,CHEMBL620528,,
8223,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,50597,N,,CHEMBL620529,,
8224,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Volume distribution at the dose of 2 mg/kg in rat,50597,N,,CHEMBL620530,,
8225,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Steady state volume of distribution was determined,50597,N,,CHEMBL620531,,
8226,,Macaca mulatta,BAO_0000218,,1,A,Intermediate,In vivo,0,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,U,,CHEMBL620532,,
8227,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,0,Compound was tested for its plasma volume distribution in Sprague Dawley rats,22224,U,,CHEMBL620533,,
8228,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,0,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,22224,U,,CHEMBL620534,,
8229,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Mean (%CV) PK parameters for Vdss(mL/kg).,50597,N,,CHEMBL620535,,
8230,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,50597,N,,CHEMBL875826,,
8231,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,50597,N,,CHEMBL620536,,
8232,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,50597,N,,CHEMBL620537,,
8233,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,50597,N,,CHEMBL618526,,
8234,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,50597,N,,CHEMBL618527,,
8235,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (Vdss) in rat,50597,N,,CHEMBL618528,,
8236,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (vdss) was measured in rat,50597,N,,CHEMBL618529,,
8237,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,50597,N,,CHEMBL618530,,
8238,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution in rat,50597,N,,CHEMBL618531,,
8239,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The pharmacokinetic parameter volume of distribution in vivo in rats,50597,N,,CHEMBL618532,,
8240,,Rattus norvegicus,BAO_0000218,,1,F,Intermediate,In vivo,1,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,N,,CHEMBL618533,,
8241,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Vdss in rat i.v. at 2 mg/kg concentration,50597,N,,CHEMBL618534,,
8242,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution after intravenous administration (1 mg/kg) in rat,50597,N,,CHEMBL618535,,
8243,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,50597,N,,CHEMBL618536,,
8244,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,50597,N,,CHEMBL618537,,
8245,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution at a dose of 10 uM/kg in rat was determined,50597,N,,CHEMBL618538,,
8246,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,50597,N,,CHEMBL618539,,
8247,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution was calculated in rat,50597,N,,CHEMBL618540,,
8248,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution was determined,50597,N,,CHEMBL618541,,
8249,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution after intravenous administration was evaluated in rat,50597,N,,CHEMBL618542,,
8250,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50597,N,,CHEMBL622544,,
8251,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",50597,N,,CHEMBL622545,,
8252,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",50597,N,,CHEMBL622546,,
8253,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",50597,N,,CHEMBL622547,,
8254,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution in steady state was determined in rat,50597,N,,CHEMBL622548,,
8255,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,50597,N,,CHEMBL622549,,
8256,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,50597,N,,CHEMBL622550,,
8257,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for area under curve when administered through oral route to mouse,50594,N,,CHEMBL622551,,
8258,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,50597,N,,CHEMBL622552,,
8259,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,50597,N,,CHEMBL622553,,
8260,,,BAO_0000218,,1,F,Autocuration,In vivo,0,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,22224,U,,CHEMBL622554,,
8261,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,50588,N,,CHEMBL622555,,
8262,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,50594,N,,CHEMBL622556,,
8263,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,50594,N,,CHEMBL622557,,
8264,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,50594,N,,CHEMBL622558,178.0,
8265,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,50594,N,,CHEMBL622559,178.0,
8266,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,50588,N,,CHEMBL622560,,
8267,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,50597,N,,CHEMBL622561,,
8268,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,50597,N,,CHEMBL622562,,
8269,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,50597,N,,CHEMBL622563,,
8270,,,BAO_0000019,,1,A,Autocuration,,0,Concentration of compound in Central nervous system,22224,U,,CHEMBL622564,,
8271,,,BAO_0000019,,1,A,Autocuration,,0,Concentration of compound in Central nervous system; Not detectable,22224,U,,CHEMBL622565,,
8272,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Concentration of diester in the blood, following oral administration in mice",50594,N,,CHEMBL622566,,
8273,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Concentration of monoester in the blood, following oral administration in mice",50594,N,,CHEMBL624515,,
8274,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,50594,N,,CHEMBL624516,,
8275,,,BAO_0000019,,1,A,Autocuration,,0,Evaluated for Pharmacokinetic property: Area under the curve,22224,U,,CHEMBL624517,,
8276,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,50594,N,,CHEMBL624518,,
8277,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,100710,N,,CHEMBL624519,,
8278,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,100710,N,,CHEMBL624520,,
8279,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,100710,N,,CHEMBL624521,,
8280,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,100710,N,,CHEMBL624522,,
8281,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,100710,N,,CHEMBL624523,,
8282,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",100710,N,,CHEMBL624409,,
8283,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",100710,N,,CHEMBL624410,,
8284,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",100710,N,,CHEMBL624411,,
8285,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",100710,N,,CHEMBL623531,,
8286,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",100710,N,,CHEMBL623532,,
8287,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",100710,N,,CHEMBL623533,,
8288,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",100710,N,,CHEMBL623534,,
8289,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,50594,N,,CHEMBL623535,,
8290,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,50594,N,,CHEMBL623536,,
8291,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,50594,N,,CHEMBL623537,,
8292,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,50594,N,,CHEMBL623538,,
8293,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,50594,N,,CHEMBL623539,,
8294,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,50594,N,,CHEMBL623540,,
8295,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",50594,N,,CHEMBL623541,,
8296,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",50594,N,,CHEMBL623542,,
8297,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",50594,N,,CHEMBL623543,,
8298,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",50594,N,,CHEMBL623544,,
8299,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",50594,N,,CHEMBL623545,,
8300,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",50594,N,,CHEMBL623546,,
8301,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,50597,N,,CHEMBL623547,1969.0,
8302,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,High i.v. clearance in Dawley rats,50597,N,,CHEMBL623548,,
8303,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vitro,1,In vitro clearance in rat liver microsomes,50597,N,,CHEMBL623549,2107.0,
8304,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vitro,1,Intrinsic clearance in rat liver microsomes was determined,50597,N,,CHEMBL623550,2107.0,
8305,401.0,Rattus norvegicus,BAO_0000218,Hepatocyte,1,A,Intermediate,In vitro,1,Intrinsic clearance in rat hepatocytes was determined,50597,N,,CHEMBL875276,2107.0,
8306,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma Clearance was determined,50597,N,,CHEMBL621872,,
8307,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,50597,N,,CHEMBL621873,,
8308,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rat.,50597,N,,CHEMBL621874,,
8309,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rats,50597,N,,CHEMBL621875,,
8310,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,50597,N,,CHEMBL621876,,
8311,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,50597,N,,CHEMBL621877,,
8312,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was measured in rat,50597,N,,CHEMBL621878,,
8313,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,50597,N,,CHEMBL621879,,
8314,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",50597,N,,CHEMBL621880,1969.0,
8315,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,50597,N,,CHEMBL621881,,
8316,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,50597,N,,CHEMBL621882,,
8317,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Total clearance at 1 mg/kg was determined in rat,50597,N,,CHEMBL875283,,
8318,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Total clearance at 10 mg/kg was determined in rat,50597,N,,CHEMBL621883,,
8319,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance in rat,50597,N,,CHEMBL621884,,
8320,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance rate determined in rats,50597,N,,CHEMBL621885,,
8321,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance of compound in rat was evaluated,50597,N,,CHEMBL621886,,
8322,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,50597,N,,CHEMBL621887,1969.0,
8323,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (blood clearance) in rat,50597,N,,CHEMBL621888,,
8324,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rat,50597,N,,CHEMBL621889,,
8325,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rats,50597,N,,CHEMBL621890,,
8326,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vitro,1,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,50597,N,,CHEMBL621891,2107.0,
8327,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance in Dawley rat,50597,N,,CHEMBL621892,,
8328,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance rat,50597,N,,CHEMBL621893,,
8329,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),50597,N,,CHEMBL621894,,
8330,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance rat; Not determined,50597,N,,CHEMBL621895,,
8331,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance rate was determined in rat at a dose of 1 mpk i.v.,50597,N,,CHEMBL875284,,
8332,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,50597,N,,CHEMBL618699,,
8333,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,50597,N,,CHEMBL618700,,
8334,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,50597,N,,CHEMBL618701,,
8335,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",50597,N,,CHEMBL876600,1969.0,
8336,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance of compound in rat after 1 mg/kg i.v. administration,50597,N,,CHEMBL618702,,
8337,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for Hepatic clearance in rat,50597,N,,CHEMBL618703,,
8338,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo clearance after 5 mg/kg dose,50597,N,,CHEMBL618704,,
8339,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for plasma clearance in rats,50597,N,,CHEMBL618705,1969.0,
8340,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Hepatic clearance after intravenous administration was evaluated in rat,50597,N,,CHEMBL618706,,
8341,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Lower clearance in rat (i.v.) at 0.5 mpk,50597,N,,CHEMBL618707,,
8342,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter expressed as plasma clearance in rat,50597,N,,CHEMBL618708,1969.0,
8343,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (Clp) in rat,50597,N,,CHEMBL618709,,
8344,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in Sprague-Dawley rats,50597,N,,CHEMBL618710,,
8345,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance (Clp) in rat,50597,N,,CHEMBL618711,,
8346,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,50597,N,,CHEMBL618712,,
8347,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,50597,N,,CHEMBL618713,,
8348,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance after intravenous administration of 1 mg/kg in rat,50597,N,,CHEMBL618714,,
8349,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,50597,N,,CHEMBL618715,,
8350,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rat was determined,50597,N,,CHEMBL618716,,
8351,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance measured in rat,50597,N,,CHEMBL876601,,
8352,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was calculated in rat,50597,N,,CHEMBL618717,,
8353,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rat,50597,N,,CHEMBL618718,,
8354,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rat,50597,N,,CHEMBL618719,,
8355,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rat,50597,N,,CHEMBL618720,,
8356,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rat,50597,N,,CHEMBL618721,,
8357,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rats,50597,N,,CHEMBL621477,,
8358,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rat,50597,N,,CHEMBL621478,,
8359,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was evaluated in rat,50597,N,,CHEMBL621479,,
8360,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was evaluated in rat; Not tested,50597,N,,CHEMBL621480,,
8361,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance rate was determined for the compound in rat,50597,N,,CHEMBL621481,,
8362,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",50597,N,,CHEMBL621482,,
8363,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",50597,N,,CHEMBL621483,,
8364,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",50597,N,,CHEMBL621484,,
8365,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL621485,948.0,
8366,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL621486,948.0,
8367,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL621487,160.0,
8368,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL621488,160.0,
8369,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL621489,160.0,
8370,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL621490,160.0,
8371,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL621491,160.0,
8372,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL621492,2113.0,
8373,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL621493,2113.0,
8374,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL621494,2113.0,
8375,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL621495,2113.0,
8376,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL621496,2113.0,
8377,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL621497,2107.0,
8378,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL621498,2107.0,
8379,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL621499,2107.0,
8380,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL618634,2107.0,
8381,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL618635,2107.0,
8382,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL618636,2048.0,
8383,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL619737,2048.0,
8384,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL619738,2048.0,
8385,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL624329,2048.0,
8386,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL624330,2048.0,
8387,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL624331,2385.0,
8388,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL624332,2385.0,
8389,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL624333,2385.0,
8390,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL624334,2385.0,
8391,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL624335,2385.0,
8392,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620016,2106.0,
8393,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620169,2106.0,
8394,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620170,2106.0,
8395,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620171,2106.0,
8396,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620172,2106.0,
8397,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620173,945.0,
8398,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620174,945.0,
8399,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620175,945.0,
8400,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620176,945.0,
8401,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620177,945.0,
8402,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620178,2037.0,
8403,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620179,2037.0,
8404,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620180,,
8405,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,50597,N,,CHEMBL620181,,
8406,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution of compound in rats after intravenous administration,50597,N,,CHEMBL620182,,
8407,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution in rat,50597,N,,CHEMBL620183,,
8408,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,50597,N,,CHEMBL620184,,
8409,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,50597,N,,CHEMBL620185,,
8410,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,50597,N,,CHEMBL620186,,
8411,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution was determined in Dawley rat,50597,N,,CHEMBL620187,,
8412,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,50597,N,,CHEMBL620188,,
8413,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution was reported in Sprague-Dawley rat,50597,N,,CHEMBL620189,,
8414,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volumes of distribution in rat after peroral administration,50597,N,,CHEMBL620190,,
8415,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volumes of distribution in rat after po administration,50597,N,,CHEMBL620191,,
8416,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volumes of distribution in rat after po administration; Not determined,50597,N,,CHEMBL620192,,
8417,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (Volume) in rat i.v.,50597,N,,CHEMBL620193,,
8418,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,50597,N,,CHEMBL620194,,
8419,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",50597,N,,CHEMBL876730,,
8420,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution in rat after oral administration at 10 mg/kg,50597,N,,CHEMBL620195,,
8421,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,50597,N,,CHEMBL620196,,
8422,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,50597,N,,CHEMBL620197,,
8423,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,50597,N,,CHEMBL620198,,
8424,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution in rats,50597,N,,CHEMBL620199,,
8425,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,50597,N,,CHEMBL620200,,
8426,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,50597,N,,CHEMBL620201,,
8427,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,N,,CHEMBL620202,,
8428,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,N,,CHEMBL620203,,
8429,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,50597,N,,CHEMBL620204,,
8430,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,N,,CHEMBL620205,,
8431,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter (Vss) in rat,50597,N,,CHEMBL624664,,
8432,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (Volume) in rat i.v.,50597,N,,CHEMBL624665,,
8433,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic property (Vss) in rat,50597,N,,CHEMBL624666,,
8434,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,50597,N,,CHEMBL624667,,
8435,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,50597,N,,CHEMBL624668,,
8436,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,N,,CHEMBL624669,,
8437,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,N,,CHEMBL624670,,
8438,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,N,,CHEMBL624671,,
8439,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Steady state volume distribution in rat,50597,N,,CHEMBL624672,,
8440,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",50597,N,,CHEMBL624673,1969.0,
8441,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Steady state volume of distribution determined in rat,50597,N,,CHEMBL624674,,
8442,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,50597,N,,CHEMBL624675,,
8443,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,50597,N,,CHEMBL621728,,
8444,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,50597,N,,CHEMBL621729,,
8445,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,50597,N,,CHEMBL621730,,
8446,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution in rat after administration of 2 mg/kg iv,50597,N,,CHEMBL621731,,
8447,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution in rat after administration of 2 mg/kg iv,50597,N,,CHEMBL621732,,
8448,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume in steady state distribution value was determined,50597,N,,CHEMBL621908,,
8449,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume in steady state distribution value was determined; ND denotes no data,50597,N,,CHEMBL875347,,
8450,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume in steady state distribution value was determined; ND denotes not determined,50597,N,,CHEMBL621909,,
8451,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,N,,CHEMBL621910,,
8452,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution at steady state was evaluated in rats,50597,N,,CHEMBL621911,,
8453,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution at steady state was observed after intravenous administration in rat,50597,N,,CHEMBL621912,,
8454,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution in steady state was determined in rat,50597,N,,CHEMBL621913,,
8455,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution in steady state was determined in rat,50597,N,,CHEMBL621914,,
8456,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution after i.v. administration,50597,N,,CHEMBL621915,,
8457,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,50597,N,,CHEMBL621916,,
8458,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,N,,CHEMBL621917,2107.0,
8459,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,N,,CHEMBL621918,2107.0,
8460,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound (oxidized form) in spleen tissue,50594,N,,CHEMBL621919,2106.0,
8461,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,N,,CHEMBL621920,2106.0,
8462,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",50594,N,,CHEMBL621921,2106.0,
8463,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,N,,CHEMBL622401,2106.0,
8464,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,N,,CHEMBL875348,2106.0,
8465,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,N,,CHEMBL622402,2106.0,
8466,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,50594,N,,CHEMBL622403,178.0,
8467,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,N,,CHEMBL622404,178.0,
8468,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,50594,N,,CHEMBL622405,955.0,
8469,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",50594,N,,CHEMBL622406,955.0,
8470,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,N,,CHEMBL622407,955.0,
8471,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,50594,N,,CHEMBL622408,948.0,
8472,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",50594,N,,CHEMBL622409,948.0,
8473,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,N,,CHEMBL622410,948.0,
8474,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,50594,N,,CHEMBL622411,2113.0,
8475,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",50594,N,,CHEMBL627864,2113.0,
8476,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,N,,CHEMBL627865,2113.0,
8477,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,50594,N,,CHEMBL627866,2107.0,
8478,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,N,,CHEMBL627751,2107.0,
8479,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,50594,N,,CHEMBL627752,2106.0,
8480,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",50594,N,,CHEMBL627753,2106.0,
8481,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,N,,CHEMBL627754,2106.0,
8482,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,50594,N,,CHEMBL627755,,
8483,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL627756,955.0,
8484,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL627757,955.0,
8485,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL627758,955.0,
8486,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL627759,955.0,
8487,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL627760,955.0,
8488,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL627761,955.0,
8489,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL876811,948.0,
8490,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL627762,948.0,
8491,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL627763,948.0,
8492,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL627764,948.0,
8493,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL627765,948.0,
8494,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL627766,948.0,
8495,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL627767,2113.0,
8496,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL627768,2113.0,
8497,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL628422,2113.0,
8498,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL628423,2113.0,
8499,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,50597,N,,CHEMBL628424,,
8500,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,50597,N,,CHEMBL628425,,
8501,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,50597,N,,CHEMBL628426,,
8502,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50597,N,,CHEMBL628427,,
8503,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,50597,N,,CHEMBL626938,,
8504,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,50597,N,,CHEMBL626939,,
8505,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,50597,N,,CHEMBL626940,,
8506,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,50597,N,,CHEMBL626941,,
8507,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was reported in Sprague-Dawley rat,50597,N,,CHEMBL626942,,
8508,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance after intravenous administration (1 mg/kg) in rat,50597,N,,CHEMBL876812,,
8509,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance of compound in rats was evaluated,50597,N,,CHEMBL626943,,
8510,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance of compound in rats was evaluated; ND indicates not determined,50597,N,,CHEMBL626944,,
8511,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,50597,N,,CHEMBL626945,,
8512,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,50597,N,,CHEMBL626946,,
8513,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance rate in Sprague-Dawley rats,50597,N,,CHEMBL626856,,
8514,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),50597,N,,CHEMBL626857,,
8515,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The compound was evaluated for plasma clearance in rat,50597,N,,CHEMBL626858,1969.0,
8516,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Total plasma clearance in rat,50597,N,,CHEMBL627018,1969.0,
8517,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,50597,N,,CHEMBL625331,178.0,
8518,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,50597,N,,CHEMBL625332,178.0,
8519,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,C max was determined at 10 mg/kg po dose in rats,50597,N,,CHEMBL877590,,
8520,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,C max was determined at 3 mg/kg po dose in rats,50597,N,,CHEMBL625333,,
8521,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax after repeated oral dose of compound at 1 mg/kg in rats,50597,N,,CHEMBL625334,,
8522,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax after single intravenous bolus of 1 mg/kg in rats,50597,N,,CHEMBL625335,,
8523,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax of compound at 5 mg/kg after po administration was determined in rat,50597,N,,CHEMBL625336,,
8524,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax 24 hr after 10 mg/kg oral administration in rats,50597,N,,CHEMBL625337,,
8525,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax 24 hr after 2 mg/kg oral administration in rats,50597,N,,CHEMBL625338,,
8526,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,50597,N,,CHEMBL625339,1969.0,
8527,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in rat after administration of 2 mg/kg iv,50597,N,,CHEMBL625340,,
8528,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in rat after administration of 2 mg/kg iv,50597,N,,CHEMBL625341,,
8529,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,50597,N,,CHEMBL622687,,
8530,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax wa determined in rat plasma at 30 mg/kg after po administration,50597,N,,CHEMBL622688,1969.0,
8531,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,50597,N,,CHEMBL622689,178.0,
8532,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,50597,N,,CHEMBL620295,178.0,
8533,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax after 10 mg/kg oral administration in rat,50597,N,,CHEMBL620296,,
8534,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax after IV dosing at 0.5 mg/kg in rat; no data,50597,N,,CHEMBL620297,,
8535,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax after IV dosing at 1 mg/kg in rat; no data,50597,N,,CHEMBL620298,,
8536,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax after oral administration at 20 mpk in rats,50597,N,,CHEMBL620299,,
8537,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax after oral administration at 20 mpk in rats; Not performed.,50597,N,,CHEMBL620300,,
8538,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax after oral administration at 20 mpk in rats d; Not performed.,50597,N,,CHEMBL620301,,
8539,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax after oral administration in rat,50597,N,,CHEMBL620302,,
8540,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax after oral administration at a dose of 2 mg/kg in rat,50597,N,,CHEMBL620303,,
8541,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax after oral administration at a dose of 4 mg/kg in rat,50597,N,,CHEMBL620304,,
8542,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in rats after 20 mg/kg oral dose,50597,N,,CHEMBL620305,,
8543,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax after peroral administration in rats at 2.4 uM/kg,50597,N,,CHEMBL620306,,
8544,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax at the dose of 2 mg/Kg administered perorally in rats,50597,N,,CHEMBL620307,,
8545,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax at the dose of 5 mg/Kg administered perorally in rats,50597,N,,CHEMBL620308,,
8546,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax by administering at 20 mg/kg p.o. in rats,50597,N,,CHEMBL620309,,
8547,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in male rat,50597,N,,CHEMBL620310,,
8548,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in rat,50597,N,,CHEMBL620311,,
8549,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in rat,50597,N,,CHEMBL620312,,
8550,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in rat,50597,N,,CHEMBL620313,,
8551,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in rat at 10 mg/kg,50597,N,,CHEMBL620314,,
8552,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in rat at the dose of 1 mg/kg i.v.,50597,N,,CHEMBL620315,,
8553,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in rat by po administration at a dose of 40 mg/kg,50597,N,,CHEMBL620316,,
8554,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in rat p.o. at 20 mg/kg concentration,50597,N,,CHEMBL620317,,
8555,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in rats,50597,N,,CHEMBL620318,,
8556,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in rats,50597,N,,CHEMBL620319,,
8557,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax was evaluated after 20 uM/kg of peroral administration,50597,N,,CHEMBL620320,,
8558,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax was measured in rats after peroral administration at 3 mg/kg,50597,N,,CHEMBL620321,,
8559,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value after oral dose at a dose of 10 mg/kg in rats.,50597,N,,CHEMBL620322,,
8560,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620323,,
8561,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620324,1870.0,
8562,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620325,1870.0,
8563,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620326,10000000.0,
8564,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620327,10000000.0,
8565,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620328,,
8566,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620329,,
8567,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620330,1891.0,
8568,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL875286,1891.0,
8569,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620331,,
8570,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620332,,
8571,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620333,2435.0,
8572,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,N,,CHEMBL620334,2435.0,
8573,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,N,,CHEMBL621015,178.0,
8574,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,N,,CHEMBL621016,178.0,
8575,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,N,,CHEMBL621191,178.0,
8576,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,N,,CHEMBL621192,178.0,
8577,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,N,,CHEMBL621193,178.0,
8578,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,N,,CHEMBL621194,178.0,
8579,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,N,,CHEMBL624204,178.0,
8580,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,N,,CHEMBL624205,178.0,
8581,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,N,,CHEMBL624206,178.0,
8582,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,N,,CHEMBL624207,178.0,
8583,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,N,,CHEMBL624208,178.0,
8584,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,N,,CHEMBL624209,178.0,
8585,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,N,,CHEMBL624210,178.0,
8586,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,N,,CHEMBL624211,178.0,
8587,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,N,,CHEMBL624212,178.0,
8588,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,N,,CHEMBL624213,178.0,
8589,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,N,,CHEMBL876611,178.0,
8590,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,N,,CHEMBL624214,178.0,
8591,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,N,,CHEMBL624215,178.0,
8592,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,N,,CHEMBL624216,178.0,
8593,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,N,,CHEMBL624217,178.0,
8594,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,N,,CHEMBL624218,178.0,
8595,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,N,,CHEMBL624219,178.0,
8596,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,N,,CHEMBL624220,178.0,
8597,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,N,,CHEMBL624221,178.0,
8598,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,N,,CHEMBL624222,,
8599,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,N,,CHEMBL624223,,
8600,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,N,,CHEMBL624224,,
8601,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,N,,CHEMBL624225,,
8602,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,50597,N,,CHEMBL622420,,
8603,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of steady state distribution after i.v. administration in rats,50597,N,,CHEMBL622421,,
8604,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Vss after intravenous administration (5.0 mg/kg) was determined in rat,50597,N,,CHEMBL622422,,
8605,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,N,,CHEMBL622423,,
8606,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Vss was determined,50597,N,,CHEMBL622424,,
8607,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Vss in rat,50597,N,,CHEMBL622425,,
8608,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Vss was evaluated after 10 uM/kg of intra arterial administration,50597,N,,CHEMBL876612,,
8609,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,volume of distribution at steady state was observed after intravenous administration in rat,50597,N,,CHEMBL622426,,
8610,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,50597,N,,CHEMBL622427,,
8611,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic (PK) parameter Vz in rat,50597,N,,CHEMBL622428,,
8612,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume distribution in rats,50597,N,,CHEMBL622429,,
8613,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution in rat; No data,50597,N,,CHEMBL622430,,
8614,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,50597,N,,CHEMBL622431,,
8615,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,% absorption predicted from in vitro rat ileum transport studies,50597,N,,CHEMBL622432,2116.0,
8616,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,50597,N,,CHEMBL622433,,
8617,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,50597,N,,CHEMBL622434,,
8618,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,50597,N,,CHEMBL622435,,
8619,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),50597,N,,CHEMBL618748,,
8620,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,50597,N,,CHEMBL618749,,
8621,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,50597,N,,CHEMBL618750,,
8622,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,50597,N,,CHEMBL618751,,
8623,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,50597,N,,CHEMBL618752,,
8624,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL618753,,
8625,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,50597,N,,CHEMBL618754,1969.0,
8626,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL618755,,
8627,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL618756,,
8628,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL618757,,
8629,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat,50597,N,,CHEMBL618758,,
8630,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (dose 30 mg/kg),50597,N,,CHEMBL621088,,
8631,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic property (cLogP) in rat,50597,N,,CHEMBL621089,,
8632,,Rattus norvegicus,BAO_0000218,,1,F,Intermediate,,1,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,50597,N,,CHEMBL621090,178.0,
8633,,Rattus norvegicus,BAO_0000218,,1,F,Intermediate,,1,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,50597,N,,CHEMBL621091,178.0,
8634,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance in rat.,50597,N,,CHEMBL876731,,
8635,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for its clearance when administered intravenously in rat,50597,N,,CHEMBL621092,,
8636,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,50597,N,,CHEMBL621093,,
8637,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Blood: Brain distribution ratio is determined in rat,50597,N,,CHEMBL621094,,
8638,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,50597,N,,CHEMBL621095,,
8639,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,50597,N,,CHEMBL621096,,
8640,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL621097,2113.0,
8641,,Rattus norvegicus,BAO_0000218,,1,F,Intermediate,,1,Percent dose excreted in 0-48 hours administered ip to male rat,50597,N,,CHEMBL621098,,
8642,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL621099,2037.0,
8643,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL621100,2037.0,
8644,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,N,,CHEMBL621101,2037.0,
8645,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL621102,2037.0,
8646,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL876732,2037.0,
8647,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL621103,,
8648,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL621104,,
8649,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,N,,CHEMBL621105,,
8650,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL621106,,
8651,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL621107,,
8652,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL621108,,
8653,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL621109,,
8654,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL621110,2113.0,
8655,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL621111,2113.0,
8656,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL622541,2107.0,
8657,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL622542,2107.0,
8658,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL622543,2107.0,
8659,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL624412,2107.0,
8660,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL624413,2107.0,
8661,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL624414,2107.0,
8662,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL624415,2048.0,
8663,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL624416,2048.0,
8664,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL624417,2048.0,
8665,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL624418,2048.0,
8666,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL624419,2048.0,
8667,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL624420,2048.0,
8668,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL624421,2385.0,
8669,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL624422,2385.0,
8670,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL624423,2385.0,
8671,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL625123,2385.0,
8672,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL625124,2385.0,
8673,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL625125,2385.0,
8674,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL625126,14.0,
8675,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL626947,14.0,
8676,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL626948,14.0,
8677,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL626949,14.0,
8678,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL626950,14.0,
8679,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL626951,14.0,
8680,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL626952,2106.0,
8681,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL626953,2106.0,
8682,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL626954,2106.0,
8683,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL626955,2106.0,
8684,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL626956,2106.0,
8685,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL626957,2106.0,
8686,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL626958,178.0,
8687,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL626959,178.0,
8688,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL626960,178.0,
8689,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL626961,178.0,
8690,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL627589,178.0,
8691,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),50594,N,,CHEMBL627590,178.0,
8692,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Time taken for EC90 was determined when tested in mouse,50594,N,,CHEMBL627591,,
8693,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,50594,N,,CHEMBL627592,,
8694,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),50594,N,,CHEMBL627593,,
8695,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Half life in mice,50594,N,,CHEMBL627594,,
8696,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period in mouse after 10 mg/Kg dose,50594,N,,CHEMBL876813,,
8697,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period in mouse after 10 mg/kg dose,50594,N,,CHEMBL627595,,
8698,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,N,,CHEMBL627596,,
8699,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value at 5 mg/kg po was determined in rat,50597,N,,CHEMBL627597,,
8700,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value evaluated in rat,50597,N,,CHEMBL627598,,
8701,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,50597,N,,CHEMBL627599,955.0,
8702,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value after administration of 20 mg/Kg oral dose in rat,50597,N,,CHEMBL627600,,
8703,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value at 1 mg/kg po in rat,50597,N,,CHEMBL627601,,
8704,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value at 5 mg/kg po in rat,50597,N,,CHEMBL627776,,
8705,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value at a dose of 10 mg/kg in male SD rats,50597,N,,CHEMBL627777,,
8706,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value at a dose of 100 mg/kg in male SD rats,50597,N,,CHEMBL627778,,
8707,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value at a dose of 50 mg/kg in male SD rats,50597,N,,CHEMBL627779,,
8708,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value in rats at 10 mg/kg,50597,N,,CHEMBL876814,,
8709,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value was evaluated in rats at a dose of 20 mg/kg,50597,N,,CHEMBL627780,,
8710,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value was determined after peroral administration of 20 mg/kg in rat,50597,N,,CHEMBL627781,,
8711,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,50597,N,,CHEMBL627782,,
8712,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,50597,N,,CHEMBL627783,1969.0,
8713,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,50597,N,,CHEMBL627784,1969.0,
8714,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,50597,N,,CHEMBL627785,,
8715,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,50597,N,,CHEMBL627786,,
8716,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,50597,N,,CHEMBL627787,1969.0,
8717,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,50597,N,,CHEMBL627788,1969.0,
8718,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,50597,N,,CHEMBL626579,1969.0,
8719,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,50597,N,,CHEMBL626580,1969.0,
8720,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,50597,N,,CHEMBL876815,,
8721,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,50597,N,,CHEMBL626581,1969.0,
8722,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,50597,N,,CHEMBL626582,1969.0,
8723,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,50597,N,,CHEMBL626583,,
8724,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,N,,CHEMBL626205,,
8725,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,N,,CHEMBL626206,,
8726,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,N,,CHEMBL626207,,
8727,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,N,,CHEMBL623882,,
8728,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,50597,N,,CHEMBL623883,,
8729,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,50597,N,,CHEMBL623884,,
8730,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",50597,N,,CHEMBL623885,1969.0,
8731,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,50597,N,,CHEMBL623886,1969.0,
8732,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal concentration in rat was determined,50597,N,,CHEMBL623887,,
8733,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal concentration after i.v. administration,50597,N,,CHEMBL623888,,
8734,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,50597,N,,CHEMBL623889,1969.0,
8735,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal plasma concentration in rat after oral administration at 50 mg/kg,50597,N,,CHEMBL623890,1969.0,
8736,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in rat plasma after oral dose (50 mg/Kg),50597,N,,CHEMBL623891,1969.0,
8737,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal plasma concentration was determined.,50597,N,,CHEMBL623892,1969.0,
8738,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal plasma drug concentration was determined,50597,N,,CHEMBL623893,1969.0,
8739,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal concentration in rats after peroral administration,50597,N,,CHEMBL877616,,
8740,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in rat after 2 mg/kg peroral administration,50597,N,,CHEMBL623894,,
8741,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in rat plasma after 5 mg/kg oral gavage,50597,N,,CHEMBL623895,1969.0,
8742,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration of compound in rat was evaluated.,50597,N,,CHEMBL623896,,
8743,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,50597,N,,CHEMBL623897,,
8744,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,50597,N,,CHEMBL623898,,
8745,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,50597,N,,CHEMBL623899,,
8746,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,50597,N,,CHEMBL623900,,
8747,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,50597,N,,CHEMBL623901,,
8748,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration was evaluated in rats,50597,N,,CHEMBL623902,,
8749,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,50597,N,,CHEMBL623903,1359.0,
8750,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,50597,N,,CHEMBL623904,1969.0,
8751,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,50597,N,,CHEMBL877617,1969.0,
8752,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,50597,N,,CHEMBL623905,,
8753,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,50597,N,,CHEMBL623906,,
8754,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,N,,CHEMBL623907,1969.0,
8755,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,N,,CHEMBL623908,,
8756,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,50597,N,,CHEMBL623909,,
8757,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,N,,CHEMBL623910,,
8758,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,N,,CHEMBL623911,,
8759,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,N,,CHEMBL623912,,
8760,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,N,,CHEMBL624616,,
8761,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,N,,CHEMBL624617,,
8762,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,N,,CHEMBL624618,,
8763,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,N,,CHEMBL624619,,
8764,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,N,,CHEMBL624794,,
8765,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,N,,CHEMBL624795,,
8766,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,N,,CHEMBL623921,,
8767,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,N,,CHEMBL623922,,
8768,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,N,,CHEMBL623923,,
8769,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,N,,CHEMBL623924,,
8770,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,N,,CHEMBL623925,,
8771,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,N,,CHEMBL623926,,
8772,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,N,,CHEMBL623927,,
8773,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,N,,CHEMBL623928,,
8774,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,N,,CHEMBL623929,,
8775,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,N,,CHEMBL623930,,
8776,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,N,,CHEMBL623931,955.0,
8777,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,N,,CHEMBL622165,955.0,
8778,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,N,,CHEMBL621249,955.0,
8779,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,N,,CHEMBL621250,955.0,
8780,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,N,,CHEMBL621448,955.0,
8781,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,N,,CHEMBL621449,955.0,
8782,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,N,,CHEMBL621450,955.0,
8783,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,N,,CHEMBL621451,955.0,
8784,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,N,,CHEMBL621452,955.0,
8785,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,N,,CHEMBL621453,955.0,
8786,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,N,,CHEMBL621454,955.0,
8787,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,N,,CHEMBL621455,955.0,
8788,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,N,,CHEMBL621456,955.0,
8789,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,N,,CHEMBL625145,955.0,
8790,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,N,,CHEMBL875847,955.0,
8791,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,N,,CHEMBL625146,955.0,
8792,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,N,,CHEMBL625147,955.0,
8793,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,N,,CHEMBL625148,955.0,
8794,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,N,,CHEMBL625149,955.0,
8795,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,N,,CHEMBL625150,955.0,
8796,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,N,,CHEMBL625151,955.0,
8797,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,N,,CHEMBL625152,955.0,
8798,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,N,,CHEMBL625153,955.0,
8799,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,N,,CHEMBL625154,955.0,
8800,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,N,,CHEMBL625155,955.0,
8801,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,N,,CHEMBL625156,,
8802,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL624354,,
8803,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL624355,10000000.0,
8804,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL624356,10000000.0,
8805,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL624357,10000000.0,
8806,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL624358,10000000.0,
8807,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL624359,2435.0,
8808,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL624360,2435.0,
8809,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,N,,CHEMBL624361,2435.0,
8810,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL624362,2435.0,
8811,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL624363,2435.0,
8812,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL624364,178.0,
8813,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL624365,178.0,
8814,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL624366,178.0,
8815,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL624367,178.0,
8816,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL624368,955.0,
8817,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL624369,955.0,
8818,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,N,,CHEMBL624370,955.0,
8819,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL625069,955.0,
8820,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL625070,955.0,
8821,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL626051,948.0,
8822,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL626052,948.0,
8823,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,N,,CHEMBL626053,948.0,
8824,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL626054,948.0,
8825,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL626055,948.0,
8826,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL626056,2113.0,
8827,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL626057,2113.0,
8828,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL625193,2113.0,
8829,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL625194,2113.0,
8830,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL625195,2107.0,
8831,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL625196,2107.0,
8832,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,N,,CHEMBL625197,2107.0,
8833,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL625198,2107.0,
8834,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL627929,2107.0,
8835,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL627074,2048.0,
8836,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL627075,2048.0,
8837,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,N,,CHEMBL627076,2048.0,
8838,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL627077,2048.0,
8839,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL627078,2048.0,
8840,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),50597,N,,CHEMBL627079,2385.0,
8841,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,50594,N,,CHEMBL873824,,
8842,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in mouse plasma was determined at dose 25 mg/kg,50594,N,,CHEMBL627080,1969.0,
8843,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Half life was determined,50594,N,,CHEMBL627081,,
8844,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,50594,N,,CHEMBL627082,,
8845,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life in male mice after 1 mg/kg intravenous dose,50594,N,,CHEMBL627083,,
8847,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Half life in mice plasma,50594,N,,CHEMBL627085,1969.0,
8848,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Half life in mouse,50594,N,,CHEMBL627086,,
8849,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in mouse plasma at dose 25 mg/kg,50594,N,,CHEMBL627087,1969.0,
8850,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,50594,N,,CHEMBL627088,,
8851,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,50594,N,,CHEMBL627089,,
8852,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,50594,N,,CHEMBL627090,,
8853,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),50594,N,,CHEMBL627091,,
8854,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",50594,N,,CHEMBL627092,,
8855,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",50594,N,,CHEMBL876785,,
8856,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life by iv administration in mouse,50594,N,,CHEMBL627093,,
8857,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life by oral administration in mouse,50594,N,,CHEMBL627094,,
8858,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Half-life in mice,50594,N,,CHEMBL627095,,
8859,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Half-life using mouse brain homogenate,50594,N,,CHEMBL627096,955.0,
8860,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Half-life was measured in mice,50594,N,,CHEMBL627097,,
8861,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life was measured in mouse after an iv dose of 1 mg/kg,50594,N,,CHEMBL627098,,
8862,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Half-life period was determined in mouse blood,50594,N,,CHEMBL627099,178.0,
8863,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",50594,N,,CHEMBL627100,955.0,
8864,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Plasma half life in mouse,50594,N,,CHEMBL627101,1969.0,
8865,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Stability of the peptide in the presence of mouse serum,50594,N,,CHEMBL627102,,
8866,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Terminal half life of compound was determined in mouse,50594,N,,CHEMBL627103,,
8867,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Terminal half life was evaluated in mice after intravenous administration,50594,N,,CHEMBL627104,,
8868,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Terminal half life was evaluated in mice after oral administration,50594,N,,CHEMBL627105,,
8869,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,50594,N,,CHEMBL876786,,
8870,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,50594,N,,CHEMBL873825,,
8871,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,50594,N,,CHEMBL627106,,
8872,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,half life period is evaluated by administering intravenously at 25 mg/kg in mice,50594,N,,CHEMBL626336,,
8873,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",50594,N,,CHEMBL877462,,
8874,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",50594,N,,CHEMBL626337,,
8875,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Half life after intraperitoneal administration of 100 mg/kg in mice,50594,N,,CHEMBL626338,,
8876,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,50594,N,,CHEMBL626339,,
8877,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,50594,N,,CHEMBL626340,,
8878,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,50594,N,,CHEMBL625377,,
8879,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,50594,N,,CHEMBL625378,,
8880,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,50594,N,,CHEMBL625379,,
8881,,Sus scrofa,BAO_0000251,,1,A,Autocuration,,0,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),22224,U,,CHEMBL625380,,
8882,,Sus scrofa,BAO_0000251,,1,A,Autocuration,,0,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),22224,U,,CHEMBL625381,,
8883,,Sus scrofa,BAO_0000019,,1,A,Autocuration,,0,Stability to porcine renal DHP-I,22224,U,,CHEMBL625382,,
8884,,Sus scrofa,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,22224,U,,CHEMBL873828,,
8885,,Sus scrofa,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,22224,U,,CHEMBL625383,,
8886,,Sus scrofa,BAO_0000019,,1,A,Autocuration,,0,Half-life of the parent prodrug in porcine esterase solution,22224,U,,CHEMBL625384,,
8887,,Sus scrofa,BAO_0000019,,1,A,Autocuration,,0,"First order rate constant, k was determined in in pig liver Esterase",22224,U,,CHEMBL625385,,
8888,,Sus scrofa,BAO_0000221,,1,A,Autocuration,,0,Half life of the in pig liver Esterase,22224,U,,CHEMBL625386,2107.0,
8889,,Sus scrofa,BAO_0000221,,1,A,Autocuration,,0,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,22224,U,,CHEMBL623571,2107.0,
8890,,Sus scrofa,BAO_0000221,,1,A,Autocuration,,0,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,22224,U,,CHEMBL623572,2107.0,
8891,,Sus scrofa,BAO_0000221,,1,A,Autocuration,,0,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,22224,U,,CHEMBL623573,2107.0,
8892,,Sus scrofa,BAO_0000221,,1,A,Autocuration,,0,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,22224,U,,CHEMBL623574,2107.0,
8893,,Sus scrofa,BAO_0000221,,1,A,Autocuration,,0,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,22224,U,,CHEMBL623575,2107.0,
8894,,Sus scrofa,BAO_0000221,,1,A,Autocuration,,0,Half-life in the presence of pig liver esterase(PLE) was evaluated.,22224,U,,CHEMBL623749,2107.0,
8895,,Sus scrofa,BAO_0000221,,1,A,Autocuration,,0,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,22224,U,,CHEMBL623750,2107.0,
8896,,Sus scrofa,BAO_0000221,,1,A,Autocuration,In vitro,0,Half-life in vitro in pig liver,22224,U,,CHEMBL623751,2107.0,
8897,,Sus scrofa,BAO_0000221,,1,A,Autocuration,,0,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,22224,U,,CHEMBL623752,2107.0,
8898,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,50597,N,,CHEMBL623753,1969.0,
8899,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,50597,N,,CHEMBL623754,1969.0,
8900,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in rat plasma was determined,50597,N,,CHEMBL623755,1969.0,
8901,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in rats,50597,N,,CHEMBL623756,,
8902,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in rats at 1-2 hours,50597,N,,CHEMBL623757,,
8903,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,50597,N,,CHEMBL623758,,
8904,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,50597,N,,CHEMBL623759,955.0,
8905,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration at the dose of 2 mg/kg in rat,50597,N,,CHEMBL623760,,
8906,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration was evaluated in rats,50597,N,,CHEMBL623761,,
8907,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,50597,N,,CHEMBL623762,1969.0,
8908,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,50597,N,,CHEMBL877594,1969.0,
8909,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,50597,N,,CHEMBL623763,1969.0,
8910,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,50597,N,,CHEMBL623764,1969.0,
8911,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,50597,N,,CHEMBL623765,1969.0,
8912,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,50597,N,,CHEMBL623766,178.0,
8913,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,50597,N,,CHEMBL623767,178.0,
8914,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,50597,N,,CHEMBL623768,178.0,
8915,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,50597,N,,CHEMBL623769,1969.0,
8916,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,50597,N,,CHEMBL623770,1969.0,
8917,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,50597,N,,CHEMBL623771,1969.0,
8918,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,50597,N,,CHEMBL623772,1969.0,
8919,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,50597,N,,CHEMBL623773,1969.0,
8920,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,50597,N,,CHEMBL623774,1969.0,
8921,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,50597,N,,CHEMBL623775,1969.0,
8922,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in rat (PO dose),50597,N,,CHEMBL623776,,
8923,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,N,,CHEMBL622191,1969.0,
8924,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,N,,CHEMBL622192,1969.0,
8925,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration determined in rat,50597,N,,CHEMBL622193,1969.0,
8926,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,50597,N,,CHEMBL622194,1969.0,
8927,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,50597,N,,CHEMBL622195,1969.0,
8928,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration in rat,50597,N,,CHEMBL622196,1969.0,
8929,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,N,,CHEMBL622197,1969.0,
8930,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,50597,N,,CHEMBL622198,1969.0,
8931,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,50597,N,,CHEMBL622199,1969.0,
8932,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration of compound was measured in rat,50597,N,,CHEMBL622200,1969.0,
8933,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration after 20 mg/kg oral administration in rat,50597,N,,CHEMBL622201,1969.0,
8934,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration after oral administration to rats,50597,N,,CHEMBL623990,1969.0,
8935,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,N,,CHEMBL623991,1969.0,
8936,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",50597,N,,CHEMBL623992,1969.0,
8937,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,N,,CHEMBL623993,1969.0,
8938,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,50597,N,,CHEMBL623994,1969.0,
8939,,Rattus norvegicus,BAO_0000218,,1,F,Intermediate,In vivo,1,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,50597,N,,CHEMBL623995,1969.0,
8940,,Rattus norvegicus,BAO_0000218,,1,F,Intermediate,In vivo,1,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,N,,CHEMBL623996,1969.0,
8941,,Rattus norvegicus,BAO_0000218,,1,F,Intermediate,In vivo,1,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,50597,N,,CHEMBL623997,1969.0,
8942,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration dosed orally in rats,50597,N,,CHEMBL623998,1969.0,
8943,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration dosed orally in rats after 6 hours,50597,N,,CHEMBL623999,1969.0,
8944,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,50597,N,,CHEMBL624000,1969.0,
8945,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,50597,N,,CHEMBL624001,1969.0,
8946,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration in rat after po administration,50597,N,,CHEMBL624002,1969.0,
8947,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",50597,N,,CHEMBL624003,1969.0,
8948,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",50597,N,,CHEMBL624004,1969.0,
8949,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,N,,CHEMBL624005,948.0,
8950,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,N,,CHEMBL624006,948.0,
8951,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,N,,CHEMBL624007,948.0,
8952,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,N,,CHEMBL624008,948.0,
8953,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,N,,CHEMBL624009,948.0,
8954,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,N,,CHEMBL874387,948.0,
8955,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,N,,CHEMBL624010,948.0,
8956,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,50597,N,,CHEMBL624011,948.0,
8957,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,N,,CHEMBL624012,948.0,
8958,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,N,,CHEMBL624013,948.0,
8959,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,N,,CHEMBL624736,948.0,
8960,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,N,,CHEMBL624737,948.0,
8961,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,N,,CHEMBL624738,948.0,
8962,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,N,,CHEMBL624739,948.0,
8963,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,N,,CHEMBL624740,948.0,
8964,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,N,,CHEMBL624896,948.0,
8965,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,N,,CHEMBL624897,948.0,
8966,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,N,,CHEMBL624108,948.0,
8967,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,N,,CHEMBL624109,948.0,
8968,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,N,,CHEMBL624110,948.0,
8969,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,N,,CHEMBL624111,948.0,
8970,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,N,,CHEMBL624112,948.0,
8971,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,N,,CHEMBL624113,948.0,
8972,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,N,,CHEMBL619709,948.0,
8973,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,N,,CHEMBL619710,948.0,
8974,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,N,,CHEMBL619711,2113.0,
8975,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,N,,CHEMBL619712,2113.0,
8976,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,N,,CHEMBL619713,2113.0,
8977,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,N,,CHEMBL619714,2113.0,
8978,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,N,,CHEMBL619715,2113.0,
8979,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,N,,CHEMBL619716,2113.0,
8980,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,N,,CHEMBL619717,2113.0,
8981,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,N,,CHEMBL619718,2113.0,
8982,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,N,,CHEMBL619719,2113.0,
8983,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,N,,CHEMBL875329,2113.0,
8984,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,N,,CHEMBL619720,2113.0,
8985,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,N,,CHEMBL619721,2113.0,
8986,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,N,,CHEMBL619722,2113.0,
8987,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,N,,CHEMBL619723,2113.0,
8988,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,N,,CHEMBL619724,2113.0,
8989,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,N,,CHEMBL619725,2113.0,
8990,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,N,,CHEMBL619726,2113.0,
8991,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,N,,CHEMBL619727,2113.0,
8992,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,N,,CHEMBL619728,2113.0,
8993,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,N,,CHEMBL619729,2113.0,
8994,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL619730,2385.0,
8995,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL619731,2385.0,
8996,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,N,,CHEMBL619732,2385.0,
8997,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL619733,2385.0,
8998,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL619734,2385.0,
8999,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL619735,14.0,
9000,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL875330,14.0,
9001,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,N,,CHEMBL628465,14.0,
9002,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL628466,14.0,
9003,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL628467,14.0,
9004,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL628468,2106.0,
9005,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL628469,2106.0,
9006,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,N,,CHEMBL628470,2106.0,
9007,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL628471,2106.0,
9008,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL628472,2106.0,
9009,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL625191,2046.0,
9010,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL625192,2046.0,
9011,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,N,,CHEMBL875337,2046.0,
9012,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL626341,2046.0,
9013,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL626342,2046.0,
9014,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,N,,CHEMBL621943,2107.0,
9015,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life in rats,50597,N,,CHEMBL621944,,
9016,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,50597,N,,CHEMBL621945,,
9017,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),50597,N,,CHEMBL621946,,
9018,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,50597,N,,CHEMBL621947,,
9019,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),50597,N,,CHEMBL621948,,
9020,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,50597,N,,CHEMBL621949,,
9021,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),50597,N,,CHEMBL621950,,
9022,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,50597,N,,CHEMBL621951,,
9023,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,50597,N,,CHEMBL621952,178.0,
9024,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Stability (%) in rat liver microsomes,50597,N,,CHEMBL621953,2107.0,
9025,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was calculated after intravenous administration,50597,N,,CHEMBL621954,,
9026,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was calculated after iv administration in rat,50597,N,,CHEMBL621955,,
9027,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was calculated in rat after peroral administration,50597,N,,CHEMBL621956,,
9028,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,50597,N,,CHEMBL621957,,
9029,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,50597,N,,CHEMBL621958,,
9030,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,50597,N,,CHEMBL621959,,
9031,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,50597,N,,CHEMBL621960,,
9032,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,50597,N,,CHEMBL621961,,
9033,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,p value of the compound,50597,N,,CHEMBL621962,,
9034,,Rattus norvegicus,BAO_0000218,,1,F,Intermediate,,1,p value of the compound,50597,N,,CHEMBL876787,,
9035,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,p value of the compound,50597,N,,CHEMBL621963,,
9036,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,N,,CHEMBL622637,945.0,
9037,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,N,,CHEMBL622638,945.0,
9038,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,N,,CHEMBL626561,945.0,
9039,,Oryctolagus cuniculus,BAO_0000019,,1,F,Autocuration,,0,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),22224,U,,CHEMBL626562,,
9040,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,,0,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),22224,U,,CHEMBL626563,,
9041,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,,0,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),22224,U,,CHEMBL626564,,
9042,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,22224,U,,CHEMBL626565,,
9043,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,22224,U,,CHEMBL626566,,
9044,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Clearance rate in rabbits,22224,U,,CHEMBL626567,,
9045,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,22224,U,,CHEMBL626568,,
9046,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,22224,U,,CHEMBL626569,,
9047,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,22224,U,,CHEMBL626570,,
9048,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,22224,U,,CHEMBL626571,,
9049,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,22224,U,,CHEMBL626572,,
9050,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,22224,U,,CHEMBL626573,1969.0,
9051,,Oryctolagus cuniculus,BAO_0000251,,1,A,Autocuration,,0,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,22224,U,,CHEMBL626574,2107.0,
9052,,Oryctolagus cuniculus,BAO_0000251,,1,A,Autocuration,,0,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,22224,U,,CHEMBL626575,2107.0,
9053,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,,0,Dose at which bioavailability of intravenously administered compound was tested in rabbit,22224,U,,CHEMBL626576,,
9054,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,,0,Dose at which bioavailability of perorally administered compound was tested in rabbit,22224,U,,CHEMBL626577,,
9055,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,In vivo,0,The compound was tested for its bioavailability in rabbit (by oral dosage).,22224,U,,CHEMBL626578,,
9056,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,22224,U,,CHEMBL625263,,
9057,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,22224,U,,CHEMBL625264,,
9058,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,22224,U,,CHEMBL625265,,
9059,,Oryctolagus cuniculus,BAO_0000251,,1,A,Autocuration,,0,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),22224,U,,CHEMBL625266,,
9060,,Oryctolagus cuniculus,BAO_0000251,,1,A,Autocuration,,0,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),22224,U,,CHEMBL876796,,
9061,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,22224,U,,CHEMBL625267,,
9062,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,22224,U,,CHEMBL625268,1969.0,
9063,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,22224,U,,CHEMBL625269,1969.0,
9064,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,22224,U,,CHEMBL624689,1969.0,
9065,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,22224,U,,CHEMBL624690,,
9066,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,,0,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),22224,U,,CHEMBL624691,1088.0,
9067,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,,0,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),22224,U,,CHEMBL624692,1088.0,
9068,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,In vivo,0,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,22224,U,,CHEMBL624693,,
9069,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,22224,U,,CHEMBL624694,,
9070,,Oryctolagus cuniculus,BAO_0000221,,1,A,Autocuration,In vitro,0,In vitro Biological half-life in crude homogenate of rabbit renal cortex,22224,U,,CHEMBL877596,,
9071,,Oryctolagus cuniculus,BAO_0000019,,1,A,Autocuration,,0,Time within which only 10% of the drug was degraded,22224,U,,CHEMBL624695,,
9072,,Oryctolagus cuniculus,BAO_0000221,,1,A,Autocuration,,0,Half life period in rabbit liver homogenate,22224,U,,CHEMBL624696,2107.0,
9073,,Oryctolagus cuniculus,BAO_0000019,,1,A,Autocuration,,0,Half life value in rabbits,22224,U,,CHEMBL624697,,
9074,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,22224,U,,CHEMBL624698,178.0,
9075,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,22224,U,,CHEMBL624699,178.0,
9076,,Oryctolagus cuniculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Half-life period in rabbits following intravenous administration at 2 mg/kg,22224,U,,CHEMBL624700,,
9077,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC 0-8 hr value in rats at 10 mg/kg,50597,N,,CHEMBL622903,1969.0,
9078,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC after administration at 2000 mg/kg/day in rats,50597,N,,CHEMBL622904,1969.0,
9079,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,50597,N,,CHEMBL622905,1969.0,
9080,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,N,,CHEMBL622906,1969.0,
9081,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,N,,CHEMBL622907,1969.0,
9082,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC in rat after oral administration at 10.5 mg/kg dose,50597,N,,CHEMBL622908,1969.0,
9083,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC in rat after oral administration at 11.2 mg/kg dose,50597,N,,CHEMBL622909,1969.0,
9084,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC in rat after oral administration at 9.7 mg/kg dose,50597,N,,CHEMBL622910,1969.0,
9085,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC in rat brain after oral administration at 10 mg/kg,50597,N,,CHEMBL622911,955.0,
9086,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC in rat p.o.,50597,N,,CHEMBL622912,1969.0,
9087,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC in rat p.o. at 20 mg/kg concentration,50597,N,,CHEMBL622913,1969.0,
9088,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC in rat plasma after oral administration at 10 mg/kg,50597,N,,CHEMBL622914,1969.0,
9089,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC in rats,50597,N,,CHEMBL622915,1969.0,
9090,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC value after IV dose at a dose of 5 mg/kg in rats.,50597,N,,CHEMBL622916,1969.0,
9091,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC value after oral dose at a dose of 10 mg/kg in rats.,50597,N,,CHEMBL622917,1969.0,
9092,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",50597,N,,CHEMBL622918,1969.0,
9093,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,50597,N,,CHEMBL622919,1969.0,
9094,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration was evaluated in rat,50597,N,,CHEMBL622920,1969.0,
9095,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,50597,N,,CHEMBL622921,1969.0,
9096,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,50597,N,,CHEMBL622922,1969.0,
9097,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,50597,N,,CHEMBL622923,1969.0,
9098,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,50597,N,,CHEMBL877604,1969.0,
9099,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,50597,N,,CHEMBL622924,1969.0,
9100,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,50597,N,,CHEMBL622925,1969.0,
9101,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,50597,N,,CHEMBL622926,1969.0,
9102,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,50597,N,,CHEMBL623625,1969.0,
9103,,Rattus norvegicus,BAO_0000218,,1,A,Expert,In vivo,1,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,N,,CHEMBL623626,1969.0,
9104,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma drug concentration was determined,50597,N,,CHEMBL623627,1969.0,
9105,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,50597,N,,CHEMBL623628,,
9106,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Mean peak plasma concentration was observed after intravenous administration in rat,50597,N,,CHEMBL623629,1969.0,
9107,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Mean peak plasma concentration was observed after oral administration in rat,50597,N,,CHEMBL623630,1969.0,
9108,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,50597,N,,CHEMBL623804,,
9109,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,50597,N,,CHEMBL623805,,
9110,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Peak oral plasma concentration was determined in rats by oral administration,50597,N,,CHEMBL623806,1969.0,
9111,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Peak plasma concentration (Cmax) was determined,50597,N,,CHEMBL623807,1969.0,
9112,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,50597,N,,CHEMBL623808,1969.0,
9113,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Peak plasma concentration (Cmax) in rats,50597,N,,CHEMBL623809,1969.0,
9114,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Peak plasma concentration at 1 mg/kg peroral administration,50597,N,,CHEMBL623810,1969.0,
9115,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Peak plasma concentration in rat,50597,N,,CHEMBL623811,1969.0,
9116,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",50597,N,,CHEMBL623812,1969.0,
9117,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,50597,N,,CHEMBL877605,,
9118,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (Cmax) in rat,50597,N,,CHEMBL623813,,
9119,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,50597,N,,CHEMBL623814,,
9120,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in rat after 3mg/kg oral dose,50597,N,,CHEMBL623815,,
9121,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,50597,N,,CHEMBL623816,,
9122,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in rats after 20 mg/kg oral dose,50597,N,,CHEMBL623145,,
9123,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in rat plasma after 30mg/kg oral dose,50597,N,,CHEMBL623146,1969.0,
9124,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma concentration after oral administration of 100 mg/kg to rats,50597,N,,CHEMBL623147,1969.0,
9125,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,50597,N,,CHEMBL623042,955.0,
9126,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for the Cmax in rat at 10 mg/kg per orally,50597,N,,CHEMBL623043,,
9127,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",50597,N,,CHEMBL623044,,
9128,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",50597,N,,CHEMBL623045,,
9129,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability as oral Cmax in rats at 30 mins,50597,N,,CHEMBL623046,,
9130,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability as oral Cmax in rats at 6hr,50597,N,,CHEMBL623226,,
9131,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The maximum concentration of compound was measured at the dose of 100 umol/kg,50597,N,,CHEMBL623227,,
9132,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The maximum concentration of compound was measured at the dose of 300 umol/kg,50597,N,,CHEMBL623228,,
9133,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The maximum concentration of compound was measured at the dose of 30 umol/kg,50597,N,,CHEMBL623229,,
9134,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The maximum plasma levels for the compounds were determined by LC-MS.,50597,N,,CHEMBL623230,1969.0,
9135,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,mean peak plasma concentration was observed after intravenous administration in rat,50597,N,,CHEMBL623231,1969.0,
9136,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,mean peak plasma concentration was observed after oral administration in rat,50597,N,,CHEMBL623232,1969.0,
9137,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,50597,N,,CHEMBL623233,,
9138,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,50597,N,,CHEMBL623234,,
9139,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration in plasma (portal) following oral dose in rats at 1 hr,50597,N,,CHEMBL623235,,
9140,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration in plasma (portal) following oral dose in rats at 2 hr,50597,N,,CHEMBL623236,,
9141,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,50597,N,,CHEMBL623237,,
9142,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration in plasma (systemic) following oral dose in rats at 1 hr,50597,N,,CHEMBL623238,,
9143,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration in plasma (systemic) following oral dose in rats at 2 hr,50597,N,,CHEMBL623239,,
9144,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,0,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,22224,U,,CHEMBL623240,1969.0,
9145,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",50597,N,,CHEMBL623241,1898.0,
9146,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",50597,N,,CHEMBL623242,1898.0,
9147,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",50597,N,,CHEMBL874394,,
9148,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",50597,N,,CHEMBL623243,,
9149,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,N,,CHEMBL623244,,
9150,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,N,,CHEMBL623245,2113.0,
9151,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,N,,CHEMBL623246,2113.0,
9152,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,N,,CHEMBL623247,2113.0,
9153,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,N,,CHEMBL623248,2113.0,
9154,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,N,,CHEMBL623249,2113.0,
9155,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,N,,CHEMBL625072,2107.0,
9156,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,N,,CHEMBL625073,2107.0,
9157,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,N,,CHEMBL625074,2107.0,
9158,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,N,,CHEMBL625075,2107.0,
9159,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,50597,N,,CHEMBL625076,2107.0,
9160,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,N,,CHEMBL625077,2107.0,
9161,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,N,,CHEMBL625078,2107.0,
9162,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,N,,CHEMBL874395,2107.0,
9163,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,N,,CHEMBL625079,2107.0,
9164,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,N,,CHEMBL625080,2107.0,
9165,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,N,,CHEMBL625081,2107.0,
9166,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,N,,CHEMBL625082,2107.0,
9167,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,N,,CHEMBL625083,2107.0,
9168,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,N,,CHEMBL625084,2107.0,
9169,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,N,,CHEMBL625085,2107.0,
9170,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,N,,CHEMBL625086,2107.0,
9171,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,N,,CHEMBL625087,2107.0,
9172,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,N,,CHEMBL625088,2107.0,
9173,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,N,,CHEMBL622205,2107.0,
9174,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,N,,CHEMBL622206,2107.0,
9175,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,N,,CHEMBL622207,2107.0,
9176,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,N,,CHEMBL622366,2107.0,
9177,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,N,,CHEMBL622367,2107.0,
9178,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,N,,CHEMBL875331,2107.0,
9179,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,N,,CHEMBL622368,2107.0,
9180,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,N,,CHEMBL622369,2048.0,
9181,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,N,,CHEMBL622370,2048.0,
9182,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,N,,CHEMBL622371,2048.0,
9183,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,N,,CHEMBL622372,2048.0,
9184,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,N,,CHEMBL622373,2048.0,
9185,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,N,,CHEMBL622374,2048.0,
9186,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,N,,CHEMBL622375,2048.0,
9187,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,50597,N,,CHEMBL622376,2048.0,
9188,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,N,,CHEMBL622377,2048.0,
9189,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,N,,CHEMBL622378,2048.0,
9190,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,N,,CHEMBL622379,2048.0,
9191,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,N,,CHEMBL622380,2048.0,
9192,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,N,,CHEMBL622381,2048.0,
9193,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,N,,CHEMBL622382,2048.0,
9194,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,50597,N,,CHEMBL622383,2048.0,
9195,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,N,,CHEMBL875332,945.0,
9196,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,N,,CHEMBL622384,945.0,
9197,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,N,,CHEMBL622385,945.0,
9198,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,N,,CHEMBL622386,945.0,
9199,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The compound was tested for the plasma binding in rat,50597,N,,CHEMBL622387,,
9200,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",50597,N,,CHEMBL622388,,
9201,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",50597,N,,CHEMBL622389,,
9202,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",50597,N,,CHEMBL622390,,
9203,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),50597,N,,CHEMBL622391,,
9204,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),50597,N,,CHEMBL622392,,
9205,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),50597,N,,CHEMBL622393,,
9206,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma level at 2 hr after administration of the compound,50597,N,,CHEMBL622394,,
9207,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,plasma level at 2 hr after administration of the compound,50597,N,,CHEMBL622395,,
9208,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Stability in rat serum measured as % recovery at 1 min,50597,N,,CHEMBL622396,1977.0,
9209,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Stability in rat serum measured as % recovery at 10 min,50597,N,,CHEMBL624894,1977.0,
9210,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Stability in rat serum measured as % recovery at 10 mins,50597,N,,CHEMBL624895,1977.0,
9211,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Stability in rat serum measured as % recovery at 2 hr,50597,N,,CHEMBL624058,1977.0,
9212,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Stability in rat serum measured as % recovery at 3 min,50597,N,,CHEMBL624059,1977.0,
9213,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Stability in rat serum measured as % recovery at 3 mins,50597,N,,CHEMBL624060,1977.0,
9214,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Stability in rat serum measured as % recovery at 5 min,50597,N,,CHEMBL624061,1977.0,
9215,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Stability in rat serum measured as % recovery at 5 mins,50597,N,,CHEMBL624062,1977.0,
9216,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,50597,N,,CHEMBL624063,,
9217,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,50597,N,,CHEMBL624064,,
9218,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,50597,N,,CHEMBL624065,1969.0,
9219,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,50597,N,,CHEMBL624066,1969.0,
9220,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life tested in mature male rat at a dose of 30 mg/kg,50597,N,,CHEMBL877490,,
9221,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life after intravenous administration of 1 mg/kg in rat,50597,N,,CHEMBL874442,,
9222,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period after administration (30 mg/kg) in rat,50597,N,,CHEMBL626890,,
9223,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period in rat after 5 mg/Kg dose,50597,N,,CHEMBL626891,,
9224,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period in rat after 5 mg/kg dose,50597,N,,CHEMBL626892,,
9225,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period was determined,50597,N,,CHEMBL626893,,
9226,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period was evaluated in rat,50597,N,,CHEMBL626894,,
9227,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period was evaluated in rat; 0.5-1.0,50597,N,,CHEMBL626895,,
9228,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period was evaluated in rat; 5.9-7.5,50597,N,,CHEMBL626896,,
9229,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in rat plasma,50597,N,,CHEMBL626897,1969.0,
9230,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life time in rat was determined,50597,N,,CHEMBL626898,,
9231,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Terminal half-life after iv administration to rats,50597,N,,CHEMBL626899,,
9232,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,50597,N,,CHEMBL626900,,
9233,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,50597,N,,CHEMBL626901,,
9234,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),50597,N,,CHEMBL626902,,
9235,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),50597,N,,CHEMBL626903,,
9236,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,50597,N,,CHEMBL874443,,
9237,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,50597,N,,CHEMBL626904,,
9238,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life in rats,50597,N,,CHEMBL626905,,
9239,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,50597,N,,CHEMBL873830,1969.0,
9240,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,50597,N,,CHEMBL626906,,
9241,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,N,,CHEMBL631076,1969.0,
9242,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Biological half-life was measured in plasma of rats,50597,N,,CHEMBL631077,1969.0,
9243,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,N,,CHEMBL631078,,
9244,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,50597,N,,CHEMBL631079,,
9245,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,50597,N,,CHEMBL631080,,
9246,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,50597,N,,CHEMBL631081,,
9247,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,50597,N,,CHEMBL631239,,
9248,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for plasma half life in rat,50597,N,,CHEMBL631240,1969.0,
9249,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC value at a dose of 5 mg/kg (p.o.) in rats,50597,N,,CHEMBL631241,1969.0,
9250,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC value after administration of 20 mg/Kg oral dose in rat,50597,N,,CHEMBL631242,1969.0,
9251,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,50597,N,,CHEMBL631243,1969.0,
9252,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC0-96 after administration at 50 mg/kg,50597,N,,CHEMBL874444,1969.0,
9253,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,50597,N,,CHEMBL631244,1969.0,
9254,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",50597,N,,CHEMBL631245,,
9255,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,50597,N,,CHEMBL627162,,
9256,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,50597,N,,CHEMBL627163,,
9257,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,50597,N,,CHEMBL627164,,
9258,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,50597,N,,CHEMBL627165,2113.0,
9259,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,50597,N,,CHEMBL627166,,
9260,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,50597,N,,CHEMBL627167,,
9261,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve (AUC) at a dose of 30 mg/kg in rats,50597,N,,CHEMBL627822,,
9262,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,50597,N,,CHEMBL627823,,
9263,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,50597,N,,CHEMBL627824,,
9264,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,50597,N,,CHEMBL627825,,
9265,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,50597,N,,CHEMBL627826,,
9266,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve (Pharmacokinetic property) was determined,50597,N,,CHEMBL627827,,
9267,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve (Pharmacokinetic property) of the compound; Not determined,50597,N,,CHEMBL627828,,
9268,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve after intravenous administration (1 mg/kg) in rat,50597,N,,CHEMBL627829,,
9269,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,50597,N,,CHEMBL627830,,
9270,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,50597,N,,CHEMBL627831,,
9271,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve in male SD rats was observed after oral administration in rat,50597,N,,CHEMBL627832,,
9272,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve of compound after iv administration of 20 mg/kg dose in rat,50597,N,,CHEMBL627833,,
9273,,Rattus norvegicus,BAO_0000218,,1,A,Expert,,1,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,N,,CHEMBL627834,,
9274,,Rattus norvegicus,BAO_0000218,,1,A,Expert,,1,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,50597,N,,CHEMBL628004,,
9275,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve at 5 mg/kg po was determined in rat,50597,N,,CHEMBL628005,,
9276,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve in Rat at a oral dose of 5 mg/kg,50597,N,,CHEMBL628006,,
9277,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,N,,CHEMBL628007,,
9278,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined,50597,N,,CHEMBL625676,,
9279,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,50597,N,,CHEMBL631309,,
9280,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve after intravenous administration at 3 mg/kg,50597,N,,CHEMBL631310,,
9281,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,50597,N,,CHEMBL631311,,
9282,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve at 4 hr in rat,50597,N,,CHEMBL631312,,
9283,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve at a dose of 30 mg/kg,50597,N,,CHEMBL631313,,
9284,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve at the dose of 2 mg/Kg administered perorally in rats,50597,N,,CHEMBL631314,,
9285,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve at the dose of 5 mg/Kg administered perorally in rats,50597,N,,CHEMBL631315,,
9286,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve for a 2-mpk po dose in SD rats,50597,N,,CHEMBL631316,,
9287,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve in SD rats,50597,N,,CHEMBL631317,,
9288,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve in rat after oral administration at 13 mg/kg dose,50597,N,,CHEMBL874471,,
9289,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve in rat by po administration at 0-24 hr,50597,N,,CHEMBL631318,,
9290,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve in rat plasma,50597,N,,CHEMBL631319,1969.0,
9291,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,50597,N,,CHEMBL631320,,
9292,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,50597,N,,CHEMBL631321,,
9293,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,50597,N,,CHEMBL631322,,
9294,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,50597,N,,CHEMBL631323,,
9295,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve value in rat at a dose of 5 mg/kg,50597,N,,CHEMBL631324,,
9296,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined after oral administration in rats,50597,N,,CHEMBL631325,,
9297,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,50597,N,,CHEMBL631326,,
9298,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined after peroral administration in rat,50597,N,,CHEMBL631327,,
9299,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined at a dose 30 mpk administered orally.,50597,N,,CHEMBL631328,,
9300,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,50597,N,,CHEMBL631329,,
9301,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,50597,N,,CHEMBL627217,,
9302,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined in male rat,50597,N,,CHEMBL626352,,
9303,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined in rat after PO administration,50597,N,,CHEMBL626353,,
9304,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined in rat after a 3 mg/kg of oral dose,50597,N,,CHEMBL626354,,
9305,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,50597,N,,CHEMBL626355,,
9306,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,50597,N,,CHEMBL626356,,
9307,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,50597,N,,CHEMBL626357,,
9308,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,N,,CHEMBL626358,,
9309,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,N,,CHEMBL626359,,
9310,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Peak plasma concentration in rat at a dose of 3 mg/kg,50597,N,,CHEMBL626360,1969.0,
9311,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration at 2 hr in rats was evaluated.,50597,N,,CHEMBL626361,,
9312,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration at 2 hr in rats was evaluated; Not available,50597,N,,CHEMBL626362,,
9313,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,N,,CHEMBL626363,,
9314,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,50597,N,,CHEMBL626970,,
9315,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,50597,N,,CHEMBL626971,,
9316,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,50597,N,,CHEMBL626972,1969.0,
9317,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,50597,N,,CHEMBL626973,1969.0,
9318,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,50597,N,,CHEMBL626974,1969.0,
9319,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,50597,N,,CHEMBL874592,1969.0,
9320,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,50597,N,,CHEMBL626975,,
9321,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,50597,N,,CHEMBL626976,,
9322,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,50597,N,,CHEMBL626977,,
9323,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,50597,N,,CHEMBL626978,,
9324,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,PK study was carried to determine the relative absorption ranking in rat.,50597,N,,CHEMBL626979,,
9325,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,50597,N,,CHEMBL626980,1969.0,
9326,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",50597,N,,CHEMBL626981,178.0,
9327,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",50597,N,,CHEMBL626982,178.0,
9328,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",50597,N,,CHEMBL626983,178.0,
9329,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",50597,N,,CHEMBL622522,178.0,
9330,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",50597,N,,CHEMBL622523,178.0,
9331,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",50597,N,,CHEMBL622524,178.0,
9332,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",50597,N,,CHEMBL622525,955.0,
9333,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",50597,N,,CHEMBL622526,955.0,
9334,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",50597,N,,CHEMBL619849,955.0,
9335,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",50597,N,,CHEMBL619850,955.0,
9336,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",50597,N,,CHEMBL623864,955.0,
9337,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",50597,N,,CHEMBL623865,955.0,
9338,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",50597,N,,CHEMBL623866,948.0,
9339,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",50597,N,,CHEMBL623867,948.0,
9340,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",50597,N,,CHEMBL877615,948.0,
9341,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",50597,N,,CHEMBL623868,948.0,
9342,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",50597,N,,CHEMBL623869,948.0,
9343,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",50597,N,,CHEMBL623870,948.0,
9344,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,50597,N,,CHEMBL623871,2048.0,
9345,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,N,,CHEMBL623872,2048.0,
9346,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,N,,CHEMBL622129,2048.0,
9347,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,N,,CHEMBL622130,2048.0,
9348,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,N,,CHEMBL622131,2048.0,
9349,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,N,,CHEMBL622132,2048.0,
9350,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,N,,CHEMBL622133,2048.0,
9351,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,N,,CHEMBL622134,2048.0,
9352,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,N,,CHEMBL622135,2048.0,
9353,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,N,,CHEMBL622136,2048.0,
9354,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,N,,CHEMBL622137,2385.0,
9355,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,N,,CHEMBL622138,2385.0,
9356,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,N,,CHEMBL623017,2385.0,
9357,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,N,,CHEMBL623018,2385.0,
9358,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,N,,CHEMBL623019,2385.0,
9359,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,N,,CHEMBL623020,2385.0,
9360,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,50597,N,,CHEMBL623021,2385.0,
9361,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,50597,N,,CHEMBL623022,2385.0,
9362,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,N,,CHEMBL623023,2385.0,
9363,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,N,,CHEMBL623024,2385.0,
9364,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,N,,CHEMBL623025,2385.0,
9365,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,N,,CHEMBL620545,2385.0,
9366,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,N,,CHEMBL620546,2385.0,
9367,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,N,,CHEMBL620547,2385.0,
9368,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,N,,CHEMBL620548,2385.0,
9369,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,N,,CHEMBL620549,2385.0,
9370,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,N,,CHEMBL620550,2385.0,
9371,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,50597,N,,CHEMBL620551,2385.0,
9372,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,N,,CHEMBL620552,2385.0,
9373,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,N,,CHEMBL620553,2385.0,
9374,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,N,,CHEMBL620554,2385.0,
9375,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,N,,CHEMBL875845,2385.0,
9376,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,N,,CHEMBL620555,2385.0,
9377,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,N,,CHEMBL620556,2385.0,
9378,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,N,,CHEMBL620557,2385.0,
9379,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,N,,CHEMBL620558,,
9380,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,N,,CHEMBL620559,,
9381,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,N,,CHEMBL622939,,
9382,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,N,,CHEMBL622940,,
9383,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,N,,CHEMBL622941,,
9384,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,N,,CHEMBL622942,,
9385,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,N,,CHEMBL622943,,
9386,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,N,,CHEMBL622944,,
9387,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,N,,CHEMBL622945,,
9388,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,N,,CHEMBL622946,,
9389,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for terminal half life in rat,50597,N,,CHEMBL622947,,
9390,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,50597,N,,CHEMBL622948,1969.0,
9391,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,50597,N,,CHEMBL622949,1969.0,
9392,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for its half life in rat,50597,N,,CHEMBL622950,,
9393,,Macaca mulatta,BAO_0000218,,1,A,Intermediate,In vivo,0,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,22224,U,,CHEMBL622951,1969.0,
9394,,Rattus norvegicus,BAO_0000366,,1,A,Intermediate,,0,Compound was tested for its plasma half life in Sprague Dawley rats,22224,U,,CHEMBL622952,1969.0,
9395,,Rattus norvegicus,BAO_0000366,,1,A,Intermediate,,0,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,22224,U,,CHEMBL622953,1969.0,
9396,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for plasma half-life period in rat,50597,N,,CHEMBL873818,1969.0,
9397,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Elimination half life after i.v. administration of compound in rats,50597,N,,CHEMBL622954,,
9398,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Elimination half-life after IV dosing at 0.5 mg/kg in rat,50597,N,,CHEMBL622955,,
9399,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Elimination half-life after IV dosing at 1 mg/kg in rat,50597,N,,CHEMBL875229,,
9400,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,50597,N,,CHEMBL622956,,
9401,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,50597,N,,CHEMBL622957,,
9402,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,50597,N,,CHEMBL622958,955.0,
9403,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,50597,N,,CHEMBL622959,1969.0,
9404,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,50597,N,,CHEMBL622960,955.0,
9405,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,50597,N,,CHEMBL622961,1969.0,
9406,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Evaluated for the half life in rat (in vivo),50597,N,,CHEMBL622962,,
9407,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Hafl life in rat,50597,N,,CHEMBL622963,,
9408,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Hafl life rat,50597,N,,CHEMBL622964,,
9409,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Hafl life rat,50597,N,,CHEMBL622965,,
9410,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Hafl life rat; Not determined,50597,N,,CHEMBL622966,,
9411,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Hafl life rat; Not determined,50597,N,,CHEMBL622967,,
9412,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,N,,CHEMBL622968,2113.0,
9413,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,N,,CHEMBL622969,2107.0,
9414,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,N,,CHEMBL875327,2048.0,
9415,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in rat after 1 mg/kg i.v. administration,50597,N,,CHEMBL628638,,
9416,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in rat after 2 mg/kg peroral administration,50597,N,,CHEMBL628639,,
9417,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,N,,CHEMBL625840,,
9418,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life of 10 mg/kg oral dose determined in rats,50597,N,,CHEMBL625841,,
9419,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,N,,CHEMBL625842,,
9420,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,N,,CHEMBL625843,,
9421,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,N,,CHEMBL625844,,
9422,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,N,,CHEMBL873822,,
9423,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,N,,CHEMBL625845,,
9424,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,N,,CHEMBL627059,,
9425,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,N,,CHEMBL627060,,
9426,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,N,,CHEMBL627061,,
9427,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life of compound at 5 mg/kg after po administration was determined in rat,50597,N,,CHEMBL627709,,
9428,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life of compound determined after intravenous administration to rat,50597,N,,CHEMBL627710,,
9429,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life of compound was determined in rat,50597,N,,CHEMBL627711,,
9430,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,N,,CHEMBL627712,1969.0,
9431,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,N,,CHEMBL627713,,
9432,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,N,,CHEMBL627714,,
9433,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,In vivo,0,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,22224,U,,CHEMBL627889,,
9434,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,0,Half life determined in rat by intravenous administration,22224,U,,CHEMBL627890,,
9435,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life determined in rats after iv administration,50597,N,,CHEMBL627891,,
9436,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in rat plasma after administration of 2 mg/kg iv,50597,N,,CHEMBL627892,1969.0,
9437,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in rat plasma after administration of 2 mg/kg iv,50597,N,,CHEMBL627893,1969.0,
9438,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life in rat plasma was determined,50597,N,,CHEMBL627894,1969.0,
9439,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life in rat plasma was determined; NA means not applicable,50597,N,,CHEMBL627895,1969.0,
9440,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life in rat was tested,50597,N,,CHEMBL627896,,
9441,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life measured in rat plasma,50597,N,,CHEMBL627897,1969.0,
9442,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life recorded in rats,50597,N,,CHEMBL627898,,
9443,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life was calculated,50597,N,,CHEMBL627899,,
9444,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life was calculated in rat,50597,N,,CHEMBL873823,,
9445,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life was determined,50597,N,,CHEMBL627900,,
9446,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life after 10 mg/kg oral administration in rat,50597,N,,CHEMBL627901,,
9447,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life after administering orally a dose of 10 mg/kg to a fasting rat,50597,N,,CHEMBL627902,,
9448,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life after administering orally a dose of 30 mg/kg,50597,N,,CHEMBL627903,,
9449,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,50597,N,,CHEMBL627904,,
9450,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,50597,N,,CHEMBL627905,,
9451,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,50597,N,,CHEMBL627906,,
9452,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,50597,N,,CHEMBL627907,,
9453,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,50597,N,,CHEMBL876783,,
9454,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,50597,N,,CHEMBL627908,,
9455,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,N,,CHEMBL627909,,
9456,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,50597,N,,CHEMBL627910,,
9457,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),50597,N,,CHEMBL627911,,
9458,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),50597,N,,CHEMBL627912,,
9459,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),50597,N,,CHEMBL627913,,
9460,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),50597,N,,CHEMBL627914,,
9461,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,50597,N,,CHEMBL627915,,
9462,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was evaluated after 20 uM/kg of peroral administration,50597,N,,CHEMBL627916,,
9463,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was measured in rat after an iv dose of 1 mg/kg,50597,N,,CHEMBL627917,,
9464,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,50597,N,,CHEMBL627918,,
9465,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,50597,N,,CHEMBL627919,,
9466,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,50597,N,,CHEMBL627920,,
9467,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve was evaluated at an oral dose of 30 mg/kg,50597,N,,CHEMBL627921,,
9468,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,N,,CHEMBL627922,,
9469,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,N,,CHEMBL876784,,
9470,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,N,,CHEMBL627923,,
9471,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,N,,CHEMBL626208,,
9472,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,N,,CHEMBL626209,,
9473,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,N,,CHEMBL626210,,
9474,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,50597,N,,CHEMBL627994,1969.0,
9475,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,50597,N,,CHEMBL627995,,
9476,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,50597,N,,CHEMBL627996,,
9477,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,50597,N,,CHEMBL627997,,
9478,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,50597,N,,CHEMBL627998,,
9479,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,50597,N,,CHEMBL628640,,
9480,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,50597,N,,CHEMBL628641,,
9481,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,50597,N,,CHEMBL628642,,
9482,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for area under the curve expressed as (h*ug/ml),50597,N,,CHEMBL628643,,
9483,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for area under curve in rat,50597,N,,CHEMBL628644,,
9484,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,50597,N,,CHEMBL628645,,
9485,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,50597,N,,CHEMBL628646,,
9486,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),50597,N,,CHEMBL628647,,
9487,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,50597,N,,CHEMBL628648,,
9488,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,50597,N,,CHEMBL625358,,
9489,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,50597,N,,CHEMBL625359,,
9490,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,50597,N,,CHEMBL625360,,
9491,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),50597,N,,CHEMBL625361,,
9492,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),50597,N,,CHEMBL625362,,
9493,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),50597,N,,CHEMBL625363,,
9494,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,50597,N,,CHEMBL625364,,
9495,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,N,,CHEMBL625365,,
9496,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,N,,CHEMBL625366,,
9497,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,N,,CHEMBL625367,,
9498,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",50597,N,,CHEMBL625368,2113.0,
9499,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",50597,N,,CHEMBL625369,2113.0,
9500,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",50597,N,,CHEMBL625370,2113.0,
9501,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",50597,N,,CHEMBL625371,2113.0,
9502,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",50597,N,,CHEMBL625372,2113.0,
9503,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",50597,N,,CHEMBL625373,2113.0,
9504,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",50597,N,,CHEMBL625374,2107.0,
9505,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",50597,N,,CHEMBL877593,2107.0,
9506,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",50597,N,,CHEMBL625375,2107.0,
9507,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",50597,N,,CHEMBL625376,2107.0,
9508,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",50597,N,,CHEMBL621973,2107.0,
9509,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",50597,N,,CHEMBL621974,2107.0,
9510,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",50597,N,,CHEMBL621975,2048.0,
9511,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",50597,N,,CHEMBL622166,2048.0,
9512,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",50597,N,,CHEMBL622167,2048.0,
9513,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",50597,N,,CHEMBL622168,2048.0,
9514,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",50597,N,,CHEMBL622169,2048.0,
9515,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",50597,N,,CHEMBL622170,2048.0,
9516,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",50597,N,,CHEMBL622171,2046.0,
9517,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",50597,N,,CHEMBL622172,2046.0,
9518,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",50597,N,,CHEMBL622173,2046.0,
9519,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",50597,N,,CHEMBL622174,2046.0,
9520,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",50597,N,,CHEMBL622175,2046.0,
9521,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",50597,N,,CHEMBL622176,2046.0,
9522,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",50597,N,,CHEMBL622177,2046.0,
9523,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",50597,N,,CHEMBL622178,2046.0,
9524,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",50597,N,,CHEMBL622179,2046.0,
9525,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",50597,N,,CHEMBL622180,2046.0,
9526,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,N,,CHEMBL622181,,
9527,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,N,,CHEMBL622182,,
9528,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,N,,CHEMBL622183,,
9529,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,N,,CHEMBL622184,,
9530,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,N,,CHEMBL622185,,
9531,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,N,,CHEMBL622186,,
9532,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,N,,CHEMBL622187,,
9533,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,50597,N,,CHEMBL625002,,
9534,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,50597,N,,CHEMBL622090,,
9535,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,N,,CHEMBL622091,,
9536,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,N,,CHEMBL622092,,
9537,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,N,,CHEMBL622093,,
9538,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,N,,CHEMBL622094,,
9539,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,N,,CHEMBL622095,,
9540,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,N,,CHEMBL622264,,
9541,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,N,,CHEMBL622265,2106.0,
9542,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,N,,CHEMBL622266,2106.0,
9543,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,N,,CHEMBL622267,2106.0,
9544,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,N,,CHEMBL622268,2106.0,
9545,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,N,,CHEMBL622269,2106.0,
9546,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,N,,CHEMBL625071,2106.0,
9547,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,N,,CHEMBL621621,2106.0,
9548,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,N,,CHEMBL621622,2106.0,
9549,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,N,,CHEMBL621623,2106.0,
9550,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,N,,CHEMBL621624,2106.0,
9551,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,N,,CHEMBL621625,2106.0,
9552,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,N,,CHEMBL621626,2106.0,
9553,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,N,,CHEMBL621627,2106.0,
9554,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,N,,CHEMBL621628,2106.0,
9555,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,N,,CHEMBL875328,2106.0,
9556,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,N,,CHEMBL621629,2106.0,
9557,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,N,,CHEMBL621630,2106.0,
9558,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,N,,CHEMBL621631,2106.0,
9559,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,N,,CHEMBL621632,2106.0,
9560,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,N,,CHEMBL621633,2106.0,
9561,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,N,,CHEMBL621634,2106.0,
9562,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,N,,CHEMBL621635,2106.0,
9563,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,N,,CHEMBL621636,2106.0,
9564,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,N,,CHEMBL621637,2106.0,
9565,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,N,,CHEMBL621638,2106.0,
9566,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,N,,CHEMBL618883,,
9567,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,N,,CHEMBL618884,,
9568,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,N,,CHEMBL628627,,
9569,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,N,,CHEMBL628628,,
9570,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,N,,CHEMBL628629,,
9571,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life after administering orally a dose of 3 mg/kg,50597,N,,CHEMBL628630,,
9572,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life after administering orally a dose of 3 mg/kg to a fasting rat,50597,N,,CHEMBL628631,,
9573,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life after administering intravenously a dose of 1 mg/kg,50597,N,,CHEMBL628632,,
9574,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life after oral dosing in rats,50597,N,,CHEMBL628633,,
9575,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,50597,N,,CHEMBL628634,,
9576,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life by intravenous administration of 3.4 mg/kg in rat,50597,N,,CHEMBL627789,,
9577,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life in rat,50597,N,,CHEMBL627790,,
9578,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life in rat,50597,N,,CHEMBL627791,,
9579,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life in rat,50597,N,,CHEMBL627792,,
9580,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in rat after intravenous administration of the compound,50597,N,,CHEMBL627793,,
9581,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,50597,N,,CHEMBL627794,1969.0,
9582,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in rat after po administration of the compound,50597,N,,CHEMBL627795,,
9583,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in rat after po administration of the compound; ND means Not determined,50597,N,,CHEMBL627796,,
9584,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,50597,N,,CHEMBL875335,1969.0,
9585,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,50597,N,,CHEMBL627797,1969.0,
9586,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in rat i.v.,50597,N,,CHEMBL627798,,
9587,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in rat i.v. at 2 mg/kg concentration,50597,N,,CHEMBL627799,,
9588,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life in rats,50597,N,,CHEMBL627800,,
9589,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in rats after intravenous administration,50597,N,,CHEMBL627801,,
9590,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life in rats at the dose of 1.0 mpk by i.v. administration,50597,N,,CHEMBL627802,,
9591,,Rattus norvegicus,BAO_0000218,,1,A,Expert,,1,Half life in rat,50597,N,,CHEMBL627803,,
9592,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life was evaluated after intravenous administration to rats,50597,N,,CHEMBL873820,,
9593,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),50597,N,,CHEMBL627804,,
9594,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life was evaluated in rat,50597,N,,CHEMBL627805,,
9595,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life was evaluated in rat,50597,N,,CHEMBL627806,,
9596,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life was evaluated in rat; Not tested,50597,N,,CHEMBL627107,,
9597,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,50597,N,,CHEMBL627108,,
9598,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,50597,N,,CHEMBL627109,,
9599,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,50597,N,,CHEMBL627110,178.0,
9600,,Primates,BAO_0000218,,1,A,Intermediate,In vivo,0,Half life was measured in monkey at dose of 10 mg/kg by po administration,22224,U,,CHEMBL627111,,
9601,,Primates,BAO_0000218,,1,A,Intermediate,In vivo,0,Half life was measured in monkey at dose of 10 mg/kg by po administration,22224,U,,CHEMBL627112,,
9602,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,0,Half life was measured in rat at dose of 30 mg/kg by iv administration,22224,U,,CHEMBL627113,,
9603,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,0,Half life was measured in rat at dose of 30 mg/kg by po administration,22224,U,,CHEMBL627114,,
9604,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life (t1/2) was determined,50597,N,,CHEMBL627115,,
9605,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period at a dose of 10 uM/kg in rat was determined,50597,N,,CHEMBL627116,,
9606,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,50597,N,,CHEMBL627117,,
9607,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period was determined,50597,N,,CHEMBL627118,,
9608,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period after intravenous administration at 20 mpk in rats,50597,N,,CHEMBL627119,,
9609,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period after intravenous administration at 20 mpk in rats; Not performed.,50597,N,,CHEMBL627120,,
9610,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period after intravenous administration in rat,50597,N,,CHEMBL626922,,
9611,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,50597,N,,CHEMBL626923,,
9612,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,50597,N,,CHEMBL626924,,
9613,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period in 80% rat plasma at 37 degree Centigrade,50597,N,,CHEMBL626925,1969.0,
9614,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period in SD rats,50597,N,,CHEMBL626926,,
9615,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),50597,N,,CHEMBL626927,1969.0,
9616,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),50597,N,,CHEMBL626928,1969.0,
9617,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,50597,N,,CHEMBL626929,1969.0,
9618,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,50597,N,,CHEMBL626930,1969.0,
9619,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period in rat,50597,N,,CHEMBL626931,,
9620,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period in rat,50597,N,,CHEMBL626932,,
9621,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period in rat,50597,N,,CHEMBL626933,,
9622,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period in rat after oral administration at 10.5 mg/kg dose,50597,N,,CHEMBL873826,,
9623,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period in rat after oral administration at 11.2 mg/kg dose,50597,N,,CHEMBL626934,,
9624,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period in rat after oral administration at 13 mg/kg dose,50597,N,,CHEMBL626935,,
9625,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period in rat after oral administration at 9.7 mg/kg dose,50597,N,,CHEMBL626936,,
9626,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,N,,CHEMBL626937,,
9627,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,50597,N,,CHEMBL625906,,
9628,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,50597,N,,CHEMBL625907,,
9629,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,PK study was carried to determine AUC (area under curve) value in rat,50597,N,,CHEMBL625908,,
9630,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC after intravenous administration to rats,50597,N,,CHEMBL625909,,
9631,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC after oral administration to rats,50597,N,,CHEMBL625910,,
9632,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,50597,N,,CHEMBL625911,,
9633,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,50597,N,,CHEMBL625912,,
9634,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,50597,N,,CHEMBL626538,,
9635,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,50597,N,,CHEMBL876794,,
9636,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,50597,N,,CHEMBL626539,,
9637,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,50597,N,,CHEMBL626540,,
9638,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,50597,N,,CHEMBL626541,,
9639,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,50597,N,,CHEMBL626542,,
9640,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,50597,N,,CHEMBL626543,,
9641,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,50597,N,,CHEMBL626544,,
9642,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,50597,N,,CHEMBL626545,,
9643,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,50597,N,,CHEMBL626546,,
9644,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter area under curve was reported,50597,N,,CHEMBL626547,,
9645,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic property (AUC) in rat,50597,N,,CHEMBL626548,,
9646,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,50597,N,,CHEMBL626549,,
9647,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,50597,N,,CHEMBL626550,,
9648,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,50597,N,,CHEMBL626551,,
9649,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic property was determined,50597,N,,CHEMBL623777,,
9650,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,50597,N,,CHEMBL623778,,
9651,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,50597,N,,CHEMBL623779,,
9652,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,50597,N,,CHEMBL623780,1969.0,
9653,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,50597,N,,CHEMBL622015,1969.0,
9654,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,50597,N,,CHEMBL622016,1969.0,
9655,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",50597,N,,CHEMBL622017,,
9656,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",50597,N,,CHEMBL622018,,
9657,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",50597,N,,CHEMBL622019,,
9658,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",50597,N,,CHEMBL622020,,
9659,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,50597,N,,CHEMBL622021,,
9660,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,50597,N,,CHEMBL622022,,
9661,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,50597,N,,CHEMBL622023,,
9662,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,50597,N,,CHEMBL622024,,
9663,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),50597,N,,CHEMBL622693,,
9664,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),50597,N,,CHEMBL622694,,
9665,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",50597,N,,CHEMBL622695,,
9666,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",50597,N,,CHEMBL622696,,
9667,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",50597,N,,CHEMBL622697,,
9668,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",50597,N,,CHEMBL622874,,
9669,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",50597,N,,CHEMBL622875,,
9670,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,50597,N,,CHEMBL622876,,
9671,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,50597,N,,CHEMBL622877,,
9672,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,50597,N,,CHEMBL622878,,
9673,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,50597,N,,CHEMBL622879,1969.0,
9674,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,50597,N,,CHEMBL877602,,
9675,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",50597,N,,CHEMBL622880,,
9676,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",50597,N,,CHEMBL622881,,
9677,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",50597,N,,CHEMBL622882,,
9678,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",50597,N,,CHEMBL622883,,
9679,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",50597,N,,CHEMBL622884,2046.0,
9680,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",50597,N,,CHEMBL622885,2046.0,
9681,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,50597,N,,CHEMBL622886,,
9682,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,50597,N,,CHEMBL622887,,
9683,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,50597,N,,CHEMBL622888,1088.0,
9684,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL622889,178.0,
9685,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,N,,CHEMBL622890,178.0,
9686,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL622891,178.0,
9687,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,N,,CHEMBL877603,178.0,
9688,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL622892,955.0,
9689,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,N,,CHEMBL622893,955.0,
9690,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL622894,955.0,
9691,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,N,,CHEMBL622895,955.0,
9692,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,50597,N,,CHEMBL622896,955.0,
9693,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL622897,948.0,
9694,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL622898,948.0,
9695,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,N,,CHEMBL622899,948.0,
9696,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL622900,2113.0,
9697,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,N,,CHEMBL624114,2113.0,
9698,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL624115,2113.0,
9699,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,N,,CHEMBL624116,2113.0,
9700,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL624117,2107.0,
9701,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,N,,CHEMBL624118,2107.0,
9702,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL624119,2107.0,
9703,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,N,,CHEMBL624120,2107.0,
9704,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL624121,2048.0,
9705,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,N,,CHEMBL624122,2048.0,
9706,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL624123,2048.0,
9707,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,N,,CHEMBL624124,2048.0,
9708,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL624125,2385.0,
9709,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,N,,CHEMBL624126,2385.0,
9710,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL624127,2385.0,
9711,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,N,,CHEMBL624128,2385.0,
9712,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL624129,14.0,
9713,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,N,,CHEMBL624130,14.0,
9714,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL622340,14.0,
9715,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,N,,CHEMBL622341,14.0,
9716,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL622342,160.0,
9717,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,N,,CHEMBL622343,160.0,
9718,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL622344,160.0,
9719,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,N,,CHEMBL622345,160.0,
9720,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL622346,2106.0,
9721,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,N,,CHEMBL622347,2106.0,
9722,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL622348,2106.0,
9723,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,N,,CHEMBL622349,2106.0,
9724,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,N,,CHEMBL622350,,
9725,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,N,,CHEMBL622351,,
9726,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,N,,CHEMBL622352,,
9727,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,N,,CHEMBL622353,,
9728,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,N,,CHEMBL622354,,
9729,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,N,,CHEMBL622355,,
9730,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,N,,CHEMBL622356,,
9731,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,N,,CHEMBL622357,,
9732,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,N,,CHEMBL622358,,
9733,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,N,,CHEMBL622359,,
9734,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,N,,CHEMBL874393,,
9735,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,N,,CHEMBL622872,,
9736,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,N,,CHEMBL622873,,
9737,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,N,,CHEMBL623047,,
9738,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,N,,CHEMBL623048,,
9739,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,N,,CHEMBL623049,,
9740,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,N,,CHEMBL623050,,
9741,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,N,,CHEMBL623051,,
9742,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,N,,CHEMBL623052,,
9743,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,N,,CHEMBL626343,,
9744,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,N,,CHEMBL626344,,
9745,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,N,,CHEMBL626345,,
9746,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,N,,CHEMBL626346,,
9747,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,N,,CHEMBL626347,,
9748,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,N,,CHEMBL626348,,
9749,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,N,,CHEMBL626349,,
9750,,Rattus norvegicus,BAO_0000218,,1,F,Intermediate,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,N,,CHEMBL626350,,
9751,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,N,,CHEMBL626351,,
9752,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,N,,CHEMBL627650,,
9753,,Rattus norvegicus,BAO_0000218,,1,F,Intermediate,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,N,,CHEMBL627651,,
9754,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,N,,CHEMBL627652,,
9755,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,N,,CHEMBL627653,,
9756,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,50597,N,,CHEMBL627654,,
9757,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,50597,N,,CHEMBL627835,,
9758,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,50597,N,,CHEMBL627836,,
9759,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,50597,N,,CHEMBL627837,,
9760,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,50597,N,,CHEMBL627838,,
9761,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,50597,N,,CHEMBL875338,,
9762,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,50597,N,,CHEMBL627839,,
9763,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,50597,N,,CHEMBL627840,,
9764,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,50597,N,,CHEMBL627841,,
9765,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,50597,N,,CHEMBL627842,,
9766,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,50597,N,,CHEMBL627843,,
9767,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,50597,N,,CHEMBL627844,,
9768,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,50597,N,,CHEMBL627845,,
9769,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period in rat by iv administration at a dose of 3 mg/kg,50597,N,,CHEMBL627846,,
9770,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),50597,N,,CHEMBL627847,1969.0,
9771,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),50597,N,,CHEMBL873821,1969.0,
9772,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,50597,N,,CHEMBL626079,1969.0,
9773,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,50597,N,,CHEMBL626080,1969.0,
9774,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period was evaluated in rat plasma,50597,N,,CHEMBL626081,1969.0,
9775,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period was evaluated in rat plasma; Not tested,50597,N,,CHEMBL875344,1969.0,
9776,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life period was evaluated in rats,50597,N,,CHEMBL626082,,
9777,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Half life period was evaluated in rats, iv",50597,N,,CHEMBL626250,,
9778,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period after intravenous administration at 5 mg/kg in rat,50597,N,,CHEMBL626251,,
9779,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,50597,N,,CHEMBL626252,,
9780,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,50597,N,,CHEMBL626253,,
9781,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life stability of compound was evaluated in rat plasma,50597,N,,CHEMBL626254,1969.0,
9782,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,50597,N,,CHEMBL626255,,
9783,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,50597,N,,CHEMBL626256,,
9784,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,50597,N,,CHEMBL626257,,
9785,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,50597,N,,CHEMBL626258,,
9786,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,50597,N,,CHEMBL626259,,
9787,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half in rat i.v.,50597,N,,CHEMBL626260,,
9788,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half period in rat after intravenous administration,50597,N,,CHEMBL875345,,
9789,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life after repeated oral dose of compound at 1 mg/kg in rats,50597,N,,CHEMBL626261,,
9790,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vitro,1,Half-life measured in in vitro Cathepsin B assay in rat liver,50597,N,,CHEMBL626262,2107.0,
9791,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life of compound was determined in rats,50597,N,,CHEMBL626263,,
9792,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life at 10 mg/kg in rat upon intravenous administration,50597,N,,CHEMBL625270,,
9793,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life determined in rat,50597,N,,CHEMBL625271,,
9794,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life determined in rat,50597,N,,CHEMBL625272,,
9795,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,50597,N,,CHEMBL625273,955.0,
9796,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",50597,N,,CHEMBL625274,1969.0,
9797,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,N,,CHEMBL625275,,
9798,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,50597,N,,CHEMBL625276,1969.0,
9799,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in rat plasma,50597,N,,CHEMBL625277,1969.0,
9800,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in rat plasma was determined,50597,N,,CHEMBL625278,1969.0,
9801,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in rat plasma; Not tested,50597,N,,CHEMBL625279,1969.0,
9802,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in rat serum,50597,N,,CHEMBL625280,1977.0,
9803,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in rat serum; na is not available,50597,N,,CHEMBL876797,1977.0,
9804,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life was calculated in rat,50597,N,,CHEMBL625281,,
9805,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life was calculated in rat plasma,50597,N,,CHEMBL873827,1969.0,
9806,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life was determined,50597,N,,CHEMBL625282,,
9807,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life was determined,50597,N,,CHEMBL625283,,
9808,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life after administration of 20 mg/Kg oral dose in rat,50597,N,,CHEMBL625284,,
9809,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life after administration of 3.2 mg/kg intravenously in male rat,50597,N,,CHEMBL625285,,
9810,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life after intravenous administration in female rat,50597,N,,CHEMBL625286,,
9811,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life after intravenous administration in male rat,50597,N,,CHEMBL625287,,
9812,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life after intravenous dose in rat,50597,N,,CHEMBL625288,,
9813,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in a rat liver homogenate preparation,50597,N,,CHEMBL625289,2107.0,
9814,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in plasma of rat,50597,N,,CHEMBL625290,1969.0,
9815,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in plasma of rat at dose of 3-10 mgkg,50597,N,,CHEMBL876798,1969.0,
9816,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in rat,50597,N,,CHEMBL625291,,
9817,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in rat,50597,N,,CHEMBL625292,,
9818,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in rat,50597,N,,CHEMBL625293,,
9819,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in rat,50597,N,,CHEMBL622832,,
9820,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in rat,50597,N,,CHEMBL622833,,
9821,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in rat,50597,N,,CHEMBL622834,,
9822,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life in rat after oral administration at 10 mg/kg,50597,N,,CHEMBL622835,,
9823,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life in rat after po administration at a dose of 10 mg/kg,50597,N,,CHEMBL622836,,
9824,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,50597,N,,CHEMBL622837,,
9825,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life in rat at 3 mg/kg dose administered intravenously,50597,N,,CHEMBL622838,,
9826,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in rat brain homogenate,50597,N,,CHEMBL622839,955.0,
9827,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in rat plasma,50597,N,,CHEMBL622840,1969.0,
9828,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in rats,50597,N,,CHEMBL622841,,
9829,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in Dawley rats,50597,N,,CHEMBL622842,,
9830,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vitro,1,Half-life in vitro in rat plasma,50597,N,,CHEMBL622843,1969.0,
9831,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vitro,1,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,50597,N,,CHEMBL622844,1969.0,
9832,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",50597,N,,CHEMBL622845,,
9833,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The area under the curve of compound was measured at the dose of 100 umol/kg,50597,N,,CHEMBL622846,,
9834,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The area under the curve of compound was measured at the dose of 300 umol/kg,50597,N,,CHEMBL622847,,
9835,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The area under the curve of compound was measured at the dose of 30 umol/kg,50597,N,,CHEMBL622848,,
9836,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability as oral AUC in rats,50597,N,,CHEMBL622849,,
9837,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The plasma concentration versus time curve (AUC) was determined,50597,N,,CHEMBL622850,1969.0,
9838,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,N,,CHEMBL876807,,
9839,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,N,,CHEMBL622851,,
9840,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,N,,CHEMBL622852,,
9841,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,50597,N,,CHEMBL622853,,
9842,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,50597,N,,CHEMBL622854,,
9843,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,N,,CHEMBL622855,,
9844,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",50597,N,,CHEMBL622856,1969.0,
9845,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",50597,N,,CHEMBL622857,1969.0,
9846,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC in rat after po administration at a dose of 10 mg/kg,50597,N,,CHEMBL622858,1969.0,
9847,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,50597,N,,CHEMBL622859,1969.0,
9848,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve value 24 hr after 10 mg/kg iv administration in rats,50597,N,,CHEMBL622860,,
9849,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve value 24 hr after 10 mg/kg oral administration in rats,50597,N,,CHEMBL622861,,
9850,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve value 24 hr after 2 mg/kg iv administration in rats,50597,N,,CHEMBL622862,,
9851,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve value 24 hr after 2 mg/kg oral administration in rats,50597,N,,CHEMBL622863,,
9852,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve value 6 hr after po administration in rat,50597,N,,CHEMBL623817,,
9853,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,N,,CHEMBL623818,,
9854,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",50597,N,,CHEMBL623819,,
9855,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,N,,CHEMBL623820,,
9856,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,50597,N,,CHEMBL623821,,
9857,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC normalized for dose (AUCN) in rat,50597,N,,CHEMBL623822,1969.0,
9858,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve in rat after p.o. administration,50597,N,,CHEMBL623823,,
9859,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve in rat after p.o. administration,50597,N,,CHEMBL623824,,
9860,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve in rat after p.o. administration; Not determined,50597,N,,CHEMBL623825,,
9861,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve in rat after peroral administration,50597,N,,CHEMBL622070,,
9862,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve (carotid artery) value of the compound,50597,N,,CHEMBL622071,,
9863,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Bioavailability expressed as the area under curve of rat carotid artery,50597,N,,CHEMBL622072,,
9864,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve in male SD rats was observed after intravenous administration in rat,50597,N,,CHEMBL622073,,
9865,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve of the compound was determined,50597,N,,CHEMBL622074,,
9866,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,50597,N,,CHEMBL622075,,
9867,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,50597,N,,CHEMBL622076,1969.0,
9868,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,50597,N,,CHEMBL622077,1969.0,
9869,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve (portal vein) value of the compound,50597,N,,CHEMBL622078,,
9870,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Bioavailability expressed as the area under curve of rat portal vein,50597,N,,CHEMBL622079,,
9871,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area Under plasma concentration time curve in rat upon peroral administration,50597,N,,CHEMBL622080,1969.0,
9872,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,50597,N,,CHEMBL877612,,
9873,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,50597,N,,CHEMBL622081,,
9874,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for oral bioavailability in rats,50597,N,,CHEMBL622082,,
9875,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for oral bioavailability in rats after iv administration,50597,N,,CHEMBL622083,,
9876,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for oral bioavailability in rats; 30-80,50597,N,,CHEMBL622084,,
9877,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for oral bioavailability in rats; 50-60,50597,N,,CHEMBL622085,,
9878,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for oral bioavailability in rats; no data,50597,N,,CHEMBL622086,,
9879,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for oral bioavailability in rats; peptide,50597,N,,CHEMBL622087,,
9880,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",50597,N,,CHEMBL622088,178.0,
9881,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",50597,N,,CHEMBL622089,178.0,
9882,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",50597,N,,CHEMBL623685,178.0,
9883,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",50597,N,,CHEMBL623686,178.0,
9884,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL623687,945.0,
9885,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,N,,CHEMBL623688,945.0,
9886,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL623689,945.0,
9887,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,N,,CHEMBL622485,945.0,
9888,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL622486,2046.0,
9889,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,N,,CHEMBL877613,2046.0,
9890,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL622487,2046.0,
9891,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,N,,CHEMBL622488,2046.0,
9892,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,N,,CHEMBL622489,948.0,
9893,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,50597,N,,CHEMBL622490,1088.0,
9894,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,50597,N,,CHEMBL622491,1088.0,
9895,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,50597,N,,CHEMBL622492,2107.0,
9896,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,50597,N,,CHEMBL622493,1088.0,
9897,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,50597,N,,CHEMBL622494,1088.0,
9898,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,N,,CHEMBL622495,2385.0,
9899,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,50597,N,,CHEMBL622496,,
9900,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,50597,N,,CHEMBL622497,1088.0,
9901,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,50597,N,,CHEMBL622498,,
9902,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,50597,N,,CHEMBL624918,1088.0,
9903,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,50597,N,,CHEMBL624919,1088.0,
9904,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound in rat blood after 5 min of administration,50597,N,,CHEMBL624920,178.0,
9905,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound in rat blood after 5 min of administration.,50597,N,,CHEMBL624921,178.0,
9906,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound in rat brain after 5 min of administration,50597,N,,CHEMBL624922,955.0,
9907,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound in rat heart after 5 min of administration,50597,N,,CHEMBL624923,948.0,
9908,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound in rat heart after 5 min of administration.,50597,N,,CHEMBL624924,948.0,
9909,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound in rat kidney after 5 min of administration,50597,N,,CHEMBL624925,2113.0,
9910,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound in rat kidney after 5 min of administration.,50597,N,,CHEMBL624926,2113.0,
9911,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound in rat liver after 5 min of administration,50597,N,,CHEMBL624927,2107.0,
9912,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound in rat liver after 5 min of administration.,50597,N,,CHEMBL874402,2107.0,
9913,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound in rat lung after 5 min of administration,50597,N,,CHEMBL624928,2048.0,
9914,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound in rat lung after 5 min of administration.,50597,N,,CHEMBL624929,2048.0,
9915,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound in rat muscle after 5 min of administration,50597,N,,CHEMBL624930,2385.0,
9916,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of compound in rat muscle after 5 min of administration.,50597,N,,CHEMBL624931,2385.0,
9917,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,N,,CHEMBL624932,948.0,
9918,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,N,,CHEMBL624933,948.0,
9919,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,N,,CHEMBL624934,2107.0,
9920,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,N,,CHEMBL624935,2107.0,
9921,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,N,,CHEMBL624936,,
9922,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,N,,CHEMBL624937,,
9923,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,N,,CHEMBL624938,2106.0,
9924,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,N,,CHEMBL624939,2106.0,
9925,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,N,,CHEMBL624940,,
9926,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,N,,CHEMBL874403,,
9927,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,50597,N,,CHEMBL624941,,
9928,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Dose required to lower urine osmolality to 300 mOsm/kg in rat,50597,N,,CHEMBL624942,1088.0,
9929,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,50597,N,,CHEMBL624943,1088.0,
9930,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,% Bioavailability after 1 day of the drug administration in rats,50597,N,,CHEMBL624944,,
9931,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,% Bioavailability after 4 day of the drug administration in rats,50597,N,,CHEMBL624945,,
9932,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Absolute bioavailability was evaluated in rat,50597,N,,CHEMBL624946,,
9933,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,50597,N,,CHEMBL624947,,
9934,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,50597,N,,CHEMBL624948,,
9935,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,50597,N,,CHEMBL624949,,
9936,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,50597,N,,CHEMBL622025,2113.0,
9937,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,50597,N,,CHEMBL622026,2113.0,
9938,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,50597,N,,CHEMBL622027,2113.0,
9939,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,50597,N,,CHEMBL622028,2113.0,
9940,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,50597,N,,CHEMBL622029,2107.0,
9941,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,50597,N,,CHEMBL622208,2107.0,
9942,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,50597,N,,CHEMBL622209,2107.0,
9943,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,50597,N,,CHEMBL622210,2107.0,
9944,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,50597,N,,CHEMBL622211,,
9945,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,50597,N,,CHEMBL622212,,
9946,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,50597,N,,CHEMBL622213,,
9947,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,50597,N,,CHEMBL874404,,
9948,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,50597,N,,CHEMBL620452,2385.0,
9949,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,50597,N,,CHEMBL620453,2385.0,
9950,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,50597,N,,CHEMBL620454,2385.0,
9951,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,50597,N,,CHEMBL624067,2385.0,
9952,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,50597,N,,CHEMBL624068,,
9953,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,50597,N,,CHEMBL624069,992.0,
9954,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,50597,N,,CHEMBL624070,992.0,
9955,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,50597,N,,CHEMBL624071,992.0,
9956,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,50597,N,,CHEMBL624072,995.0,
9957,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,50597,N,,CHEMBL624073,995.0,
9958,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,50597,N,,CHEMBL624788,995.0,
9959,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,50597,N,,CHEMBL624789,995.0,
9960,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,50597,N,,CHEMBL624790,,
9961,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,50597,N,,CHEMBL624791,,
9962,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,50597,N,,CHEMBL624792,,
9963,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,50597,N,,CHEMBL624793,,
9964,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,50597,N,,CHEMBL877491,2385.0,
9965,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,50597,N,,CHEMBL624957,2385.0,
9966,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,50597,N,,CHEMBL624958,2385.0,
9967,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,50597,N,,CHEMBL624959,2385.0,
9968,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Dissociation constant was determined,50597,N,,CHEMBL624960,,
9969,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",50597,N,,CHEMBL624961,,
9970,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",50597,N,,CHEMBL624962,,
9971,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",50597,N,,CHEMBL624963,,
9972,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Observed rate constant in 80% rat plasma at 37 degree Centigrade,50597,N,,CHEMBL624964,,
9973,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,LogP value was evaluated in the in situ rat gut perfusion assay,50597,N,,CHEMBL624965,,
9974,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,50597,N,,CHEMBL624966,,
9975,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,50597,N,,CHEMBL624967,,
9976,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,50597,N,,CHEMBL624968,,
9977,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,N,,CHEMBL624969,,
9978,,Rattus norvegicus,BAO_0000218,,1,F,Expert,,1,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,50597,N,,CHEMBL624970,,
9979,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life was evaluated after 10 uM/kg of intra arterial administration,50597,N,,CHEMBL624971,,
9980,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life was evaluated after 20 uM/kg of peroral administration,50597,N,,CHEMBL624972,,
9981,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,50597,N,,CHEMBL624973,,
9982,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life was evaluated in plasma of rat,50597,N,,CHEMBL624974,1969.0,
9983,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,50597,N,,CHEMBL624975,,
9984,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life was evaluated in rats at an oral dose of 30 mg/kg,50597,N,,CHEMBL877492,,
9985,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life was measured in rat after an iv dose of 1 mg/kg,50597,N,,CHEMBL624976,,
9986,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life period of compound in rats after peroral administration,50597,N,,CHEMBL624977,,
9987,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life period of compound was measured in rat plasma.,50597,N,,CHEMBL626848,1969.0,
9988,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life period of compound was measured in rat plasma; ND is not determined,50597,N,,CHEMBL626849,1969.0,
9989,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life period of compound was measured in rat plasma; not determined,50597,N,,CHEMBL626850,1969.0,
9990,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,50597,N,,CHEMBL626851,,
9991,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life period in rat by iv administration,50597,N,,CHEMBL626852,,
9992,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life period in rats following intravenous administration at 2 mg/kg,50597,N,,CHEMBL626853,,
9993,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50597,N,,CHEMBL626854,,
9994,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life period was determined for the compound in rat,50597,N,,CHEMBL627486,,
9995,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",50597,N,,CHEMBL627487,,
9996,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",50597,N,,CHEMBL627488,,
9997,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life value after IV dose at a dose of 5 mg/kg in rats.,50597,N,,CHEMBL627489,,
9998,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,50597,N,,CHEMBL627490,,
9999,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life was determined in rat after intravenous administration (0.5 mg/kg),50597,N,,CHEMBL873829,,
10000,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life was determined in rat at a dose of 1 mpk i.v.,50597,N,,CHEMBL627655,,
10001,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,50597,N,,CHEMBL625994,,
10002,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,50597,N,,CHEMBL625995,,
10003,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life in rat,50597,N,,CHEMBL625996,,
10004,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vitro,1,In vitro half life in rat plasma,50597,N,,CHEMBL625850,1969.0,
10005,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vitro,1,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",50597,N,,CHEMBL625851,1969.0,
10006,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vitro,1,In vitro half life in rat,50597,N,,CHEMBL625852,,
10007,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo half life period after intravenous administration in rat,50597,N,,CHEMBL625853,,
10008,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,50597,N,,CHEMBL625854,,
10009,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,50597,N,,CHEMBL874450,,
10010,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,N,,CHEMBL625855,,
10011,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,N,,CHEMBL625856,,
10012,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,N,,CHEMBL625857,,
10013,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,N,,CHEMBL873831,,
10014,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Longer half-life in rat (i.v.) at 0.5 mpk,50597,N,,CHEMBL625858,,
10015,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Longer half-life in rat (p.o.) at 2.0 mpk,50597,N,,CHEMBL625859,,
10016,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic property (half life) in rat,50597,N,,CHEMBL625860,,
10017,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,50597,N,,CHEMBL625861,,
10018,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,50597,N,,CHEMBL625862,,
10019,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,50597,N,,CHEMBL625863,,
10020,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,50597,N,,CHEMBL625864,,
10021,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,50597,N,,CHEMBL625865,,
10022,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic half time was determined intravenously in rats.,50597,N,,CHEMBL625866,,
10023,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,50597,N,,CHEMBL625867,1969.0,
10024,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma half life of hydrolysis of the compound,50597,N,,CHEMBL625868,1969.0,
10025,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,50597,N,,CHEMBL625869,1969.0,
10026,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma half life period was calculated in rat,50597,N,,CHEMBL874451,1969.0,
10027,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma half-life in Sprague-Dawley rats,50597,N,,CHEMBL625870,1969.0,
10028,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma half-life in Sprague-Dawley rats; Not determined,50597,N,,CHEMBL625871,1969.0,
10029,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma half-life in rats,50597,N,,CHEMBL625872,1969.0,
10030,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma half-life in rats; <MQL,50597,N,,CHEMBL625873,1969.0,
10031,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma half-life period (0-8 h) was determined,50597,N,,CHEMBL625874,1969.0,
10032,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,50597,N,,CHEMBL625875,1969.0,
10033,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,50597,N,,CHEMBL625876,1969.0,
10034,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,50597,N,,CHEMBL631258,1969.0,
10035,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,50597,N,,CHEMBL631259,1969.0,
10036,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,50597,N,,CHEMBL631260,1969.0,
10037,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",50597,N,,CHEMBL631261,178.0,
10038,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",50597,N,,CHEMBL631262,178.0,
10039,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",50597,N,,CHEMBL631263,178.0,
10040,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",50597,N,,CHEMBL631264,,
10041,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",50597,N,,CHEMBL631265,,
10042,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",50597,N,,CHEMBL631266,,
10043,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",50597,N,,CHEMBL631267,,
10044,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",50597,N,,CHEMBL631268,,
10045,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",50597,N,,CHEMBL631269,,
10046,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",50597,N,,CHEMBL631270,,
10047,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",50597,N,,CHEMBL631271,948.0,
10048,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",50597,N,,CHEMBL631272,948.0,
10049,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",50597,N,,CHEMBL631273,948.0,
10050,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",50597,N,,CHEMBL631274,948.0,
10051,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",50597,N,,CHEMBL631275,948.0,
10052,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",50597,N,,CHEMBL626984,948.0,
10053,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",50597,N,,CHEMBL626985,948.0,
10054,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",50597,N,,CHEMBL626986,2107.0,
10055,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",50597,N,,CHEMBL626987,2107.0,
10056,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",50597,N,,CHEMBL626988,2107.0,
10057,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",50597,N,,CHEMBL626989,2107.0,
10058,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",50597,N,,CHEMBL626990,2107.0,
10059,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",50597,N,,CHEMBL626991,2107.0,
10060,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",50597,N,,CHEMBL626992,2107.0,
10061,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",50597,N,,CHEMBL626993,2048.0,
10062,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",50597,N,,CHEMBL874593,2048.0,
10063,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",50597,N,,CHEMBL626994,2048.0,
10064,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",50597,N,,CHEMBL626995,2048.0,
10065,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",50597,N,,CHEMBL626190,2048.0,
10066,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",50597,N,,CHEMBL626191,2048.0,
10067,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",50597,N,,CHEMBL626364,2048.0,
10068,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",50597,N,,CHEMBL626365,2046.0,
10069,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",50597,N,,CHEMBL626366,2046.0,
10070,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",50597,N,,CHEMBL626367,2046.0,
10071,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",50597,N,,CHEMBL626368,2046.0,
10072,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",50597,N,,CHEMBL626369,2046.0,
10073,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",50597,N,,CHEMBL626370,2046.0,
10074,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",50597,N,,CHEMBL626371,,
10075,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",50597,N,,CHEMBL626372,,
10076,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability after a dose of 10 mg/kg p.o.,50597,N,,CHEMBL626373,,
10077,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability after peroral administration (10 mg/kg) was determined in rat,50597,N,,CHEMBL626374,,
10078,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,50597,N,,CHEMBL626375,,
10079,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),50597,N,,CHEMBL626376,,
10080,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat po was determined,50597,N,,CHEMBL626377,,
10081,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability of compound at 10 mg/kg in rat after oral administration,50597,N,,CHEMBL626378,,
10082,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,50597,N,,CHEMBL626379,,
10083,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),50597,N,,CHEMBL626380,,
10084,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),50597,N,,CHEMBL626381,,
10085,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat,50597,N,,CHEMBL626382,,
10086,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (Sprague-Dawley) (female),50597,N,,CHEMBL626383,,
10087,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,N,,CHEMBL874652,,
10088,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),50597,N,,CHEMBL626384,,
10089,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,50597,N,,CHEMBL626385,,
10090,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat at an oral dose of 2 mg/kg,50597,N,,CHEMBL626386,,
10091,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat,50597,N,,CHEMBL626387,,
10092,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat,50597,N,,CHEMBL626388,,
10093,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat,50597,N,,CHEMBL626389,,
10094,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat,50597,N,,CHEMBL626390,,
10095,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,50597,N,,CHEMBL626391,,
10096,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat,50597,N,,CHEMBL626392,,
10097,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL626393,,
10098,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was determined in rat,50597,N,,CHEMBL623026,,
10099,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability,50597,N,,CHEMBL623027,,
10100,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability,50597,N,,CHEMBL623028,,
10101,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat after 1 day dosing,50597,N,,CHEMBL623029,,
10102,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat after 4 day dosing,50597,N,,CHEMBL623030,,
10103,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,50597,N,,CHEMBL623031,,
10104,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability after IV dosing at 1 mg/kg in rat; no data,50597,N,,CHEMBL623032,,
10105,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability after oral administration at a dose of 2 mg/kg in rat,50597,N,,CHEMBL623033,,
10106,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability after oral administration at a dose of 4 mg/kg in rat,50597,N,,CHEMBL623034,,
10107,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,50597,N,,CHEMBL623035,,
10108,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,N,,CHEMBL623036,,
10109,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),50597,N,,CHEMBL623037,,
10110,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability by intravenous administration of 3.4 mg/kg in rat,50597,N,,CHEMBL623038,,
10111,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,50597,N,,CHEMBL874385,1969.0,
10112,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (Fisher) (fasted),50597,N,,CHEMBL623039,,
10113,,Primates,BAO_0000218,,1,A,Intermediate,In vivo,0,Bioavailability in monkey after po administration of 10 mg/kg dose,22224,U,,CHEMBL623040,,
10114,,Primates,BAO_0000218,,1,A,Intermediate,In vivo,0,Oral bioavailability in monkey (dose 10 mg/kg),22224,U,,CHEMBL623041,,
10115,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat,50597,N,,CHEMBL623741,,
10116,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat,50597,N,,CHEMBL623742,,
10117,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat,50597,N,,CHEMBL623743,,
10118,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat,50597,N,,CHEMBL623744,,
10119,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (dose 2.0 mg/kg p.o.),50597,N,,CHEMBL623745,,
10120,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),50597,N,,CHEMBL623746,,
10121,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (dose 5 mg/kg p.o.),50597,N,,CHEMBL623747,,
10122,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,0,Bioavailability in rat after po administration of 30 mg/kg dose,22224,U,,CHEMBL623748,,
10123,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,0,Bioavailability in rat after po administration of 30 mg/kg dose,22224,U,,CHEMBL623916,,
10124,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,50597,N,,CHEMBL623917,,
10125,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (dose 2 mg/kg i.v.),50597,N,,CHEMBL623918,,
10126,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat,50597,N,,CHEMBL874386,,
10127,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat; Only traces detected in rat plasma,50597,N,,CHEMBL623919,1969.0,
10128,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat,50597,N,,CHEMBL623920,,
10129,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability upon oral administration of compound,50597,N,,CHEMBL623148,,
10130,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),50597,N,,CHEMBL623149,,
10131,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat,50597,N,,CHEMBL623150,,
10132,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",50597,N,,CHEMBL623151,,
10133,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",50597,N,,CHEMBL623152,,
10134,,Rattus norvegicus,BAO_0000218,,1,F,Expert,,1,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,50597,N,,CHEMBL623153,,
10135,,Rattus norvegicus,BAO_0000218,,1,F,Expert,,1,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,50597,N,,CHEMBL623154,,
10136,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro and metabolic stability was determined,50597,N,,CHEMBL623155,,
10137,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro metabolic stability in rat hepatocytes,50597,N,,CHEMBL623156,,
10138,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,50597,N,,CHEMBL623157,,
10139,401.0,Rattus norvegicus,BAO_0000218,Hepatocyte,1,A,Intermediate,In vitro,1,Metabolic rate for compound was observed in rat hepatocytes,50597,N,,CHEMBL623158,2107.0,
10140,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,50597,N,,CHEMBL623159,,
10141,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),50597,N,,CHEMBL874390,,
10142,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),50597,N,,CHEMBL623160,,
10143,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Metabolism of compound in rat S9 microsomes; Trace,50597,N,,CHEMBL623161,,
10144,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,50597,N,,CHEMBL623162,,
10145,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,50597,N,,CHEMBL623163,,
10146,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,50597,N,,CHEMBL623164,,
10147,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,50597,N,,CHEMBL623165,,
10148,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,50597,N,,CHEMBL623166,,
10149,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,50597,N,,CHEMBL624983,,
10150,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,50597,N,,CHEMBL624984,,
10151,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,50597,N,,CHEMBL624985,,
10152,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,50597,N,,CHEMBL622970,,
10153,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,50597,N,,CHEMBL622971,,
10154,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,50597,N,,CHEMBL622972,,
10155,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,50597,N,,CHEMBL622973,,
10156,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,50597,N,,CHEMBL622974,,
10157,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,50597,N,,CHEMBL622975,,
10158,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,50597,N,,CHEMBL622976,,
10159,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,50597,N,,CHEMBL622977,,
10160,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,50597,N,,CHEMBL624351,,
10161,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,50597,N,,CHEMBL624352,,
10162,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,50597,N,,CHEMBL624353,,
10163,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,50597,N,,CHEMBL622397,,
10164,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,50597,N,,CHEMBL622398,,
10165,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,50597,N,,CHEMBL622399,,
10166,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,50597,N,,CHEMBL622400,,
10167,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,50597,N,,CHEMBL628428,,
10168,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,50597,N,,CHEMBL628590,,
10169,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,50597,N,,CHEMBL628591,,
10170,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,50597,N,,CHEMBL628592,,
10171,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,50597,N,,CHEMBL628593,,
10172,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,50597,N,,CHEMBL875333,,
10173,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,50597,N,,CHEMBL628594,,
10174,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,50597,N,,CHEMBL628595,1969.0,
10175,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Stability in rat plasma was determined,50597,N,,CHEMBL628596,1969.0,
10176,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Stability in rat plasma was determined; ND= no data,50597,N,,CHEMBL628597,1969.0,
10177,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested for plasma half life period in rat (0-8 hr),50597,N,,CHEMBL628598,1969.0,
10178,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested for plasma half life period in rat (0-8 hr); Not determined,50597,N,,CHEMBL628599,1969.0,
10179,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,50597,N,,CHEMBL628600,,
10180,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,50597,N,,CHEMBL628601,,
10181,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested for the half life in rat,50597,N,,CHEMBL628602,,
10182,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vitro,1,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,50597,N,,CHEMBL628603,,
10183,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vitro,1,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,50597,N,,CHEMBL628604,,
10184,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vitro,1,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,50597,N,,CHEMBL628605,,
10185,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vitro,1,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,50597,N,,CHEMBL628606,,
10186,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vitro,1,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,50597,N,,CHEMBL628607,,
10187,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The biological half life the compound was measured at the dose of 100 umol/kg,50597,N,,CHEMBL628608,,
10188,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The biological half life the compound was measured at the dose of 30 umol/kg,50597,N,,CHEMBL628609,,
10189,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The compound was evaluated for plasma half life period in rat,50597,N,,CHEMBL628610,1969.0,
10190,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",50597,N,,CHEMBL873819,,
10191,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",50597,N,,CHEMBL628611,,
10192,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The pharmacokinetic parameter half-life period in vivo in rats,50597,N,,CHEMBL628612,,
10193,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"The pharmacokinetic property, Half-life was determined",50597,N,,CHEMBL628613,,
10194,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"The pharmacokinetic property, Half-life in rat in vivo",50597,N,,CHEMBL628614,,
10195,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"The pharmacokinetic property, Half-life was determined; ND denotes no data",50597,N,,CHEMBL628615,,
10196,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",50597,N,,CHEMBL628616,,
10197,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The plasma half life period in rats,50597,N,,CHEMBL627924,1969.0,
10198,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,50597,N,,CHEMBL627925,2107.0,
10199,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,50597,N,,CHEMBL627926,,
10200,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,t1/2 (apparent elimination)of the compound was determined,50597,N,,CHEMBL627927,,
10201,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,t1/2 value in rat,50597,N,,CHEMBL627928,,
10202,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life in rat,50597,N,,CHEMBL627539,,
10203,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",50597,N,,CHEMBL876790,1969.0,
10204,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,50597,N,,CHEMBL858186,,
10205,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half-life period in fasted rats,50597,N,,CHEMBL627540,,
10206,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,50597,N,,CHEMBL627541,,
10207,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,50597,N,,CHEMBL627715,,
10208,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,50597,N,,CHEMBL627716,,
10209,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Maximum time required to achieve Cmax was determined in rat,50597,N,,CHEMBL627717,,
10210,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,N,,CHEMBL627718,,
10211,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,N,,CHEMBL627719,,
10212,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,50597,N,,CHEMBL627720,,
10213,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,50597,N,,CHEMBL627721,,
10214,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,50597,N,,CHEMBL627722,,
10215,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,N,,CHEMBL627723,,
10216,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,N,,CHEMBL626058,,
10217,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,N,,CHEMBL626059,,
10218,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,N,,CHEMBL626060,,
10219,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,N,,CHEMBL626061,1969.0,
10220,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,N,,CHEMBL876791,,
10221,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,N,,CHEMBL626062,,
10222,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax at the dose of 2 mg/Kg administered perorally in rats,50597,N,,CHEMBL626063,,
10223,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tmax at the dose of 5 mg/Kg administered perorally in rats,50597,N,,CHEMBL626064,,
10224,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,50597,N,,CHEMBL626065,1969.0,
10225,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,50597,N,,CHEMBL626066,1969.0,
10226,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,tmax upon peroral administration of 10.0 mg/Kg dose in rat,50597,N,,CHEMBL626067,,
10227,,Rattus norvegicus,BAO_0000218,,1,F,Intermediate,,1,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,50597,N,,CHEMBL626068,,
10228,,Rattus norvegicus,BAO_0000218,,1,F,Intermediate,,1,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,50597,N,,CHEMBL626069,,
10229,,Rattus norvegicus,BAO_0000218,,1,F,Intermediate,,1,Percent total excretion of 3-methoxyacetaminophen glucuronide,50597,N,,CHEMBL626070,,
10230,,Rattus norvegicus,BAO_0000218,,1,F,Intermediate,,1,Percent total excretion of N-methoxyacetaminophen glucuronide,50597,N,,CHEMBL626071,,
10231,,Rattus norvegicus,BAO_0000218,,1,F,Intermediate,,1,Percent total excretion of N-methoxyacetaminophen sulfate,50597,N,,CHEMBL626072,,
10232,,Rattus norvegicus,BAO_0000218,,1,F,Intermediate,,1,Percent total excretion of acetaminophen,50597,N,,CHEMBL626073,,
10233,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",50597,N,,CHEMBL626741,2046.0,
10234,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",50597,N,,CHEMBL626742,,
10235,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,50597,N,,CHEMBL626743,,
10236,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,50597,N,,CHEMBL876792,,
10237,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,50597,N,,CHEMBL626744,,
10238,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for antidiuretic activity in rats,50597,N,,CHEMBL626745,,
10239,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,AUC in rat after 3mg/kg oral dose,50597,N,,CHEMBL626746,1969.0,
10240,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,50597,N,,CHEMBL626747,,
10241,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,50597,N,,CHEMBL626748,,
10242,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Bioavailability administered orally at a dose of 10 mg/kg to rats,50597,N,,CHEMBL626749,,
10243,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral Bioavailability was determined,50597,N,,CHEMBL626750,,
10244,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral bioavailability in rat,50597,N,,CHEMBL626751,,
10245,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral bioavailability in rat; Not performed.,50597,N,,CHEMBL626913,,
10246,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Bioavailability,50597,N,,CHEMBL626914,,
10247,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Bioavailability was determined; ND denotes no data,50597,N,,CHEMBL626915,,
10248,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,50597,N,,CHEMBL626916,,
10249,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,50597,N,,CHEMBL626917,,
10250,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Binding towards rat plasma protein at 10 uM,50597,N,,CHEMBL626918,,
10251,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Binding towards rat plasma protein at 100 uM,50597,N,,CHEMBL626919,,
10252,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (dose 20 mg/kg p.o.),50597,N,,CHEMBL626920,,
10253,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,50597,N,,CHEMBL621976,,
10254,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat after 5 mg/kg oral gavage,50597,N,,CHEMBL877599,,
10255,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat,50597,N,,CHEMBL621977,,
10256,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (dose 1 mg/kg i.v.),50597,N,,CHEMBL621978,,
10257,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (dose 3 mg/kg p.o.),50597,N,,CHEMBL621979,,
10258,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL621980,,
10259,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability of the compound in rats after administration of 30 mg/kg,50597,N,,CHEMBL621981,,
10260,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability after administration of 10 mg/kg in rats,50597,N,,CHEMBL621982,,
10261,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability after administration of 2 mg/kg in rats,50597,N,,CHEMBL882953,,
10262,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,50597,N,,CHEMBL621983,,
10263,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in dogs was determined; high,50597,N,,CHEMBL621984,,
10264,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in monkey after intravenous administration at 1 mpk,50597,N,,CHEMBL621985,,
10265,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in monkey after peroral administration at 10 mpk,50597,N,,CHEMBL621986,,
10266,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat after intravenous administration at 1 mpk,50597,N,,CHEMBL621987,,
10267,,Rattus norvegicus,BAO_0000218,,1,F,Intermediate,In vivo,1,Bioavailability in rat after intravenous administration at 2 mpk,50597,N,,CHEMBL877600,,
10268,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat after peroral administration at 30 mpk,50597,N,,CHEMBL621988,,
10269,,Rattus norvegicus,BAO_0000218,,1,F,Intermediate,In vivo,1,Bioavailability in rat after peroral administration at at 100 mpk,50597,N,,CHEMBL621989,,
10270,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rats was evaluated,50597,N,,CHEMBL621990,,
10271,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,50597,N,,CHEMBL621991,,
10272,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,50597,N,,CHEMBL621992,,
10273,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,50597,N,,CHEMBL621993,,
10274,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,50597,N,,CHEMBL621994,,
10275,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat,50597,N,,CHEMBL621995,,
10276,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat,50597,N,,CHEMBL621996,,
10277,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (dose 10 mg/kg),50597,N,,CHEMBL621997,,
10278,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,50597,N,,CHEMBL621998,,
10279,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,50597,N,,CHEMBL621999,,
10280,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL622000,,
10281,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was measured in rat after oral administration; 2-4,50597,N,,CHEMBL622001,,
10282,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was measured in rat after oral administration; 3-7,50597,N,,CHEMBL622002,,
10283,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (intraduodenal administration),50597,N,,CHEMBL622003,,
10284,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (intraduodenal administration),50597,N,,CHEMBL877601,,
10285,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL624871,,
10286,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL622004,,
10287,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),50597,N,,CHEMBL882954,,
10288,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,50597,N,,CHEMBL622005,,
10289,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,50597,N,,CHEMBL622006,,
10290,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was measured in rat,50597,N,,CHEMBL622007,,
10291,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was reported,50597,N,,CHEMBL622008,,
10292,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,N,,CHEMBL622009,,
10293,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),50597,N,,CHEMBL622010,,
10294,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,50597,N,,CHEMBL622011,,
10295,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),50597,N,,CHEMBL622012,,
10296,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),50597,N,,CHEMBL622013,,
10297,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,50597,N,,CHEMBL622014,,
10298,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was determined at 3 mg/kg po dose in rats,50597,N,,CHEMBL624749,,
10299,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (dose 2 mg/kg),50597,N,,CHEMBL624750,,
10300,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",50597,N,,CHEMBL624751,,
10301,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",50597,N,,CHEMBL624752,,
10302,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",50597,N,,CHEMBL624753,,
10303,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,50597,N,,CHEMBL624754,,
10304,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,50597,N,,CHEMBL624755,,
10305,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,50597,N,,CHEMBL624756,,
10306,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat,50597,N,,CHEMBL624757,,
10307,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,50597,N,,CHEMBL624758,,
10308,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,50597,N,,CHEMBL622270,,
10309,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (Sprague-Dawley),50597,N,,CHEMBL622271,,
10310,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat at the dose of 2 mg/kg,50597,N,,CHEMBL622272,,
10311,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL622273,,
10312,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (cannulated) (dose 2 mg/kg),50597,N,,CHEMBL622274,,
10313,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability value of compound in rats was determined after peroral administration,50597,N,,CHEMBL622275,,
10314,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (dose 20 mg/kg),50597,N,,CHEMBL622276,,
10315,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL622277,,
10316,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (dose 5 mg/kg),50597,N,,CHEMBL622278,,
10317,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL622279,,
10318,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL622280,,
10319,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for oral bioavailability in rats; 15-27 %,50597,N,,CHEMBL624083,,
10320,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,50597,N,,CHEMBL624084,,
10321,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),50597,N,,CHEMBL624085,,
10322,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for bioavailability in rats,50597,N,,CHEMBL624086,,
10323,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat,50597,N,,CHEMBL624087,,
10324,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL624088,,
10325,,Macaca mulatta,BAO_0000218,,1,A,Intermediate,In vivo,0,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,22224,U,,CHEMBL624089,,
10326,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,0,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),22224,U,,CHEMBL624090,,
10327,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Evaluated for the bioavailability in rat (in vivo),50597,N,,CHEMBL624091,,
10328,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,F value of compound in rats was determined after peroral administration,50597,N,,CHEMBL624092,,
10329,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,N,,CHEMBL624093,,
10330,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,N,,CHEMBL624094,,
10331,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,N,,CHEMBL624095,,
10332,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,N,,CHEMBL624096,,
10333,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",50597,N,,CHEMBL624097,,
10334,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum fall in carotid flow in rat,50597,N,,CHEMBL624098,,
10335,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,50597,N,,CHEMBL874392,,
10336,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (dose 5 mg/kg),50597,N,,CHEMBL624099,,
10337,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,50597,N,,CHEMBL624100,,
10338,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,50597,N,,CHEMBL624101,,
10339,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (male Wistar),50597,N,,CHEMBL624102,,
10340,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability after administration (30 mg/kg) in rat; good,50597,N,,CHEMBL624103,,
10341,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability at the dose of 2 mg/kg in rat,50597,N,,CHEMBL624104,,
10342,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability determined in rats,50597,N,,CHEMBL624105,,
10343,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),50597,N,,CHEMBL624106,,
10344,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (dose single 10 mg/kg),50597,N,,CHEMBL624107,,
10345,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (dose single 10 mg/kg),50597,N,,CHEMBL623943,,
10346,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (dose 5 mg/kg,50597,N,,CHEMBL623944,,
10347,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,50597,N,,CHEMBL623945,,
10348,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,50597,N,,CHEMBL623946,,
10349,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,50597,N,,CHEMBL623947,,
10350,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,50597,N,,CHEMBL623948,,
10351,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,50597,N,,CHEMBL623949,,
10352,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,50597,N,,CHEMBL623950,,
10353,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,50597,N,,CHEMBL874398,,
10354,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,50597,N,,CHEMBL623951,,
10355,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,50597,N,,CHEMBL623952,,
10356,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,50597,N,,CHEMBL623953,,
10357,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,50597,N,,CHEMBL623954,,
10358,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,50597,N,,CHEMBL623955,,
10359,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,50597,N,,CHEMBL623956,,
10360,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,50597,N,,CHEMBL627807,,
10361,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,50597,N,,CHEMBL627808,,
10362,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,50597,N,,CHEMBL627809,,
10363,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,50597,N,,CHEMBL627810,,
10364,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",50597,N,,CHEMBL627811,,
10365,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",50597,N,,CHEMBL627812,,
10366,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",50597,N,,CHEMBL627813,,
10367,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",50597,N,,CHEMBL627814,,
10368,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",50597,N,,CHEMBL875336,,
10369,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",50597,N,,CHEMBL627815,,
10370,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",50597,N,,CHEMBL627816,,
10371,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",50597,N,,CHEMBL627817,,
10372,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",50597,N,,CHEMBL627818,,
10373,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",50597,N,,CHEMBL627819,,
10374,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",50597,N,,CHEMBL627820,,
10375,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",50597,N,,CHEMBL627821,,
10376,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,50597,N,,CHEMBL628464,,
10377,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,50597,N,,CHEMBL626239,,
10378,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,50597,N,,CHEMBL626240,,
10379,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,50597,N,,CHEMBL626241,,
10380,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,50597,N,,CHEMBL626242,,
10381,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,50597,N,,CHEMBL626243,,
10382,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,50597,N,,CHEMBL626244,,
10383,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,50597,N,,CHEMBL626907,,
10384,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,50597,N,,CHEMBL626908,,
10385,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,50597,N,,CHEMBL626909,,
10386,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,50597,N,,CHEMBL626910,,
10387,,Rattus norvegicus,BAO_0000218,,1,F,Intermediate,,1,Percent total excretion of acetaminophen cysteine conjugate,50597,N,,CHEMBL875342,,
10388,,Rattus norvegicus,BAO_0000218,,1,F,Intermediate,,1,Percent total excretion of acetaminophen glucuronide,50597,N,,CHEMBL626911,,
10389,,Rattus norvegicus,BAO_0000218,,1,F,Intermediate,,1,Percent total excretion of acetaminophen sulfate,50597,N,,CHEMBL626912,,
10390,,Rattus norvegicus,BAO_0000218,,1,F,Intermediate,,1,Percent total excretion of acetaminophen-mercapturic acid,50597,N,,CHEMBL627065,,
10391,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,50597,N,,CHEMBL627066,1088.0,
10392,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,50597,N,,CHEMBL627067,,
10393,,ratrat,BAO_0000218,,1,A,Autocuration,In vivo,0,Biodistribution of compound in rat muscle after 5 min of administration,22224,U,,CHEMBL627068,2385.0,
10394,,ratrat,BAO_0000218,,1,A,Autocuration,In vivo,0,Biodistribution of compound in rat muscle after 5 min of administration.,22224,U,,CHEMBL627069,2385.0,
10395,,Ovis aries,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),22224,U,,CHEMBL627070,,
10396,,Ovis aries,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),22224,U,,CHEMBL627071,,
10397,,Ovis aries,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),22224,U,,CHEMBL627072,,
10398,,Ovis aries,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),22224,U,,CHEMBL627073,,
10399,,Ovis aries,BAO_0000218,,1,A,Autocuration,In vivo,0,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),22224,U,,CHEMBL625387,,
10400,,Ovis aries,BAO_0000218,,1,A,Autocuration,In vivo,0,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),22224,U,,CHEMBL625388,,
10401,,Ovis aries,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),22224,U,,CHEMBL625389,1969.0,
10402,,Ovis aries,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),22224,U,,CHEMBL875343,1969.0,
10403,,Serpentes,BAO_0000218,,1,A,Intermediate,,1,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),50497,N,,CHEMBL876795,,
10404,,Serpentes,BAO_0000218,,1,A,Intermediate,,1,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,50497,N,,CHEMBL626552,,
10405,,Serpentes,BAO_0000218,,1,A,Intermediate,,1,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,50497,N,,CHEMBL626553,,
10406,,Homo sapiens,BAO_0000366,,1,A,Autocuration,,0,The human biological plasma half life of the compound,22224,U,,CHEMBL626554,1969.0,
10407,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,50597,N,,CHEMBL626555,1088.0,
10408,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,50597,N,,CHEMBL626556,,
10409,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,50597,N,,CHEMBL626557,,
10410,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,50597,N,,CHEMBL626558,,
10411,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,50597,N,,CHEMBL626559,,
10412,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,50597,N,,CHEMBL626560,,
10413,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,50597,N,,CHEMBL876803,,
10414,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,50597,N,,CHEMBL627964,,
10415,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,50597,N,,CHEMBL627965,,
10416,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,50597,N,,CHEMBL627966,,
10417,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,50597,N,,CHEMBL627967,,
10418,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,50597,N,,CHEMBL627968,,
10419,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,50597,N,,CHEMBL627969,,
10420,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,50597,N,,CHEMBL627970,,
10421,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,50597,N,,CHEMBL627971,178.0,
10422,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,50597,N,,CHEMBL627972,178.0,
10423,,Homo sapiens,BAO_0000357,,1,B,Expert,,9,Dissociation constant against binding to human cyclophilin A,180,D,,CHEMBL856029,,
10424,,Bos taurus,BAO_0000019,,1,B,Expert,,8,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,11591,H,,CHEMBL627973,,
10425,,,BAO_0000019,,1,A,Autocuration,,0,-Log C was determined by performing the electroshock minimum test,22224,U,,CHEMBL627974,,
10426,,,BAO_0000019,,1,A,Autocuration,,0,-Log C was determined by performing the foot shock test,22224,U,,CHEMBL627975,,
10427,,,BAO_0000019,,1,A,Autocuration,,0,-Log C was determined by performing the incl screen test,22224,U,,CHEMBL627976,,
10428,,,BAO_0000019,,1,A,Autocuration,,0,-Log C was determined by performing the maximum electroshock test,22224,U,,CHEMBL627977,,
10429,,,BAO_0000019,,1,A,Autocuration,,0,-Log C was determined by performing the pentylenetetrazole test,22224,U,,CHEMBL627978,,
10430,,,BAO_0000019,,1,A,Autocuration,,0,Tested for experimental arotinoid inhibitory dose,22224,U,,CHEMBL627979,,
10431,,,BAO_0000019,,1,A,Autocuration,,0,Negative log transformed activity,22224,U,,CHEMBL876804,,
10432,,,BAO_0000019,,1,A,Autocuration,,0,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",22224,U,,CHEMBL627980,,
10433,,Cavia porcellus,BAO_0000218,,1,A,Intermediate,,1,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,50512,N,,CHEMBL627981,,
10434,,Cavia porcellus,BAO_0000218,,1,A,Intermediate,,1,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,50512,N,,CHEMBL627982,,
10435,,Cavia porcellus,BAO_0000218,,1,A,Intermediate,,1,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,50512,N,,CHEMBL627983,,
10436,,Cavia porcellus,BAO_0000218,,1,A,Intermediate,,1,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,50512,N,,CHEMBL627984,2116.0,
10437,,,BAO_0000100,,1,P,Autocuration,,0,Solubility in water was determined; values expressed as -log,22229,U,,CHEMBL627985,,
10438,,,BAO_0000019,,1,A,Autocuration,,0,Ratio of Kcat to that of Km was determined,22224,U,,CHEMBL627986,,
10439,,,BAO_0000019,,1,A,Autocuration,,0,Observed first order rate constant,22224,U,,CHEMBL627987,,
10440,,,BAO_0000019,,1,A,Autocuration,,0,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,22224,U,,CHEMBL627988,,
10441,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,50597,N,,CHEMBL627989,,
10442,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,50597,N,,CHEMBL627990,,
10443,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral Bioavailability after administration of 10 mg/kg in male rat,50597,N,,CHEMBL876805,,
10444,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),50597,N,,CHEMBL627991,,
10445,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL627992,,
10446,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,50597,N,,CHEMBL627993,,
10447,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability at 1 mg/kg was determined in rat,50597,N,,CHEMBL622817,,
10448,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability at 10 mg/kg was determined in rat,50597,N,,CHEMBL622818,,
10449,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",50597,N,,CHEMBL622819,,
10450,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL872267,,
10451,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL622820,,
10452,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability after intravenous administration in rats at 24 uM/kg,50597,N,,CHEMBL622821,,
10453,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL622822,,
10454,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL622823,,
10455,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL622824,,
10456,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat at a dose of 3 mg/kg,50597,N,,CHEMBL622825,,
10457,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat after oral administration at 10 mg/kg,50597,N,,CHEMBL622901,,
10458,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL622902,,
10459,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL621844,,
10460,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in Dawley rats,50597,N,,CHEMBL621845,,
10461,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability,50597,N,,CHEMBL621846,,
10462,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (dose 30 mg/kg),50597,N,,CHEMBL621847,,
10463,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,50597,N,,CHEMBL877609,,
10464,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (dose 3 mg/kg i.v.),50597,N,,CHEMBL621848,,
10465,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,50597,N,,CHEMBL621849,,
10466,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (dose 60 mg/kg p.o.),50597,N,,CHEMBL622030,,
10467,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Percent oral bioavailability determined in rats,50597,N,,CHEMBL622031,,
10468,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,50597,N,,CHEMBL622032,,
10469,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The compound was evaluated for bioavailability in rats; 32-51,50597,N,,CHEMBL622033,,
10470,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (dose 20 mg/kg p.o.),50597,N,,CHEMBL622034,,
10471,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL622035,,
10472,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability percent in rat at the dose of 2 mg/kg,50597,N,,CHEMBL882966,,
10473,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was evaluated after 20 uM/kg of peroral administration,50597,N,,CHEMBL622036,,
10474,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL622037,,
10475,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL622038,,
10476,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rats,50597,N,,CHEMBL622039,,
10477,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,50597,N,,CHEMBL622040,178.0,
10478,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,50597,N,,CHEMBL622041,178.0,
10479,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,50597,N,,CHEMBL622042,178.0,
10480,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,50597,N,,CHEMBL622043,178.0,
10481,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,50597,N,,CHEMBL622044,178.0,
10482,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,50597,N,,CHEMBL622045,10000001.0,
10483,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,50597,N,,CHEMBL622046,10000001.0,
10484,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,50597,N,,CHEMBL622047,10000001.0,
10485,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,50597,N,,CHEMBL877610,10000001.0,
10486,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,50597,N,,CHEMBL622048,955.0,
10487,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,50597,N,,CHEMBL622049,955.0,
10488,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,50597,N,,CHEMBL622050,955.0,
10489,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,50597,N,,CHEMBL622051,955.0,
10490,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,50597,N,,CHEMBL622052,,
10491,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,50597,N,,CHEMBL622053,,
10492,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,50597,N,,CHEMBL622054,,
10493,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,50597,N,,CHEMBL622055,,
10494,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rats was determined; High,50597,N,,CHEMBL622056,,
10495,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in the rat was determined,50597,N,,CHEMBL622057,,
10496,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,50597,N,,CHEMBL628008,,
10497,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),50597,N,,CHEMBL622058,,
10498,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,N,,CHEMBL622059,,
10499,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,N,,CHEMBL622060,,
10500,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,N,,CHEMBL622061,,
10501,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,N,,CHEMBL622062,,
10502,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,50597,N,,CHEMBL622063,,
10503,,Rattus norvegicus,BAO_0000218,,1,A,Expert,In vivo,1,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,N,,CHEMBL877611,,
10504,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability of compound in Sprague Dawley rats,50597,N,,CHEMBL622064,,
10505,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability of compound in rat,50597,N,,CHEMBL622065,,
10506,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (dose 2 mg/kg),50597,N,,CHEMBL622066,,
10507,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability of compound in rat was determined,50597,N,,CHEMBL622067,,
10508,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability of compound in rats,50597,N,,CHEMBL622068,,
10509,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability of compound was determined in rats,50597,N,,CHEMBL622069,,
10510,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability at a dose of 30 mg/kg in rats,50597,N,,CHEMBL624796,,
10511,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (dose 10 mg/kg),50597,N,,CHEMBL624797,,
10512,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (dose 10 mg/kg),50597,N,,CHEMBL623053,,
10513,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability evaluated in rat,50597,N,,CHEMBL623054,,
10514,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in fasted rat,50597,N,,CHEMBL623055,,
10515,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in fed rat,50597,N,,CHEMBL623056,,
10516,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (mature male) (dose 30 mg/kg),50597,N,,CHEMBL623057,,
10517,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL623058,,
10518,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (dose 10 mg/kg p.o.),50597,N,,CHEMBL623059,,
10519,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat after administration of 10 mg/kg po,50597,N,,CHEMBL623060,,
10520,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL623061,,
10521,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL623062,,
10522,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL623063,,
10523,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL623064,,
10524,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in ratrs,50597,N,,CHEMBL623065,,
10525,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL623066,,
10526,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL623067,,
10527,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rats was determined; High,50597,N,,CHEMBL623068,,
10528,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL623069,,
10529,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL623070,,
10530,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability was calculated in rat,50597,N,,CHEMBL623071,,
10531,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability,50597,N,,CHEMBL623072,,
10532,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability,50597,N,,CHEMBL623073,,
10533,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability,50597,N,,CHEMBL623074,,
10534,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability,50597,N,,CHEMBL623075,,
10535,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability after i.v. administration,50597,N,,CHEMBL623076,,
10536,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,N,,CHEMBL623077,,
10537,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (Sprague-Dawley),50597,N,,CHEMBL623078,,
10538,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in Sprague-Dawley rats,50597,N,,CHEMBL623079,,
10539,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,N,,CHEMBL623080,,
10540,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),50597,N,,CHEMBL623081,,
10541,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,50597,N,,CHEMBL623082,,
10542,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in fasted rat,50597,N,,CHEMBL874400,,
10543,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in fed rat,50597,N,,CHEMBL623083,,
10544,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL623084,,
10545,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL623085,,
10546,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL623086,,
10547,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL623087,,
10548,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL623088,,
10549,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL623089,,
10550,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL623090,,
10551,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL623091,,
10552,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL623092,,
10553,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL623093,,
10554,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL874401,,
10555,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL623094,,
10556,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL623095,,
10557,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat after peroral administration at 10 mg/kg,50597,N,,CHEMBL623096,,
10558,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat after peroral administration at 5 mg/kg,50597,N,,CHEMBL624913,,
10559,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),50597,N,,CHEMBL624914,,
10560,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,50597,N,,CHEMBL624915,,
10561,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat; Not measured,50597,N,,CHEMBL624916,,
10562,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL624917,,
10563,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,50597,N,,CHEMBL625157,,
10564,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro metabolic potential in rat liver microsomes,50597,N,,CHEMBL625158,2107.0,
10565,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",50597,N,,CHEMBL625159,,
10566,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",50597,N,,CHEMBL625160,,
10567,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,50597,N,,CHEMBL625161,,
10568,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL625162,,
10569,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL625163,,
10570,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rats at 10 mg/kg,50597,N,,CHEMBL625164,,
10571,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50597,N,,CHEMBL625165,,
10572,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL625166,,
10573,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,50597,N,,CHEMBL625167,,
10574,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,50597,N,,CHEMBL625168,,
10575,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance of the compound,50597,N,,CHEMBL625169,,
10576,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance at 10 mg/kg in rat upon intravenous administration,50597,N,,CHEMBL626264,,
10577,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,50597,N,,CHEMBL626265,,
10578,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The compound was tested for plasma clearance in rat,50597,N,,CHEMBL626266,1969.0,
10579,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,50597,N,,CHEMBL626267,1969.0,
10580,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration upon oral administration of 1 mg/Kg in rats,50597,N,,CHEMBL626268,,
10581,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,50597,N,,CHEMBL626269,,
10582,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,50597,N,,CHEMBL626270,,
10583,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,50597,N,,CHEMBL626271,,
10584,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",50597,N,,CHEMBL626272,,
10585,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",50597,N,,CHEMBL626273,,
10586,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",50597,N,,CHEMBL875346,,
10587,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",50597,N,,CHEMBL626274,,
10588,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for protein binding in rat plasma,50597,N,,CHEMBL626275,,
10589,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,50597,N,,CHEMBL624646,,
10590,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,50597,N,,CHEMBL624647,,
10591,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,50597,N,,CHEMBL624648,2107.0,
10592,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve ratio was determined (po/iv) in rat,50597,N,,CHEMBL624649,,
10593,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,50597,N,,CHEMBL624650,,
10594,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,50597,N,,CHEMBL624651,,
10595,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,50597,N,,CHEMBL624652,,
10596,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,50597,N,,CHEMBL624653,,
10597,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Ratio of AUCbrain to AUCplasma,50597,N,,CHEMBL624654,,
10598,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Ratio of brain to plasma,50597,N,,CHEMBL624655,,
10599,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,50597,N,,CHEMBL624656,,
10600,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,50597,N,,CHEMBL624657,,
10601,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,50597,N,,CHEMBL624658,,
10602,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,50597,N,,CHEMBL624659,,
10603,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,50597,N,,CHEMBL624660,,
10604,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,50597,N,,CHEMBL624661,,
10605,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Steady state brain :blood ratio was determined,50597,N,,CHEMBL624662,,
10606,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,50597,N,,CHEMBL625199,,
10607,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,50597,N,,CHEMBL625200,,
10608,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,50597,N,,CHEMBL625201,,
10609,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,50597,N,,CHEMBL625202,,
10610,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percentage recovery after 3h incubation with rat hapatocytes was determined,50597,N,,CHEMBL625203,,
10611,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,50597,N,,CHEMBL625204,,
10612,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,50597,N,,CHEMBL625205,,
10613,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,50597,N,,CHEMBL625206,,
10614,,,BAO_0000019,,1,A,Autocuration,,0,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",22224,U,,CHEMBL625207,,
10615,,,BAO_0000019,,1,A,Autocuration,,0,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,22224,U,,CHEMBL625208,,
10616,495.0,Homo sapiens,BAO_0000218,Caco-2,1,A,Intermediate,,1,In vivo absorption in Caco-2 cell line monolayers was determined,50587,N,,CHEMBL625209,,
10617,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL625210,,
10618,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determine after peroral administration at 10 mpk in Rat,50597,N,,CHEMBL625211,,
10619,,Macaca mulatta,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determine after peroral administration at 10 mpk in Rhesus,50797,N,,CHEMBL625212,,
10620,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determine after peroral administration at 160 mpk in Rat,50597,N,,CHEMBL625213,,
10621,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determine after peroral administration at 20 mpk in Rat,50597,N,,CHEMBL625214,,
10622,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve was determine after peroral administration at 50 mpk in Rat,50597,N,,CHEMBL874542,,
10623,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP) (AlogP),22229,U,,CHEMBL625215,,
10624,,,BAO_0000019,,1,A,Autocuration,,0,Activated partial thromboplastin time measured,22224,U,,CHEMBL625216,,
10625,,,BAO_0000100,,1,P,Autocuration,,0,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),22224,U,,CHEMBL625217,,
10626,,,BAO_0000100,,1,P,Autocuration,,0,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),22224,U,,CHEMBL625218,,
10627,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,50588,N,,CHEMBL622864,1969.0,
10628,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,50597,N,,CHEMBL622865,1969.0,
10629,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,50597,N,,CHEMBL622866,1969.0,
10630,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,50588,N,,CHEMBL622867,1969.0,
10631,,Cavia porcellus,BAO_0000218,,1,A,Intermediate,,1,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,50512,N,,CHEMBL876808,1969.0,
10632,,,BAO_0000019,,1,A,Autocuration,,0,AUC in brain,22224,U,,CHEMBL627725,955.0,
10633,,,BAO_0000019,,1,A,Autocuration,,0,AUC in serum,22224,U,,CHEMBL627726,1977.0,
10634,,,BAO_0000019,,1,A,Autocuration,,0,AUC was determined,22224,U,,CHEMBL627727,1969.0,
10635,,,BAO_0000019,,1,A,Autocuration,,0,AUC of the compound.,22224,U,,CHEMBL627728,1969.0,
10636,,,BAO_0000019,,1,A,Autocuration,,0,AUC value (0-4 hr),22224,U,,CHEMBL627729,1969.0,
10637,,,BAO_0000019,,1,A,Autocuration,,0,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",22224,U,,CHEMBL627730,1969.0,
10638,,,BAO_0000019,,1,A,Autocuration,,0,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,22224,U,,CHEMBL627731,1969.0,
10639,,,BAO_0000019,,1,A,Autocuration,,0,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",22224,U,,CHEMBL627732,1969.0,
10640,,,BAO_0000019,,1,A,Autocuration,,0,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",22224,U,,CHEMBL627733,1969.0,
10641,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC(area under curve) was determined after intravenous administration in rats,50597,N,,CHEMBL627734,1969.0,
10642,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC(area under curve) was determined after oral administration in rats,50597,N,,CHEMBL627735,1969.0,
10643,,Cavia porcellus,BAO_0000218,,1,A,Intermediate,,1,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,50512,N,,CHEMBL627736,1969.0,
10644,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,50597,N,,CHEMBL876809,1969.0,
10645,,,BAO_0000019,,1,A,Autocuration,,0,Area Under Curve after oral dosing of 100 uM/Kg,22224,U,,CHEMBL627737,,
10646,,,BAO_0000019,,1,A,Autocuration,,0,Area Under Curve after oral dosing of 30 uM/Kg,22224,U,,CHEMBL627738,,
10647,,,BAO_0000019,,1,A,Autocuration,,0,Area Under Curve was measured by ploting the graph between concentration verses time,22224,U,,CHEMBL627739,,
10648,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,50588,N,,CHEMBL626143,,
10649,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,22224,U,,CHEMBL626144,,
10650,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,50592,N,,CHEMBL626145,,
10651,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,50597,N,,CHEMBL626146,,
10652,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,50597,N,,CHEMBL626147,178.0,
10653,,,BAO_0000019,,1,A,Autocuration,,0,Area under curve (AUC) was determined,22224,U,,CHEMBL626148,,
10654,,,BAO_0000218,,1,A,Autocuration,,0,Area under curve (AUC) following ip administration at 1 mg/kg,22224,U,,CHEMBL626149,,
10655,,,BAO_0000019,,1,A,Autocuration,,0,Area under curve (AUC) was determined; ND is Not determined,22224,U,,CHEMBL626150,,
10656,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,50588,N,,CHEMBL626151,,
10657,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,50588,N,,CHEMBL626152,,
10658,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,50588,N,,CHEMBL626153,,
10659,,,BAO_0000019,,1,A,Autocuration,,0,Area under curve (AUR) was determined,22224,U,,CHEMBL626154,,
10660,,,BAO_0000019,,1,A,Autocuration,,0,Area under curve at 1 uM/dg administered intravenously,22224,U,,CHEMBL626155,,
10661,,,BAO_0000019,,1,A,Autocuration,,0,Area under curve at 10 uM/dg administered perorally,22224,U,,CHEMBL626156,,
10662,,,BAO_0000019,,1,A,Autocuration,,0,Area under curve at 2 uM/dg administered intravenously,22224,U,,CHEMBL626157,,
10663,,,BAO_0000019,,1,A,Autocuration,,0,Area under curve at 20 uM/dg administered perorally,22224,U,,CHEMBL626158,,
10664,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve at a peroral dose of 3 mg/kg in dog,50588,N,,CHEMBL626159,,
10665,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve at a peroral dose of 3 mg/kg in rat,50597,N,,CHEMBL626160,,
10666,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve at an iv dose of 1 mg/kg in dog,50588,N,,CHEMBL626161,,
10667,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under curve at an iv dose of 1 mg/kg in rat,50597,N,,CHEMBL626162,,
10668,,,BAO_0000019,,1,A,Autocuration,,0,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,22224,U,,CHEMBL626163,,
10669,,,BAO_0000019,,1,A,Autocuration,,0,Area under curve gives the effective duration for the angiotensin II antagonist effect.,22224,U,,CHEMBL626164,,
10670,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve measured as conc vs time after intravenous administration to mice.,50594,N,,CHEMBL626165,,
10671,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Area under curve measured as conc vs time after peroral administration to mice.,50594,N,,CHEMBL626166,,
10672,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,50588,N,,CHEMBL626167,,
10673,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,50588,N,,CHEMBL626168,,
10674,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,50588,N,,CHEMBL877463,,
10675,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,50588,N,,CHEMBL626169,,
10676,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,50597,N,,CHEMBL626170,948.0,
10677,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,50597,N,,CHEMBL626171,948.0,
10678,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,50597,N,,CHEMBL626172,948.0,
10679,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,50597,N,,CHEMBL626173,948.0,
10680,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,50597,N,,CHEMBL626174,2113.0,
10681,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,50597,N,,CHEMBL626175,2113.0,
10682,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,50597,N,,CHEMBL626176,2113.0,
10683,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,50597,N,,CHEMBL626177,2113.0,
10684,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,50597,N,,CHEMBL622499,2113.0,
10685,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,50597,N,,CHEMBL622500,2107.0,
10686,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,50597,N,,CHEMBL622501,2107.0,
10687,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,50597,N,,CHEMBL622502,2107.0,
10688,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,50597,N,,CHEMBL622503,2107.0,
10689,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,50597,N,,CHEMBL877614,2107.0,
10690,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,50597,N,,CHEMBL624839,2048.0,
10691,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,50597,N,,CHEMBL624840,2048.0,
10692,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,50597,N,,CHEMBL624841,2048.0,
10693,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,50597,N,,CHEMBL624842,2048.0,
10694,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,50597,N,,CHEMBL624843,2385.0,
10695,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,50597,N,,CHEMBL624844,2385.0,
10696,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,50597,N,,CHEMBL624845,2385.0,
10697,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,50597,N,,CHEMBL621904,2385.0,
10698,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,50597,N,,CHEMBL621905,178.0,
10699,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,50597,N,,CHEMBL874382,178.0,
10700,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,50597,N,,CHEMBL621906,178.0,
10701,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,50597,N,,CHEMBL621907,955.0,
10702,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,50597,N,,CHEMBL622096,955.0,
10703,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,50597,N,,CHEMBL622097,955.0,
10704,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,50597,N,,CHEMBL622098,948.0,
10705,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,50597,N,,CHEMBL622099,948.0,
10706,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,50597,N,,CHEMBL622100,948.0,
10707,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,50597,N,,CHEMBL622101,2113.0,
10708,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,50597,N,,CHEMBL622102,2113.0,
10709,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,50597,N,,CHEMBL622103,2113.0,
10710,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,50597,N,,CHEMBL622104,2107.0,
10711,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,50597,N,,CHEMBL622105,2107.0,
10712,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,50597,N,,CHEMBL622106,2107.0,
10713,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,50597,N,,CHEMBL622107,2048.0,
10714,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,50597,N,,CHEMBL622108,2048.0,
10715,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,50597,N,,CHEMBL622109,2048.0,
10716,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,50597,N,,CHEMBL622110,2385.0,
10717,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,50597,N,,CHEMBL622111,2385.0,
10718,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,50597,N,,CHEMBL874383,2385.0,
10719,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,50597,N,,CHEMBL622112,14.0,
10720,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,50597,N,,CHEMBL622113,14.0,
10721,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,50597,N,,CHEMBL622114,14.0,
10722,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,50597,N,,CHEMBL622115,2106.0,
10723,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,50597,N,,CHEMBL622116,2106.0,
10724,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL622117,,
10725,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL622118,,
10726,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rats at 6 mg/kg,50597,N,,CHEMBL622119,,
10727,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (dose 6 mg/kg),50597,N,,CHEMBL622120,,
10728,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rats at 6 mg/kg dose; Not tested,50597,N,,CHEMBL622121,,
10729,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL622122,,
10730,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL622123,,
10731,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL622124,,
10732,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat,50597,N,,CHEMBL622125,,
10733,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability,50597,N,,CHEMBL622126,,
10734,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),50597,N,,CHEMBL620455,,
10735,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL620456,,
10736,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL620457,,
10737,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability was evaluated; Not tested,50597,N,,CHEMBL620458,,
10738,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability,50597,N,,CHEMBL620459,,
10739,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat by oral dosing,50597,N,,CHEMBL620460,,
10740,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (dose 10 mg/kg p.o.),50597,N,,CHEMBL620461,,
10741,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (Sprague-Dawley),50597,N,,CHEMBL620462,,
10742,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,N,,CHEMBL620463,,
10743,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,N,,CHEMBL620464,,
10744,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),50597,N,,CHEMBL620465,,
10745,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),50597,N,,CHEMBL620466,,
10746,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,50597,N,,CHEMBL620467,,
10747,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,50597,N,,CHEMBL620468,,
10748,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,50597,N,,CHEMBL620469,,
10749,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,50597,N,,CHEMBL620470,,
10750,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL620471,,
10751,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL620472,,
10752,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,50597,N,,CHEMBL620473,,
10753,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL620474,,
10754,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),50597,N,,CHEMBL620475,,
10755,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL620476,,
10756,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL620477,,
10757,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,50597,N,,CHEMBL620478,,
10758,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,50597,N,,CHEMBL618768,,
10759,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat after oral administration at 13 mg/kg dose,50597,N,,CHEMBL618769,,
10760,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,50597,N,,CHEMBL618770,,
10761,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability (dose 20 mg/kg p.o.),50597,N,,CHEMBL618771,,
10762,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,50597,N,,CHEMBL618772,,
10763,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat at 10 mg/kg of the compound,50597,N,,CHEMBL618773,,
10764,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,50597,N,,CHEMBL875842,,
10765,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (dose 3 mg/kg i.v.),50597,N,,CHEMBL618774,,
10766,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,50597,N,,CHEMBL618775,,
10767,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (dose 60 mg/kg p.o.),50597,N,,CHEMBL618776,,
10768,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Percent bioavailability (F) in rats after iv administration,50597,N,,CHEMBL618777,,
10769,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,50597,N,,CHEMBL618778,,
10770,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (dose 5 uM/kg p.o.),50597,N,,CHEMBL618779,,
10771,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability,50597,N,,CHEMBL618780,,
10772,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat (dose 2 mg/kg p.o.),50597,N,,CHEMBL618781,,
10773,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,50597,N,,CHEMBL618782,,
10774,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (dose 20 mg/kg),50597,N,,CHEMBL618783,,
10775,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL618784,,
10776,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Percent oral bioavailability evaluated in rat,50597,N,,CHEMBL618785,,
10777,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL618786,,
10778,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Percent oral bioavailability in rat; Not determined,50597,N,,CHEMBL618787,,
10779,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat,50597,N,,CHEMBL618788,,
10780,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability in rat,50597,N,,CHEMBL618789,,
10781,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),50597,N,,CHEMBL618790,,
10782,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),50597,N,,CHEMBL618791,,
10783,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,50597,N,,CHEMBL875843,,
10784,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat (dose 20 mg/kg p.o.),50597,N,,CHEMBL618792,,
10785,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax at a dose of 30 mg/kg in rat,50597,N,,CHEMBL623395,,
10786,,Simiiformes,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax in monkeys at a dose of 1 mg/kg,22224,U,,CHEMBL623396,,
10787,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in rat,50597,N,,CHEMBL623397,,
10788,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in rats at a dose of 1 mg/kg,50597,N,,CHEMBL623398,,
10789,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax was measured in mice after an oral dose of 50 mg/kg.,50594,N,,CHEMBL623399,,
10790,,,BAO_0000218,,1,A,Autocuration,In vivo,0,"Cmax value at a dose of 12.7 uM/kg, po",22224,U,,CHEMBL623400,,
10791,,,BAO_0000218,,1,A,Autocuration,In vivo,0,"Cmax value at a dose of 6.3 uM/kg, iv",22224,U,,CHEMBL623401,,
10792,,,BAO_0000218,,1,A,Autocuration,In vivo,0,"Cmax value at a dose of 7.1 uM/kg, iv",22224,U,,CHEMBL623402,,
10793,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax value of compound was determined after 1 hr,22224,U,,CHEMBL623403,,
10794,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax value of the compound,22224,U,,CHEMBL623404,,
10795,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value administered intraintestinal in rats.,50597,N,,CHEMBL625997,,
10796,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value administered perorally was determined in rat; Not determined,50597,N,,CHEMBL625998,,
10797,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax value at the dose of 2.3 mg/kg,22224,U,,CHEMBL625999,,
10798,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax value at the dose of 5 mg/kg,22224,U,,CHEMBL626000,,
10799,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax value in the period of 8 hr after dosing. ,22224,U,,CHEMBL626001,,
10800,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax value at a oral dose of 20 mg/kg; Not tested,22224,U,,CHEMBL626002,,
10801,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax value at a oral dose of 20 mg/kg,22224,U,,CHEMBL626003,,
10802,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,50597,N,,CHEMBL626004,,
10803,,Cavia porcellus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,50512,N,,CHEMBL626005,,
10804,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,50597,N,,CHEMBL626006,,
10805,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,50597,N,,CHEMBL626007,1969.0,
10806,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,50594,N,,CHEMBL626008,1969.0,
10807,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,50588,N,,CHEMBL626009,2107.0,
10808,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,50588,N,,CHEMBL626010,,
10809,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,50594,N,,CHEMBL626011,178.0,
10810,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,50594,N,,CHEMBL626012,178.0,
10811,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,50594,N,,CHEMBL626013,178.0,
10812,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,50594,N,,CHEMBL626014,178.0,
10813,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,50594,N,,CHEMBL877496,178.0,
10814,,Canis lupus familiaris,BAO_0000218,,1,F,Intermediate,In vivo,1,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,50588,N,,CHEMBL626015,,
10815,,Canis lupus familiaris,BAO_0000218,,1,F,Intermediate,In vivo,1,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,50588,N,,CHEMBL626016,,
10816,,Canis lupus familiaris,BAO_0000218,,1,F,Intermediate,In vivo,1,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,50588,N,,CHEMBL626017,,
10817,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability as maximal plasma concentration in dogs,50588,N,,CHEMBL626018,1969.0,
10818,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability as maximal plasma concentration in dogs,50588,N,,CHEMBL626692,1969.0,
10819,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability as maximal plasma concentration in rats,50597,N,,CHEMBL626693,1969.0,
10820,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability as maximal plasma concentration in rats,22224,U,,CHEMBL626694,1969.0,
10821,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,N,,CHEMBL626695,178.0,
10822,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,N,,CHEMBL626696,178.0,
10823,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,N,,CHEMBL626697,178.0,
10824,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,50588,N,,CHEMBL626859,178.0,
10825,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,N,,CHEMBL626860,178.0,
10826,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,N,,CHEMBL626861,178.0,
10827,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,50597,N,,CHEMBL626296,,
10828,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,22224,U,,CHEMBL626297,,
10829,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,22224,U,,CHEMBL626298,1969.0,
10830,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",50597,N,,CHEMBL626299,1969.0,
10831,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,50597,N,,CHEMBL626300,1969.0,
10832,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,50597,N,,CHEMBL626301,1969.0,
10833,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,50597,N,,CHEMBL626962,1969.0,
10834,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,50597,N,,CHEMBL626963,1969.0,
10835,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,50597,N,,CHEMBL626964,1969.0,
10836,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,100710,N,,CHEMBL626965,1969.0,
10837,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,N,,CHEMBL626966,1969.0,
10838,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,N,,CHEMBL626967,1969.0,
10839,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,100710,N,,CHEMBL626968,1969.0,
10840,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,50597,N,,CHEMBL626969,948.0,
10841,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,50597,N,,CHEMBL627126,948.0,
10842,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,50597,N,,CHEMBL631276,948.0,
10843,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,50597,N,,CHEMBL631277,948.0,
10844,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,50597,N,,CHEMBL631278,948.0,
10845,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,50597,N,,CHEMBL874457,948.0,
10846,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,50597,N,,CHEMBL631279,948.0,
10847,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,50597,N,,CHEMBL631280,948.0,
10848,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,50597,N,,CHEMBL631281,948.0,
10849,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,50597,N,,CHEMBL631968,948.0,
10850,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,50597,N,,CHEMBL631969,948.0,
10851,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,50597,N,,CHEMBL631970,948.0,
10852,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,50597,N,,CHEMBL631971,948.0,
10853,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,50597,N,,CHEMBL631972,948.0,
10854,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,50597,N,,CHEMBL630435,948.0,
10855,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,50597,N,,CHEMBL630436,948.0,
10856,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,50597,N,,CHEMBL630437,948.0,
10857,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,50597,N,,CHEMBL630438,948.0,
10858,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,50597,N,,CHEMBL630439,948.0,
10859,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,50597,N,,CHEMBL630440,2113.0,
10860,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,50597,N,,CHEMBL630441,2113.0,
10861,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,50597,N,,CHEMBL630442,2113.0,
10862,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,50597,N,,CHEMBL625234,2113.0,
10863,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,50597,N,,CHEMBL625235,2113.0,
10864,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,50597,N,,CHEMBL625236,2113.0,
10865,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,50597,N,,CHEMBL625237,2113.0,
10866,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,50597,N,,CHEMBL626125,2113.0,
10867,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,50597,N,,CHEMBL626126,2113.0,
10868,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,50597,N,,CHEMBL626127,2113.0,
10869,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,50597,N,,CHEMBL626128,2113.0,
10870,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,50597,N,,CHEMBL626129,2113.0,
10871,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,50597,N,,CHEMBL626130,2113.0,
10872,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,50597,N,,CHEMBL626131,2113.0,
10873,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,50597,N,,CHEMBL626132,2113.0,
10874,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,50597,N,,CHEMBL626752,2113.0,
10875,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,50597,N,,CHEMBL626753,2113.0,
10876,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,50597,N,,CHEMBL626754,2113.0,
10877,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,50597,N,,CHEMBL626755,2113.0,
10878,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,50597,N,,CHEMBL626756,2107.0,
10879,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,50597,N,,CHEMBL626757,2107.0,
10880,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,50597,N,,CHEMBL626758,2107.0,
10881,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,50597,N,,CHEMBL626759,2107.0,
10882,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,50597,N,,CHEMBL626760,2107.0,
10883,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),50588,N,,CHEMBL626394,,
10884,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,50588,N,,CHEMBL626395,,
10885,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),50588,N,,CHEMBL626396,,
10886,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),50588,N,,CHEMBL626397,,
10887,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),50588,N,,CHEMBL626398,,
10888,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),50588,N,,CHEMBL626399,,
10889,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,50597,N,,CHEMBL874653,,
10890,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,N,,CHEMBL626400,,
10891,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),50597,N,,CHEMBL626401,,
10892,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),50597,N,,CHEMBL626402,,
10893,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),50597,N,,CHEMBL626403,,
10894,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,N,,CHEMBL626404,,
10895,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,50597,N,,CHEMBL626405,,
10896,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,N,,CHEMBL625529,,
10897,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),50597,N,,CHEMBL625530,,
10898,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),50597,N,,CHEMBL625531,,
10899,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),50597,N,,CHEMBL625532,,
10900,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,N,,CHEMBL625533,,
10901,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,50597,N,,CHEMBL875474,,
10902,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,N,,CHEMBL625534,,
10903,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),50597,N,,CHEMBL625535,,
10904,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),50597,N,,CHEMBL625536,,
10905,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),50597,N,,CHEMBL625537,,
10906,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,N,,CHEMBL625538,,
10907,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,50597,N,,CHEMBL625539,,
10908,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,N,,CHEMBL625540,,
10909,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),50597,N,,CHEMBL625541,,
10910,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),50597,N,,CHEMBL625542,,
10911,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),50597,N,,CHEMBL625543,,
10912,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,N,,CHEMBL625544,,
10913,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,50588,N,,CHEMBL625545,,
10914,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),50588,N,,CHEMBL625546,,
10915,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,50588,N,,CHEMBL625547,,
10916,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),50588,N,,CHEMBL625548,,
10917,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),50588,N,,CHEMBL625549,,
10918,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),50588,N,,CHEMBL625550,,
10919,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),50588,N,,CHEMBL625551,,
10920,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),50588,N,,CHEMBL875475,,
10921,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),50588,N,,CHEMBL625552,,
10922,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),50588,N,,CHEMBL625553,,
10923,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),50588,N,,CHEMBL625554,,
10924,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),50588,N,,CHEMBL625555,,
10925,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),50588,N,,CHEMBL625556,,
10926,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,50588,N,,CHEMBL624986,,
10927,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),50588,N,,CHEMBL624987,,
10928,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),50588,N,,CHEMBL624988,,
10929,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,50588,N,,CHEMBL624989,1637.0,
10930,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,50588,N,,CHEMBL624990,1637.0,
10931,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,50588,N,,CHEMBL874391,1637.0,
10932,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,50588,N,,CHEMBL624991,1637.0,
10933,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,50588,N,,CHEMBL624992,1637.0,
10934,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,50588,N,,CHEMBL624993,1637.0,
10935,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,50588,N,,CHEMBL624994,1637.0,
10936,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,50588,N,,CHEMBL624995,1637.0,
10937,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,50588,N,,CHEMBL624996,1637.0,
10938,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,50588,N,,CHEMBL624997,1637.0,
10939,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,50588,N,,CHEMBL624998,1637.0,
10940,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,50588,N,,CHEMBL624999,1637.0,
10941,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,50588,N,,CHEMBL882955,1637.0,
10942,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,50588,N,,CHEMBL625000,1637.0,
10943,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,50588,N,,CHEMBL625001,1637.0,
10944,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,50588,N,,CHEMBL625089,1637.0,
10945,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,50588,N,,CHEMBL625090,1637.0,
10946,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,50588,N,,CHEMBL625091,1637.0,
10947,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,50588,N,,CHEMBL625092,1637.0,
10948,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,50588,N,,CHEMBL625093,1637.0,
10949,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,50588,N,,CHEMBL625094,1637.0,
10950,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,50588,N,,CHEMBL625095,1637.0,
10951,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for its bioavailability in the dogs,50588,N,,CHEMBL625096,,
10952,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for its bioavailability in the rats,50597,N,,CHEMBL625097,,
10953,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound was evaluated for oral bioavailability,22224,U,,CHEMBL882956,,
10954,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for percentage of Oral bioavailability in rats,50597,N,,CHEMBL625098,,
10955,,Cavia porcellus,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in guinea pig,22224,U,,CHEMBL625099,,
10956,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for the oral bioavailability in rat,50597,N,,CHEMBL625100,,
10957,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for the oral bioavailability in dog,50588,N,,CHEMBL625101,,
10958,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for the oral bioavailability in rat,50597,N,,CHEMBL874396,,
10959,,Canis lupus familiaris,BAO_0000218,,1,F,Autocuration,In vivo,0,Bioavailability in dog (dosed i.v.),22224,U,,CHEMBL625102,,
10960,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for in vivo bioavailability in dog,50588,N,,CHEMBL625103,,
10961,,Cricetinae,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for in vivo bioavailability in hamsters,100712,N,,CHEMBL625104,,
10962,,Simiiformes,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound was tested for in vivo bioavailability in monkey,22224,U,,CHEMBL625105,,
10963,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for in vivo bioavailability in rat,50597,N,,CHEMBL625106,,
10964,,Mus musculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in mouse,22224,U,,CHEMBL625107,,
10965,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for percent of oral bioavailability in mice; 56-74,50594,N,,CHEMBL625108,,
10966,,Mus musculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),22224,U,,CHEMBL625109,,
10967,,Macaca fascicularis,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),22224,U,,CHEMBL625110,,
10968,,Macaca fascicularis,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),22224,U,,CHEMBL625111,,
10969,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),50594,N,,CHEMBL625112,,
10970,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in nude mice,50594,N,,CHEMBL875334,,
10971,,Primates,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in monkey (i.d. dosing),22224,U,,CHEMBL628617,,
10972,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in rat,22224,U,,CHEMBL628618,,
10973,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,22224,U,,CHEMBL628619,,
10974,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,22224,U,,CHEMBL628620,,
10975,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,In vivo,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",100710,N,,CHEMBL628621,,
10976,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,In vivo,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",100710,N,,CHEMBL628622,,
10977,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,In vivo,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",100710,N,,CHEMBL628623,,
10978,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,100710,N,,CHEMBL628624,1969.0,
10979,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,N,,CHEMBL628625,1969.0,
10980,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,100710,N,,CHEMBL628626,1969.0,
10981,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,N,,CHEMBL627041,1969.0,
10982,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,N,,CHEMBL627042,1969.0,
10983,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,N,,CHEMBL627043,1969.0,
10984,,,BAO_0000218,,1,A,Autocuration,In vivo,0,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,22224,U,,CHEMBL627044,1969.0,
10985,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in mouse plasma,50594,N,,CHEMBL627045,1969.0,
10986,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,22224,U,,CHEMBL627046,1969.0,
10987,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal plasma concentration in rat,50597,N,,CHEMBL627047,1969.0,
10988,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,50597,N,,CHEMBL627048,1969.0,
10989,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,50597,N,,CHEMBL627049,,
10990,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,50597,N,,CHEMBL627050,,
10991,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,50597,N,,CHEMBL627051,,
10992,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,50597,N,,CHEMBL627052,,
10993,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,50597,N,,CHEMBL627053,,
10994,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,50597,N,,CHEMBL627054,,
10995,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,50594,N,,CHEMBL627055,,
10996,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,50594,N,,CHEMBL627056,,
10997,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),50594,N,,CHEMBL627057,,
10998,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,50594,N,,CHEMBL627058,,
10999,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,50594,N,,CHEMBL626211,,
11000,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum Concentration of the compound.,22224,U,,CHEMBL626212,,
11001,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum Concentration was measured after iv administration into Beagle dog,50588,N,,CHEMBL626213,,
11002,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum Concentration was measured after iv administration into Beagle dog.,50588,N,,CHEMBL626214,,
11003,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum Concentration was measured after po administration into Beagle dog,50588,N,,CHEMBL626215,,
11004,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum Concentration was measured after po administration into Beagle dog.,50588,N,,CHEMBL626216,,
11005,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,22224,U,,CHEMBL626217,178.0,
11006,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum blood level reached after an iv dose of 12.2 uM/kg,22224,U,,CHEMBL626218,178.0,
11007,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,22224,U,,CHEMBL626219,178.0,
11008,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,22224,U,,CHEMBL626220,178.0,
11009,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum blood level reached after an oral dose of 5.0 mg/kg,22224,U,,CHEMBL626221,178.0,
11010,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum blood level reached at dose of 10.6 uM/kg orally,22224,U,,CHEMBL626222,178.0,
11011,,Cavia porcellus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,50512,N,,CHEMBL626223,,
11012,,Cavia porcellus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,50512,N,,CHEMBL626224,,
11013,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,50597,N,,CHEMBL626225,955.0,
11014,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,50597,N,,CHEMBL626226,955.0,
11015,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,50597,N,,CHEMBL626227,955.0,
11016,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,50597,N,,CHEMBL626228,955.0,
11017,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,50597,N,,CHEMBL626229,,
11018,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,50597,N,,CHEMBL626921,,
11019,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,50597,N,,CHEMBL876793,,
11020,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,50597,N,,CHEMBL625309,,
11021,,Bacillus subtilis,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),50278,N,,CHEMBL625310,,
11022,,Simiiformes,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,22224,U,,CHEMBL625311,,
11023,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,50597,N,,CHEMBL625312,,
11024,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,22224,U,,CHEMBL625313,,
11025,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,50594,N,,CHEMBL625314,,
11026,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in male rats after iv administration of 20 mg/kg,50597,N,,CHEMBL625315,,
11027,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,50597,N,,CHEMBL625316,2107.0,
11028,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,50597,N,,CHEMBL625317,2107.0,
11029,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,50597,N,,CHEMBL625318,2107.0,
11030,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,50597,N,,CHEMBL625319,2107.0,
11031,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,50597,N,,CHEMBL625320,2107.0,
11032,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,50597,N,,CHEMBL625321,2107.0,
11033,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,50597,N,,CHEMBL625322,2107.0,
11034,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,50597,N,,CHEMBL876801,2107.0,
11035,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,50597,N,,CHEMBL625323,2107.0,
11036,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,50597,N,,CHEMBL625324,2107.0,
11037,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,50597,N,,CHEMBL625325,2107.0,
11038,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,50597,N,,CHEMBL625326,2107.0,
11039,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,50597,N,,CHEMBL625327,2107.0,
11040,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,50597,N,,CHEMBL625328,2107.0,
11041,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,50597,N,,CHEMBL625329,2048.0,
11042,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,50597,N,,CHEMBL625330,2048.0,
11043,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,50597,N,,CHEMBL627774,2048.0,
11044,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,50597,N,,CHEMBL627775,2048.0,
11045,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,50597,N,,CHEMBL627949,2048.0,
11046,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,50597,N,,CHEMBL627950,2048.0,
11047,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,50597,N,,CHEMBL627951,2048.0,
11048,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,50597,N,,CHEMBL627952,2048.0,
11049,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,50597,N,,CHEMBL627953,2048.0,
11050,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,50597,N,,CHEMBL627954,2048.0,
11051,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,50597,N,,CHEMBL627955,2048.0,
11052,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,50597,N,,CHEMBL627956,2048.0,
11053,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,50597,N,,CHEMBL876802,2048.0,
11054,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,50597,N,,CHEMBL627957,2048.0,
11055,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,50597,N,,CHEMBL627958,2048.0,
11056,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,50597,N,,CHEMBL627959,2048.0,
11057,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,50597,N,,CHEMBL627960,2048.0,
11058,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,50597,N,,CHEMBL627961,2048.0,
11059,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,50597,N,,CHEMBL627962,2048.0,
11060,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,50597,N,,CHEMBL627963,,
11061,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,50597,N,,CHEMBL624759,,
11062,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,50597,N,,CHEMBL624760,,
11063,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,50597,N,,CHEMBL624761,,
11064,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,50597,N,,CHEMBL877607,,
11065,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,50597,N,,CHEMBL624762,2107.0,
11066,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,50597,N,,CHEMBL624763,2107.0,
11067,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,50597,N,,CHEMBL624764,2107.0,
11068,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,50597,N,,CHEMBL624765,2107.0,
11069,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,50597,N,,CHEMBL624766,2107.0,
11070,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),50588,N,,CHEMBL624767,,
11071,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,50588,N,,CHEMBL624768,,
11072,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),50588,N,,CHEMBL624769,,
11073,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),50588,N,,CHEMBL624770,,
11074,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),50588,N,,CHEMBL624771,,
11075,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),50588,N,,CHEMBL624772,,
11076,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,50597,N,,CHEMBL624773,,
11077,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,N,,CHEMBL624774,,
11078,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),50597,N,,CHEMBL624775,,
11079,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),50597,N,,CHEMBL624776,,
11080,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),50597,N,,CHEMBL624777,,
11081,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,N,,CHEMBL624778,,
11082,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,50597,N,,CHEMBL624779,,
11083,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),50597,N,,CHEMBL624780,,
11084,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),50597,N,,CHEMBL624781,,
11085,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,N,,CHEMBL877608,,
11086,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),50597,N,,CHEMBL624782,,
11087,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,N,,CHEMBL624783,,
11088,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,50597,N,,CHEMBL624784,,
11089,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,N,,CHEMBL624785,,
11090,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),50597,N,,CHEMBL624786,,
11091,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),50597,N,,CHEMBL624787,,
11092,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,N,,CHEMBL628676,,
11093,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,50597,N,,CHEMBL621842,,
11094,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,N,,CHEMBL621843,,
11095,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),50597,N,,CHEMBL623873,,
11096,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),50597,N,,CHEMBL623874,,
11097,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),50597,N,,CHEMBL623875,,
11098,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,N,,CHEMBL623876,,
11099,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,50588,N,,CHEMBL623877,,
11100,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),50588,N,,CHEMBL623878,,
11101,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,50588,N,,CHEMBL623879,,
11102,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),50588,N,,CHEMBL623880,,
11103,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),50588,N,,CHEMBL623881,,
11104,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),50588,N,,CHEMBL623957,,
11105,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),50588,N,,CHEMBL623958,,
11106,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),50588,N,,CHEMBL623959,,
11107,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),50588,N,,CHEMBL623960,,
11108,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),50588,N,,CHEMBL623961,,
11109,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),50588,N,,CHEMBL623962,,
11110,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),50588,N,,CHEMBL624676,,
11111,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),50588,N,,CHEMBL624677,,
11112,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,50588,N,,CHEMBL624678,,
11113,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),50588,N,,CHEMBL624679,,
11114,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),50588,N,,CHEMBL624680,,
11115,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,22224,U,,CHEMBL624849,,
11116,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,22224,U,,CHEMBL624850,,
11117,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,22224,U,,CHEMBL874399,,
11118,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,22224,U,,CHEMBL624851,,
11119,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,22224,U,,CHEMBL624852,,
11120,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in rat (dose 10 mg/kg),22224,U,,CHEMBL624853,,
11121,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in rat (Sprague-Dawley),22224,U,,CHEMBL624854,,
11122,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in rat,22224,U,,CHEMBL624855,,
11123,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in rats was determined in vivo,22224,U,,CHEMBL624856,,
11124,,Canis lupus familiaris,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in dog,22224,U,,CHEMBL882957,,
11125,,Simiiformes,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability of compound in monkey,22224,U,,CHEMBL624857,,
11126,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability of compound in rat,50597,N,,CHEMBL622202,,
11127,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in rat of PMEA prodrug,22224,U,,CHEMBL622203,,
11128,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,50597,N,,CHEMBL625522,,
11129,,Macaca mulatta,BAO_0000218,,1,A,Autocuration,In vivo,0,Serum conc at 3 hours following 25 mg/kg dose,22224,U,,CHEMBL622868,,
11130,,Macaca mulatta,BAO_0000218,,1,A,Autocuration,In vivo,0,Urine conc 0-5 hours following 25 mg/kg dose,22224,U,,CHEMBL622869,1088.0,
11131,,Macaca mulatta,BAO_0000218,,1,A,Autocuration,In vivo,0,Urine conc 0-24 hours following 25 mg/kg dose,22224,U,,CHEMBL622870,1088.0,
11132,,Chlorocebus aethiops,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in African green monkeys; 20-25,22224,U,,CHEMBL622871,,
11133,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in cynomolgus monkey.,100710,N,,CHEMBL620560,,
11134,,Canis lupus familiaris,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in dog,22224,U,,CHEMBL620561,,
11135,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in dog at 10 mg/kg oral dose,50588,N,,CHEMBL620562,,
11136,,Cricetinae,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in hamster at 10 mg/kg oral dose,100712,N,,CHEMBL620563,,
11137,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability in rat at 10 mg/kg oral dose,50597,N,,CHEMBL620564,,
11138,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in rat,22224,U,,CHEMBL872265,,
11139,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in rat,22224,U,,CHEMBL620565,,
11140,,Eutheria,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability,22224,U,,CHEMBL620566,,
11141,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability was determined; range 49-102%,22224,U,,CHEMBL620567,,
11142,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability was determined in dogs,50588,N,,CHEMBL620568,,
11143,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in rat,22224,U,,CHEMBL620569,,
11144,,Eutheria,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability,22224,U,,CHEMBL620570,,
11145,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability was determined; Not orally available,22224,U,,CHEMBL620571,,
11146,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),50594,N,,CHEMBL620572,,
11147,,Mus musculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),22224,U,,CHEMBL620573,,
11148,,Mus musculus,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,22224,U,,CHEMBL620574,,
11149,,Macaca mulatta,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in Rhesus monkey,22224,U,,CHEMBL620575,,
11150,,Canis lupus familiaris,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in dog (female mongrel),22224,U,,CHEMBL620576,,
11151,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,22224,U,,CHEMBL875846,,
11152,,Canis lupus familiaris,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in dog,22224,U,,CHEMBL620577,,
11153,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Percentage Bioavailability was evaluated.,22224,U,,CHEMBL620578,,
11154,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in rat administered i.d.,22224,U,,CHEMBL620579,,
11155,,Eutheria,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability,22224,U,,CHEMBL621248,,
11156,,Canis lupus familiaris,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in dog (male Beagle) i.v. administration,22224,U,,CHEMBL625390,,
11157,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",22224,U,,CHEMBL625391,,
11158,,Primates,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),22224,U,,CHEMBL872266,,
11159,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in rat (Sprague-Dawley) (male),22224,U,,CHEMBL625392,,
11160,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The oral bioavailability was measured on rats after oral administration,50597,N,,CHEMBL625393,,
11161,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,50597,N,,CHEMBL625394,,
11162,,Macaca mulatta,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,50797,N,,CHEMBL625395,,
11163,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in rat (dose 10 mg/kg i.d.),22224,U,,CHEMBL625396,,
11164,,Canis lupus familiaris,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in dog (male Beagle) i.v. administration,22224,U,,CHEMBL625397,,
11165,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL625398,,
11166,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL625399,178.0,
11167,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL626074,2037.0,
11168,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL626075,,
11169,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,50597,N,,CHEMBL626076,1969.0,
11170,,Macaca mulatta,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,50797,N,,CHEMBL626077,1969.0,
11171,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),50597,N,,CHEMBL626078,178.0,
11172,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),22224,U,,CHEMBL625846,178.0,
11173,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),22224,U,,CHEMBL625847,178.0,
11174,,Rattus norvegicus,BAO_0000218,,1,A,Expert,In vivo,1,Maximum concentration observed in rats at an oral dose of 50 mg/kg,50597,N,,CHEMBL625848,,
11175,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration of compound in plasma administered orally to rats,50597,N,,CHEMBL625849,1969.0,
11176,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",50588,N,,CHEMBL626023,1969.0,
11177,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",50588,N,,CHEMBL626024,1969.0,
11178,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",50588,N,,CHEMBL626025,1969.0,
11179,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration after 10 mg/kg by oral administration,22224,U,,CHEMBL626026,,
11180,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration at a dose of 1.5 mg/kg,22224,U,,CHEMBL626027,,
11181,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration at a dose of 2.0 mg/kg,22224,U,,CHEMBL626028,,
11182,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in dog plasma,50588,N,,CHEMBL626029,1969.0,
11183,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,22224,U,,CHEMBL626030,1969.0,
11184,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,22224,U,,CHEMBL626031,1969.0,
11185,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,22224,U,,CHEMBL626032,1969.0,
11186,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,22224,U,,CHEMBL626033,1969.0,
11187,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,22224,U,,CHEMBL626034,1969.0,
11188,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in plasma after oral administration in dog (25 mg/kg),50588,N,,CHEMBL626035,1969.0,
11189,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration in plasma at Tmax,22224,U,,CHEMBL626036,1969.0,
11190,,Canis lupus familiaris,BAO_0000218,,1,A,Expert,In vivo,1,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,50588,N,,CHEMBL626037,1969.0,
11191,,Cricetinae,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,100712,N,,CHEMBL626038,1969.0,
11192,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,50597,N,,CHEMBL626039,1969.0,
11193,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,50597,N,,CHEMBL626040,1969.0,
11194,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,50592,N,,CHEMBL626041,1969.0,
11195,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration was calculated,22224,U,,CHEMBL626042,,
11196,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration was calculated.,22224,U,,CHEMBL626043,,
11197,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration at a peroral dose of 10 mg/kg,22224,U,,CHEMBL626044,,
11198,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration of the drug at 10 uM/dg administered perorally,22224,U,,CHEMBL626045,,
11199,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration of the drug at 2 uM/dg administered intravenously,22224,U,,CHEMBL626046,,
11200,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",50588,N,,CHEMBL626047,1969.0,
11201,,Cricetinae,BAO_0000218,,1,A,Intermediate,In vivo,1,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",100712,N,,CHEMBL626048,1969.0,
11202,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",50597,N,,CHEMBL626049,1969.0,
11203,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,50597,N,,CHEMBL626050,1969.0,
11204,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,50588,N,,CHEMBL874541,1969.0,
11205,,Cricetinae,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,100712,N,,CHEMBL622826,1969.0,
11206,,Cricetinae,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,100712,N,,CHEMBL622827,1969.0,
11207,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,50597,N,,CHEMBL622828,1969.0,
11208,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,50597,N,,CHEMBL622829,1969.0,
11209,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration reached following intravenous administration in male rat,50597,N,,CHEMBL876806,,
11210,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,50588,N,,CHEMBL622830,,
11211,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,50597,N,,CHEMBL622831,,
11212,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,50588,N,,CHEMBL626794,,
11213,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,50597,N,,CHEMBL626795,,
11214,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,50597,N,,CHEMBL626796,,
11215,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,50597,N,,CHEMBL626797,,
11216,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum drug concentration is determined after oral dosing in rats.,50597,N,,CHEMBL626798,,
11217,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum observed concentration in oral (5 mg/kg) fasted dogs,50588,N,,CHEMBL626799,,
11218,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum observed concentration in oral (5 mg/kg) fed dogs,50588,N,,CHEMBL626800,,
11219,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum plasma concentration,22224,U,,CHEMBL626801,1969.0,
11220,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,50597,N,,CHEMBL876816,1969.0,
11221,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,50597,N,,CHEMBL626802,1969.0,
11222,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,50588,N,,CHEMBL626803,1969.0,
11223,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum plasma concentration following oral administration of 30 umol/kg,22224,U,,CHEMBL626804,1969.0,
11224,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,50597,N,,CHEMBL626805,1969.0,
11225,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,50597,N,,CHEMBL626309,1969.0,
11226,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,50597,N,,CHEMBL626310,1969.0,
11227,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,50597,N,,CHEMBL626311,1969.0,
11228,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,50597,N,,CHEMBL626312,1969.0,
11229,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,50597,N,,CHEMBL626313,995.0,
11230,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,50597,N,,CHEMBL626314,995.0,
11231,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,50597,N,,CHEMBL626315,995.0,
11232,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,50597,N,,CHEMBL626316,995.0,
11233,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,50597,N,,CHEMBL626317,995.0,
11234,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),50597,N,,CHEMBL626318,,
11235,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),50597,N,,CHEMBL626319,,
11236,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),50597,N,,CHEMBL626320,,
11237,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),50597,N,,CHEMBL875053,,
11238,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),50597,N,,CHEMBL626321,,
11239,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),50597,N,,CHEMBL626322,,
11240,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),50597,N,,CHEMBL626323,,
11241,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),50597,N,,CHEMBL626324,,
11242,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),50597,N,,CHEMBL626325,,
11243,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),50597,N,,CHEMBL626326,,
11244,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),50597,N,,CHEMBL626327,,
11245,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),50597,N,,CHEMBL626328,,
11246,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL626329,178.0,
11247,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL626330,178.0,
11248,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL626331,178.0,
11249,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL626332,178.0,
11250,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL626333,178.0,
11251,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL626334,178.0,
11252,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL626335,178.0,
11253,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL624798,178.0,
11254,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",50597,N,,CHEMBL624799,955.0,
11255,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",50597,N,,CHEMBL624800,955.0,
11256,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",50597,N,,CHEMBL624801,955.0,
11257,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",50597,N,,CHEMBL624802,955.0,
11258,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",50597,N,,CHEMBL624803,955.0,
11259,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",50597,N,,CHEMBL624804,955.0,
11260,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",50597,N,,CHEMBL624805,955.0,
11261,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",50597,N,,CHEMBL624806,955.0,
11262,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL624807,,
11263,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL624808,,
11264,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL624809,,
11265,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL624810,,
11266,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL877618,,
11267,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL624811,,
11268,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL624812,,
11269,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL624813,,
11270,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL624814,,
11271,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL624815,,
11272,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL624816,,
11273,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL624817,,
11274,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),50588,N,,CHEMBL624818,,
11275,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,50588,N,,CHEMBL624819,,
11276,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),50588,N,,CHEMBL624820,,
11277,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),50588,N,,CHEMBL624821,,
11278,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),50588,N,,CHEMBL624822,,
11279,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),50588,N,,CHEMBL624823,,
11280,,Escherichia coli,BAO_0000218,,1,A,Intermediate,,1,Observed diffusion coefficient in organic solvent for Escherichia coli,50212,N,,CHEMBL624824,,
11281,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",50597,N,,CHEMBL624825,178.0,
11282,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",50597,N,,CHEMBL624826,178.0,
11283,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",50597,N,,CHEMBL876817,2081.0,
11284,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",50597,N,,CHEMBL624827,2081.0,
11285,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",50597,N,,CHEMBL624828,,
11286,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",50597,N,,CHEMBL624829,,
11287,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",50597,N,,CHEMBL624830,2107.0,
11288,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",50597,N,,CHEMBL624831,2107.0,
11289,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",50597,N,,CHEMBL624832,2081.0,
11290,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",50597,N,,CHEMBL624833,2081.0,
11291,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",50597,N,,CHEMBL624834,,
11292,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",50597,N,,CHEMBL624835,,
11293,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",50597,N,,CHEMBL624836,2106.0,
11294,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",50597,N,,CHEMBL624837,2106.0,
11295,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,50597,N,,CHEMBL624838,178.0,
11296,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,50597,N,,CHEMBL622188,178.0,
11297,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,50597,N,,CHEMBL622189,948.0,
11298,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,50597,N,,CHEMBL622190,948.0,
11299,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,50597,N,,CHEMBL625170,948.0,
11300,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,50597,N,,CHEMBL625171,2113.0,
11301,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,50597,N,,CHEMBL625172,2113.0,
11302,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,50597,N,,CHEMBL625173,2113.0,
11303,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,50597,N,,CHEMBL625174,2107.0,
11304,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,50597,N,,CHEMBL625175,2107.0,
11305,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,50597,N,,CHEMBL625176,2107.0,
11306,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,50597,N,,CHEMBL625177,2048.0,
11307,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,50597,N,,CHEMBL625178,2048.0,
11308,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,50597,N,,CHEMBL625179,2048.0,
11309,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,50597,N,,CHEMBL625180,2048.0,
11310,,,BAO_0000218,,1,A,Autocuration,,0,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",22224,U,,CHEMBL625181,,
11311,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,50594,N,,CHEMBL625182,1088.0,
11312,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,50597,N,,CHEMBL625183,,
11313,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,50597,N,,CHEMBL875848,,
11314,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,50597,N,,CHEMBL622260,,
11315,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,50597,N,,CHEMBL622261,,
11316,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,50597,N,,CHEMBL622262,,
11317,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,50597,N,,CHEMBL622263,2113.0,
11318,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,50597,N,,CHEMBL622418,2113.0,
11319,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,50597,N,,CHEMBL622419,2107.0,
11320,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL623388,,
11321,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL623389,2107.0,
11322,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL623390,,
11323,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL623391,,
11324,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL623392,178.0,
11325,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL623393,2037.0,
11326,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL623394,,
11327,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL618885,,
11328,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL618886,2107.0,
11329,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL618887,,
11330,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL619535,,
11331,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL619536,178.0,
11332,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL619537,2037.0,
11333,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL619705,,
11334,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL619706,,
11335,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL619707,2107.0,
11336,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL619708,,
11337,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL625219,,
11338,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL625220,178.0,
11339,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL625221,2037.0,
11340,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL625222,,
11341,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL625223,,
11342,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL625224,2107.0,
11343,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,N,,CHEMBL625225,,
11344,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat blood after 24 hours of iv administration,50597,N,,CHEMBL625226,178.0,
11345,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,50597,N,,CHEMBL625227,178.0,
11346,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat blood after 30 minutes of iv administration,50597,N,,CHEMBL625228,178.0,
11347,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,50597,N,,CHEMBL875354,178.0,
11348,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat blood after 5 minutes of iv administration,50597,N,,CHEMBL625229,178.0,
11349,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,50597,N,,CHEMBL625230,178.0,
11350,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat heart after 24 hours of iv administration,50597,N,,CHEMBL625231,948.0,
11351,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,50597,N,,CHEMBL625900,948.0,
11352,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat heart after 30 minutes of iv administration,50597,N,,CHEMBL625901,948.0,
11353,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,50597,N,,CHEMBL625902,948.0,
11354,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat heart after 5 minutes of iv administration,50597,N,,CHEMBL625903,948.0,
11355,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,50597,N,,CHEMBL625904,948.0,
11356,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat liver after 24 hours of iv administration,50597,N,,CHEMBL625905,2107.0,
11357,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,50597,N,,CHEMBL627861,2107.0,
11358,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat liver after 30 minutes of iv administration,50597,N,,CHEMBL627862,2107.0,
11359,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,50597,N,,CHEMBL627863,2107.0,
11360,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat liver after 30 minutes of iv administration,50597,N,,CHEMBL627769,2107.0,
11361,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,50588,N,,CHEMBL627770,1969.0,
11362,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in cynomolgus monkey (PO dose),100710,N,,CHEMBL627771,,
11363,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in rat (PO dose),50597,N,,CHEMBL627772,,
11364,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in rat (PO dose),50597,N,,CHEMBL627773,,
11365,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,50597,N,,CHEMBL621922,1969.0,
11366,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in rat plasma after oral dose (10 mg/kg),50597,N,,CHEMBL621923,1969.0,
11367,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax in plasma after oral dose (10 mg/kg),22224,U,,CHEMBL621924,1969.0,
11368,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,50588,N,,CHEMBL621925,1969.0,
11369,,Simiiformes,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,22224,U,,CHEMBL621926,1969.0,
11370,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,50592,N,,CHEMBL621927,1969.0,
11371,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,50597,N,,CHEMBL621928,1969.0,
11372,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,50597,N,,CHEMBL621929,1969.0,
11373,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,50594,N,,CHEMBL621930,1969.0,
11374,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration after oral dosing in rat,50597,N,,CHEMBL621931,1969.0,
11375,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,22224,U,,CHEMBL621932,1969.0,
11376,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,22224,U,,CHEMBL621933,1969.0,
11377,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,50588,N,,CHEMBL621934,1969.0,
11378,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,50588,N,,CHEMBL621935,1969.0,
11379,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,50597,N,,CHEMBL621936,1969.0,
11380,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum plasma concentration was determined,22224,U,,CHEMBL621937,1969.0,
11381,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,22224,U,,CHEMBL621938,1969.0,
11382,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,22224,U,,CHEMBL621939,1969.0,
11383,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,22224,U,,CHEMBL621940,1969.0,
11384,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,22224,U,,CHEMBL621941,1969.0,
11385,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,22224,U,,CHEMBL621942,1969.0,
11386,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,22224,U,,CHEMBL626178,1969.0,
11387,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,22224,U,,CHEMBL626179,1969.0,
11388,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,22224,U,,CHEMBL626180,1969.0,
11389,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma Cmax in rat (PO dose),50597,N,,CHEMBL626181,1969.0,
11390,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum serum concentration after po dose of 5.22 mg/kg in rats,50597,N,,CHEMBL626182,,
11391,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum serum concentration after po dose of 5.46 mg/kg in rats,50597,N,,CHEMBL626183,,
11392,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,50597,N,,CHEMBL626184,,
11393,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,50597,N,,CHEMBL626185,,
11394,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,50588,N,,CHEMBL626186,1969.0,
11395,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,50588,N,,CHEMBL877589,1969.0,
11396,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration of the drug at 1 uM/dg administered intravenously,22224,U,,CHEMBL626187,,
11397,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration of the drug at 20 uM/dg administered perorally,22224,U,,CHEMBL626188,,
11398,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,22224,U,,CHEMBL626189,,
11399,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,22224,U,,CHEMBL626855,178.0,
11400,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,22224,U,,CHEMBL623781,178.0,
11401,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,22224,U,,CHEMBL623782,178.0,
11402,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,50597,N,,CHEMBL623783,1969.0,
11403,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in dog plasma after 1mg/kg oral dose,50588,N,,CHEMBL623784,1969.0,
11404,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,50588,N,,CHEMBL623785,1969.0,
11405,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,50597,N,,CHEMBL623786,1969.0,
11406,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral maximum concentration in rat,50597,N,,CHEMBL623787,,
11407,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral maximum concentration in rat,50597,N,,CHEMBL623788,,
11408,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,50594,N,,CHEMBL623789,1969.0,
11409,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Peak concentration in blood after intravenous administration to mice,50594,N,,CHEMBL623790,178.0,
11410,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Peak concentration in blood after peroral administration to mice,50594,N,,CHEMBL623791,178.0,
11411,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Peak concentration in rat plasma was determined,50597,N,,CHEMBL623792,1969.0,
11412,,Simiiformes,BAO_0000218,,1,A,Autocuration,In vivo,0,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,22224,U,,CHEMBL623793,1969.0,
11413,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,50594,N,,CHEMBL623794,1969.0,
11414,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,50597,N,,CHEMBL623795,1969.0,
11415,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL623796,,
11416,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL623797,,
11417,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL623798,,
11418,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL623799,,
11419,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL624490,160.0,
11420,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL624491,160.0,
11421,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL624492,160.0,
11422,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL624493,160.0,
11423,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL877595,160.0,
11424,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL624494,160.0,
11425,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL624495,160.0,
11426,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL624681,160.0,
11427,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL624682,,
11428,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL624683,,
11429,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL624684,,
11430,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL624685,,
11431,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL624686,,
11432,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL624687,,
11433,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL624688,,
11434,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL627161,,
11435,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL622127,,
11436,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL622128,,
11437,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL874384,,
11438,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL624898,,
11439,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL624899,,
11440,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL624900,,
11441,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL624901,,
11442,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL624902,,
11443,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL624903,,
11444,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL624904,,
11445,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL624905,,
11446,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL624906,,
11447,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL624907,,
11448,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL624908,,
11449,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL624909,,
11450,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL624910,,
11451,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL624911,2385.0,
11452,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL874388,2385.0,
11453,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL624912,2385.0,
11454,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL622930,2385.0,
11455,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL623121,2385.0,
11456,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL623122,2385.0,
11457,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL623123,2385.0,
11458,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL623124,2385.0,
11459,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL623125,,
11460,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL623126,,
11461,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL623127,,
11462,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL623128,,
11463,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL623129,,
11464,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL623130,,
11465,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL623131,,
11466,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL623132,,
11467,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,50597,N,,CHEMBL623133,2107.0,
11468,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,50597,N,,CHEMBL623134,,
11469,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,50597,N,,CHEMBL874389,,
11470,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,50597,N,,CHEMBL623135,,
11471,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,50597,N,,CHEMBL623136,,
11472,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,50597,N,,CHEMBL623137,,
11473,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,50597,N,,CHEMBL623138,,
11474,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,50597,N,,CHEMBL623139,2113.0,
11475,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,50597,N,,CHEMBL623140,2113.0,
11476,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,50597,N,,CHEMBL623141,2107.0,
11477,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,50597,N,,CHEMBL623142,2107.0,
11478,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,50597,N,,CHEMBL623143,,
11479,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,50594,N,,CHEMBL623144,1088.0,
11480,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,50597,N,,CHEMBL623405,1088.0,
11481,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,50597,N,,CHEMBL624074,,
11482,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,50597,N,,CHEMBL624075,,
11483,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,50597,N,,CHEMBL624076,,
11484,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,50597,N,,CHEMBL624077,,
11485,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,50597,N,,CHEMBL624078,,
11486,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,50597,N,,CHEMBL624079,2113.0,
11487,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,50597,N,,CHEMBL624261,2113.0,
11488,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,50597,N,,CHEMBL624262,,
11489,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,50597,N,,CHEMBL624263,,
11490,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,50597,N,,CHEMBL624264,,
11491,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,50597,N,,CHEMBL624265,,
11492,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,50597,N,,CHEMBL624266,,
11493,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,50597,N,,CHEMBL624267,,
11494,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,50597,N,,CHEMBL624268,,
11495,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,50597,N,,CHEMBL875227,,
11496,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,50597,N,,CHEMBL624269,2113.0,
11497,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,50597,N,,CHEMBL624270,2113.0,
11498,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,50597,N,,CHEMBL624271,,
11499,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,50597,N,,CHEMBL624272,,
11500,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,50597,N,,CHEMBL624273,,
11501,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,50597,N,,CHEMBL624274,1088.0,
11502,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,50597,N,,CHEMBL624275,1088.0,
11503,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,50597,N,,CHEMBL624276,1088.0,
11504,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,50597,N,,CHEMBL624277,1088.0,
11505,,,BAO_0000019,,1,A,Autocuration,,0,% dose converted to 2-amino-5-chlorophenyl sulfate,22224,U,,CHEMBL624278,,
11506,,,BAO_0000019,,1,A,Autocuration,,0,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),22224,U,,CHEMBL624279,,
11507,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",50597,N,,CHEMBL624280,1988.0,
11508,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",50597,N,,CHEMBL624281,1988.0,
11509,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",50597,N,,CHEMBL622933,1988.0,
11510,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",50597,N,,CHEMBL622934,1988.0,
11511,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,50597,N,,CHEMBL622935,2107.0,
11512,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat liver after 5 minutes of iv administration,50597,N,,CHEMBL622936,2107.0,
11513,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,50597,N,,CHEMBL875228,2107.0,
11514,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat lung after 24 hours of iv administration,50597,N,,CHEMBL622937,2048.0,
11515,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,50597,N,,CHEMBL622938,2048.0,
11516,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat lung after 30 minutes of iv administration,50597,N,,CHEMBL619736,2048.0,
11517,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,50597,N,,CHEMBL625117,2048.0,
11518,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat lung after 5 minutes of iv administration,50597,N,,CHEMBL625118,2048.0,
11519,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,50597,N,,CHEMBL625119,2048.0,
11520,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",50597,N,,CHEMBL625120,2037.0,
11521,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",50597,N,,CHEMBL625121,,
11522,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",50597,N,,CHEMBL625122,10000006.0,
11523,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,N,,CHEMBL622204,178.0,
11524,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,N,,CHEMBL877503,178.0,
11525,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,N,,CHEMBL627127,178.0,
11526,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,22224,U,,CHEMBL627128,10000000.0,
11527,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,22224,U,,CHEMBL627129,10000000.0,
11528,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,22224,U,,CHEMBL627130,10000000.0,
11529,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,N,,CHEMBL627131,955.0,
11530,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,N,,CHEMBL627132,955.0,
11531,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,N,,CHEMBL627133,955.0,
11532,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,N,,CHEMBL627134,2037.0,
11533,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,N,,CHEMBL627135,2037.0,
11534,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,N,,CHEMBL627136,2037.0,
11535,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,N,,CHEMBL628435,,
11536,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,N,,CHEMBL628436,,
11537,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,N,,CHEMBL628437,,
11538,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,N,,CHEMBL628438,948.0,
11539,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,N,,CHEMBL628439,948.0,
11540,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,N,,CHEMBL628440,948.0,
11541,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,N,,CHEMBL628441,10000000.0,
11542,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,N,,CHEMBL628442,10000000.0,
11543,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,N,,CHEMBL628443,10000000.0,
11544,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,N,,CHEMBL628444,2113.0,
11545,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,N,,CHEMBL628445,2113.0,
11546,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,N,,CHEMBL877504,2113.0,
11547,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,N,,CHEMBL628446,2107.0,
11548,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,N,,CHEMBL626874,2107.0,
11549,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,N,,CHEMBL626875,2107.0,
11550,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,N,,CHEMBL626876,2048.0,
11551,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,N,,CHEMBL626877,2048.0,
11552,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,N,,CHEMBL626878,2048.0,
11553,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,N,,CHEMBL626879,2385.0,
11554,,Simiiformes,BAO_0000218,,1,A,Autocuration,In vivo,0,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,22224,U,,CHEMBL626880,1969.0,
11555,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,50594,N,,CHEMBL626881,1969.0,
11556,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,50597,N,,CHEMBL626882,1969.0,
11557,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Peak plasma concentration was measured in dogs,50588,N,,CHEMBL626883,1969.0,
11558,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,50597,N,,CHEMBL626884,,
11559,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,50597,N,,CHEMBL626885,,
11560,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,50597,N,,CHEMBL626886,,
11561,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,50597,N,,CHEMBL626887,,
11562,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,50597,N,,CHEMBL626888,,
11563,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,50588,N,,CHEMBL626889,,
11564,,Simiiformes,BAO_0000218,,1,A,Autocuration,In vivo,0,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,22224,U,,CHEMBL626761,,
11565,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,50588,N,,CHEMBL626762,,
11566,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,50588,N,,CHEMBL626763,,
11567,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,50597,N,,CHEMBL626764,,
11568,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,50597,N,,CHEMBL626765,,
11569,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,50588,N,,CHEMBL626766,,
11570,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,50597,N,,CHEMBL626767,,
11571,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,50597,N,,CHEMBL626768,,
11572,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,50588,N,,CHEMBL626769,,
11573,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,50588,N,,CHEMBL874463,,
11574,,Simiiformes,BAO_0000218,,1,A,Autocuration,In vivo,0,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,22224,U,,CHEMBL626770,,
11575,,Simiiformes,BAO_0000218,,1,A,Autocuration,In vivo,0,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,22224,U,,CHEMBL626771,,
11576,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,50597,N,,CHEMBL626772,,
11577,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,100710,N,,CHEMBL626773,,
11578,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,50594,N,,CHEMBL626774,,
11579,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,50588,N,,CHEMBL626775,,
11580,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,50588,N,,CHEMBL626776,,
11581,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximum concentration (Cmax) in rat when administered orally,50597,N,,CHEMBL626777,,
11582,,Simiiformes,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximal concentration in monkey plasma after 25 mg/kg oral dose,22224,U,,CHEMBL626778,1969.0,
11583,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",22224,U,,CHEMBL626779,,
11584,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",22224,U,,CHEMBL626780,,
11585,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,22224,U,,CHEMBL626781,1969.0,
11586,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic profile Cmax was evaluated in rats,50597,N,,CHEMBL632164,,
11587,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),50588,N,,CHEMBL632165,,
11588,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),50594,N,,CHEMBL632166,,
11589,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),50588,N,,CHEMBL632167,,
11590,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),50594,N,,CHEMBL632168,,
11591,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax in rat plasma,22224,U,,CHEMBL632169,1969.0,
11592,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in dog plasma after 30mg/kg oral dose,50588,N,,CHEMBL632170,1969.0,
11593,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax in rat plasma after 30mg/kg oral dose,50597,N,,CHEMBL632171,1969.0,
11594,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma level in rats at 30 mg/kg,50597,N,,CHEMBL632172,1969.0,
11595,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for maximum plasma concentration in mice,50594,N,,CHEMBL632173,1969.0,
11596,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",50597,N,,CHEMBL632174,,
11597,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The Cmax values in female wistar rats.,50597,N,,CHEMBL632175,,
11598,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,50588,N,,CHEMBL632176,1969.0,
11599,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,50597,N,,CHEMBL632177,1969.0,
11600,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,50597,N,,CHEMBL632178,1969.0,
11601,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,50597,N,,CHEMBL632179,,
11602,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,50597,N,,CHEMBL632180,178.0,
11603,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,50597,N,,CHEMBL632181,178.0,
11604,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,50597,N,,CHEMBL632182,178.0,
11605,,Mus musculus,BAO_0000218,,1,A,Autocuration,In vivo,0,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,22224,U,,CHEMBL632183,178.0,
11606,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,50588,N,,CHEMBL632184,,
11607,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,50597,N,,CHEMBL874470,,
11608,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL631302,,
11609,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL631303,,
11610,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL631304,,
11611,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL631305,,
11612,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL631306,,
11613,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL631307,,
11614,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL631308,,
11615,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL625557,,
11616,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL625558,2106.0,
11617,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL625559,2106.0,
11618,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL625560,2106.0,
11619,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL625561,2106.0,
11620,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL625562,2106.0,
11621,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL875320,2106.0,
11622,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL625563,2106.0,
11623,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL625564,2106.0,
11624,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL625565,995.0,
11625,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL625566,995.0,
11626,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL625567,995.0,
11627,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL625568,995.0,
11628,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL628217,995.0,
11629,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",50597,N,,CHEMBL628218,995.0,
11630,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL628219,995.0,
11631,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",50597,N,,CHEMBL628220,995.0,
11632,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the blood after 120 min of intravenous administration,22224,U,,CHEMBL628221,,
11633,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the blood after 15 min of intravenous administration,22224,U,,CHEMBL628222,,
11634,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the blood after 30 min of intravenous administration,22224,U,,CHEMBL628223,,
11635,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the blood after 5 min of intravenous administration,22224,U,,CHEMBL628224,,
11636,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the blood after 60 min of intravenous administration,22224,U,,CHEMBL628225,,
11637,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the blood after 90 min of intravenous administration,22224,U,,CHEMBL628226,,
11638,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the bone after 120 min of intravenous administration,22224,U,,CHEMBL628227,,
11639,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the bone after 15 min of intravenous administration,22224,U,,CHEMBL875481,,
11640,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the bone after 30 min of intravenous administration,22224,U,,CHEMBL628228,,
11641,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the bone after 5 min of intravenous administration,22224,U,,CHEMBL628229,,
11642,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the bone after 60 min of intravenous administration,22224,U,,CHEMBL628230,,
11643,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the bone after 90 min of intravenous administration,22224,U,,CHEMBL628231,,
11644,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the heart after 120 min of intravenous administration,22224,U,,CHEMBL628232,,
11645,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the heart after 15 min of intravenous administration,22224,U,,CHEMBL628233,,
11646,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the heart after 30 min of intravenous administration,22224,U,,CHEMBL628234,,
11647,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the heart after 5 min of intravenous administration,22224,U,,CHEMBL628235,,
11648,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the heart after 60 min of intravenous administration,22224,U,,CHEMBL628236,,
11649,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the heart after 90 min of intravenous administration,22224,U,,CHEMBL628237,,
11650,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the kidneys after 120 min of intravenous administration,22224,U,,CHEMBL628238,,
11651,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the kidneys after 15 min of intravenous administration,22224,U,,CHEMBL628239,,
11652,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the kidneys after 30 min of intravenous administration,22224,U,,CHEMBL628240,,
11653,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the kidneys after 5 min of intravenous administration,22224,U,,CHEMBL628241,,
11654,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the kidneys after 60 min of intravenous administration,22224,U,,CHEMBL628242,,
11655,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the kidneys after 90 min of intravenous administration,22224,U,,CHEMBL875482,,
11656,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the liver after 120 min of intravenous administration,22224,U,,CHEMBL628243,,
11657,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the liver after 15 min of intravenous administration,22224,U,,CHEMBL628244,,
11658,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the liver after 30 min of intravenous administration,22224,U,,CHEMBL628245,,
11659,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the liver after 5 min of intravenous administration,22224,U,,CHEMBL628246,,
11660,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the liver after 60 min of intravenous administration,22224,U,,CHEMBL628247,,
11661,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the liver after 90 min of intravenous administration,22224,U,,CHEMBL628248,,
11662,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the lung after 120 min of intravenous administration,22224,U,,CHEMBL628249,,
11663,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",50594,N,,CHEMBL625452,,
11664,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",50594,N,,CHEMBL625453,,
11665,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",50594,N,,CHEMBL625454,,
11666,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",50594,N,,CHEMBL623844,,
11667,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,50597,N,,CHEMBL623845,,
11668,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,50597,N,,CHEMBL623846,,
11669,,,BAO_0000218,,1,A,Autocuration,,0,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,22224,U,,CHEMBL623847,,
11670,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,100710,N,,CHEMBL623848,,
11671,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,100710,N,,CHEMBL623849,,
11672,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,100710,N,,CHEMBL623850,,
11673,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,100710,N,,CHEMBL623851,,
11674,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,22224,U,,CHEMBL623852,,
11675,,Mustela putorius furo,BAO_0000218,,1,A,Intermediate,,1,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,50506,N,,CHEMBL624551,,
11676,,Mustela putorius furo,BAO_0000218,,1,A,Intermediate,,1,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",50506,N,,CHEMBL624552,,
11677,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,22224,U,,CHEMBL624553,,
11678,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,22224,U,,CHEMBL624554,,
11679,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,50597,N,,CHEMBL624555,,
11680,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",50597,N,,CHEMBL624741,,
11681,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",50588,N,,CHEMBL624742,,
11682,,Cricetinae,BAO_0000218,,1,A,Intermediate,,1,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",100712,N,,CHEMBL624743,,
11683,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",50597,N,,CHEMBL877606,,
11684,,,BAO_0000218,,1,A,Autocuration,,0,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,22224,U,,CHEMBL624744,,
11685,,,BAO_0000218,,1,A,Autocuration,,0,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,22224,U,,CHEMBL624745,178.0,
11686,,,BAO_0000218,,1,A,Autocuration,,0,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,22224,U,,CHEMBL624746,178.0,
11687,,,BAO_0000218,,1,A,Autocuration,,0,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,22224,U,,CHEMBL624747,178.0,
11688,,,BAO_0000019,,1,A,Autocuration,,0,Oral absorption expressed as Area under curve was determined,22224,U,,CHEMBL624748,,
11689,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,50588,N,,CHEMBL622504,,
11690,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",50588,N,,CHEMBL622505,,
11691,,Cricetinae,BAO_0000218,,1,A,Intermediate,,1,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",100712,N,,CHEMBL622506,,
11692,,Cricetinae,BAO_0000218,,1,A,Intermediate,,1,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",100712,N,,CHEMBL622507,,
11693,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",50597,N,,CHEMBL622508,,
11694,,,BAO_0000019,,1,A,Autocuration,,0,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,22224,U,,CHEMBL622509,,
11695,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,50597,N,,CHEMBL622510,,
11696,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),50597,N,,CHEMBL622511,,
11697,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,100710,N,,CHEMBL622512,,
11698,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,100710,N,,CHEMBL622513,,
11699,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,100710,N,,CHEMBL622514,,
11700,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,50588,N,,CHEMBL622515,,
11701,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,50588,N,,CHEMBL622516,,
11702,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,50597,N,,CHEMBL622517,,
11703,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,50597,N,,CHEMBL622518,,
11704,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,50597,N,,CHEMBL622519,,
11705,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,N,,CHEMBL622520,2385.0,
11706,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,N,,CHEMBL622521,2385.0,
11707,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,50594,N,,CHEMBL625113,14.0,
11708,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,N,,CHEMBL625114,14.0,
11709,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,N,,CHEMBL874397,14.0,
11710,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,N,,CHEMBL625115,2106.0,
11711,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,N,,CHEMBL625116,2106.0,
11712,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,N,,CHEMBL623932,2106.0,
11713,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,N,,CHEMBL623933,2435.0,
11714,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,N,,CHEMBL623934,2435.0,
11715,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,N,,CHEMBL623935,2435.0,
11716,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,N,,CHEMBL623936,2046.0,
11717,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,N,,CHEMBL623937,2046.0,
11718,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,N,,CHEMBL623938,2046.0,
11719,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,50594,N,,CHEMBL623939,,
11720,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,50594,N,,CHEMBL623940,,
11721,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,50594,N,,CHEMBL623941,,
11722,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,N,,CHEMBL627216,,
11723,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,N,,CHEMBL623942,,
11724,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,50594,N,,CHEMBL618793,955.0,
11725,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,N,,CHEMBL618794,955.0,
11726,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,N,,CHEMBL618795,955.0,
11727,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,N,,CHEMBL618796,,
11728,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,N,,CHEMBL618797,,
11729,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,50594,N,,CHEMBL618798,2113.0,
11730,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,50594,N,,CHEMBL618799,2113.0,
11731,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,50594,N,,CHEMBL618800,2113.0,
11732,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,50594,N,,CHEMBL618801,2113.0,
11733,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,N,,CHEMBL618802,2113.0,
11734,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,N,,CHEMBL618803,2113.0,
11735,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,50594,N,,CHEMBL618804,2107.0,
11736,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,50594,N,,CHEMBL618805,2107.0,
11737,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,50594,N,,CHEMBL618806,2107.0,
11738,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,50594,N,,CHEMBL618807,2107.0,
11739,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,N,,CHEMBL618808,2107.0,
11740,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,N,,CHEMBL618809,2107.0,
11741,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,50594,N,,CHEMBL618810,2385.0,
11742,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,50594,N,,CHEMBL618811,2385.0,
11743,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,50594,N,,CHEMBL875844,2385.0,
11744,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,N,,CHEMBL618812,2385.0,
11745,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,N,,CHEMBL618813,2385.0,
11746,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,50594,N,,CHEMBL618814,,
11747,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,N,,CHEMBL618815,,
11748,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,N,,CHEMBL618816,,
11749,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,N,,CHEMBL618817,,
11750,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,N,,CHEMBL620544,,
11751,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,50597,N,,CHEMBL626230,,
11752,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,50597,N,,CHEMBL626231,,
11753,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,50597,N,,CHEMBL626232,,
11754,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,50588,N,,CHEMBL626233,1969.0,
11755,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,50597,N,,CHEMBL626234,1969.0,
11756,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,50597,N,,CHEMBL875341,1969.0,
11757,,Homo sapiens,BAO_0000218,,1,A,Intermediate,In vivo,1,The maximum plasma concentration (100 mg/kg) administered orally in human,50587,N,,CHEMBL626235,1969.0,
11758,,Callithrix,BAO_0000218,,1,A,Autocuration,In vivo,0,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,22224,U,,CHEMBL626236,1969.0,
11759,,Simiiformes,BAO_0000218,,1,A,Autocuration,In vivo,0,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,22224,U,,CHEMBL626237,1969.0,
11760,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,50588,N,,CHEMBL626238,1969.0,
11761,,Homo sapiens,BAO_0000218,,1,A,Intermediate,In vivo,1,The maximum plasma concentration (200 mg/kg) administered orally in human,50587,N,,CHEMBL622412,1969.0,
11762,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,50597,N,,CHEMBL623114,1969.0,
11763,,Callithrix,BAO_0000218,,1,A,Autocuration,In vivo,0,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,22224,U,,CHEMBL623115,1969.0,
11764,,Simiiformes,BAO_0000218,,1,A,Autocuration,In vivo,0,The maximum plasma concentration (25 mg/kg) administered orally in monkey,22224,U,,CHEMBL623116,1969.0,
11765,,Canis lupus familiaris,BAO_0000218,,1,A,Autocuration,In vivo,0,The maximum plasma concentration (30 mg/kg) administered orally in dog,22224,U,,CHEMBL623117,1969.0,
11766,,Homo sapiens,BAO_0000218,,1,A,Intermediate,In vivo,1,The maximum plasma concentration (400 mg/kg) administered orally in human,50587,N,,CHEMBL623118,1969.0,
11767,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,50597,N,,CHEMBL623119,1969.0,
11768,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The maximum plasma concentration (50 mg/kg) administered orally in rat,50597,N,,CHEMBL623120,1969.0,
11769,,Homo sapiens,BAO_0000218,,1,A,Intermediate,In vivo,1,The maximum plasma concentration (800 mg/kg) administered orally in human,50587,N,,CHEMBL623286,1969.0,
11770,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The maximum plasma concentration was measured on rats,50597,N,,CHEMBL623287,1969.0,
11771,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The maximum plasma concentration was measured on rats after oral administration,50597,N,,CHEMBL623288,1969.0,
11772,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma drug Cmax in rat (PO dose),50597,N,,CHEMBL623289,1969.0,
11773,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,22224,U,,CHEMBL623290,,
11774,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,maximum Plasma concentration in Dog was determined after Peroral administration,50588,N,,CHEMBL623291,1969.0,
11775,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,maximum Plasma concentration in Rats was determined after Peroral administration,50597,N,,CHEMBL623292,1969.0,
11776,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,50588,N,,CHEMBL623293,1969.0,
11777,,Simiiformes,BAO_0000218,,1,A,Autocuration,In vivo,0,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,22224,U,,CHEMBL623294,1969.0,
11778,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,50597,N,,CHEMBL623295,1969.0,
11779,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,maximum concentration was measured when administered through oral route in mice,50594,N,,CHEMBL623296,,
11780,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,50594,N,,CHEMBL875349,,
11781,,Simiiformes,BAO_0000019,,1,A,Autocuration,,0,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,22224,U,,CHEMBL623297,,
11782,,Simiiformes,BAO_0000019,,1,A,Autocuration,,0,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,22224,U,,CHEMBL623298,,
11783,,Simiiformes,BAO_0000019,,1,A,Autocuration,,0,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,22224,U,,CHEMBL623299,,
11784,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter was evaluated in rats,50597,N,,CHEMBL623300,,
11785,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,50594,N,,CHEMBL623301,,
11786,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,50594,N,,CHEMBL623302,,
11787,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,50594,N,,CHEMBL623303,,
11788,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,50594,N,,CHEMBL623304,,
11789,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,50594,N,,CHEMBL623305,,
11790,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,50597,N,,CHEMBL623306,1969.0,
11791,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,50597,N,,CHEMBL623307,1969.0,
11792,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,50597,N,,CHEMBL623308,1969.0,
11793,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,50594,N,,CHEMBL623309,1969.0,
11794,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Plasma Concentration after 120 min of oral administration to mice,50594,N,,CHEMBL623310,,
11795,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Plasma Concentration after 30 min of oral administration to mice,50594,N,,CHEMBL623311,,
11796,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,Plasma Concentration after 60 min of oral administration to mice,100710,N,,CHEMBL623312,,
11797,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Plasma Concentration after 60 min of oral administration to mice; Not determined,50594,N,,CHEMBL875350,,
11798,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Plasma Concentration after 90 min of oral administration to mice,50594,N,,CHEMBL628635,,
11799,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,50597,N,,CHEMBL628636,,
11800,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,50597,N,,CHEMBL628637,,
11801,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,50597,N,,CHEMBL628058,,
11802,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,50597,N,,CHEMBL628059,,
11803,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,50597,N,,CHEMBL628060,,
11804,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the lung after 15 min of intravenous administration,22224,U,,CHEMBL628061,,
11805,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the lung after 30 min of intravenous administration,22224,U,,CHEMBL628062,,
11806,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the lung after 5 min of intravenous administration,22224,U,,CHEMBL628063,,
11807,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the lung after 60 min of intravenous administration,22224,U,,CHEMBL628064,,
11808,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the lung after 90 min of intravenous administration,22224,U,,CHEMBL628065,,
11809,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the muscle after 120 min of intravenous administration,22224,U,,CHEMBL628066,2385.0,
11810,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the muscle after 15 min of intravenous administration,22224,U,,CHEMBL628067,2385.0,
11811,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Distribution in the muscle after 30 min of intravenous administration,50594,N,,CHEMBL874646,2385.0,
11812,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the muscle after 5 min of intravenous administration,22224,U,,CHEMBL628068,2385.0,
11813,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the muscle after 60 min of intravenous administration,22224,U,,CHEMBL628069,2385.0,
11814,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the muscle after 90 min of intravenous administration,22224,U,,CHEMBL628070,2385.0,
11815,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the spleen after 120 min of intravenous administration,22224,U,,CHEMBL628071,2106.0,
11816,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the spleen after 15 min of intravenous administration,22224,U,,CHEMBL628072,2106.0,
11817,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the spleen after 30 min of intravenous administration,22224,U,,CHEMBL628073,2106.0,
11818,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the spleen after 5 min of intravenous administration,22224,U,,CHEMBL628074,2106.0,
11819,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the spleen after 60 min of intravenous administration,22224,U,,CHEMBL628075,2106.0,
11820,,,BAO_0000019,,1,A,Autocuration,,0,Distribution in the spleen after 90 min of intravenous administration,22224,U,,CHEMBL628076,2106.0,
11821,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,50597,N,,CHEMBL628077,1235.0,
11822,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,50597,N,,CHEMBL628078,178.0,
11823,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,50597,N,,CHEMBL628079,2107.0,
11824,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,50597,N,,CHEMBL628080,992.0,
11825,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,50597,N,,CHEMBL628081,2046.0,
11826,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,50597,N,,CHEMBL628082,1235.0,
11827,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,50597,N,,CHEMBL874647,178.0,
11828,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,50597,N,,CHEMBL626406,2107.0,
11829,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,50597,N,,CHEMBL626407,992.0,
11830,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,50597,N,,CHEMBL626408,2046.0,
11831,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",50597,N,,CHEMBL626409,178.0,
11832,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",50597,N,,CHEMBL626410,178.0,
11833,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",50597,N,,CHEMBL626411,178.0,
11834,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",50597,N,,CHEMBL626412,178.0,
11835,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",50597,N,,CHEMBL626413,178.0,
11836,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",50597,N,,CHEMBL626414,178.0,
11837,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",50597,N,,CHEMBL626415,178.0,
11838,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",50597,N,,CHEMBL626416,178.0,
11839,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",50597,N,,CHEMBL627062,178.0,
11840,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",50597,N,,CHEMBL627063,178.0,
11841,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",50597,N,,CHEMBL627064,178.0,
11842,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",50597,N,,CHEMBL627227,178.0,
11843,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",50597,N,,CHEMBL627228,178.0,
11844,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",50597,N,,CHEMBL627229,178.0,
11845,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",50597,N,,CHEMBL625792,178.0,
11846,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",50597,N,,CHEMBL625793,178.0,
11847,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",50597,N,,CHEMBL625794,178.0,
11848,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",50597,N,,CHEMBL625795,178.0,
11849,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,50594,N,,CHEMBL625796,,
11850,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,50588,N,,CHEMBL625797,,
11851,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,50588,N,,CHEMBL625798,,
11852,,,BAO_0000218,,1,A,Autocuration,,0,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,22224,U,,CHEMBL875613,,
11853,,,BAO_0000218,,1,A,Autocuration,,0,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,22224,U,,CHEMBL625799,,
11854,,,BAO_0000218,,1,A,Autocuration,,0,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,22224,U,,CHEMBL625800,,
11855,,,BAO_0000218,,1,A,Autocuration,,0,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,22224,U,,CHEMBL625801,,
11856,,,BAO_0000218,,1,A,Autocuration,,0,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,22224,U,,CHEMBL625802,,
11857,,,BAO_0000218,,1,A,Autocuration,,0,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,22224,U,,CHEMBL625803,,
11858,,,BAO_0000019,,1,A,Autocuration,,0,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,22224,U,,CHEMBL625804,,
11859,,,BAO_0000218,,1,A,Autocuration,,0,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,22224,U,,CHEMBL622530,,
11860,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,50594,N,,CHEMBL622531,,
11861,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),50594,N,,CHEMBL622532,,
11862,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),50594,N,,CHEMBL623176,,
11863,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),50594,N,,CHEMBL623177,,
11864,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),50594,N,,CHEMBL623178,,
11865,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,50594,N,,CHEMBL623179,,
11866,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),50594,N,,CHEMBL623180,,
11867,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),50594,N,,CHEMBL623181,,
11868,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),50594,N,,CHEMBL624131,,
11869,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),50594,N,,CHEMBL624132,,
11870,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),50594,N,,CHEMBL624133,,
11871,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,50594,N,,CHEMBL624846,,
11872,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),50594,N,,CHEMBL624847,,
11873,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),50594,N,,CHEMBL624848,,
11874,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),50594,N,,CHEMBL625012,,
11875,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),50594,N,,CHEMBL625013,,
11876,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,50594,N,,CHEMBL625014,,
11877,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),50594,N,,CHEMBL625015,,
11878,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),50594,N,,CHEMBL625016,,
11879,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,50594,N,,CHEMBL625017,,
11880,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),50594,N,,CHEMBL625018,,
11881,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),50594,N,,CHEMBL625019,,
11882,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),50594,N,,CHEMBL625020,,
11883,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,50594,N,,CHEMBL625021,,
11884,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,50597,N,,CHEMBL625022,,
11885,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,50594,N,,CHEMBL625023,,
11886,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,100710,N,,CHEMBL625024,,
11887,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,100710,N,,CHEMBL627626,,
11888,,,BAO_0000218,,1,A,Autocuration,,0,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,22224,U,,CHEMBL627627,955.0,
11889,,,BAO_0000218,,1,A,Autocuration,,0,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,22224,U,,CHEMBL627628,1977.0,
11890,,,BAO_0000218,,1,A,Autocuration,,0,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,22224,U,,CHEMBL627629,955.0,
11891,,,BAO_0000218,,1,A,Autocuration,,0,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,22224,U,,CHEMBL627630,1977.0,
11892,,,BAO_0000019,,1,A,Autocuration,,0,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),22224,U,,CHEMBL627631,,
11893,,,BAO_0000218,,1,A,Autocuration,,0,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),22224,U,,CHEMBL629515,,
11894,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,50594,N,,CHEMBL629516,2106.0,
11895,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,N,,CHEMBL629517,2106.0,
11896,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,N,,CHEMBL629518,2106.0,
11897,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,50594,N,,CHEMBL877499,,
11898,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,50594,N,,CHEMBL629519,,
11899,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,N,,CHEMBL629520,,
11900,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,N,,CHEMBL629521,,
11901,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),50594,N,,CHEMBL629522,,
11902,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),50594,N,,CHEMBL629523,,
11903,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),50594,N,,CHEMBL629524,,
11904,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),50594,N,,CHEMBL629525,,
11905,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),50594,N,,CHEMBL629526,,
11906,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),50594,N,,CHEMBL629527,,
11907,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),50594,N,,CHEMBL629528,,
11908,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),50594,N,,CHEMBL629529,,
11909,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),50594,N,,CHEMBL629530,,
11910,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),50594,N,,CHEMBL629531,,
11911,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),50594,N,,CHEMBL628656,,
11912,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),50594,N,,CHEMBL628657,,
11913,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",50597,N,,CHEMBL628658,,
11914,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,N,,CHEMBL628659,,
11915,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,N,,CHEMBL877500,,
11916,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,N,,CHEMBL628660,,
11917,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,N,,CHEMBL628661,,
11918,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,N,,CHEMBL628662,,
11919,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,N,,CHEMBL628663,,
11920,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,N,,CHEMBL628664,,
11921,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,N,,CHEMBL628665,178.0,
11922,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,N,,CHEMBL628666,178.0,
11923,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,N,,CHEMBL628667,178.0,
11924,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,N,,CHEMBL628668,178.0,
11925,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,N,,CHEMBL628669,178.0,
11926,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,N,,CHEMBL628670,178.0,
11927,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,N,,CHEMBL628671,178.0,
11928,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,N,,CHEMBL628672,10000001.0,
11929,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,N,,CHEMBL630300,10000001.0,
11930,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,N,,CHEMBL629787,10000001.0,
11931,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,N,,CHEMBL629788,10000001.0,
11932,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,N,,CHEMBL629789,955.0,
11933,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,N,,CHEMBL629790,955.0,
11934,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,N,,CHEMBL629791,955.0,
11935,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,N,,CHEMBL629792,955.0,
11936,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,N,,CHEMBL629793,955.0,
11937,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,N,,CHEMBL629794,955.0,
11938,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,50597,N,,CHEMBL874459,,
11939,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,50597,N,,CHEMBL629795,,
11940,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,50597,N,,CHEMBL629796,,
11941,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,50597,N,,CHEMBL629797,,
11942,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,50597,N,,CHEMBL629798,,
11943,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,N,,CHEMBL629799,2369.0,
11944,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL629800,2369.0,
11945,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL629801,2369.0,
11946,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,50597,N,,CHEMBL629802,2369.0,
11947,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL629803,2369.0,
11948,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,N,,CHEMBL629804,178.0,
11949,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL629805,178.0,
11950,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,50597,N,,CHEMBL629806,178.0,
11951,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL629807,178.0,
11952,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL629808,178.0,
11953,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,N,,CHEMBL629809,955.0,
11954,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL629810,955.0,
11955,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,50597,N,,CHEMBL629811,955.0,
11956,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL629812,955.0,
11957,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,50597,N,,CHEMBL629813,955.0,
11958,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL874460,955.0,
11959,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,N,,CHEMBL629814,,
11960,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL629815,,
11961,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL629816,,
11962,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL629817,,
11963,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,N,,CHEMBL626643,2113.0,
11964,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL626644,2113.0,
11965,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL626806,2113.0,
11966,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL626807,2113.0,
11967,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627261,2107.0,
11968,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627262,2107.0,
11969,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627263,2107.0,
11970,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627264,2107.0,
11971,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627265,2048.0,
11972,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627266,2048.0,
11973,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627267,2048.0,
11974,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627268,2048.0,
11975,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627269,2385.0,
11976,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627270,2385.0,
11977,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",50597,N,,CHEMBL627271,,
11978,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",50597,N,,CHEMBL627946,,
11979,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",50597,N,,CHEMBL875472,,
11980,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",50597,N,,CHEMBL627947,,
11981,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",50597,N,,CHEMBL627948,,
11982,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",50597,N,,CHEMBL628113,,
11983,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",50597,N,,CHEMBL628114,,
11984,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",50597,N,,CHEMBL628115,,
11985,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",50597,N,,CHEMBL628116,,
11986,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",50597,N,,CHEMBL628117,,
11987,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",50597,N,,CHEMBL628118,,
11988,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",50597,N,,CHEMBL628119,,
11989,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",50597,N,,CHEMBL628120,,
11990,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",50597,N,,CHEMBL628121,,
11991,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",50597,N,,CHEMBL628122,,
11992,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",50597,N,,CHEMBL627297,,
11993,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",50597,N,,CHEMBL627298,,
11994,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",50597,N,,CHEMBL627299,,
11995,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",50597,N,,CHEMBL627300,,
11996,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",50597,N,,CHEMBL627301,,
11997,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",50597,N,,CHEMBL627302,,
11998,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",50597,N,,CHEMBL627303,,
11999,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",50597,N,,CHEMBL627304,,
12000,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",50597,N,,CHEMBL627305,,
12001,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",50597,N,,CHEMBL627306,,
12002,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",50597,N,,CHEMBL623982,,
12003,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",50597,N,,CHEMBL623983,,
12004,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",50597,N,,CHEMBL623984,,
12005,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",50597,N,,CHEMBL623985,,
12006,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",50597,N,,CHEMBL623986,,
12007,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",50597,N,,CHEMBL623987,,
12008,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",50597,N,,CHEMBL623988,,
12009,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",50597,N,,CHEMBL623989,,
12010,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",50597,N,,CHEMBL622215,,
12011,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",50597,N,,CHEMBL622216,,
12012,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",50597,N,,CHEMBL877481,,
12013,,,BAO_0000218,,1,A,Autocuration,,0,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),22224,U,,CHEMBL622217,,
12014,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),50594,N,,CHEMBL622218,,
12015,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic profile AUC was evaluated in rats,50597,N,,CHEMBL622219,,
12016,,,BAO_0000019,,1,A,Autocuration,,0,Pharmacokinetic property (Area under curve),22224,U,,CHEMBL622220,,
12017,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",50588,N,,CHEMBL622221,,
12018,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",50594,N,,CHEMBL622222,,
12019,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",50588,N,,CHEMBL622223,,
12020,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",50594,N,,CHEMBL622224,,
12021,,,BAO_0000019,,1,A,Autocuration,,0,Plasma concentration (AUC) was determined,22224,U,,CHEMBL622225,,
12022,,,BAO_0000019,,1,A,Autocuration,,0,Plasma concentration (AUC) was determined; Not detectable,22224,U,,CHEMBL622226,,
12023,,Cavia porcellus,BAO_0000218,,1,A,Intermediate,,1,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),50512,N,,CHEMBL624154,,
12024,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,50597,N,,CHEMBL624155,,
12025,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,50597,N,,CHEMBL624156,,
12026,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,50597,N,,CHEMBL624157,,
12027,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,50597,N,,CHEMBL624158,,
12028,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,50597,N,,CHEMBL624159,,
12029,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,50597,N,,CHEMBL624160,,
12030,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,50597,N,,CHEMBL624161,,
12031,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,50597,N,,CHEMBL624162,,
12032,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,50588,N,,CHEMBL624163,,
12033,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",50597,N,,CHEMBL624164,,
12034,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The AUC(0-infinity) values in female wistar rats.,50597,N,,CHEMBL624165,,
12035,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",50597,N,,CHEMBL624166,,
12036,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",50597,N,,CHEMBL624167,,
12037,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The AUC(0-t)values in female wistar rats.,50597,N,,CHEMBL624168,,
12038,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The Area under the concentration time curve of compound was measured on rats,50597,N,,CHEMBL624169,,
12039,,Homo sapiens,BAO_0000218,,1,A,Intermediate,,1,The area under curve (100 mg/kg) administered orally in humans,50587,N,,CHEMBL624170,,
12040,,Callithrix,BAO_0000218,,1,A,Autocuration,,0,The area under curve (12.5 mg/kg) administered intravenously in marmoset,22224,U,,CHEMBL624171,,
12041,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,The area under curve (12.5 mg/kg) administered intravenously in monkey,22224,U,,CHEMBL624172,,
12042,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,The area under curve (15 mg/kg) administered intravenously in dog,50588,N,,CHEMBL624173,,
12043,,Homo sapiens,BAO_0000218,,1,A,Intermediate,,1,The area under curve (200 mg/kg) administered orally in humans,50587,N,,CHEMBL877488,,
12044,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The area under curve (25 mg/kg) administered intravenously in rat,50597,N,,CHEMBL624174,,
12045,,Callithrix,BAO_0000218,,1,A,Autocuration,,0,The area under curve (25 mg/kg) administered orally in marmoset,22224,U,,CHEMBL624175,,
12046,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,The area under curve (25 mg/kg) administered orally in monkey,22224,U,,CHEMBL624176,,
12047,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,The area under curve (30 mg/kg) administered orally in dog,50588,N,,CHEMBL624177,,
12048,,Homo sapiens,BAO_0000218,,1,A,Intermediate,,1,The area under curve (400 mg/kg) administered orally in humans,50587,N,,CHEMBL624178,,
12049,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The area under curve (50 mg/kg) administered orally in fasted rat,50597,N,,CHEMBL624179,,
12050,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The area under curve (50 mg/kg) administered orally in rat,50597,N,,CHEMBL627689,,
12051,,Homo sapiens,BAO_0000218,,1,A,Intermediate,,1,The area under curve (800 mg/kg) administered orally in humans,50587,N,,CHEMBL627690,,
12052,,,BAO_0000019,,1,A,Autocuration,,0,The compound was evaluated for area under the curve,22224,U,,CHEMBL627691,,
12053,,Callithrix,BAO_0000019,,1,A,Autocuration,,0,The compound was evaluated for area under the curve in marmosets,22224,U,,CHEMBL627692,,
12054,,Callithrix,BAO_0000019,,1,A,Autocuration,,0,The compound was evaluated for area under the curve in marmosets,22224,U,,CHEMBL627693,,
12055,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,50597,N,,CHEMBL627694,,
12056,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,50597,N,,CHEMBL627695,,
12057,,,BAO_0000218,,1,A,Autocuration,,0,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),22224,U,,CHEMBL627696,,
12058,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,50597,N,,CHEMBL627697,,
12059,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,50597,N,,CHEMBL627698,,
12060,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,50597,N,,CHEMBL627699,,
12061,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,50597,N,,CHEMBL627700,,
12062,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total drug exposure is determined after oral dosing in rats.,50597,N,,CHEMBL627701,,
12063,,,BAO_0000218,,1,A,Autocuration,,0,Total drug exposure (5 mg/kg) when administered intravenously,22224,U,,CHEMBL627702,,
12064,,,BAO_0000218,,1,A,Autocuration,,0,Total drug exposure (5 mg/kg) when administered orally,22224,U,,CHEMBL627703,,
12065,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,22224,U,,CHEMBL626873,,
12066,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,50597,N,,CHEMBL629583,,
12067,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,50588,N,,CHEMBL629584,,
12068,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,50588,N,,CHEMBL629585,,
12069,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,N,,CHEMBL629586,955.0,
12070,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,N,,CHEMBL629587,955.0,
12071,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,N,,CHEMBL629588,,
12072,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,N,,CHEMBL629589,,
12073,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,N,,CHEMBL629590,,
12074,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,N,,CHEMBL629591,,
12075,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,N,,CHEMBL629592,,
12076,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,N,,CHEMBL629593,,
12077,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,N,,CHEMBL629594,,
12078,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,N,,CHEMBL629595,948.0,
12079,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,N,,CHEMBL630290,948.0,
12080,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,N,,CHEMBL627137,948.0,
12081,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,N,,CHEMBL627138,948.0,
12082,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,N,,CHEMBL627139,948.0,
12083,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,N,,CHEMBL627140,948.0,
12084,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,N,,CHEMBL627141,948.0,
12085,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,N,,CHEMBL627142,2113.0,
12086,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,N,,CHEMBL627143,2113.0,
12087,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,N,,CHEMBL874449,2113.0,
12088,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,N,,CHEMBL627144,2113.0,
12089,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,N,,CHEMBL627145,2113.0,
12090,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,N,,CHEMBL627146,2113.0,
12091,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,N,,CHEMBL627147,2113.0,
12092,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,N,,CHEMBL627148,2107.0,
12093,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,N,,CHEMBL627149,2048.0,
12094,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,N,,CHEMBL632160,2048.0,
12095,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,N,,CHEMBL632161,2048.0,
12096,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,N,,CHEMBL632162,2048.0,
12097,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,N,,CHEMBL632163,2048.0,
12098,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,N,,CHEMBL874469,2048.0,
12099,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,N,,CHEMBL627182,2048.0,
12100,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,N,,CHEMBL627183,2385.0,
12101,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,N,,CHEMBL627184,2385.0,
12102,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,N,,CHEMBL627185,2385.0,
12103,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,N,,CHEMBL627186,2385.0,
12104,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,N,,CHEMBL627187,2385.0,
12105,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,N,,CHEMBL627188,2385.0,
12106,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,N,,CHEMBL627189,2385.0,
12107,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,N,,CHEMBL627190,,
12108,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,N,,CHEMBL627191,2107.0,
12109,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,N,,CHEMBL627192,2107.0,
12110,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,N,,CHEMBL627193,2107.0,
12111,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,50597,N,,CHEMBL874590,2385.0,
12112,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627194,2385.0,
12113,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627195,2385.0,
12114,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627196,992.0,
12115,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627197,992.0,
12116,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627198,992.0,
12117,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,50597,N,,CHEMBL627199,992.0,
12118,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627200,992.0,
12119,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627201,1969.0,
12120,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627202,1969.0,
12121,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627203,1969.0,
12122,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627204,1969.0,
12123,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627205,2106.0,
12124,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627206,2106.0,
12125,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627207,2106.0,
12126,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627208,2106.0,
12127,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627209,2046.0,
12128,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627210,2046.0,
12129,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627211,2046.0,
12130,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627212,2046.0,
12131,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,N,,CHEMBL627213,995.0,
12132,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL626599,995.0,
12133,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL626600,995.0,
12134,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,N,,CHEMBL626601,995.0,
12135,,,BAO_0000019,,1,A,Autocuration,,0,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,22224,U,,CHEMBL627484,,
12136,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),100710,N,,CHEMBL627485,1969.0,
12137,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,100710,N,,CHEMBL628147,1969.0,
12138,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,100710,N,,CHEMBL628148,1969.0,
12139,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),50588,N,,CHEMBL628149,1969.0,
12140,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,50588,N,,CHEMBL628150,1969.0,
12141,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,50588,N,,CHEMBL628318,1969.0,
12142,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,50588,N,,CHEMBL628319,1969.0,
12143,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",50588,N,,CHEMBL875609,,
12144,,,BAO_0000019,,1,A,Autocuration,,0,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,22224,U,,CHEMBL628320,,
12145,,,BAO_0000019,,1,A,Autocuration,,0,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,22224,U,,CHEMBL628321,,
12146,,,BAO_0000019,,1,A,Autocuration,,0,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,22224,U,,CHEMBL628322,,
12147,,,BAO_0000019,,1,A,Autocuration,,0,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,22224,U,,CHEMBL628323,,
12148,,,BAO_0000019,,1,A,Autocuration,,0,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,22224,U,,CHEMBL628324,,
12149,,,BAO_0000019,,1,A,Autocuration,,0,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,22224,U,,CHEMBL628325,,
12150,,,BAO_0000019,,1,A,Autocuration,,0,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,22224,U,,CHEMBL628326,,
12151,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",50588,N,,CHEMBL628327,1236.0,
12152,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",50588,N,,CHEMBL628328,1236.0,
12153,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in blood of dog 1, after administering intravenously",50588,N,,CHEMBL628329,178.0,
12154,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",50597,N,,CHEMBL628330,2107.0,
12155,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",50597,N,,CHEMBL628331,2107.0,
12156,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",50597,N,,CHEMBL628332,2107.0,
12157,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",50597,N,,CHEMBL628333,2107.0,
12158,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",50597,N,,CHEMBL628334,2107.0,
12159,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",50597,N,,CHEMBL628335,2107.0,
12160,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",50597,N,,CHEMBL628336,2107.0,
12161,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",50597,N,,CHEMBL628337,2107.0,
12162,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",50597,N,,CHEMBL628338,2107.0,
12163,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",50597,N,,CHEMBL875610,2107.0,
12164,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",50597,N,,CHEMBL628339,2107.0,
12165,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",50597,N,,CHEMBL628340,2107.0,
12166,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",50597,N,,CHEMBL628341,2107.0,
12167,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",50597,N,,CHEMBL622214,2107.0,
12168,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",50597,N,,CHEMBL623167,2107.0,
12169,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",50597,N,,CHEMBL623168,2107.0,
12170,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",50597,N,,CHEMBL623169,2107.0,
12171,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",50597,N,,CHEMBL623170,2107.0,
12172,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",50597,N,,CHEMBL627224,2048.0,
12173,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",50597,N,,CHEMBL875634,2048.0,
12174,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",50597,N,,CHEMBL627225,2048.0,
12175,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",50597,N,,CHEMBL627226,2048.0,
12176,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",50597,N,,CHEMBL626083,2048.0,
12177,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",50597,N,,CHEMBL626084,2048.0,
12178,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",50597,N,,CHEMBL626085,2048.0,
12179,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",50597,N,,CHEMBL626086,2048.0,
12180,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",50597,N,,CHEMBL626087,2048.0,
12181,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",50597,N,,CHEMBL626088,2048.0,
12182,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",50597,N,,CHEMBL626089,2048.0,
12183,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",50597,N,,CHEMBL626090,2048.0,
12184,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",50597,N,,CHEMBL626091,2048.0,
12185,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",50597,N,,CHEMBL626092,2048.0,
12186,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",50597,N,,CHEMBL626093,2048.0,
12187,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",50597,N,,CHEMBL626094,2048.0,
12188,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",50597,N,,CHEMBL626095,2048.0,
12189,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",50597,N,,CHEMBL626096,2048.0,
12190,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,22224,U,,CHEMBL626097,,
12191,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,50597,N,,CHEMBL626098,,
12192,,,BAO_0000218,,1,A,Autocuration,,0,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,22224,U,,CHEMBL626099,1969.0,
12193,,,BAO_0000218,,1,A,Autocuration,,0,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,22224,U,,CHEMBL626100,1969.0,
12194,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,AUC 0-inf in dog,50588,N,,CHEMBL626101,1969.0,
12195,,Cavia porcellus,BAO_0000218,,1,A,Intermediate,,1,AUC 0-inf in guinea pig,50512,N,,CHEMBL626102,1969.0,
12196,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,AUC 0-t in dog,50588,N,,CHEMBL626103,1969.0,
12197,,Cavia porcellus,BAO_0000218,,1,A,Intermediate,,1,AUC 0-t in guinea pig,50512,N,,CHEMBL628391,1969.0,
12198,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The compound was tested for brain to plasma partition in rat,50597,N,,CHEMBL628392,,
12199,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The compound was tested for brain to plasma partition in rat.,50597,N,,CHEMBL628393,,
12200,,,BAO_0000019,,1,A,Autocuration,,0,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,22224,U,,CHEMBL628394,178.0,
12201,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,50588,N,,CHEMBL628395,,
12202,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,22224,U,,CHEMBL628396,,
12203,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,50592,N,,CHEMBL628397,,
12204,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,50597,N,,CHEMBL628398,,
12205,,Macaca mulatta,BAO_0000218,,1,A,Intermediate,,1,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,50797,N,,CHEMBL628399,,
12206,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,50588,N,,CHEMBL628400,,
12207,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,50597,N,,CHEMBL874907,,
12208,,,BAO_0000019,,1,A,Autocuration,,0,Area under curve of the compound was determined,22224,U,,CHEMBL628401,,
12209,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,AUC in monkeys at a dose of 1 mg/kg,22224,U,,CHEMBL628402,1969.0,
12210,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,AUC in rats at a dose of 1 mg/kg,50597,N,,CHEMBL628403,1969.0,
12211,,,BAO_0000019,,1,A,Autocuration,,0,Compound was evaluated for the overall absorbance loss at pH of 2,22224,U,,CHEMBL628404,,
12212,,,BAO_0000019,,1,A,Autocuration,,0,Compound was evaluated for the overall absorbance loss at pH of 4,22224,U,,CHEMBL628405,,
12213,,,BAO_0000019,,1,A,Autocuration,,0,Compound was evaluated for the overall absorbance loss at pH of 7,22224,U,,CHEMBL628406,,
12214,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for its absorption in the rats,50597,N,,CHEMBL628407,,
12215,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,50597,N,,CHEMBL628408,1088.0,
12216,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,50597,N,,CHEMBL629171,1088.0,
12217,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,50597,N,,CHEMBL629172,1088.0,
12218,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,50597,N,,CHEMBL629173,1088.0,
12219,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro percent permeability into rat ileum,50597,N,,CHEMBL629174,,
12220,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro percent permeability into rat ileum; Range is 10-17,50597,N,,CHEMBL629175,,
12221,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro percent permeability into rat ileum; Range is 10-18,50597,N,,CHEMBL629176,,
12222,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro percent permeability into rat ileum; Range is 10-19,50597,N,,CHEMBL629177,,
12223,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro percent permeability into rat ileum; Range is 12-15,50597,N,,CHEMBL629178,,
12224,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro percent permeability into rat ileum; Range is 13-19,50597,N,,CHEMBL631869,,
12225,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro percent permeability into rat ileum; Range is 14-17,50597,N,,CHEMBL631870,,
12226,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro percent permeability into rat ileum; Range is 15-18,50597,N,,CHEMBL631871,,
12227,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro percent permeability into rat ileum; Range is 2-5,50597,N,,CHEMBL631872,,
12228,,,BAO_0000221,,1,A,Autocuration,,0,In vitro percent permeability into rat ileum; Range is 23-42,22224,U,,CHEMBL875775,2116.0,
12229,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro percent permeability into rat ileum; Range is 28-36,50597,N,,CHEMBL631873,,
12230,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro percent permeability into rat ileum; Range is 29-35,50597,N,,CHEMBL631874,,
12231,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro percent permeability into rat ileum; Range is 46-66,50597,N,,CHEMBL631875,,
12232,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro percent permeability into rat ileum; Range is 50-68,50597,N,,CHEMBL631876,,
12233,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro percent permeability into rat ileum; Range is 78-81,50597,N,,CHEMBL631877,,
12234,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,50597,N,,CHEMBL631878,,
12235,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro percent permeability into rat ileum; nd indicates not detected,50597,N,,CHEMBL631879,,
12236,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro percent permeability into rat ileum; nt indicates not detected,50597,N,,CHEMBL631880,,
12237,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro percent permeability into rat ileum; nt indicates not tested,50597,N,,CHEMBL631881,,
12238,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for oral absorption in bile-duct cannulated rats,50597,N,,CHEMBL631882,,
12239,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for oral absorption in bile-duct cannulated rats.,50597,N,,CHEMBL630749,,
12240,,Homo sapiens,BAO_0000218,,1,A,Intermediate,,1,Oral absorption using Caco-2 cell monolayers.,50587,N,,CHEMBL630750,,
12241,,Homo sapiens,BAO_0000218,,1,A,Intermediate,,1,Percent of the drug absorbed after administration to humans was determined,50587,N,,CHEMBL630253,,
12242,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,50597,N,,CHEMBL630254,1969.0,
12243,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,50597,N,,CHEMBL630255,1969.0,
12244,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,50597,N,,CHEMBL630256,1969.0,
12245,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,N,,CHEMBL875781,2107.0,
12246,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,N,,CHEMBL630257,2107.0,
12247,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,N,,CHEMBL630258,2107.0,
12248,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",50597,N,,CHEMBL630259,,
12249,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",50597,N,,CHEMBL630260,2435.0,
12250,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",50597,N,,CHEMBL630261,2435.0,
12251,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,50597,N,,CHEMBL630262,,
12252,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,50597,N,,CHEMBL630263,,
12253,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,50597,N,,CHEMBL630264,,
12254,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,50597,N,,CHEMBL630265,,
12255,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,50597,N,,CHEMBL630266,,
12256,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,50597,N,,CHEMBL630267,2113.0,
12257,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,50597,N,,CHEMBL630268,2113.0,
12258,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,50597,N,,CHEMBL630269,,
12259,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,50597,N,,CHEMBL630270,,
12260,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,50597,N,,CHEMBL630141,2048.0,
12261,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,50597,N,,CHEMBL630142,2048.0,
12262,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,50597,N,,CHEMBL630143,2385.0,
12263,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,50597,N,,CHEMBL630144,2385.0,
12264,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,50597,N,,CHEMBL630145,2367.0,
12265,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,50597,N,,CHEMBL630146,2367.0,
12266,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,50597,N,,CHEMBL630147,,
12267,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,50597,N,,CHEMBL630148,,
12268,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,50597,N,,CHEMBL630149,,
12269,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,50597,N,,CHEMBL630150,2106.0,
12270,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,50597,N,,CHEMBL630151,2106.0,
12271,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,50597,N,,CHEMBL632031,2046.0,
12272,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,50597,N,,CHEMBL632032,2046.0,
12273,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,50597,N,,CHEMBL632033,,
12274,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,50597,N,,CHEMBL632034,,
12275,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,50597,N,,CHEMBL632035,2385.0,
12276,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,50597,N,,CHEMBL632036,,
12277,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,50597,N,,CHEMBL632037,2046.0,
12278,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,50597,N,,CHEMBL632038,178.0,
12279,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,50597,N,,CHEMBL632039,178.0,
12280,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,50597,N,,CHEMBL632040,178.0,
12281,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,50597,N,,CHEMBL632041,178.0,
12282,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in blood of dog 2, after administering intravenously",50588,N,,CHEMBL632042,178.0,
12283,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in left ventricle of dog 1, after administering intravenously",50588,N,,CHEMBL632043,,
12284,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in left ventricle of dog 2, after administering intravenously",50588,N,,CHEMBL632044,,
12285,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in liver of dog 1, after administering intravenously",50588,N,,CHEMBL632045,2107.0,
12286,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in liver of dog 2, after administering intravenously",50588,N,,CHEMBL632046,2107.0,
12287,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in lung of dog 1, after administering intravenously",50588,N,,CHEMBL632047,2048.0,
12288,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in lung of dog 2, after administering intravenously",50588,N,,CHEMBL632048,2048.0,
12289,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in muscle of dog 1, after administering intravenously",50588,N,,CHEMBL632049,2385.0,
12290,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in muscle of dog 2, after administering intravenously",50588,N,,CHEMBL876418,2385.0,
12291,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in spleen of dog 1,after administering intravenously",50588,N,,CHEMBL632050,2106.0,
12292,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Concentration of compound in spleen of dog 2, after administering intravenously",50588,N,,CHEMBL632051,2106.0,
12293,,,BAO_0000218,,1,F,Autocuration,,0,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,22224,U,,CHEMBL632052,,
12294,,,BAO_0000218,,1,F,Autocuration,,0,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,22224,U,,CHEMBL632053,,
12295,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,22224,U,,CHEMBL632054,,
12296,,,BAO_0000218,,1,F,Autocuration,,0,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,22224,U,,CHEMBL632055,,
12297,,,BAO_0000218,,1,F,Autocuration,,0,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,22224,U,,CHEMBL631181,,
12298,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,22224,U,,CHEMBL631182,,
12299,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,22224,U,,CHEMBL631183,,
12300,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,22224,U,,CHEMBL631184,,
12301,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,22224,U,,CHEMBL629774,,
12302,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,22224,U,,CHEMBL629775,,
12303,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,22224,U,,CHEMBL876549,,
12304,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,22224,U,,CHEMBL628172,,
12305,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,22224,U,,CHEMBL628173,,
12306,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,22224,U,,CHEMBL628174,,
12307,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,22224,U,,CHEMBL628175,,
12308,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,22224,U,,CHEMBL628176,,
12309,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,22224,U,,CHEMBL628177,,
12310,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,22224,U,,CHEMBL628178,,
12311,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,22224,U,,CHEMBL628179,,
12312,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,22224,U,,CHEMBL628180,,
12313,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,22224,U,,CHEMBL628181,,
12314,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,22224,U,,CHEMBL628182,,
12315,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,22224,U,,CHEMBL628183,,
12316,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,22224,U,,CHEMBL628184,,
12317,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,22224,U,,CHEMBL628185,,
12318,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,22224,U,,CHEMBL875617,,
12319,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,22224,U,,CHEMBL628186,,
12320,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,22224,U,,CHEMBL628187,,
12321,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,22224,U,,CHEMBL628188,,
12322,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,22224,U,,CHEMBL628189,,
12323,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,22224,U,,CHEMBL628190,,
12324,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,22224,U,,CHEMBL628191,,
12325,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,22224,U,,CHEMBL626513,,
12326,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",50597,N,,CHEMBL626514,2046.0,
12327,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",50597,N,,CHEMBL626515,2046.0,
12328,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",50597,N,,CHEMBL626516,2046.0,
12329,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",50597,N,,CHEMBL626517,2046.0,
12330,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",50597,N,,CHEMBL626518,2046.0,
12331,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",50597,N,,CHEMBL626519,2046.0,
12332,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",50597,N,,CHEMBL626520,2046.0,
12333,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",50597,N,,CHEMBL626521,2046.0,
12334,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",50597,N,,CHEMBL626522,2046.0,
12335,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",50597,N,,CHEMBL626523,2046.0,
12336,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",50597,N,,CHEMBL626524,2046.0,
12337,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",50597,N,,CHEMBL626688,2046.0,
12338,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",50597,N,,CHEMBL626689,2046.0,
12339,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",50597,N,,CHEMBL626690,2046.0,
12340,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",50597,N,,CHEMBL626691,2046.0,
12341,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",50597,N,,CHEMBL627319,2046.0,
12342,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",50597,N,,CHEMBL624052,2046.0,
12343,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",50597,N,,CHEMBL624053,2046.0,
12344,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,N,,CHEMBL624054,,
12345,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,N,,CHEMBL624055,,
12346,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,N,,CHEMBL624056,,
12347,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,N,,CHEMBL624057,995.0,
12348,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,N,,CHEMBL622281,995.0,
12349,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,N,,CHEMBL622282,995.0,
12350,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,N,,CHEMBL622283,995.0,
12351,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,N,,CHEMBL622284,995.0,
12352,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,N,,CHEMBL622285,995.0,
12353,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,N,,CHEMBL622286,995.0,
12354,,,BAO_0000100,,1,P,Autocuration,,0,Distribution coefficient (D %) between octanol and buffer of pH 7.4,22224,U,,CHEMBL622287,,
12355,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Partition coefficient (logD7.4),50594,N,,CHEMBL622288,,
12356,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",50594,N,,CHEMBL622289,,
12357,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",50594,N,,CHEMBL622290,955.0,
12358,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,50594,N,,CHEMBL622291,,
12359,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,50594,N,,CHEMBL622292,955.0,
12360,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",50594,N,,CHEMBL622293,,
12361,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",50594,N,,CHEMBL622294,955.0,
12362,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,50594,N,,CHEMBL622295,,
12363,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,50597,N,,CHEMBL622296,955.0,
12364,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,50597,N,,CHEMBL874409,1969.0,
12365,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,50597,N,,CHEMBL622297,1969.0,
12366,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,50597,N,,CHEMBL622298,1969.0,
12367,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,50597,N,,CHEMBL622299,1969.0,
12368,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,50597,N,,CHEMBL622300,1969.0,
12369,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,50597,N,,CHEMBL622301,1969.0,
12370,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,50597,N,,CHEMBL622302,1969.0,
12371,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,50597,N,,CHEMBL622303,1969.0,
12372,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,50597,N,,CHEMBL622304,1969.0,
12373,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,50597,N,,CHEMBL622305,1969.0,
12374,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,50597,N,,CHEMBL622306,1969.0,
12375,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,50597,N,,CHEMBL626864,1969.0,
12376,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,50597,N,,CHEMBL626865,1969.0,
12377,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,50597,N,,CHEMBL626866,1969.0,
12378,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,50597,N,,CHEMBL626867,1969.0,
12379,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,50597,N,,CHEMBL626868,1969.0,
12380,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,50597,N,,CHEMBL626869,1969.0,
12381,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,50597,N,,CHEMBL626870,1969.0,
12382,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,50597,N,,CHEMBL626871,1969.0,
12383,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,50597,N,,CHEMBL626872,1969.0,
12384,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,50597,N,,CHEMBL632185,1969.0,
12385,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,50597,N,,CHEMBL632186,1969.0,
12386,,,BAO_0000019,,1,A,Autocuration,,0,Amount of acetic acid produced by the compound,22224,U,,CHEMBL629310,,
12387,,,BAO_0000019,,1,A,Autocuration,,0,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,22224,U,,CHEMBL629311,,
12388,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Log of (Cbrain/Cblood) in rats,50597,N,,CHEMBL629312,,
12389,,,BAO_0000221,,1,A,Autocuration,,0,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),22224,U,,CHEMBL629313,,
12390,,,BAO_0000221,,1,A,Autocuration,,0,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),22224,U,,CHEMBL629314,,
12391,,,BAO_0000221,,1,A,Autocuration,,0,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),22224,U,,CHEMBL629315,,
12392,,,BAO_0000219,,1,B,Autocuration,,0,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),22224,U,,CHEMBL629316,,
12393,,,BAO_0000221,,1,A,Autocuration,,0,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),22224,U,,CHEMBL629317,,
12394,,,BAO_0000019,,1,A,Autocuration,,0,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),22224,U,,CHEMBL629318,,
12395,,,BAO_0000019,,1,A,Autocuration,,0,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),22224,U,,CHEMBL877497,,
12396,,,BAO_0000019,,1,A,Autocuration,,0,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),22224,U,,CHEMBL629319,,
12397,,,BAO_0000019,,1,A,Autocuration,,0,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),22224,U,,CHEMBL629320,,
12398,,,BAO_0000019,,1,A,Autocuration,,0,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),22224,U,,CHEMBL629496,,
12399,,,BAO_0000019,,1,A,Autocuration,,0,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),22224,U,,CHEMBL629497,,
12400,,,BAO_0000019,,1,A,Autocuration,,0,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),22224,U,,CHEMBL629498,,
12401,,,BAO_0000019,,1,A,Autocuration,,0,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),22224,U,,CHEMBL629499,,
12402,,,BAO_0000019,,1,A,Autocuration,,0,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),22224,U,,CHEMBL629500,,
12403,,,BAO_0000019,,1,A,Autocuration,,0,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),22224,U,,CHEMBL629501,,
12404,,,BAO_0000019,,1,A,Autocuration,,0,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),22224,U,,CHEMBL629502,,
12405,,,BAO_0000218,,1,F,Autocuration,In vivo,0,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,22224,U,,CHEMBL629503,,
12406,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,50588,N,,CHEMBL629504,,
12407,,,BAO_0000019,,1,A,Autocuration,,0,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,22224,U,,CHEMBL629505,,
12408,,,BAO_0000019,,1,A,Autocuration,,0,Compound was evaluated for total body clearance,22224,U,,CHEMBL629506,,
12409,,,BAO_0000019,,1,A,Autocuration,,0,Compound was evaluated for volume of distribution at steady state,22224,U,,CHEMBL629507,,
12410,,,BAO_0000019,,1,A,Autocuration,,0,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,22224,U,,CHEMBL877498,,
12411,,,BAO_0000019,,1,A,Autocuration,,0,Percentage of the diamine which is monoprotonated at pH 7.4,22224,U,,CHEMBL629508,,
12412,,,BAO_0000019,,1,A,Autocuration,,0,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,22224,U,,CHEMBL629509,,
12413,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,50597,N,,CHEMBL629510,178.0,
12414,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,50597,N,,CHEMBL629511,178.0,
12415,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,50597,N,,CHEMBL629512,178.0,
12416,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,50597,N,,CHEMBL629513,178.0,
12417,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,50597,N,,CHEMBL629514,178.0,
12418,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,50597,N,,CHEMBL628447,178.0,
12419,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,50597,N,,CHEMBL628448,178.0,
12420,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,50597,N,,CHEMBL628449,178.0,
12421,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,50597,N,,CHEMBL631119,178.0,
12422,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,50597,N,,CHEMBL631120,178.0,
12423,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,50597,N,,CHEMBL631121,178.0,
12424,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,50597,N,,CHEMBL874458,178.0,
12425,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,50597,N,,CHEMBL631122,178.0,
12426,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,50597,N,,CHEMBL631123,178.0,
12427,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,50597,N,,CHEMBL631124,178.0,
12428,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,50597,N,,CHEMBL631125,178.0,
12429,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,50597,N,,CHEMBL631290,178.0,
12430,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,50597,N,,CHEMBL631291,178.0,
12431,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,50597,N,,CHEMBL631292,178.0,
12432,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,50597,N,,CHEMBL631293,178.0,
12433,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,50597,N,,CHEMBL631294,178.0,
12434,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,50597,N,,CHEMBL631295,178.0,
12435,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,50597,N,,CHEMBL631296,178.0,
12436,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,50597,N,,CHEMBL631297,178.0,
12437,,,BAO_0000218,,1,A,Autocuration,,0,Maximum biodistribution (Bmax) was determined.,22224,U,,CHEMBL631298,,
12438,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,50594,N,,CHEMBL631299,,
12439,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,50594,N,,CHEMBL631300,,
12440,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,50594,N,,CHEMBL631301,,
12441,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,50594,N,,CHEMBL630291,,
12442,,,BAO_0000218,,1,A,Autocuration,,0,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,22224,U,,CHEMBL630292,,
12443,,,BAO_0000218,,1,A,Autocuration,,0,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,22224,U,,CHEMBL630293,,
12444,,,BAO_0000218,,1,A,Autocuration,,0,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,22224,U,,CHEMBL630294,,
12445,,,BAO_0000218,,1,A,Autocuration,,0,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,22224,U,,CHEMBL630295,,
12446,,,BAO_0000218,,1,A,Autocuration,,0,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,22224,U,,CHEMBL630296,,
12447,,,BAO_0000218,,1,A,Autocuration,,0,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,22224,U,,CHEMBL626782,,
12448,,,BAO_0000218,,1,A,Autocuration,,0,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,22224,U,,CHEMBL626783,,
12449,,,BAO_0000218,,1,A,Autocuration,,0,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,22224,U,,CHEMBL626784,,
12450,,,BAO_0000218,,1,A,Autocuration,,0,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,22224,U,,CHEMBL626785,,
12451,,,BAO_0000218,,1,A,Autocuration,,0,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,22224,U,,CHEMBL626786,,
12452,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,22224,U,,CHEMBL626787,,
12453,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,22224,U,,CHEMBL626788,,
12454,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,22224,U,,CHEMBL625927,,
12455,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,N,,CHEMBL625928,178.0,
12456,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,50597,N,,CHEMBL625929,178.0,
12457,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,50597,N,,CHEMBL625930,178.0,
12458,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",50597,N,,CHEMBL625931,178.0,
12459,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,50597,N,,CHEMBL627230,178.0,
12460,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,N,,CHEMBL627231,178.0,
12461,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,50597,N,,CHEMBL627232,178.0,
12462,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,50597,N,,CHEMBL627233,178.0,
12463,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,N,,CHEMBL875470,178.0,
12464,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,N,,CHEMBL627234,178.0,
12465,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,N,,CHEMBL627235,178.0,
12466,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,N,,CHEMBL627236,178.0,
12467,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,N,,CHEMBL627237,178.0,
12468,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,N,,CHEMBL627238,178.0,
12469,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,N,,CHEMBL627239,178.0,
12470,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,N,,CHEMBL627240,178.0,
12471,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,N,,CHEMBL627241,178.0,
12472,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,N,,CHEMBL627242,178.0,
12473,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,50597,N,,CHEMBL627243,178.0,
12474,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,50597,N,,CHEMBL627244,178.0,
12475,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,N,,CHEMBL627245,178.0,
12476,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,N,,CHEMBL627246,178.0,
12477,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,N,,CHEMBL627247,178.0,
12478,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,N,,CHEMBL627248,178.0,
12479,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,N,,CHEMBL627249,178.0,
12480,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,N,,CHEMBL625569,178.0,
12481,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,N,,CHEMBL625570,178.0,
12482,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,N,,CHEMBL625571,178.0,
12483,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,50597,N,,CHEMBL625572,178.0,
12484,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,50597,N,,CHEMBL625573,178.0,
12485,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,50597,N,,CHEMBL625574,178.0,
12486,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,50597,N,,CHEMBL626245,178.0,
12487,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,N,,CHEMBL626246,178.0,
12488,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,22224,U,,CHEMBL626247,,
12489,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,22224,U,,CHEMBL626248,,
12490,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,22224,U,,CHEMBL626249,,
12491,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,22224,U,,CHEMBL626420,,
12492,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,22224,U,,CHEMBL626421,,
12493,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,22224,U,,CHEMBL626422,,
12494,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,22224,U,,CHEMBL626423,,
12495,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,22224,U,,CHEMBL626424,,
12496,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,50588,N,,CHEMBL626425,,
12497,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,50597,N,,CHEMBL875476,,
12498,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,100710,N,,CHEMBL626426,,
12499,,,BAO_0000100,,1,P,Autocuration,,0,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,22224,U,,CHEMBL626427,,
12500,,,BAO_0000100,,1,P,Autocuration,,0,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,22224,U,,CHEMBL626428,,
12501,,,BAO_0000019,,1,A,Autocuration,,0,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,22224,U,,CHEMBL626429,,
12502,,,BAO_0000019,,1,A,Autocuration,,0,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,22224,U,,CHEMBL625025,1088.0,
12503,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,50597,N,,CHEMBL625026,178.0,
12504,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,50597,N,,CHEMBL625027,178.0,
12505,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,50597,N,,CHEMBL874410,178.0,
12506,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,50597,N,,CHEMBL625028,178.0,
12507,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,50597,N,,CHEMBL625029,178.0,
12508,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,50597,N,,CHEMBL625030,178.0,
12509,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,N,,CHEMBL625031,178.0,
12510,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,50597,N,,CHEMBL625032,178.0,
12511,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,50597,N,,CHEMBL625033,178.0,
12512,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,50597,N,,CHEMBL625034,178.0,
12513,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,50597,N,,CHEMBL624872,948.0,
12514,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL624873,948.0,
12515,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,50597,N,,CHEMBL624874,948.0,
12516,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,50597,N,,CHEMBL624875,948.0,
12517,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,50597,N,,CHEMBL624876,948.0,
12518,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,50597,N,,CHEMBL624877,948.0,
12519,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,50597,N,,CHEMBL624878,948.0,
12520,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,50597,N,,CHEMBL624879,948.0,
12521,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,N,,CHEMBL624880,948.0,
12522,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,50597,N,,CHEMBL624881,948.0,
12523,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",50597,N,,CHEMBL624882,948.0,
12524,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,50597,N,,CHEMBL624883,2113.0,
12525,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,50597,N,,CHEMBL624884,2113.0,
12526,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,50597,N,,CHEMBL624885,2113.0,
12527,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,50597,N,,CHEMBL624886,2113.0,
12528,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,50597,N,,CHEMBL624887,2113.0,
12529,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,50597,N,,CHEMBL624888,2113.0,
12530,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,50597,N,,CHEMBL624889,2113.0,
12531,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,50597,N,,CHEMBL624890,2113.0,
12532,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,N,,CHEMBL621964,2113.0,
12533,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,50597,N,,CHEMBL621965,2113.0,
12534,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,50597,N,,CHEMBL621966,2107.0,
12535,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,50597,N,,CHEMBL621967,2107.0,
12536,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,50597,N,,CHEMBL622164,2107.0,
12537,,,BAO_0000019,,1,A,Autocuration,,0,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),22224,U,,CHEMBL623097,,
12538,,,BAO_0000019,,1,A,Autocuration,,0,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),22224,U,,CHEMBL623098,,
12539,,,BAO_0000019,,1,A,Autocuration,,0,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,22224,U,,CHEMBL623099,,
12540,,,BAO_0000019,,1,A,Autocuration,,0,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,22224,U,,CHEMBL623100,,
12541,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",50597,N,,CHEMBL628673,,
12542,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",50597,N,,CHEMBL628674,,
12543,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",50597,N,,CHEMBL628675,,
12544,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",50597,N,,CHEMBL627644,,
12545,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",50597,N,,CHEMBL627645,,
12546,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",50597,N,,CHEMBL627646,,
12547,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",50597,N,,CHEMBL627647,,
12548,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",50597,N,,CHEMBL627648,,
12549,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Free level in rat plasma,50597,N,,CHEMBL627649,,
12550,,,BAO_0000019,,1,A,Autocuration,,0,Level reaching in blood plasma of rat or human was determined,22224,U,,CHEMBL628313,,
12551,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Log (Cbrain/Cblood) in rats,50597,N,,CHEMBL628314,,
12552,,,BAO_0000019,,1,A,Autocuration,,0,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,22224,U,,CHEMBL628315,,
12553,,,BAO_0000019,,1,A,Autocuration,,0,Mean percentage of compound transport through membrane; expressed as membrane transport,22224,U,,CHEMBL628316,,
12554,,,BAO_0000218,,1,A,Autocuration,,0,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,22224,U,,CHEMBL628317,,
12555,,,BAO_0000019,,1,A,Autocuration,,0,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,22224,U,,CHEMBL628473,,
12556,,,BAO_0000019,,1,A,Autocuration,,0,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",22224,U,,CHEMBL628474,,
12557,,,BAO_0000019,,1,A,Autocuration,,0,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,22224,U,,CHEMBL628475,,
12558,,,BAO_0000019,,1,A,Autocuration,,0,Net water uptake by a carrier mediated transport (%cm) mechanism,22224,U,,CHEMBL628476,,
12559,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,22224,U,,CHEMBL628477,,
12560,,Mustela putorius furo,BAO_0000218,,1,A,Intermediate,,1,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,50506,N,,CHEMBL628478,,
12561,,Mustela putorius furo,BAO_0000218,,1,A,Intermediate,,1,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",50506,N,,CHEMBL628479,,
12562,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,22224,U,,CHEMBL628480,,
12563,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",22224,U,,CHEMBL628481,,
12564,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,50597,N,,CHEMBL628482,,
12565,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",50597,N,,CHEMBL628483,,
12566,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",50597,N,,CHEMBL628484,1969.0,
12567,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",50597,N,,CHEMBL628485,1969.0,
12568,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",100710,N,,CHEMBL628486,1969.0,
12569,,Homo sapiens,BAO_0000218,,1,A,Intermediate,,1,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",50587,N,,CHEMBL628487,1969.0,
12570,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",50597,N,,CHEMBL628488,1969.0,
12571,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",50597,N,,CHEMBL628489,1969.0,
12572,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",50597,N,,CHEMBL628490,1969.0,
12573,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,100710,N,,CHEMBL628491,,
12574,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,,1,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,100710,N,,CHEMBL877507,,
12575,,,BAO_0000218,,1,A,Autocuration,,0,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,22224,U,,CHEMBL628492,,
12576,,Simiiformes,BAO_0000019,,1,A,Autocuration,,0,% metabolized in monkey S-9 after 2 hours (10 ug/mL),22224,U,,CHEMBL628493,,
12577,,Simiiformes,BAO_0000019,,1,A,Autocuration,,0,% metabolized in monkey S-9 after 2 hours (1 ug/ml),22224,U,,CHEMBL628494,,
12578,,Simiiformes,BAO_0000019,,1,A,Autocuration,,0,% metabolized in monkey S-9 after 2 hours (10 ug/ml),22224,U,,CHEMBL628495,,
12579,,Homo sapiens,BAO_0000218,,1,A,Intermediate,,1,Permeability in Caco-2 assay at 10E-6,50587,N,,CHEMBL628496,,
12580,,,BAO_0000218,,1,A,Autocuration,,0,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,22224,U,,CHEMBL628497,955.0,
12581,,,BAO_0000218,,1,A,Autocuration,,0,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,22224,U,,CHEMBL628498,955.0,
12582,,,BAO_0000019,,1,A,Autocuration,,0,Plasma protein binding was determined,22224,U,,CHEMBL628499,,
12583,,,BAO_0000218,,1,A,Autocuration,,0,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,22224,U,,CHEMBL627656,,
12584,,,BAO_0000218,,1,A,Autocuration,,0,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,22224,U,,CHEMBL627657,,
12585,,,BAO_0000218,,1,A,Autocuration,,0,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,22224,U,,CHEMBL626808,,
12586,,,BAO_0000218,,1,A,Autocuration,,0,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,22224,U,,CHEMBL626809,,
12587,,,BAO_0000218,,1,A,Autocuration,,0,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,22224,U,,CHEMBL626810,,
12588,,,BAO_0000218,,1,A,Autocuration,,0,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,22224,U,,CHEMBL626811,,
12589,,,BAO_0000218,,1,A,Autocuration,,0,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,22224,U,,CHEMBL874465,,
12590,,,BAO_0000218,,1,A,Autocuration,,0,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,22224,U,,CHEMBL626812,,
12591,,,BAO_0000218,,1,A,Autocuration,,0,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,22224,U,,CHEMBL626813,,
12592,,,BAO_0000218,,1,A,Autocuration,,0,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,22224,U,,CHEMBL626814,,
12593,,,BAO_0000019,,1,A,Autocuration,,0,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,22224,U,,CHEMBL626815,,
12594,,,BAO_0000019,,1,A,Autocuration,,0,Partition coefficient (logP),22224,U,,CHEMBL628566,,
12595,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP) (CLOGP3 V3.4),22229,U,,CHEMBL628567,,
12596,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL628568,,
12597,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,C max in dog,50588,N,,CHEMBL628569,,
12598,,Cavia porcellus,BAO_0000218,,1,A,Intermediate,In vivo,1,C max in guinea pig,50512,N,,CHEMBL628570,,
12599,,,BAO_0000218,,1,A,Autocuration,In vivo,0,C max value was evaluated,22224,U,,CHEMBL628571,,
12600,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax value after oral dose of 0.1 mg//kg,22224,U,,CHEMBL628572,,
12601,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax value after oral dose of 0.3 mg/kg,22224,U,,CHEMBL628573,,
12602,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax value after oral dose of 1 mg/kg,22224,U,,CHEMBL628574,,
12603,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax value after oral dose of 10 mg/kg,22224,U,,CHEMBL628575,,
12604,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax value after oral dose of 23.4 mg/kg,22224,U,,CHEMBL628576,,
12605,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax value after oral dose of 3 mg/kg,22224,U,,CHEMBL628577,,
12606,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax value after oral dose of 3.87 mg/kg,22224,U,,CHEMBL628578,,
12607,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value in female Beagle dogs,50588,N,,CHEMBL874466,,
12608,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value in male rats,50597,N,,CHEMBL628579,,
12609,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax value in rat plasma when administered 20 mg/kg perorally,50597,N,,CHEMBL628580,1969.0,
12610,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,50588,N,,CHEMBL628581,1969.0,
12611,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,50588,N,,CHEMBL628582,1969.0,
12612,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,50588,N,,CHEMBL628583,,
12613,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,22224,U,,CHEMBL625782,,
12614,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,50592,N,,CHEMBL625783,,
12615,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,50597,N,,CHEMBL625784,,
12616,,Macaca mulatta,BAO_0000218,,1,A,Intermediate,,1,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,50797,N,,CHEMBL625785,1969.0,
12617,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,50597,N,,CHEMBL625786,,
12618,,,BAO_0000019,,1,A,Autocuration,,0,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,22224,U,,CHEMBL874467,,
12619,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",50588,N,,CHEMBL625787,,
12620,,Human immunodeficiency virus,BAO_0000218,,1,A,Intermediate,,1,cytotoxicity against HIV protease enzyme.,50677,N,,CHEMBL625964,,
12621,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,50594,N,,CHEMBL625965,,
12622,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Apparent clearance in mice after oral administration of 100 mg/kg of dose,50594,N,,CHEMBL625966,,
12623,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,The plasma clearance in dog.,50588,N,,CHEMBL625967,1969.0,
12624,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The plasma clearance in rat.,50597,N,,CHEMBL625968,1969.0,
12625,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance from plasma in male Sprague-Dawley rats,50597,N,,CHEMBL625969,1969.0,
12626,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance from plasma in male cynomolgus monkeys,100710,N,,CHEMBL625970,1969.0,
12627,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",50588,N,,CHEMBL625971,1969.0,
12628,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance of compound in dog plasma,50588,N,,CHEMBL625972,1969.0,
12629,,Homo sapiens,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance of compound in human plasma,50587,N,,CHEMBL625973,1969.0,
12630,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,50588,N,,CHEMBL625974,,
12631,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance of compound when administered intravenously as an individual dose to a single dog.,50588,N,,CHEMBL625975,,
12632,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,"Clearance (10 mg/kg, intravenously) in dog plasma",50588,N,,CHEMBL625976,1969.0,
12633,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance value in dog,50588,N,,CHEMBL625977,,
12634,,Cavia porcellus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance value in guinea pig,50512,N,,CHEMBL625978,,
12635,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance values in rats after iv administration.,50597,N,,CHEMBL874468,,
12636,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,22224,U,,CHEMBL625421,1969.0,
12637,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,In vivo,1,In vivo clearance (5 mg/kg) was determined in rabbits,50592,N,,CHEMBL625422,,
12638,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma Clearance rate was determined for the compound in rats,50597,N,,CHEMBL625423,,
12639,,Saimiri,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma Clearance rate was determined for the compound in squirrel monkeys,22224,U,,CHEMBL625424,,
12640,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in rat,50597,N,,CHEMBL625425,,
12641,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance of the compound,22224,U,,CHEMBL625426,,
12642,,Cavia porcellus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,50512,N,,CHEMBL625427,,
12643,,Cavia porcellus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,50512,N,,CHEMBL625428,,
12644,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance was determined,22224,U,,CHEMBL625429,,
12645,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,50588,N,,CHEMBL625430,,
12646,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance rate was determined for the compound in rats,50597,N,,CHEMBL625431,,
12647,,Saimiri,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance rate was determined for the compound in squirrel monkeys,22224,U,,CHEMBL627307,,
12648,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Slow clearance (CL) was determined,22224,U,,CHEMBL627308,,
12649,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,22224,U,,CHEMBL627309,,
12650,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,22224,U,,CHEMBL627310,,
12651,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,22224,U,,CHEMBL627311,,
12652,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,22224,U,,CHEMBL627312,,
12653,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,22224,U,,CHEMBL627313,,
12654,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,22224,U,,CHEMBL627314,,
12655,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,22224,U,,CHEMBL627315,,
12656,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,22224,U,,CHEMBL627316,,
12657,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,22224,U,,CHEMBL627317,,
12658,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,22224,U,,CHEMBL627318,,
12659,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,22224,U,,CHEMBL627999,,
12660,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,22224,U,,CHEMBL628000,,
12661,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,22224,U,,CHEMBL628001,,
12662,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,22224,U,,CHEMBL628002,,
12663,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,22224,U,,CHEMBL625610,,
12664,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,22224,U,,CHEMBL625611,,
12665,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,22224,U,,CHEMBL625612,,
12666,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,22224,U,,CHEMBL625613,,
12667,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,22224,U,,CHEMBL875479,,
12668,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,22224,U,,CHEMBL625614,,
12669,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,22224,U,,CHEMBL625615,,
12670,,,BAO_0000218,,1,A,Autocuration,,0,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,22224,U,,CHEMBL626302,,
12671,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,N,,CHEMBL626303,178.0,
12672,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,N,,CHEMBL627420,178.0,
12673,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,50597,N,,CHEMBL627421,,
12674,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,50597,N,,CHEMBL625695,,
12675,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,50597,N,,CHEMBL625696,,
12676,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Distribution of compound in mice brain was measured after 1 hr,50594,N,,CHEMBL875606,955.0,
12677,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Distribution of compound in mice brain was measured after 24 hr r,50594,N,,CHEMBL625697,955.0,
12678,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Distribution of compound in mice brain was measured after 2 hr,50594,N,,CHEMBL625698,955.0,
12679,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Distribution of compound in mice brain was measured after 3 hr,50594,N,,CHEMBL625699,955.0,
12680,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Distribution of compound in mice brain was measured after 6 hr,50594,N,,CHEMBL625700,955.0,
12681,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Distribution of compound in mice liver was measured after 1 hr,50594,N,,CHEMBL625701,,
12682,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,50594,N,,CHEMBL625702,,
12683,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Distribution of compound in mice liver was measured after 2 hr,50594,N,,CHEMBL625703,,
12684,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Distribution of compound in mice liver was measured after 3 hr,50594,N,,CHEMBL625704,,
12685,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Distribution of compound in mice liver was measured after 6 hr,50594,N,,CHEMBL625705,,
12686,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in dog adrenal medulla 30 min after administration.,50588,N,,CHEMBL625706,1236.0,
12687,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in dog adrenal medulla 72 hours after administration.,50588,N,,CHEMBL625707,1236.0,
12688,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog Ovary 24 hours after administration.,50588,N,,CHEMBL625708,,
12689,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog Ovary 72 hours after administration.,50588,N,,CHEMBL625709,,
12690,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog adipose 24 hours after administration.,50588,N,,CHEMBL624180,,
12691,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog adipose 72 hours after administration.,50588,N,,CHEMBL624181,,
12692,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog adrenal cortex 72 hours after administration.,50588,N,,CHEMBL624182,1235.0,
12693,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog adrenal cortex 72 hours after administration.,50588,N,,CHEMBL624183,1235.0,
12694,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,50597,N,,CHEMBL624184,2107.0,
12695,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,50597,N,,CHEMBL877489,2107.0,
12696,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,N,,CHEMBL624185,2107.0,
12697,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,50597,N,,CHEMBL624186,2107.0,
12698,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,50597,N,,CHEMBL624187,2107.0,
12699,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,50597,N,,CHEMBL624188,2107.0,
12700,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,50597,N,,CHEMBL624189,2048.0,
12701,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,50597,N,,CHEMBL624190,2048.0,
12702,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,50597,N,,CHEMBL624191,2048.0,
12703,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,50597,N,,CHEMBL624192,2048.0,
12704,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,50597,N,,CHEMBL624193,2048.0,
12705,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,50597,N,,CHEMBL624194,2048.0,
12706,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,50597,N,,CHEMBL624891,2048.0,
12707,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,50597,N,,CHEMBL624892,2048.0,
12708,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,50597,N,,CHEMBL624893,2048.0,
12709,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,N,,CHEMBL627632,2048.0,
12710,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,50597,N,,CHEMBL627633,,
12711,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,50597,N,,CHEMBL627634,,
12712,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,50597,N,,CHEMBL627635,,
12713,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,50597,N,,CHEMBL627636,,
12714,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,50597,N,,CHEMBL626816,,
12715,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,50597,N,,CHEMBL626817,,
12716,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,50597,N,,CHEMBL626818,,
12717,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,50597,N,,CHEMBL626819,,
12718,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,50597,N,,CHEMBL626820,,
12719,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,N,,CHEMBL626821,,
12720,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,50597,N,,CHEMBL626822,2046.0,
12721,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,50597,N,,CHEMBL626823,2046.0,
12722,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,50597,N,,CHEMBL626824,2046.0,
12723,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,50597,N,,CHEMBL626825,2046.0,
12724,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,50597,N,,CHEMBL626826,2046.0,
12725,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,50597,N,,CHEMBL626827,2046.0,
12726,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,50597,N,,CHEMBL626828,2046.0,
12727,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,50597,N,,CHEMBL626829,2046.0,
12728,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,N,,CHEMBL626830,2046.0,
12729,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,50597,N,,CHEMBL627150,,
12730,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,N,,CHEMBL627151,,
12731,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,50597,N,,CHEMBL627152,,
12732,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,N,,CHEMBL627153,,
12733,,,BAO_0000019,,1,A,Autocuration,,0,Rate of acetate production by the compound was determined,22224,U,,CHEMBL627154,,
12734,,,BAO_0000019,,1,A,Autocuration,,0,Rate of acetate production by the compound was determined; Not determined,22224,U,,CHEMBL627155,,
12735,,,BAO_0000019,,1,A,Autocuration,,0,Rate of hydrolysis of nitrocefin by compound was evaluated in water,22224,U,,CHEMBL627156,,
12736,,,BAO_0000019,,1,A,Autocuration,,0,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,22224,U,,CHEMBL627157,,
12737,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,50592,N,,CHEMBL627158,,
12738,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,50592,N,,CHEMBL627159,1969.0,
12739,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,50594,N,,CHEMBL627160,,
12740,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,50597,N,,CHEMBL628540,,
12741,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,50597,N,,CHEMBL628541,1969.0,
12742,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,50597,N,,CHEMBL628542,1969.0,
12743,,,BAO_0000100,,1,P,Autocuration,,0,Solubility after at a pH 1.2,22229,U,,CHEMBL628543,,
12744,,,BAO_0000100,,1,P,Autocuration,,0,Solubility after at pH 1.2,22229,U,,CHEMBL628544,,
12745,,,BAO_0000100,,1,P,Autocuration,,0,Solubility after injection of water,22229,U,,CHEMBL628545,,
12746,,,BAO_0000019,,1,A,Autocuration,,0,Statistical significance of IC 50 values; Expressed as R value,22224,U,,CHEMBL628546,,
12747,,,BAO_0000019,,1,A,Autocuration,,0,Systemic availability with respect to methyldopa was determined,22224,U,,CHEMBL874455,,
12748,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,50597,N,,CHEMBL628547,,
12749,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,50597,N,,CHEMBL628548,1969.0,
12750,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",50592,N,,CHEMBL628549,1988.0,
12751,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",50592,N,,CHEMBL628550,1988.0,
12752,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",50592,N,,CHEMBL628551,1988.0,
12753,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",50592,N,,CHEMBL628552,1088.0,
12754,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",50592,N,,CHEMBL628553,1088.0,
12755,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",50592,N,,CHEMBL628554,1088.0,
12756,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",50592,N,,CHEMBL628555,1088.0,
12757,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",50592,N,,CHEMBL628556,1088.0,
12758,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",50592,N,,CHEMBL628557,2113.0,
12759,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",50592,N,,CHEMBL628558,1988.0,
12760,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",50592,N,,CHEMBL628559,1988.0,
12761,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",50592,N,,CHEMBL628560,1988.0,
12762,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",50592,N,,CHEMBL874456,1088.0,
12763,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",50592,N,,CHEMBL628561,1988.0,
12764,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",50592,N,,CHEMBL628562,1988.0,
12765,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",50592,N,,CHEMBL628563,1088.0,
12766,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",50592,N,,CHEMBL628564,1088.0,
12767,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",50592,N,,CHEMBL628565,1088.0,
12768,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",50592,N,,CHEMBL631248,1088.0,
12769,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",50592,N,,CHEMBL631249,1088.0,
12770,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",50592,N,,CHEMBL627214,2113.0,
12771,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",50592,N,,CHEMBL874591,1988.0,
12772,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",50592,N,,CHEMBL627215,1988.0,
12773,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,50592,N,,CHEMBL625471,1988.0,
12774,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,50592,N,,CHEMBL625472,,
12775,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,50592,N,,CHEMBL625473,,
12776,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,50588,N,,CHEMBL625474,,
12777,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,50588,N,,CHEMBL625475,,
12778,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,50597,N,,CHEMBL625476,,
12779,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,50597,N,,CHEMBL625477,,
12780,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,50597,N,,CHEMBL625478,,
12781,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vitro,1,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,50597,N,,CHEMBL625479,,
12782,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vitro,1,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,50597,N,,CHEMBL625480,,
12783,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,50597,N,,CHEMBL625481,1969.0,
12784,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,50597,N,,CHEMBL625482,,
12785,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,50597,N,,CHEMBL625483,,
12786,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,50597,N,,CHEMBL625484,,
12787,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,50597,N,,CHEMBL625485,,
12788,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,50588,N,,CHEMBL625486,1969.0,
12789,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,50597,N,,CHEMBL625487,1969.0,
12790,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,50597,N,,CHEMBL625488,1969.0,
12791,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,50597,N,,CHEMBL625489,1969.0,
12792,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,50597,N,,CHEMBL625490,1969.0,
12793,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,50588,N,,CHEMBL625491,1969.0,
12794,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,50597,N,,CHEMBL625492,1969.0,
12795,,Homo sapiens,BAO_0000218,,1,A,Intermediate,In vivo,1,plasma clearance in human,50587,N,,CHEMBL625493,1969.0,
12796,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,50597,N,,CHEMBL625494,,
12797,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,50597,N,,CHEMBL625495,,
12798,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,50597,N,,CHEMBL625496,,
12799,,,BAO_0000100,,1,P,Autocuration,,0,1-Octanol/water partition coefficient measured at 7.4,22229,U,,CHEMBL625497,,
12800,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL625498,,
12801,,,BAO_0000019,,1,A,Autocuration,,0,Partition coefficient (logP),22224,U,,CHEMBL625499,,
12802,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL625500,,
12803,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL625501,,
12804,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL625502,,
12805,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP) (relative to BAY K 8644),22229,U,,CHEMBL625503,,
12806,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL625504,,
12807,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL625505,,
12808,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient of the compound,22229,U,,CHEMBL625506,,
12809,,,BAO_0000019,,1,A,Autocuration,,0,Partition coefficient (logP),22224,U,,CHEMBL625507,,
12810,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL625508,,
12811,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL625509,,
12812,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL625510,,
12813,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL883125,,
12814,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL625511,,
12815,,,BAO_0000019,,1,A,Autocuration,,0,Partition coefficient of the compound,22224,U,,CHEMBL874650,,
12816,,,BAO_0000019,,1,A,Autocuration,,0,Partition coefficient of the compound,22224,U,,CHEMBL625512,,
12817,,,BAO_0000019,,1,A,Autocuration,,0,Partition coefficient of compound was determined,22224,U,,CHEMBL625513,,
12818,,,BAO_0000019,,1,A,Autocuration,,0,Partition coefficient was determined,22224,U,,CHEMBL625514,,
12819,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL625515,,
12820,,,BAO_0000100,,1,P,Autocuration,,0,partition coefficient of compound was determined,22229,U,,CHEMBL625516,,
12821,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,The total body administered intravenously in dog,50588,N,,CHEMBL625517,,
12822,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The total body administered intravenously in rats,50597,N,,CHEMBL625518,,
12823,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Time taken for the administration to female NIH mice weighing 25-30 g.,50594,N,,CHEMBL625519,,
12824,,,BAO_0000019,,1,A,Autocuration,,0,Time taken for the administration,22224,U,,CHEMBL625520,,
12825,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,50588,N,,CHEMBL874651,,
12826,,Simiiformes,BAO_0000218,,1,A,Autocuration,In vivo,0,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,22224,U,,CHEMBL625521,,
12827,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,50592,N,,CHEMBL623171,,
12828,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,50597,N,,CHEMBL623853,,
12829,,,BAO_0000019,,1,A,Autocuration,,0,Plasma clearance for the compound was determined.,22224,U,,CHEMBL623854,,
12830,,,BAO_0000100,,1,P,Autocuration,,0,CLog P value of the compound,22224,U,,CHEMBL874405,,
12831,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL623855,,
12832,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL623856,,
12833,,,BAO_0000100,,1,P,Autocuration,,0,ClogP value of the compound; nd ='no data',22224,U,,CHEMBL623857,,
12834,,,BAO_0000100,,1,P,Autocuration,,0,ClogP value of the compound; nd ='not determined',22224,U,,CHEMBL623858,,
12835,,,BAO_0000100,,1,P,Autocuration,,0,CLog P was determined,22224,U,,CHEMBL623859,,
12836,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL839829,,
12837,,,BAO_0000019,,1,A,Autocuration,,0,CLogP was calculated,22224,U,,CHEMBL623860,,
12838,,,BAO_0000019,,1,A,Autocuration,,0,CLogP value was determined,22224,U,,CHEMBL623861,,
12839,,,BAO_0000019,,1,A,Autocuration,,0,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,22224,U,,CHEMBL623862,,
12840,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL874406,,
12841,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL623863,,
12842,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL624021,,
12843,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog adrenal medulla 24 hours after administration.,50588,N,,CHEMBL624022,1236.0,
12844,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog adrenal medulla 72 hours after administration.,50588,N,,CHEMBL624023,1236.0,
12845,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog bile 24 hours after administration.,50588,N,,CHEMBL624024,,
12846,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog bile 72 hr after administration.,50588,N,,CHEMBL624025,,
12847,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog blood 24 hours after administration.,50588,N,,CHEMBL624026,,
12848,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog blood 72 hours after administration.,50588,N,,CHEMBL624027,,
12849,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog heart 24 hours after administration.,50588,N,,CHEMBL624028,,
12850,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog heart 72 hours after administration.,50588,N,,CHEMBL624029,,
12851,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog kidney 24 hours after administration.,50588,N,,CHEMBL624030,,
12852,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog kidney 72 hours after administration.,50588,N,,CHEMBL624031,,
12853,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog large intestine 24 hours after administration.,50588,N,,CHEMBL624032,160.0,
12854,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog large intestine 72 hours after administration.,50588,N,,CHEMBL874407,160.0,
12855,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog liver 24 hours after administration.,50588,N,,CHEMBL624033,,
12856,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog liver 72 hours after administration.,50588,N,,CHEMBL624034,,
12857,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog lung 24 hours after administration.,50588,N,,CHEMBL624035,,
12858,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog lung 72 hours after administration.,50588,N,,CHEMBL624036,,
12859,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog muscle 24 hours after administration.,50588,N,,CHEMBL624037,2385.0,
12860,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog muscle 72 hours after administration.,50588,N,,CHEMBL624038,2385.0,
12861,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog pancreas 24 hours after administration.,50588,N,,CHEMBL624039,,
12862,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog pancreas 72 hours after administration.,50588,N,,CHEMBL624040,,
12863,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog small intestine 24 hours after administration.,50588,N,,CHEMBL624041,160.0,
12864,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog small intestine 72 hours after administration.,50588,N,,CHEMBL624042,160.0,
12865,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog spleen 24 hours after administration.,50588,N,,CHEMBL624043,2106.0,
12866,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog spleen 72 hours after administration.,50588,N,,CHEMBL624044,2106.0,
12867,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog stomach 24 hours after administration.,50588,N,,CHEMBL624045,945.0,
12868,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog stomach 72 hours after administration.,50588,N,,CHEMBL624046,945.0,
12869,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog thyroid 24 hours after administration.,50588,N,,CHEMBL624047,2046.0,
12870,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog thyroid 72 hours after administration.,50588,N,,CHEMBL624048,2046.0,
12871,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog urine 24 hours after administration.,50588,N,,CHEMBL874408,1088.0,
12872,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Distribution in female dog urine 72 hr after administration.,50588,N,,CHEMBL624049,1088.0,
12873,,,BAO_0000218,,1,A,Autocuration,,0,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,22224,U,,CHEMBL624050,1969.0,
12874,,,BAO_0000019,,1,A,Autocuration,,0,Plasma concentration at 7 hr after intravenous dosing,22224,U,,CHEMBL624051,,
12875,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,50597,N,,CHEMBL623278,,
12876,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,50597,N,,CHEMBL623279,,
12877,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration of 3 mg/kg iv after 1 hr in rats,50597,N,,CHEMBL623280,,
12878,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration of 3 mg/kg iv after 2 hr in rats,50597,N,,CHEMBL623963,,
12879,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration of 3 mg/kg iv after 4 hr in rats,50597,N,,CHEMBL623964,,
12880,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration of 3 mg/kg iv after 6 hr in rats,50597,N,,CHEMBL623965,,
12881,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,50597,N,,CHEMBL623966,,
12882,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,50597,N,,CHEMBL874415,,
12883,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,50597,N,,CHEMBL623967,,
12884,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,50597,N,,CHEMBL623968,,
12885,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,50597,N,,CHEMBL623969,,
12886,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,50597,N,,CHEMBL628409,,
12887,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,50597,N,,CHEMBL628410,,
12888,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,50597,N,,CHEMBL628411,,
12889,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,50597,N,,CHEMBL628412,,
12890,,,BAO_0000019,,1,A,Autocuration,,0,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,22224,U,,CHEMBL628413,,
12891,,,BAO_0000019,,1,A,Autocuration,,0,The concentration in plasmat; Not determined,22224,U,,CHEMBL628414,1969.0,
12892,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue level at 10 mg/kg/po in wistar rats in blood,50597,N,,CHEMBL628415,,
12893,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue level at 10 mg/kg/po in wistar rats in brown fat,50597,N,,CHEMBL628416,,
12894,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue level at 10 mg/kg/po in wistar rats in heart,50597,N,,CHEMBL628417,,
12895,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue level at 10 mg/kg/po in wistar rats in liver,50597,N,,CHEMBL874908,2107.0,
12896,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue level at 10 mg/kg/po in wistar rats in plasma,50597,N,,CHEMBL628418,,
12897,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,50597,N,,CHEMBL628419,2385.0,
12898,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,50597,N,,CHEMBL628420,,
12899,,,BAO_0000019,,1,A,Autocuration,,0,Water solubility at 37 degree C.,22224,U,,CHEMBL628421,,
12900,,,BAO_0000100,,1,P,Autocuration,,0,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,22229,U,,CHEMBL626726,,
12901,,,BAO_0000100,,1,P,Autocuration,,0,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,22229,U,,CHEMBL626727,,
12902,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL626728,178.0,
12903,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL626729,178.0,
12904,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL626730,178.0,
12905,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL626731,178.0,
12906,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL626732,178.0,
12907,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL626733,948.0,
12908,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL626734,948.0,
12909,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL626735,948.0,
12910,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL874909,948.0,
12911,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL626736,948.0,
12912,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL626737,2113.0,
12913,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL630999,2113.0,
12914,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL631000,2113.0,
12915,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL631001,2113.0,
12916,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL631002,2113.0,
12917,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL631003,2107.0,
12918,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL631004,2107.0,
12919,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL631005,2107.0,
12920,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL631006,2107.0,
12921,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL631007,2107.0,
12922,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL631008,2048.0,
12923,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL631009,2048.0,
12924,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL631010,2048.0,
12925,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL631011,2048.0,
12926,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL631012,2048.0,
12927,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL630271,2046.0,
12928,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL630272,2046.0,
12929,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL630273,2046.0,
12930,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL630274,2046.0,
12931,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL630275,2046.0,
12932,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL875782,,
12933,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL630276,,
12934,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL630277,,
12935,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL630278,,
12936,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,50597,N,,CHEMBL630279,,
12937,,,BAO_0000019,,1,A,Autocuration,,0,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,22224,U,,CHEMBL630280,,
12938,,,BAO_0000019,,1,A,Autocuration,,0,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,22224,U,,CHEMBL630281,,
12939,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,50592,N,,CHEMBL630282,,
12940,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,50592,N,,CHEMBL630283,,
12941,,,BAO_0000019,,1,A,Autocuration,,0,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),22224,U,,CHEMBL630284,,
12942,,,BAO_0000019,,1,A,Autocuration,,0,Alkylating activity was determined,22224,U,,CHEMBL630285,,
12943,,,BAO_0000251,,1,A,Autocuration,,0,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),22224,U,,CHEMBL630286,,
12944,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",50592,N,,CHEMBL630069,,
12945,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",50592,N,,CHEMBL630070,,
12946,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",50592,N,,CHEMBL630071,,
12947,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",50592,N,,CHEMBL630072,,
12948,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",50592,N,,CHEMBL875110,,
12949,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for antidiuretic activity in rats,50597,N,,CHEMBL630073,,
12950,,,BAO_0000019,,1,A,Autocuration,,0,Compound was tested for inactivation kinetic values,22224,U,,CHEMBL630074,,
12951,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,22224,U,,CHEMBL630075,,
12952,,,BAO_0000019,,1,A,Autocuration,,0,Dissociation rate calculated from the first-order equation using the t1/2 value,22224,U,,CHEMBL630076,,
12953,,,BAO_0000100,,1,P,Autocuration,,0,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,22229,U,,CHEMBL630077,,
12954,,,BAO_0000100,,1,P,Autocuration,,0,Aqueous solubility was measured,22229,U,,CHEMBL630078,,
12955,,,BAO_0000100,,1,P,Autocuration,,0,Aqueous solubility was measured at a pH 4,22229,U,,CHEMBL630079,,
12956,,,BAO_0000100,,1,P,Autocuration,,0,Aqueous solubility (pH 7),22229,U,,CHEMBL630080,,
12957,,,BAO_0000100,,1,P,Autocuration,,0,Aqueous solubility was measured at a pH 9,22229,U,,CHEMBL630081,,
12958,,,BAO_0000019,,1,A,Autocuration,,0,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",22224,U,,CHEMBL630082,,
12959,,,BAO_0000019,,1,A,Autocuration,,0,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",22224,U,,CHEMBL630083,,
12960,,,BAO_0000019,,1,A,Autocuration,,0,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",22224,U,,CHEMBL630084,,
12961,,,BAO_0000100,,1,P,Autocuration,,0,Aqueous solubility of the compound,22229,U,,CHEMBL629198,,
12962,,,BAO_0000100,,1,P,Autocuration,,0,Aqueous solubility at 37 degree Celsius at pH 7.38,22229,U,,CHEMBL629199,,
12963,,,BAO_0000100,,1,P,Autocuration,,0,Aqueous solubility in pH 7.4 phosphate buffer,22229,U,,CHEMBL629200,,
12964,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,50588,N,,CHEMBL629201,,
12965,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,50588,N,,CHEMBL629202,,
12966,,Homo sapiens,BAO_0000218,,1,A,Intermediate,,1,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,50587,N,,CHEMBL875111,,
12967,,Homo sapiens,BAO_0000218,,1,A,Intermediate,,1,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,50587,N,,CHEMBL629203,,
12968,,Homo sapiens,BAO_0000218,,1,A,Intermediate,,1,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,50587,N,,CHEMBL629204,,
12969,,Homo sapiens,BAO_0000218,,1,A,Intermediate,,1,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,50587,N,,CHEMBL629205,,
12970,,Homo sapiens,BAO_0000218,,1,A,Intermediate,,1,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,50587,N,,CHEMBL629206,,
12971,,,BAO_0000019,,1,A,Autocuration,,0,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,22224,U,,CHEMBL631185,,
12972,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for the average bile flow rat in rats,50597,N,,CHEMBL631186,,
12973,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",50592,N,,CHEMBL631187,,
12974,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",50592,N,,CHEMBL631188,,
12975,,,BAO_0000019,,1,A,Autocuration,,0,Average half life period was determined,22224,U,,CHEMBL876419,,
12976,,,BAO_0000019,,1,A,Autocuration,,0,Average half life period was determined,22224,U,,CHEMBL631189,,
12977,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,50602,N,,CHEMBL631190,,
12978,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,50602,N,,CHEMBL631191,,
12979,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,50602,N,,CHEMBL631192,,
12980,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,50602,N,,CHEMBL632400,,
12981,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,50602,N,,CHEMBL630564,,
12982,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,50602,N,,CHEMBL630565,,
12983,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,50602,N,,CHEMBL630566,,
12984,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,50602,N,,CHEMBL631229,,
12985,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,50602,N,,CHEMBL631230,,
12986,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL876428,,
12987,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL631231,,
12988,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP) (MacLogP),22229,U,,CHEMBL631232,,
12989,,,BAO_0000019,,1,A,Autocuration,,0,Hydrophilicity was determined,22224,U,,CHEMBL631233,,
12990,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL631234,,
12991,,,BAO_0000019,,1,A,Autocuration,,0,Increased absorption was determined,22224,U,,CHEMBL883126,,
12992,,,BAO_0000100,,1,P,Autocuration,,0,Lipophilicity value was evaluated,22224,U,,CHEMBL631235,,
12993,,,BAO_0000100,,1,P,Autocuration,,0,Log P value of the compound.,22224,U,,CHEMBL631236,,
12994,,,BAO_0000019,,1,A,Autocuration,,0,Partition coefficient of compound was determined,22224,U,,CHEMBL631237,,
12995,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL631238,,
12996,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL876429,,
12997,,,BAO_0000019,,1,A,Autocuration,,0,Partition coefficient was measured by medchem software; Not calculated,22224,U,,CHEMBL631414,,
12998,,,BAO_0000100,,1,P,Autocuration,,0,Partition coefficient was measured by octanol-water using standard shake-flask method,22224,U,,CHEMBL631415,,
12999,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL631416,,
13000,,,BAO_0000019,,1,A,Autocuration,,0,Partition coefficient (logP),22224,U,,CHEMBL631417,,
13001,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL631418,,
13002,,,BAO_0000100,,1,P,Autocuration,,0,The Octanol/Water partition coefficient CLogP,22229,U,,CHEMBL631419,,
13003,,,BAO_0000019,,1,A,Autocuration,,0,The pharmacokinetic parameter C Log p was reported,22224,U,,CHEMBL631420,,
13004,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL631421,,
13005,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL631422,,
13006,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL631423,,
13007,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,50597,N,,CHEMBL876430,1969.0,
13008,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,50597,N,,CHEMBL631424,1969.0,
13009,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was administered intravenously in dog to evaluate plasma clearance values,50588,N,,CHEMBL631425,1969.0,
13010,,Simiiformes,BAO_0000218,,1,A,Autocuration,In vivo,0,Compound was administered intravenously in monkey to evaluate plasma clearance values,22224,U,,CHEMBL631426,1969.0,
13011,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was administered intravenously in mouse to evaluate plasma clearance values,50594,N,,CHEMBL631427,1969.0,
13012,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,50588,N,,CHEMBL631428,1969.0,
13013,,Macaca mulatta,BAO_0000218,,1,A,Intermediate,In vitro,1,Intrinsic clearance in Rhesus liver microsome,50797,N,,CHEMBL631429,2107.0,
13014,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vitro,1,Intrinsic clearance in dog liver microsome,50588,N,,CHEMBL631430,2107.0,
13015,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vitro,1,Intrinsic clearance in rat liver microsome,50597,N,,CHEMBL631431,2107.0,
13016,,Macaca mulatta,BAO_0000218,,1,A,Intermediate,In vivo,1,Low plasma clearance was calculated in rhesus monkey,50797,N,,CHEMBL631432,1969.0,
13017,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,50588,N,,CHEMBL631433,,
13018,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance after intravenous dose of 0.3 mg/kg,22224,U,,CHEMBL631434,,
13019,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance after intravenous dose of 1 mg/kg,22224,U,,CHEMBL631435,,
13020,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance after intravenous dose of 3 mg/kg,22224,U,,CHEMBL631436,,
13021,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance after intravenous dose of 3.87 mg/kg,22224,U,,CHEMBL631437,,
13022,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance after peroral administration at 10 mpk in Rat,50597,N,,CHEMBL631438,,
13023,,Macaca mulatta,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance after peroral administration at 10 mpk in Rhesus,50797,N,,CHEMBL876431,,
13024,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance after peroral administration at 10 mpk in dog,50588,N,,CHEMBL631439,,
13025,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,50597,N,,CHEMBL631440,,
13026,,,BAO_0000019,,1,A,Autocuration,,0,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),22224,U,,CHEMBL631441,,
13027,,,BAO_0000019,,1,A,Autocuration,,0,Critical Micellar concentration was determined,22224,U,,CHEMBL631442,,
13028,,,BAO_0000019,,1,A,Autocuration,,0,Critical Micellar concentration of the compound. was determined,22224,U,,CHEMBL626525,,
13029,,,BAO_0000019,,1,A,Autocuration,,0,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,22224,U,,CHEMBL627168,,
13030,,,BAO_0000019,,1,A,Autocuration,,0,Critical micellar concentration was measured in water by the dye solubilization method,22224,U,,CHEMBL875618,,
13031,,,BAO_0000019,,1,B,Autocuration,,0,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,22224,U,,CHEMBL626612,,
13032,,,BAO_0000019,,1,A,Autocuration,,0,CMR value (relative to BAY K 8644),22224,U,,CHEMBL626613,,
13033,,,BAO_0000019,,1,A,Autocuration,,0,Carbamoylating activity was determined,22224,U,,CHEMBL626614,,
13034,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,22224,U,,CHEMBL626615,,
13035,,,BAO_0000019,,1,A,Autocuration,,0,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,22224,U,,CHEMBL626616,,
13036,,,BAO_0000019,,1,A,Autocuration,,0,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,22224,U,,CHEMBL626617,,
13037,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,50588,N,,CHEMBL626618,1969.0,
13038,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,50597,N,,CHEMBL626619,1969.0,
13039,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,"Clearance rate at 0.46 mg/kg, iv, in dogs",50588,N,,CHEMBL626620,,
13040,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Clearance rate at 5.5 mg/kg, iv, in rat",50597,N,,CHEMBL626621,,
13041,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,100710,N,,CHEMBL626622,,
13042,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,100710,N,,CHEMBL626623,,
13043,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,50588,N,,CHEMBL626624,,
13044,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,50597,N,,CHEMBL626625,,
13045,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,Ex vivo,1,Clearance rate constant using isolated perfused rat liver (IPRL) assay,50597,N,,CHEMBL626626,2107.0,
13046,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Tested for the total clearance of the compound,22224,U,,CHEMBL626627,,
13047,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,50588,N,,CHEMBL626628,,
13048,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Total body clearance was determined,22224,U,,CHEMBL626629,,
13049,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,50597,N,,CHEMBL626630,,
13050,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,50597,N,,CHEMBL626631,,
13051,,,BAO_0000100,,1,P,Autocuration,,0,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,22229,U,,CHEMBL626632,,
13052,,,BAO_0000100,,1,P,Autocuration,,0,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,22229,U,,CHEMBL626633,,
13053,,,BAO_0000100,,1,P,Autocuration,,0,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,22229,U,,CHEMBL626634,,
13054,,,BAO_0000100,,1,P,Autocuration,,0,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,22229,U,,CHEMBL626635,,
13055,,,BAO_0000100,,1,P,Autocuration,,0,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,22229,U,,CHEMBL626636,,
13056,,,BAO_0000100,,1,P,Autocuration,,0,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,22229,U,,CHEMBL626637,,
13057,,Pneumocystis carinii,BAO_0000218,,1,A,Intermediate,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),50339,N,,CHEMBL626638,,
13058,,Pneumocystis carinii,BAO_0000218,,1,A,Intermediate,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,50339,N,,CHEMBL626639,,
13059,,Pneumocystis carinii,BAO_0000218,,1,A,Intermediate,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,50339,N,,CHEMBL626640,,
13060,,Pneumocystis carinii,BAO_0000218,,1,A,Intermediate,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,50339,N,,CHEMBL626641,,
13061,,Pneumocystis carinii,BAO_0000218,,1,A,Intermediate,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,50339,N,,CHEMBL627272,,
13062,,Pneumocystis carinii,BAO_0000218,,1,A,Intermediate,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,50339,N,,CHEMBL627273,,
13063,,Pneumocystis carinii,BAO_0000218,,1,A,Intermediate,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),50339,N,,CHEMBL627441,,
13064,,Pneumocystis carinii,BAO_0000218,,1,A,Intermediate,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),50339,N,,CHEMBL628355,,
13065,,Pneumocystis carinii,BAO_0000218,,1,A,Intermediate,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),50339,N,,CHEMBL628356,,
13066,,Pneumocystis carinii,BAO_0000218,,1,A,Intermediate,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),50339,N,,CHEMBL628357,,
13067,,Pneumocystis carinii,BAO_0000218,,1,A,Intermediate,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),50339,N,,CHEMBL628358,,
13068,,Pneumocystis carinii,BAO_0000218,,1,A,Intermediate,,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),50339,N,,CHEMBL622307,,
13069,,,BAO_0000019,,1,A,Autocuration,,0,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,22224,U,,CHEMBL622527,,
13070,,,BAO_0000019,,1,A,Autocuration,,0,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,22224,U,,CHEMBL622528,,
13071,,,BAO_0000019,,1,A,Autocuration,,0,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,22224,U,,CHEMBL622529,,
13072,,,BAO_0000019,,1,A,Autocuration,,0,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,22224,U,,CHEMBL622992,,
13073,,,BAO_0000019,,1,A,Autocuration,,0,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,22224,U,,CHEMBL622993,,
13074,,,BAO_0000019,,1,A,Autocuration,,0,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,22224,U,,CHEMBL622994,,
13075,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",50597,N,,CHEMBL622995,,
13076,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",50597,N,,CHEMBL622996,,
13077,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",50597,N,,CHEMBL622997,,
13078,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",50597,N,,CHEMBL622998,,
13079,,,BAO_0000218,,1,A,Autocuration,,0,Cp max following ip administration at 1 mg/kg,22224,U,,CHEMBL622999,,
13080,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration in plasma was reported at 0.5 hour,22224,U,,CHEMBL623000,1969.0,
13081,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Maximum concentration in plasma was reported at 2 hour,22224,U,,CHEMBL623001,1969.0,
13082,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,50594,N,,CHEMBL623002,,
13083,,,BAO_0000100,,1,P,Autocuration,,0,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),22229,U,,CHEMBL623003,,
13084,,,BAO_0000019,,1,A,Autocuration,,0,Steady state concentration was evaluated,22224,U,,CHEMBL623004,,
13085,,,BAO_0000019,,1,A,Autocuration,,0,Partition coefficient (logP),22224,U,,CHEMBL623005,,
13086,,,BAO_0000019,,1,A,Autocuration,,0,Partition coefficient (logD7.4),22224,U,,CHEMBL623006,,
13087,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,50597,N,,CHEMBL623007,2107.0,
13088,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,50597,N,,CHEMBL623008,10000001.0,
13089,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,50597,N,,CHEMBL876654,2037.0,
13090,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,50597,N,,CHEMBL623009,,
13091,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,50597,N,,CHEMBL623010,,
13092,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,50597,N,,CHEMBL623011,948.0,
13093,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,50597,N,,CHEMBL623012,160.0,
13094,,,BAO_0000019,,1,A,Autocuration,,0,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,22224,U,,CHEMBL623013,,
13095,,,BAO_0000019,,1,A,Autocuration,,0,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,22224,U,,CHEMBL623014,,
13096,,,BAO_0000019,,1,A,Autocuration,,0,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,22224,U,,CHEMBL623015,1088.0,
13097,,,BAO_0000019,,1,A,Autocuration,,0,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,22224,U,,CHEMBL623016,1088.0,
13098,,,BAO_0000019,,1,A,Autocuration,,0,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,22224,U,,CHEMBL624858,1088.0,
13099,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,50597,N,,CHEMBL624859,,
13100,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,50597,N,,CHEMBL624860,,
13101,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,50597,N,,CHEMBL624861,,
13102,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,50597,N,,CHEMBL624862,,
13103,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,50597,N,,CHEMBL624863,,
13104,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,50597,N,,CHEMBL876655,,
13105,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,50588,N,,CHEMBL624864,,
13106,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,50588,N,,CHEMBL624865,,
13107,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,50588,N,,CHEMBL624866,,
13108,,Canis lupus familiaris,BAO_0000218,,1,F,Expert,,1,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,50588,N,,CHEMBL624867,,
13109,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,50588,N,,CHEMBL624868,,
13110,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,50588,N,,CHEMBL628450,,
13111,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,50588,N,,CHEMBL628451,,
13112,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,50588,N,,CHEMBL628452,,
13113,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,50588,N,,CHEMBL628453,,
13114,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,50588,N,,CHEMBL628454,,
13115,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,50588,N,,CHEMBL628455,,
13116,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,50588,N,,CHEMBL628456,,
13117,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,50588,N,,CHEMBL628457,,
13118,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,50588,N,,CHEMBL877505,,
13119,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,50588,N,,CHEMBL628458,,
13120,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,50588,N,,CHEMBL628459,,
13121,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,50588,N,,CHEMBL628460,,
13122,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,50588,N,,CHEMBL628461,,
13123,,,BAO_0000218,,1,B,Autocuration,,0,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",22224,U,,CHEMBL628462,,
13124,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,50588,N,,CHEMBL628463,,
13125,,Rattus norvegicus,BAO_0000218,,1,F,Expert,,1,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",50597,N,,CHEMBL625666,,
13126,,,BAO_0000218,,1,B,Autocuration,,0,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,22224,U,,CHEMBL625667,,
13127,,Rattus norvegicus,BAO_0000218,,1,A,Expert,,1,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,50597,N,,CHEMBL625668,,
13128,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,50597,N,,CHEMBL625669,,
13129,,,BAO_0000019,,1,A,Autocuration,,0,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,22224,U,,CHEMBL625670,,
13130,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,50597,N,,CHEMBL625671,,
13131,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,50602,N,,CHEMBL625672,,
13132,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,50602,N,,CHEMBL625673,,
13133,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,50602,N,,CHEMBL625674,,
13134,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,50602,N,,CHEMBL625675,,
13135,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,50602,N,,CHEMBL627637,,
13136,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,50602,N,,CHEMBL627638,,
13137,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,50602,N,,CHEMBL627639,,
13138,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,50602,N,,CHEMBL627640,,
13139,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,50602,N,,CHEMBL627641,,
13140,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,50602,N,,CHEMBL627642,,
13141,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,50602,N,,CHEMBL877506,,
13142,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,50594,N,,CHEMBL627275,,
13143,,Mustela putorius furo,BAO_0000218,,1,A,Intermediate,,1,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",50506,N,,CHEMBL627643,,
13144,,Mustela putorius furo,BAO_0000218,,1,A,Intermediate,,1,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",50506,N,,CHEMBL631246,,
13145,,Mustela putorius furo,BAO_0000218,,1,A,Intermediate,,1,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",50506,N,,CHEMBL631247,,
13146,,Mustela putorius furo,BAO_0000218,,1,A,Intermediate,,1,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,50506,N,,CHEMBL629532,,
13147,,Mustela putorius furo,BAO_0000218,,1,A,Intermediate,,1,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,50506,N,,CHEMBL629533,,
13148,,Mustela putorius furo,BAO_0000218,,1,A,Intermediate,,1,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,50506,N,,CHEMBL629534,,
13149,,Mustela putorius furo,BAO_0000218,,1,A,Intermediate,,1,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,50506,N,,CHEMBL629535,,
13150,,,BAO_0000019,,1,A,Autocuration,,0,Pharmacokinetic parameter :drug bound to plasma was reported,22224,U,,CHEMBL625932,,
13151,,,BAO_0000019,,1,A,Autocuration,,0,compound was evaluated for drug bound in plasma,22224,U,,CHEMBL625933,,
13152,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,50597,N,,CHEMBL625934,,
13153,,Eutheria,BAO_0000218,,1,A,Autocuration,,0,Bioavailability,22224,U,,CHEMBL625935,,
13154,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,50597,N,,CHEMBL625936,,
13155,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,50597,N,,CHEMBL625937,,
13156,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,50588,N,,CHEMBL625938,,
13157,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,50597,N,,CHEMBL625939,1970.0,
13158,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,50597,N,,CHEMBL625940,1970.0,
13159,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,50597,N,,CHEMBL874464,1970.0,
13160,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,50597,N,,CHEMBL625941,1970.0,
13161,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,50597,N,,CHEMBL625942,1970.0,
13162,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,50597,N,,CHEMBL625943,1970.0,
13163,,Homo sapiens,BAO_0000218,,1,A,Intermediate,,1,In vitro protein binding in human serum at 5 ug/ml,50587,N,,CHEMBL625944,1977.0,
13164,,,BAO_0000019,,1,A,Autocuration,,0,Serum protein binding ability was measured,22224,U,,CHEMBL625945,,
13165,,,BAO_0000019,,1,A,Autocuration,,0,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),22224,U,,CHEMBL625946,,
13166,,Canis lupus familiaris,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability in dog,22224,U,,CHEMBL625947,,
13167,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,50597,N,,CHEMBL625948,,
13168,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Absolute oral bioavailability at an iv dose of 14 mg/kg,22224,U,,CHEMBL625949,,
13169,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,22224,U,,CHEMBL625950,,
13170,,Eutheria,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability (dose 15 mg/kg i.v.),22224,U,,CHEMBL625951,,
13171,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,22224,U,,CHEMBL625952,,
13172,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,22224,U,,CHEMBL625953,,
13173,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,22224,U,,CHEMBL625954,,
13174,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,22224,U,,CHEMBL882959,,
13175,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,50588,N,,CHEMBL625955,,
13176,,Mustela putorius furo,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in ferret,22224,U,,CHEMBL625956,,
13177,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,100710,N,,CHEMBL625957,,
13178,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,50597,N,,CHEMBL625958,,
13179,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,50597,N,,CHEMBL625959,,
13180,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,50597,N,,CHEMBL626642,,
13181,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,50597,N,,CHEMBL631330,,
13182,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,50597,N,,CHEMBL631331,,
13183,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,50597,N,,CHEMBL631332,,
13184,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,50597,N,,CHEMBL631333,,
13185,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,50597,N,,CHEMBL632018,,
13186,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,50597,N,,CHEMBL632019,,
13187,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,50597,N,,CHEMBL632020,,
13188,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,50597,N,,CHEMBL632021,,
13189,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,50597,N,,CHEMBL632022,,
13190,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,50597,N,,CHEMBL632023,,
13191,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,50597,N,,CHEMBL632024,,
13192,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,50597,N,,CHEMBL874472,,
13193,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,50597,N,,CHEMBL632025,,
13194,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,50597,N,,CHEMBL632026,,
13195,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,50597,N,,CHEMBL632027,,
13196,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,50597,N,,CHEMBL632028,,
13197,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,50597,N,,CHEMBL626430,,
13198,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,50597,N,,CHEMBL626431,,
13199,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,50597,N,,CHEMBL626432,,
13200,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,50597,N,,CHEMBL626433,,
13201,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,50597,N,,CHEMBL626434,,
13202,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,50597,N,,CHEMBL627280,,
13203,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,50597,N,,CHEMBL627281,,
13204,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,50597,N,,CHEMBL627282,,
13205,,,BAO_0000019,,1,A,Autocuration,,0,Total body clearance was measured at given dose,22224,U,,CHEMBL627283,,
13206,,,BAO_0000218,,1,A,Autocuration,,0,Total body clearance was measured at given dose.,22224,U,,CHEMBL627284,,
13207,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Metabolic clearance from the body in rat,50597,N,,CHEMBL627285,,
13208,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Renal clearance from the body,22224,U,,CHEMBL627286,,
13209,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Renal clearance from the body in rat,50597,N,,CHEMBL875477,,
13210,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,50597,N,,CHEMBL627287,,
13211,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,50588,N,,CHEMBL627288,,
13212,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total clearance from the body in rat,50597,N,,CHEMBL627289,,
13213,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance into cortex from rat plasma or PBS,50597,N,,CHEMBL627290,1969.0,
13214,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,22224,U,,CHEMBL627291,,
13215,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,22224,U,,CHEMBL627292,,
13216,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,22224,U,,CHEMBL627293,,
13217,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,22224,U,,CHEMBL627294,,
13218,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,22224,U,,CHEMBL875478,,
13219,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Clearance was determined,22224,U,,CHEMBL627295,,
13220,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,50594,N,,CHEMBL627296,,
13221,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,50592,N,,CHEMBL626119,,
13222,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,50597,N,,CHEMBL626120,,
13223,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance in rat after iv dose (100 ug/kg),50597,N,,CHEMBL626121,,
13224,,Cavia porcellus,BAO_0000218,,1,A,Autocuration,In vivo,0,Clearance in guinea pig,22224,U,,CHEMBL626122,,
13225,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for clearance in rat,50597,N,,CHEMBL626123,,
13226,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for the clearance in dog,50588,N,,CHEMBL623456,,
13227,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for the clearance in rat,50597,N,,CHEMBL623457,,
13228,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested in vivo for clearance after iv administration in the rat,50597,N,,CHEMBL623458,,
13229,,,BAO_0000218,,1,A,Autocuration,In vivo,0,IV clearance determined at an iv dose of 14 mg/kg,22224,U,,CHEMBL623459,,
13230,,,BAO_0000218,,1,A,Autocuration,In vivo,0,IV clearance determined at an iv dose of 15.2 mg/kg,22224,U,,CHEMBL875484,,
13231,,,BAO_0000218,,1,A,Autocuration,In vivo,0,IV clearance determined at an iv dose of 15 mg/kg,22224,U,,CHEMBL623460,,
13232,,,BAO_0000218,,1,A,Autocuration,In vivo,0,IV clearance determined at an peroral dose of 30 mg/kg.,22224,U,,CHEMBL623461,,
13233,,,BAO_0000218,,1,A,Autocuration,In vivo,0,IV clearance determined at an peroral dose of 30.2 mg/kg.,22224,U,,CHEMBL623462,,
13234,,,BAO_0000218,,1,A,Autocuration,In vivo,0,IV clearance determined at an peroral dose of 30.3 mg/kg.,22224,U,,CHEMBL627386,,
13235,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,50597,N,,CHEMBL627387,2113.0,
13236,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,50597,N,,CHEMBL627388,2107.0,
13237,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,50597,N,,CHEMBL627389,2048.0,
13238,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,50597,N,,CHEMBL627390,2385.0,
13239,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,50597,N,,CHEMBL627391,1969.0,
13240,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,50597,N,,CHEMBL627392,,
13241,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,50597,N,,CHEMBL627393,2106.0,
13242,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,50597,N,,CHEMBL627394,3126.0,
13243,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,50597,N,,CHEMBL627395,10000001.0,
13244,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,50597,N,,CHEMBL875485,2037.0,
13245,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,50597,N,,CHEMBL627396,,
13246,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,50597,N,,CHEMBL627397,,
13247,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,50597,N,,CHEMBL627398,948.0,
13248,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,50597,N,,CHEMBL627399,10000001.0,
13249,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,50597,N,,CHEMBL627400,2113.0,
13250,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,50597,N,,CHEMBL627401,2107.0,
13251,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,50597,N,,CHEMBL627402,2048.0,
13252,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,50597,N,,CHEMBL627403,2385.0,
13253,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,50597,N,,CHEMBL627404,1969.0,
13254,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,50597,N,,CHEMBL623101,,
13255,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,50597,N,,CHEMBL877480,2106.0,
13256,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,50597,N,,CHEMBL623102,3126.0,
13257,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,50597,N,,CHEMBL623103,10000001.0,
13258,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,50597,N,,CHEMBL623104,2037.0,
13259,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,50597,N,,CHEMBL623105,,
13260,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,50597,N,,CHEMBL623106,,
13261,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,50597,N,,CHEMBL623107,948.0,
13262,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,50597,N,,CHEMBL623108,160.0,
13263,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,50597,N,,CHEMBL623109,2113.0,
13264,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,50597,N,,CHEMBL623110,2107.0,
13265,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,50597,N,,CHEMBL623111,2048.0,
13266,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,50597,N,,CHEMBL625060,2385.0,
13267,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,50597,N,,CHEMBL625061,1969.0,
13268,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,50597,N,,CHEMBL625062,,
13269,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,50597,N,,CHEMBL625063,2106.0,
13270,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,50597,N,,CHEMBL625064,3126.0,
13271,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,50597,N,,CHEMBL625065,10000001.0,
13272,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,50597,N,,CHEMBL625066,2037.0,
13273,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,50597,N,,CHEMBL625067,,
13274,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,50597,N,,CHEMBL625068,,
13275,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,50597,N,,CHEMBL622159,948.0,
13276,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,50597,N,,CHEMBL622160,160.0,
13277,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,50597,N,,CHEMBL622161,2113.0,
13278,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,50597,N,,CHEMBL622162,2048.0,
13279,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,50597,N,,CHEMBL622163,2385.0,
13280,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,50597,N,,CHEMBL622313,1969.0,
13281,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,50597,N,,CHEMBL622314,,
13282,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,50597,N,,CHEMBL622315,2106.0,
13283,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,50597,N,,CHEMBL622316,3126.0,
13284,,Escherichia coli,BAO_0000218,,1,A,Intermediate,,1,Normal diffusion coefficient in water for Escherichia coli,50212,N,,CHEMBL877486,,
13285,,,BAO_0000019,,1,A,Autocuration,,0,Average max percent decrease in RVR (renal vascular resistance) was determined,22224,U,,CHEMBL622317,,
13286,,,BAO_0000019,,1,A,Autocuration,,0,Average max percent decrease in RVR (renal vascular resistance) was determined.,22224,U,,CHEMBL622318,,
13287,,,BAO_0000019,,1,A,Autocuration,,0,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,22224,U,,CHEMBL622319,,
13288,,,BAO_0000019,,1,A,Autocuration,,0,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,22224,U,,CHEMBL622320,,
13289,,,BAO_0000019,,1,A,Autocuration,,0,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,22224,U,,CHEMBL622321,,
13290,,,BAO_0000019,,1,A,Autocuration,,0,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,22224,U,,CHEMBL622322,,
13291,,,BAO_0000019,,1,A,Autocuration,,0,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,22224,U,,CHEMBL622323,,
13292,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,50597,N,,CHEMBL622324,,
13293,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",50588,N,,CHEMBL622325,1088.0,
13294,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",50588,N,,CHEMBL622326,1088.0,
13295,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",50588,N,,CHEMBL877487,1088.0,
13296,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",50588,N,,CHEMBL622327,1088.0,
13297,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",50588,N,,CHEMBL622328,1088.0,
13298,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",50588,N,,CHEMBL622329,1088.0,
13299,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",50588,N,,CHEMBL622330,1088.0,
13300,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",50588,N,,CHEMBL622331,1088.0,
13301,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",50588,N,,CHEMBL622332,1088.0,
13302,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",50588,N,,CHEMBL622333,1088.0,
13303,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",22224,U,,CHEMBL627658,1088.0,
13304,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",22224,U,,CHEMBL630428,1088.0,
13305,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",22224,U,,CHEMBL630429,1088.0,
13306,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",22224,U,,CHEMBL630430,1088.0,
13307,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",22224,U,,CHEMBL630431,1088.0,
13308,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",50597,N,,CHEMBL630432,1088.0,
13309,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",50597,N,,CHEMBL630433,1088.0,
13310,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",50597,N,,CHEMBL630434,1088.0,
13311,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",50597,N,,CHEMBL629372,1088.0,
13312,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",50597,N,,CHEMBL629553,1088.0,
13313,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",50597,N,,CHEMBL629554,1088.0,
13314,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",50597,N,,CHEMBL874447,1088.0,
13315,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",50597,N,,CHEMBL629555,1088.0,
13316,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",50597,N,,CHEMBL629556,1088.0,
13317,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",50597,N,,CHEMBL629557,1088.0,
13318,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",50597,N,,CHEMBL629558,1088.0,
13319,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",50597,N,,CHEMBL629559,1088.0,
13320,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",50597,N,,CHEMBL629560,1088.0,
13321,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",50588,N,,CHEMBL629561,1088.0,
13322,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",50588,N,,CHEMBL629562,1088.0,
13323,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",50588,N,,CHEMBL629563,1088.0,
13324,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",50588,N,,CHEMBL629564,1088.0,
13325,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",50588,N,,CHEMBL629565,1088.0,
13326,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",50588,N,,CHEMBL629566,1088.0,
13327,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",50588,N,,CHEMBL629567,1088.0,
13328,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",50588,N,,CHEMBL629568,1088.0,
13329,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",50588,N,,CHEMBL629569,1088.0,
13330,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",50588,N,,CHEMBL629570,1088.0,
13331,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",22224,U,,CHEMBL629571,1088.0,
13332,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,22224,U,,CHEMBL629572,,
13333,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,22224,U,,CHEMBL629573,,
13334,,Eutheria,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability (dose 20 mg/kg),22224,U,,CHEMBL629574,,
13335,,Canis lupus familiaris,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in dog,22224,U,,CHEMBL629575,,
13336,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in rat (Sprague-Dawley) (male),22224,U,,CHEMBL874448,,
13337,,Primates,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in monkey (dose 10 mg/kg i.d.),22224,U,,CHEMBL629576,,
13338,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in rat,22224,U,,CHEMBL629577,,
13339,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in rat,22224,U,,CHEMBL629578,,
13340,,Canis lupus familiaris,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in dog (dose 3.0 mg/kg p.o.),22224,U,,CHEMBL629579,,
13341,,Canis lupus familiaris,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,22224,U,,CHEMBL882958,,
13342,,Pan troglodytes,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,50505,N,,CHEMBL629580,,
13343,,Eutheria,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability,22224,U,,CHEMBL629581,,
13344,,Saimiri,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in squirrel monkey,22224,U,,CHEMBL629582,,
13345,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was evaluated in dog,50588,N,,CHEMBL628522,,
13346,,Cricetinae,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was evaluated in hamster,100712,N,,CHEMBL625432,,
13347,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in rat,22224,U,,CHEMBL625433,,
13348,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,50597,N,,CHEMBL625434,1969.0,
13349,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,50597,N,,CHEMBL625435,1969.0,
13350,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in rat (dose 10 mg/kg p.o.),22224,U,,CHEMBL625436,,
13351,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was measured in cynomolgus monkeys.,100710,N,,CHEMBL874588,,
13352,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Bioavailability was measured in nude mice.,50594,N,,CHEMBL625437,,
13353,,Mustela putorius furo,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in ferret (dose 10 mg/kg i.d.),22224,U,,CHEMBL625438,,
13354,,Simiiformes,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),22224,U,,CHEMBL625439,,
13355,,Simiiformes,BAO_0000218,,1,A,Autocuration,In vivo,0,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",22224,U,,CHEMBL625440,,
13356,,Simiiformes,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),22224,U,,CHEMBL625441,,
13357,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability in rat (dose 10 mg/kg i.d.),22224,U,,CHEMBL625442,,
13358,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",50597,N,,CHEMBL625443,,
13359,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Bioavailability was determined; extremely poor,22224,U,,CHEMBL625444,,
13360,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,% bioavailability in mice after oral administration of prodrug,50594,N,,CHEMBL625445,,
13361,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,50588,N,,CHEMBL625446,,
13362,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,50588,N,,CHEMBL882960,,
13363,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,50588,N,,CHEMBL625447,,
13364,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,50588,N,,CHEMBL625448,,
13365,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,50588,N,,CHEMBL625449,,
13366,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),50588,N,,CHEMBL874589,,
13367,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,50588,N,,CHEMBL625450,,
13368,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,50588,N,,CHEMBL625451,,
13369,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,50588,N,,CHEMBL626584,,
13370,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,50588,N,,CHEMBL626585,,
13371,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,50588,N,,CHEMBL626586,,
13372,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,50588,N,,CHEMBL626587,,
13373,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,50588,N,,CHEMBL626588,,
13374,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,50588,N,,CHEMBL626589,,
13375,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,50588,N,,CHEMBL626590,,
13376,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,50588,N,,CHEMBL626591,,
13377,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,50588,N,,CHEMBL627181,,
13378,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,50588,N,,CHEMBL628083,,
13379,,,BAO_0000218,,1,A,Autocuration,In vivo,0,IV clearance determined at an peroral dose of 15 mg/kg.,22224,U,,CHEMBL628084,,
13380,,Hymenolepis nana,BAO_0000218,,1,F,Expert,In vivo,1,Mouse oral clearance was measured against Hymenolepiasis nana.,50064,N,,CHEMBL628085,,
13381,,Heligmosomoides polygyrus,BAO_0000218,,1,F,Expert,In vivo,1,Mouse oral clearance was measured against Nematospiroides dubius,50545,N,,CHEMBL628086,,
13382,,,BAO_0000218,,1,F,Autocuration,In vivo,0,Mouse oral clearance was measured against N. dubius; NT is Not Tested,22224,U,,CHEMBL628087,,
13383,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Mouse oral clearance was measured against N. nana; NT is Not Tested,50594,N,,CHEMBL628088,,
13384,,,BAO_0000218,,1,B,Autocuration,In vivo,0,Mouse oral clearance was measured against N. nana; NT is Not Tested,22224,U,,CHEMBL628089,,
13385,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,22224,U,,CHEMBL628090,,
13386,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,22224,U,,CHEMBL628091,,
13387,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,22224,U,,CHEMBL628092,,
13388,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,22224,U,,CHEMBL628093,,
13389,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,22224,U,,CHEMBL875607,,
13390,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,22224,U,,CHEMBL625710,,
13391,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,22224,U,,CHEMBL625711,,
13392,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,22224,U,,CHEMBL625712,,
13393,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,22224,U,,CHEMBL625713,,
13394,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,50588,N,,CHEMBL625714,,
13395,,Macaca mulatta,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,50797,N,,CHEMBL625715,,
13396,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,50597,N,,CHEMBL625716,,
13397,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,50597,N,,CHEMBL625717,,
13398,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance was determined for the compound in rats,50597,N,,CHEMBL625718,,
13399,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,50597,N,,CHEMBL625719,,
13400,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,50597,N,,CHEMBL625720,,
13401,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,50597,N,,CHEMBL625721,,
13402,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,50597,N,,CHEMBL625722,,
13403,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,50597,N,,CHEMBL625723,,
13404,,Heligmosomoides polygyrus,BAO_0000218,,1,A,Intermediate,In vivo,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,50545,N,,CHEMBL625724,,
13405,,Heligmosomoides polygyrus,BAO_0000218,,1,A,Intermediate,In vivo,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,50545,N,,CHEMBL625725,,
13406,,Heligmosomoides polygyrus,BAO_0000218,,1,A,Intermediate,In vivo,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,50545,N,,CHEMBL625726,,
13407,,Heligmosomoides polygyrus,BAO_0000218,,1,A,Intermediate,In vivo,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,50545,N,,CHEMBL875608,,
13408,,Heligmosomoides polygyrus,BAO_0000218,,1,A,Intermediate,In vivo,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,50545,N,,CHEMBL625727,,
13409,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,22224,U,,CHEMBL625728,1088.0,
13410,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,22224,U,,CHEMBL625729,,
13411,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,22224,U,,CHEMBL625730,,
13412,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,22224,U,,CHEMBL625731,1088.0,
13413,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Urinary clearance was determined in rat at 25 mg/kg os dosage,22224,U,,CHEMBL626417,1088.0,
13414,,Homo sapiens,BAO_0000218,,1,A,Intermediate,In vivo,1,Urinary clearance was determined at 100 mg/kg oral dosage in human,50587,N,,CHEMBL626418,1088.0,
13415,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,50588,N,,CHEMBL626419,1088.0,
13416,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,50588,N,,CHEMBL626592,1969.0,
13417,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,50597,N,,CHEMBL626593,1969.0,
13418,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,50597,N,,CHEMBL626594,,
13419,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Clearance rate in dogs,50588,N,,CHEMBL625035,,
13420,,,BAO_0000019,,1,A,Autocuration,In vitro,0,Compound was measured for intrinsic clearance,22224,U,,CHEMBL625036,,
13421,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL625037,,
13422,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL625038,,
13423,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL625039,,
13424,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL625040,,
13425,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL625041,,
13426,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL625042,,
13427,,,BAO_0000019,,1,A,Autocuration,,0,Partition coefficient of the compound,22224,U,,CHEMBL874411,,
13428,,,BAO_0000019,,1,A,Autocuration,,0,Permeability,22224,U,,CHEMBL625043,,
13429,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL625044,,
13430,,,BAO_0000019,,1,A,Autocuration,,0,Partition coefficient (logD),22224,U,,CHEMBL625045,,
13431,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP) (CLOGP3 V3.4),22229,U,,CHEMBL625046,,
13432,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP) (CLOGP3 V3.4),22229,U,,CHEMBL625047,,
13433,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL625048,,
13434,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL625049,,
13435,,,BAO_0000100,,1,P,Autocuration,,0,Calculated logarithm of partition coefficient (P) was determined,22229,U,,CHEMBL625050,,
13436,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL625051,,
13437,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL874412,,
13438,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL625052,,
13439,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL625053,,
13440,,,BAO_0000019,,1,A,Autocuration,,0,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,22224,U,,CHEMBL623250,,
13441,,,BAO_0000019,,1,A,Autocuration,,0,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,22224,U,,CHEMBL623251,,
13442,,,BAO_0000019,,1,A,Autocuration,,0,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,22224,U,,CHEMBL623252,,
13443,,,BAO_0000019,,1,A,Autocuration,,0,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,22224,U,,CHEMBL623253,,
13444,,,BAO_0000019,,1,A,Autocuration,,0,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,22224,U,,CHEMBL623254,,
13445,,,BAO_0000019,,1,A,Autocuration,,0,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,22224,U,,CHEMBL623255,,
13446,,,BAO_0000019,,1,A,Autocuration,,0,Percent degradation of compound at a pH of 1 over a 18 hr period,22224,U,,CHEMBL626831,,
13447,,,BAO_0000019,,1,A,Autocuration,,0,Percent degradation of compound at pH of 1 over an 18 hr period,22224,U,,CHEMBL877494,,
13448,,,BAO_0000019,,1,A,Autocuration,,0,Delta Logarithm of Partition Coefficient value was determined.,22224,U,,CHEMBL626832,,
13449,,,BAO_0000019,,1,A,Autocuration,,0,Delta logPoct-cyc,22224,U,,CHEMBL626833,,
13450,,,BAO_0000100,,1,P,Autocuration,,0,Lipophilicity estimated on reversed phase TLC,22224,U,,CHEMBL626834,,
13451,,,BAO_0000019,,1,A,Autocuration,,0,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,22224,U,,CHEMBL626835,,
13452,,,BAO_0000019,,1,A,Autocuration,,0,Delta logPoct-cyc,22224,U,,CHEMBL626836,,
13453,,,BAO_0000100,,1,P,Autocuration,,0,Change in logarithm of partition coefficient of the compound,22229,U,,CHEMBL626837,,
13454,,,BAO_0000019,,1,A,Autocuration,,0,Delta logD (pH 6.5),22224,U,,CHEMBL626838,,
13455,,,BAO_0000100,,1,P,Autocuration,,0,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",22224,U,,CHEMBL626839,,
13456,,,BAO_0000019,,1,A,Autocuration,,0,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,22224,U,,CHEMBL626840,,
13457,,,BAO_0000019,,1,A,Autocuration,,0,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),22224,U,,CHEMBL626841,,
13458,,,BAO_0000219,,1,A,Autocuration,,0,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,22224,U,,CHEMBL626842,,
13459,,,BAO_0000219,,1,A,Autocuration,,0,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,22224,U,,CHEMBL626843,,
13460,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,50597,N,,CHEMBL626844,,
13461,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of deuterium retained was reported after normal workup in rats,50597,N,,CHEMBL877495,,
13462,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,50597,N,,CHEMBL626845,,
13463,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,50597,N,,CHEMBL626846,,
13464,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,50597,N,,CHEMBL626847,,
13465,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,50597,N,,CHEMBL628677,,
13466,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,50597,N,,CHEMBL628678,,
13467,,,BAO_0000019,,1,A,Autocuration,,0,Compound was subjected to electrochemical oxidation,22224,U,,CHEMBL628679,,
13468,,,BAO_0000019,,1,A,Autocuration,,0,Compound was subjected to photochemical oxidation,22224,U,,CHEMBL628680,,
13469,,,BAO_0000019,,1,A,Autocuration,,0,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,22224,U,,CHEMBL628681,,
13470,,,BAO_0000019,,1,A,Autocuration,,0,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,22224,U,,CHEMBL628682,,
13471,,,BAO_0000019,,1,A,Autocuration,,0,Oxidation of compound by methemoglobin in presence of hydroperoxide,22224,U,,CHEMBL628683,,
13472,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percent diffusion through fuzzy rat skin after 48 h of incubation,50597,N,,CHEMBL628684,,
13473,,,BAO_0000100,,1,P,Autocuration,,0,Dissociation constant (pKa),22229,U,,CHEMBL877501,,
13474,,,BAO_0000100,,1,P,Autocuration,,0,Dissociation constant value of the compound; ND means not determined.,22224,U,,CHEMBL628685,,
13475,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,50597,N,,CHEMBL628686,178.0,
13476,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,50597,N,,CHEMBL628687,178.0,
13477,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,50597,N,,CHEMBL628688,,
13478,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,50597,N,,CHEMBL628689,,
13479,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,50597,N,,CHEMBL628690,2107.0,
13480,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,50597,N,,CHEMBL629363,2107.0,
13481,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,50597,N,,CHEMBL629364,2106.0,
13482,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,50597,N,,CHEMBL629365,2106.0,
13483,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,50597,N,,CHEMBL629366,,
13484,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,50597,N,,CHEMBL629367,1088.0,
13485,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,50597,N,,CHEMBL629368,1988.0,
13486,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,50597,N,,CHEMBL877502,1088.0,
13487,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,50594,N,,CHEMBL629369,2037.0,
13488,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,50594,N,,CHEMBL629370,955.0,
13489,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",22224,U,,CHEMBL629371,1088.0,
13490,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",22224,U,,CHEMBL626276,1088.0,
13491,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",22224,U,,CHEMBL626277,1088.0,
13492,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",22224,U,,CHEMBL631250,1088.0,
13493,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",50597,N,,CHEMBL631251,1088.0,
13494,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",50597,N,,CHEMBL631252,1088.0,
13495,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",50597,N,,CHEMBL631253,1088.0,
13496,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",50597,N,,CHEMBL631254,1088.0,
13497,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",50597,N,,CHEMBL631255,1088.0,
13498,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",50597,N,,CHEMBL631256,1088.0,
13499,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",50597,N,,CHEMBL631257,1088.0,
13500,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",50597,N,,CHEMBL628009,1088.0,
13501,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",50597,N,,CHEMBL628010,1088.0,
13502,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",50597,N,,CHEMBL628011,1088.0,
13503,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",50597,N,,CHEMBL628012,1088.0,
13504,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",50597,N,,CHEMBL628013,1088.0,
13505,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",50597,N,,CHEMBL628014,1088.0,
13506,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",50588,N,,CHEMBL628015,1088.0,
13507,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",50588,N,,CHEMBL628016,1088.0,
13508,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",50588,N,,CHEMBL874461,1088.0,
13509,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",50588,N,,CHEMBL628017,1088.0,
13510,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",50588,N,,CHEMBL628018,1088.0,
13511,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",50588,N,,CHEMBL628019,1088.0,
13512,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",50588,N,,CHEMBL628020,1088.0,
13513,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",50588,N,,CHEMBL628021,1088.0,
13514,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",50588,N,,CHEMBL628022,1088.0,
13515,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",50588,N,,CHEMBL628023,1088.0,
13516,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",22224,U,,CHEMBL628024,1088.0,
13517,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",22224,U,,CHEMBL628025,1088.0,
13518,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",22224,U,,CHEMBL628026,1088.0,
13519,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",22224,U,,CHEMBL628027,1088.0,
13520,,Simiiformes,BAO_0000218,,1,A,Autocuration,,0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",22224,U,,CHEMBL628028,1088.0,
13521,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",50597,N,,CHEMBL628029,1088.0,
13522,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",50597,N,,CHEMBL628030,1088.0,
13523,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",50597,N,,CHEMBL628031,1088.0,
13524,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",50597,N,,CHEMBL628032,1088.0,
13525,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",50597,N,,CHEMBL628033,1088.0,
13526,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",50597,N,,CHEMBL628034,1088.0,
13527,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",50597,N,,CHEMBL628035,1088.0,
13528,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",50597,N,,CHEMBL628036,1088.0,
13529,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",50597,N,,CHEMBL874462,1088.0,
13530,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,50588,N,,CHEMBL628037,,
13531,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,50588,N,,CHEMBL628123,,
13532,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,50588,N,,CHEMBL628124,,
13533,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,50588,N,,CHEMBL628125,,
13534,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,50588,N,,CHEMBL628126,,
13535,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),50588,N,,CHEMBL628127,,
13536,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,50588,N,,CHEMBL628128,,
13537,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,50588,N,,CHEMBL628129,,
13538,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,50588,N,,CHEMBL628130,,
13539,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,50588,N,,CHEMBL628131,,
13540,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,50588,N,,CHEMBL628132,,
13541,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,50588,N,,CHEMBL628133,,
13542,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,50588,N,,CHEMBL628134,,
13543,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,50588,N,,CHEMBL628135,,
13544,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,50588,N,,CHEMBL628136,,
13545,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,50588,N,,CHEMBL628137,,
13546,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,50588,N,,CHEMBL628138,,
13547,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,50588,N,,CHEMBL628139,,
13548,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,50588,N,,CHEMBL628140,,
13549,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,50588,N,,CHEMBL628141,,
13550,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,50588,N,,CHEMBL628142,,
13551,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,50588,N,,CHEMBL628143,,
13552,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,50588,N,,CHEMBL628144,,
13553,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,50588,N,,CHEMBL628145,,
13554,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,50588,N,,CHEMBL628146,,
13555,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,50588,N,,CHEMBL625355,,
13556,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,50588,N,,CHEMBL625356,,
13557,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,50588,N,,CHEMBL625357,,
13558,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,50588,N,,CHEMBL625527,,
13559,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),50588,N,,CHEMBL875473,,
13560,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,50588,N,,CHEMBL625528,,
13561,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,50597,N,,CHEMBL626304,,
13562,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,50588,N,,CHEMBL624138,1637.0,
13563,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL624139,,
13564,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL624140,,
13565,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL624141,,
13566,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL624142,,
13567,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL624143,,
13568,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL624144,,
13569,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL624145,,
13570,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL624146,,
13571,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL624147,,
13572,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP) (MacLogP),22229,U,,CHEMBL883123,,
13573,,,BAO_0000019,,1,A,Autocuration,,0,Partition coefficient (logP),22224,U,,CHEMBL624148,,
13574,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter was determined,22224,U,,CHEMBL874416,,
13575,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL624149,,
13576,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL624150,,
13577,,,BAO_0000100,,1,P,Autocuration,,0,Lipophilicity was determined,22224,U,,CHEMBL624151,,
13578,,,BAO_0000100,,1,P,Autocuration,,0,Lipophilicity was determined,22224,U,,CHEMBL624152,,
13579,,,BAO_0000100,,1,P,Autocuration,,0,Lipophilicity was determined,22224,U,,CHEMBL622139,,
13580,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL622140,,
13581,,,BAO_0000100,,1,P,Autocuration,,0,Lipophilicity was determined,22224,U,,CHEMBL622141,,
13582,,,BAO_0000100,,1,P,Autocuration,,0,Lipophilicity in octanol-water,22224,U,,CHEMBL622142,,
13583,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL622143,,
13584,,,BAO_0000100,,1,P,Autocuration,,0,Octanol-water partition coefficient was determined,22229,U,,CHEMBL622144,,
13585,,,BAO_0000019,,1,A,Autocuration,,0,Partition coefficient (logP),22224,U,,CHEMBL877473,,
13586,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL622145,,
13587,,,BAO_0000019,,1,A,Autocuration,,0,Partition coefficient was determined; ND means not determined,22224,U,,CHEMBL622146,,
13588,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP),22229,U,,CHEMBL622147,,
13589,,,BAO_0000019,,1,A,Autocuration,,0,Partition coefficient of the compound,22224,U,,CHEMBL622148,,
13590,,,BAO_0000019,,1,A,Autocuration,,0,Permeability was determined,22224,U,,CHEMBL883124,,
13591,,,BAO_0000100,,1,P,Autocuration,,0,The compound was evaluated for the partition coefficient,22229,U,,CHEMBL622149,,
13592,,,BAO_0000019,,1,A,Autocuration,,0,Partition coefficient (logP),22224,U,,CHEMBL622150,,
13593,,,BAO_0000100,,1,P,Autocuration,,0,The lipophilicity was reported,22224,U,,CHEMBL622151,,
13594,,,BAO_0000100,,1,P,Autocuration,,0,logarithm of the octanol-water partition coefficient for the compound,22229,U,,CHEMBL622152,,
13595,,,BAO_0000019,,1,A,Autocuration,,0,Clogp value was determined,22224,U,,CHEMBL622153,,
13596,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Clp at a dose of 1.5 mg/kg,22224,U,,CHEMBL877474,,
13597,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Clp at a dose of 2.0 mg/kg,22224,U,,CHEMBL622154,,
13598,,,BAO_0000218,,1,A,Autocuration,In vivo,0,"Clp, plasma clearance at a dose of 10 mg/kg",22224,U,,CHEMBL622155,1969.0,
13599,,,BAO_0000218,,1,A,Autocuration,In vivo,0,"Clp, plasma clearance at a dose of 50 mg/kg",22224,U,,CHEMBL622156,1969.0,
13600,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for plasma clearance in rat,50597,N,,CHEMBL622157,1969.0,
13601,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Compound was tested for plasma clearance in rat; Not determined,50597,N,,CHEMBL622158,1969.0,
13602,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,50597,N,,CHEMBL622807,,
13603,,Macaca mulatta,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,50797,N,,CHEMBL622808,,
13604,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance by iv administration at a dose 0.003 ug/mL,22224,U,,CHEMBL622809,,
13605,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Plasma clearance determined,22224,U,,CHEMBL622810,,
13606,,Cricetinae,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance after iv administration at 3 mg/kg in hamster,100712,N,,CHEMBL876653,,
13607,,Cricetinae,BAO_0000218,,1,A,Intermediate,In vivo,1,Plasma clearance after iv administration at 4 mg/kg in hamster,100712,N,,CHEMBL622811,,
13608,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Rate of clearance in rat was determined,50597,N,,CHEMBL622986,,
13609,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,50597,N,,CHEMBL622987,1969.0,
13610,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Total plasma clearance after iv dose of 5.10 mg/kg in rats,50597,N,,CHEMBL622988,1969.0,
13611,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,50597,N,,CHEMBL622989,1969.0,
13612,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,50597,N,,CHEMBL622990,1969.0,
13613,,Simiiformes,BAO_0000218,,1,A,Autocuration,In vivo,0,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,22224,U,,CHEMBL622991,1969.0,
13614,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,50597,N,,CHEMBL622227,1969.0,
13615,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,50588,N,,CHEMBL622228,1969.0,
13616,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Clpl value in rat,50597,N,,CHEMBL622229,,
13617,,Cavia porcellus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,50512,N,,CHEMBL622230,,
13618,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,50597,N,,CHEMBL622231,,
13619,,Macaca fascicularis,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,100710,N,,CHEMBL622232,,
13620,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,22224,U,,CHEMBL622233,,
13621,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,22224,U,,CHEMBL622234,,
13622,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,22224,U,,CHEMBL622235,,
13623,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,22224,U,,CHEMBL622236,,
13624,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,22224,U,,CHEMBL622237,,
13625,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax in minutes at a po dose of 10.0(pmol/g/h).,22224,U,,CHEMBL877482,,
13626,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax in minutes at a po dose of 20.0(pmol/g/h).,22224,U,,CHEMBL622238,,
13627,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax in minutes at a po dose of 40.0(pmol/g/h).,22224,U,,CHEMBL622239,,
13628,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax was calculated as maximum concentration reached in the blood,22224,U,,CHEMBL622240,178.0,
13629,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,22224,U,,CHEMBL622241,178.0,
13630,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax was determine after peroral administration at 10 mpk in Rat,50597,N,,CHEMBL631013,,
13631,,Macaca mulatta,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax was determine after peroral administration at 10 mpk in Rhesus,50797,N,,CHEMBL631014,,
13632,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax was determine after peroral administration at 10 mpk in dog,50588,N,,CHEMBL631015,,
13633,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax was determine after peroral administration at 160 mpk in Rat,50597,N,,CHEMBL631016,,
13634,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax was determine after peroral administration at 20 mpk in Rat,50597,N,,CHEMBL631017,,
13635,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Cmax was determine after peroral administration at 50 mpk in Rat,50597,N,,CHEMBL631018,,
13636,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Cmax was determined,22224,U,,CHEMBL631019,,
13637,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,50594,N,,CHEMBL875761,955.0,
13638,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,50594,N,,CHEMBL631020,955.0,
13639,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,50594,N,,CHEMBL631669,955.0,
13640,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,50594,N,,CHEMBL631670,955.0,
13641,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,50594,N,,CHEMBL631671,2435.0,
13642,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,50597,N,,CHEMBL631672,178.0,
13643,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,50597,N,,CHEMBL631673,178.0,
13644,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,50597,N,,CHEMBL631856,178.0,
13645,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,50597,N,,CHEMBL631857,178.0,
13646,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,50597,N,,CHEMBL631858,178.0,
13647,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,50597,N,,CHEMBL631859,178.0,
13648,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,50597,N,,CHEMBL631860,178.0,
13649,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,50597,N,,CHEMBL631861,178.0,
13650,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,50597,N,,CHEMBL631862,178.0,
13651,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,50597,N,,CHEMBL631863,178.0,
13652,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,50597,N,,CHEMBL631864,178.0,
13653,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,50597,N,,CHEMBL631865,178.0,
13654,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,50597,N,,CHEMBL631866,178.0,
13655,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,50597,N,,CHEMBL629360,178.0,
13656,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,50597,N,,CHEMBL629361,178.0,
13657,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,50597,N,,CHEMBL629362,178.0,
13658,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,50597,N,,CHEMBL630740,178.0,
13659,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,50597,N,,CHEMBL630741,178.0,
13660,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,50597,N,,CHEMBL630742,178.0,
13661,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,50597,N,,CHEMBL630743,,
13662,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,50597,N,,CHEMBL630744,,
13663,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,50597,N,,CHEMBL630745,,
13664,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,50597,N,,CHEMBL630746,,
13665,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,50597,N,,CHEMBL630747,,
13666,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,50597,N,,CHEMBL630748,,
13667,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,50597,N,,CHEMBL632056,,
13668,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,50597,N,,CHEMBL632057,,
13669,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,50597,N,,CHEMBL632058,,
13670,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,50597,N,,CHEMBL632059,,
13671,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,50597,N,,CHEMBL632060,,
13672,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,50597,N,,CHEMBL632061,,
13673,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,50597,N,,CHEMBL629207,,
13674,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,50597,N,,CHEMBL629208,,
13675,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,50597,N,,CHEMBL629209,,
13676,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,50597,N,,CHEMBL629210,,
13677,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,50597,N,,CHEMBL629211,,
13678,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,50597,N,,CHEMBL629212,,
13679,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,50597,N,,CHEMBL629213,,
13680,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",50597,N,,CHEMBL629214,1088.0,
13681,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",50597,N,,CHEMBL629215,1088.0,
13682,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",50597,N,,CHEMBL635154,1088.0,
13683,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),50597,N,,CHEMBL629216,,
13684,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,50597,N,,CHEMBL629217,,
13685,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,N,,CHEMBL629218,,
13686,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),50597,N,,CHEMBL629219,,
13687,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),50597,N,,CHEMBL629220,,
13688,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),50597,N,,CHEMBL629221,,
13689,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,N,,CHEMBL631127,,
13690,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,50597,N,,CHEMBL631128,,
13691,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,N,,CHEMBL631129,,
13692,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),50597,N,,CHEMBL631130,,
13693,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),50597,N,,CHEMBL631131,,
13694,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),50597,N,,CHEMBL631132,,
13695,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,N,,CHEMBL631133,,
13696,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,50597,N,,CHEMBL631134,,
13697,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,N,,CHEMBL875120,,
13698,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),50597,N,,CHEMBL631135,,
13699,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),50597,N,,CHEMBL631136,,
13700,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),50597,N,,CHEMBL631137,,
13701,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,N,,CHEMBL631138,,
13702,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,50597,N,,CHEMBL631139,,
13703,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,N,,CHEMBL631140,,
13704,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),50597,N,,CHEMBL631141,,
13705,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),50597,N,,CHEMBL631142,,
13706,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),50597,N,,CHEMBL631143,,
13707,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,N,,CHEMBL631144,,
13708,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,50588,N,,CHEMBL631145,,
13709,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),50588,N,,CHEMBL631146,,
13710,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,50588,N,,CHEMBL631147,,
13711,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),50588,N,,CHEMBL631148,,
13712,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),50588,N,,CHEMBL631149,,
13713,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),50588,N,,CHEMBL631150,,
13714,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),50588,N,,CHEMBL631151,,
13715,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),50588,N,,CHEMBL631152,,
13716,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),50588,N,,CHEMBL631443,,
13717,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),50588,N,,CHEMBL631444,,
13718,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),50588,N,,CHEMBL631445,,
13719,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),50588,N,,CHEMBL631446,,
13720,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),50588,N,,CHEMBL631447,,
13721,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),50588,N,,CHEMBL631448,,
13722,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,50588,N,,CHEMBL631449,,
13723,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),50588,N,,CHEMBL631450,,
13724,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),50588,N,,CHEMBL629724,,
13725,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,N,,CHEMBL629725,14.0,
13726,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,N,,CHEMBL629726,14.0,
13727,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,N,,CHEMBL629727,2106.0,
13728,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,N,,CHEMBL630404,2106.0,
13729,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,N,,CHEMBL630405,2106.0,
13730,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,N,,CHEMBL630406,2106.0,
13731,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,N,,CHEMBL630407,945.0,
13732,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,N,,CHEMBL630573,945.0,
13733,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,N,,CHEMBL630574,945.0,
13734,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,N,,CHEMBL630575,945.0,
13735,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,N,,CHEMBL630576,,
13736,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,N,,CHEMBL630577,,
13737,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,N,,CHEMBL630578,,
13738,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,N,,CHEMBL630579,,
13739,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),50594,N,,CHEMBL630580,2113.0,
13740,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,50594,N,,CHEMBL630581,2113.0,
13741,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),50594,N,,CHEMBL630582,2113.0,
13742,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,50594,N,,CHEMBL630583,,
13743,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),50594,N,,CHEMBL630584,,
13744,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,50594,N,,CHEMBL630585,,
13745,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),50594,N,,CHEMBL630586,,
13746,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,50594,N,,CHEMBL630587,,
13747,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),50594,N,,CHEMBL630588,,
13748,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,50594,N,,CHEMBL630589,,
13749,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),50594,N,,CHEMBL630590,,
13750,,,BAO_0000019,,1,A,Autocuration,,0,Removal of 238-Plutonium(IV) in feces at 24 h,22224,U,,CHEMBL630591,1988.0,
13751,,,BAO_0000019,,1,A,Autocuration,,0,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),22224,U,,CHEMBL630592,1988.0,
13752,,,BAO_0000019,,1,A,Autocuration,,0,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,22224,U,,CHEMBL630593,,
13753,,,BAO_0000019,,1,A,Autocuration,,0,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),22224,U,,CHEMBL630594,,
13754,,,BAO_0000019,,1,A,Autocuration,,0,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),22224,U,,CHEMBL630595,1088.0,
13755,,,BAO_0000019,,1,A,Autocuration,,0,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),22224,U,,CHEMBL630596,1088.0,
13756,,,BAO_0000019,,1,A,Autocuration,,0,Removal of 238-Plutonium(IV) in urine after 0-24 h,22224,U,,CHEMBL630597,1088.0,
13757,,,BAO_0000019,,1,A,Autocuration,,0,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),22224,U,,CHEMBL630598,1088.0,
13758,,,BAO_0000019,,1,A,Autocuration,,0,Removal of 238-Plutonium(IV) in urine after 0-4 h,22224,U,,CHEMBL630599,1088.0,
13759,,,BAO_0000019,,1,A,Autocuration,,0,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),22224,U,,CHEMBL630600,1088.0,
13760,,,BAO_0000019,,1,A,Autocuration,,0,Removal of 238-Plutonium(IV) in urine after 4-24 h,22224,U,,CHEMBL630601,1088.0,
13761,,,BAO_0000019,,1,A,Autocuration,,0,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),22224,U,,CHEMBL630602,1088.0,
13762,,,BAO_0000019,,1,A,Autocuration,,0,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),22224,U,,CHEMBL630603,1088.0,
13763,,,BAO_0000019,,1,A,Autocuration,,0,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),22224,U,,CHEMBL630604,1088.0,
13764,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL624869,178.0,
13765,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL624870,178.0,
13766,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL623189,178.0,
13767,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL623190,178.0,
13768,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL623191,178.0,
13769,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL623192,,
13770,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL623193,,
13771,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL623194,,
13772,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL623195,,
13773,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL623196,,
13774,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,50597,N,,CHEMBL623197,,
13775,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,50597,N,,CHEMBL623198,,
13776,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,50597,N,,CHEMBL623199,,
13777,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,50597,N,,CHEMBL623200,2385.0,
13778,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,50597,N,,CHEMBL623201,2385.0,
13779,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,50597,N,,CHEMBL623202,2385.0,
13780,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,50597,N,,CHEMBL623203,2385.0,
13781,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,50597,N,,CHEMBL623204,2385.0,
13782,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,50597,N,,CHEMBL623205,2385.0,
13783,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,50597,N,,CHEMBL623206,2385.0,
13784,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,50597,N,,CHEMBL623207,2385.0,
13785,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,50597,N,,CHEMBL623208,2385.0,
13786,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,50597,N,,CHEMBL623209,2385.0,
13787,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,50597,N,,CHEMBL623210,2385.0,
13788,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,50597,N,,CHEMBL623211,,
13789,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,50597,N,,CHEMBL623212,995.0,
13790,,,BAO_0000019,,1,A,Autocuration,,0,Tested in vitro for intrinsic activity relative to quinpirole,22224,U,,CHEMBL623213,,
13791,,,BAO_0000019,,1,A,Autocuration,,0,"Relative ion enhancement, determined in pulsed ultrafiltration",22224,U,,CHEMBL623214,,
13792,,,BAO_0000019,,1,A,Autocuration,,0,% ionization at the pH 7.4 at 37 degree Centigrade,22224,U,,CHEMBL623215,,
13793,,,BAO_0000019,,1,A,Autocuration,,0,Percentage ionization was measured,22224,U,,CHEMBL623216,,
13794,,Bos taurus,BAO_0000218,,1,A,Intermediate,,1,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,50591,N,,CHEMBL623217,,
13795,,,BAO_0000019,,1,A,Autocuration,,0,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,22224,U,,CHEMBL623218,,
13796,,,BAO_0000019,,1,A,Autocuration,,0,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,22224,U,,CHEMBL623913,,
13797,,,BAO_0000019,,1,A,Autocuration,,0,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,22224,U,,CHEMBL623914,,
13798,,,BAO_0000100,,1,P,Autocuration,,0,Compound was evaluated for the partition coefficient in octanol/water,22229,U,,CHEMBL623915,,
13799,,,BAO_0000100,,1,P,Autocuration,,0,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),22229,U,,CHEMBL624080,,
13800,,,BAO_0000019,,1,A,Autocuration,,0,Equilibrium constant measured by the pulse radiolysis at pH 7,22224,U,,CHEMBL624081,,
13801,,Homo sapiens,BAO_0000218,,1,A,Intermediate,,1,In vitro hydrolytic rate constant determined in human blood,50587,N,,CHEMBL624082,,
13802,,Homo sapiens,BAO_0000218,,1,A,Intermediate,,1,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,50587,N,,CHEMBL625054,,
13803,,,BAO_0000019,,1,A,Autocuration,,0,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,22224,U,,CHEMBL877485,,
13804,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,50594,N,,CHEMBL625055,,
13805,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,50594,N,,CHEMBL625056,,
13806,,Homo sapiens,BAO_0000218,,1,A,Intermediate,,1,In vitro oxidation of compound in presence of human plasma,50587,N,,CHEMBL625057,,
13807,,,BAO_0000019,,1,A,Autocuration,,0,In vitro oxidation of compound in presence of hydrogen peroxide,22224,U,,CHEMBL625058,,
13808,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vitro oxidation of compound in presence of mouse brain homogenate,50594,N,,CHEMBL625059,,
13809,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vitro oxidation of compound in presence of mouse liver homogenate,50594,N,,CHEMBL629536,,
13810,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,50597,N,,CHEMBL629537,,
13811,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,50597,N,,CHEMBL629538,,
13812,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,50597,N,,CHEMBL629539,,
13813,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,50597,N,,CHEMBL874445,,
13814,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,50597,N,,CHEMBL629540,,
13815,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,50597,N,,CHEMBL629541,,
13816,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,50597,N,,CHEMBL629542,,
13817,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,50597,N,,CHEMBL630243,,
13818,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,50597,N,,CHEMBL630244,,
13819,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,50597,N,,CHEMBL630245,,
13820,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,50597,N,,CHEMBL630246,,
13821,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,50597,N,,CHEMBL630247,,
13822,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,50597,N,,CHEMBL630248,,
13823,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood at 240 minutes after dose administration.,50597,N,,CHEMBL630249,178.0,
13824,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood at 30 minutes after dose administration.,50597,N,,CHEMBL630250,178.0,
13825,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood at 360 minutes after dose administration.,50597,N,,CHEMBL630251,178.0,
13826,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood at 3 hr after dose administration.,50597,N,,CHEMBL630252,178.0,
13827,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood at 60 minutes after dose administration.,50597,N,,CHEMBL630408,178.0,
13828,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat cerebellum at 120 minutes after dose administration.,50597,N,,CHEMBL630409,2037.0,
13829,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,50597,N,,CHEMBL874446,2037.0,
13830,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat cerebellum at 15 minutes after dose administration.,50597,N,,CHEMBL630410,2037.0,
13831,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat cerebellum at 240 minutes after dose administration.,50597,N,,CHEMBL630411,2037.0,
13832,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat cerebellum at 30 minutes after dose administration.,50597,N,,CHEMBL630412,2037.0,
13833,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat cerebellum at 360 minutes after dose administration.,50597,N,,CHEMBL630413,2037.0,
13834,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat cerebellum at 3 hr after dose administration.,50597,N,,CHEMBL630414,2037.0,
13835,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat cerebellum at 60 minutes after dose administration.,50597,N,,CHEMBL630415,2037.0,
13836,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat cortex at 120 minutes after dose administration.,50597,N,,CHEMBL630416,,
13837,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat cortex at 1440 minutes after dose administration.,50597,N,,CHEMBL630417,,
13838,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat cortex at 15 minutes after dose administration.,50597,N,,CHEMBL630418,,
13839,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat cortex at 240 minutes after dose administration.,50597,N,,CHEMBL630419,,
13840,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat cortex at 30 minutes after dose administration.,50597,N,,CHEMBL630420,,
13841,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat cortex at 360 minutes after dose administration.,50597,N,,CHEMBL630421,,
13842,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat cortex at 3 hr after dose administration.,50597,N,,CHEMBL630422,,
13843,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat cortex at 60 minutes after dose administration.,50597,N,,CHEMBL630423,,
13844,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart at 120 minutes after dose administration.,50597,N,,CHEMBL630424,948.0,
13845,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart at 15 minutes after dose administration.,50597,N,,CHEMBL630425,948.0,
13846,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart at 240 minutes after dose administration.,50597,N,,CHEMBL629462,948.0,
13847,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart at 30 minutes after dose administration.,50597,N,,CHEMBL630426,948.0,
13848,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart at 360 minutes after dose administration.,50597,N,,CHEMBL630427,948.0,
13849,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart at 3 hr after dose administration.,50597,N,,CHEMBL625877,948.0,
13850,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart at 60 minutes after dose administration.,50597,N,,CHEMBL625878,948.0,
13851,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,50597,N,,CHEMBL625879,10000000.0,
13852,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat hippocampus at 240 minutes after dose administration.,50597,N,,CHEMBL625880,10000000.0,
13853,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat hippocampus at 30 minutes after dose administration.,50597,N,,CHEMBL625881,10000000.0,
13854,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat hippocampus at 360 minutes after dose administration.,50597,N,,CHEMBL625882,10000000.0,
13855,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat hippocampus at 15 minutes after dose administration.,50597,N,,CHEMBL625883,10000000.0,
13856,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat kidney at 120 minutes after dose administration.,50597,N,,CHEMBL625884,2113.0,
13857,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat kidney at 1440 minutes after dose administration.,50597,N,,CHEMBL625885,2113.0,
13858,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat kidney at 15 minutes after dose administration.,50597,N,,CHEMBL628649,2113.0,
13859,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat kidney at 240 minutes after dose administration.,50597,N,,CHEMBL628650,2113.0,
13860,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat kidney at 30 minutes after dose administration.,50597,N,,CHEMBL628651,2113.0,
13861,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat kidney at 360 minutes after dose administration.,50597,N,,CHEMBL628652,2113.0,
13862,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat kidney at 60 minutes after dose administration.,50597,N,,CHEMBL628653,2113.0,
13863,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver at 120 minutes after dose administration.,50597,N,,CHEMBL628654,2107.0,
13864,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver at 1440 minutes after dose administration.,50597,N,,CHEMBL628655,2107.0,
13865,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver at 15 minutes after dose administration.,50597,N,,CHEMBL625238,2107.0,
13866,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver at 240 minutes after dose administration.,50597,N,,CHEMBL625239,2107.0,
13867,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver at 30 minutes after dose administration.,50597,N,,CHEMBL625240,2107.0,
13868,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver at 360 minutes after dose administration.,50597,N,,CHEMBL625241,2107.0,
13869,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver at 60 minutes after dose administration.,50597,N,,CHEMBL625242,2107.0,
13870,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat lung at 120 minutes after dose administration.,50597,N,,CHEMBL874587,2048.0,
13871,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat lung at 1440 minutes after dose administration.,50597,N,,CHEMBL625405,2048.0,
13872,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat lung at 15 minutes after dose administration.,50597,N,,CHEMBL625406,2048.0,
13873,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat lung at 240 minutes after dose administration.,50597,N,,CHEMBL625407,2048.0,
13874,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat lung at 30 minutes after dose administration.,50597,N,,CHEMBL625408,2048.0,
13875,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat lung at 360 minutes after dose administration.,50597,N,,CHEMBL625409,2048.0,
13876,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,50597,N,,CHEMBL625410,1515.0,
13877,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,50597,N,,CHEMBL625411,1515.0,
13878,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,50597,N,,CHEMBL625412,1515.0,
13879,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,50597,N,,CHEMBL625413,1515.0,
13880,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percent of maximal contractile response to compound in rat thoracic aorta strips v,50597,N,,CHEMBL625414,1515.0,
13881,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,50597,N,,CHEMBL625415,1515.0,
13882,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,50597,N,,CHEMBL625416,1515.0,
13883,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,50597,N,,CHEMBL625417,1088.0,
13884,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,50597,N,,CHEMBL625418,1988.0,
13885,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,50597,N,,CHEMBL625419,1088.0,
13886,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,50597,N,,CHEMBL625420,,
13887,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,50597,N,,CHEMBL626996,,
13888,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",50597,N,,CHEMBL626997,1988.0,
13889,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",50597,N,,CHEMBL626998,1088.0,
13890,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",50597,N,,CHEMBL626999,,
13891,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,50594,N,,CHEMBL627000,,
13892,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,50594,N,,CHEMBL627001,,
13893,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,50594,N,,CHEMBL627002,,
13894,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,50594,N,,CHEMBL627003,,
13895,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,50594,N,,CHEMBL627004,1088.0,
13896,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,50594,N,,CHEMBL627005,1088.0,
13897,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,50594,N,,CHEMBL874594,1088.0,
13898,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,50594,N,,CHEMBL627006,1088.0,
13899,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,50594,N,,CHEMBL627007,1088.0,
13900,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,50594,N,,CHEMBL627884,1088.0,
13901,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,50594,N,,CHEMBL627885,1088.0,
13902,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,50594,N,,CHEMBL627886,1088.0,
13903,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,50594,N,,CHEMBL627887,1088.0,
13904,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,50594,N,,CHEMBL627888,1088.0,
13905,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,50594,N,,CHEMBL628057,1088.0,
13906,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,50594,N,,CHEMBL627405,1088.0,
13907,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,50588,N,,CHEMBL627406,1088.0,
13908,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,50588,N,,CHEMBL627407,1088.0,
13909,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,50588,N,,CHEMBL627408,1088.0,
13910,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,50588,N,,CHEMBL627409,1088.0,
13911,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,50588,N,,CHEMBL875486,1088.0,
13912,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,50588,N,,CHEMBL627410,1088.0,
13913,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,50588,N,,CHEMBL627411,1088.0,
13914,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,50588,N,,CHEMBL627412,1088.0,
13915,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,50588,N,,CHEMBL627413,1088.0,
13916,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,50588,N,,CHEMBL627414,1088.0,
13917,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,50588,N,,CHEMBL627415,1088.0,
13918,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,50588,N,,CHEMBL627416,1088.0,
13919,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,50588,N,,CHEMBL627417,1088.0,
13920,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,50588,N,,CHEMBL627418,1088.0,
13921,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,50588,N,,CHEMBL627419,1088.0,
13922,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,50588,N,,CHEMBL627320,1088.0,
13923,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,50588,N,,CHEMBL627321,1088.0,
13924,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL627322,2113.0,
13925,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL627323,2113.0,
13926,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL627491,2113.0,
13927,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL627492,2113.0,
13928,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL627493,2113.0,
13929,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL627494,2107.0,
13930,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL627495,2107.0,
13931,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL627496,2107.0,
13932,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL627497,2107.0,
13933,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL627498,2107.0,
13934,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL627499,2048.0,
13935,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL627500,2048.0,
13936,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL627501,2048.0,
13937,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL625616,2048.0,
13938,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL625617,2048.0,
13939,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL625618,2385.0,
13940,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL625619,2385.0,
13941,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL625620,2385.0,
13942,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL625621,2385.0,
13943,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL625622,2385.0,
13944,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL625788,2106.0,
13945,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL625789,2106.0,
13946,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL625790,2106.0,
13947,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL625791,2106.0,
13948,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL622334,2106.0,
13949,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL622335,2046.0,
13950,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL622336,2046.0,
13951,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL622337,2046.0,
13952,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL622338,2046.0,
13953,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL622339,2046.0,
13954,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL624153,,
13955,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL628430,,
13956,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL628431,,
13957,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL628432,,
13958,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL628433,,
13959,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",50597,N,,CHEMBL628434,2106.0,
13960,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",50597,N,,CHEMBL626789,2106.0,
13961,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",50597,N,,CHEMBL626790,2106.0,
13962,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",50597,N,,CHEMBL626791,2106.0,
13963,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",50597,N,,CHEMBL626792,2106.0,
13964,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",50597,N,,CHEMBL626793,2106.0,
13965,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,50597,N,,CHEMBL627436,,
13966,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,50597,N,,CHEMBL627437,,
13967,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,50597,N,,CHEMBL627438,,
13968,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,50597,N,,CHEMBL627439,,
13969,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,50597,N,,CHEMBL627440,,
13970,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,50597,N,,CHEMBL627602,,
13971,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,50597,N,,CHEMBL627603,,
13972,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,50597,N,,CHEMBL627604,,
13973,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,50597,N,,CHEMBL627605,,
13974,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,50597,N,,CHEMBL627606,,
13975,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,50597,N,,CHEMBL627607,,
13976,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,50597,N,,CHEMBL627608,,
13977,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,50597,N,,CHEMBL627609,,
13978,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,50597,N,,CHEMBL627610,,
13979,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,50597,N,,CHEMBL627611,,
13980,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,50597,N,,CHEMBL627612,,
13981,,,BAO_0000100,,1,P,Autocuration,,0,Octanol:water partition coefficient is evaluated,22229,U,,CHEMBL627613,,
13982,,,BAO_0000100,,1,P,Autocuration,,0,Partition coefficient in 1-octanol/water system,22224,U,,CHEMBL627614,,
13983,,,BAO_0000100,,1,P,Autocuration,,0,Partition coefficient in 1-octanol/water system measured using radio active compounds,22224,U,,CHEMBL627615,,
13984,,,BAO_0000100,,1,P,Autocuration,,0,Partition coefficient in octanol/water system was determined,22224,U,,CHEMBL627616,,
13985,,,BAO_0000100,,1,P,Autocuration,,0,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,22224,U,,CHEMBL627617,,
13986,,,BAO_0000019,,1,A,Autocuration,,0,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,22224,U,,CHEMBL627618,,
13987,,,BAO_0000019,,1,A,Autocuration,,0,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",22224,U,,CHEMBL627619,,
13988,,,BAO_0000019,,1,A,Autocuration,,0,Pseudo-first-order rate constant of the compound,22224,U,,CHEMBL627620,,
13989,,,BAO_0000019,,1,A,Autocuration,,0,Pseudo-first-order rate constant with 1-min time point,22224,U,,CHEMBL627621,,
13990,,,BAO_0000019,,1,A,Autocuration,,0,Pseudo-first-order rate constant without 1-min time point,22224,U,,CHEMBL627622,,
13991,,,BAO_0000019,,1,A,Autocuration,,0,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,22224,U,,CHEMBL627623,,
13992,,,BAO_0000019,,1,A,Autocuration,,0,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,22224,U,,CHEMBL627624,,
13993,,,BAO_0000019,,1,A,Autocuration,,0,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,22224,U,,CHEMBL627625,,
13994,,,BAO_0000019,,1,A,Autocuration,,0,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,22224,U,,CHEMBL628523,,
13995,,,BAO_0000019,,1,A,Autocuration,,0,The alkaline hydrolysis second order rate constant(K OH) of the compound,22224,U,,CHEMBL628524,,
13996,,,BAO_0000019,,1,A,Autocuration,,0,The efflux rate constant of the compound,22224,U,,CHEMBL628525,,
13997,,,BAO_0000019,,1,A,Autocuration,,0,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,22224,U,,CHEMBL625732,,
13998,,,BAO_0000019,,1,A,Autocuration,,0,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,22224,U,,CHEMBL625733,,
13999,,,BAO_0000019,,1,F,Autocuration,,0,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,22224,U,,CHEMBL625734,,
14000,,,BAO_0000019,,1,A,Autocuration,,0,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,22224,U,,CHEMBL625913,,
14001,,,BAO_0000019,,1,A,Autocuration,,0,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,22224,U,,CHEMBL625914,,
14002,,,BAO_0000019,,1,A,Autocuration,,0,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,22224,U,,CHEMBL625915,,
14003,,,BAO_0000019,,1,A,Autocuration,,0,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,22224,U,,CHEMBL625916,,
14004,,,BAO_0000019,,1,A,Autocuration,,0,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),22224,U,,CHEMBL625917,,
14005,,,BAO_0000019,,1,A,Autocuration,,0,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL625918,,
14006,,,BAO_0000019,,1,A,Autocuration,,0,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL625919,,
14007,,,BAO_0000019,,1,A,Autocuration,,0,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL625920,,
14008,,,BAO_0000019,,1,A,Autocuration,,0,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL874453,,
14009,,,BAO_0000019,,1,A,Autocuration,,0,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL625921,,
14010,,,BAO_0000019,,1,A,Autocuration,,0,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,22224,U,,CHEMBL625922,,
14011,,,BAO_0000019,,1,A,Autocuration,,0,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL625923,,
14012,,,BAO_0000019,,1,A,Autocuration,,0,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL625924,,
14013,,,BAO_0000019,,1,A,Autocuration,,0,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL625925,,
14014,,,BAO_0000019,,1,A,Autocuration,,0,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL625926,,
14015,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat lung at 60 minutes after dose administration.,50597,N,,CHEMBL627704,2048.0,
14016,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,50597,N,,CHEMBL627705,,
14017,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,50597,N,,CHEMBL627706,,
14018,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,50597,N,,CHEMBL627707,,
14019,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,50597,N,,CHEMBL627708,,
14020,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,50597,N,,CHEMBL628361,,
14021,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,50597,N,,CHEMBL628362,,
14022,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat striatum at 120 minutes after dose administration.,50597,N,,CHEMBL628363,2435.0,
14023,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat striatum at 1440 minutes after dose administration.,50597,N,,CHEMBL628364,2435.0,
14024,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat striatum at 15 minutes after dose administration.,50597,N,,CHEMBL628365,2435.0,
14025,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat striatum at 240 minutes after dose administration.,50597,N,,CHEMBL874454,2435.0,
14026,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat striatum at 30 minutes after dose administration.,50597,N,,CHEMBL628531,2435.0,
14027,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat striatum at 360 minutes after dose administration.,50597,N,,CHEMBL628532,2435.0,
14028,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat striatum at 3 hr after dose administration.,50597,N,,CHEMBL628533,2435.0,
14029,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat striatum at 60 minutes after dose administration.,50597,N,,CHEMBL628534,2435.0,
14030,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat thyroid at 120 minutes after dose administration.,50597,N,,CHEMBL628535,2046.0,
14031,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat thyroid at 1440 minutes after dose administration.,50597,N,,CHEMBL628536,2046.0,
14032,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat thyroid at 15 minutes after dose administration.,50597,N,,CHEMBL628537,2046.0,
14033,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat thyroid at 240 minutes after dose administration.,50597,N,,CHEMBL628538,2046.0,
14034,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat thyroid at 30 minutes after dose administration.,50597,N,,CHEMBL628539,2046.0,
14035,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat thyroid at 360 minutes after dose administration.,50597,N,,CHEMBL630297,2046.0,
14036,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat thyroid at 60 minutes after dose administration.,50597,N,,CHEMBL630298,2046.0,
14037,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rest of brain of rat 120 minutes after dose administration.,50597,N,,CHEMBL630299,955.0,
14038,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,50597,N,,CHEMBL628094,955.0,
14039,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,50597,N,,CHEMBL628095,955.0,
14040,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,50597,N,,CHEMBL874648,955.0,
14041,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,50597,N,,CHEMBL628096,955.0,
14042,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,50597,N,,CHEMBL628097,955.0,
14043,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,50597,N,,CHEMBL628098,955.0,
14044,,,BAO_0000019,,1,A,Autocuration,,0,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",22224,U,,CHEMBL628099,,
14045,,,BAO_0000019,,1,A,Autocuration,,0,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",22224,U,,CHEMBL628100,,
14046,,,BAO_0000019,,1,A,Autocuration,,0,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),22224,U,,CHEMBL628101,,
14047,,,BAO_0000019,,1,A,Autocuration,,0,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",22224,U,,CHEMBL628102,,
14048,,,BAO_0000019,,1,A,Autocuration,,0,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",22224,U,,CHEMBL628103,,
14049,,,BAO_0000019,,1,A,Autocuration,,0,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",22224,U,,CHEMBL628104,,
14050,,,BAO_0000019,,1,A,Autocuration,,0,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",22224,U,,CHEMBL628105,,
14051,,,BAO_0000019,,1,A,Autocuration,,0,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",22224,U,,CHEMBL628106,,
14052,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,50597,N,,CHEMBL628107,1088.0,
14053,,,BAO_0000218,,1,F,Autocuration,,0,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,22224,U,,CHEMBL628108,1088.0,
14054,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,50597,N,,CHEMBL628109,1088.0,
14055,,,BAO_0000218,,1,F,Autocuration,,0,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,22224,U,,CHEMBL625299,1088.0,
14056,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,50597,N,,CHEMBL625300,1088.0,
14057,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,50597,N,,CHEMBL625301,1088.0,
14058,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,50597,N,,CHEMBL625302,1088.0,
14059,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,50597,N,,CHEMBL874649,1088.0,
14060,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,50597,N,,CHEMBL625303,,
14061,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,50597,N,,CHEMBL625463,,
14062,,Homo sapiens,BAO_0000218,,1,A,Intermediate,,1,In vitro metabolism in human liver microsomes,50587,N,,CHEMBL625464,2107.0,
14063,,Homo sapiens,BAO_0000218,,1,A,Intermediate,,1,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,50587,N,,CHEMBL625465,,
14064,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,50588,N,,CHEMBL625466,1088.0,
14065,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,50588,N,,CHEMBL625467,1088.0,
14066,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,50597,N,,CHEMBL625468,1088.0,
14067,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,50597,N,,CHEMBL625469,1088.0,
14068,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,50597,N,,CHEMBL625470,1088.0,
14069,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,50597,N,,CHEMBL632418,1088.0,
14070,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,50597,N,,CHEMBL627250,1088.0,
14071,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,50597,N,,CHEMBL627251,1088.0,
14072,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,50597,N,,CHEMBL627252,1088.0,
14073,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,50597,N,,CHEMBL627253,1088.0,
14074,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,50597,N,,CHEMBL627254,1088.0,
14075,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,50597,N,,CHEMBL875471,1088.0,
14076,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,50597,N,,CHEMBL627255,1088.0,
14077,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,50597,N,,CHEMBL627256,1088.0,
14078,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,50597,N,,CHEMBL627257,1088.0,
14079,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,50597,N,,CHEMBL627258,1088.0,
14080,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,50597,N,,CHEMBL627259,1088.0,
14081,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,50597,N,,CHEMBL627260,1088.0,
14082,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,50597,N,,CHEMBL623256,1088.0,
14083,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,50597,N,,CHEMBL874413,1088.0,
14084,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,50597,N,,CHEMBL623257,1088.0,
14085,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,50597,N,,CHEMBL623258,1088.0,
14086,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,50597,N,,CHEMBL623259,1088.0,
14087,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,50597,N,,CHEMBL623260,1088.0,
14088,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,50597,N,,CHEMBL623261,1088.0,
14089,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,50597,N,,CHEMBL623262,1088.0,
14090,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,50597,N,,CHEMBL623263,1088.0,
14091,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,50597,N,,CHEMBL623264,1088.0,
14092,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,50597,N,,CHEMBL623265,1088.0,
14093,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,50597,N,,CHEMBL623266,1088.0,
14094,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,50597,N,,CHEMBL623267,1088.0,
14095,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,50597,N,,CHEMBL623268,1088.0,
14096,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,50597,N,,CHEMBL623269,1088.0,
14097,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,50597,N,,CHEMBL623270,1088.0,
14098,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,50597,N,,CHEMBL623271,1088.0,
14099,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,50597,N,,CHEMBL623272,1088.0,
14100,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,50597,N,,CHEMBL623273,1088.0,
14101,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,50597,N,,CHEMBL623274,1088.0,
14102,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,50597,N,,CHEMBL874414,1088.0,
14103,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,50597,N,,CHEMBL623275,1088.0,
14104,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,50597,N,,CHEMBL629150,1088.0,
14105,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,50597,N,,CHEMBL623276,1088.0,
14106,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,50597,N,,CHEMBL623277,1088.0,
14107,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,50597,N,,CHEMBL623112,1088.0,
14108,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,50597,N,,CHEMBL623113,1088.0,
14109,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,50597,N,,CHEMBL623800,1088.0,
14110,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,50597,N,,CHEMBL623801,1088.0,
14111,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",50597,N,,CHEMBL623802,2106.0,
14112,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL623803,995.0,
14113,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL623970,995.0,
14114,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL623971,995.0,
14115,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),50597,N,,CHEMBL623972,178.0,
14116,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),50597,N,,CHEMBL623973,178.0,
14117,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),50597,N,,CHEMBL623974,178.0,
14118,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),50597,N,,CHEMBL623975,178.0,
14119,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),50597,N,,CHEMBL623976,955.0,
14120,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),50597,N,,CHEMBL623977,955.0,
14121,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),50597,N,,CHEMBL623978,955.0,
14122,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),50597,N,,CHEMBL623979,955.0,
14123,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),50597,N,,CHEMBL623980,,
14124,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),50597,N,,CHEMBL623981,,
14125,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),50597,N,,CHEMBL626278,,
14126,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),50597,N,,CHEMBL626279,,
14127,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in mice bladder plus excreted urine was determined,50594,N,,CHEMBL626280,,
14128,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage biodistribution in mouse blood, 10 minutes post injection",50594,N,,CHEMBL626281,,
14129,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage biodistribution in mouse blood, 30 minutes post injection",50594,N,,CHEMBL626282,,
14130,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage biodistribution in mouse blood, 5 minutes post injection",50594,N,,CHEMBL626283,,
14131,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage biodistribution in mouse blood, 60 minutes post injection",50594,N,,CHEMBL626284,,
14132,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage biodistribution in mouse brain, 10 minutes post injection",50594,N,,CHEMBL626285,955.0,
14133,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage biodistribution in mouse brain, 30 minutes post injection",50594,N,,CHEMBL626286,955.0,
14134,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage biodistribution in mouse brain, 5 minutes post injection",50594,N,,CHEMBL626287,955.0,
14135,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage biodistribution in mouse brain, 60 minutes post injection",50594,N,,CHEMBL626288,955.0,
14136,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage biodistribution in mouse heart, 10 minutes post injection",50594,N,,CHEMBL626289,,
14137,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage biodistribution in mouse heart, 30 minutes post injection",50594,N,,CHEMBL626290,,
14138,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage biodistribution in mouse heart, 5 minutes post injection",50594,N,,CHEMBL626291,,
14139,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage biodistribution in mouse heart, 60 minutes post injection",50594,N,,CHEMBL839888,,
14140,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage biodistribution in mouse intestine, 10 minutes post injection",50594,N,,CHEMBL626292,160.0,
14141,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage biodistribution in mouse intestine, 30 minutes post injection",50594,N,,CHEMBL626293,160.0,
14142,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage biodistribution in mouse intestine, 5 minutes post injection",50594,N,,CHEMBL626294,160.0,
14143,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage biodistribution in mouse intestine, 60 minutes post injection",50594,N,,CHEMBL626295,160.0,
14144,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage biodistribution in mouse liver, 10 minutes post injection",50594,N,,CHEMBL627659,2107.0,
14145,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage biodistribution in mouse liver, 30 minutes of post injection",50594,N,,CHEMBL627660,2107.0,
14146,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage biodistribution in mouse liver, 5 minutes post injection",50594,N,,CHEMBL627661,2107.0,
14147,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in mice liver at 60 minutes of post injection,50594,N,,CHEMBL627662,2107.0,
14148,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in mice lungs at 10 min of post injection,50594,N,,CHEMBL627663,2048.0,
14149,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage biodistribution in mouse lung, 30 minutes post injection",50594,N,,CHEMBL627664,,
14150,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,"Percentage biodistribution in mousee lung, 5 minutes post injection",50594,N,,CHEMBL627665,,
14151,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in mice lungs at 60 min of post injection,50594,N,,CHEMBL627666,2048.0,
14152,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Percentage biodistribution in mouse spleen,50594,N,,CHEMBL627667,2106.0,
14153,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Percentage biodistribution in mouse stomach,50594,N,,CHEMBL627668,945.0,
14154,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,50594,N,,CHEMBL627669,1088.0,
14155,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,22224,U,,CHEMBL627670,1255.0,
14156,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,22224,U,,CHEMBL627671,178.0,
14157,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,22224,U,,CHEMBL627672,1474.0,
14158,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,22224,U,,CHEMBL627673,,
14159,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,22224,U,,CHEMBL627674,2113.0,
14160,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,22224,U,,CHEMBL627675,2107.0,
14161,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,22224,U,,CHEMBL627676,2048.0,
14162,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,22224,U,,CHEMBL627677,2385.0,
14163,,,BAO_0000019,,1,A,Autocuration,,0,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL627678,,
14164,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Affinity for protein binding expressed as association constant in fresh rat serum,50597,N,,CHEMBL627679,1977.0,
14165,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,22224,U,,CHEMBL627680,,
14166,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,22224,U,,CHEMBL627681,,
14167,,,BAO_0000019,,1,A,Autocuration,,0,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,22224,U,,CHEMBL627682,,
14168,,,BAO_0000019,,1,A,Autocuration,,0,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,22224,U,,CHEMBL627683,,
14169,,,BAO_0000019,,1,A,Autocuration,,0,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,22224,U,,CHEMBL627684,,
14170,,,BAO_0000019,,1,A,Autocuration,,0,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",22224,U,,CHEMBL874441,,
14171,,,BAO_0000019,,1,A,Autocuration,,0,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,22224,U,,CHEMBL627685,,
14172,,,BAO_0000019,,1,A,Autocuration,,0,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",22224,U,,CHEMBL627686,,
14173,,,BAO_0000019,,1,A,Autocuration,,0,Apparent rate constant Koff for inactivation of dTMP synthase.,22224,U,,CHEMBL627687,,
14174,,,BAO_0000019,,1,A,Autocuration,,0,The irreversible inhibitor activity by second order rate equation.,22224,U,,CHEMBL627688,,
14175,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,50597,N,,CHEMBL628038,,
14176,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,50597,N,,CHEMBL628039,,
14177,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,50597,N,,CHEMBL628040,,
14178,,,BAO_0000019,,1,A,Autocuration,,0,Dissociation rate calculated from the first-order equation using t1/2 value,22224,U,,CHEMBL628041,,
14179,,,BAO_0000019,,1,A,Autocuration,,0,The compound was tested for Binding constant against DNA,22224,U,,CHEMBL630226,,
14180,,,BAO_0000019,,1,A,Autocuration,,0,First order rate constant for cyclization of the compound,22224,U,,CHEMBL628042,,
14181,,,BAO_0000019,,1,A,Autocuration,,0,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,22224,U,,CHEMBL625232,,
14182,,,BAO_0000019,,1,A,Autocuration,,0,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,22224,U,,CHEMBL625233,,
14183,,,BAO_0000019,,1,A,Autocuration,,0,Hydrolysis rate constant was determined,22224,U,,CHEMBL625979,,
14184,,,BAO_0000019,,1,A,Autocuration,,0,Observed first order rate constant,22224,U,,CHEMBL625980,,
14185,,,BAO_0000019,,1,A,Autocuration,,0,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,22224,U,,CHEMBL625981,,
14186,,,BAO_0000019,,1,A,Autocuration,,0,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,22224,U,,CHEMBL625982,,
14187,,,BAO_0000019,,1,A,Autocuration,,0,Second-order rate constant for attack on PNPA at 25 degree Centigrade,22224,U,,CHEMBL625983,,
14188,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL625984,,
14189,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL625985,,
14190,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL625986,,
14191,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL625987,,
14192,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL625988,,
14193,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL625989,,
14194,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL625990,,
14195,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL625991,,
14196,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL625992,,
14197,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL625993,,
14198,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL631973,,
14199,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL632143,,
14200,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL632144,,
14201,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL632145,,
14202,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL632146,,
14203,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL632147,,
14204,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL632148,,
14205,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL632149,,
14206,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL632150,,
14207,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL632151,,
14208,,Homo sapiens,BAO_0000218,,1,A,Intermediate,,1,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,50587,N,,CHEMBL632152,,
14209,,Homo sapiens,BAO_0000218,,1,A,Intermediate,,1,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,50587,N,,CHEMBL632153,,
14210,,Homo sapiens,BAO_0000218,,1,A,Intermediate,,1,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,50587,N,,CHEMBL632154,,
14211,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,50602,N,,CHEMBL632155,,
14212,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,50602,N,,CHEMBL632156,,
14213,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,50602,N,,CHEMBL632157,,
14214,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,50602,N,,CHEMBL632158,,
14215,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,50602,N,,CHEMBL632159,,
14216,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,50602,N,,CHEMBL626305,,
14217,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,50602,N,,CHEMBL626306,,
14218,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,50602,N,,CHEMBL626307,,
14219,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,50602,N,,CHEMBL626308,,
14220,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,50602,N,,CHEMBL626479,,
14221,,Human herpesvirus 1,BAO_0000218,,1,A,Intermediate,,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,50602,N,,CHEMBL626480,,
14222,,,BAO_0000100,,1,P,Autocuration,,0,Calculated partition coefficient (clogP) (MlogP),22229,U,,CHEMBL626481,,
14223,,,BAO_0000019,,1,A,Autocuration,,0,Equipotent potent ratio relative to carbachol (nicotinic activity),22224,U,,CHEMBL626482,,
14224,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",50588,N,,CHEMBL626483,,
14225,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",50588,N,,CHEMBL626484,,
14226,,,BAO_0000100,,1,P,Autocuration,,0,Solubility at pH 7.4 in micro g/mL;NA denotes available,22229,U,,CHEMBL626485,,
14227,,,BAO_0000100,,1,P,Autocuration,,0,Solubility at pH 7.4 in micro g/mL;NA denotes not available,22229,U,,CHEMBL626486,,
14228,,,BAO_0000100,,1,P,Autocuration,,0,Solubility at pH 7.4 in ug/mL;NA denotes not available,22229,U,,CHEMBL626487,,
14229,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,In vivo,1,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,50588,N,,CHEMBL626488,1969.0,
14230,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,50597,N,,CHEMBL626489,1977.0,
14231,,,BAO_0000019,,1,A,Autocuration,,0,Area under the MAP curve measured over 5 min; ND means Not determined,22224,U,,CHEMBL626490,,
14232,,,BAO_0000100,,1,P,Autocuration,,0,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,22224,U,,CHEMBL626491,,
14233,,,BAO_0000100,,1,P,Autocuration,,0,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,22229,U,,CHEMBL626492,,
14234,,,BAO_0000019,,1,A,Autocuration,,0,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,22224,U,,CHEMBL626493,,
14235,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,50597,N,,CHEMBL626494,,
14236,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Half life after oral tested,22224,U,,CHEMBL626495,,
14237,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Half life was determined in plasma of rat; NT indicates not tested,50597,N,,CHEMBL626496,1969.0,
14238,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,50597,N,,CHEMBL626497,,
14239,,,BAO_0000218,,1,A,Autocuration,In vivo,0,Oral bioavailability after oral tested,22224,U,,CHEMBL626498,,
14240,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),50597,N,,CHEMBL626499,,
14241,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),50597,N,,CHEMBL626500,,
14242,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,half life was determined in plasma of rat; NT indicates not tested,50597,N,,CHEMBL626501,1969.0,
14243,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,half life was determined in plasma of rat; NT means not tested,50597,N,,CHEMBL626502,1969.0,
14244,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,50597,N,,CHEMBL626503,,
14245,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); inactive,50597,N,,CHEMBL626504,,
14246,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,50597,N,,CHEMBL626505,,
14247,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,50597,N,,CHEMBL626506,,
14248,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,50597,N,,CHEMBL626507,,
14249,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,50597,N,,CHEMBL626508,,
14250,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,50597,N,,CHEMBL626509,,
14251,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,50597,N,,CHEMBL875480,,
14252,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,50597,N,,CHEMBL626510,,
14253,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,50597,N,,CHEMBL626511,,
14254,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,50597,N,,CHEMBL626512,,
14255,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,50597,N,,CHEMBL628208,,
14256,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,50597,N,,CHEMBL628209,,
14257,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,50597,N,,CHEMBL628210,,
14258,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,50597,N,,CHEMBL628211,,
14259,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,50597,N,,CHEMBL628212,,
14260,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,50597,N,,CHEMBL628213,,
14261,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,50597,N,,CHEMBL628214,1088.0,
14262,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,50597,N,,CHEMBL628215,1088.0,
14263,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,50597,N,,CHEMBL628216,1088.0,
14264,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,50597,N,,CHEMBL626595,1088.0,
14265,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,50597,N,,CHEMBL626596,1088.0,
14266,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,50597,N,,CHEMBL626597,1088.0,
14267,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,50597,N,,CHEMBL626598,1088.0,
14268,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,50597,N,,CHEMBL622242,1088.0,
14269,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,50597,N,,CHEMBL622243,1088.0,
14270,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,50597,N,,CHEMBL622244,1088.0,
14271,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,50597,N,,CHEMBL622245,1088.0,
14272,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,50597,N,,CHEMBL622246,1088.0,
14273,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,50597,N,,CHEMBL622247,1088.0,
14274,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,50597,N,,CHEMBL622248,1088.0,
14275,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,50597,N,,CHEMBL877483,1088.0,
14276,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,50597,N,,CHEMBL622249,1088.0,
14277,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,50588,N,,CHEMBL622250,1088.0,
14278,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,50588,N,,CHEMBL622251,1088.0,
14279,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,50588,N,,CHEMBL622252,1088.0,
14280,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,50588,N,,CHEMBL622253,1088.0,
14281,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,50588,N,,CHEMBL622254,1088.0,
14282,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,50588,N,,CHEMBL622255,1088.0,
14283,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,50588,N,,CHEMBL622256,1088.0,
14284,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,50588,N,,CHEMBL622257,1088.0,
14285,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,50588,N,,CHEMBL622258,1088.0,
14286,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,50588,N,,CHEMBL622259,1088.0,
14287,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,50588,N,,CHEMBL622927,1088.0,
14288,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,50588,N,,CHEMBL622928,1088.0,
14289,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,50588,N,,CHEMBL622929,1088.0,
14290,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,50588,N,,CHEMBL623182,1088.0,
14291,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,50588,N,,CHEMBL623183,1088.0,
14292,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,50597,N,,CHEMBL623184,1088.0,
14293,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,50597,N,,CHEMBL623185,1088.0,
14294,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,50597,N,,CHEMBL877484,1088.0,
14295,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,50597,N,,CHEMBL627274,1088.0,
14296,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,50597,N,,CHEMBL623186,1088.0,
14297,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,50597,N,,CHEMBL623187,1088.0,
14298,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,50597,N,,CHEMBL623188,1088.0,
14299,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,50597,N,,CHEMBL628055,1088.0,
14300,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,50597,N,,CHEMBL628056,1088.0,
14301,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,50597,N,,CHEMBL628200,1088.0,
14302,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,50597,N,,CHEMBL628201,1088.0,
14303,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,50597,N,,CHEMBL628202,1088.0,
14304,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,50597,N,,CHEMBL628203,1088.0,
14305,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,50597,N,,CHEMBL628204,1088.0,
14306,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,50597,N,,CHEMBL628205,1088.0,
14307,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,50597,N,,CHEMBL628206,1088.0,
14308,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),22224,U,,CHEMBL628207,2367.0,
14309,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,22224,U,,CHEMBL627220,2367.0,
14310,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,22224,U,,CHEMBL627221,2385.0,
14311,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),22224,U,,CHEMBL627222,2367.0,
14312,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,22224,U,,CHEMBL627223,,
14313,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,22224,U,,CHEMBL632062,2385.0,
14314,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,22224,U,,CHEMBL632063,2106.0,
14315,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,22224,U,,CHEMBL632064,1255.0,
14316,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,22224,U,,CHEMBL632065,178.0,
14317,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,22224,U,,CHEMBL632066,1474.0,
14318,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,22224,U,,CHEMBL632067,,
14319,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,22224,U,,CHEMBL629188,2113.0,
14320,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,22224,U,,CHEMBL629189,2107.0,
14321,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,22224,U,,CHEMBL629190,2048.0,
14322,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,22224,U,,CHEMBL629191,2385.0,
14323,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),22224,U,,CHEMBL629192,2367.0,
14324,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,22224,U,,CHEMBL629193,2385.0,
14325,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),22224,U,,CHEMBL629194,2367.0,
14326,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,22224,U,,CHEMBL629195,,
14327,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,22224,U,,CHEMBL629373,2385.0,
14328,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,22224,U,,CHEMBL629374,2106.0,
14329,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,22224,U,,CHEMBL629375,2367.0,
14330,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,22224,U,,CHEMBL629376,1255.0,
14331,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,22224,U,,CHEMBL629377,178.0,
14332,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,22224,U,,CHEMBL629378,1474.0,
14333,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,22224,U,,CHEMBL629379,,
14334,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,22224,U,,CHEMBL629151,2113.0,
14335,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,22224,U,,CHEMBL629152,2107.0,
14336,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,22224,U,,CHEMBL629153,2048.0,
14337,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,22224,U,,CHEMBL629154,2385.0,
14338,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),22224,U,,CHEMBL629155,2367.0,
14339,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,22224,U,,CHEMBL629156,2367.0,
14340,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,22224,U,,CHEMBL629157,2385.0,
14341,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),22224,U,,CHEMBL629158,2367.0,
14342,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,22224,U,,CHEMBL629159,,
14343,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,22224,U,,CHEMBL629160,2385.0,
14344,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,22224,U,,CHEMBL629161,2106.0,
14345,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,22224,U,,CHEMBL629162,1255.0,
14346,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,22224,U,,CHEMBL629163,178.0,
14347,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,22224,U,,CHEMBL629164,1474.0,
14348,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,22224,U,,CHEMBL629165,,
14349,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,22224,U,,CHEMBL629166,2107.0,
14350,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,22224,U,,CHEMBL629167,2048.0,
14351,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,22224,U,,CHEMBL629168,2385.0,
14352,,,BAO_0000019,,1,A,Autocuration,,0,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,22224,U,,CHEMBL629169,,
14353,,,BAO_0000019,,1,A,Autocuration,,0,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,22224,U,,CHEMBL629170,,
14354,,,BAO_0000019,,1,A,Autocuration,,0,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,22224,U,,CHEMBL631153,,
14355,,,BAO_0000019,,1,A,Autocuration,,0,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,22224,U,,CHEMBL875121,,
14356,,,BAO_0000019,,1,A,Autocuration,,0,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,22224,U,,CHEMBL631154,,
14357,,,BAO_0000019,,1,A,Autocuration,,0,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,22224,U,,CHEMBL631155,,
14358,,,BAO_0000019,,1,A,Autocuration,,0,Hydrolysis rate constant was determined,22224,U,,CHEMBL631156,,
14359,,,BAO_0000019,,1,A,Autocuration,,0,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",22224,U,,CHEMBL631157,,
14360,,,BAO_0000019,,1,A,Autocuration,,0,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",22224,U,,CHEMBL631158,,
14361,,,BAO_0000019,,1,A,Autocuration,,0,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",22224,U,,CHEMBL631159,,
14362,,,BAO_0000019,,1,A,Autocuration,,0,Observed second order rate constant,22224,U,,CHEMBL631160,,
14363,,,BAO_0000019,,1,A,Autocuration,,0,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,22224,U,,CHEMBL631161,,
14364,,,BAO_0000019,,1,A,Autocuration,,0,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,22224,U,,CHEMBL631162,,
14365,,,BAO_0000019,,1,A,Autocuration,,0,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,22224,U,,CHEMBL630313,,
14366,,,BAO_0000019,,1,A,Autocuration,,0,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",22224,U,,CHEMBL630314,,
14367,,,BAO_0000019,,1,A,Autocuration,,0,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",22224,U,,CHEMBL630315,,
14368,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL630316,,
14369,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL630986,,
14370,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL630987,,
14371,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL630988,,
14372,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL630989,,
14373,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL630990,,
14374,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL630991,,
14375,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL630992,,
14376,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL630993,,
14377,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,U,,CHEMBL630994,,
14378,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,50597,N,,CHEMBL630995,,
14379,,,BAO_0000019,,1,A,Autocuration,,0,Association constant for compound at 31 degree C was determined,22224,U,,CHEMBL629252,,
14380,,,BAO_0000019,,1,A,Autocuration,,0,Calculated antagonist equilibrium dissociation constant of the compound,22224,U,,CHEMBL629253,,
14381,,,BAO_0000019,,1,A,Autocuration,,0,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,22224,U,,CHEMBL629944,,
14382,,Cavia porcellus,BAO_0000218,,1,A,Intermediate,,1,Dissociation constants vs LTE4 on guinea pig trachea,50512,N,,CHEMBL629945,3126.0,
14383,,,BAO_0000019,,1,A,Autocuration,,0,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",22224,U,,CHEMBL629946,,
14384,,,BAO_0000019,,1,A,Autocuration,,0,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",22224,U,,CHEMBL629947,,
14385,,,BAO_0000019,,1,A,Autocuration,,0,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",22224,U,,CHEMBL629948,,
14386,,,BAO_0000019,,1,A,Autocuration,,0,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",22224,U,,CHEMBL856024,,
14387,,,BAO_0000019,,1,A,Autocuration,,0,Affinity constant KD value was derived from TMP,22224,U,,CHEMBL629949,,
14388,,,BAO_0000019,,1,A,Autocuration,,0,Apparent dissociation (binding) rate constant was evaluated,22224,U,,CHEMBL629950,,
14389,,,BAO_0000100,,1,P,Autocuration,,0,Dissociation constant (KD) of the compound,22224,U,,CHEMBL630127,,
14390,,,BAO_0000100,,1,P,Autocuration,,0,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,22224,U,,CHEMBL630128,,
14391,,,BAO_0000100,,1,P,Autocuration,,0,Dissociation constant from ESR titration experiments,22224,U,,CHEMBL630129,,
14392,,,BAO_0000019,,1,,Autocuration,,0,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),22224,U,,CHEMBL630130,,
14393,,,BAO_0000100,,1,P,Autocuration,,0,Dissociation constant was evaluated.,22224,U,,CHEMBL875234,,
14394,,,BAO_0000100,,1,P,Autocuration,,0,Dissociation constant was reported,22224,U,,CHEMBL630131,,
14395,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Dissociation constant was determined in rat pituitary cells.,50597,N,,CHEMBL630132,,
14396,,,BAO_0000019,,1,A,Autocuration,,0,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,22224,U,,CHEMBL630133,,
14397,,,BAO_0000019,,1,A,Autocuration,,0,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,22224,U,,CHEMBL630134,,
14398,,,BAO_0000019,,1,A,Autocuration,,0,Equilibrium dissociation constant of the compound,22224,U,,CHEMBL630135,,
14399,,,BAO_0000019,,1,A,Autocuration,,0,Equilibrium dissociation constant was determined,22224,U,,CHEMBL630136,,
14400,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic constant KD was evaluated,22224,U,,CHEMBL630137,,
14401,,,BAO_0000019,,1,A,Autocuration,,0,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,22224,U,,CHEMBL630138,,
14402,,,BAO_0000019,,1,A,Autocuration,,0,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,22224,U,,CHEMBL630139,,
14403,,,BAO_0000019,,1,A,Autocuration,,0,Rate constant for hydrolysis in aqueous acetone.,22224,U,,CHEMBL630140,,
14404,,,BAO_0000019,,1,A,Autocuration,,0,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,22224,U,,CHEMBL875235,,
14405,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,50597,N,,CHEMBL876439,,
14406,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,50597,N,,CHEMBL630605,,
14407,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,50597,N,,CHEMBL630606,,
14408,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,50597,N,,CHEMBL630607,,
14409,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,50597,N,,CHEMBL630608,,
14410,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,50597,N,,CHEMBL630609,,
14411,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,50597,N,,CHEMBL630610,,
14412,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,50597,N,,CHEMBL630611,,
14413,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,50597,N,,CHEMBL629552,,
14414,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,50597,N,,CHEMBL629733,,
14415,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,50597,N,,CHEMBL629734,,
14416,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,50597,N,,CHEMBL629735,,
14417,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,50597,N,,CHEMBL629736,,
14418,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,50597,N,,CHEMBL629737,,
14419,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,50597,N,,CHEMBL629738,,
14420,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,50597,N,,CHEMBL629739,,
14421,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,50597,N,,CHEMBL629740,,
14422,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,50597,N,,CHEMBL629741,,
14423,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,50597,N,,CHEMBL629742,,
14424,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,50597,N,,CHEMBL629743,,
14425,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,50597,N,,CHEMBL629744,,
14426,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,50597,N,,CHEMBL629745,,
14427,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,50597,N,,CHEMBL629746,,
14428,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,50597,N,,CHEMBL629747,,
14429,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,50597,N,,CHEMBL629748,,
14430,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,50597,N,,CHEMBL629749,,
14431,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,50597,N,,CHEMBL629750,,
14432,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,50597,N,,CHEMBL629751,,
14433,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,50597,N,,CHEMBL629752,,
14434,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,50597,N,,CHEMBL629753,,
14435,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,50597,N,,CHEMBL629754,,
14436,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,50597,N,,CHEMBL629755,,
14437,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,50597,N,,CHEMBL629756,,
14438,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,50597,N,,CHEMBL629757,,
14439,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,50597,N,,CHEMBL629758,,
14440,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,50597,N,,CHEMBL629759,,
14441,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,50597,N,,CHEMBL629760,,
14442,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,50597,N,,CHEMBL876443,,
14443,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,50588,N,,CHEMBL629761,,
14444,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,50588,N,,CHEMBL629762,,
14445,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,50594,N,,CHEMBL629763,,
14446,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,50594,N,,CHEMBL629764,,
14447,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,50594,N,,CHEMBL629765,,
14448,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,50594,N,,CHEMBL629766,,
14449,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,50594,N,,CHEMBL629767,,
14450,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,50588,N,,CHEMBL629768,,
14451,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,50594,N,,CHEMBL629769,,
14452,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,50588,N,,CHEMBL629770,,
14453,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,50588,N,,CHEMBL629771,,
14454,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,50594,N,,CHEMBL629772,,
14455,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,50594,N,,CHEMBL629773,,
14456,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,50594,N,,CHEMBL625455,,
14457,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,50594,N,,CHEMBL625456,,
14458,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,50594,N,,CHEMBL625457,,
14459,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,50597,N,,CHEMBL625458,1088.0,
14460,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,50597,N,,CHEMBL625459,1088.0,
14461,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,50597,N,,CHEMBL875483,1088.0,
14462,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,50597,N,,CHEMBL634779,1088.0,
14463,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,50597,N,,CHEMBL625460,1088.0,
14464,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,50597,N,,CHEMBL626117,1088.0,
14465,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,50597,N,,CHEMBL626118,1088.0,
14466,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,50597,N,,CHEMBL628342,1088.0,
14467,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,50597,N,,CHEMBL628343,1088.0,
14468,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,50597,N,,CHEMBL628344,1088.0,
14469,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,50597,N,,CHEMBL628345,1088.0,
14470,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,50597,N,,CHEMBL628346,1088.0,
14471,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,50597,N,,CHEMBL628347,1088.0,
14472,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,50597,N,,CHEMBL628348,1088.0,
14473,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,50597,N,,CHEMBL628349,1088.0,
14474,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,50597,N,,CHEMBL875611,1088.0,
14475,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,50597,N,,CHEMBL628350,1088.0,
14476,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,50597,N,,CHEMBL628351,1088.0,
14477,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,50597,N,,CHEMBL628352,1088.0,
14478,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,50597,N,,CHEMBL628353,1088.0,
14479,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,50597,N,,CHEMBL628354,1088.0,
14480,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,50597,N,,CHEMBL626667,1088.0,
14481,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,50597,N,,CHEMBL626668,1088.0,
14482,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,50597,N,,CHEMBL626669,1088.0,
14483,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,50597,N,,CHEMBL626670,1088.0,
14484,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,50597,N,,CHEMBL626671,1088.0,
14485,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,50597,N,,CHEMBL626672,1088.0,
14486,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,50597,N,,CHEMBL626673,1088.0,
14487,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,50597,N,,CHEMBL626674,1088.0,
14488,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,50597,N,,CHEMBL626675,1088.0,
14489,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,50597,N,,CHEMBL626676,1088.0,
14490,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,50597,N,,CHEMBL626677,1088.0,
14491,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,50597,N,,CHEMBL626678,1088.0,
14492,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,50597,N,,CHEMBL626679,1088.0,
14493,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,50597,N,,CHEMBL875612,1088.0,
14494,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,50597,N,,CHEMBL626680,1088.0,
14495,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,50597,N,,CHEMBL626681,1088.0,
14496,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,50597,N,,CHEMBL626682,1088.0,
14497,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,50597,N,,CHEMBL626683,1088.0,
14498,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,50597,N,,CHEMBL626684,1088.0,
14499,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,50597,N,,CHEMBL626685,1088.0,
14500,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,50597,N,,CHEMBL626686,1088.0,
14501,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,50597,N,,CHEMBL626687,1088.0,
14502,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,50597,N,,CHEMBL624978,1088.0,
14503,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,50597,N,,CHEMBL624979,1088.0,
14504,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,50597,N,,CHEMBL624980,1088.0,
14505,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,50597,N,,CHEMBL624981,1088.0,
14506,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,50588,N,,CHEMBL624982,1088.0,
14507,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),22224,U,,CHEMBL627564,2367.0,
14508,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),22224,U,,CHEMBL627565,2367.0,
14509,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,22224,U,,CHEMBL627566,,
14510,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,22224,U,,CHEMBL627567,2385.0,
14511,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,22224,U,,CHEMBL627568,2106.0,
14512,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,22224,U,,CHEMBL627569,2113.0,
14513,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,22224,U,,CHEMBL627570,1255.0,
14514,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,22224,U,,CHEMBL627571,178.0,
14515,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,22224,U,,CHEMBL627572,1474.0,
14516,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,22224,U,,CHEMBL627573,,
14517,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,22224,U,,CHEMBL627574,2113.0,
14518,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,22224,U,,CHEMBL627575,2107.0,
14519,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,22224,U,,CHEMBL627576,2048.0,
14520,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,22224,U,,CHEMBL627577,2385.0,
14521,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),22224,U,,CHEMBL627578,2367.0,
14522,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,22224,U,,CHEMBL627579,2367.0,
14523,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,22224,U,,CHEMBL627580,2385.0,
14524,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),22224,U,,CHEMBL627581,2367.0,
14525,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,22224,U,,CHEMBL627582,,
14526,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,22224,U,,CHEMBL627583,2385.0,
14527,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,22224,U,,CHEMBL627584,2106.0,
14528,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,22224,U,,CHEMBL627585,2367.0,
14529,,,BAO_0000218,,1,A,Autocuration,In vivo,0,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,22224,U,,CHEMBL627586,2385.0,
14530,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,50597,N,,CHEMBL627587,,
14531,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,50597,N,,CHEMBL627588,,
14532,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,50597,N,,CHEMBL628250,,
14533,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,50597,N,,CHEMBL628251,,
14534,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,50597,N,,CHEMBL628252,10000000.0,
14535,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,50597,N,,CHEMBL628253,10000000.0,
14536,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,50597,N,,CHEMBL628254,1898.0,
14537,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,50597,N,,CHEMBL877493,1898.0,
14538,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,50597,N,,CHEMBL628255,,
14539,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,50597,N,,CHEMBL628256,,
14540,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,50597,N,,CHEMBL628257,10000000.0,
14541,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,50597,N,,CHEMBL628258,1898.0,
14542,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,50597,N,,CHEMBL628259,,
14543,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,50597,N,,CHEMBL628429,,
14544,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,50597,N,,CHEMBL626862,10000000.0,
14545,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,50597,N,,CHEMBL626863,1898.0,
14546,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,50597,N,,CHEMBL625886,2037.0,
14547,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,50597,N,,CHEMBL625887,2037.0,
14548,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the [11C]-radiolabeled compound in rat cortex,50597,N,,CHEMBL625888,,
14549,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,50597,N,,CHEMBL625889,,
14550,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,50597,N,,CHEMBL625890,10000000.0,
14551,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,50597,N,,CHEMBL625891,10000000.0,
14552,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,50597,N,,CHEMBL625892,1898.0,
14553,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,50597,N,,CHEMBL625893,1898.0,
14554,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,50597,N,,CHEMBL625894,2037.0,
14555,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the [18F]-radiolabeled compound in rat cortex,50597,N,,CHEMBL625895,,
14556,,,BAO_0000019,,1,A,Autocuration,,0,Reaction rate parameter value for phosphate with transfer with respect to ATP,22224,U,,CHEMBL625896,,
14557,,,BAO_0000019,,1,A,Autocuration,,0,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",22224,U,,CHEMBL625897,,
14558,,,BAO_0000019,,1,A,Autocuration,,0,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",22224,U,,CHEMBL625898,,
14559,,,BAO_0000019,,1,A,Autocuration,,0,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",22224,U,,CHEMBL625899,,
14560,,,BAO_0000019,,1,A,Autocuration,,0,Reaction rate parameter value for phosphate with transfer with respect to ATP,22224,U,,CHEMBL626124,,
14561,,Escherichia coli,BAO_0000218,,1,A,Intermediate,,1,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,50212,N,,CHEMBL628500,,
14562,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",50597,N,,CHEMBL857856,,
14563,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",50597,N,,CHEMBL628501,,
14564,,,BAO_0000019,,1,A,Autocuration,,0,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",22224,U,,CHEMBL628502,,
14565,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,22224,U,,CHEMBL628503,,
14566,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,22224,U,,CHEMBL628504,,
14567,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",22224,U,,CHEMBL628505,,
14568,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",22224,U,,CHEMBL874452,,
14569,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",22224,U,,CHEMBL628506,,
14570,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",22224,U,,CHEMBL628507,,
14571,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",22224,U,,CHEMBL628508,,
14572,,,BAO_0000019,,1,A,Autocuration,,0,Michaelis constant (KM) was evaluated,22224,U,,CHEMBL628509,,
14573,,,BAO_0000019,,1,A,Autocuration,,0,Reaction rate parameter value for phosphate with transfer with respect to ATP,22224,U,,CHEMBL628510,,
14574,,,BAO_0000019,,1,B,Autocuration,,0,Substrate concentration for half maximal velocity was reported for rat hexokinase I,22224,U,,CHEMBL628511,,
14575,,,BAO_0000019,,1,B,Autocuration,,0,Substrate concentration for half maximal velocity was reported for rat hexokinase II,22224,U,,CHEMBL628512,,
14576,,,BAO_0000019,,1,B,Autocuration,,0,Substrate concentration for half maximal velocity was reported for rat hexokinase III,22224,U,,CHEMBL628513,,
14577,,,BAO_0000019,,1,B,Autocuration,,0,Substrate concentration for half maximal velocity was reported for yeast hexokinase,22224,U,,CHEMBL628514,,
14578,,,BAO_0000019,,1,A,Autocuration,,0,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,22224,U,,CHEMBL628515,,
14579,,,BAO_0000019,,1,A,Autocuration,,0,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,22224,U,,CHEMBL628516,,
14580,,,BAO_0000019,,1,A,Autocuration,,0,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),22224,U,,CHEMBL628517,,
14581,,,BAO_0000019,,1,A,Autocuration,,0,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),22224,U,,CHEMBL628518,,
14582,,,BAO_0000019,,1,A,Autocuration,,0,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,22224,U,,CHEMBL628519,,
14583,,,BAO_0000019,,1,A,Autocuration,,0,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,22224,U,,CHEMBL628520,,
14584,,,BAO_0000019,,1,A,Autocuration,,0,Binding constant was determined,22224,U,,CHEMBL628521,,
14585,,,BAO_0000019,,1,A,Autocuration,,0,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,22224,U,,CHEMBL630443,,
14586,,,BAO_0000019,,1,A,Autocuration,,0,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,22224,U,,CHEMBL630444,,
14587,,,BAO_0000019,,1,A,Autocuration,,0,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,22224,U,,CHEMBL857732,,
14588,,,BAO_0000100,,1,P,Autocuration,,0,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,22224,U,,CHEMBL630445,,
14589,,,BAO_0000019,,1,A,Autocuration,,0,Catalytic rate constant of the compound,22224,U,,CHEMBL630446,,
14590,,,BAO_0000019,,1,B,Autocuration,,0,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,22224,U,,CHEMBL630447,,
14591,,,BAO_0000019,,1,A,Autocuration,,0,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),22224,U,,CHEMBL630448,,
14592,,,BAO_0000019,,1,A,Autocuration,,0,Catalytic rate constant against phospholipase A2 was determined,22224,U,,CHEMBL630449,,
14593,,,BAO_0000019,,1,A,Autocuration,,0,"Compound was evaluated for catalytic constant, Kcat",22224,U,,CHEMBL630450,,
14594,,,BAO_0000019,,1,A,Autocuration,,0,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,22224,U,,CHEMBL630451,,
14595,,,BAO_0000019,,1,A,Autocuration,,0,Kcat calculated from 0.693/T1/2,22224,U,,CHEMBL630452,,
14596,,,BAO_0000019,,1,A,Autocuration,,0,Kcat was determined,22224,U,,CHEMBL630453,,
14597,,,BAO_0000019,,1,A,Autocuration,,0,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,22224,U,,CHEMBL630454,,
14598,,,BAO_0000019,,1,A,Autocuration,,0,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,22224,U,,CHEMBL630455,,
14599,,,BAO_0000019,,1,A,Autocuration,,0,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,22224,U,,CHEMBL631487,,
14600,,,BAO_0000019,,1,A,Autocuration,,0,Kcat value was determined,22224,U,,CHEMBL631488,,
14601,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,22224,U,,CHEMBL876440,,
14602,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,22224,U,,CHEMBL631489,,
14603,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",22224,U,,CHEMBL857742,,
14604,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",22224,U,,CHEMBL631490,,
14605,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",22224,U,,CHEMBL631491,,
14606,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",22224,U,,CHEMBL631492,,
14607,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",22224,U,,CHEMBL631493,,
14608,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter for rate of conversion to PABA was determined,22224,U,,CHEMBL631494,,
14609,,,BAO_0000019,,1,A,Autocuration,,0,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,22224,U,,CHEMBL631495,,
14610,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",50597,N,,CHEMBL631496,1988.0,
14611,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",50597,N,,CHEMBL631497,1088.0,
14612,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",50597,N,,CHEMBL631498,1088.0,
14613,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",50597,N,,CHEMBL629776,1088.0,
14614,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",50597,N,,CHEMBL629777,1088.0,
14615,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",50597,N,,CHEMBL629778,1088.0,
14616,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,50597,N,,CHEMBL630456,,
14617,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,50597,N,,CHEMBL630457,,
14618,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,50597,N,,CHEMBL630458,,
14619,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,50597,N,,CHEMBL630459,,
14620,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,50597,N,,CHEMBL630460,,
14621,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,50597,N,,CHEMBL876550,,
14622,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,50597,N,,CHEMBL630461,,
14623,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,50597,N,,CHEMBL630462,,
14624,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,50597,N,,CHEMBL630463,,
14625,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,50597,N,,CHEMBL630464,,
14626,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,50597,N,,CHEMBL630465,,
14627,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,50597,N,,CHEMBL630466,,
14628,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,50597,N,,CHEMBL630467,,
14629,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,50597,N,,CHEMBL630633,,
14630,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,50597,N,,CHEMBL630634,,
14631,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,50597,N,,CHEMBL630635,,
14632,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,50597,N,,CHEMBL630636,,
14633,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,50597,N,,CHEMBL630637,,
14634,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",50592,N,,CHEMBL630638,1988.0,
14635,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",50592,N,,CHEMBL630639,1988.0,
14636,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",50592,N,,CHEMBL630640,1988.0,
14637,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",50592,N,,CHEMBL876551,1988.0,
14638,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",50592,N,,CHEMBL630641,1088.0,
14639,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",50592,N,,CHEMBL630642,1088.0,
14640,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",50592,N,,CHEMBL630643,1088.0,
14641,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",50592,N,,CHEMBL630644,1088.0,
14642,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",50592,N,,CHEMBL630645,1088.0,
14643,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",50592,N,,CHEMBL625599,1988.0,
14644,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",50592,N,,CHEMBL625600,1988.0,
14645,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",50592,N,,CHEMBL625601,1988.0,
14646,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",50592,N,,CHEMBL625602,1988.0,
14647,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",50592,N,,CHEMBL627470,1088.0,
14648,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",50592,N,,CHEMBL627471,1088.0,
14649,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",50592,N,,CHEMBL627472,1088.0,
14650,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",50592,N,,CHEMBL627473,1088.0,
14651,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",50592,N,,CHEMBL627474,1088.0,
14652,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,N,,CHEMBL627475,178.0,
14653,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,N,,CHEMBL627476,178.0,
14654,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,50588,N,,CHEMBL627477,1088.0,
14655,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,50588,N,,CHEMBL627478,1088.0,
14656,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,50588,N,,CHEMBL627479,1088.0,
14657,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,50588,N,,CHEMBL627480,1088.0,
14658,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,50588,N,,CHEMBL627481,1088.0,
14659,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,50588,N,,CHEMBL627482,1088.0,
14660,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,50588,N,,CHEMBL627483,1088.0,
14661,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,50588,N,,CHEMBL875636,1088.0,
14662,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,50588,N,,CHEMBL625764,1088.0,
14663,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,50588,N,,CHEMBL625765,1088.0,
14664,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,50588,N,,CHEMBL625766,1088.0,
14665,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,50588,N,,CHEMBL625767,1088.0,
14666,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,50588,N,,CHEMBL625768,1088.0,
14667,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,50588,N,,CHEMBL625769,1088.0,
14668,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,50588,N,,CHEMBL625770,1088.0,
14669,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,50588,N,,CHEMBL625771,1088.0,
14670,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,50588,N,,CHEMBL625772,1088.0,
14671,,Canis lupus familiaris,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,50588,N,,CHEMBL625773,1088.0,
14672,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,50597,N,,CHEMBL625774,1088.0,
14673,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,50597,N,,CHEMBL625775,1088.0,
14674,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,50597,N,,CHEMBL625776,1088.0,
14675,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,50597,N,,CHEMBL625777,1088.0,
14676,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,50597,N,,CHEMBL625778,1088.0,
14677,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,50597,N,,CHEMBL625779,1088.0,
14678,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,50597,N,,CHEMBL625780,1088.0,
14679,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,50597,N,,CHEMBL625781,1088.0,
14680,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,50597,N,,CHEMBL875637,1088.0,
14681,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,50597,N,,CHEMBL626473,1088.0,
14682,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,50597,N,,CHEMBL626474,1088.0,
14683,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,50597,N,,CHEMBL626475,1088.0,
14684,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,50597,N,,CHEMBL626476,1088.0,
14685,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,50597,N,,CHEMBL634397,1088.0,
14686,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,50597,N,,CHEMBL626477,1088.0,
14687,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,50597,N,,CHEMBL631069,1088.0,
14688,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,50597,N,,CHEMBL631070,1088.0,
14689,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,50597,N,,CHEMBL631071,1088.0,
14690,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,50597,N,,CHEMBL631072,1088.0,
14691,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,50597,N,,CHEMBL631073,1088.0,
14692,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,50597,N,,CHEMBL631074,1088.0,
14693,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,50597,N,,CHEMBL631075,1088.0,
14694,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,50597,N,,CHEMBL631725,1088.0,
14695,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,50597,N,,CHEMBL631726,1088.0,
14696,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,50597,N,,CHEMBL631727,1088.0,
14697,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,50597,N,,CHEMBL631728,1088.0,
14698,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,50597,N,,CHEMBL631729,1088.0,
14699,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,50597,N,,CHEMBL631730,1088.0,
14700,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,50597,N,,CHEMBL631731,1088.0,
14701,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,50597,N,,CHEMBL631910,1088.0,
14702,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,50597,N,,CHEMBL631911,10000000.0,
14703,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,50597,N,,CHEMBL631912,1898.0,
14704,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,50597,N,,CHEMBL631913,1898.0,
14705,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL631914,178.0,
14706,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL631915,178.0,
14707,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL875778,178.0,
14708,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL631916,178.0,
14709,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL631917,178.0,
14710,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL631918,178.0,
14711,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL631919,178.0,
14712,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL631920,178.0,
14713,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL631921,178.0,
14714,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL631922,178.0,
14715,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL631923,178.0,
14716,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL631924,,
14717,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630234,,
14718,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL630235,,
14719,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630236,,
14720,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630237,,
14721,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630238,,
14722,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630239,,
14723,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL630303,,
14724,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630304,,
14725,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630305,,
14726,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630306,2113.0,
14727,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630307,2113.0,
14728,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL630308,2113.0,
14729,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630309,2113.0,
14730,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL629309,2113.0,
14731,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL629993,2113.0,
14732,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL629994,2113.0,
14733,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL629995,2113.0,
14734,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL631993,2113.0,
14735,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL631994,2113.0,
14736,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL631995,2113.0,
14737,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL631996,2107.0,
14738,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL631997,2107.0,
14739,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL631998,2107.0,
14740,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL631999,2107.0,
14741,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL632000,2107.0,
14742,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL632001,2107.0,
14743,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL874424,2107.0,
14744,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL632002,2107.0,
14745,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL632003,2107.0,
14746,,,BAO_0000019,,1,A,Autocuration,,0,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,22224,U,,CHEMBL632004,,
14747,,,BAO_0000019,,1,A,Autocuration,,0,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,22224,U,,CHEMBL632005,,
14748,,,BAO_0000019,,1,A,Autocuration,,0,Compound was tested for amidase rate in the presence of N62C screen enzyme,22224,U,,CHEMBL632006,,
14749,,,BAO_0000019,,1,A,Autocuration,,0,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,22224,U,,CHEMBL632007,,
14750,,,BAO_0000019,,1,A,Autocuration,,0,Compound was tested for amidase rate in the presence of S166C screen enzyme,22224,U,,CHEMBL632008,,
14751,,,BAO_0000019,,1,A,Autocuration,,0,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,22224,U,,CHEMBL632009,,
14752,,,BAO_0000019,,1,A,Autocuration,,0,Compound was tested for esterase rate in the presence of N62C screen enzyme,22224,U,,CHEMBL632010,,
14753,,,BAO_0000019,,1,A,Autocuration,,0,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,22224,U,,CHEMBL857750,,
14754,,,BAO_0000019,,1,A,Autocuration,,0,Compound was tested for esterase rate in the presence of S166C screen enzyme,22224,U,,CHEMBL632011,,
14755,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",22224,U,,CHEMBL632012,,
14756,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",22224,U,,CHEMBL632013,,
14757,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",22224,U,,CHEMBL632014,,
14758,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",22224,U,,CHEMBL629622,,
14759,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",22224,U,,CHEMBL629623,,
14760,,,BAO_0000019,,1,A,Autocuration,,0,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",22224,U,,CHEMBL629624,,
14761,,,BAO_0000019,,1,A,Autocuration,,0,Ratio of Kcat to that of Km was determined,22224,U,,CHEMBL629625,,
14762,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",22224,U,,CHEMBL629626,,
14763,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",22224,U,,CHEMBL629627,,
14764,,,BAO_0000019,,1,A,Autocuration,,0,"Compound was evaluated for constant, Kd",22224,U,,CHEMBL629628,,
14765,,,BAO_0000019,,1,A,Autocuration,,0,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,22224,U,,CHEMBL629629,,
14766,,,BAO_0000019,,1,A,Autocuration,,0,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,22224,U,,CHEMBL629630,,
14767,,,BAO_0000019,,1,A,Autocuration,,0,Dissociation Constant of compound determined,22224,U,,CHEMBL856030,,
14768,,,BAO_0000019,,1,B,Autocuration,,0,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,22224,U,,CHEMBL629631,,
14769,,,BAO_0000019,,1,B,Autocuration,,0,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,22224,U,,CHEMBL629632,,
14770,,,BAO_0000100,,1,P,Autocuration,,0,Dissociation constant of compound with Fructose was determined,22224,U,,CHEMBL629633,,
14771,,,BAO_0000100,,1,P,Autocuration,,0,Dissociation constant of compound with Fructose was determined; Not determined,22224,U,,CHEMBL629634,,
14772,,,BAO_0000100,,1,P,Autocuration,,0,Dissociation constant of compound with Lactulose was determined,22224,U,,CHEMBL629635,,
14773,,,BAO_0000100,,1,P,Autocuration,,0,Dissociation constant of compound with Lactulose was determined; Not determined,22224,U,,CHEMBL629636,,
14774,,,BAO_0000100,,1,P,Autocuration,,0,Dissociation constant of the Compound,22224,U,,CHEMBL629637,,
14775,,,BAO_0000100,,1,P,Autocuration,,0,Dissociation constant by non-linear regression analysis,22224,U,,CHEMBL629638,,
14776,,,BAO_0000100,,1,P,Autocuration,,0,Dissociation constant was determined,22224,U,,CHEMBL629639,,
14777,,,BAO_0000100,,1,P,Autocuration,,0,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,22224,U,,CHEMBL629640,,
14778,,,BAO_0000100,,1,P,Autocuration,,0,Dissociation constant was determined,22224,U,,CHEMBL629641,,
14779,,,BAO_0000100,,1,P,Autocuration,,0,Dissociation constant was determined,22224,U,,CHEMBL631344,,
14780,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,50597,N,,CHEMBL631345,2385.0,
14781,,,BAO_0000019,,1,A,Autocuration,,0,The dissociation constant determined by fluorescence displacement assay,22224,U,,CHEMBL631346,,
14782,,,BAO_0000019,,1,A,Autocuration,,0,kd value surface plasmon resonance (SPR) method,22224,U,,CHEMBL631524,,
14783,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,50597,N,,CHEMBL631525,2385.0,
14784,,,BAO_0000019,,1,F,Autocuration,,0,First dissociation constant of the binding of compound to V30M TTR,22224,U,,CHEMBL631526,,
14785,,,BAO_0000019,,1,F,Autocuration,,0,Second dissociation constant of the binding of compound to V30M TTR,22224,U,,CHEMBL631527,,
14786,,,BAO_0000019,,1,A,Autocuration,,0,"Compound was evaluated for equilibrium constant, Ke",22224,U,,CHEMBL631528,,
14787,,,BAO_0000019,,1,A,Autocuration,,0,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,22224,U,,CHEMBL631529,1898.0,
14788,,,BAO_0000019,,1,A,Autocuration,,0,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,22224,U,,CHEMBL631530,1898.0,
14789,,,BAO_0000019,,1,A,Autocuration,,0,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,22224,U,,CHEMBL631531,,
14790,,,BAO_0000019,,1,A,Autocuration,,0,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,22224,U,,CHEMBL631532,,
14791,,,BAO_0000019,,1,A,Autocuration,,0,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,22224,U,,CHEMBL631533,,
14792,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,50594,N,,CHEMBL876552,,
14793,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,50594,N,,CHEMBL631534,,
14794,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,50594,N,,CHEMBL631535,,
14795,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,50594,N,,CHEMBL631536,,
14796,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,50594,N,,CHEMBL631537,,
14797,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,50594,N,,CHEMBL631538,,
14798,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,50594,N,,CHEMBL631539,,
14799,,Mus musculus,BAO_0000218,,1,A,Intermediate,,1,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,50594,N,,CHEMBL631540,,
14800,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,50597,N,,CHEMBL625637,,
14801,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,50597,N,,CHEMBL625638,,
14802,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",50597,N,,CHEMBL625639,,
14803,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,N,,CHEMBL625640,955.0,
14804,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,N,,CHEMBL625641,955.0,
14805,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,N,,CHEMBL625642,948.0,
14806,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,N,,CHEMBL625643,948.0,
14807,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,N,,CHEMBL625644,2113.0,
14808,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,N,,CHEMBL625645,2113.0,
14809,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,N,,CHEMBL625646,2107.0,
14810,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,N,,CHEMBL625647,2107.0,
14811,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,N,,CHEMBL625648,2048.0,
14812,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,50597,N,,CHEMBL625649,2048.0,
14813,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,N,,CHEMBL625650,2385.0,
14814,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,N,,CHEMBL625651,2385.0,
14815,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,N,,CHEMBL625652,14.0,
14816,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,N,,CHEMBL625653,14.0,
14817,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,N,,CHEMBL625654,2106.0,
14818,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,N,,CHEMBL625655,2106.0,
14819,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of Compound in rat blood after 15 minutes of administration,50597,N,,CHEMBL625656,178.0,
14820,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of Compound in rat blood after 2 minutes of administration,50597,N,,CHEMBL625657,178.0,
14821,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of Compound in rat brain after 15 minutes of administration,50597,N,,CHEMBL625658,955.0,
14822,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of Compound in rat brain after 2 minutes of administration,50597,N,,CHEMBL625659,955.0,
14823,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of Compound in rat heart after 15 minutes of administration,50597,N,,CHEMBL625660,948.0,
14824,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of Compound in rat heart after 2 minutes of administration,50597,N,,CHEMBL625661,948.0,
14825,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of Compound in rat liver after 15 minutes of administration,50597,N,,CHEMBL625662,2107.0,
14826,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of Compound in rat liver after 2 minutes of administration,50597,N,,CHEMBL625663,2107.0,
14827,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of Compound in rat lung after 15 minutes of administration,50597,N,,CHEMBL875621,2048.0,
14828,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of Compound in rat lung after 2 minutes of administration,50597,N,,CHEMBL628382,2048.0,
14829,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of Compound in rat muscle after 15 minutes of administration,50597,N,,CHEMBL628383,2385.0,
14830,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution of Compound in rat muscle after 2 minutes of administration,50597,N,,CHEMBL628384,2385.0,
14831,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,50597,N,,CHEMBL628385,,
14832,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,50597,N,,CHEMBL875753,,
14833,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,50597,N,,CHEMBL628386,,
14834,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Organ distribution in rat blood 2 minutes after intravenous injection,50597,N,,CHEMBL628387,,
14835,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Organ distribution in rat blood 2 hr after intravenous injection,50597,N,,CHEMBL628388,,
14836,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Organ distribution in rat blood 30 minutes after intravenous injection,50597,N,,CHEMBL628389,,
14837,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Organ distribution in rat blood 30 min after intravenous injection,50597,N,,CHEMBL632756,,
14838,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Organ distribution in rat brain 2 minutes after intravenous injection,50597,N,,CHEMBL628390,,
14839,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Organ distribution in rat brain 2 hr after intravenous injection,50597,N,,CHEMBL631811,,
14840,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Organ distribution in rat brain 30 minutes after intravenous injection,50597,N,,CHEMBL631812,,
14841,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Organ distribution in rat heart 2 minutes after intravenous injection,50597,N,,CHEMBL631813,,
14842,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Organ distribution in rat heart 2 hr after intravenous injection,50597,N,,CHEMBL631814,,
14843,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Organ distribution in rat heart 30 minutes after intravenous injection,50597,N,,CHEMBL631815,,
14844,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Organ distribution in rat kidney 2 minutes after intravenous injection,50597,N,,CHEMBL631816,,
14845,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Organ distribution in rat kidney 2 hr after intravenous injection,50597,N,,CHEMBL875758,,
14846,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Organ distribution in rat kidney 30 minutes after intravenous injection,50597,N,,CHEMBL631817,,
14847,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Organ distribution in rat liver 2 minutes after intravenous injection,50597,N,,CHEMBL631818,2107.0,
14848,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Organ distribution in rat liver 2 hr after intravenous injection,50597,N,,CHEMBL631819,2107.0,
14849,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Organ distribution in rat liver 30 minutes after intravenous injection,50597,N,,CHEMBL631820,2107.0,
14850,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Organ distribution in rat lung 2 minutes after intravenous injection,50597,N,,CHEMBL631821,,
14851,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Organ distribution in rat lung 2 hr after intravenous injection,50597,N,,CHEMBL631822,,
14852,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Organ distribution in rat lung 30 minutes after intravenous injection,50597,N,,CHEMBL631823,,
14853,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Organ distribution in rat muscle 2 minutes after intravenous injection,50597,N,,CHEMBL631824,2385.0,
14854,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Organ distribution in rat muscle 2 hr after intravenous injection,50597,N,,CHEMBL631825,2385.0,
14855,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Organ distribution in rat muscle 30 minutes after intravenous injection,50597,N,,CHEMBL631826,2385.0,
14856,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),50594,N,,CHEMBL631827,,
14857,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),50594,N,,CHEMBL631828,,
14858,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),50594,N,,CHEMBL631829,,
14859,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,50597,N,,CHEMBL875759,1088.0,
14860,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,50597,N,,CHEMBL631830,1088.0,
14861,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,50597,N,,CHEMBL631831,1088.0,
14862,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,50597,N,,CHEMBL631832,1088.0,
14863,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,50597,N,,CHEMBL631833,1088.0,
14864,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,50597,N,,CHEMBL631834,1088.0,
14865,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,50597,N,,CHEMBL631835,1088.0,
14866,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,50597,N,,CHEMBL631836,1088.0,
14867,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,50597,N,,CHEMBL631837,1088.0,
14868,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,50597,N,,CHEMBL631838,1088.0,
14869,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,50597,N,,CHEMBL631839,1088.0,
14870,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,50597,N,,CHEMBL631840,1088.0,
14871,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,50597,N,,CHEMBL631841,1088.0,
14872,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,50597,N,,CHEMBL631842,1088.0,
14873,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,50597,N,,CHEMBL631843,1088.0,
14874,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,50597,N,,CHEMBL631844,1088.0,
14875,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,50597,N,,CHEMBL631845,1088.0,
14876,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,50597,N,,CHEMBL631846,1088.0,
14877,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,50597,N,,CHEMBL875760,1088.0,
14878,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,50597,N,,CHEMBL632199,1088.0,
14879,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,50597,N,,CHEMBL631847,1088.0,
14880,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,50597,N,,CHEMBL631848,1088.0,
14881,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,50597,N,,CHEMBL628707,1088.0,
14882,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,50597,N,,CHEMBL628708,1088.0,
14883,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,50597,N,,CHEMBL628709,1088.0,
14884,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,50597,N,,CHEMBL628710,1088.0,
14885,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,50597,N,,CHEMBL628711,1088.0,
14886,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,50597,N,,CHEMBL628712,1088.0,
14887,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,50597,N,,CHEMBL628713,1088.0,
14888,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,50597,N,,CHEMBL628714,1088.0,
14889,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",50597,N,,CHEMBL628715,,
14890,,,BAO_0000019,,1,A,Autocuration,,0,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,22224,U,,CHEMBL629179,,
14891,,,BAO_0000019,,1,A,Autocuration,,0,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,22224,U,,CHEMBL629180,,
14892,,,BAO_0000019,,1,A,Autocuration,,0,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,22224,U,,CHEMBL875108,,
14893,,,BAO_0000019,,1,A,Autocuration,,0,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,22224,U,,CHEMBL629181,1235.0,
14894,,,BAO_0000019,,1,A,Autocuration,,0,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,22224,U,,CHEMBL629182,1235.0,
14895,,,BAO_0000019,,1,A,Autocuration,,0,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,22224,U,,CHEMBL629183,,
14896,,,BAO_0000019,,1,A,Autocuration,,0,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,22224,U,,CHEMBL629184,,
14897,,,BAO_0000019,,1,A,Autocuration,,0,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,22224,U,,CHEMBL629185,1235.0,
14898,,,BAO_0000019,,1,A,Autocuration,,0,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,22224,U,,CHEMBL629186,1235.0,
14899,,,BAO_0000019,,1,A,Autocuration,,0,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,22224,U,,CHEMBL629187,,
14900,,,BAO_0000019,,1,A,Autocuration,,0,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,22224,U,,CHEMBL629887,,
14901,,,BAO_0000019,,1,A,Autocuration,,0,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,22224,U,,CHEMBL629888,,
14902,,,BAO_0000019,,1,A,Autocuration,,0,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,22224,U,,CHEMBL629889,,
14903,,,BAO_0000019,,1,A,Autocuration,,0,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,22224,U,,CHEMBL629890,1235.0,
14904,,,BAO_0000019,,1,A,Autocuration,,0,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,22224,U,,CHEMBL629891,,
14905,,,BAO_0000019,,1,A,Autocuration,,0,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,22224,U,,CHEMBL629892,,
14906,,,BAO_0000019,,1,A,Autocuration,,0,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,22224,U,,CHEMBL629893,1235.0,
14907,,,BAO_0000019,,1,A,Autocuration,,0,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,22224,U,,CHEMBL629894,,
14908,,,BAO_0000019,,1,A,Autocuration,,0,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,22224,U,,CHEMBL629895,,
14909,,Canis lupus familiaris,BAO_0000218,,1,A,Autocuration,In vivo,0,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",22224,U,,CHEMBL875109,,
14910,,Macaca fascicularis,BAO_0000218,,1,A,Autocuration,In vivo,0,Absolute bioavailability in male cynomolgus monkeys,22224,U,,CHEMBL629896,,
14911,,Rattus norvegicus,BAO_0000218,,1,A,Autocuration,In vivo,0,Absolute bioavailability in maleSprague-Dawley rats,22224,U,,CHEMBL629897,,
14912,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL629898,2107.0,
14913,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630057,2107.0,
14914,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630058,2107.0,
14915,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630059,2048.0,
14916,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630060,2048.0,
14917,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL630061,2048.0,
14918,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630062,2048.0,
14919,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630063,2048.0,
14920,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630064,2048.0,
14921,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630065,2048.0,
14922,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL630066,2048.0,
14923,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630067,2048.0,
14924,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630068,2048.0,
14925,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL631113,2385.0,
14926,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL631114,2385.0,
14927,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL631115,2385.0,
14928,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL631116,2385.0,
14929,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630528,2385.0,
14930,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630529,2385.0,
14931,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630530,2385.0,
14932,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL630531,2385.0,
14933,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630532,2385.0,
14934,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630533,2385.0,
14935,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal mice blood after 120 hr,50594,N,,CHEMBL630534,178.0,
14936,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal mice blood after 24 hr,50594,N,,CHEMBL630535,178.0,
14937,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal mice blood after 4 hr,50594,N,,CHEMBL630536,178.0,
14938,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal mice bone after 120 hr,50594,N,,CHEMBL630537,10000001.0,
14939,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal mice bone after 24 hr,50594,N,,CHEMBL630538,10000001.0,
14940,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal mice bone after 4 hr,50594,N,,CHEMBL630539,10000001.0,
14941,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal mice heart after 120 hr,50594,N,,CHEMBL630540,948.0,
14942,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal mice heart after 24 hr,50594,N,,CHEMBL630541,948.0,
14943,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal mice heart after 4 hr,50594,N,,CHEMBL630542,948.0,
14944,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal mice kidney after 120 hr,50594,N,,CHEMBL630543,2113.0,
14945,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal mice kidney after 24 hr,50594,N,,CHEMBL630544,2113.0,
14946,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal mice kidney after 4 hr,50594,N,,CHEMBL630545,2113.0,
14947,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal mice liver after 120 hr,50594,N,,CHEMBL630546,2107.0,
14948,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal mice liver after 24 hr,50594,N,,CHEMBL630547,2107.0,
14949,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal mice liver after 4 hr,50594,N,,CHEMBL630548,2107.0,
14950,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal mice spleen after 120 hr,50594,N,,CHEMBL630549,2106.0,
14951,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal mice spleen after 24 hr,50594,N,,CHEMBL630550,2106.0,
14952,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in normal mice spleen after 4 hr,50594,N,,CHEMBL876426,2106.0,
14953,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630551,2106.0,
14954,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630552,2106.0,
14955,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL630553,2106.0,
14956,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630554,2106.0,
14957,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630555,2106.0,
14958,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630556,2106.0,
14959,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630557,2106.0,
14960,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,N,,CHEMBL630558,2106.0,
14961,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630559,2106.0,
14962,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL630560,2106.0,
14963,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,N,,CHEMBL876427,2046.0,
14964,,Rattus norvegicus,BAO_0000218,,1,A,Intermediate,,1,The Kel values in female wistar rats.,50597,N,,CHEMBL630561,,
14965,,,BAO_0000019,,1,A,Autocuration,,0,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,22224,U,,CHEMBL630562,,
14966,,,BAO_0000019,,1,A,Autocuration,,0,Hydrolysis rate constant of the compound,22224,U,,CHEMBL630563,,
14967,,,BAO_0000100,,1,P,Autocuration,,0,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,22229,U,,CHEMBL629673,,
14968,,,BAO_0000019,,1,A,Autocuration,,0,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",22224,U,,CHEMBL629674,,
14969,,,BAO_0000019,,1,A,Autocuration,,0,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",22224,U,,CHEMBL629675,,
14970,,,BAO_0000019,,1,A,Autocuration,,0,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",22224,U,,CHEMBL629676,,
14971,,,BAO_0000019,,1,A,Autocuration,,0,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",22224,U,,CHEMBL629677,,
14972,,,BAO_0000019,,1,A,Autocuration,,0,Apparent inactivation rate constant was evaluated,22224,U,,CHEMBL629678,,
14973,,,BAO_0000019,,1,A,Autocuration,,0,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,22224,U,,CHEMBL629679,,
14974,,,BAO_0000019,,1,A,Autocuration,,0,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,22224,U,,CHEMBL629680,,
14975,,,BAO_0000019,,1,A,Autocuration,,0,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,22224,U,,CHEMBL629681,,
14976,,,BAO_0000019,,1,A,Autocuration,,0,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,22224,U,,CHEMBL629682,,
14977,,,BAO_0000019,,1,A,Autocuration,,0,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,22224,U,,CHEMBL629683,,
14978,,,BAO_0000019,,1,F,Autocuration,,0,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,22224,U,,CHEMBL629684,,
14979,,,BAO_0000100,,1,P,Autocuration,,0,Dissociation constant was determined,22224,U,,CHEMBL629685,,
14980,,,BAO_0000100,,1,P,Autocuration,,0,Dissociation constant was determined,22224,U,,CHEMBL629686,,
14981,,,BAO_0000100,,1,P,Autocuration,,0,Dissociation constant at pH 7.4,22224,U,,CHEMBL872932,,
14982,,,BAO_0000100,,1,P,Autocuration,,0,Dissociation constant in presence of 1 mM dithiothreitol,22224,U,,CHEMBL629687,,
14983,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,22224,U,,CHEMBL872931,,
14984,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,22224,U,,CHEMBL628151,,
14985,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,22224,U,,CHEMBL628152,,
14986,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,22224,U,,CHEMBL628153,,
14987,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic constant for aromatization of androstenedione,22224,U,,CHEMBL628154,,
14988,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic constant for aromatization of testosterone,22224,U,,CHEMBL628155,,
14989,,,BAO_0000019,,1,A,Autocuration,,0,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,22224,U,,CHEMBL628156,,
14990,,,BAO_0000019,,1,A,Autocuration,,0,Local inhibition constant was determined,22224,U,,CHEMBL628157,,
14991,,Saccharomyces cerevisiae,BAO_0000218,,1,A,Intermediate,,1,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,50347,N,,CHEMBL857533,,
14992,,,BAO_0000100,,1,P,Autocuration,,0,Dissociation constant value of the compound,22224,U,,CHEMBL628158,,
14993,,,BAO_0000019,,1,A,Autocuration,,0,In vitro permeability through cornea without epithelium,22224,U,,CHEMBL628159,964.0,
14994,,,BAO_0000019,,1,A,Autocuration,,0,In vitro permeability through intact cornea,22224,U,,CHEMBL875616,964.0,
14995,,Oryctolagus cuniculus,BAO_0000218,,1,A,Intermediate,,1,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,50592,N,,CHEMBL628160,964.0,
14996,,,BAO_0000019,,1,A,Autocuration,,0,Rate of enzyme inactivation for the compound was determined,22224,U,,CHEMBL628161,,
14997,,,BAO_0000019,,1,A,Autocuration,,0,In vitro permeability through cornea without epithelium,22224,U,,CHEMBL628162,964.0,
14998,,,BAO_0000019,,1,A,Autocuration,,0,In vitro permeability through intact cornea,22224,U,,CHEMBL628163,964.0,
14999,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL628164,,
15000,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL628165,,
15001,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL628166,,
15002,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL628167,,
15003,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL628168,,
15004,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL628169,,
15005,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL628170,,
15006,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL628171,,
15007,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL627434,,
15008,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL627435,,
15009,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL628110,,
15010,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL628111,,
15011,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL628112,,
15012,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL628260,,
15013,,,BAO_0000019,,1,A,Autocuration,,0,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,U,,CHEMBL628261,,
15014,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),50594,N,,CHEMBL628262,,
15015,,Homo sapiens,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,50587,N,,CHEMBL628263,,
15016,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),50594,N,,CHEMBL628264,,
15017,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),50594,N,,CHEMBL628265,,
15018,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),50594,N,,CHEMBL628266,,
15019,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),50594,N,,CHEMBL628267,,
15020,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,50594,N,,CHEMBL628268,,
15021,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),50594,N,,CHEMBL628269,,
15022,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),50594,N,,CHEMBL628270,,
15023,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),50594,N,,CHEMBL628271,,
15024,,Mus musculus,BAO_0000218,,1,A,Intermediate,In vivo,1,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),50594,N,,CHEMBL628272,,
